PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	FONG, TM; HUANG, RRC; STRADER, CD				FONG, TM; HUANG, RRC; STRADER, CD			LOCALIZATION OF AGONIST AND ANTAGONIST BINDING DOMAINS OF THE HUMAN NEUROKININ-1 RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BETA-ADRENERGIC-RECEPTOR; LIGAND-BINDING; SUBSTANCE-P; ANALOGS; SPECIFICITY; AFFINITY	To identify the molecular determinants of ligand-receptor interactions, the extracellular domain of the human neurokinin-1 receptor was systematically substituted with the corresponding sequences from the other two neurokinin receptor subtypes. Three residues within the first extracellular segment and 2 residues of the second segment are required for the optimal binding of all three natural peptide agonists. The divergent nature of 4 of the 5 residues supports the hypothesis that the peptide binding site on the neurokinin-1 receptor is not highly conserved in the other two receptor subtypes. In contrast, substitution of part of the third extracellular segment and the fourth extracellular segment with the corresponding amino acids of the human neurokinin-3 receptor results in an increase in neurokinin B affinity without affecting substance P binding, suggesting that the two peptides do not interact with the same set of functional groups on the receptor. Among the four extracellular regions, only parts of the third and fourth segments affect the binding of the quinuclidine antagonist L-703,606, and these two regions may partially account for the neurokinin-1 receptor subtype specificity of this non-peptide antagonist. These studies demonstrate that both the extracellular and transmembrane domains of the neurokinin-1 receptor are involved in the binding of substance P and related peptides.			FONG, TM (corresponding author), MERCK SHARP & DOHME LTD,DEPT MOLEC PHARMACOL & BIOCHEM,80 M-213,POB 2000,RAHWAY,NJ 07065, USA.							BUCK SH, 1988, TRENDS PHARMACOL SCI, V9, P3, DOI 10.1016/0165-6147(88)90228-3; CASCIERI MA, 1986, MOL PHARMACOL, V29, P34; CASCIERI MA, 1992, MOL PHARMACOL, V42, P458; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; FONG TM, 1992, MOL PHARMACOL, V41, P24; FONG TM, 1992, IN PRESS BIOCHEMISTR; Fong Tung Ming, 1992, Society for Neuroscience Abstracts, V18, P454; Gether U., 1992, Society for Neuroscience Abstracts, V18, P400; HELKE CJ, 1990, FASEB J, V4, P1606, DOI 10.1096/fasebj.4.6.1969374; HUANG RRC, 1992, BIOCHEM BIOPH RES CO, V184, P966, DOI 10.1016/0006-291X(92)90685-E; IVERSEN LL, 1987, TOP MED CHEM, V65, P1; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LEVIANTEITELBAUM D, 1989, BIOPOLYMERS, V28, P51, DOI 10.1002/bip.360280108; MAGGIO JE, 1988, ANN REV NEUROSCI, V11, P12; MUNEKATA E, 1991, COMP BIOCHEM PHYS C, V98, P171; NAKANISHI S, 1991, ANNU REV NEUROSCI, V14, P123, DOI 10.1146/annurev.ne.14.030191.001011; QUIOCHO FA, 1989, NATURE, V340, P404, DOI 10.1038/340404a0; REGOLI D, 1989, PHARMACOLOGY, V38, P1, DOI 10.1159/000138512; SAVIANO G, 1991, BIOCHEMISTRY-US, V30, P10175, DOI 10.1021/bi00106a015; SCHWYZER R, 1987, EMBO J, V6, P2255, DOI 10.1002/j.1460-2075.1987.tb02498.x; SNIDER RM, 1991, SCIENCE, V251, P435, DOI 10.1126/science.1703323; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; TAKAHASHI K, 1992, EUR J BIOCHEM, V204, P1025, DOI 10.1111/j.1432-1033.1992.tb16724.x; WADSWORTH HL, 1990, SCIENCE, V249, P1423, DOI 10.1126/science.2169649; WHEATLEY M, 1988, Trends in Pharmacological Sciences, P19	27	267	274	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25664	25667						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1281470				2022-12-27	WOS:A1992KD07300012
J	ADAMSKA, I; KLOPPSTECH, K; OHAD, I				ADAMSKA, I; KLOPPSTECH, K; OHAD, I			UV-LIGHT STRESS INDUCES THE SYNTHESIS OF THE EARLY LIGHT-INDUCIBLE PROTEIN AND PREVENTS ITS DEGRADATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PISUM-SATIVUM-L; PHOTOSYSTEM-II; MESSENGER-RNA; CHLOROPLAST MEMBRANES; POLYACRYLAMIDE GELS; THYLAKOID PROTEINS; PEA; ACCUMULATION; GENES; TRANSCRIPTS	ELIP is a nuclear-encoded protein localized in the thylakoid membranes. The protein is specifically induced by blue light in mature, light-grown plants (Adamska, I., Ohad, I., and Kloppstech, K. (1992) Proc. Natl. Acad. Sci. U. S. A. 89,2610-2613), as well as in plants developed in the light in which pigment synthesis and plastid development were inhibited by the bleaching herbicide norflurazon. ELIP transcription and protein accumulation are induced also by UVA but not by UVB light. However, UVB light allows ELIP synthesis induced by superimposed white light. The protein is stable under light stress including UVA and UVB light, but it is rapidly degraded upon cessation of the light stress conditions. ELIP synthesis and integration into the chloroplast membranes is related neither to chloroplast translation activity nor to photosynthetic electron flow. Inhibition of carotenoid synthesis by fluridone, a bleaching herbicide which causes extensive damage to the photosynthetic apparatus, does not affect induction of ELIP transcription during light stress but greatly enhances ELIP accumulation. Based on these results it is proposed that ELIP turnover is related to the light stress and recovery process in plants.	HEBREW UNIV JERUSALEM, DEPT BIOL CHEM, IL-91904 JERUSALEM, ISRAEL; UNIV HANNOVER, INST BOT, W-3000 HANNOVER 21, GERMANY	Hebrew University of Jerusalem; Leibniz University Hannover								ADAMSKA I, 1991, PLANT MOL BIOL, V16, P209, DOI 10.1007/BF00020553; ADAMSKA I, 1992, P NATL ACAD SCI USA, V89, P2610, DOI 10.1073/pnas.89.7.2610; ADIR N, 1988, J BIOL CHEM, V263, P283; Andersson B., 1991, CURRENT TOPICS BIOEN, V16, P1; APEL K, 1979, EUR J BIOCHEM, V97, P183, DOI 10.1111/j.1432-1033.1979.tb13101.x; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BILGER W, 1989, PLANT PHYSIOL, V91, P542, DOI 10.1104/pp.91.2.542; BOARDMAN NK, 1971, BIOCHIM BIOPHYS ACTA, V253, P222, DOI 10.1016/0005-2728(71)90248-9; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CHAMOVITZ D, 1990, Z NATURFORSCH C, V45, P482; DEMMIGADAMS B, 1990, BIOCHIM BIOPHYS ACTA, V1020, P1, DOI 10.1016/0005-2728(90)90088-L; FLUHR R, 1986, SCIENCE, V232, P1106, DOI 10.1126/science.232.4754.1106; GABA V, 1987, PLANT PHYSIOL, V84, P348, DOI 10.1104/pp.84.2.348; GREENBERG BM, 1989, P NATL ACAD SCI USA, V86, P6617, DOI 10.1073/pnas.86.17.6617; GRIMM B, 1989, PLANT MOL BIOL, V13, P583, DOI 10.1007/BF00027318; GRIMM B, 1987, EUR J BIOCHEM, V167, P493, DOI 10.1111/j.1432-1033.1987.tb13364.x; JORDAN BR, 1991, FEBS LETT, V284, P5, DOI 10.1016/0014-5793(91)80748-R; KLOPPSTECH K, 1984, COMPARTMENTS ALGAL C, P36; KOLANUS W, 1987, MOL GEN GENET, V209, P234, DOI 10.1007/BF00329648; KYLE DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4070, DOI 10.1073/pnas.81.13.4070; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERS A, 1991, J BIOL CHEM, V266, P13698; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; MATTOO AK, 1984, P NATL ACAD SCI-BIOL, V81, P1380, DOI 10.1073/pnas.81.5.1380; MEYER G, 1984, EUR J BIOCHEM, V176, P493; OELMULLER R, 1989, PLANT MOL BIOL, V13, P223, DOI 10.1007/BF00016140; OHAD I, 1985, EMBO J, V4, P1655, DOI 10.1002/j.1460-2075.1985.tb03833.x; OTTO B, 1988, PLANT PHYSIOL, V88, P21, DOI 10.1104/pp.88.1.21; PALOMARES R, 1991, J PHOTOCH PHOTOBIO B, V11, P151, DOI 10.1016/1011-1344(91)80257-I; PEMBERTON RE, 1975, ANAL BIOCHEM, V66, P18, DOI 10.1016/0003-2697(75)90720-4; PRASIL O, 1992, TOPICS PHOTOSYNTHESI, V11, P295; ROBERTS BE, 1973, P NATL ACAD SCI USA, V70, P2330, DOI 10.1073/pnas.70.8.2330; SANDMANN G, 1990, Z NATURFORSCH C, V45, P487; SCHARNHORST C, 1985, PLANT MOL BIOL, V4, P241, DOI 10.1007/BF02418242; SIEFERMANNHARMS D, 1987, PHYSIOL PLANTARUM, V69, P561, DOI 10.1111/j.1399-3054.1987.tb09240.x; SILVERTHORNE J, 1984, P NATL ACAD SCI-BIOL, V81, P1112, DOI 10.1073/pnas.81.4.1112; SIMPSON J, 1986, SCIENCE, V233, P34, DOI 10.1126/science.233.4759.34; THOMPSON WF, 1991, ANNU REV PLANT PHYS, V42, P423, DOI 10.1146/annurev.pp.42.060191.002231; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	39	70	71	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24732	24737						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1280268				2022-12-27	WOS:A1992KA26300087
J	SAKAGUCHI, K				SAKAGUCHI, K			ACIDIC FIBROBLAST GROWTH-FACTOR AUTOCRINE SYSTEM AS A MEDIATOR OF CALCIUM-REGULATED PARATHYROID CELL-GROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBENDOTHELIAL EXTRACELLULAR-MATRIX; HEPARAN-SULFATE PROTEOGLYCAN; CAPILLARY ENDOTHELIAL-CELLS; HIGH-AFFINITY RECEPTOR; NUCLEOTIDE-SEQUENCE; PRIMARY CULTURES; BOVINE; LINE; BINDING; PROLIFERATION	Both parathyroid hormone secretion and cell growth are negatively regulated by extracellular calcium in parathyroid cells. The mechanism of growth regulation by calcium has been unknown. Previously, we reported that clonal parathyroid cells (PT-r cells) bear two high affinity receptors for acidic fibroblast growth factor (aFGF) and that at least a subpopulation of the receptors with a higher molecular mass carries heparan sulfate (HS) glycosaminoglycan chains which give the receptor higher affinity (Sakaguchi, K., Yanagishita, M., Takeuchi, Y., and Aurbach, G. D. (1991) J. Biol. Chem. 266, 7270-7278). Here, I have found that the parathyroid cells expressed aFGF and that aFGF receptors with lower affinity apparently translocated in response to changing extracellular calcium concentrations. Expression of both aFGF mRNA and peptide was suppressed by calcium. Cells had more ligand-accessible receptors on the cell surface at lower calcium concentrations. This apparent translocation was temperature-dependent but independent of de novo protein synthesis. Heparin or HS glycosaminoglycans are a prerequisite for the FGF receptor encoded by flg gene to bind basic FGF (Yayon, A., Klagsbrun, M., Esko, J. D., Leder, P., and Ornitz, D. M. (1991) Cell 64, 841-848). In PT-r cells, major cellular HS proteoglycans redistribute between intracellular and extracellular compartments with more HS proteoglycans expressed on the cell surface at lower calcium concentrations (Takeuchi, Y., Sakaguchi, K., Yanagishita, M., Aurbach, G. D., and Hascall, V. C. (1990) J. Biol. Chem. 265, 13661-13668). However, this redistribution of HS proteoglycans cannot explain the difference in bindability of radiolabeled aFGF to its receptors in different calcium concentrations, since addition of heparin did not change the binding of radiolabeled aFGF to the receptors either at high or low calcium conditions. In concordance with the apparent translocation of aFGF receptors, thymidine incorporation was stimulated by decreasing extracellular calcium concentrations with further stimulation by added aFGF. Anti-aFGF antibody inhibited thymidine incorporation by more than 32% in the cells exposed to 0.05 mM Ca2+ shortly before adding [H-3]thymidine, whereas the incorporation was not significantly affected by the antibody at 0.7 mM Ca2+. Cell growth was also stimulated by low calcium. Anti-aFGF antibody inhibited cell growth significantly only at low calcium concentrations. From these observations, an aFGF autocrine system including the apparent translocation of aFGF receptors may explain, if not entirely, the mechanism by which calcium regulates parathyroid cell growth.			SAKAGUCHI, K (corresponding author), NIDDKD,METAB DIS BRANCH,BETHESDA,MD 20892, USA.							ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; AURBACH GD, 1991, WILLIAMS TXB ENDOCRI, P1397; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BRANDI ML, 1990, FASEB J, V4, P3152, DOI 10.1096/fasebj.4.13.1698682; BRANDI ML, 1986, P NATL ACAD SCI USA, V83, P1709, DOI 10.1073/pnas.83.6.1709; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; IKEDA K, 1989, BIOCHEM BIOPH RES CO, V162, P108, DOI 10.1016/0006-291X(89)91969-4; JAYE M, 1987, J BIOL CHEM, V262, P16612; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; KAN M, 1988, J BIOL CHEM, V263, P11306; KREMER R, 1989, ENDOCRINOLOGY, V125, P935, DOI 10.1210/endo-125-2-935; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBOFF MS, 1983, ENDOCRINOLOGY, V113, P277, DOI 10.1210/endo-113-1-277; LEE MJ, 1975, LAB INVEST, V33, P72; LOBB RR, 1988, BIOCHEMISTRY-US, V27, P2572, DOI 10.1021/bi00407a045; MACGREGOR RR, 1983, MOL CELL ENDOCRINOL, V30, P313, DOI 10.1016/0303-7207(83)90067-9; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; MUNSON PJ, 1984, COMPUTERS ENDOCRINOL, P117; NYGREN P, 1988, BONE MINER, V4, P123; OLWIN BB, 1986, BIOCHEMISTRY-US, V25, P3487, DOI 10.1021/bi00360a001; RAISZ LG, 1963, NATURE, V197, P1115, DOI 10.1038/1971115a0; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROSENGART TK, 1988, BIOCHEM BIOPH RES CO, V152, P432, DOI 10.1016/S0006-291X(88)80732-0; SAKAGUCHI K, 1991, J BIOL CHEM, V266, P7270; SAKAGUCHI K, 1987, P NATL ACAD SCI USA, V84, P3269, DOI 10.1073/pnas.84.10.3269; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SCHREIBER AB, 1985, P NATL ACAD SCI USA, V82, P6138, DOI 10.1073/pnas.82.18.6138; SLATOPOLSKY E, 1984, J CLIN INVEST, V74, P2136, DOI 10.1172/JCI111639; SZABO A, 1989, KIDNEY INT, V35, P1049, DOI 10.1038/ki.1989.89; TAKEUCHI Y, 1990, J BIOL CHEM, V265, P13661; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; VIGNY M, 1988, J CELL PHYSIOL, V137, P321, DOI 10.1002/jcp.1041370216; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; YANAGISHITA M, 1989, J BIOL CHEM, V264, P15714; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	39	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24554	24562						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1280262				2022-12-27	WOS:A1992KA26300062
J	GUPTA, SK; GALLEGO, C; JOHNSON, GL; HEASLEY, LE				GUPTA, SK; GALLEGO, C; JOHNSON, GL; HEASLEY, LE			MAP KINASE IS CONSTITUTIVELY ACTIVATED IN GIP2 AND SRC TRANSFORMED RAT-1A FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-KINASE; JUN ENCODES; ONCOGENES; BINDING; AP-1	Rat 1a fibroblasts transformed by the G(i2) oncogene, gip2, exhibit a constitutively elevated mitogen-activated protein (MAP) kinase activity that correlates with enhanced tyrosine phosphorylation of the p42 MAP kinase polypeptide. The MAP kinase activity in gip2 transformed cells is 50-60% of the pertussis toxin-sensitive, thrombin-stimulated activity observed in wild-type Rat 1a cells. A similar activation of MAP kinase is observed in src but not ras or raf transformed Rat 1a cells, indicating that the persistent MAP kinase activity results from the action of the specific oncoprotein and is not the consequence of cellular transformation. The enhanced transactivation function of c-Jun characteristic of the transformed phenotype, measured using a collagenase promoter-CAT reporter gene, is observed in gip2, src, ras, and raf transformed Rat 1a cells. The regulatory networks controlled by the four transforming oncogenes therefore alter the activity of specific transcription factors, but only gip2 and src constitutively activate MAP kinase. The findings demonstrate that the catalytic activity of growth factor-regulated cytoplasmic kinases are selectively and stably activated as a consequence of specific oncogene expression.	NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,1400 JACKSON ST,DENVER,CO 80206; UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262; UNIV COLORADO,SCH MED,DEPT MED,DIV RENAL,DENVER,CO 80262	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Gallego, Carme/K-6573-2014	Gallego, Carme/0000-0001-6961-3524				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11495; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERRELL JE, 1990, MOL CELL BIOL, V10, P3020, DOI 10.1128/MCB.10.6.3020; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; GUPTA SK, 1992, MOL BIOL CELL, V3, P123, DOI 10.1091/mbc.3.1.123; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LOWNDES JM, 1991, J BIOL CHEM, V266, P14193; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MALLER J, 1991, Current Biology, V1, P334, DOI 10.1016/0960-9822(91)90104-5; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; ROY CB, 1988, P NATL ACAD SCI USA, V85, P3753; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0	35	224	228	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					7987	7990						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1314814				2022-12-27	WOS:A1992HQ18500008
J	ZHANG, XP; ZHOU, YH; EBRIGHT, YW; EBRIGHT, RH				ZHANG, XP; ZHOU, YH; EBRIGHT, YW; EBRIGHT, RH			CATABOLITE GENE ACTIVATOR PROTEIN (CAP) IS NOT AN ACIDIC ACTIVATING REGION TRANSCRIPTION ACTIVATOR PROTEIN - NEGATIVELY CHARGED AMINO-ACIDS OF CAP THAT ARE SOLVENT-ACCESSIBLE IN THE CAP-DNA COMPLEX PLAY NO ROLE IN TRANSCRIPTION ACTIVATION AT THE LAC PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP RECEPTOR PROTEIN; ESCHERICHIA-COLI; CYCLIC-AMP; FUNCTIONAL DISSECTION; POSITIVE CONTROL; BASE PAIR; REPRESSOR; BINDING; YEAST; SITE	It has been suggested that the catabolite gene activator protein (CAP) uses an "acidic activating region" transcription activation mechanism and that Glu171 of CAP is the critical amino acid of the "acidic activating region" of CAP (Irwin, N., and Ptashne, M. (1987) Proc. Natl. Acad. Sci. U.S.A. 84, 8315-8319). In this paper, we show, contrary to the previously published report, that substitution of Glu171 of CAP fails to result in a specific defect in transcription activation at the lac promoter. Furthermore, in this paper, we show that substitution of each other negatively charged amino acid of CAP that is solvent-accessible in the CAP-DNA complex fails to result in a specific defect in transcription activation at the lac promoter. We conclude that CAP does not use an acidic activating region transcription activation mechanism in transcription activation at the lac promoter.	RUTGERS STATE UNIV,WAKSMAN INST,NEW BRUNSWICK,NJ 08855; RUTGERS STATE UNIV,DEPT CHEM,NEW BRUNSWICK,NJ 08855	Rutgers State University New Brunswick; Rutgers State University New Brunswick			Ebright, Richard/O-3321-2019	Ebright, Richard/0000-0001-8915-7140	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041376] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41376] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIBA H, 1982, NUCLEIC ACIDS RES, V10, P1345, DOI 10.1093/nar/10.4.1345; BELL A, 1990, NUCLEIC ACIDS RES, V18, P7243, DOI 10.1093/nar/18.24.7243; BUSHMAN FD, 1989, CELL, V58, P1163, DOI 10.1016/0092-8674(89)90514-X; BUSHMAN FD, 1988, CELL, V54, P191, DOI 10.1016/0092-8674(88)90551-X; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DECROMBRUGGHE B, 1984, SCIENCE, V224, P831, DOI 10.1126/science.6372090; EBRIGHT RH, 1985, J MOL BIOL, V182, P91, DOI 10.1016/0022-2836(85)90030-0; EBRIGHT RH, 1985, J BIOMOL STRUCT DYN, V3, P281, DOI 10.1080/07391102.1985.10508417; EBRIGHT RH, 1989, NUCLEIC ACIDS RES, V17, P10295, DOI 10.1093/nar/17.24.10295; EBRIGHT RH, 1990, P NATL ACAD SCI USA, V87, P2882, DOI 10.1073/pnas.87.8.2882; ESCHENLAUER AC, 1991, J BACTERIOL, V173, P5024, DOI 10.1128/jb.173.16.5024-5029.1991; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P2236, DOI 10.1073/pnas.79.7.2236; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HEITMAN J, 1989, NUCLEIC ACIDS RES, V17, P4413, DOI 10.1093/nar/17.11.4413; HOCHSCHILD A, 1983, CELL, V32, P319, DOI 10.1016/0092-8674(83)90451-8; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; IRWIN N, 1987, P NATL ACAD SCI USA, V84, P8315, DOI 10.1073/pnas.84.23.8315; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MALAN TP, 1984, J MOL BIOL, V180, P881, DOI 10.1016/0022-2836(84)90262-6; OGATA R, 1977, P NATL ACAD SCI USA, V74, P4973, DOI 10.1073/pnas.74.11.4973; PASTAN I, 1976, BACTERIOL REV, V40, P527, DOI 10.1128/MMBR.40.3.527-551.1976; PORSCHKE D, 1984, EMBO J, V3, P2873, DOI 10.1002/j.1460-2075.1984.tb02223.x; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; SABOURIN D, 1975, J BACTERIOL, V122, P338, DOI 10.1128/JB.122.1.338-340.1975; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZHANG XP, 1991, J BIOMOL STRUCT DYN, V9, P463, DOI 10.1080/07391102.1991.10507929; ZHANG XP, 1990, J BIOL CHEM, V265, P12400; Zhou Y., UNPUB	40	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8136	8139						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1314818				2022-12-27	WOS:A1992HQ18500028
J	ENG, J; KLEINMAN, WA; SINGH, L; SINGH, G; RAUFMAN, JP				ENG, J; KLEINMAN, WA; SINGH, L; SINGH, G; RAUFMAN, JP			ISOLATION AND CHARACTERIZATION OF EXENDIN-4, AN EXENDIN-3 ANALOG, FROM HELODERMA-SUSPECTUM VENOM - FURTHER EVIDENCE FOR AN EXENDIN RECEPTOR ON DISPERSED ACINI FROM GUINEA-PIG PANCREAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE INTESTINAL PEPTIDE; GILA MONSTER VENOM; SECRETIN; CELLS; VIP	The recent identification in Heloderma horridum venom of exendin-3, a new member of the glucagon superfamily that acts as a pancreatic secretagogue, prompted a search for a similar peptide in Heloderma suspectum venom. An amino acid sequencing assay for peptides containing an amino-terminal histidine residue (His1) was used to isolate a 39-amino acid peptide, exendin-4, from H. suspectum venom. Exendin-4 differs from exendin-3 by two amino acid substitutions, Gly2-Glu3 in place of Ser2-Asp3, but is otherwise identical. The structural differences make exendin-4 distinct from exendin-3 in its bioactivity. In dispersed acini from guinea pig pancreas, natural and synthetic exendin-4 stimulate a monophasic increase in cAMP beginning at 100 pM that plateaus at 10 nM. The exendin-4-induced increase in cAMP is inhibited progressively by increasing concentrations of the exendin receptor antagonist, exendin-(9-39) amide. Unlike exendin-3, exendin-4 does not stimulate a second rise in acinar cAMP at concentrations > 100 nM, does not stimulate amylase release, and does not inhibit the binding of radiolabeled vasoactive intestinal peptide to acini. This indicates that in dispersed pancreatic acini, exendin-4 interacts only with the recently described exendin receptor.	CUNY MT SINAI SCH MED,DEPT MED,NEW YORK,NY 10029; SUNY HLTH SCI CTR,DEPT MED,DIV DIGEST DIS,BROOKLYN,NY 11203	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	ENG, J (corresponding author), VET AFFAIRS MED CTR,SOLOMON A BERSON RES LAB,BRONX,NY 10468, USA.							BISSONNETTE BM, 1984, AM J PHYSIOL, V246, pG710, DOI 10.1152/ajpgi.1984.246.6.G710; CHRISTOPHE JP, 1976, J BIOL CHEM, V251, P4629; ENG J, 1990, J BIOL CHEM, V265, P20259; GARDNER JD, 1979, BIOCHIM BIOPHYS ACTA, V583, P491, DOI 10.1016/0304-4165(79)90066-7; HOSHINO M, 1984, FEBS LETT, V178, P233, DOI 10.1016/0014-5793(84)80607-9; MCARTHUR KE, 1987, AM J PHYSIOL, V252, pG404, DOI 10.1152/ajpgi.1987.252.3.G404; PARKER DS, 1984, J BIOL CHEM, V259, P1751; RAUFMAN JP, 1991, J BIOL CHEM, V266, P2897; ROBBERECHT P, 1976, J BIOL CHEM, V251, P4635; SCHILD HO, 1949, BRIT J PHARM CHEMOTH, V4, P277, DOI 10.1111/j.1476-5381.1949.tb00548.x	10	753	886	0	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7402	7405						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1313797				2022-12-27	WOS:A1992HN48500031
J	LIGGETT, SB; OSTROWSKI, J; CHESNUT, LC; KUROSE, H; RAYMOND, JR; CARON, MG; LEFKOWITZ, RJ				LIGGETT, SB; OSTROWSKI, J; CHESNUT, LC; KUROSE, H; RAYMOND, JR; CARON, MG; LEFKOWITZ, RJ			SITES IN THE 3RD INTRACELLULAR LOOP OF THE ALPHA-2A-ADRENERGIC RECEPTOR CONFER SHORT-TERM AGONIST-PROMOTED DESENSITIZATION - EVIDENCE FOR A RECEPTOR KINASE-MEDIATED MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; ALPHA-2-ADRENERGIC RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; DOWN-REGULATION; PHOSPHORYLATION SITES; ADENYLATE-CYCLASE; BINDING; CELLS; PATHWAYS; DELINEATION	To investigate the mechanisms of agonist-promoted desensitization of the alpha-2-adrenergic receptor (alpha-2AR), the human alpha(2A)AR and a mutated form of the receptor were expressed in CHW cells. After cells were exposed to epinephrine for 30 min, the ability of the wild type alpha(2A)AR to mediate inhibition of forskolin-stimulated adenylyl cyclase was depressed by approximately 78%. To assess the role of receptor phosphorylation during desensitization, cells were incubated With P-32(i) exposed to agonist, and alpha(2A)AR purified by immunoprecipitation with a fusion protein antibody. Agonist-promoted desensitization was found to be accompanied by phosphorylation of the alpha(2A)AR in vivo. The beta-adrenergic receptor kinase (beta-ARK) is known to phosphorylate purified alpha(2A)AR in vitro. We found that heparin, a beta-ARK inhibitor, ablated short term agonist-induced desensitization of alpha(2A)AR, while such desensitization was unaffected by inhibition of protein kinase A. To further assess the role of beta-ARK, we constructed a mutated alpha(2A)AR which has a portion of the third intracellular loop containing 9 serines and threonines (potential phosphorylation sites) deleted. This mutated alpha(2A)AR failed to undergo short term agonist-induced desensitization. Agonist promoted in vivo phosphorylation of this mutated receptor was reduced by 90%, consistent with the notion that receptor phosphorylation at sites in the third intracellular loop plays a critical role in alpha(2A)AR desensitization. After 24 h of agonist exposure, an even more profound desensitization of alpha(2A)AR occurred, which was not accompanied by a decrease in receptor expression. Rather, long term agonist-induced desensitization was found to be due in part to a decrease in the amount of cellular G(i), which was not dependent on receptor third loop phosphorylation sites.	DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PULM,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CARDIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT NEPHROL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Duke University; Duke University; Duke University	LIGGETT, SB (corresponding author), DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710, USA.		liggett, stephen b/E-7453-2012; Lefkowitz, Robert/AAW-2649-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL045967, R37HL016037, R01HL016037, R01HL045967] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45967, HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AARONS RD, 1983, J PHARMACOL EXP THER, V224, P1; BENOVIC JL, 1989, J BIOL CHEM, V264, P6707; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1985, J BIOL CHEM, V260, P7094; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BRODDE OE, 1982, EUR J CLIN PHARMACOL, V23, P403, DOI 10.1007/BF00605989; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; DOHLMAN HG, 1987, J BIOL CHEM, V262, P14282; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; GUYER CA, 1990, J BIOL CHEM, V265, P17307; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; INSEL PA, 1988, ALPHA 2 ADRENERGIC R, P281; JONES SB, 1990, J PHARMACOL EXP THER, V254, P294; KARLINER JS, 1982, MOL PHARMACOL, V21, P36; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; LIGGETT SB, 1989, MOL PHARMACOL, V36, P641; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; MCKERNAN RM, 1987, MOL PHARMACOL, V32, P258; MIKUNI M, 1983, EUR J PHARMACOL, V89, P313, DOI 10.1016/0014-2999(83)90513-7; MOTULSKY HJ, 1986, MOL PHARMACOL, V29, P1; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PARSONS WJ, 1987, J BIOL CHEM, V262, P841; RAYMOND JR, 1991, J BIOL CHEM, V266, P14747; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SNAVELY MD, 1983, ENDOCRINOLOGY, V113, P354, DOI 10.1210/endo-113-1-354; THOMAS JM, 1986, ENDOCRINOLOGY, V119, P1305, DOI 10.1210/endo-119-3-1305; VILLENEUVE A, 1985, J PHARMACOL EXP THER, V233, P433	30	127	131	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4740	4746						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1311318				2022-12-27	WOS:A1992HF64200069
J	FRIEDMAN, DL; ROBERTS, R				FRIEDMAN, DL; ROBERTS, R			PURIFICATION AND LOCALIZATION OF BRAIN-TYPE CREATINE-KINASE IN SODIUM-CHLORIDE TRANSPORTING EPITHELIA OF THE SPINY DOGFISH, SQUALUS-ACANTHIAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; RECTAL GLAND; SKELETAL-MUSCLE; PHOSPHOKINASE; ENERGY; SHUTTLE; METABOLISM; MECHANISM; SECRETION; MEMBRANE	The targeting of creatine kinase isoenzymes to specific sites within muscle cells provides a system for the regeneration of ATP in situ from ADP and creatine phosphate. We have recently reported the colocalization of brain-type (B) creatine kinase and the nonsarcomeric mitochondrial creatine kinase isoenzymes in the thick ascending limb of the loop of Henle in the rat kidney, suggesting that creatine kinase may regenerate ATP for sodium transport (Friedman, D. L., and Perryman, M. B. (1991) J. Biol. Chem. 266, 22404-22410). In order to test the hypothesis regarding the association of B creatine kinase with sodium transport, we examined the creatine kinase enzymes in the rectal (salt-secreting) gland of the dogfish shark which contains high levels of the Na+/K+-ATPase. The creatine kinase isoform composition was determined by nondenaturing electrophoresis, immunoblotting, protein purification, and amino acid sequence analysis. The results demonstrate both B creatine kinase and mitochondrial creatine kinase proteins are present in the rectal gland, an isoform composition which is the same as in the mammalian kidney. By using a combination of chromatographic techniques, shark B creatine kinase was purified to homogeneity and partial sequence data was obtained from two cyanogen bromide peptide fragments. One of these fragments contains the active site and is identical at all sequenced residues with the corresponding region from the echinoderm sperm flagellar creatine kinase, and is 96% homologous with both chicken and rat B creatine kinase subunits. The other fragment corresponds to a region near the N-terminal of mammalian creatine kinases and is 89% homologous with B creatine kinase from chicken. The localization of these isoforms was examined by immunocytochemistry using subunit specific antisera. Mitochondrial creatine kinase and B creatine kinase immunoreactivity are detected in all tubules, and is restricted to the basal region of the cells, which is the site of the Na+/K+-ATPase. The conservation of creatine kinase isoform expression in excretory tissue, and the localization of creatine kinase immunoreactivity in the basal region of the tubule cells, demonstrate that subcellular compartmentation of B creatine kinase may underlie the functional coupling of creatine kinase activity with sodium transport.			FRIEDMAN, DL (corresponding author), BAYLOR COLL MED,DEPT MED,MOLEC CARDIOL UNIT,ONE BAYLOR PL,RM 506C,HOUSTON,TX 77030, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042267] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50-HL-42267] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASKIN RJ, 1970, J BIOL CHEM, V245, P1345; BASTIN J, 1987, KIDNEY INT, V31, P1239, DOI 10.1038/ki.1987.137; BENFIELD PA, 1985, GENE, V39, P263, DOI 10.1016/0378-1119(85)90321-X; BESSMAN SP, 1972, ISRAEL J MED SCI, V8, P344; BESSMAN SP, 1985, ANNU REV BIOCHEM, V54, P831, DOI 10.1146/annurev.bi.54.070185.004151; BONTING SL, 1966, COMP BIOCHEM PHYSIOL, V17, P953, DOI 10.1016/0010-406X(66)90134-4; BULGER RE, 1963, ANAT REC, V147, P95, DOI 10.1002/ar.1091470108; BURGER JW, 1965, PHYSIOL ZOOL, V38, P191, DOI 10.1086/physzool.38.3.30152829; Epstein F.H., 1982, Bulletin of the Mount Desert Island Biological Laboratory, V21, P14; EPSTEIN FH, 1983, J EXP BIOL, V106, P25; EVERLOFF J, 1978, PFLUEGERS ARCH, V378, P87; FRIEDMAN DL, 1991, J BIOL CHEM, V266, P22404; HOKIN LE, 1973, J BIOL CHEM, V248, P2593; HOSSLE JP, 1986, NUCLEIC ACIDS RES, V14, P1449, DOI 10.1093/nar/14.3.1449; JACOBUS WE, 1973, J BIOL CHEM, V248, P4803; LEVITSKY DO, 1978, MEMBRANE BIOCHEM, V2, P81, DOI 10.3109/09687687809063859; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OTTAWAY JH, 1967, NATURE, V215, P521, DOI 10.1038/215521b0; PAUL RJ, 1983, AM J PHYSIOL, V244, pC399, DOI 10.1152/ajpcell.1983.244.5.C399; PERRYMAN MB, 1985, J BIOL CHEM, V260, P9399; ROSSI AM, 1990, J BIOL CHEM, V265, P5258; SAKS VA, 1978, CAN J PHYSIOL PHARM, V56, P691, DOI 10.1139/y78-113; SAKS VA, 1977, BIOCHIM BIOPHYS ACTA, V465, P550, DOI 10.1016/0005-2736(77)90272-3; SAVABI F, 1983, BIOCHEM BIOPH RES CO, V114, P785, DOI 10.1016/0006-291X(83)90850-1; SCHOLTE HR, 1973, BIOCHIM BIOPHYS ACTA, V291, P764, DOI 10.1016/0005-2736(73)90479-3; SHAROV VG, 1977, BIOCHIM BIOPHYS ACTA, V468, P495, DOI 10.1016/0005-2736(77)90299-1; SILVA P, 1977, AM J PHYSIOL, V233, pF298, DOI 10.1152/ajprenal.1977.233.4.F298; TOMBES RM, 1985, CELL, V41, P325, DOI 10.1016/0092-8674(85)90085-6; TURNER DC, 1973, P NATL ACAD SCI USA, V70, P702, DOI 10.1073/pnas.70.3.702; WALLIMANN T, 1977, J CELL BIOL, V75, P297, DOI 10.1083/jcb.75.2.297; WOTHE DD, 1990, P NATL ACAD SCI USA, V87, P5203, DOI 10.1073/pnas.87.13.5203; ZELEZNIKAR RJ, 1991, J BIOL CHEM, V266, P15110	32	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4270	4276						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1310991				2022-12-27	WOS:A1992HE60700100
J	LU, XP; KOCH, KS; LEW, DJ; DULIC, V; PINES, J; REED, SI; HUNTER, T; LEFFERT, HL				LU, XP; KOCH, KS; LEW, DJ; DULIC, V; PINES, J; REED, SI; HUNTER, T; LEFFERT, HL			INDUCTION OF CYCLIN MESSENGER-RNA AND CYCLIN-ASSOCIATED HISTONE-H1 KINASE DURING LIVER-REGENERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ADULT-RAT-HEPATOCYTES; CELL-CYCLE; HORMONAL-CONTROL; GROWTH-CONTROL; EXPRESSION; CULTURES; PHASE; YEAST; GENE	Cyclins and cyclin-associated cdc kinases are key regulators of oocyte maturation (Maller, J. L. (1990) in The Biology and Medicine of Signal Transduction (Nishizuka, Y., Endo, M., and Tanaka, C., eds) pp. 323-328, Raven Press, New York), yeast cell cycles (Nurse, P. (1990) Nature 344, 503-508), DNA replication in cell-free systems (D'Urso, F., Marraccino, R. L., Marshak, R. R., and Roberts, J. M. (1990) Science 250, 786-791), and amphibian cell proliferative transitions (Hunt, T. (1991) Nature 350, 462-463). The extent to which these regulatory molecules participate in the growth control of differentiated epithelial cells like hepatocytes is unknown. Therefore, we investigated the expression of ''G1'' (E, C, and D) and ''G2/M'' (A, B1, and B2) cyclin mRNAs, the relative levels of cyclin A- and B1-associated histone H1-kinase activity, and the appearance of cyclin-associated kinases (p32/p33cdk2 and p33/p34cdc2) in regenerating rat liver and in control tissues from sham hepatectomized rats. To do this, we exploited a battery of human cyclin cDNAs and cyclin antisera that recognize rat molecules. The results suggest an apparent sequence of regeneration-specific changes: 1) elevated and induced expression of cyclins E (2.1 kilobases (kb)) and C (4 kb), and D mRNAs (4 kb), within 12 h, respectively; 2) induction of cyclins A (3.4 and 1.8 kb), B1 (2.5 and 1.8 kb), and B2 (1.9 kb) mRNAs at 24 h; 3) induction of cyclin A- and B1-associated nuclear histone H1 kinase at 24 h; and 4) enhanced levels of PSTAIRE-containing proteins of M(r) approximately 32-33 and 33-34 kDa in nuclear extracts from 24-h regenerating liver that co-immunoprecipitate with cyclin A and B1 antisera, respectively. These observations provide an intellectual framework that unifies the biology of hepatocyte mitogenesis, proto-oncogene expression, and the machinery of the cell cycle.	UNIV CALIF SAN DIEGO, SCH MED, DEPT PHARMACOL, MAIL CODE 0636, LA JOLLA, CA 92093 USA; Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; SALK INST BIOL STUDIES, MOLEC BIOL & VIROL LAB, SAN DIEGO, CA 92186 USA; UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; Scripps Research Institute; Salk Institute; University of California System; University of California San Diego				Dulic, Vjekoslav/0000-0003-1201-3901; Pines, Jonathon/0000-0002-5227-6004				BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRENNER DA, 1989, DNA-J MOLEC CELL BIO, V8, P279, DOI 10.1089/dna.1.1989.8.279; BUCHER NLR, 1978, CIBA F S, V55, P95; BUCHER NLR, 1971, NEW ENGL J MED, P1; CHAMBERS TC, 1990, J BIOL CHEM, V265, P16940; DEHEMPTINNE B, 1983, ENDOCRINOLOGY, V112, P1224, DOI 10.1210/endo-112-4-1224; HARTWELL LH, 1974, BACTERIOL REV, V38, P164, DOI 10.1128/MMBR.38.2.164-198.1974; HUNT T, 1991, NATURE, V350, P462, DOI 10.1038/350462a0; Koch K S, 1980, Ann N Y Acad Sci, V349, P111, DOI 10.1111/j.1749-6632.1980.tb29520.x; KOCH KS, 1990, IN VITRO CELL DEV B, V26, P1011; KOCH KS, 1979, CELL, V18, P153, DOI 10.1016/0092-8674(79)90364-7; KRUIJER W, 1986, J BIOL CHEM, V261, P7929; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEFFERT H, 1975, P NATL ACAD SCI USA, V72, P4033, DOI 10.1073/pnas.72.10.4033; LEFFERT HL, 1979, GASTROENTEROLOGY, V76, P1470; LEFFERT HL, 1974, J CELL BIOL, V62, P792, DOI 10.1083/jcb.62.3.792; LEFFERT HL, 1988, LIVER BIOL PATHOBIOL, P833; LEFFERT HL, 1977, GROWTH NUTRITION MET, P225; LEFFERT HL, 1982, COLD SPRING HARBOR C, V9, P597; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LU XP, 1991, J BIOL CHEM, V266, P9276; MALLER JL, 1990, ADV SEC MESS PHOSPH, V24, P323; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WHITFIELD JF, 1987, CANCER METAST REV, V5, P205, DOI 10.1007/BF00046999	33	91	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					2841	2844						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1310673				2022-12-27	WOS:A1992HD15400002
J	MAENHAUT, C; BRABANT, G; VASSART, G; DUMONT, JE				MAENHAUT, C; BRABANT, G; VASSART, G; DUMONT, JE			INVITRO AND INVIVO REGULATION OF THYROTROPIN RECEPTOR MESSENGER-RNA LEVELS IN DOG AND HUMAN THYROID-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROGLOBULIN GENE-EXPRESSION; EPIDERMAL GROWTH-FACTOR; BETA-ADRENERGIC RECEPTORS; STEADY-STATE LEVELS; CYCLIC-AMP; RIBONUCLEIC-ACID; MOLECULAR-CLONING; DIFFERENTIATION EXPRESSION; FUNCTIONAL EXPRESSION; EPITHELIAL-CELLS	Regulation of thyrotropin (TSH) receptor (TSHr) mRNA accumulation as compared with two other thyroid differentiation markers (thyroglobulin and thyroperoxidase (TPO)) has been investigated by Northern blot. In dogs in vivo, chronic stimulation of the thyroid by treatment with antithyroid drugs did not modify TSHr mRNA although it increased the levels of thyroglobulin and TPO mRNA. In dogs treated with thyroxin, the quiescent thyroids expressed normal levels of TSHr and TPO mRNA but depressed levels of thyroglobulin mRNA. In primary cultures of dog thyrocytes, dedifferentiation of the cells by treatment with epidermal growth factor or 12-O-tetradecanoylphorbol-13-acetate led to decreased TSHr mRNA levels and nearly abolished thyroglobulin and TPO gene expression. However, TSHr mRNA was always present, compatible with the fact that these cells, when treated by TSH, reexpress differentiation. Treatment of the cells with TSH or forskolin transiently increased the TSHr mRNA level after 20 h, an effect inhibited by cycloheximide. This up-regulation was confirmed at the protein level: forskolin-treated cells showed an enhanced cAMP response to TSH and an increased binding of labeled TSH to their membranes. Long term TSH treatment led to a slight down-regulation of TSHr mRNA in dog thyrocytes, but in human thyroid cells no marked down-regulation was observed.	UNIV LIBRE BRUXELLES,DEPT GENET,B-1070 BRUSSELS,BELGIUM; HANNOVER MED SCH,DEPT CLIN ENDOCRINOL,W-3000 HANNOVER 61,GERMANY	Universite Libre de Bruxelles; Hannover Medical School	MAENHAUT, C (corresponding author), UNIV LIBRE BRUXELLES,INST RECH INTERDISCIPLINAIRE,CAMPUS ERASME,808 ROUTE DE LENNIK,B-1070 BRUSSELS,BELGIUM.							AKAMIZU T, 1990, P NATL ACAD SCI USA, V87, P5677, DOI 10.1073/pnas.87.15.5677; AOUANI A, 1987, MOL CELL ENDOCRINOL, V52, P151, DOI 10.1016/0303-7207(87)90108-0; AVVEDIMENTO VE, 1984, BIOCHEM BIOPH RES CO, V122, P472; BERTHOIS Y, 1990, MOL CELL ENDOCRINOL, V74, P11, DOI 10.1016/0303-7207(90)90201-I; BONE E, 1986, BIOCHEM BIOPH RES CO, V141, P1261, DOI 10.1016/S0006-291X(86)80181-4; Brooker G, 1979, Adv Cyclic Nucleotide Res, V10, P1; CHAZENBALK G, 1987, MOL ENDOCRINOL, V1, P913, DOI 10.1210/mend-1-12-913; CHAZENBALK GD, 1990, ENDOCRINOLOGY, V127, P1240, DOI 10.1210/endo-127-3-1240; CHEBATH J, 1977, BIOCHEM BIOPH RES CO, V79, P267, DOI 10.1016/0006-291X(77)90090-0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COCLET J, 1989, CLIN ENDOCRINOL, V31, P655, DOI 10.1111/j.1365-2265.1989.tb01290.x; COLLINS S, 1990, J BIOL CHEM, V265, P19330; COLLINS S, 1989, P NATL ACAD SCI USA, V86, P4853, DOI 10.1073/pnas.86.13.4853; COLLISON KS, 1989, J MOL ENDOCRINOL, V3, P1, DOI 10.1677/jme.0.0030001; DAMANTE G, 1989, ENDOCRINOLOGY, V124, P2889, DOI 10.1210/endo-124-6-2889; DAVIES TF, 1985, ENDOCRINOLOGY, V117, P201, DOI 10.1210/endo-117-1-201; DELBEKE D, 1982, METABOLISM, V31, P797, DOI 10.1016/0026-0495(82)90078-6; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; Dumont J E, 1971, Vitam Horm, V29, P287; DUMONT JE, 1981, ADV CYCL NUCL RES<D>, V14, P479; DUMONT JE, 1987, ENDOCR REV, V8, P448, DOI 10.1210/edrv-8-4-448; EARP HS, 1988, J BIOL CHEM, V263, P13868; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GERARD CM, 1989, MOL ENDOCRINOL, V3, P2110, DOI 10.1210/mend-3-12-2110; GERARD CM, 1989, MOL CELL ENDOCRINOL, V61, P23, DOI 10.1016/0303-7207(89)90186-X; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P8415, DOI 10.1073/pnas.85.22.8415; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P5021, DOI 10.1073/pnas.85.14.5021; Ingbar SH, 1986, THYROID, P53; ISOZAKI O, 1989, MOL ENDOCRINOL, V3, P1681, DOI 10.1210/mend-3-11-1681; IZZO NJ, 1990, P NATL ACAD SCI USA, V87, P6268, DOI 10.1073/pnas.87.16.6268; KIMURA S, 1987, P NATL ACAD SCI USA, V84, P5555, DOI 10.1073/pnas.84.16.5555; LEE NT, 1989, J BIOL CHEM, V264, P7523; LIBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250, DOI 10.1016/0006-291X(89)92736-8; MACIEL RMB, 1988, J CLIN INVEST, V82, P1546, DOI 10.1172/JCI113764; MAENHAUT C, 1990, HORM METAB RES, V23, P51; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MULLIS PE, 1991, MOL CELL ENDOCRINOL, V76, P125, DOI 10.1016/0303-7207(91)90267-V; NAGAYAMA Y, 1989, J CLIN ENDOCR METAB, V68, P1155, DOI 10.1210/jcem-68-6-1155; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; NAGAYAMA Y, 1990, J CLIN ENDOCR METAB, V71, P384, DOI 10.1210/jcem-71-2-384; OHTA K, 1991, BIOCHEM BIOPH RES CO, V174, P1148, DOI 10.1016/0006-291X(91)91540-S; ORON Y, 1987, SCIENCE, V238, P1406, DOI 10.1126/science.2825350; OSSENDORP FA, 1990, ENDOCRINOLOGY, V127, P419, DOI 10.1210/endo-127-1-419; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; PENHOAT A, 1989, P NATL ACAD SCI USA, V86, P4978, DOI 10.1073/pnas.86.13.4978; POHL V, 1990, J CELL BIOL, V111, P663, DOI 10.1083/jcb.111.2.663; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROGER P, 1988, J CLIN ENDOCR METAB, V66, P1158, DOI 10.1210/jcem-66-6-1158; ROGER PP, 1985, EUR J BIOCHEM, V152, P239, DOI 10.1111/j.1432-1033.1985.tb09189.x; ROGER PP, 1986, CANCER RES, V46, P898; ROGER PP, 1987, J CELL PHYSIOL, V130, P58, DOI 10.1002/jcp.1041300110; ROGER PP, 1984, MOL CELL ENDOCRINOL, V36, P79, DOI 10.1016/0303-7207(84)90087-X; ROGER PP, 1982, MOL CELL ENDOCRINOL, V26, P165, DOI 10.1016/0303-7207(82)90014-4; SANTISTEBAN P, 1987, J BIOL CHEM, V262, P4048; SAUNIER B, 1990, J BIOL CHEM, V265, P19942; SCHUMAN SJ, 1976, J CLIN INVEST, V57, P1132; TAKASU N, 1977, FEBS LETT, V84, P191, DOI 10.1016/0014-5793(77)81087-9; TASKEN KA, 1991, MOL ENDOCRINOL, V5, P21, DOI 10.1210/mend-5-1-21; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VANHEUVERSWYN B, 1984, P NATL ACAD SCI-BIOL, V81, P5941; VANHEUVERSWYN B, 1985, FEBS LETT, V188, P192, DOI 10.1016/0014-5793(85)80370-7; VASSART G, 1977, FEBS LETT, V79, P15, DOI 10.1016/0014-5793(77)80340-2; WANG H, 1991, J BIOL CHEM, V266, P780; WEINTRAUB BD, 1982, ANN INTERN MED, V95, P393; WILKIN TJ, 1979, BRIT MED J, V1, P188; ZARRILLI R, 1990, MOL ENDOCRINOL, V4, P39, DOI 10.1210/mend-4-1-39	66	74	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3000	3007						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1310679				2022-12-27	WOS:A1992HD15400031
J	BEDGOOD, RM; STALLCUP, MR				BEDGOOD, RM; STALLCUP, MR			A NOVEL INTERMEDIATE IN PROCESSING OF MURINE LEUKEMIA-VIRUS ENVELOPE GLYCOPROTEINS - PROTEOLYTIC CLEAVAGE IN THE LATE GOLGI REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; MEMBRANE-GLYCOPROTEINS; MAMMALIAN-CELLS; ENDOPROTEOLYTIC CLEAVAGE; SUBCELLULAR ORGANIZATION; PROTEIN; GLYCOSYLATION; MATURATION; TRANSPORT; BIOSYNTHESIS	The intracellular processing of the murine leukemia virus envelope glycoprotein precursor Pr85 to the mature products gp70 and p15e was analyzed in the mouse T-lymphoma cell line W7MG1. Kinetic (pulse-chase) analysis of synthesis and processing, coupled with endoglycosidase (endo H) and neuraminidase digestions revealed the existence of a novel high molecular weight processing intermediate, gp95, containing endo H-resistant terminally glycosylated oligosaccharide chains. In contrast to previously published conclusions, our data indicate that proteolytic cleavage of the envelope precursor occurs after the acquisition of endo H-resistant chains and terminal glycosylation and thus after the mannosidase II step. In the same W7MG1 cell line, the type and order of murine leukemia virus envelope protein processing events was identical to that for the mouse mammary tumor virus envelope protein. Interestingly, complete mouse mammary tumor virus envelope protein processing requires the addition of glucocorticoid hormone, whereas murine leukemia virus envelope protein processing occurs constitutively in these W7MG1 cells. We propose that all retroviral envelope proteins share a common processing pathway in which proteolytic processing is a late event that follows acquisition of endo H resistance and terminal glycosylation.	UNIV SO CALIF,HLTH SCI CTR,DEPT PATHOL,HMR 301,2011 ZONAL AVE,LOS ANGELES,CA 90033; UNIV SO CALIF,HLTH SCI CTR,DEPT BIOCHEM,LOS ANGELES,CA 90033	University of Southern California; University of Southern California								BENTLEY AK, 1986, CELL, V45, P343, DOI 10.1016/0092-8674(86)90319-3; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; COREY JL, 1990, CELL REGUL, V1, P531, DOI 10.1091/mbc.1.7.531; COREY JL, 1992, IN PRESS MOL ENDOCRI; DANIELSEN M, 1983, MOL CELL BIOL, V3, P1310, DOI 10.1128/MCB.3.7.1310; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DICKSON C, 1983, MOUSE MAMMARY TUMOR, P1; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FIRESTONE GL, 1982, NATURE, V300, P221, DOI 10.1038/300221a0; FITTING T, 1982, J BIOL CHEM, V257, P4011; FREEDMAN RB, 1984, TRENDS BIOCHEM SCI, V9, P438, DOI 10.1016/0968-0004(84)90152-X; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; IKUTA K, 1986, VIROLOGY, V154, P195, DOI 10.1016/0042-6822(86)90441-1; KARSHIN WL, 1977, J VIROL, V23, P787, DOI 10.1128/JVI.23.3.787-798.1977; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LINGAPPA VR, 1989, J CLIN INVEST, V83, P739, DOI 10.1172/JCI113952; MACHIDA CA, 1982, J BIOL CHEM, V257, P4018; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; PAYNE GS, 1989, SCIENCE, V245, P1358, DOI 10.1126/science.2675311; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PEREZ LG, 1987, J VIROL, V61, P1609, DOI 10.1128/JVI.61.5.1609-1614.1987; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; POLONOFF E, 1982, J BIOL CHEM, V257, P4023; RABINDRAN SK, 1987, MOL ENDOCRINOL, V1, P491, DOI 10.1210/mend-1-7-491; RABINDRAN SK, 1987, SOMAT CELL MOLEC GEN, V13, P131, DOI 10.1007/BF01534693; ROBBINS PW, 1977, CELL, V12, P893, DOI 10.1016/0092-8674(77)90153-2; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; ROTHMAN JE, 1977, NATURE, V269, P775, DOI 10.1038/269775a0; SCHLESINGER MJ, 1987, ADV VIRUS RES, V33, P1, DOI 10.1016/S0065-3527(08)60315-2; SCHMIDT MFG, 1979, CELL, V17, P813, DOI 10.1016/0092-8674(79)90321-0; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMITH AI, 1988, ENDOCR REV, V9, P159, DOI 10.1210/edrv-9-1-159; SNIDER LD, 1990, MOL ENDOCRINOL, V4, P749, DOI 10.1210/mend-4-5-749; STEIN BS, 1990, J BIOL CHEM, V265, P2640; STRAUSS JH, 1986, POSITIVE STRAND RNA, P209; THOMAS G, 1986, SCIENCE, V232, P1641, DOI 10.1126/science.3754979; THOMAS G, 1988, SCIENCE, V241, P226, DOI 10.1126/science.3291117; TSAI WP, 1988, J VIROL, V62, P3167, DOI 10.1128/JVI.62.9.3167-3174.1988; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULMER JB, 1991, J BIOL CHEM, V266, P9173; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WILLEY RL, 1988, P NATL ACAD SCI USA, V85, P9580, DOI 10.1073/pnas.85.24.9580; WILLS JW, 1984, J CELL BIOL, V99, P2011, DOI 10.1083/jcb.99.6.2011	49	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					7060	7065						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1313032				2022-12-27	WOS:A1992HM05300092
J	DEUTSCH, PJ; SUN, Y				DEUTSCH, PJ; SUN, Y			THE 38-AMINO ACID FORM OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE STIMULATES DUAL SIGNALING CASCADES IN PC12 CELLS AND PROMOTES NEURITE OUTGROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; PROTEIN KINASE-C; VASOACTIVE INTESTINAL POLYPEPTIDE; SUPERIOR CERVICAL-GANGLION; PHEOCHROMOCYTOMA CELLS; MORPHOLOGICAL-DIFFERENTIATION; CATECHOLAMINE SECRETION; BINDING-SITES; TUMOR CELLS; CYCLIC-AMP	Vasoactive intestinal peptide (VIP) activates adenylylcyclase in sympathoadrenal cells at concentrations > 10(-6) M. We demonstrate here that two forms of a newly discovered peptide with homology to VIP named pituitary adenylate cyclase-activating polypeptide (PACAP) are much more potent activators of signal transduction in PC12 cells. Both the 27- and 38-amino acid forms of PACAP elevate cAMP levels in PC12 cells and stimulate adenylylcyclase in PC12 membranes, with an EC50 near 10(-9) M. PACAP38 additionally is a potent activator of the inositol lipid cascade in PC12 cells, elevating the content of inositol phosphates by 8-fold at 10(-8) M (EC50 = 7 x 10(-9) M). PACAP38 and PACAP27 have been thought to have essentially identical actions, but PACAP27 is 2-3 logs less potent in increasing inositol lipid levels. Moreover, PACAP38 at 10(-8) M is an effective inducer of neuronal morphology in PC12 cells, whereas PACAP27 is much less active in promoting neurite outgrowth. In contrast to the PACAP-preferring receptors on PC 12 cells, another class of PACAP-binding sites with equal high affinities for VIP, PACAP38, and PACAP27 has been identified on several other cell types. We find that the cAMP content of rat CH3 pituitary cells, known to have high affinity VIP receptors, is in fact potently elevated by PACAP27 and PACAP38 as well as by VIP. However, PACAP38, even at 10(-6) M, is not capable of significant activation of inositol lipid turnover via these VIP/PACAP nondiscriminating sites.	CORNELL UNIV,MED CTR,COLL MED,PROGRAM CELL BIOL & GENET,NEW YORK,NY 10021	Cornell University	DEUTSCH, PJ (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DEPT MED,DIV ENDOCRINOL & METAB,NEW YORK,NY 10021, USA.				NCRR NIH HHS [SO7-RR05396] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005396] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALBERT PR, 1990, J BIOL CHEM, V265, P2098; AUDIGIER S, 1986, BRAIN RES, V376, P363, DOI 10.1016/0006-8993(86)90200-3; BURSTEIN DE, 1982, BRAIN RES, V247, P115, DOI 10.1016/0006-8993(82)91033-2; BUSCAIL L, 1990, FEBS LETT, V262, P77, DOI 10.1016/0014-5793(90)80158-F; CAUVIN A, 1991, PEPTIDES, V12, P139, DOI 10.1016/0196-9781(91)90180-W; CUBITT AB, 1990, J BIOL CHEM, V265, P9707; DAMON DH, 1990, J CELL BIOL, V110, P1333, DOI 10.1083/jcb.110.4.1333; DEUTSCH PJ, 1990, J BIOL CHEM, V265, P10274; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; GLOWACKA D, 1990, J NEUROSCI RES, V25, P453, DOI 10.1002/jnr.490250403; GOTTSCHALL PE, 1990, ENDOCRINOLOGY, V127, P272, DOI 10.1210/endo-127-1-272; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GREENE LA, 1979, SOC NEUROSCIENCE S, V4, P153; GUNNING PW, 1981, J CELL BIOL, V89, P240, DOI 10.1083/jcb.89.2.240; HALL FL, 1988, J BIOL CHEM, V263, P4460; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; HOUCHI H, 1987, BIOCHEM PHARMACOL, V36, P1551, DOI 10.1016/0006-2952(87)90125-0; IP NY, 1982, P NATL ACAD SCI-BIOL, V79, P7566, DOI 10.1073/pnas.79.23.7566; KIM UH, 1991, J BIOL CHEM, V266, P1359; KIMURA C, 1990, BIOCHEM BIOPH RES CO, V166, P81, DOI 10.1016/0006-291X(90)91914-E; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; MALHOTRA RK, 1989, J NEUROSCI, V9, P4150; MALHOTRA RK, 1988, J BIOL CHEM, V263, P2123; MARTIN TFJ, 1983, J BIOL CHEM, V258, P4816; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MIYATA A, 1990, BIOCHEM BIOPH RES CO, V170, P643, DOI 10.1016/0006-291X(90)92140-U; MONACO ME, 1987, J BIOL CHEM, V262, P13001; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OGI K, 1990, BIOCHEM BIOPH RES CO, V173, P1271, DOI 10.1016/S0006-291X(05)80924-6; OHTAKI T, 1990, BIOCHEM BIOPH RES CO, V171, P838, DOI 10.1016/0006-291X(90)91222-E; PINCUS DW, 1990, BRAIN RES, V514, P355, DOI 10.1016/0006-8993(90)91433-H; PINCUS DW, 1990, NATURE, V343, P564, DOI 10.1038/343564a0; RICHTERLANDSBERG C, 1986, J CELL BIOL, V102, P821, DOI 10.1083/jcb.102.3.821; ROBBERECHT P, 1991, FEBS LETT, V286, P133, DOI 10.1016/0014-5793(91)80958-6; ROBBERECHT P, 1991, AM J PHYSIOL, V260, pG97, DOI 10.1152/ajpgi.1991.260.1.G97; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SANDQUIST D, 1978, EXP CELL RES, V113, P375, DOI 10.1016/0014-4827(78)90378-6; SCHUBERT D, 1978, NATURE, V273, P718, DOI 10.1038/273718a0; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHIVERS BD, 1991, ENDOCRINOLOGY, V128, P3055, DOI 10.1210/endo-128-6-3055; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SREEDHARAN SP, 1991, P NATL ACAD SCI USA, V88, P4986, DOI 10.1073/pnas.88.11.4986; SUDA K, 1991, J CLIN ENDOCR METAB, V72, P958, DOI 10.1210/jcem-72-5-958; TATSUNO I, 1990, BIOCHEM BIOPH RES CO, V168, P1027, DOI 10.1016/0006-291X(90)91132-C; TATSUNO I, 1991, ENDOCRINOLOGY, V128, P728, DOI 10.1210/endo-128-2-728; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TISCHLER AS, 1985, NEUROSCI LETT, V61, P141, DOI 10.1016/0304-3940(85)90415-X; VANSANDE J, 1990, MOL CELL ENDOCRINOL, V74, pR1, DOI 10.1016/0303-7207(90)90209-Q; WATANABE T, 1990, BIOCHEM BIOPH RES CO, V173, P252, DOI 10.1016/S0006-291X(05)81049-6; WONG SKF, 1990, J BIOL CHEM, V265, P6219; WOOD CL, 1985, REGUL PEPTIDES, V12, P237, DOI 10.1016/0167-0115(85)90065-5	51	345	352	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5108	5113						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1312085				2022-12-27	WOS:A1992HH74700019
J	HARTMAN, DA; KUO, SR; BROKER, TR; CHOW, LT; WELLS, RD				HARTMAN, DA; KUO, SR; BROKER, TR; CHOW, LT; WELLS, RD			INTERMOLECULAR TRIPLEX FORMATION DISTORTS THE DNA DUPLEX IN THE REGULATORY REGION OF HUMAN PAPILLOMAVIRUS TYPE-11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX FORMATION; E2 PROTEINS; BOX REGION; PLASMIDS; SEQUENCE; ENHANCER; CONFORMATION; INHIBITION; PROMOTER; DYNAMICS	A conformational distortion in the DNA duplex at the regulatory region of human papillomavirus type-11 next to an intermolecular triplex, formed with a synthetic oligonucleotide, was investigated with several chemical probes. The sequence targeted for triplex formation borders on the binding sites for the regulatory proteins encoded by the viral E2 open reading frame. Dimethyl sulfate, diethyl pyrocarbonate, and OsO4 all react to a greater extent with nucleotides in the duplex that are immediately adjacent to the triplex as compared to other bases throughout the duplex. This hypermodification was observed on both the polypurine and polypyrimidine strands of the duplex DNA. Similar hyperreactivity of bases flanking a triplex also was seen when the contiguous target polypurine tract was effectively extended by mutating interrupting pyrimidines in the human papillomavirus type-11 sequence to purines. We propose that this hyperreactivity is due to a structural distortion caused by the junction between the triplex and the duplex tracts.	UNIV ALABAMA,SCH DENT,BIRMINGHAM,AL 35294; UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642; TEXAS A&M UNIV SYST,INST BIOSCI & TECHNOL,COLLEGE STN,TX 77843	University of Alabama System; University of Alabama Birmingham; University of Rochester; Texas A&M University System; Texas A&M University College Station	HARTMAN, DA (corresponding author), UNIV ALABAMA,SCH MED,DEPT BIOCHEM,BIRMINGHAM,AL 35294, USA.				NCI NIH HHS [CA36200] Funding Source: Medline; NIAID NIH HHS [AI07150] Funding Source: Medline; NIGMS NIH HHS [GM 30822] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007150] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030822] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOTT S, 1974, J MOL BIOL, V88, P509, DOI 10.1016/0022-2836(74)90498-7; ARNOTT S, 1976, NUCLEIC ACIDS RES, V3, P2459, DOI 10.1093/nar/3.10.2459; BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; CHIANG CM, 1991, J VIROL, V65, P3317, DOI 10.1128/JVI.65.6.3317-3329.1991; CHIN MT, 1988, J VIROL, V62, P2994, DOI 10.1128/JVI.62.8.2994-3002.1988; CHIN MT, 1989, J VIROL, V63, P2967, DOI 10.1128/JVI.63.7.2967-2976.1989; COLLIER DA, 1990, J BIOL CHEM, V265, P10652; COLLIER DA, 1991, J AM CHEM SOC, V113, P1457, DOI 10.1021/ja00004a081; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DELOSSANTOS C, 1989, BIOCHEMISTRY-US, V28, P7282, DOI 10.1021/bi00444a021; DERVAN PB, 1989, OLIGODEOXYNUCLEOTIDE, P197; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; FURLONG JC, 1986, NUCLEIC ACIDS RES, V14, P3995, DOI 10.1093/nar/14.10.3995; GLOSS B, 1990, J VIROL, V64, P5577, DOI 10.1128/JVI.64.11.5577-5584.1990; GRIFFIN LC, 1989, SCIENCE, V245, P967, DOI 10.1126/science.2549639; HANVEY JC, 1990, NUCLEIC ACIDS RES, V18, P157, DOI 10.1093/nar/18.1.157; HANVEY JC, 1988, J BIOL CHEM, V263, P7386; HANVEY JC, 1989, J BIOL CHEM, V264, P5950; HELENE C, 1990, STRUCTURE METHODS, V1, P51; HIROCHIKA H, 1988, GENE DEV, V2, P54, DOI 10.1101/gad.2.1.54; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; LYAMICHEV VI, 1990, NATURE, V344, P568, DOI 10.1038/344568a0; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MAYER LJ, 1989, SCIENCE, V245, P725; PATEL DJ, 1985, BIOCHEMISTRY-US, V24, P936, DOI 10.1021/bi00325a019; PATEL DJ, 1985, BIOCHEMISTRY-US, V24, P926, DOI 10.1021/bi00325a018; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; RAJAGOPAL P, 1989, BIOCHEMISTRY-US, V28, P7859, DOI 10.1021/bi00445a048; RAJAGOPALAN M, 1990, J BIOL CHEM, V265, P17294; SAMBROOK J, 1989, MOL CLONING LABORATO, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELSING E, 1979, J BIOL CHEM, V254, P5417; SELSING E, 1979, J BIOL CHEM, V254, P5410; SULLIVAN JK, 1991, BIOCHEMISTRY-US, V30, P2664, DOI 10.1021/bi00224a015; USTAV M, 1991, EMBO J, V10, P4321, DOI 10.1002/j.1460-2075.1991.tb05010.x; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; Wells RD, 1987, UNUSUAL DNA STRUCTUR; WILSON VG, 1991, J VIROL, V65, P5314, DOI 10.1128/JVI.65.10.5314-5322.1991; WILSON WD, 1987, NUCLEIC ACIDS RES, V15, P105, DOI 10.1093/nar/15.1.105; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	41	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5488	5494						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1312091				2022-12-27	WOS:A1992HH74700074
J	GUDERMANN, T; BIRNBAUMER, M; BIRNBAUMER, L				GUDERMANN, T; BIRNBAUMER, M; BIRNBAUMER, L			EVIDENCE FOR DUAL COUPLING OF THE MURINE LUTEINIZING-HORMONE RECEPTOR TO ADENYLYL CYCLASE AND PHOSPHOINOSITIDE BREAKDOWN AND CA2+ MOBILIZATION - STUDIES WITH THE CLONED MURINE LUTEINIZING-HORMONE RECEPTOR EXPRESSED IN L-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; HUMAN CHORIO-GONADOTROPIN; CYTOSOLIC-FREE CA-2+; N-COMPONENT ACTIVITY; RAT GRANULOSA-CELLS; MOLECULAR-CLONING; INOSITOL TRISPHOSPHATE; ALPHA-SUBUNIT; CYCLIC-AMP; CDNA	The murine receptor for luteinizing hormone (LHR) was cloned and expressed in L cells. This LHR (mature protein of 674 amino acids) is very similar to that of the rat (same length, 36 amino acid differences) but differs significantly more from that of man (673 amino acids, 109 differences). Expression of the murine LHR in L cells led to the appearance of binding sites for human chorionic gonadotropin (hCG) with a K(d) of 150 pm and an LH- and hCG-stimulable adenylyl cyclase activity (EC50 = 50-100 pM hCG). Upon labeling pools of phosphoinositides with [H-3]myo-inositol, L cells expressing the murine LHR responded to hCG with an increase in their rate of phosphoinositide hydrolysis (EC50 = 2,400 pM hCG). This was accompanied by an increase in intracellular Ca2+ ([Ca2+]i), as determined by the Fura2 method. This increase in [Ca2+]i in response to hCG was dependent on the LHR, for HCG did not affect [Ca2+]i in L cells not expressing the LHR. The effect was not due to the cAMP-forming activity of the LH receptor, for neither forskolin nor prostaglandin E1, which both increase cAMP levels in L cells, had a similar effect in either control or LHR-expressing cells and isoproterenol had no effect in L cells expressing a functionally active hamster beta-adrenergic receptor. The effect was also not due to overexpression of a G(s)-coupled receptor, for L cells expressing 8-fold higher levels of the human V2 vasopressin receptor did not mimic the Ca2+-mobilizing response of the LH receptor. We conclude that the LH receptor has the capability of activating two intracellular signaling pathways: one leading to stimulation of adenylyl cyclase and resulting in increases in cAMP and a second leading to stimulation of phospholipase C and resulting in formation of inositol phosphates and elevations in [Ca2+]i. These data correlate positively with and provide a mechanistic explanation for previous reports on the ability of hCG to mobilize phosphoinositides and increasing [Ca2+]i in luteal and granulosa cells (e.g. Davis, J. S., West, L. A., and Farese, R. V. (1984) J. Biol. Chem. 259, 15028-15034).	BAYLOR COLL MED, DEPT MOLEC PHYSIOL & BIOPHYS, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DIV NEUROSCI, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	GUDERMANN, T (corresponding author), BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA.				NHLBI NIH HHS [HL-45198] Funding Source: Medline; NICHD NIH HHS [HD-09581] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD009581] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045198] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMOWITZ J, 1982, ENDOCRINOLOGY, V110, P336, DOI 10.1210/endo-110-2-336; ABRAMOWITZ J, 1980, FUNCTIONAL CORRELATE, P335; ASCOLI M, 1989, J BIOL CHEM, V264, P6674; ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BIRNBAUMER M, 1990, MOL ENDOCRINOL, V4, P245, DOI 10.1210/mend-4-2-245; BOCKAERT J, 1976, J BIOL CHEM, V251, P2653; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIS JS, 1987, J BIOL CHEM, V262, P8515; DAVIS JS, 1984, J BIOL CHEM, V259, P5028; DAVIS JS, 1986, BIOCHEM J, V238, P597, DOI 10.1042/bj2380597; DIMINO MJ, 1987, BIOL REPROD, V37, P1129, DOI 10.1095/biolreprod37.5.1129; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; DUFAU ML, 1977, P NATL ACAD SCI USA, V74, P3419, DOI 10.1073/pnas.74.8.3419; FARGIN A, 1989, J BIOL CHEM, V264, P14848; FOX SR, 1985, ENDOCRINOLOGY, V116, P1485, DOI 10.1210/endo-116-4-1485; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HERTELENDY F, 1989, BIOL REPROD, V40, P1144, DOI 10.1095/biolreprod40.6.1144; HSU WH, 1990, J BIOL CHEM, V265, P11220; JAN JH, 1987, BIOCHEMISTRY-US, V26, P1617; KIRCHICK HJ, 1983, ENDOCRINOLOGY, V113, P1629, DOI 10.1210/endo-113-5-1629; KIRCHICK HJ, 1983, ENDOCRINOLOGY, V113, P1638, DOI 10.1210/endo-113-5-1638; KOO YB, 1991, ENDOCRINOLOGY, V128, P2297, DOI 10.1210/endo-128-5-2297; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIAO CF, 1989, J BIOL CHEM, V264, P7328; LIAO CF, 1990, J BIOL CHEM, V265, P11273; LIBERT F, 1990, SCIENCE, V246, P1620; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARSH JM, 1970, J BIOL CHEM, V245, P1596; MATTERA R, 1986, FEBS LETT, V206, P36, DOI 10.1016/0014-5793(86)81336-9; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MINEGISH T, 1990, BIOCHEM BIOPH RES CO, V172, P1049, DOI 10.1016/0006-291X(90)91552-4; ROCHE PC, 1989, J BIOL CHEM, V264, P4636; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; TSAIMORRIS CH, 1991, J BIOL CHEM, V266, P11355; VALLAR L, 1990, J BIOL CHEM, V265, P10320; VANSANDE J, 1990, MOL CELL ENDOCRINOL, V74, pR1; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; [No title captured]	47	355	365	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4479	4488						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1311310				2022-12-27	WOS:A1992HF64200033
J	BERENS, C; ALTSCHMIED, L; HILLEN, W				BERENS, C; ALTSCHMIED, L; HILLEN, W			THE ROLE OF THE N-TERMINUS IN TET REPRESSOR FOR TET OPERATOR BINDING DETERMINED BY A MUTATIONAL ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-TURN-HELIX; TN10-ENCODED TETRACYCLINE RESISTANCE; DOMINANT NEGATIVE MUTATIONS; NUCLEAR-MAGNETIC-RESONANCE; HOMEODOMAIN-DNA COMPLEX; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; SECONDARY-STRUCTURE; LAMBDA-REPRESSOR; TRP REPRESSOR	The N-terminal residues preceding the alpha-helix-turn-alpha-helix motif of the Tn10 Tet repressor protein were probed by oligonucleotide-directed deletion mutagenesis for their role in protein activity. All deletion mutants showed decreased repression in vivo, emphasizing the importance of the N terminus for tet operator binding. Only two of the mutants, TetR-DELTA-2-23 and TetR-DELTA-3-8 displayed a reduced intracellular protein level. The remaining deletion mutants showed either reduced binding to tet operator and inducibility by tetracycline or transdominance. We conclude that these deletions do not affect stability and overall protein structure. DNA binding activities of residue-wise increasing deletions, TetR-DELTA-9 through TetR-DELTA-9-13, reveal a pattern consistent with an alpha-helical structure of the affected residues. This conclusion is supported by the helical wheel projection and the hydrophobic moment profile calculated for the protein segment ranging from residues S7-V20. We propose that these residues form an amphipathic alpha-helix which packs closely against the alpha-helix-turn-alpha-helix motif and is essential for Tet repressor activity. The residues preceding this putative alpha-helix contribute to DNA binding, but no direct interactions with base pairs of tet operator were revealed in a loss of contact analysis. Individual mutation of the 4 charged residues to alanine at the N terminus shows that no single residue can account for the reduction in repression observed for the deletion mutants.	UNIV ERLANGEN NURNBERG,INST MIKROBIOL & BIOCHEM,LEHRSTUHL MIKROBIOL,STAUDSTR 5,W-8520 ERLANGEN,GERMANY	University of Erlangen Nuremberg				Altschmied, Lothar/0000-0002-7692-2971				ALBER T, 1989, ANNU REV BIOCHEM, V58, P765, DOI 10.1146/annurev.biochem.58.1.765; ALTSCHMIED L, 1988, EMBO J, V7, P4011, DOI 10.1002/j.1460-2075.1988.tb03290.x; ARROWSMITH CH, 1989, BIOCHEMISTRY-US, V28, P3875, DOI 10.1021/bi00435a037; BECK CF, 1982, J BACTERIOL, V150, P633, DOI 10.1128/JB.150.2.633-642.1982; BERTRAND KP, 1984, J BACTERIOL, V158, P910, DOI 10.1128/JB.158.3.910-919.1984; BETZ JL, 1988, GENE, V67, P147, DOI 10.1016/0378-1119(88)90392-7; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; CAREY J, 1989, J BIOL CHEM, V264, P1941; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CORNETTE JL, 1987, J MOL BIOL, V195, P659, DOI 10.1016/0022-2836(87)90189-6; DERVYN E, 1990, J BACTERIOL, V172, P7098, DOI 10.1128/jb.172.12.7098-7103.1990; DODD IB, 1987, J MOL BIOL, V194, P557, DOI 10.1016/0022-2836(87)90681-4; EBRIGHT RH, 1986, P NATL ACAD SCI USA, V83, P303, DOI 10.1073/pnas.83.2.303; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; EISENBERG D, 1989, PREDICTION PROTEIN S, P635; GAIT MJ, 1982, CHEM ENZYMATIC SYNTH, P1; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; GOTTESMAN S, 1990, METHOD ENZYMOL, V185, P119; HANSEN D, 1987, J BIOL CHEM, V262, P12269; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HECHT MH, 1984, P NATL ACAD SCI-BIOL, V81, P5685, DOI 10.1073/pnas.81.18.5685; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HILLEN W, 1989, TOPICS MOL STRUCTURA, V10, P143; HOCHSCHILD A, 1986, CELL, V47, P807, DOI 10.1016/0092-8674(86)90523-4; ISACKSON PJ, 1985, P NATL ACAD SCI USA, V82, P6226, DOI 10.1073/pnas.82.18.6226; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KENDREW JC, 1961, NATURE, V190, P666, DOI 10.1038/190666a0; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANIATIS T, 1982, MOL LCONING LABORATO; MATTEUCCI MD, 1981, J AM CHEM SOC, V103, P3185, DOI 10.1021/ja00401a041; MEIER I, 1988, EMBO J, V7, P567, DOI 10.1002/j.1460-2075.1988.tb02846.x; Miller J.H., 1972, EXPT MOL GENETICS; MONDRAGON A, 1991, J MOL BIOL, V219, P321, DOI 10.1016/0022-2836(91)90568-Q; MULLERHILL B, 1968, P NATL ACAD SCI USA, V59, P1259, DOI 10.1073/pnas.59.4.1259; OEHMICHEN R, 1984, EMBO J, V3, P539, DOI 10.1002/j.1460-2075.1984.tb01843.x; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PABO CO, 1990, SCIENCE, V247, P1210, DOI 10.1126/science.2315694; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; PAKULA AA, 1986, P NATL ACAD SCI USA, V83, P8829, DOI 10.1073/pnas.83.23.8829; PARSELL DA, 1989, J BIOL CHEM, V264, P7590; POSTLE K, 1984, NUCLEIC ACIDS RES, V12, P4849, DOI 10.1093/nar/12.12.4849; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SIZEMORE C, 1990, NUCLEIC ACIDS RES, V18, P2875, DOI 10.1093/nar/18.10.2875; SMITH LD, 1988, J MOL BIOL, V203, P949, DOI 10.1016/0022-2836(88)90120-9; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; STRUHL K, 1989, TRENDS BIOCHEM SCI, V14, P137, DOI 10.1016/0968-0004(89)90145-X; SU TZ, 1988, GENE, V69, P81, DOI 10.1016/0378-1119(88)90380-0; TOVAR K, 1988, MOL GEN GENET, V215, P76, DOI 10.1007/BF00331306; WISSMANN A, 1991, GENETICS, V128, P225; WRAY LV, 1983, J BACTERIOL, V156, P1188, DOI 10.1128/JB.156.3.1188-1191.1983; WRAY LV, 1981, J BACTERIOL, V147, P297, DOI 10.1128/JB.147.2.297-304.1981; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZUIDERWEG ERP, 1983, P NATL ACAD SCI-BIOL, V80, P5837, DOI 10.1073/pnas.80.19.5837	59	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1945	1952						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1309804				2022-12-27	WOS:A1992HA48500084
J	COTECCHIA, S; OSTROWSKI, J; KJELSBERG, MA; CARON, MG; LEFKOWITZ, RJ				COTECCHIA, S; OSTROWSKI, J; KJELSBERG, MA; CARON, MG; LEFKOWITZ, RJ			DISCRETE AMINO-ACID-SEQUENCES OF THE ALPHA-1-ADRENERGIC RECEPTOR DETERMINE THE SELECTIVITY OF COUPLING TO PHOSPHATIDYLINOSITOL HYDROLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-2-ADRENERGIC RECEPTOR; BETA-ADRENERGIC-RECEPTOR; MOLECULAR-CLONING; EXPRESSION; PROTEIN; DOMAINS; POLYMERASE; GENES; CDNA; AMPLIFICATION	We have constructed a variety of chimeric beta-2/alpha-1 adrenergic receptors (AR) in which selected portions of the third intracellular loop of the alpha(1B)AR were substituted into the corresponding regions of the beta-2AR. The mutant receptors were both transiently and permanently expressed in COS-7 or L-cells, respectively, and tested for their ability to mediate epinephrine-induced activation of polyphosphoinositide (PI) hydrolysis and adenylylcyclase. We have determined that 27 amino acids of the alpha(1B)AR (residues 233-259) derived from the N-terminal portion of the third intracellular loop represent the structural determinant conferring to the beta-2AR the ability to activate PI hydrolysis. This finding suggests that in the alpha(1B)AR the N-terminal portion of the third intracellular loop plays a major role in determining the selectivity of receptor-G protein coupling. However, replacement of alpha-1B sequences in the third intracellular loop of the beta-2AR did not abolish the latter receptor's coupling to activation of adenylylcyclase, thus resulting in chimeric adrenergic receptors which activated both PI hydrolysis and adenylylcyclase. These results indicate that, even if the N-terminal portion of the third intracellular loop is a major determinant of the selectivity of receptor-G protein coupling, other structural domains of the receptors also modulate this property. The comparison of the amino acid sequences which determine the selectivity of G protein coupling in functionally similar receptors may help to elucidate the structural basis for activation of specific G protein-effector systems.	DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, POB 3821, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Duke University			Lefkowitz, Robert/AAW-2649-2021		NHLBI NIH HHS [HL16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; CASEY PJ, 1988, J BIOL CHEM, V263, P2577; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DELEAN A, 1982, MOL PHARMACOL, V21, P5; DIXON RAF, 1988, COLD SPRING HARB SYM, V53, P487, DOI 10.1101/SQB.1988.053.01.056; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; LOMASNEY JW, 1991, J BIOL CHEM, V266, P6365; MARTIN TFJ, 1983, J BIOL CHEM, V258, P4816; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCHWINN DA, 1990, J BIOL CHEM, V265, P8183; SMZCKA AV, 1991, SCIENCE, V25, P804; STRADER CD, 1987, J BIOL CHEM, V262, P16439; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; WESS J, 1989, FEBS LETT, V258, P133, DOI 10.1016/0014-5793(89)81633-3; WESS J, 1990, MOL PHARMACOL, V38, P517; WONG SKF, 1990, J BIOL CHEM, V265, P6219; YOLOV AA, 1990, NUCLEIC ACIDS RES, V18, P3983, DOI 10.1093/nar/18.13.3983; YON J, 1989, NUCLEIC ACIDS RES, V17, P4895, DOI 10.1093/nar/17.12.4895	39	149	156	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1633	1639						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1309789				2022-12-27	WOS:A1992HA48500038
J	MONTEROLOMELI, M; DEMEIS, L				MONTEROLOMELI, M; DEMEIS, L			GLUCOSE-6-PHOSPHATE AND HEXOKINASE CAN BE USED AS AN ATP-REGENERATING SYSTEM BY THE CA2+-ATPASE OF SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENERGY; HYDROLYSIS; WATER; PH	In the presence of hexokinase, vesicles derived from the sarcoplasmic reticulum of skeletal muscle are able to accumulate Ca2+ in a medium containing ADP and glucose 6-phosphate. No significant Ca2+ uptake is observed if one of these components is omitted from the assay medium. Due to its high affinity for ATP, the Ca2+-ATPase can use the very low concentrations of ATP formed from glucose 6-phosphate and ADP to form a Ca2+ gradient. This finding indicates that glucose 6-phosphate and hexokinase can be used as an ATP-regenerating system. The Ca2+ uptake supported by glucose 6-phosphate and ADP is inhibited by glucose and D-xylose. Half-maximal inhibition is observed in the presence of 0.4 mm glucose and 100 mM D-xylose. The transport ratio (Ca2+ transported:substrate utilized) is the same for glucose 6-phosphate and ATP. The Ca2+ gradient formed when glucose 6-phosphate and ADP are the substrates can be used to synthesize ATP from ADP and P(i). The concentration of ATP formed after reversal of the Ca2+ pump is much higher than that expected from direct equilibration of the reaction between glucose 6-phosphate and ADP.			MONTEROLOMELI, M (corresponding author), UNIV FED RIO DE JANEIRO, INST CIENCIAS BIOMED, DEPT BIOQUIM, CIDADE UNIV, ILHA FUNDAO, BR-21941 RIO DE JANEIRO, BRAZIL.							ALBERTY RA, 1969, J BIOL CHEM, V244, P3290; de Meis L, 1973, J Biol Chem, V248, P3691; DELAFUENTE G, 1970, EUR J BIOCHEM, V16, P240, DOI 10.1111/j.1432-1033.1970.tb01077.x; DEMEIS L, 1984, J BIOL CHEM, V259, P6090; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DEMEIS L, 1988, METHOD ENZYMOL, V157, P190; DEMEIS L, 1981, TRANSPORT LIFE SCI, V2; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; GEORGE P, 1970, BIOCHIM BIOPHYS ACTA, V223, P1, DOI 10.1016/0005-2728(70)90126-X; GLYNN IM, 1976, J PHYSIOL-LONDON, V256, P465, DOI 10.1113/jphysiol.1976.sp011333; GRUBMEYER C, 1982, J BIOL CHEM, V257, P1202; INESI G, 1967, J BIOL CHEM, V242, P4637; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; MEYERHOF O, 1949, J BIOL CHEM, V178, P655; NEUFELD AH, 1969, J BIOL CHEM, V244, P6493; PENINGROTH SM, 1980, J BIOL CHEM, V255, P9545; PHILLIPS RC, 1969, J BIOL CHEM, V244, P3330; ROMERO PJ, 1989, J BIOL CHEM, V264, P7869; SCHUEGRAF A, 1960, J BIOL CHEM, V235, P3597; SENIOR AE, 1983, J MEMBRANE BIOL, V73, P105, DOI 10.1007/BF01870434; VEECH RL, 1979, J BIOL CHEM, V254, P6538; WOOD HG, 1966, J BIOL CHEM, V241, P5692	22	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1829	1833						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1309800				2022-12-27	WOS:A1992HA48500067
J	NGUYEN, G; SELF, SJ; CAMANI, C; KRUITHOF, EKO				NGUYEN, G; SELF, SJ; CAMANI, C; KRUITHOF, EKO			DEMONSTRATION OF A SPECIFIC CLEARANCE RECEPTOR FOR TISSUE-TYPE PLASMINOGEN-ACTIVATOR ON RAT NOVIKOFF HEPATOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITOR TYPE-1; SINGLE-CHAIN; UROKINASE; LIVER; IDENTIFICATION; DEGRADATION; PROTEIN; PHARMACOKINETICS; CATABOLISM; COMPLEXES	The binding, internalization, and degradation of tissue-type plasminogen activator (t-PA) were studied in a rat hepatoma (Novikoff) cell line. Binding of t-PA to specific saturable high affinity binding sites (K(d) = 12 nM, 54,000 sites/cell) was followed by internalization and degradation and did not require a functional active site. The catabolism of t-PA was not inhibited by an excess of urokinase-type plasminogen activator (u-PA), and t-PA bound to Novikoff membranes was not complexed to PAI-1, suggesting a mechanism independent of PAI-1. Additionally, a mannose receptor is not involved since t-PA binding was not influenced by an excess of mannose, galactose, ovalbumin, or EDTA. Furthermore, the degradation of t-PA was not influenced by 10 mM 6-aminohexanoic acid, a lysine analogue. The t-PA receptor binds to and can be eluted from wheat germ agglutinin-Sepharose. Cross-linking of t-PA with partially purified receptor and ligand blot analysis, suggest that t-PA binds to two proteins, a principal one of 55 kDa and a minor one of 43 kDa. Novikoff cells are able also to bind (K(d) = 1.4 nM, 25,000 sites/cell) and degrade u-PA. The binding was inhibited by pro-u-PA and the amino-terminal fragment of u-PA, but not by an excess of t-PA. The u-PA receptor, but not the t-PA receptor, was removed by treatment with phosphatidylinositol-specific phospholipase C. Our results show that the clearance receptor for t-PA on Novikoff cells is different from the mannose receptor and the PAI-1-dependent receptor described in other cells. The rat hepatoma cells are thus a good model to study the PAI-1 independent hepatocyte-specific clearance of t-PA.	CHU VAUDOIS,DIV HEMATOL,CH-1011 LAUSANNE,SWITZERLAND; CHU VAUDOIS,DEPT INTERNAL MED,CH-1011 LAUSANNE,SWITZERLAND	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)			Kruithof, Egbert/AGR-4755-2022					BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; BROWNE MJ, 1988, J BIOL CHEM, V263, P1599; COLLEN D, 1988, BLOOD, V71, P216; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; DODD I, 1988, THROMB HAEMOSTASIS, V59, P523; EINARSSON M, 1988, THROMB HAEMOSTASIS, V59, P474; EMEIS JJ, 1985, THROMB HAEMOSTASIS, V54, P661; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HIRAMATSU R, 1989, FIBRINOLYSIS, V3, P147, DOI 10.1016/0268-9499(89)90012-X; HWANG SB, 1987, ARCH BIOCHEM BIOPHYS, V257, P339, DOI 10.1016/0003-9861(87)90574-1; KRAUSE J, 1990, BIOCHEM J, V267, P647, DOI 10.1042/bj2670647; KRAUSE J, 1988, Fibrinolysis, V2, P133, DOI 10.1016/0268-9499(88)90026-4; KUIPER J, 1988, J BIOL CHEM, V263, P18220; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIESI P, 1990, EXP BRAIN RES, V79, P642; LIJNEN HR, 1987, EUR J BIOCHEM, V162, P351, DOI 10.1111/j.1432-1033.1987.tb10608.x; MORTON PA, 1990, J BIOL CHEM, V265, P14093; MORTON PA, 1989, J BIOL CHEM, V264, P7228; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; OTTER M, 1991, J BIOL CHEM, V266, P13931; OWENSBY DA, 1989, J BIOL CHEM, V264, P18180; PANNEKOEK H, 1988, Fibrinolysis, V2, P123, DOI 10.1016/0268-9499(88)90025-2; PARKKINEN J, 1991, J BIOL CHEM, V266, P16730; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PLOUG M, 1991, J BIOL CHEM, V266, P1926; SEYDEL W, 1991, DRUG RES, V41, P182; SMEDSROD B, 1990, THROMB HAEMOSTASIS, V63, P60; STUMP DC, 1987, J PHARMACOL EXP THER, V242, P245; WING LR, 1991, FEBS LETT, V278, P95, DOI 10.1016/0014-5793(91)80092-H; WING LR, 1991, J LAB CLIN MED, V117, P109	32	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6249	6256						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1313432				2022-12-27	WOS:A1992HK31800080
J	VASSALLO, RR; KIEBEREMMONS, T; CICHOWSKI, K; BRASS, LF				VASSALLO, RR; KIEBEREMMONS, T; CICHOWSKI, K; BRASS, LF			STRUCTURE-FUNCTION-RELATIONSHIPS IN THE ACTIVATION OF PLATELET THROMBIN RECEPTORS BY RECEPTOR-DERIVED PEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS; CYCLASE	According to present models, thrombin activates platelets by cleaving its receptors after Arg41, creating a new N terminus which acts as a tethered ligand. In support of this model, a peptide (SFLLRNPNDKYEPF or TRP42/55) corresponding to residues 42-55 has been shown to activate the receptor. In the present studies, the structural basis for thrombin receptor activation was examined using fragments of this peptide, as well as variants of the peptide with selected amino acid substitutions. The results show that the features of SFLLRNPNDKYEPF required to mimic the effects of thrombin reside within the first 6 residues, SFLLRN. A hexapeptide comprised of these residues was approximately 5 times more potent than the parent peptide in assays of platelet aggregation and, in addition, caused tyrosine phosphorylation, inhibition of cAMP formation, and an increase in cytosolic Ca2+. Omission of either the Ser residue or the Arg and Asn residues greatly diminished peptide activity, as did the substitution of Ala for Phe or Arg. Substitution of Ala for Ser or the initial Leu, on the other hand, had little adverse effect. The inactive peptides SALLRN and NPNDKYEPF had no effect on platelet activation initiated by SFLLRN, but FLLRN inhibited platelet aggregation in response to both SFLLRN and thrombin. These results suggest that within SFLLRN the Phe and Arg residues are particularly important and that Phe must be preceded by another amino acid, the identity of which is not tightly constrained. This observation and comparisons with the homologous domains of proteins whose tertiary structure is known were used to predict the conformation of the SFLLR sequence. The model which emerged suggests that the SFLLR domain may be part of an extended beta-structure in the intact receptor and that cleavage by thrombin causes it to contract and assume a modified helical configuration. In this predicted conformation the side chains of Phe and Arg point in the same direction, potentially into a pocket formed by the remainder of the receptor.	UNIV PENN,DEPT MED,HEMATOL ONCOL SECT,3400 SPRUCE ST,SILVERSTEIN 7,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PATHOL,PHILADELPHIA,PA 19104; UNIV PENN,DEPT MICROBIOL,PHILADELPHIA,PA 19104; WISTAR INST,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; The Wistar Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL40387] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENEDETTI E, 1983, INT J PEPT PROT RES, V22, P1; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLUNDELL TL, 1987, NATURE, V326, P347, DOI 10.1038/326347a0; BRASS LF, 1992, BIOCHEM J, V281, P73, DOI 10.1042/bj2810073; BRASS LF, 1992, J BIOL CHEM, V267, P6044; BRASS LF, 1988, J BIOL CHEM, V263, P5348; DRUCKER BJ, 1989, NEW ENGL J MED, V321, P1383; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GREER J, 1981, J MOL BIOL, V153, P1027, DOI 10.1016/0022-2836(81)90465-4; HUANG RS, 1991, J BIOL CHEM, V266, P18435; KIEBEREMMONS T, 1990, VACCINES 90, P321; KIEBEREMMONS T, 1992, IN PRESS PATHOBIOLOG; KIEBEREMMONS T, 1991, MONOCLONAL ANTIBODIE, P53; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU LW, 1991, J BIOL CHEM, V266, P16977; MANNING DR, 1991, THROMB HAEMOSTASIS, V66, P393; MOULT J, 1988, PROTEINS, V3, P71; NGAIZA JR, 1991, BIOCHEM BIOPH RES CO, V179, P1656, DOI 10.1016/0006-291X(91)91765-5; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; RICHARDS FM, 1988, PROTEINS, V3, P71, DOI 10.1002/prot.340030202; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHATTIL SJ, 1987, BLOOD, V70, P307; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; VUTKH, 1991, CELL, V64, P1057; WILLIAMS WV, 1991, J BIOL CHEM, V266, P9241; WILLIAMS WV, 1991, J BIOL CHEM, V266, P5182	29	315	338	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6081	6085						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1313429				2022-12-27	WOS:A1992HK31800056
J	MUNZER, JS; SILVIUS, JR; BLOSTEIN, R				MUNZER, JS; SILVIUS, JR; BLOSTEIN, R			DELIVERY OF ION PUMPS FROM EXOGENOUS MEMBRANE-RICH SOURCES INTO MAMMALIAN RED-BLOOD-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; ADENOSINE-TRIPHOSPHATASE; SARCOPLASMIC-RETICULUM; POLYETHYLENE-GLYCOL; TRANSPORT MODES; FUSION; ERYTHROCYTES; PERMEABILITY; EXPRESSION; VESICLES	Using polyethylene glycol-mediated fusion of ATPase-enriched (native) microsomes with red blood cells, we have delivered sarcoplasmic reticulum (SR) Ca-ATPase and kidney Na,K-ATPase into the mammalian erythrocyte membrane. Experiments involving delivery of the SR Ca-ATPase into human red cells were first carried out to assess the feasibility of the fusion protocol. Whereas there was little detectable Ca-45(2+) uptake into control cells in either the absence or presence of extracellular ATP, a marked time-dependent uptake of Ca-45(2+) was observed in the presence of ATP in cells fused with SR Ca-ATPase. Comparison of the kinetics of uptake into microsome-fused cells versus native SR vesicles supports the conclusion of true delivery of pumps into the red cell membrane. Thus, the time to reach steady state was more than two orders of magnitude longer in the (large) cells versus the native SR vesicles. Na,K-ATPase from dog and rat kidney microsomes were fused with red cells of humans, sheep, and dogs. Using dog kidney microsomes fused with dog red cells which are practically devoid of Na,K-ATPase, functional incorporation of sodium pumps was evidenced in ouabain-sensitive Rb+ uptake and Na+ efflux energized by intracellular ATP, as well as in ATP-stimulated Na+ influx and Rb+ efflux from inside-out membrane vesicles prepared from the fusion-treated cells. From analysis of the biphasic kinetics of ouabain-sensitive Na+ efflux under conditions of limited intracellular Na+ concentration, it is concluded that the kidney pumps are incorporated into a relatively small fraction (approximately 15%) of the red cells. This system provides a uniquely useful system for studying the behavior of native sodium pumps in a compartment (red cell) of small surface/volume ratio. The newly incorporated native kidney pumps, while of the same isoform as the endogenous red cell pump, behave differently from the endogenous red cell sodium pump with respect to their very low "uncoupled" Na+/O flux activity.	MCGILL UNIV, DEPT MED, MONTREAL H3G 1A4, QUEBEC, CANADA; MCGILL UNIV, DEPT BIOCHEM, MONTREAL H3G 1A4, QUEBEC, CANADA	McGill University; McGill University								ANNER BM, 1985, BIOCHIM BIOPHYS ACTA, V822, P319, DOI 10.1016/0304-4157(85)90013-9; BALAKRISHNAN K, 1983, BIOCHIM BIOPHYS ACTA, V731, P121, DOI 10.1016/0005-2736(83)90405-4; BAUMANN H, 1980, J BIOL CHEM, V255, P1; BEELER T, 1984, BIOCHIM BIOPHYS ACTA, V773, P99, DOI 10.1016/0005-2736(84)90554-6; BLOSTEIN R, 1985, J BIOL CHEM, V260, P829; BLOSTEIN R, 1988, METHOD ENZYMOL, V156, P171; BROTHERUS JR, 1979, BIOCHEMISTRY-US, V18, P5043, DOI 10.1021/bi00590a003; CHEHAB FF, 1987, P NATL ACAD SCI USA, V84, P7901, DOI 10.1073/pnas.84.22.7901; CORNELIUS F, 1991, BIOCHIM BIOPHYS ACTA, V1071, P19, DOI 10.1016/0304-4157(91)90011-K; CORREAFREIRE MC, 1984, J IMMUNOL, V132, P69; COUSIN JL, 1976, J PHYSIOL-LONDON, V256, P61, DOI 10.1113/jphysiol.1976.sp011311; DHIR R, 1990, BIOCHIM BIOPHYS ACTA, V1026, P141, DOI 10.1016/0005-2736(90)90056-T; DISSING S, 1990, J GEN PHYSIOL, V96, P167, DOI 10.1085/jgp.96.1.167; ERIKSSON H, 1985, BIOCHIM BIOPHYS ACTA, V815, P417, DOI 10.1016/0005-2736(85)90369-4; EYTAN GD, 1980, J BIOL CHEM, V255, P4992; FORBUSH B, 1983, ANAL BIOCHEM, V128, P159, DOI 10.1016/0003-2697(83)90356-1; FRYE LD, 1970, J CELL SCI, V7, P319; GAD AE, 1979, FEBS LETT, V102, P230, DOI 10.1016/0014-5793(79)80007-1; GARRAHAN PJ, 1967, J PHYSIOL-LONDON, V192, P159, DOI 10.1113/jphysiol.1967.sp008294; GARRAHAN PJ, 1967, J PHYSIOL-LONDON, V192, P189, DOI 10.1113/jphysiol.1967.sp008296; GEORGE SK, 1991, BIOCHIM BIOPHYS ACTA, V1066, P131, DOI 10.1016/0005-2736(91)90179-C; GOLDSHLEGER R, 1990, J MEMBRANE BIOL, V113, P139, DOI 10.1007/BF01872888; GUERRA M, 1990, BIOCHIM BIOPHYS ACTA, V1023, P73, DOI 10.1016/0005-2736(90)90011-C; HASSELBACH W, 1962, BIOCHEM BIOPH RES CO, V7, P132, DOI 10.1016/0006-291X(62)90161-4; HOEKSTRA D, 1986, J VIROL, V58, P87, DOI 10.1128/JVI.58.1.87-95.1986; HONDA K, 1981, BIOCHEM BIOPH RES CO, V100, P442, DOI 10.1016/S0006-291X(81)80116-7; HUANG SK, 1986, BIOCHIM BIOPHYS ACTA, V860, P539; JORGENSEN PL, 1971, BIOCHIM BIOPHYS ACTA, V233, P366, DOI 10.1016/0005-2736(71)90334-8; JULIANO RL, 1976, NATURE, V261, P235, DOI 10.1038/261235a0; KARLISH SJD, 1974, ANN NY ACAD SCI, V242, P461, DOI 10.1111/j.1749-6632.1974.tb19110.x; KNUTTON S, 1979, J CELL SCI, V36, P61; LEW VL, 1973, BIOCHIM BIOPHYS ACTA, V323, P251, DOI 10.1016/0005-2736(73)90149-1; LEW VL, 1971, BIOCHIM BIOPHYS ACTA, V233, P827, DOI 10.1016/0005-2736(71)90185-4; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; Markwell M A, 1981, Methods Enzymol, V72, P296; MARTONOSI A, 1964, J BIOL CHEM, V239, P659; MOUNEIMNE Y, 1991, BIOCHIM BIOPHYS ACTA, V1066, P83, DOI 10.1016/0005-2736(91)90254-6; PARKER JC, 1983, AM J PHYSIOL, V244, pC324, DOI 10.1152/ajpcell.1983.244.5.C324; PARKER JC, 1972, AM J PHYSIOL, V223, P888, DOI 10.1152/ajplegacy.1972.223.4.888; Post R.L., 1967, METHODS ENZYMOLOGY, P762; PRUJANSKYJAKOBOVITS A, 1980, P NATL ACAD SCI-BIOL, V77, P7247, DOI 10.1073/pnas.77.12.7247; SACHS JR, 1977, J PHYSIOL-LONDON, V273, P489, DOI 10.1113/jphysiol.1977.sp012106; SCHRAMM M, 1979, P NATL ACAD SCI USA, V76, P1174, DOI 10.1073/pnas.76.3.1174; SMITH CL, 1982, BIOCHIM BIOPHYS ACTA, V692, P109, DOI 10.1016/0005-2736(82)90508-9; STANLEY PE, 1969, ANAL BIOCHEM, V29, P381, DOI 10.1016/0003-2697(69)90323-6; Steck T. L., 1974, METHODS MEMBRANE BIO, V2, P245; SZOKA F, 1981, P NATL ACAD SCI-BIOL, V78, P1685, DOI 10.1073/pnas.78.3.1685; VOLSKY DJ, 1979, P NATL ACAD SCI USA, V76, P5440, DOI 10.1073/pnas.76.11.5440; WEIGENSBERG AM, 1983, P NATL ACAD SCI-BIOL, V80, P4978, DOI 10.1073/pnas.80.16.4978; WOJCIESZYN JW, 1983, J CELL BIOL, V96, P151, DOI 10.1083/jcb.96.1.151	50	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5202	5210						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1312086				2022-12-27	WOS:A1992HH74700034
J	LIN, H; KONIECZNY, SF				LIN, H; KONIECZNY, SF			IDENTIFICATION OF MRF4, MYOGENIN, AND E12 OLIGOMER COMPLEXES BY CHEMICAL CROSS-LINKING AND 2-DIMENSIONAL GEL-ELECTROPHORESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC ENHANCER; CREATINE-KINASE GENE; DNA-BINDING; SEX DETERMINATION; MYC-HOMOLOGY; MYOD FAMILY; SEQUENCE; PROTEIN; EXPRESSION; ACTIVATION	The muscle-specific regulatory factors MRF4 and myogenin, as well as the ubiquitous factor E12, belong to a protein family which shares a common structural motif referred to as the basic helix-loop-helix domain. Recent studies have demonstrated that MRF4 and myogenin, in the presence of E12, bind efficiently to enhancer regions of muscle-specific genes, thereby activating their transcription. Although several lines of evidence suggest that MRF4 and E12 or myogenin and E12 hetero-oligomers exist, direct studies revealing the composition of these protein complexes have not been reported. Here, we demonstrate that MRF4 and myogenin preferentially form heterodimers with E12 in solution and that heterodimer formation in vitro is greatly enhanced when the two proteins are co-synthesized. Utilizing a novel two-dimensional gel electrophoresis system, we have found that MRF4 and myogenin, when complexed with E12, bind as heterodimers to the E-box consensus sequences associated with the troponin I, M-creatine kinase, and myosin light chain gene enhancers. In all cases, higher order oligomer structures were not detected, demonstrating that in vitro DNA binding abilities of these basic helix-loop-helix proteins require heterodimer formation.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus								ABDELLA PM, 1979, BIOCHEM BIOPH RES CO, V87, P734, DOI 10.1016/0006-291X(79)92020-5; ALONSO MC, 1988, EMBO J, V7, P2585, DOI 10.1002/j.1460-2075.1988.tb03108.x; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2878; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; CRONMILLER C, 1988, GENE DEV, V2, P1666, DOI 10.1101/gad.2.12a.1666; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; Emerson CP, 1990, CURR OPIN CELL BIOL, V2, P1065, DOI 10.1016/0955-0674(90)90157-A; FRENCH BA, 1991, MOL CELL BIOL, V11, P2439, DOI 10.1128/MCB.11.5.2439; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LIN H, 1991, MOL CELL BIOL, V11, P267, DOI 10.1128/MCB.11.1.267; LOMANT AJ, 1976, J MOL BIOL, V104, P243, DOI 10.1016/0022-2836(76)90011-5; LUDWIG SR, 1989, P NATL ACAD SCI USA, V86, P7092, DOI 10.1073/pnas.86.18.7092; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PARTIS MD, 1983, J PROTEIN CHEM, V2, P263, DOI 10.1007/BF01025358; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; YUTZEY KE, 1989, MOL CELL BIOL, V9, P1397, DOI 10.1128/MCB.9.4.1397; YUTZEY KE, 1990, MOL CELL BIOL, V10, P3934, DOI 10.1128/MCB.10.8.3934	41	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4773	4780						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1311321				2022-12-27	WOS:A1992HF64200074
J	WANG, K; FARLEY, RA				WANG, K; FARLEY, RA			LYSINE-480 IS NOT AN ESSENTIAL RESIDUE FOR ATP BINDING OR HYDROLYSIS BY NA,K-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMINO-ACID-SEQUENCE; PLASMA-MEMBRANE; CA-2+-TRANSPORTING ATPASE; ADENOSINE-TRIPHOSPHATASE; SARCOPLASMIC-RETICULUM; MOLECULAR-CLONING; COMPLEMENTARY-DNA; ACTIVE-SITE; IDENTIFICATION; QUANTITATION	Lysine 480 has been suggested to be essential for ATP binding and hydrolysis by Na,K-ATPase because it is labeled by reagents that are thought to react with the ATPase from within the ATP binding site. In order to test this hypothesis, Lys-480 was changed to Ala, Arg, or Glu by site-directed mutagenesis, and the resultant Na,K-ATPase molecules were expressed in yeast cells. The ATPase activity of each of the mutants was similar to the activity of the wild type enzyme indicating that Lys-480 is not essential for ATP hydrolysis. The binding of [H-3]ouabain in both ATP-dependent and inorganic phosphate-dependent reactions was used to determine the apparent affinity of each mutant for ATP or P(i). The K0.5(ATP) for ouabain binding to phosphoenzyme formed from ATP was 1-3-mu-M for Lys-480, Arg-480, and Ala-480, whereas for Glu-480 the K0.5(ATP) was 18-mu-M. The K0.5(P(i)) for ouabain binding to phosphoenzyme formed from inorganic phosphate was 16-28-mu-M for Lys-480, Arg-480, and Ala-480, but was 74-mu-M for Glu-480. The K(d) for ouabain binding was similar for both the wild type and mutant Na,K-ATPase molecules (3-6 nM). These data indicate that the substitution of an acidic amino acid for lysine at position 480 appears to reduce the affinity of the Na,K-ATPase for both ATP and phosphate. It is concluded that Lys-480 is not essential for ATP binding or hydrolysis or for phosphate binding by Na,K-ATPase but is likely to be located within the ATP binding site of the Na,K-ATPase.	UNIV SO CALIF,SCH MED,DEPT PHYSIOL & BIOPHYS,2025 ZONAL AVE,LOS ANGELES,CA 90033	University of Southern California					NHLBI NIH HHS [HL39295] Funding Source: Medline; NIGMS NIH HHS [GM28673] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039295] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028673] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BONTING SL, 1985, SODIUM PUMP, P209; FARLEY RA, 1985, J BIOL CHEM, V260, P3899; FORBUSH B, 1983, CURR TOP MEMBR TRANS, V19, P167; FU YF, 1985, BIOCHIM BIOPHYS ACTA, V817, P7, DOI 10.1016/0005-2736(85)90062-8; HEGYVARY C, 1971, J BIOL CHEM, V246, P5234; HINZ HR, 1990, J BIOL CHEM, V265, P10260; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; JOHNSON C, 1984, BIOCHIM BIOPHYS ACTA, V860, P549; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; OHTA T, 1986, P NATL ACAD SCI USA, V83, P2071, DOI 10.1073/pnas.83.7.2071; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P111, DOI 10.1016/0014-5793(87)81253-X; PEDEMONTE CH, 1990, AM J PHYSIOL, V258, pC1, DOI 10.1152/ajpcell.1990.258.1.C1; RESH MD, 1988, METHOD ENZYMOL, V156, P119; RESH MD, 1982, J BIOL CHEM, V257, P1946; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHEINERBOBIS G, 1991, SODIUM PUMP STRUCTUR, P43; SERRANO R, 1991, BIOCHIM BIOPHYS ACTA, V1062, P157, DOI 10.1016/0005-2736(91)90387-N; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; TAMURA S, 1989, J BIOL CHEM, V264, P8580; TRAN CM, 1988, BIOPHYS J, V53, pA343; XU KY, 1989, BIOCHEMISTRY-US, V28, P5764, DOI 10.1021/bi00440a010; YAMAMOTO H, 1988, J BIOCHEM-TOKYO, V103, P452, DOI 10.1093/oxfordjournals.jbchem.a122291; YODA S, 1987, J BIOL CHEM, V262, P103	29	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3577	3580						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1310976				2022-12-27	WOS:A1992HE60700007
J	CLELAND, JL; RANDOLPH, TW				CLELAND, JL; RANDOLPH, TW			MECHANISM OF POLYETHYLENE-GLYCOL INTERACTION WITH THE MOLTEN GLOBULE FOLDING INTERMEDIATE OF BOVINE CARBONIC ANHYDRASE-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANIDINE-HYDROCHLORIDE; CRYSTAL-STRUCTURE; PROTEINS; SPECTRA	Polyethylene glycol has been shown to bind to the molten globule intermediate on the bovine carbonic anhydrase B folding pathway. The mechanism of this interaction has been extensively probed. Polyethylene glycol (PEG) binds weakly to the molten globule first intermediate as measured by hydrophobic interaction chromatography, but PEG does not bind to either the native state or the second intermediate. The binding of PEG to the molten globule has been confirmed with both intrinsic fluorescence and fluorescence quenching experiments which indicate a single PEG-binding site on the molten globule. Electron paramagnetic resonance spectroscopic studies with nitroxide-labeled PEG also indicate a single binding site. Additional electron paramagnetic resonance studies with spin-labeled carbonic anhydrase B suggest that a conformational change occurs in the molten globule intermediate after PEG binds to the surface. The formation of a PEG-molten globule complex results in a reduction in self-association of this compact hydrophobic structure. PEG-molten globule complex formation is analogous to the observed interaction between chaperonins and a molten globule intermediate (Martin, J., Langer, T., Boteva, R., Schramel, A., Horwich, A. L., and Hartl, F.-U. (1991) Nature 352, 36-42).	YALE UNIV, DEPT CHEM ENGN, NEW HAVEN, CT 06520 USA; GENENTECH INC, DIV PHARMACEUT RES & DEV, San Francisco, CA 94080 USA	Yale University; Roche Holding; Genentech								BARRATT MD, 1969, BIOCHIM BIOPHYS ACTA, V194, P600, DOI 10.1016/0005-2795(69)90123-8; CAPIOMONT A, 1974, J CHEM PHYS, V60, P2530, DOI 10.1063/1.1681393; CLELAND JL, 1990, BIO-TECHNOL, V8, P1274, DOI 10.1038/nbt1290-1274; CLELAND JL, 1990, BIOCHEMISTRY-US, V29, P11072, DOI 10.1021/bi00502a009; CLELAND JL, 1991, ACS SYM SER, V470, P169; CLELAND JL, 1992, IN PRESS BIOTECH PRO; CREIGHTON TE, 1984, PROTEINS STRUCTURES, P16; EBERT B, 1990, STUD BIOPHYS, V137, P125; ERIKSSON AE, 1988, PROTEINS, V4, P274, DOI 10.1002/prot.340040406; FIELDS R, 1971, BIOCHEM J, V124, P581, DOI 10.1042/bj1240581; INGRAHAM RH, 1991, HIGH PERFORMANCE LIQ; LILJAS A, 1972, NATURE-NEW BIOL, V235, P131, DOI 10.1038/newbio235131a0; MALINOWSKI ER, 1977, ANAL CHEM, V49, P606, DOI 10.1021/ac50012a026; MALINOWSKI ER, 1977, ANAL CHEM, V49, P284, DOI 10.1021/ac50010a026; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; PESCE AJ, 1971, FLUORESCENCE SPECTRO, P206; PRESS WH, 1989, NUMERICAL RECIPES AR, P335; RODIONOVA NA, 1989, MOL BIOL+, V23, P528; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; Schneider D. J., 1989, BIOL MAGN RESON, V8, P1; SEMISOTNOV GV, 1987, FEBS LETT, V224, P9, DOI 10.1016/0014-5793(87)80412-X; SEMISOTNOV GV, 1990, J MOL BIOL, V213, P561, DOI 10.1016/S0022-2836(05)80215-3; SOKOLOVS.M, 1966, BIOCHEMISTRY-US, V5, P3582, DOI 10.1021/bi00875a029; STEIN PJ, 1978, J BIOL CHEM, V253, P8016; WONG KP, 1973, J BIOL CHEM, V248, P8518; YAZGAN A, 1972, BIOCHEMISTRY-US, V11, P1314, DOI 10.1021/bi00757a031	26	92	96	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3147	3153						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1310682				2022-12-27	WOS:A1992HD15400052
J	LEMIEUX, LJ; CALHOUN, MW; THOMAS, JW; INGLEDEW, WJ; GENNIS, RB				LEMIEUX, LJ; CALHOUN, MW; THOMAS, JW; INGLEDEW, WJ; GENNIS, RB			DETERMINATION OF THE LIGANDS OF THE LOW-SPIN HEME OF THE CYTOCHROME-O UBIQUINOL OXIDASE COMPLEX USING SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AEROBIC RESPIRATORY-CHAIN; X-RAY ABSORPTION; ESCHERICHIA-COLI; C OXIDASE; TERMINAL OXIDASES; SUBUNIT-I; PARACOCCUS-DENITRIFICANS; QUINOL OXIDASE; PROTON PUMP; COPPER	The cytochrome o complex of Escherichia coli is a ubiquinol oxidase which is the predominant respiratory terminal oxidase when the bacteria are grown under high oxygen tension. The amino acid sequences of three of the subunits of this quinol oxidase reveal a substantial relationship to the aa3-type cytochrome c oxidases. The two cytochrome components (b563.5 and o) and the single copper (Cu(B)) present in the E. coli quinol oxidase appear to be equivalent to cytochrome a, cytochrome a3, and Cu(B) of the aa3-type cytochrome c oxidases, respectively. These three prosthetic groups are all located within subunit I of the oxidase. Sequence alignments indicate only six totally conserved histidine residues among all known sequences of subunit I of the cytochrome c oxidases of various species plus the E. coli quinol oxidase. Site-directed mutagenesis has been used to change each of these totally conserved histidines with the presumption that two of these six must ligate to the low spin cytochrome center of the E. coli oxidase. The presence of the low spin cytochrome b563.5 component of the oxidase can be evaluated both by visible absorbance properties and by its EPR spectrum. The results unambiguously indicate that His-106 and His-421 are the ligands of the six-coordinate low spin cytochrome b563.5. Although the data are not definitive in making additional metal ligation assignments of the remaining four totally conserved histidines, a reasonable model is suggested for the structure of the catalytic core of the cytochrome o complex and, by extrapolation, of cytochrome c oxidase.	UNIV ILLINOIS,SCH CHEM SCI,505 S MATHEWS ST,URBANA,IL 61801; UNIV ST ANDREWS,DEPT BIOCHEM & MOLEC BIOL,ST ANDREWS KY16 9ST,FIFE,SCOTLAND	University of Illinois System; University of Illinois Urbana-Champaign; University of St Andrews								ANRAKU Y, 1987, TRENDS BIOCHEM SCI, V12, P262, DOI 10.1016/0968-0004(87)90131-9; ANRAKU Y, 1988, ANNU REV BIOCHEM, V57, P101, DOI 10.1146/annurev.bi.57.070188.000533; AU DCT, 1987, J BACTERIOL, V169, P3237, DOI 10.1128/jb.169.7.3237-3242.1987; BOTT M, 1990, MOL MICROBIOL, V4, P2147, DOI 10.1111/j.1365-2958.1990.tb00576.x; CHAN SI, 1990, BIOCHEMISTRY-US, V29, P1, DOI 10.1021/bi00453a001; CHEPURI V, 1990, J BIOL CHEM, V265, P11185; CHEPURI V, 1990, J BIOL CHEM, V265, P12978; CHEPURI V, 1990, BIOCHIM BIOPHYS ACTA, V1018, P124, DOI 10.1016/0005-2728(90)90231-R; CLINE J, 1983, J BIOL CHEM, V258, P5124; FELLAY R, 1987, GENE, V52, P147, DOI 10.1016/0378-1119(87)90041-2; GABEL C, 1990, NUCLEIC ACIDS RES, V18, P6143, DOI 10.1093/nar/18.20.6143; GENNIS RB, 1991, BIOCHIM BIOPHYS ACTA, V1058, P21, DOI 10.1016/S0005-2728(05)80260-9; HOLM L, 1987, EMBO J, V6, P2819, DOI 10.1002/j.1460-2075.1987.tb02578.x; KITA K, 1984, J BIOL CHEM, V259, P3368; KITA K, 1984, J BIOL CHEM, V259, P3375; LI PM, 1987, BIOCHEMISTRY-US, V26, P2091, DOI 10.1021/bi00382a005; Maniatis T., 1982, MOL CLONING; MARTIN CT, 1985, J BIOL CHEM, V260, P2857; MATSUSHITA K, 1984, BIOCHEMISTRY-US, V23, P4703, DOI 10.1021/bi00315a028; MEINHARDT SW, 1989, BIOCHIM BIOPHYS ACTA, V975, P175, DOI 10.1016/S0005-2728(89)80216-6; MINAGAWA J, 1992, J BIOL CHEM, V267, P2096; MINGHETTI KC, 1988, BIOCHEM BIOPH RES CO, V155, P243; MULLER M, 1988, P NATL ACAD SCI USA, V85, P6647, DOI 10.1073/pnas.85.18.6647; NAKAMURA H, 1990, J BIOL CHEM, V265, P11193; OLIVEBERG M, 1991, BIOCHEMISTRY-US, V30, P7053, DOI 10.1021/bi00243a003; PORTER TD, 1991, J BIOL CHEM, V266, P13469; POWERS L, 1987, J BIOL CHEM, V262, P3160; POWERS L, 1989, BIOCHEMISTRY-US, V28, P4461, DOI 10.1021/bi00436a051; PUUSTINEN A, 1989, FEBS LETT, V249, P163, DOI 10.1016/0014-5793(89)80616-7; PUUSTINEN A, 1991, P NATL ACAD SCI USA, V88, P6122, DOI 10.1073/pnas.88.14.6122; PUUSTINEN A, 1991, BIOCHEMISTRY-US, V30, P3936, DOI 10.1021/bi00230a019; ROTHERY RA, 1989, BIOCHEM J, V261, P437, DOI 10.1042/bj2610437; SALERNO JC, 1990, J BIOL CHEM, V265, P4364; SALERNO JC, 1989, FEBS LETT, V247, P101, DOI 10.1016/0014-5793(89)81249-9; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SARASTE M, 1989, ANN NY ACAD SCI, V550, P314; SHERMAN D, 1991, P NATL ACAD SCI USA, V88, P4265, DOI 10.1073/pnas.88.10.4265; STEVENS TH, 1981, J BIOL CHEM, V256, P1069; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8	40	115	116	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					2105	2113						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1309809				2022-12-27	WOS:A1992HA48500104
J	CAPASSO, JM; HOVING, S; TAL, DM; GOLDSHLEGER, R; KARLISH, SJD				CAPASSO, JM; HOVING, S; TAL, DM; GOLDSHLEGER, R; KARLISH, SJD			EXTENSIVE DIGESTION OF NA+,K+-ATPASE BY SPECIFIC AND NONSPECIFIC PROTEASES WITH PRESERVATION OF CATION OCCLUSION SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA+ + K+)-ATPASE; AMINO-ACID-SEQUENCE; BETA-SUBUNIT; SARCOPLASMIC-RETICULUM; ALPHA-SUBUNIT; CHYMOTRYPTIC CLEAVAGE; TRANSMEMBRANE DOMAIN; COMPLEMENTARY-DNA; CATALYTIC SUBUNIT; OUTER MEDULLA	This paper extends our recent report that renal Na+,K+-ATPase is digested by trypsin in the absence of Ca2+ and presence of Rb+ ions to a stable 19-kDa fragment and smaller membrane-embedded fragments of the alpha-chain and essentially intact beta-chain. These are referred to as "19-kDa membranes." Occlusion of both Rb+ (K+) or Na+ ions is preserved, but ATP-dependent functions are lost (Karlish, S. J. D., Goldshleger, R., and Stein, W. D. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 4566-4570). We now show that extensive digestion with nonselective fungal proteases (Pronase and proteinase K) alone, in combination, or after tryptic digestion can remove up to 70% of membrane protein without destroying Rb+ occlusion. In the most heavily digested membranes, the 19-kDa fragment or a slightly shorter 18.5-kDa fragment and smaller fragments of the alpha-chain remain, whereas the beta-chain is largely digested, leaving smaller membrane-embedded fragments (13-15 kDa). For either trypsin or Pronase digestion, preservation of Rb+ occlusion and the specific fragmentation pattern is observed only in the absence of divalent metal ions (Mg2+ or Ca2+) and presence of either Rb+ or Na+ or congener ions. Tryptic digestion at pH 7.0 can split the beta-chain into two fragments of almost-equal-to 50 and 16 kDa joined by an S-S bridge. The 16-kDa fragment is protected against further digestion by the presence of Rb+ ions, but probably is not directly involved in occluding cations. Tryptic 19-kDa membranes show a clear and reproducible fragmentation pattern in which all predicted membrane segments are identifiable. Families of fragments from 19-kDa membranes, including seven peptides of 7.6-11.7 kDa, have been separated by size-exclusion high performance liquid chromatography, concentrated, and resolved on 16.5% Tricine gels. N-terminal sequences of the different fragments have been determined after transfer to polyvinylidene difluoride paper. The most interesting findings are as follows. (a) Whereas the 19-kDa tryptic fragment begins at Asn831 as reported previously, the 18.5-kDa Pronase fragment begins at Thr834. (b) Fragments in tryptic 19-kDa membranes of 7.6-11.7 kDa begin at Asp68, Ile263, and Gln737, respectively. These include all putative transmembrane segments other than those in the 19-kDa fragment. (c) A Pronase fragment of 7.8 kDa begins at Thr834, i.e apparently the 19-kDa fragment has been partially cut, without loss of Rb+ occlusion. (d) Tryptic 16- and almost-equal-to 50-kDa fragments of the beta-chain begin at Ala5 and Gly143, respectively. Immunoblots with an antibody against the terminal 4 residues of the alpha-chain show that both the 19-kDa tryptic and 18.5-kDa Pronase fragments extend to the C terminus of the chain. The experiments with trypsin, Pronase, and proteinase K strongly suggest that Rb+ occlusion sites are located within transmembrane segments, including those of the 19-kDa fragment and at least one of the smaller fragments. The resistance of the 19-kDa fragment to further digestion implies that it is largely embedded within the membrane and is inaccessible to essentially any protease. Different possibilities for transmembrane folding of the tryptic fragments are discussed with the purpose of constructing models of cation sites. The findings with the nonselective proteases are most easily understood on the basis of models with 10 transmembrane segments, as proposed for sarcoplasmic reticulum Ca2+-ATPase.	WEIZMANN INST SCI, DEPT BIOCHEM, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science					PHS HHS [322286] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAYER R, 1990, BIOCHEMISTRY-US, V29, P2251, DOI 10.1021/bi00461a007; BROWN TA, 1987, BIOCHIM BIOPHYS ACTA, V912, P244, DOI 10.1016/0167-4838(87)90095-1; CHIN GJ, 1985, BIOCHEMISTRY-US, V24, P5943, DOI 10.1021/bi00342a038; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; COLLINS JH, 1987, BIOCHEMISTRY-US, V26, P8665, DOI 10.1021/bi00400a026; FARLEY RA, 1986, BIOCHIM BIOPHYS ACTA, V873, P136, DOI 10.1016/0167-4838(86)90199-8; FORBUSH B, 1983, CURR TOP MEMBR TRANS, V19, P167; GERSHONI JM, 1988, METHOD BIOCHEM ANAL, V33, P1; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GOLDSHLEGER R, 1990, BIOPHYS J, V57, pA17; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P53, DOI 10.1016/0005-2736(74)90293-4; JORGENSEN PL, 1986, BIOCHIM BIOPHYS ACTA, V860, P570, DOI 10.1016/0005-2736(86)90555-9; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; JORGENSEN PL, 1985, BIOCHIM BIOPHYS ACTA, V821, P319, DOI 10.1016/0005-2736(85)90102-6; JORGENSEN PL, 1975, BIOCHIM BIOPHYS ACTA, V401, P399, DOI 10.1016/0005-2736(75)90239-4; Karlish S J, 1991, Soc Gen Physiol Ser, V46, P129; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KARLISH SJD, 1984, BIOCHIM BIOPHYS ACTA, V776, P288, DOI 10.1016/0005-2736(84)90218-9; KARLISH SJD, 1992, IN PRESS ACTA PHYSL; KAWAKAMI K, 1985, NATURE, V316, P733, DOI 10.1038/316733a0; KIRLEY TL, 1989, J BIOL CHEM, V264, P7185; KRAMER T, 1990, J GEN PHYSIOL, V96, pA32; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATTHEWS I, 1989, BIOCHEM BIOPH RES CO, V161, P683, DOI 10.1016/0006-291X(89)92653-3; MCDONOUGH AA, 1990, FASEB J, V4, P1598, DOI 10.1096/fasebj.4.6.2156741; MILLER RP, 1988, BIOCHIM BIOPHYS ACTA, V954, P50, DOI 10.1016/0167-4838(88)90054-4; MILLER RP, 1990, BIOCHEMISTRY-US, V29, P1524, DOI 10.1021/bi00458a025; MODYANOV NN, 1992, IN PRESS ACTA PHYSL; MOOS M, 1988, J BIOL CHEM, V263, P6005; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P269, DOI 10.1016/0014-5793(87)80676-2; OVCHINNIKOV YA, 1988, FEBS LETT, V227, P230, DOI 10.1016/0014-5793(88)80904-9; SACHS G, 1992, IN PRESS ACTA PHYSL; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHANI M, 1987, BIOCHIM BIOPHYS ACTA, V904, P13, DOI 10.1016/0005-2736(87)90081-2; SHANISEKLER M, 1988, J BIOL CHEM, V263, P19331; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; STREHLER EE, 1991, J MEMBRANE BIOL, V120, P1, DOI 10.1007/BF01868586; XU QY, 1988, ANAL BIOCHEM, V170, P19, DOI 10.1016/0003-2697(88)90084-X	43	163	163	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1150	1158						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1309764				2022-12-27	WOS:A1992GY96000075
J	RAKSHIT, D; VASAK, M				RAKSHIT, D; VASAK, M			STUDIES ON THE ASSEMBLY AND STABILITY OF THE METAL-THIOLATE CLUSTERS OF METALLOTHIONEIN IN DIMETHYL-SULFOXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; 3-DIMENSIONAL STRUCTURE; LIVER; COBALT(II)-METALLOTHIONEIN; SPECTROSCOPY; COMPLEXES; SPECTRA; MCD	Solvent perturbation studies in 100% dimethyl sulfoxide (Me2SO) have been carried out on rabbit liver metallothionein (MT) in an effort to learn more about the factors stabilizing the three-dimensional structure and the mechanism of cluster formation. As indicated by the electronic absorption spectra of Co7-metallothionein, the reconstituted protein preserves its structural integrity in this solvent. Minor spectral differences between water and Me2SO were fully reversible. The titration of apoMT with cobalt(II) in Me2SO, followed by UV-visible-near-infrared electronic absorption, circular dichroism, magnetic circular dichroism, and EPR spectroscopy, indicate that the protein can refold in this solvent. A comparison with the previous titration data in water reveals that the first four titration steps in both solvents are identical, indicating a thermodynamically controlled folding process. However, the reversed order of the cluster completion between Me2SO and water may suggest the involvement of a kinetically controlled folding process in the last three titration steps. A new cluster form developed with approximately nine Co(II) equivalents.	UNIV ZURICH,INST BIOCHEM,WINTERTHURERSTR 190,CH-8057 ZURICH,SWITZERLAND	University of Zurich								ARSENIEV A, 1988, J MOL BIOL, V201, P637, DOI 10.1016/0022-2836(88)90644-4; BERTINI I, 1989, J AM CHEM SOC, V111, P7296, DOI 10.1021/ja00201a002; BUHLER RHO, 1979, METALLOTHIONEIN, P211; CAAI W, 1988, J AM CHEM SOC, V110, P7872; DANCE IG, 1979, J AM CHEM SOC, V101, P6264, DOI 10.1021/ja00515a018; DENNING HG, 1969, S FARADAY SOC, V3, P84; DIXON BA, 1987, RECL TRAV CHIM PAY B, V106, P188; FUREY WF, 1986, SCIENCE, V231, P704, DOI 10.1126/science.3945804; GALE R, 1976, CHEM PHYS LETT, V38, P446, DOI 10.1016/0009-2614(76)80012-7; GOOD M, 1988, BIOCHEMISTRY-US, V27, P7163, DOI 10.1021/bi00418a074; GRASSETTI DR, 1967, ARCH BIOCHEM BIOPHYS, V119, P41, DOI 10.1016/0003-9861(67)90426-2; HAGEN KS, 1984, INORG CHEM, V23, P418, DOI 10.1021/ic00172a009; JACOBSON AL, 1980, BIOCHEMISTRY-US, V19, P4534, DOI 10.1021/bi00560a023; JOHNSON BA, 1987, INORG CHEM, V26, P3139, DOI 10.1021/ic00266a016; KAGI JHR, 1988, BIOCHEMISTRY-US, V27, P8509, DOI 10.1021/bi00423a001; KAGI JHR, 1974, J BIOL CHEM, V249, P3537; KAGI JHR, 1987, EXPER S BASEL, V52, P21; KATO H, 1974, J AM CHEM SOC, V96, P1351, DOI 10.1021/ja00812a016; KIMURA M, 1979, METALLOTHIONEIN, P163; KLIBANOV A M, 1986, Chemtech, V16, P354; MASSON A, 1973, FEBS LETT, V31, P114, DOI 10.1016/0014-5793(73)80086-9; MESSERLE BA, 1990, J MOL BIOL, V214, P765, DOI 10.1016/0022-2836(90)90291-S; MONTELIONE GT, 1989, ACCOUNTS CHEM RES, V22, P70, DOI 10.1021/ar00158a004; OTVOS JD, 1980, P NATL ACAD SCI-BIOL, V77, P7094, DOI 10.1073/pnas.77.12.7094; Palmer G., 1967, METHOD ENZYMOL, V10, P594; ROBBINS AH, 1991, IN PRESS J MOL BIOL; SCHULTZE P, 1988, J MOL BIOL, V203, P251, DOI 10.1016/0022-2836(88)90106-4; TANFORD C, 1968, ADVANCES PROTEIN CHE, V23, P122; VASAK M, 1981, BIOCHEMISTRY-US, V20, P6659, DOI 10.1021/bi00526a021; VASAK M, 1980, J AM CHEM SOC, V102, P3953, DOI 10.1021/ja00531a048; VASAK M, 1981, P NATL ACAD SCI-BIOL, V78, P6709, DOI 10.1073/pnas.78.11.6709; VASAK M, 1983, MET IONS BIOL SYST, V15, P213; WAGNER G, 1986, J MOL BIOL, V187, P131, DOI 10.1016/0022-2836(86)90413-4; WEAKLIEM HA, 1962, J CHEM PHYS, V36, P2117, DOI 10.1063/1.1732840; ZAKS A, 1988, J BIOL CHEM, V263, P3194; ZENG J, 1990, Experientia (Basel), V46, pA37	36	3	3	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					235	238						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1309734				2022-12-27	WOS:A1992GY43900041
J	YONEZAWA, K; YOKONO, K; SHII, K; OGAWA, W; ANDO, A; HARA, K; BABA, S; KABURAGI, Y; YAMAMOTOHONDA, R; MOMOMURA, K; KADOWAKI, T; KASUGA, M				YONEZAWA, K; YOKONO, K; SHII, K; OGAWA, W; ANDO, A; HARA, K; BABA, S; KABURAGI, Y; YAMAMOTOHONDA, R; MOMOMURA, K; KADOWAKI, T; KASUGA, M			INVITRO ASSOCIATION OF PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY WITH THE ACTIVATED INSULIN-RECEPTOR TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SIGNAL TRANSDUCTION; INTACT-CELLS; BOVINE BRAIN; BETA-SUBUNIT; FACTOR-I; PHOSPHORYLATION; PROTEIN; IDENTIFICATION; RESIDUES	We previously have shown that insulin treatment of cells greatly increases the activity of phosphatidylinositol (PI) 3-kinase in immunoprecipitates made with an antibody to phosphotyrosine. However, the association of PI 3-kinase activity with the activated insulin receptor is not significant under these conditions. In the present study, we have attempted to reconstitute the association of PI 3-kinase activity with the activated insulin receptor in vitro. PI 3-kinase activity does indeed associate with the autophosphorylated insulin receptor in our in vitro system. The autophosphorylation of the insulin receptor and/or its associated conformational change appear to be necessary for the association of PI 3-kinase activity with the receptor, since kinase negative receptor failed to bind PI 3-kinase activity. After binding, PI 3-kinase or its associated protein seems to be released from the activated receptor after the completion of its tyrosine phosphorylation by the receptor. Tyr960 in the juxtamembrane region of the insulin receptor beta-subunit seems to be involved in the association of PI 3-kinase activity with the receptor, but not C terminus region of the beta-subunit including two tyrosine autophosphorylation sites (Tyr1316 and Tyr1322). The in vitro assay system for the association of PI 3-kinase activity with the insulin receptor can be utilized to study the mechanism of interaction of these molecules and will be an useful method to detect other associated molecules with the insulin receptor.	KOBE UNIV,SCH MED,DEPT INTERNAL MED 2,7-5-1 KUSUNOKI CHO,CHUO KU,KOBE 650,JAPAN; HYOGO INST CLIN RES,AKASHI 673,JAPAN; UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN	Kobe University; University of Tokyo			OGAWA, Wataru/AAQ-9586-2020					AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1990, J BIOL CHEM, V265, P16450; BECKER AB, 1990, ANNU REV MED, V41, P99; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CAPENTER CL, 1990, J BIOL CHEM, V265, P19704; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; FUKUI Y, 1989, ONCOGENE RES, V4, P283; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KADOWAKI H, 1989, GENE, V76, P161, DOI 10.1016/0378-1119(89)90018-8; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KASUGA M, 1983, P NATL ACAD SCI-BIOL, V80, P2137, DOI 10.1073/pnas.80.8.2137; KASUGA M, 1990, DIABETES CARE, V13, P317, DOI 10.2337/diacare.13.3.317; KOSHIO O, 1989, FEBS LETT, V254, P22, DOI 10.1016/0014-5793(89)81001-4; LEWIS RE, 1990, BIOCHEMISTRY-US, V29, P1807, DOI 10.1021/bi00459a020; LIPS DL, 1989, J BIOL CHEM, V264, P8759; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MYERS MG, 1991, J BIOL CHEM, V266, P10616; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; ROTH RA, 1988, COLD SPRING HARB SYM, V53, P537, DOI 10.1101/SQB.1988.053.01.062; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WHITE MF, 1987, J BIOL CHEM, V262, P9769; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YAMAMOTOHONDA R, 1990, J BIOL CHEM, V265, P14777; YONEZAWA K, 1991, IN PRESS INSULIN INS	50	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					440	446						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1309746				2022-12-27	WOS:A1992GY43900071
J	SUGIYAMA, H; CHEN, P; HUNTER, M; TAFFS, R; SITKOVSKY, M				SUGIYAMA, H; CHEN, P; HUNTER, M; TAFFS, R; SITKOVSKY, M			THE DUAL ROLE OF THE CAMP-DEPENDENT PROTEIN-KINASE C-ALPHA SUBUNIT IN T-CELL RECEPTOR-TRIGGERED LYMPHOCYTES-T EFFECTOR FUNCTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE CARDIAC-MUSCLE; AMINO-ACID-SEQUENCE; REGULATORY SUBUNIT; CATALYTIC SUBUNIT; CYCLIC-AMP; ANTISENSE OLIGONUCLEOTIDES; MEDIATED CYTOTOXICITY; GENE-EXPRESSION; INHIBITION; TRANSCRIPTION	In order to directly evaluate the role of the cAMP-dependent protein kinase (PKA) catalytic (C) subunit in T-cell receptor- (TCR) triggered cytotoxic T-lymphocytes (CTL) effector functions, cells were studied after pretreatment with antisense oligomers complementary to mRNA for the Calpha or Cbeta subunits. Calpha subunit is shown to be predominantly expressed in CTL. In some experiments the pretreatment of the CTL with the Calpha antisense, but not with the control or Cbeta antisense oligomers, resulted in the inhibition of cAMP-independent PKA activity without significantly affecting the level of total cAMP-inducible PKA activity. In parallel assays, CTL which were pretreated with the Calpha antisense oligomer had enhanced antigen-bearing target cell-triggered-, anti-TCR monoclonal antibody-triggered-, and phorbol 12-myristate 13-acetate/A23187-triggered exocytosis of granules, as well as enhanced antigen-specific cytotoxicity. In contrast, the TCR-triggered gamma-interferon mRNA expression and gamma-interferon secretion were inhibited in Calpha antisense-pretreated CTL. These results suggest that the Calpha subunit of PKA may have a dual role in regulation of T-lymphocytes effector functions: (i) it may down-regulate TCR-triggered protein-synthesis independent responses such as cytotoxicity and exocytosis, thereby counteracting TCR-triggered activation even in the absence of the second messenger, cAMP, and (ii) the Calpha subunit activity is likely to be required for the nuclear and/or cytoplasmic events in CTL's activation involved in lymphokine synthesis and secretion.	NIAID, IMMUNOL LAB, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								ACHAORBEA H, 1990, EMBO J, V9, P3815, DOI 10.1002/j.1460-2075.1990.tb07599.x; ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; BOSHART M, 1991, CELL, V66, P849, DOI 10.1016/0092-8674(91)90432-X; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; COHEN JS, 1989, OLIGODEOXYNUCLEOTIDE; CORBIN JD, 1975, J BIOL CHEM, V250, P218; CURRY RC, 1987, J IMMUNOL METHODS, V104, P137, DOI 10.1016/0022-1759(87)90497-2; ERICKSON RP, 1991, GENE REGULATION BIOL; ERLICHMAN J, 1974, J BIOL CHEM, V249, P5000; FORTIER AH, 1989, CELL IMMUNOL, V124, P64, DOI 10.1016/0008-8749(89)90112-3; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GRABSTEIN K, 1980, SELECTED METHODS CEL, P124; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; LEONETTI JP, 1991, P NATL ACAD SCI USA, V88, P2702, DOI 10.1073/pnas.88.7.2702; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MATSUKURA M, 1987, P NATL ACAD SCI USA, V84, P7706, DOI 10.1073/pnas.84.21.7706; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MOSMANN TR, 1989, J IMMUNOL METHODS, V116, P151, DOI 10.1016/0022-1759(89)90198-1; PASTERNACK MS, 1986, NATURE, V322, P740, DOI 10.1038/322740a0; PETERS KA, 1977, BIOCHEMISTRY-US, V16, P5691, DOI 10.1021/bi00645a007; RIABOWOL KT, 1988, NATURE, V336, P83, DOI 10.1038/336083a0; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; SHOJI S, 1981, P NATL ACAD SCI-BIOL, V78, P848, DOI 10.1073/pnas.78.2.848; SITKOVSKY MV, 1988, ANN NY ACAD SCI, V532, P350, DOI 10.1111/j.1749-6632.1988.tb36352.x; SITKOVSKY MV, 1988, IMMUNOL REV, V103, P127, DOI 10.1111/j.1600-065X.1988.tb00754.x; STAERZ UD, 1985, NATURE, V314, P628, DOI 10.1038/314628a0; STAERZ UD, 1985, J IMMUNOL, V134, P3994; TAFFS RE, 1991, J IMMUNOL, V147, P722; TAKAYAMA H, 1988, J BIOL CHEM, V263, P2330; TAKAYAMA H, 1987, J EXP MED, V166, P725, DOI 10.1084/jem.166.3.725; TAKIO K, 1982, P NATL ACAD SCI-BIOL, V79, P2544, DOI 10.1073/pnas.79.8.2544; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; TORTORA G, 1990, P NATL ACAD SCI USA, V87, P705, DOI 10.1073/pnas.87.2.705; TOULME JJ, 1988, GENE, V72, P51, DOI 10.1016/0378-1119(88)90127-8; UHLER MD, 1986, J BIOL CHEM, V261, P5360; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WALSH DA, 1971, J BIOL CHEM, V246, P1977; WATSON PH, 1991, CANCER RES, V51, P3996; WHITEHOUSE S, 1983, METHOD ENZYMOL, V99, P80; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z	48	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25256	25263						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1281154				2022-12-27	WOS:A1992KB60300054
J	TORCHIA, J; LYTLE, C; PON, DJ; FORBUSH, B; SEN, AK				TORCHIA, J; LYTLE, C; PON, DJ; FORBUSH, B; SEN, AK			THE NA-K-CL COTRANSPORTER OF AVIAN SALT-GLAND - PHOSPHORYLATION IN RESPONSE TO CAMP-DEPENDENT AND CALCIUM-DEPENDENT SECRETAGOGUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ION-TRANSPORT; CYCLIC-AMP; PROTEIN-PHOSPHORYLATION; NA/K/2CL COTRANSPORT; BUMETANIDE BINDING; CELLS; CHLORIDE; STIMULATION; RECEPTORS; MEMBRANES	The effect of a cAMP-dependent secretogogue (VIP) on the phosphorylation of an endogenous, membrane-bound protein (pp170) was assessed in an intact cell preparation from the avian salt gland. The addition of VIP, in the presence of 100 muM isobutylmethylxanthine, resulted in a concentration-dependent increase in phosphorylation of pp170. This effect was rapid and transient with a 3-5-fold increase in phosphorylation occurring 1 min after the addition of VIP. Under similar incubation conditions, VIP stimulated a 4.6-fold increase in cAMP accumulation that paralleled phosphorylation. Exposure of cells to either forskolin or 8-Br-cAMP resulted in a 5-8-fold increase in the phosphorylation of pp170. The effect of forskolin was dose dependent with an EC50 similar to that for stimulation of secretion (35 nM). These results implicate an involvement for a cAMP-dependent protein kinase in the phosphorylation of pp170. The identity of pp170 was assessed utilizing a monoclonal antibody (Q3) directed against pp170. Q3 recognized a single 170-kDa band on Western blots of salt gland membrane protein. Immunoprecipitation of pp170 from salt gland cells resulted in the selective extraction of a single protein whose phosphorylation state was increased approximately 5-fold in response to carbachol or VIP. The identity of pp170 was established using two criteria. First, Q3 recognized affinity-purified Na:K:Cl cotransporter preparations from shark rectal gland membranes. Second, pp170 was selectively immunoprecipitated by monoclonal antibodies (J3, J4, and J7) that recognize different epitopes of the shark transport protein. These results suggest that pp170 is homologous to the shark rectal gland Na-K-Cl cotransporter, and thus the proteins may be functionally similar.	YALE UNIV,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06520; MERCK FROSST CANADA INC,MERCK FROSST CTR THERAPEUT RES,KIRKLAND H9H 3L1,QUEBEC,CANADA	Yale University; Merck & Company	TORCHIA, J (corresponding author), UNIV TORONTO,DEPT PHARMACOL,TORONTO M5S 1A8,ONTARIO,CANADA.			Lytle, Christian/0000-0001-5442-1546	NIDDK NIH HHS [DK-17433] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK017433] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; COHEN JA, 1987, AM J PHYSIOL, V253, pG420; COHN JA, 1990, AM J PHYSIOL, V258, pC227, DOI 10.1152/ajpcell.1990.258.2.C227; DHARMSATHAPHORN K, 1985, J CLIN INVEST, V75, P462, DOI 10.1172/JCI111721; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; ERNST SA, 1982, J PHYSIOL-LONDON, V325, P333, DOI 10.1113/jphysiol.1982.sp014153; FANGE R, 1958, AM J PHYSIOL, V195, P321, DOI 10.1152/ajplegacy.1958.195.2.321; FORBUSH B, 1992, AM J PHYSIOL, V262, pC1000, DOI 10.1152/ajpcell.1992.262.4.C1000; FOSKETT JK, 1982, J COMP PHYSIOL, V146, P27, DOI 10.1007/BF00688713; FREDHOLM BB, 1982, ACTA PHYSIOL SCAND, V114, P157, DOI 10.1111/j.1748-1716.1982.tb06966.x; GERSTBERGER R, 1988, AM J PHYSIOL, V255, pR575, DOI 10.1152/ajpregu.1988.255.4.R575; HAAS M, 1986, J BIOL CHEM, V261, P8434; HAAS M, 1989, ANNU REV PHYSIOL, V51, P443, DOI 10.1146/annurev.physiol.51.1.443; HAAS M, 1988, BIOCHIM BIOPHYS ACTA, V939, P131, DOI 10.1016/0005-2736(88)90054-5; HOLMES WN, 1985, BIOL REV, V60, P213, DOI 10.1111/j.1469-185X.1985.tb00715.x; HOOTMAN SR, 1980, AM J PHYSIOL, V238, pC184, DOI 10.1152/ajpcell.1980.238.5.C184; HOOTMAN SR, 1982, AM J PHYSIOL, V243, pC254, DOI 10.1152/ajpcell.1982.243.5.C254; HOOTMAN SR, 1981, J CELL BIOL, V91, P781, DOI 10.1083/jcb.91.3.781; LEVITAN IB, 1988, ANNU REV NEUROSCI, V11, P119, DOI 10.1146/annurev.neuro.11.1.119; LOWY RJ, 1987, AM J PHYSIOL, V253, pR801, DOI 10.1152/ajpregu.1987.253.6.R801; LOWY RJ, 1987, AM J PHYSIOL, V252, pC670, DOI 10.1152/ajpcell.1987.252.6.C670; LOWY RJ, 1989, AM J PHYSIOL, V256, pR1184, DOI 10.1152/ajpregu.1989.256.6.R1184; LYTLE C, 1990, J GEN PHYSIOL, V96, pA44; LYTLE C, 1992, J BIOL CHEM, P25438; MARSHALL J, 1991, J BIOL CHEM, V266, P22749; OGRADY SM, 1987, AM J PHYSIOL, V253, pC177, DOI 10.1152/ajpcell.1987.253.2.C177; PEWITT EB, 1990, J BIOL CHEM, V265, P14364; PEWITT EB, 1990, J BIOL CHEM, V265, P20747; REUSS L, 1984, FED PROC, V43, P2488; SEAMON KB, 1983, TRENDS PHARMACOL SCI, V4, P120, DOI 10.1016/0165-6147(83)90326-7; SEN AK, 1964, J BIOL CHEM, V239, P345; SHUTTLEWORTH TJ, 1987, AM J PHYSIOL, V252, pR428, DOI 10.1152/ajpregu.1987.252.2.R428; SHUTTLEWORTH TJ, 1989, AM J PHYSIOL 1, V257, pC1020; STEWARD CM, 1990, ELECTROLYTE WATER TR; STOFF JS, 1979, AM J PHYSIOL, V237, pF138, DOI 10.1152/ajprenal.1979.237.2.F138; STUENKEL EL, 1990, AM J PHYSIOL, V258, pC289, DOI 10.1152/ajpcell.1990.258.2.C289; TORCHIA J, 1991, AM J PHYSIOL, V261, pC543, DOI 10.1152/ajpcell.1991.261.3.C543; WELSH MJ, 1987, PHYSIOL REV, V67, P1143, DOI 10.1152/physrev.1987.67.4.1143	38	65	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25444	25450						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1281159				2022-12-27	WOS:A1992KB60300081
J	MORITZ, A; DEGRAAN, PNE; GISPEN, WH; WIRTZ, KWA				MORITZ, A; DEGRAAN, PNE; GISPEN, WH; WIRTZ, KWA			PHOSPHATIDIC-ACID IS A SPECIFIC ACTIVATOR OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DIACYLGLYCEROL KINASE; INOSITOL TRISPHOSPHATE; PLATELET ACTIVATION; PHOSPHOLIPASE-C; 2ND MESSENGER; RAT-BRAIN; PURIFICATION; 4,5-BISPHOSPHATE; SPHINGOSINE; INHIBITION	The lipid dependence of phosphatidylinositol-4-phosphate (PIP) kinase purified from bovine brain membranes was investigated. In the assay used, PIP-Triton X-100 micelles containing the lipid to be tested were presented to the enzyme. Under these conditions, phosphatidic acid (PA) stimulated the enzyme activity in a concentration-dependent manner up to 20-fold when an equal molar ratio of PA to PIP was attained. Stimulation by PA was highly specific; other lipids including lyso-PA and dicetylphosphate had a relatively small effect. The activation by PA was completely suppressed by phosphatidylinositol 4,5-bisphosphate (PIP2). To investigate the effect of PA on PIP kinase activity in natural membranes, endogenous PA was generated in rat brain synaptosomal plasma membranes by incubation with phospholipase D. Subsequent phosphorylation with [gamma-P-32]ATP yielded an enhanced labeling of PIP2 but not of PIP in these membranes. These results suggest that PIP kinase activity may be under control of PA levels in membranes. This may have important implications for the regulation of cellular responses by agonist-induced phosphoinositide turnover.	UNIV UTRECHT,CTR BIOMEMBRANES & LIPID ENZYMOL,POB 80054,3508 TB UTRECHT,NETHERLANDS; UNIV UTRECHT,RUDOLF MAGNUS INST,DIV MOLEC NEUROBIOL,3508 TB UTRECHT,NETHERLANDS; UNIV UTRECHT,INST MOLEC BIOL & MED BIOTECHNOL,3508 TB UTRECHT,NETHERLANDS	Utrecht University; Utrecht University; Utrecht University								BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; COCHET C, 1986, BIOCHEM J, V237, P25, DOI 10.1042/bj2370025; DECOURCELLES DD, 1989, J BIOL CHEM, V264, P3274; FARAGO A, 1990, FEBS LETT, V268, P350, DOI 10.1016/0014-5793(90)81284-U; GADELLA TWJ, 1990, BIOCHEMISTRY-US, V29, P3389, DOI 10.1021/bi00465a035; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HENDRICKSON HS, 1964, J BIOL CHEM, V239, P1369; JACKOWSKI S, 1989, ARCH BIOCHEM BIOPHYS, V268, P516, DOI 10.1016/0003-9861(89)90318-4; JALINK K, 1990, J BIOL CHEM, V265, P12232; JOLLES J, 1981, BIOCHEM J, V194, P283, DOI 10.1042/bj1940283; KANOH H, 1983, J BIOL CHEM, V258, P1767; KNAUSS TC, 1990, J BIOL CHEM, V265, P14457; KRISTJANSSON GI, 1982, J NEUROCHEM, V39, P371, DOI 10.1111/j.1471-4159.1982.tb03958.x; KROLL MH, 1989, J CELL PHYSIOL, V139, P558, DOI 10.1002/jcp.1041390315; LEE MH, 1991, BIOCHEMISTRY-US, V30, P1041, DOI 10.1021/bi00218a023; LING LE, 1989, J BIOL CHEM, V264, P5080; MICHELL RH, 1975, BIOCHIM BIOPHYS ACTA, V415, P81, DOI 10.1016/0304-4157(75)90017-9; MORITZ A, 1990, J NEUROCHEM, V54, P351, DOI 10.1111/j.1471-4159.1990.tb13322.x; MURAYAMA T, 1987, J BIOL CHEM, V262, P5522; QUIAN Z, 1990, J BIOL CHEM, V265, P3607; QUIAN Z, 1991, FASEB J, V5, P315; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; SAKANE F, 1989, FEBS LETT, V255, P409, DOI 10.1016/0014-5793(89)81134-2; SHUKLA SD, 1991, LIFE SCI, V48, P851, DOI 10.1016/0024-3205(91)90031-6; SHUTO S, 1987, TETRAHEDRON LETT, V28, P199, DOI 10.1016/S0040-4039(00)95685-5; TONER M, 1988, BIOCHEMISTRY-US, V27, P7435, DOI 10.1021/bi00419a039	29	340	346	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7207	7210						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1313792				2022-12-27	WOS:A1992HN48500004
J	ECKE, S; GEIGER, M; RESCH, I; JERABEK, I; STINGL, L; MAIER, M; BINDER, BR				ECKE, S; GEIGER, M; RESCH, I; JERABEK, I; STINGL, L; MAIER, M; BINDER, BR			INHIBITION OF TISSUE KALLIKREIN BY PROTEIN-C INHIBITOR - EVIDENCE FOR IDENTITY OF PROTEIN-C INHIBITOR WITH THE KALLIKREIN BINDING-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLANDULAR KALLIKREIN; URINARY KALLIKREIN; PLASMA; PURIFICATION; UROKINASE; ALPHA-1-ANTITRYPSIN; IDENTIFICATION; EXPRESSION; FAMILY	We studied the inhibition of tissue kallikrein by protein C inhibitor (PCI), a relatively unspecific heparin-dependent serine protease inhibitor present in plasma and urine. PCI inhibited the amidolytic activity (cleavage of H-D-valyl-L-leucyl-arginine-p-nitroaniline) of urinary kallikrein with an apparent second order rate constant of 2.3 x 10(4) M-1 s-1 and formed stable complexes (85 kDa) with urinary kallikrein as judged from silver-stained sodium dodecyl sulfate-polyacrylamide gels. Complex formation was time-dependent and was paralleled by a decrease in the intensity of the main PCI protein band (M(r) = 57,000) and an increase in the intensity of the lower M(r) (54,000) PCI form (cleaved inhibitor). Heparin interfered with the inhibition of tissue kallikrein by PCI and with the formation of tissue kallikrein-PCI complexes in a dose-dependent fashion and completely abolished PCI-tissue kallikrein interaction at 300-mu-g/ml. This is in contrast to findings on the interaction of PCI with all other target proteases studied so far (i.e. stimulation of inhibition by heparin) but is similar to the reaction pattern of I-125-labeled tissue kallikrein with so called kallikrein binding protein described in serum and other systems. To study a possible relationship between PCI and this kallikrein binding protein we incubated I-125-labeled urinary kallikrein in serum and in PCI-immunodepleted serum in the absence and presence of heparin and analyzed complex formation using sodium dodecyl sulfate-polyacrylamide gel electrophoresis. In normal serum, formed complexes co-migrated with complexes of purified PCI and I-125-kallikrein and were less intense in the presence of heparin. No complex formation at all was seen in PCI-depleted serum. Our data indicate that PCI may be a physiologically important endogenous inhibitor of tissue kallikrein and provide evidence that PCI may be identical to the previously described kallikrein binding protein.	UNIV VIENNA,DEPT MED PHYSIOL,CLIN EXPTL PHYSIOL LAB,SCHWARZSPANIERSTR 17,A-1090 VIENNA,AUSTRIA; TECHNOCLONE LTD,A-1090 VIENNA,AUSTRIA	University of Vienna				Geiger, Margarethe/0000-0003-2021-5319				ASAKAWA K, 1980, NATURE, V288, P705; BRADY JM, 1990, ARCH BIOCHEM BIOPHYS, V278, P342, DOI 10.1016/0003-9861(90)90269-5; CHAO J, 1986, BIOCHEM J, V239, P325, DOI 10.1042/bj2390325; CHAO J, 1987, DEC P S REN FUNCT HY, P67; CHEN LM, 1990, BIOCHEM J, V267, P79, DOI 10.1042/bj2670079; CLEMENTS JA, 1989, ENDOCR REV, V10, P393, DOI 10.1210/edrv-10-4-393; ELTHAHER TS, 1990, BIOCHIM BIOPHYS ACTA, V1034, P157, DOI 10.1016/0304-4165(90)90070-D; GEIGER M, 1988, Fibrinolysis, V2, P183, DOI 10.1016/0268-9499(88)90011-2; GEIGER M, 1989, BLOOD, V74, P722; GEIGER R, 1981, H-S Z PHYSIOL CHEM, V362, P317, DOI 10.1515/bchm2.1981.362.1.317; HEEB MJ, 1987, J BIOL CHEM, V262, P15813; HIWADA K, 1983, HYPERTENSION, V5, P191, DOI 10.1161/01.HYP.5.2.191; IDEISHI M, 1990, NEPHRON, V55, P62; JOVOV B, 1990, AM J PHYSIOL, V259, pC869, DOI 10.1152/ajpcell.1990.259.6.C869; KAMADA M, 1990, CHEM PHARM BULL, V38, P1053; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURELL M, 1991, THROMB HAEMOSTASIS, V65, P854; LAURELL M, 1990, BLOOD, V76, P2290; MAIER M, 1988, CLIN CHIM ACTA, V178, P127, DOI 10.1016/0009-8981(88)90219-7; MARKWELL MAK, 1978, BIOCHEMISTRY-US, V17, P4807, DOI 10.1021/bi00615a031; MARUTA H, 1983, BIOCHEM J, V213, P193, DOI 10.1042/bj2130193; MEIJERS JCM, 1988, BIOCHEMISTRY-US, V27, P4231, DOI 10.1021/bi00412a005; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; OLEMOIYOI O, 1979, P NATL ACAD SCI USA, V76, P3121, DOI 10.1073/pnas.76.7.3121; RESCH I, 1991, INT C KIN 91 8 14 SE, P199; SCICLI AG, 1986, KIDNEY INT, V29, P120, DOI 10.1038/ki.1986.14; STUMP DC, 1986, J BIOL CHEM, V261, P2759; SUZUKI K, 1989, THROMB HAEMOSTASIS, V61, P337; SUZUKI K, 1984, J BIOCHEM, V95, P187, DOI 10.1093/oxfordjournals.jbchem.a134583; WOJTA J, 1986, THROMB HAEMOSTASIS, V55, P347	30	76	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					7048	7052						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1313031				2022-12-27	WOS:A1992HM05300090
J	HAWKES, MJ; NELSON, TE; HAMILTON, SL				HAWKES, MJ; NELSON, TE; HAMILTON, SL			[H-3] RYANODINE AS A PROBE OF CHANGES IN THE FUNCTIONAL-STATE OF THE CA2+-RELEASE CHANNEL IN MALIGNANT HYPERTHERMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; CA-2+ RELEASE CHANNEL; PURIFIED RYANODINE RECEPTOR; INDUCED CA RELEASE; SKELETAL-MUSCLE; CALCIUM-RELEASE; MOLECULAR-CLONING; ADENINE-NUCLEOTIDES; BINDING; PURIFICATION	The defect in malignant hyperthermia (MH) alters the binding of [H-3]ryanodine to the Ca2+-release channel by increasing its apparent affinity for the binding site. In sarcoplasmic reticulum (SR) membranes from both normal and mutant pigs the apparent K(d) is dependent on a number of parameters. Adenosine 5'-(beta,gamma-methylene)triphosphate, ionic strength, and Ca2+ each increase the apparent affinity of the binding site for [H-3]ryanodine. Equilibrium and kinetic evaluation of the binding of [H-3]ryanodine to these membranes demonstrates that the MH defect in pigs increases the apparent affinity of the membranes for [H-3]ryanodine by increasing the amount of high affinity relative to low affinity binding sites. Both the association and dissociation of [H-3]ryanodine with all three types of membranes (normal, heterozygous MH, homozygous MH) are characterized by two or more components, with the relative ratios of these components altered by the MH defect. These findings suggest that the observed K(d) is the weighted average of the binding of ryanodine to two or more interconvertible states of the channel. Dilution of [H-3]ryanodine bound to normal membranes at high Ca2+ into low Ca2+ solutions enhances the rate of dissociation. This conversion occurs to a much lesser extent with MH membranes, suggesting that the MH defect may alter the rate at which the high affinity form of the protein converts to the low affinity form.	BAYLOR COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030; UNIV TEXAS,HLTH SCI CTR,DEPT ANESTHESIOL,HOUSTON,TX 77030	Baylor College of Medicine; University of Texas System; University of Texas Health Science Center Houston				Hamilton, Susan/0000-0003-0241-9369	NHLBI NIH HHS [HL-37028] Funding Source: Medline; NIGMS NIH HHS [GM-23875] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037028] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023875] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRITT BA, 1987, MALIGNANT HYPERTHERM, pR10; CAMPBELL KP, 1987, J BIOL CHEM, V262, P6460; CHU A, 1990, MOL PHARMACOL, V37, P735; ELLIS FR, 1984, BRIT J ANAESTH, V56, P1267; ENDO M, 1983, BIOMED RES-TOKYO, V4, P83, DOI 10.2220/biomedres.4.83; FILL M, 1990, BIOPHYS J, V50, P471; FUJII J, 1991, SCIENCE, V253, P448, DOI 10.1126/science.1862346; GOLDSTEIN DA, 1979, BIOPHYS J, V26, P235, DOI 10.1016/S0006-3495(79)85247-9; HAMILTON SL, 1989, ANAL BIOCHEM, V183, P31, DOI 10.1016/0003-2697(89)90167-X; HAWKES MJ, 1989, MEMBRANE BIOCHEM, V8, P133, DOI 10.3109/09687688909025827; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P1740; KALOW W, 1970, LANCET, V2, P895, DOI 10.1016/S0140-6736(70)92069-6; KIM DH, 1984, BIOCHIM BIOPHYS ACTA, V775, P320, DOI 10.1016/0005-2736(84)90187-1; KNUDSON CM, 1990, J BIOL CHEM, V265, P2421; LAI FA, 1989, J BIOL CHEM, V264, P16776; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; MACLENNAN DH, 1990, NATURE, V343, P559, DOI 10.1038/343559a0; MARKS AR, 1989, P NATL ACAD SCI USA, V86, P8683, DOI 10.1073/pnas.86.22.8683; MCGREW SG, 1989, BIOCHEMISTRY-US, V28, P1686, DOI 10.1021/bi00430a039; MCSWEENEY DM, 1990, INT J BIOCHEM, V22, P329, DOI 10.1016/0020-711X(90)90134-O; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; MICHALAK M, 1988, BIOCHIM BIOPHYS ACTA, V939, P587, DOI 10.1016/0005-2736(88)90106-X; MICKELSON JR, 1988, J BIOL CHEM, V263, P9310; MICKELSON JR, 1989, AM J PHYSIOL, V257, pC787, DOI 10.1152/ajpcell.1989.257.4.C787; MICKELSON JR, 1986, BIOCHIM BIOPHYS ACTA, V862, P318, DOI 10.1016/0005-2736(86)90234-8; MICKELSON JR, 1990, ARCH BIOCHEM BIOPHYS, V278, P251, DOI 10.1016/0003-9861(90)90255-W; NELSON TE, 1983, ANESTH ANALG, V62, P545; NELSON TE, 1991, J PHARMACOL EXP THER, V256, P645; NELSON TE, 1983, J CLIN INVEST, V72, P862, DOI 10.1172/JCI111057; NELSON TE, 1973, INT S MALIGNANT HYPE, P191; OHNISHI ST, 1983, FEBS LETT, V161, P103; OHTA T, 1989, AM J PHYSIOL, V256, pC358, DOI 10.1152/ajpcell.1989.256.2.C358; OTSU K, 1990, J BIOL CHEM, V265, P13472; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; PESSAH IN, 1991, MOL PHARMACOL, V39, P679; ROUSSEAU E, 1988, ARCH BIOCHEM BIOPHYS, V267, P75, DOI 10.1016/0003-9861(88)90010-0; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; SMITH JS, 1985, NATURE, V316, P446, DOI 10.1038/316446a0; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; WYSKOVSKY W, 1990, EUR J BIOCHEM, V194, P549, DOI 10.1111/j.1432-1033.1990.tb15651.x; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	44	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6702	6709						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1313019				2022-12-27	WOS:A1992HM05300039
J	VASQUEZVIVAR, J; AUGUSTO, O				VASQUEZVIVAR, J; AUGUSTO, O			HYDROXYLATED METABOLITES OF THE ANTIMALARIAL DRUG PRIMAQUINE - OXIDATION AND REDOX CYCLING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPIN-RESONANCE-SPECTRA; HUMAN-ERYTHROCYTES; HYDROGEN-PEROXIDE; RADICAL FORMATION; SUPEROXIDE ANION; BLOOD-CELLS; AUTOXIDATION; INVITRO; SYSTEMS; IDENTIFICATION	Oxidation and redox cycling of the hydroxylated metabolites of the antimalarial drug primaquine (i.e. 5-hydroxyprimaquine, 5-hydroxydemethylprimaquine, and 5,6-dihydroxy-8-aminoquinoline) were studied. The three metabolites readily oxidized under physiological conditions, forming hydrogen peroxide and the corresponding quinone-imine derivatives as the main products. The latter compounds were characterized by visible, NMR, and infrared spectroscopy. Concomitant formation of drug-derived radicals and hydroxyl radicals was attested by direct and spin-trapping EPR experiments, respectively. The use of the spin stabilization method indicated that the radicals derived from 5-hydroxydemethylprimaquine and 5,6-dihydroxy-8-aminoquinoline are of the o-semiquinone type. Tentative structures are proposed for the radicals based on product identification and computer simulation of the experimental EPR spectra. The quinone-imines obtained from the reduced metabolites did not react at appreciable rates with NADPH but underwent redox cycling upon addition of ferredoxin:NADP+ oxidoreductase, forming hydrogen peroxide and hydroxyl radicals. The effect of antioxidant enzymes on hydroxyl radical yield obtained during oxidation and redox cycling indicates that the main route for hydroxyl radical formation is the metal ion-catalyzed reaction between the drug-derived radicals and hydrogen peroxide. Taken together, the results indicate that hydrogen peroxide is the potential toxic product formed from the primaquine metabolites.	UNIV SAO PAULO, INST QUIM, DEPT BIOCHEM, CXP 20780, BR-01498 SAO PAULO, BRAZIL	Universidade de Sao Paulo			Augusto, Ohara/D-3839-2012	Augusto, Ohara/0000-0002-7220-4286				AGARWAL S, 1991, BIOCHEM PHARMACOL, V41, P17, DOI 10.1016/0006-2952(91)90005-P; ALLAHYARI R, 1984, J MED CHEM, V27, P407, DOI 10.1021/jm00369a031; AUGUSTO O, 1986, ARCH BIOCHEM BIOPHYS, V244, P147, DOI 10.1016/0003-9861(86)90103-7; AUGUSTO O, 1988, BIOCHEM PHARMACOL, V37, P2791, DOI 10.1016/0006-2952(88)90042-1; BAIRD JK, 1986, BIOCHEM PHARMACOL, V35, P1091, DOI 10.1016/0006-2952(86)90144-9; Berger S., 1988, CHEM QUINONOID COMPO, P29; Beutler E, 1983, METABOLIC BASIS INHE, P1629; BRUNMARK A, 1989, FREE RADICAL BIO MED, V7, P435, DOI 10.1016/0891-5849(89)90126-3; BRUSTOLON M, 1981, J CHEM SOC DALTON, P604, DOI 10.1039/dt9810000604; BUETTNER GR, 1978, BIOCHEM BIOPH RES CO, V83, P69, DOI 10.1016/0006-291X(78)90398-4; BUETTNER GR, 1987, FREE RADICAL BIO MED, V3, P259, DOI 10.1016/S0891-5849(87)80033-3; CARSON PE, 1956, SCIENCE, V124, P484, DOI 10.1126/science.124.3220.484-a; CLAY JDR, 1981, J CHEM SOC FARAD T 2, V77, P1589, DOI 10.1039/f29817701589; COHEN G, 1964, BIOCHEMISTRY-US, V3, P895, DOI 10.1021/bi00895a006; COHEN G, 1963, BIOCHEMISTRY-US, V2, P1420, DOI 10.1021/bi00906a038; EYER P, 1984, BIOCHEM PHARMACOL, V33, P1005, DOI 10.1016/0006-2952(84)90507-0; FELIX CC, 1981, J AM CHEM SOC, V103, P2831, DOI 10.1021/ja00400a056; FLETCHER KA, 1988, BIOCHEM PHARMACOL, V37, P2683, DOI 10.1016/0006-2952(88)90263-8; GAETANI GF, 1989, BLOOD, V73, P334; GIULIVI C, 1990, J BIOL CHEM, V265, P19453; GREENSTOCK CL, 1975, BIOCHIM BIOPHYS ACTA, V396, P11, DOI 10.1016/0005-2728(75)90184-X; GUTTERIDGE JMC, 1985, BIOCHEM PHARMACOL, V34, P4099, DOI 10.1016/0006-2952(85)90200-X; HUFFORD CD, 1983, J HETEROCYCLIC CHEM, V20, P273, DOI 10.1002/jhet.5570200203; KALYANARAMAN B, 1985, ENVIRON HEALTH PERSP, V64, P185, DOI 10.2307/3430009; KAPPUS H, 1986, BIOCHEM PHARMACOL, V35, P1, DOI 10.1016/0006-2952(86)90544-7; KIRKMAN HN, 1987, J BIOL CHEM, V262, P660; Koppenol W. H., 1985, ADV FREE RADICALS BI, V1, P91, DOI DOI 10.1016/8755-9668(85)90005-5; LINK CM, 1985, TOXICOL APPL PHARM, V81, P192, DOI 10.1016/0041-008X(85)90155-3; LOWN JW, 1979, BIOCHEM PHARMACOL, V28, P2563, DOI 10.1016/0006-2952(79)90027-3; MCBRYDE WAE, 1964, CAN J CHEM, V42, P1917, DOI 10.1139/v64-284; MCWHIRTER RB, 1990, BIOCHEMISTRY-US, V29, P6919, DOI 10.1021/bi00481a023; MILLER DM, 1990, FREE RADICAL BIO MED, V8, P95, DOI 10.1016/0891-5849(90)90148-C; MOTTEN A, 1986, J MAGN RESON, V67, P42, DOI 10.1016/0022-2364(86)90407-5; NOVAK M, 1986, J AM CHEM SOC, V108, P112, DOI 10.1021/ja00261a019; OEHLER UM, 1982, CAN J CHEM, V60, P1542, DOI 10.1139/v82-501; PLACHY WZ, 1977, J MAGN RESON, V27, P237, DOI 10.1016/0022-2364(77)90071-3; POWIS G, 1987, CANCER RES, V47, P2363; ROBINSON J, 1970, ANAL BIOCHEM, V33, P390, DOI 10.1016/0003-2697(70)90310-6; Rosen G.M., 1985, ADV FREE RADIC BIOL, V1, P345, DOI [10.1016/8755-9668(85)90012-2, DOI 10.1016/8755-9668(85)90012-2]; SCHREIBER J, 1987, J AM CHEM SOC, V109, P348, DOI 10.1021/ja00236a009; SHIPLEY LA, 1990, XENOBIOTICA, V20, P31, DOI 10.3109/00498259009046810; STROTHER A, 1984, DRUG METAB DISPOS, V12, P35; STROTHER A, 1981, B WORLD HEALTH ORGAN, V59, P413; STROTHER A, 1984, PRIMAQUINE PHARMACOK, P27; TARLOV AR, 1962, ARCH INTERN MED, V109, P209, DOI 10.1001/archinte.1962.03620140081013; THORNALLEY PJ, 1983, BIOCHEM PHARMACOL, V32, P3571, DOI 10.1016/0006-2952(83)90305-2; VASQUEZVIVAR J, 1990, FREE RADICAL RES COM, V9, P383, DOI 10.3109/10715769009145698; WATANABE H, 1990, FREE RADICAL BIO MED, V8, P507, DOI 10.1016/0891-5849(90)90150-H; WINTERBOURN CC, 1989, BIOCHEM PHARMACOL, V38, P611, DOI 10.1016/0006-2952(89)90206-2; YAMAZAKI I, 1990, J BIOL CHEM, V265, P652	50	72	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6848	6854						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1313024				2022-12-27	WOS:A1992HM05300060
J	MORI, S; HELDIN, CH; CLAESSONWELSH, L				MORI, S; HELDIN, CH; CLAESSONWELSH, L			LIGAND-INDUCED POLYUBIQUITINATION OF THE PLATELET-DERIVED GROWTH-FACTOR BETA-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEIN LIGASE; B-TYPE RECEPTOR; PDGF RECEPTOR; PROTEOLYTIC SYSTEM; HUMAN-FIBROBLASTS; CDNA CLONING; BINDING; MECHANISM; INTERNALIZATION; PURIFICATION	We have analyzed the nature of ligand-induced shift to higher molecular weight forms of the beta-receptor for platelet-derived growth factor expressed in porcine aortic endothelial cells. The modification of the beta-receptor was found to be due to polyubiquitination, as judged by immunoblotting using an anti-ubiquitin antiserum. A mutant beta-receptor made kinase negative by a point mutation (K634A mutant) did not undergo ubiquitination in response to ligand stimulation. A mutant in which carboxyl-terminal 98 amino acids were deleted (CT98 mutant) and which retained kinase activity was likewise not ubiquitinated. These data suggest that the kinase activity, as well as the carboxyl-terminal 98 amino acids, is required for ubiquitination of the beta-receptor. Ligand-induced degradation of the receptor-bound ligand, as well as of the receptor itself, was partially impaired in the CT98-receptor-expressing cells, suggesting that the ubiquitination is of importance for efficient degradation of the ligand-receptor complex.			MORI, S (corresponding author), LUDWIG INST CANC RES,CTR BIOMED,BOX 595,S-75124 UPPSALA,SWEDEN.			Claesson-Welsh, Lena/0000-0003-4275-2000				BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CIECHANOVER A, 1980, P NATL ACAD SCI-BIOL, V77, P1365, DOI 10.1073/pnas.77.3.1365; CIECHANOVER A, 1981, P NATL ACAD SCI-BIOL, V78, P761, DOI 10.1073/pnas.78.2.761; CIECHANOVER A, 1989, TRENDS BIOCHEM SCI, V14, P483, DOI 10.1016/0968-0004(89)90180-1; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; GOLDSTEIN G, 1975, P NATL ACAD SCI USA, V72, P11, DOI 10.1073/pnas.72.1.11; HAAS AL, 1982, J BIOL CHEM, V257, P329; HAAS AL, 1988, J BIOL CHEM, V263, P13268; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MCKEEHAN WL, 1976, P NATL ACAD SCI USA, V73, P2023, DOI 10.1073/pnas.73.6.2023; MIYAZONO K, 1987, J BIOL CHEM, V262, P4098; MORI S, 1991, J BIOL CHEM, V266, P21158; NILSSON J, 1983, P NATL ACAD SCI-BIOL, V80, P5592, DOI 10.1073/pnas.80.18.5592; NISHIZUKA Y, 1968, J BIOL CHEM, V243, P3765; Ostman A, 1989, GROWTH FACTORS, V1, P271, DOI 10.3109/08977198908998003; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PICKART CM, 1988, J BIOL CHEM, V263, P15076; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; REISS Y, 1988, J BIOL CHEM, V263, P2693; RONNSTRAND L, 1987, J BIOL CHEM, V262, P2929; ROSENFELD ME, 1984, J CELL PHYSIOL, V121, P263, DOI 10.1002/jcp.1041210202; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; WEIMA SM, 1990, EXP CELL RES, V186, P324, DOI 10.1016/0014-4827(90)90312-X; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	43	161	164	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6429	6434						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1313434				2022-12-27	WOS:A1992HK31800106
J	PETERKOFSKY, B; PRATHER, W				PETERKOFSKY, B; PRATHER, W			A POSTTRANSLATIONAL MODIFICATION, UNRELATED TO HYDROXYLATION, IN THE COLLAGENOUS DOMAIN OF NONHELICAL PRO-ALPHA-2(I) PROCOLLAGEN CHAINS SECRETED BY CHEMICALLY TRANSFORMED HAMSTER FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERINATAL OSTEOGENESIS IMPERFECTA; I COLLAGEN; TISSUE; HYDROXYLYSINE; DEGRADATION; METABOLISM; PROTEINS; CELLS; GENE	Transformed Syrian hamster embryo (NQT-SHE) fibroblasts do not synthesize the pro-alpha-1 subunit of type I procollagen, but secrete two modified forms of the pro-alpha-2(I) subunit that migrate more slowly than the normal chain during gel electrophoresis (Peterkofsky, B., and Prather, W. (1986) J. Biol. Chem. 261, 16818-16826). By electrophoretic analysis of cyanogen bromide and V8 protease-derived peptides from the collagenous domains of intra- and extracellular pro-alpha-2(1) chains, we find that the modification occurs almost exclusively in secreted molecules, is located in the region spanned by the cyanogen bromide peptide CB3,5, and persists when hydroxylation is inhibited. Thus, modification is due to a post-translational reaction other than hydroxylation. The modified chains appear to be secreted in the denatured state since: 1) helical structures formed at 4-degrees-C under acidic conditions were unstable under neutral conditions at 37-degrees-C; 2) conditions that destabilize the type I procollagen helix and thus inhibit its secretion, i.e. inhibition of proline hydroxylation or incorporation of the proline analog cis-hydroxyproline, did not affect secretion of the modified chains. The time courses for secretion of nonhelical modified chains from NQT-SHE and of hydroxylated helical procollagen I from control cells, as a proportion of total collagen synthesized, were similar. Although cis-hydroxyproline did not inhibit the secretion of the modified chains, it induced their rapid intracellular degradation.			PETERKOFSKY, B (corresponding author), NCI,BIOCHEM LAB,BLDG 37,RM 4C18,BETHESDA,MD 20892, USA.							BATEMAN JF, 1984, BIOCHEM J, V217, P103, DOI 10.1042/bj2170103; BERG RA, 1980, P NATL ACAD SCI-BIOL, V77, P4746, DOI 10.1073/pnas.77.8.4746; BLANCK TJJ, 1975, ARCH BIOCHEM BIOPHYS, V171, P259, DOI 10.1016/0003-9861(75)90031-4; BONADIO J, 1985, J BIOL CHEM, V260, P1734; BROEK DL, 1985, J BIOL CHEM, V260, P555; CIECHANOVER A, 1989, TRENDS BIOCHEM SCI, V14, P483, DOI 10.1016/0968-0004(89)90180-1; DICKSON LA, 1984, P NATL ACAD SCI-BIOL, V81, P4524, DOI 10.1073/pnas.81.14.4524; FESSLER JH, 1985, J CELL BIOCHEM, V28, P183; GEBHART AM, 1986, BIOESSAYS, V4, P213, DOI 10.1002/bies.950040507; JIMENEZ S, 1974, ARCH BIOCHEM BIOPHYS, V163, P459, DOI 10.1016/0003-9861(74)90502-5; KAO WWY, 1978, J BIOL CHEM, V254, P2234; KIVIRIKKO KI, 1973, BIOCHEMISTRY-US, V12, P4966, DOI 10.1021/bi00748a023; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; Kuroki T, 1981, Carcinog Compr Surv, V6, P93; MAJMUDAR G, 1988, J BIOL CHEM, V263, P5555; NIMNI ME, 1983, SEMIN ARTHRITIS RHEU, V13, P1, DOI 10.1016/0049-0172(83)90024-0; PETERKOFSKY B, 1972, BIOCHEM BIOPH RES CO, V49, P1343, DOI 10.1016/0006-291X(72)90614-6; PETERKOFSKY B, 1986, J BIOL CHEM, V261, P6818; PETERKOFSKY B, 1982, IMMUNOCHEMISTRY EXTR, V2, P19; PIEZ KA, 1964, BIOCHEMISTRY-US, V3, P908, DOI 10.1021/bi00895a009; PINNELL SR, 1972, NEW ENGL J MED, V286, P1013, DOI 10.1056/NEJM197205112861901; Prockop D.J., 1976, BIOCH COLLAGENS, P163; RAO VH, 1989, J BIOL CHEM, V264, P1793; RHODES RK, 1981, COLLAGEN REL RES, V1, P337; Rivett A.J., 1990, Essays in Biochemistry, V25, P39; SCHNIEKE A, 1987, P NATL ACAD SCI USA, V84, P764, DOI 10.1073/pnas.84.3.764; TKOCZ C, 1969, EUR J BIOCHEM, V7, P454; VANDEKERCKHOVE J, 1980, CELL, V22, P893, DOI 10.1016/0092-8674(80)90566-8; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201	29	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5388	5395						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1312089				2022-12-27	WOS:A1992HH74700060
J	SCHULZEOSTHOFF, K; BAKKER, AC; VANHAESEBROECK, B; BEYAERT, R; JACOB, WA; FIERS, W				SCHULZEOSTHOFF, K; BAKKER, AC; VANHAESEBROECK, B; BEYAERT, R; JACOB, WA; FIERS, W			CYTOTOXIC ACTIVITY OF TUMOR-NECROSIS-FACTOR IS MEDIATED BY EARLY DAMAGE OF MITOCHONDRIAL FUNCTIONS - EVIDENCE FOR THE INVOLVEMENT OF MITOCHONDRIAL RADICAL GENERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID METABOLISM; CYTO-TOXICITY; SUPEROXIDE-DISMUTASE; HYDROGEN-PEROXIDE; MOLECULAR-CLONING; DNA FRAGMENTATION; ACTIVATED MACROPHAGES; ELECTRON-TRANSPORT; HEART-MITOCHONDRIA; FACTOR-ALPHA	Structural mitochondrial damage accompanies the cytotoxic effects of several drugs including tumor necrosis factor (TNF). Using various inhibitors of mitochondrial electron transport we have investigated the mechanism of TNF-mediated cytotoxicity in L929 and WEHI 164 clone 13 mouse fibrosarcoma cells. Inhibitors with different sites of action modulated TNF cytotoxicity, however, with contrasting effects on final cell viability. Inhibition of mitochondrial electron transport at complex III (cytochrome c reductase) by antimycin A resulted in a marked potentiation of TNF-mediated injury. In contrast, when the electron flow to ubiquinone was blocked, either at complex I (NADH-ubiquinone oxidoreductase) with amytal or at complex II (succinate-ubiquinone reductase) with thenoyltrifluoroacetone, cells were markedly protected against TNF cytotoxicity. Neither uncouplers nor inhibitors of oxidative phosphorylation nor complex IV (cytochrome c oxidase) inhibitors significantly interfered with TNF-mediated effects, ruling out the involvement of energy-coupled phenomena. In addition, the toxic effects of TNF were counteracted by the addition of antioxidants and iron chelators. Furthermore, we analyzed the direct effect of TNF on mitochondrial morphology and functions. Treatment of L929 cells with TNF led to an early degeneration of the mitochondrial ultrastructure without any pronounced damage of other cellular organelles. Analysis of the mitochondrial electron flow revealed that TNF treatment led to a rapid inhibition of the mitochondria to oxidize succinate and NADH-linked substrates. The inhibition of electron transport was dose-dependent and became readily detectable 60 min after the start of TNF treatment, thus preceding the onset of cell death by at least 3-6 h. In contrast, only minor effects were observed on complex IV activity. The different effects observed with the mitochondrial respiratory chain inhibitors provide suggestive evidence that mitochondrial production of oxygen radicals mainly generated at the ubisemiquinone site is a causal mechanism of TNF cytotoxicity. This conclusion is further supported by the protective effect of antioxidants as well as the selective pattern of damage of mitochondrial chain components and characteristic alterations of the mitochondrial ultrastructure.	STATE UNIV GHENT, MOLEC BIOL LAB, B-9000 GHENT, BELGIUM; UNIV INSTELLING ANTWERP, DEPT MED, B-2610 WILRIJK, BELGIUM	Ghent University; University of Antwerp			Beyaert, Rudi/B-2589-2009; Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Beyaert, Rudi/0000-0002-5704-582X				BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; Boobis AR, 1990, CURR OPIN CELL BIOL, V2, P231, DOI 10.1016/0955-0674(90)90011-3; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; BURTON KP, 1984, AM J PHYSIOL, V246, pH776, DOI 10.1152/ajpheart.1984.246.6.H776; CADENAS E, 1980, BIOCHEM J, V188, P31, DOI 10.1042/bj1880031; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CINO M, 1989, ARCH BIOCHEM BIOPHYS, V269, P623, DOI 10.1016/0003-9861(89)90148-3; DEALTRY GB, 1987, EUR J IMMUNOL, V17, P689, DOI 10.1002/eji.1830170517; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; FRANSEN L, 1985, NUCLEIC ACIDS RES, V13, P4417, DOI 10.1093/nar/13.12.4417; FREEMAN BA, 1982, LAB INVEST, V47, P412; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; GRANGER DL, 1982, J CELL BIOL, V95, P527, DOI 10.1083/jcb.95.2.527; GRUNFELD C, 1991, BIOTHERAPY, V3, P143, DOI 10.1007/BF02172087; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HEIKKILA RE, 1976, J BIOL CHEM, V251, P2182; HEPBURN A, 1987, BIOCHEM BIOPH RES CO, V149, P815, DOI 10.1016/0006-291X(87)90440-2; KILBOURN RG, 1984, J IMMUNOL, V133, P2577; KLOSTERGAARD J, 1987, CANCER RES, V47, P2014; KONSTANTINOV AA, 1987, BIOCHIM BIOPHYS ACTA, V894, P1, DOI 10.1016/0005-2728(87)90206-4; LANCASTER JR, 1989, FEBS LETT, V248, P169, DOI 10.1016/0014-5793(89)80454-5; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LASTER SM, 1988, J IMMUNOL, V141, P2629; LIDDIL JD, 1989, CANCER RES, V49, P2722; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LOSCHEN G, 1974, FEBS LETT, V42, P68, DOI 10.1016/0014-5793(74)80281-4; MATTHEWS N, 1983, BRIT J CANCER, V48, P405, DOI 10.1038/bjc.1983.205; MATTHEWS N, 1987, IMMUNOLOGY, V62, P153; MATTHEWS N, 1987, LYMPHOKINES, V14, P223; MISRA HP, 1984, J BIOL CHEM, V259, P2678; NEALE ML, 1988, IMMUNOLOGY, V64, P81; OSTROVE JM, 1979, P SOC EXP BIOL MED, V160, P354; RICHTER C, 1988, FREE RADICAL BIO MED, V4, P365, DOI 10.1016/0891-5849(88)90088-3; RUFF MR, 1981, LYMPHOKINES, V2, P215; RUGGIERO V, 1987, CELL IMMUNOL, V107, P317, DOI 10.1016/0008-8749(87)90240-1; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHMID DS, 1987, LYMPHOKINE RES, V6, P195; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SUFFYS P, 1987, BIOCHEM BIOPH RES CO, V149, P735, DOI 10.1016/0006-291X(87)90429-3; SUFFYS P, 1988, EUR J BIOCHEM, V178, P257, DOI 10.1111/j.1432-1033.1988.tb14451.x; TADA H, 1986, J IMMUNOL METHODS, V93, P157, DOI 10.1016/0022-1759(86)90183-3; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; VISNER GA, 1990, J BIOL CHEM, V265, P2856; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; WALLACH D, 1988, J IMMUNOL, V140, P2994; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; YAMAUCHI N, 1990, INT J CANCER, V46, P884, DOI 10.1002/ijc.2910460522; YAMAUCHI N, 1989, CANCER RES, V49, P1671; ZHANG Y, 1990, J BIOL CHEM, V265, P16330; ZIMMERMAN RJ, 1989, CANCER RES, V49, P1644	53	876	888	2	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5317	5323						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1312087				2022-12-27	WOS:A1992HH74700050
J	LI, L; LIN, K; KURLAND, IJ; CORREIA, JJ; PILKIS, SJ				LI, L; LIN, K; KURLAND, IJ; CORREIA, JJ; PILKIS, SJ			SITE-DIRECTED MUTAGENESIS IN RAT-LIVER 6-PHOSPHOFRUCTO-2-KINASE - MUTATION AT THE FRUCTOSE 6-PHOSPHATE BINDING-SITE AFFECTS PHOSPHATE ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PHOSPHOFRUCTOKINASE; ALLOSTERIC BEHAVIOR; ACTIVE-SITE; CDNA CLONE; FRUCTOSE-2,6-BISPHOSPHATASE; EXPRESSION; SEQUENCE; DOMAIN; RNA; DNA	To identify those residues involved in fructose 6-phosphate binding to the kinase domain of rat liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase site-directed mutations were engineered at Lys194, Arg195, Arg230, and Arg238. The mutant enzymes were purified to homogeneity by anion exchange and Blue-Sepharose chromatography and/or substrate elution from phosphocellulose columns. Circular dichroism experiments demonstrated that all of the single amino acid mutations had no effect on the secondary structure of the protein. In addition, when fructose-2,6-bisphosphatase activity was measured, all mutants had K(m) values for fructose 2,6-bisphosphate, K(i) values for fructose 6-phosphate, and maximal velocities similar to that of the wild-type enzyme. Mutation of Arg195 --> Ala, or His, had little or no effect on the maximal velocity of the kinase but increased the K(m) for fructose 6-phosphate greater than 3,000-fold. Furthermore, the K(a) for phosphate for Arg195Ala was increased 100-fold compared with the wild-type enzyme. Mutation of Lys194 --> Ala had no effect on maximal velocity or the K(m) for fructose 6-phosphate. Mutation of either Arg230 or Arg238 --> Ala increased the maximal velocity and the K(m) for fructose-6 phosphate of the kinase by 2-3-fold but had no effect on fructose-2,6-bisphosphatase. However, the K(m) values for ATP of the Arg230Ala and Arg238Ala mutants were 30-40-fold higher than that for the wild-type enzyme. Mutation of Gly48 --> Ala resulted in a form with no kinase activity, but fructose-2, 6-bisphosphatase activity was identical to that of the wild-type enzyme. The results indicate that: 1) Arg195 is a critical residue for the binding of fructose 6-phosphate to the 6-phosphofructo-2-kinase domain, and that interaction of the sugar phosphate with Arg195 is highly specific since mutation of the adjacent Lys194 --> Ala had no effect on fructose 6-phosphate binding; 2) Arg195 also play an important role in the binding of inorganic phosphate; and 3) Gly48 is an important residue in the nucleotide binding fold of 6-phosphofructo-2-kinase and that both Arg230 and Arg238 are also involved in ATP binding; and 4) the bifunctional enzyme has two separate and independent fructose 6-phosphate binding sites.	SUNY STONY BROOK, DEPT PHYSIOL & BIOPHYS, STONY BROOK, NY 11794 USA; UNIV MISSISSIPPI, MED CTR, DEPT BIOCHEM, JACKSON, MS 39216 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Mississippi; University of Mississippi Medical Center					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038354, T32DK007521, R37DK038354] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041117] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32DK07521-01A1, DK 38354] Funding Source: Medline; NIGMS NIH HHS [GM 41117] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS SL, 1971, J BIOL CHEM, V246, P2464; BAZAN F, FRUCTOSE 2 6 BISPHOS, P125; BAZAN JF, 1989, P NATL ACAD SCI USA, V86, P9642, DOI 10.1073/pnas.86.24.9642; BERGER SA, 1990, NATURE, V343, P575, DOI 10.1038/343575a0; BLANGY D, 1968, J MOL BIOL, V31, P13, DOI 10.1016/0022-2836(68)90051-X; COLOSIA AD, 1988, J BIOL CHEM, V263, P18669; COLOSIA AD, 1987, BIOCHEM BIOPH RES CO, V143, P1092, DOI 10.1016/0006-291X(87)90364-0; DARVILLE MI, 1987, FEBS LETT, V224, P317, DOI 10.1016/0014-5793(87)80476-3; ELMAGHRABI MR, 1986, P NATL ACAD SCI USA, V83, P5005, DOI 10.1073/pnas.83.14.5005; ELMAGHRABI MR, 1984, J BIOL CHEM, V259, P3096; EVANS PR, 1981, PHILOS T ROY SOC B, V293, P53, DOI 10.1098/rstb.1981.0059; HELLINGA HW, 1987, NATURE, V327, P437, DOI 10.1038/327437a0; HENGARTNER H, 1975, FEBS LETT, V55, P282, DOI 10.1016/0014-5793(75)81012-X; KEMP RG, 1983, MOL CELL BIOCHEM, V57, P147, DOI 10.1007/BF00849191; KOUNTZ PD, 1985, ARCH BIOCHEM BIOPHYS, V238, P531, DOI 10.1016/0003-9861(85)90197-3; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lin K, 1990, Protein Expr Purif, V1, P169, DOI 10.1016/1046-5928(90)90012-N; LIN K, 1992, IN PRESS J BIOL CHEM, V267; LIVELY MO, 1988, J BIOL CHEM, V263, P839; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PILKIS SJ, 1982, MOL CELL ENDOCRINOL, V25, P245, DOI 10.1016/0303-7207(82)90082-X; PILKIS SJ, 1991, ANNU REV NUTR, V11, P465, DOI 10.1146/annurev.nu.11.070191.002341; PILKIS SJ, 1990, DIABETES CARE, V13, P582, DOI 10.2337/diacare.13.6.582; PILKIS SJ, 1990, FRUCTOSE 2 6 BISPHOS, P1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANWAL BD, 1970, BACTERIOL REV, V34, P20, DOI 10.1128/MMBR.34.1.20-39.1970; SCHIRMER T, 1990, NATURE, V343, P140, DOI 10.1038/343140a0; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAULER A, 1989, P NATL ACAD SCI USA, V86, P7316, DOI 10.1073/pnas.86.19.7316; TAULER A, 1988, P NATL ACAD SCI USA, V85, P6642, DOI 10.1073/pnas.85.18.6642; TAULER A, 1990, J BIOL CHEM, V265, P15617; Uyeda K, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P193; VALDEZ BC, 1989, J BIOL CHEM, V264, P131; YOUNATHAN ES, 1981, REGULATION CARBOHYDR, P69	36	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4386	4393						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1311308				2022-12-27	WOS:A1992HF64200022
J	MITSUMOTO, Y; KLIP, A				MITSUMOTO, Y; KLIP, A			DEVELOPMENTAL REGULATION OF THE SUBCELLULAR-DISTRIBUTION AND GLYCOSYLATION OF GLUT1 AND GLUT4 GLUCOSE TRANSPORTERS DURING MYOGENESIS OF L6 MUSCLE-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GROWTH-FACTOR; RAT SKELETAL-MUSCLE; 1,4-DIHYDROPYRIDINE RECEPTOR; ENDOGLYCOSIDASE-F; HUMAN-ERYTHROCYTE; PLASMA-MEMBRANE; FACTOR-BETA; INSULIN; EXPRESSION; GENE	L6 myoblasts spontaneously undergo differentiation and cell fusion into myotubes. These cells express both GLUT1 and GLUT4 glucose transporters, but their expression varies during myogenesis. We now report that the subcellular distribution and the protein processing by glycosylation of both glucose transporter isoforms also change during myogenesis. Crude plasma membrane and light microsome fractions were isolated from either myoblasts or myotubes and characterized by the presence of two functional proteins, the Na+/K+-ATPase and the dihydropyridine receptor (DHPR). Immunoreactive alpha-1 subunit of the Na+/K+-ATPase was faint in the crude plasma membrane fraction from myoblasts, but abundant in both membrane fractions from myotubes. In contrast, the alpha-1 subunit of the DHPR, which is expressed only in differentiated muscle, was detected in crude plasma membrane from myotubes but not from myoblasts. Therefore, crude plasma membrane fractions from myoblasts and myotubes contain cell surface markers, and the composition of these membranes appears to be developmentally regulated during myogenesis. GLUT1 protein was more abundant in the crude plasma membrane relative to the light microsome fraction prepared from either myoblasts or myotubes. The molecular size in sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the GLUT1 transporters in myotubes was smaller than that in myoblasts (M(r) 47,000 and 53,000, respectively). GLUT4 protein (M(r) 48,000) was barely detectable in the crude plasma membrane fraction and was almost absent in the light microsome fraction prepared from myoblasts. However, GLUT4 protein was abundant in myotubes and was predominantly located in the light microsome fraction. Treatment with endoglycosidase F reduced the molecular size of the transporters in all fractions to M(r) 46,000 for GLUT1 and M(r) 47,000 for GLUT4 proteins. In myotubes, acute insulin treatment increased the crude plasma membrane content of GLUT1 marginally and of GLUT4 markedly, with a concomitant decrease in the light microsomal fraction. These results indicate that: (a) the subcellular distribution of glucose transporters is regulated during myogenesis, GLUT4 being preferentially sorted to intracellular membranes; (b) both GLUT1 and GLUT4 transporters are processed by N-linked glycosylation to form the mature transporters in the course of myogenesis; and (c) insulin causes modest recruitment of GLUT1 transporters and marked recruitment of GLUT4 transporters, from light microsomes to plasma membranes in L6 myotubes.	HOSP SICK CHILDREN,DIV CELL BIOL,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								BIRNBAUM MJ, 1987, SCIENCE, V235, P1495, DOI 10.1126/science.3029870; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BISCHOFF R, 1990, J CELL BIOL, V111, P201, DOI 10.1083/jcb.111.1.201; BISCHOFF R, 1969, J CELL BIOL, V41, P188, DOI 10.1083/jcb.41.1.188; BLAU HM, 1981, P NATL ACAD SCI-BIOL, V78, P5623, DOI 10.1073/pnas.78.9.5623; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURDETT E, 1987, ARCH BIOCHEM BIOPHYS, V253, P279, DOI 10.1016/0003-9861(87)90661-8; CALDERHEAD DM, 1990, BIOCHEM J, V269, P597, DOI 10.1042/bj2690597; CATTERALL WA, 1988, J BIOL CHEM, V263, P3535; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; DOUEN AG, 1991, ENDOCRINOLOGY, V128, P611, DOI 10.1210/endo-128-1-611; DOUEN AG, 1990, J BIOL CHEM, V265, P13247; ELDER JH, 1982, P NATL ACAD SCI-BIOL, V79, P4540, DOI 10.1073/pnas.79.15.4540; EWTON DZ, 1987, ENDOCRINOLOGY, V120, P115, DOI 10.1210/endo-120-1-115; FELSENFELD DP, 1988, J BIOL CHEM, V263, P10932; FLORINI JR, 1986, AM J PHYSIOL, V250, pC771, DOI 10.1152/ajpcell.1986.250.5.C771; FLORINI JR, 1988, J CELL PHYSIOL, V135, P301, DOI 10.1002/jcp.1041350218; HEINO J, 1990, J BIOL CHEM, V265, P10181; HIRAKI Y, 1988, J BIOL CHEM, V263, P13655; HIRSHMAN MF, 1990, J BIOL CHEM, V265, P987; KIDOKORO Y, 1975, J PHYSIOL-LONDON, V244, P129, DOI 10.1113/jphysiol.1975.sp010787; KLIP A, 1984, BIOCHEM BIOPH RES CO, V122, P218, DOI 10.1016/0006-291X(84)90462-5; KLIP A, 1990, BIOCHEM BIOPH RES CO, V172, P728, DOI 10.1016/0006-291X(90)90735-6; KLIP A, 1990, DIABETES CARE, V13, P228, DOI 10.2337/diacare.13.3.228; KLIP A, 1984, AM J PHYSIOL, V247, pE291, DOI 10.1152/ajpendo.1984.247.3.E291; KOIVISTO UM, 1991, J BIOL CHEM, V266, P2615; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSAR AB, 1986, CELL, V47, P649, DOI 10.1016/0092-8674(86)90507-6; LEUNG AT, 1987, J BIOL CHEM, V262, P7943; LIENHARD GE, 1984, BIOCHIM BIOPHYS ACTA, V769, P404, DOI 10.1016/0005-2736(84)90324-9; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; MITSUMOTO Y, 1991, BIOCHEM BIOPH RES CO, V175, P652, DOI 10.1016/0006-291X(91)91615-J; OMATSUKANBE M, 1990, BIOCHEM J, V272, P727, DOI 10.1042/bj2720727; ORLOWSKI J, 1988, J BIOL CHEM, V263, P17817; RAMPE D, 1988, BIOCHEM BIOPH RES CO, V152, P769, DOI 10.1016/S0006-291X(88)80104-9; ROMEY G, 1989, P NATL ACAD SCI USA, V86, P2933, DOI 10.1073/pnas.86.8.2933; SARABIA V, 1989, BIOCHEM BIOPH RES CO, V165, P1130, DOI 10.1016/0006-291X(89)92720-4; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SCHIMMEL SD, 1973, P NATL ACAD SCI USA, V70, P3195, DOI 10.1073/pnas.70.11.3195; SEED J, 1988, DEV BIOL, V128, P40, DOI 10.1016/0012-1606(88)90264-3; SIVITZ W, 1989, ENDOCRINOLOGY, V124, P1875, DOI 10.1210/endo-124-4-1875; WALKER PS, 1990, J BIOL CHEM, V265, P1516; WANG C, 1991, BIOCHEM BIOPH RES CO, V177, P1095, DOI 10.1016/0006-291X(91)90651-M; WEILAND M, 1990, BIOCHEM J, V270, P331, DOI 10.1042/bj2700331; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Yaffe D, 1969, Curr Top Dev Biol, V4, P37, DOI 10.1016/S0070-2153(08)60480-9; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P447	48	163	166	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4957	4962						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1311324				2022-12-27	WOS:A1992HF64200098
J	ZHANG, J; FRY, MJ; WATERFIELD, MD; JAKEN, S; LIAO, L; FOX, JEB; RITTENHOUSE, SE				ZHANG, J; FRY, MJ; WATERFIELD, MD; JAKEN, S; LIAO, L; FOX, JEB; RITTENHOUSE, SE			ACTIVATED PHOSPHOINOSITIDE 3-KINASE ASSOCIATES WITH MEMBRANE SKELETON IN THROMBIN-EXPOSED PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; I PHOSPHATIDYLINOSITOL KINASE; ACTIN POLYMERIZATION; SIGNAL TRANSDUCTION; BLOOD-PLATELETS; A431 CELLS; IDENTIFICATION; CYTOSKELETON; RECEPTOR; TRISPHOSPHATE	Human platelets undergo a rapid, major reorganization of the cytoskeletal matrix upon exposure to thrombin, and accumulate 3-phosphorylated phosphoinositides in a protein kinase C (PKC)-dependent manner. These phosphoinositides have been suggested to be involved in actin polymerization/depolymerization. We reasoned that, if newly generated 3-phosphorylated phosphoinositide modulates cytoskeletal reorganization, a prerequisite for such action would be generation near cytoskeletal proteins. We have found that, after platelet activation, phosphatidylinositol 3-kinase and phosphatidylinositol(4)P 3-kinase activities, antibody-detectable phosphoinositide 3-kinase, and PKC become markedly and specifically enriched in a Triton X-100-insoluble cytoskeletal fraction that contains GPIIb/IIIa (integrin) and pp60c-src. The cytoskeletal fraction then accounts for up to 70% of total phosphoinositide 3-kinase activity, a function of recruited activated enzyme. These proteins are not occluded or directly associated with newly polymerized actin, since blockage by cytochalasin D of actin polymerization, and consequent inhibition of accumulation of about 40% of incremental protein and actin in this fraction, has no effect on its content of phosphoinositide 3-kinase, GPIIb/IIIa, pp60c-src, or PKC. Depolymerization of actin with DNase I, or inhibition of ligand binding to GPIIb/IIIa by RGDS, however, in combination with cytochalasin D, further depletes actin and significantly decreases sedimentability of GPIIb/IIIa as well as phosphoinositide 3-kinase, pp60c-src, and PKC, without inhibiting total 3-kinase activity. Our results suggest that, as a function of platelet activation, enzymes that regulate the synthesis of 3-phosphorylated phosphoinositides rapidly associate with the membrane skeleton and that skeletally associated phosphoinositide 3-kinase is more active than the Triton-soluble form.	UNIV VERMONT,DEPT BIOCHEM,BURLINGTON,VT 05405; GLADSTONE LABS,SAN FRANCISCO,CA 94110; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND; W ALTON JONES CELL SCI CTR,LAKE PLACID,NY 12946	University of Vermont; University of California System; University of California San Francisco; The J David Gladstone Institutes; Ludwig Institute for Cancer Research				Fry, Michael/0000-0001-8518-1370	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038622, R23HL030657, R01HL030657, R37HL030657] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-30657, HL-38622] Funding Source: Medline; PHS HHS [GCRC-R109] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ASIJEE GM, 1990, EUR J BIOCHEM, V189, P131, DOI 10.1111/j.1432-1033.1990.tb15469.x; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BLIKSTAD I, 1978, CELL, V15, P935, DOI 10.1016/0092-8674(78)90277-5; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CASELLA JF, 1981, NATURE, V293, P302, DOI 10.1038/293302a0; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; DOWNES CP, 1989, BIOCHEM SOC T, V17, P259, DOI 10.1042/bst0170259; EBERLE M, 1990, J BIOL CHEM, V265, P16725; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FOX JEB, 1984, J CELL BIOL, V98, P1985, DOI 10.1083/jcb.98.6.1985; FOX JEB, 1988, J CELL BIOL, V106, P1525, DOI 10.1083/jcb.106.5.1525; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; FOX JEB, 1981, NATURE, V292, P650, DOI 10.1038/292650a0; FOX JEB, 1992, IN PRESS METHODS ENZ; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HARTWIG JH, 1991, J CELL BIOL, V112, P407, DOI 10.1083/jcb.112.3.407; HUANG RS, 1991, J BIOL CHEM, V266, P18435; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KILEY SC, 1990, MOL ENDOCRINOL, V4, P59, DOI 10.1210/mend-4-1-59; KING WG, 1989, J BIOL CHEM, V264, P6070; KING WG, 1991, BIOCHEM J, V278, P475, DOI 10.1042/bj2780475; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LANDRETH GE, 1985, J CELL BIOL, V101, P1341, DOI 10.1083/jcb.101.4.1341; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LAUDANO AP, 1978, P NATL ACAD SCI USA, V75, P3085, DOI 10.1073/pnas.75.7.3085; LEACH KL, 1988, J BIOL CHEM, V263, P13223; MITCHELL CA, 1990, P NATL ACAD SCI USA, V87, P9396, DOI 10.1073/pnas.87.23.9396; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; NOLAN RD, 1990, J BIOL CHEM, V265, P2441; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAINTER RG, 1985, J CELL BIOL, V100, P652, DOI 10.1083/jcb.100.2.652; PHILLIPS DR, 1980, J CELL BIOL, V86, P77, DOI 10.1083/jcb.86.1.77; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RITTENHOUSE SE, 1984, BIOCHEM J, V222, P103, DOI 10.1042/bj2220103; SHATTIL SJ, 1987, J BIOL CHEM, V262, P992; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; STEPHENS L, 1989, BIOCHEM J, V259, P267, DOI 10.1042/bj2590267; SULTAN C, 1990, BIOCHEM J, V269, P831, DOI 10.1042/bj2690831; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TREVES S, 1987, EXP CELL RES, V168, P285, DOI 10.1016/0014-4827(87)90001-2; TUSZYNSKI GP, 1984, J BIOL CHEM, V259, P5247; VADNAL RE, 1989, BIOCHEM BIOPH RES CO, V163, P995, DOI 10.1016/0006-291X(89)92320-6; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WALSETH TF, 1979, BIOCHIM BIOPHYS ACTA, V562, P11, DOI 10.1016/0005-2787(79)90122-9; WHEELER ME, 1984, J CLIN INVEST, V74, P1080, DOI 10.1172/JCI111475; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WIEGANT FAC, 1986, J CELL BIOL, V103, P87, DOI 10.1083/jcb.103.1.87	56	197	197	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4686	4692						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1311317				2022-12-27	WOS:A1992HF64200063
J	TEPIKIN, AV; VORONINA, SG; GALLACHER, DV; PETERSEN, OH				TEPIKIN, AV; VORONINA, SG; GALLACHER, DV; PETERSEN, OH			ACETYLCHOLINE-EVOKED INCREASE IN THE CYTOPLASMIC CA2+ CONCENTRATION AND CA2+ EXTRUSION MEASURED SIMULTANEOUSLY IN SINGLE-MOUSE PANCREATIC ACINAR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MEMBRANE CA-2+ PUMP; PLASMA-MEMBRANE; CALCIUM-TRANSPORT; EXOCRINE PANCREAS; SECRETAGOGUES; OSCILLATIONS; CALMODULIN; SECRETION; ATP; STIMULATION	The intracellular free Ca2+ concentration ([free Ca2+]i) was measured simultaneously with the Ca2+ extrusion from single isolated mouse pancreatic acinar cells placed in a microdroplet of extracellular solution using the fluorescent probes fura-2 and fluo-3. The extracellular solution had a low total calcium concentration (15-35-mu-M), and acetylcholine (ACh), applied by microionophoresis, therefore only evoked a transient elevation of [free Ca2+]i lasting about 2-5 min. The initial sharp rise in [free Ca2+]i from about 100 nM toward 0.5-1-mu-M was followed within seconds by an increase in the total calcium concentration in the microdroplet solution ([Ca]o). The rate of this rise of [Ca]o was dependent on the [free Ca2+]i elevation, and as [free Ca2+]i gradually decreased Ca2+ extrusion declined with the same time course. Ca2+ extrusion following ACh stimulation was not influenced by removal of all Na+ in the microdroplet solution indicating that the Ca2+ extrusion is not mediated by Na+-Ca2+ exchange but by the Ca2+ pump. The amount of Ca2+ extruded during the ACh-evoked transient rise in [free Ca2+]i corresponded to a decrease in the total intracellular Ca concentration of about 0.7 mM which is close to previously reported values (0.5-1 mM) for the total concentration of mobilizable calcium in these cells. Our results therefore demonstrate directly the ability of the Ca2+ pump to rapidly remove the large amount of Ca2+ released from the intracellular pools during receptor activation.	UNIV LIVERPOOL,PHYSIOL LAB,SECRETORY CONTROL RES GRP,POB 147,LIVERPOOL L69 3BX,ENGLAND	University of Liverpool			Petersen, Ole H/E-8708-2010	Tepikin, Alexei/0000-0002-8172-7513; Petersen, Ole/0000-0002-6998-0380	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMBUDKAR IS, 1988, J MEMBRANE BIOL, V102, P59, DOI 10.1007/BF01875353; AMBUDKAR IS, 1989, ARCH BIOCHEM BIOPHYS, V268, P576, DOI 10.1016/0003-9861(89)90325-1; BAYERDORFFER E, 1985, J MEMBRANE BIOL, V84, P45, DOI 10.1007/BF01871647; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CHANG A, 1989, HDB PHYSL GASTROINTE, V3, P531; CLEMENTE F, 1975, J CELL BIOL, V65, P88, DOI 10.1083/jcb.65.1.88; DORMER RL, 1981, AM J PHYSIOL, V240, pG38, DOI 10.1152/ajpgi.1981.240.1.G38; DUDDY SK, 1989, J BIOL CHEM, V264, P20863; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; KONDO S, 1976, J MEMBRANE BIOL, V29, P185, DOI 10.1007/BF01868959; LARSEN FL, 1979, SCIENCE, V204, P306, DOI 10.1126/science.155309; MISSIAEN L, 1991, PHARMACOL THERAPEUT, V50, P191, DOI 10.1016/0163-7258(91)90014-D; MUALLEM S, 1988, J MEMBRANE BIOL, V102, P153, DOI 10.1007/BF01870453; MUALLEM S, 1988, J MEMBRANE BIOL, V106, P57, DOI 10.1007/BF01871767; MUALLEM S, 1989, ANNU REV PHYSIOL, V51, P83; MUALLEM S, 1988, AM J PHYSIOL, V255, pG221, DOI 10.1152/ajpgi.1988.255.2.G221; MUALLEM S, 1981, BIOCHIM BIOPHYS ACTA, V647, P73, DOI 10.1016/0005-2736(81)90296-0; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PETERSEN OH, 1990, J MEMBRANE BIOL, V118, P93, DOI 10.1007/BF01868467; PETERSEN OH, 1987, PHYSIOL REV, V67, P1054, DOI 10.1152/physrev.1987.67.3.1054; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; PETERSEN OH, 1976, J PHYSIOL-LONDON, V254, P583, DOI 10.1113/jphysiol.1976.sp011248; PRALONG WF, 1988, FEBS LETT, V242, P79, DOI 10.1016/0014-5793(88)80989-X; RANDRIAMAMPITA C, 1990, J BIOL CHEM, V265, P18059; REEVES JP, 1990, INTRACELLULAR CALCIU, P305; SCHATZMANN HJ, 1989, ANNU REV PHYSIOL, V51, P473, DOI 10.1146/annurev.ph.51.030189.002353; SCHULZ I, 1980, ANNU REV PHYSIOL, V42, P127, DOI 10.1146/annurev.ph.42.030180.001015; TEPIKIN AV, 1991, J MEMBRANE BIOL, V123, P43, DOI 10.1007/BF01993961; TSIEN RY, 1989, ANNU REV NEUROSCI, V12, P227, DOI 10.1146/annurev.neuro.12.1.227; YULE DI, 1988, FEBS LETT, V239, P358, DOI 10.1016/0014-5793(88)80951-7; YULE DI, 1991, CELL CALCIUM, V12, P145, DOI 10.1016/0143-4160(91)90016-8	34	110	111	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3569	3572						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1310974				2022-12-27	WOS:A1992HE60700005
J	YANG, SW; HUANG, P; PLUNKETT, W; BECKER, FF; CHAN, JYH				YANG, SW; HUANG, P; PLUNKETT, W; BECKER, FF; CHAN, JYH			DUAL MODE OF INHIBITION OF PURIFIED DNA LIGASE-I FROM HUMAN-CELLS BY 9-BETA-D-ARABINOFURANOSYL-2-FLUOROADENINE TRIPHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIC LYMPHOCYTES; ANTILEUKEMIC DRUGS; ADENYLATE COMPLEX; HUMAN THYMOCYTES; MECHANISM; DATP; FLUDARABINE; POLYMERASES; EUKARYOTES; METABOLISM	9-beta-D-Arabinofuranosyl-2-fluoroadenine (F-ara-A) is an analogue of adenosine and deoxyadenosine with potent anti-tumor activity. The mechanism of action for this compound has been elucidated as the inhibition of DNA and RNA synthesis, induction of DNA fragmentation, and genetic damage. This study demonstrated that DNA ligase I, an enzyme involved in DNA replication, is a target for the drug action. F-ara-adenine triphosphate (F-ara-ATP) at 80-mu-M inhibited the activity of DNA ligase I by more than 90%. In contrast, eight other related nucleoside analogues showed no effect on the enzyme activity at 200-mu-M. F-ara-ATP inhibited DNA ligation in two distinct ways. First, F-ara-ATP directly interacted with DNA ligase I and inhibited the formation of the ligase-AMP complex. This inhibition could not be reversed when free F-ara-ATP was eliminated from the treated enzyme; however, the addition of pyrophosphate, followed by gel filtration chromatography, restored enzyme activity, indicating that F-ara-ATP bound to the enzyme and altered the AMP-binding site. Secondly, the activity of DNA ligase I was inhibited when F-ara-ATP was incorporated into the 3' terminus of the DNA substrate. The dual mode of inhibition of DNA ligase I by F-ara-ATP indicates that its effect on DNA ligation may be important in the inhibition of DNA synthesis and the cytotoxicity of F-ara-A.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC PATHOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MED ONCOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA028596, R01CA047276] Funding Source: NIH RePORTER; NCI NIH HHS [CA28596, CA47276] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BROCKMAN RW, 1977, BIOCHEM PHARMACOL, V26, P2193, DOI 10.1016/0006-2952(77)90275-1; CHAN JYH, 1988, J BIOL CHEM, V263, P18231; DAVID JC, 1985, CANCER RES, V45, P2177; GOFFIN C, 1987, NUCLEIC ACIDS RES, V15, P8755, DOI 10.1093/nar/15.21.8755; HUANG P, 1989, MUTAT RES, V210, P291, DOI 10.1016/0027-5107(89)90090-0; HUANG P, 1990, J BIOL CHEM, V265, P16617; HUANG P, 1990, MOL PHARMACOL, V39, P449; KEATING MJ, 1989, BLOOD, V74, P19; LAMBALLE F, 1988, LEUKEMIA, V2, P363; LAMBALLE F, 1989, LEUKEMIA, V3, P97; LASKO DD, 1990, MUTAT RES, V236, P277, DOI 10.1016/0921-8777(90)90011-S; LEHMAN IR, 1974, SCIENCE, V186, P790; MIKITA T, 1988, BIOCHEMISTRY-US, V27, P4698, DOI 10.1021/bi00413a018; MONTECUCCO A, 1991, NUCLEIC ACIDS RES, V19, P1067, DOI 10.1093/nar/19.5.1067; MONTECUCCO A, 1990, BIOCHEM J, V271, P265, DOI 10.1042/bj2710265; NILSSON SV, 1982, NUCLEIC ACIDS RES, V10, P1425, DOI 10.1093/nar/10.5.1425; NOVOTNY L, 1990, NUCL ACID CHEM 4, P337; PARKER WB, 1991, CANCER RES, V51, P2386; PARKER WB, 1988, MOL PHARMACOL, V34, P485; PLUNKETT W, 1990, SEMIN ONCOL, V17, P3; PLUNKETT W, 1980, CANCER RES, V40, P2349; SAULIER B, 1988, CARCINOGENESIS, V9, P965, DOI 10.1093/carcin/9.6.965; SIGNORET J, 1986, INT REV CYTOL, V103, P249, DOI 10.1016/S0074-7696(08)60837-2; SODERHALL S, 1976, FEBS LETT, V67, P1, DOI 10.1016/0014-5793(76)80858-7; SODERHALL S, 1975, EUR J BIOCHEM, V51, P129, DOI 10.1111/j.1432-1033.1975.tb03913.x; SODERHALL S, 1973, J BIOL CHEM, V248, P672; WIADERKIEWICZ R, 1987, NUCLEIC ACIDS RES, V15, P7831, DOI 10.1093/nar/15.19.7831; YANG SW, 1990, J BIOL CHEM, V265, P18130; ZITTOUN J, 1991, LEUKEMIA RES, V15, P157, DOI 10.1016/0145-2126(91)90097-D	29	82	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2345	2349						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1310314				2022-12-27	WOS:A1992HB53200037
J	MURPHY, PM; MCDERMOTT, D				MURPHY, PM; MCDERMOTT, D			THE GUANINE NUCLEOTIDE-BINDING PROTEIN-GS ACTIVATES A NOVEL CALCIUM TRANSPORTER IN XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIN ADP-RIBOSYLATES; CHOLERA-TOXIN; HUMAN-NEUTROPHILS; ADENYLYL CYCLASE; BACTERIAL TOXINS; ION CHANNELS; RECEPTOR; ALPHA; CELLS; EXPRESSION	Calcium influx is an important aspect of receptor-mediated signal transduction, yet limited information is available regarding the pathways of calcium influx into nonexcitable cells. We show that treatment of oocytes from Xenopus laevis with cholera toxin, a potent activator of the guanine nucleotide-binding protein G(s), specifically stimulates a sustained inward whole cell flux of calcium through a novel membrane transporter. The calcium is distributed into a mobilizable pool. The flux is voltage-independent and is completely and specifically blocked by microinjection of oocytes with an antiserum directed against G(s)alpha. The flux is not activated by treatment of the cells with forskolin or 8-bromo-cyclic adenosine monophosphate indicating that the effect of G(s)alpha on the transporter occurs independently of adenylylcyclase activation. Transporter activity is insensitive to benzyl amiloride, does not require a sodium gradient, and is rot stimulated by external calcium, indicating that it is not a sodium-calcium exchanger. The G(s)-activated flux is dramatically potentiated by lanthanum ion and other trivalent cations but not by any of six divalent cations that were tested; all other known calcium channels and exchangers are, in contrast, potently blocked by lanthanum. The divalent cation cadmium inhibited transporter activity in a concentration-dependent manner. This novel calcium transporter may be important for receptor-mediated calcium influx in the oocyte and perhaps other cell types.			MURPHY, PM (corresponding author), NIAID, HOST DEF LAB, BLDG 10, RM 11N113, BETHESDA, MD 20892 USA.		McDermott, David/AAP-2459-2021	McDermott, David/0000-0001-6978-0867				ANDERSON DL, 1989, J IMMUNOL, V143, P3647; BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BOUCEK MM, 1976, SCIENCE, V193, P905, DOI 10.1126/science.948752; EWALD DA, 1989, NEURON, V2, P1185, DOI 10.1016/0896-6273(89)90185-2; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; GIERSCHIK P, 1987, FEBS LETT, V224, P219, DOI 10.1016/0014-5793(87)80451-9; GILL DM, 1976, BIOCHEMISTRY-US, V15, P1242, DOI 10.1021/bi00651a011; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; GROSS RA, 1989, J NEUROPHYSIOL, V61, P97, DOI 10.1152/jn.1989.61.1.97; IMBODEN JB, 1986, P NATL ACAD SCI USA, V83, P5673, DOI 10.1073/pnas.83.15.5673; KASLOW HR, 1980, J BIOL CHEM, V255, P3736; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLINZ FJ, 1989, BIOCHEM BIOPH RES CO, V165, P554, DOI 10.1016/S0006-291X(89)80002-6; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; KWAN CY, 1990, J BIOL CHEM, V265, P678; LESTER HA, 1989, ANN NY ACAD SCI, V560, P174, DOI 10.1111/j.1749-6632.1989.tb24094.x; MAENZ DD, 1986, CAN J PHYSIOL PHARM, V64, P568, DOI 10.1139/y86-094; MATTERA R, 1989, SCIENCE, V243, P804, DOI 10.1126/science.2536957; MCCLOSKEY MA, 1988, P NATL ACAD SCI USA, V85, P7260, DOI 10.1073/pnas.85.19.7260; MIDDLEBROOK JL, 1984, MICROBIOL REV, V48, P199, DOI 10.1128/MMBR.48.3.199-221.1984; MILLIGAN G, 1988, BIOCHEM J, V252, P369, DOI 10.1042/bj2520369; MOSS J, 1976, P NATL ACAD SCI USA, V73, P3480, DOI 10.1073/pnas.73.10.3480; MURPHY PM, 1990, J BIOL CHEM, V265, P11615; NARASIMHAN V, 1988, J BIOL CHEM, V263, P19626; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; OWENS JR, 1985, J BIOL CHEM, V260, P5946; SIMCHOWITZ L, 1988, AM J PHYSIOL, V254, pC150, DOI 10.1152/ajpcell.1988.254.1.C150; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; TOSELLI M, 1989, PFLUG ARCH EUR J PHY, V415, P255, DOI 10.1007/BF00370874; TOSTESON MT, 1978, NATURE, V275, P142, DOI 10.1038/275142a0; TOSTESON MT, 1980, ACTA PHYSIOL SCAND, P21; TSIEN RW, 1987, ANNU REV BIOPHYS BIO, V16, P265; UI M, 1990, ADP RIBOSYLATING TOX, P45; VANHEYNINGEN S, 1977, BIOL REV, V52, P509; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390; YATANI A, 1988, J BIOL CHEM, V263, P9887; YATANI A, 1987, SCIENCE, V235, P207, DOI 10.1126/science.2432660	39	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					883	888						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1309778				2022-12-27	WOS:A1992GY96000033
J	TANAKA, T; MAKINO, R; ISHIMURA, Y				TANAKA, T; MAKINO, R; ISHIMURA, Y			CYTOSOLIC COMPONENTS INVOLVED IN PORCINE NEUTROPHIL OXIDASE ACTIVATION - PURIFICATION OF A 47-KILODALTON PROTEIN AND RECONSTITUTION OF THE ACTIVATION SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; DEPENDENT SUPEROXIDE PRODUCTION; ADENINE-DINUCLEOTIDE PHOSPHATE; GENERATING NADPH OXIDASE; SODIUM DODECYL-SULFATE; FATTY-ACIDS; GUANINE-NUCLEOTIDES; ARACHIDONIC-ACID	Two cytosolic components, which cooperate with a 63-kDa cytosolic factor (Tanaka, T., Imajoh-Ohmi, S., Kanegasaki, S., Takagi, Y., Makino, R., and Ishimura, Y. (1990) J. Biol. Chem. 265, 18717-18720) in activation of the O2--generating NADPH-oxidase in neutrophil membrane, were isolated and characterized from porcine neutrophils. One, which was purified to electrophoretic homogeneity, was a 47-kDa protein cross-reactive to an antibody raised against a portion of human 47-kDa cytosolic factor, a component of the human NADPH-oxidase activation system. Another one, designated here as the third component, was partially purified and found to contain 49- and 55-kDa proteins as the major constituents. No colored prosthetic group such as heme, flavin, and non-heme iron was detected in both cytosolic components. In a reconstituted assay system with a solubilized membrane preparation containing the dormant oxidase and with oleate as a stimulus, the 47-kDa protein together with the 63-kDa factor was essential for activating the dormant oxidase, while the third component was not essential for the activation of but enhanced the O2--generation evoked by the former two components. Thus, the 47- and 63-kDa cytosolic proteins are the principal constituents of the activation system, while the other factors such as those contained in the third component may regulate the activity induced by the essential components.	KEIO UNIV,SCH MED,DEPT BIOCHEM,35 SHINANOMACHI,SHINJUKU KU,TOKYO 160,JAPAN	Keio University								BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BELLAVITE P, 1988, FREE RADICAL BIO MED, V4, P225, DOI 10.1016/0891-5849(88)90044-5; BOLSCHER BGJM, 1989, J CLIN INVEST, V83, P757, DOI 10.1172/JCI113954; BOLSCHER BGJM, 1990, J BIOL CHEM, V265, P15782; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; CLARK RA, 1987, J BIOL CHEM, V262, P4065; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CROSS AR, 1982, BIOCHEM J, V204, P479, DOI 10.1042/bj2040479; CURNUTTE JT, 1989, P NATL ACAD SCI USA, V86, P825, DOI 10.1073/pnas.86.3.825; CURNUTTE JT, 1988, J CLIN INVEST, V81, P606, DOI 10.1172/JCI113360; CURNUTTE JT, 1987, J BIOL CHEM, V262, P5563; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; DOUSSIERE J, 1990, BIOCHEMISTRY-US, V29, P2225, DOI 10.1021/bi00461a004; FUJITA I, 1987, BIOCHIM BIOPHYS ACTA, V931, P41, DOI 10.1016/0167-4889(87)90048-6; GABIG TG, 1987, J BIOL CHEM, V262, P1685; HEYNEMAN RA, 1984, J LEUKOCYTE BIOL, V36, P751, DOI 10.1002/jlb.36.6.751; IIZUKA T, 1985, J BIOL CHEM, V260, P2049; ISHIDA K, 1989, FEBS LETT, V243, P169, DOI 10.1016/0014-5793(89)80123-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LIGETI E, 1988, BIOCHEMISTRY-US, V27, P193, DOI 10.1021/bi00401a029; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; LOMAX KJ, 1989, SCIENCE, V246, P987, DOI 10.1126/science.2587992; MAKINO R, 1986, J BIOL CHEM, V261, P1444; MAKINO R, 1972, J BIOCHEM-TOKYO, V72, P655, DOI 10.1093/oxfordjournals.jbchem.a129943; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; PILLOUDDAGHER MC, 1991, BIOCHEMISTRY-US, V30, P2753, DOI 10.1021/bi00225a003; SEIFERT R, 1987, EUR J BIOCHEM, V162, P563, DOI 10.1111/j.1432-1033.1987.tb10676.x; SHAAG D, 1990, BIOCHIM BIOPHYS ACTA, V1037, P405, DOI 10.1016/0167-4838(90)90044-G; SHAAG D, 1988, BIOCHIM BIOPHYS ACTA, V952, P213, DOI 10.1016/0167-4838(88)90118-5; SMITH RM, 1989, J BIOL CHEM, V264, P1958; TAKASUGI S, 1989, J BIOCHEM-TOKYO, V105, P155, DOI 10.1093/oxfordjournals.jbchem.a122630; TANAKA T, 1990, J BIOL CHEM, V265, P18717; TANAKA T, 1987, BIOCHEM BIOPH RES CO, V144, P606, DOI 10.1016/S0006-291X(87)80009-8; TANAKA T, 1988, J BIOL CHEM, V263, P13670; TEAHAN CG, 1990, BIOCHEM J, V267, P485, DOI 10.1042/bj2670485; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P9563	42	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1239	1244						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1309766				2022-12-27	WOS:A1992GY96000087
J	SEGER, R; SEGER, D; LOZEMAN, FJ; AHN, NG; GRAVES, LM; CAMPBELL, JS; ERICSSON, L; HARRYLOCK, M; JENSEN, AM; KREBS, EG				SEGER, R; SEGER, D; LOZEMAN, FJ; AHN, NG; GRAVES, LM; CAMPBELL, JS; ERICSSON, L; HARRYLOCK, M; JENSEN, AM; KREBS, EG			HUMAN T-CELL MITOGEN-ACTIVATED PROTEIN-KINASE KINASES ARE RELATED TO YEAST SIGNAL TRANSDUCTION KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYCLE CONTROL; IDENTIFICATION; FEATURES; SEQUENCE; CASCADE	Mitogen-activated protein (MAP) kinase kinases, intermediates in a growth factor-stimulated protein kinase cascade, are dual specificity protein kinases that specifically phosphorylate and activate MAP kinases in response to extracellular signals. Here, we report the cloning of two forms of cDNA that encode this protein from human T-cells. MKK1a encodes a protein with predicted molecular size of 43,439 Da. Overexpression of this clone in COS cells led to elevated levels of protein and phorbol ester-stimulated MAP kinase kinase activity, confirming that MKK1a encodes the predicted protein. MKK1b, which appears to be an alternatively spliced form of the MKK1a gene, encodes a protein with predicted molecular size of 40,745 Da. Northern analysis revealed that the MKK1 cDNA hybridizes with a single 2.6-kilobase mRNA species in all human tissues examined. Sequence comparison shows homology to a group of yeast kinases that participate in signal transduction and to subdomain XI of other dual specificity kinase.	UNIV WASHINGTON,DEPT PHARMACOL,SL-15,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	KREBS, EG (corresponding author), UNIV WASHINGTON,DEPT PHARMACOL,SL-15,SEATTLE,WA 98195, USA.		Graves, Lee/AAG-5470-2021	Campbell, Jean/0000-0002-9187-2204	NIDDK NIH HHS [DK 42528] Funding Source: Medline; NIGMS NIH HHS [GM 42508] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM042508] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970; ADAMS PD, 1992, J BIOL CHEM, V267, P13135; AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1992, J NEUROCHEM, V59, P147, DOI 10.1111/j.1471-4159.1992.tb08885.x; AHN NG, 1992, IN PRESS CURR OPIN C; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; KASAKO H, 1992, EMBO J, V11, P2903; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LALLEMAIN G, 1992, MOL CELL BIOL, V12, P2222, DOI 10.1128/MCB.12.5.2222; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P44, DOI 10.1016/0005-2744(81)90106-6; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHIRAKABE K, 1992, J BIOL CHEM, V267, P16685; SONNENBURG WK, 1991, J BIOL CHEM, V266, P17655; SONNENBURG WK, 1993, IN PRESS J BIOL CHEM; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; ZHOU Z, 1992, IN PRESS EMBO J	37	186	192	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25628	25631						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1281467				2022-12-27	WOS:A1992KD07300003
J	VANLINT, J; AGOSTINIS, P; VANDEVOORDE, V; HAEGEMAN, G; FIERS, W; MERLEVEDE, W; VANDENHEEDE, JR				VANLINT, J; AGOSTINIS, P; VANDEVOORDE, V; HAEGEMAN, G; FIERS, W; MERLEVEDE, W; VANDENHEEDE, JR			TUMOR-NECROSIS-FACTOR STIMULATES MULTIPLE SERINE THREONINE PROTEIN-KINASES IN SWISS 3T3 AND L929 CELLS - IMPLICATION OF CASEIN KINASE-2 AND EXTRACELLULAR SIGNAL-REGULATED KINASES IN THE TUMOR-NECROSIS-FACTOR SIGNAL TRANSDUCTION PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-ALPHA; PHOSPHORYLATION SITES; MOLECULAR-CLONING; ENDOTHELIAL-CELLS; HUMAN FIBROBLASTS; SKELETAL-MUSCLE; FACTOR RECEPTOR; RAPID TYROSINE; CYTO-TOXICITY; MAP KINASE	Incubation of Swiss 3T3 or L929 cells with tumor necrosis factor (TNF) leads to the rapid stimulation of several cytosolic Ser/Thr kinases active toward myelin basic protein, the S6 peptide (RRLSSLR), the G peptide (SPQPSRRGSESSEE), and Kemptide (LRRASLG). This confirms the hypothesis that kinases other than protein kinases A and C may be involved in the TNF signal transduction. Chromatography on Mono Q resolved multiple kinase peaks with each substrate tested and moreover revealed a TNF-mediated casein kinase-2 activation in both cell lines, measurable with the specific RRREEESEEE peptide or with the G peptide. The TNF-stimulated myelin basic protein kinases-1 and -2 were identified as extracellular signal-regulated kinases-2 and -1, respectively, based on their elution pattern on Mono Q chromatography, their inactivation by protein phosphatase action, their reaction with phosphothreonine and phosphotyrosine antibodies, and by their migration on sodium dodecyl sulfate-polyacrylamide gel electrophoresis as 42- and 44-kDa proteins recognized by anti-extracellular signal-regulated kinase antibodies.	CATHOLIC UNIV LEUVEN, FAC GENEESKUNDE, AFDELING BIOCHEM, CAMPUS GASTHUISBERG, B-3000 LOUVAIN, BELGIUM; STATE UNIV GHENT, MOLEC BIOL LAB, B-9000 Ghent, BELGIUM	KU Leuven; Ghent University	VANDENHEEDE, JR (corresponding author), CATHOLIC UNIV LEUVEN, FAC GENEESKUNDE, AFDELING BIOCHEM, CAMPUS GASTHUISBERG, B-3000 LOUVAIN, BELGIUM.		Agostinis, Patrizia/ABI-1177-2020; Agostinis, Patrizia/AAO-2468-2020; Van Lint, Johan/P-9073-2019	Agostinis, Patrizia/0000-0003-1314-2115; Van Lint, Johan/0000-0002-0275-571X				AGOSTINIS P, 1992, J BIOL CHEM, V267, P9732; AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; AHN NG, 1990, J BIOL CHEM, V265, P11495; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BIRD TA, 1991, J BIOL CHEM, V266, P22661; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CAMUSSI G, 1991, EUR J BIOCHEM, V202, P3, DOI 10.1111/j.1432-1033.1991.tb16337.x; CHENG HC, 1986, J BIOL CHEM, V261, P989; CLARK MA, 1988, BIOCHEM J, V250, P125, DOI 10.1042/bj2500125; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COOPER JA, 1984, MOL CELL BIOL, V4, P30, DOI 10.1128/MCB.4.1.30; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; EVANS JPM, 1990, BLOOD, V75, P88; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FIOL CJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P797, DOI 10.1016/0003-9861(88)90089-6; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GUY GR, 1991, J BIOL CHEM, V266, P14343; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; IMAMURA K, 1988, J BIOL CHEM, V263, P10247; JENSENIUS JC, 1981, J IMMUNOL METHODS, V46, P63, DOI 10.1016/0022-1759(81)90333-1; KAMPS MP, 1988, ONCOGENE, V2, P305; KAUR P, 1988, FEBS LETT, V241, P6, DOI 10.1016/0014-5793(88)81019-6; KOHNO M, 1990, BIOCHEM J, V267, P91, DOI 10.1042/bj2670091; KRIEG J, 1988, J BIOL CHEM, V263, P11473; KRONKE M, 1991, TUMOR NECROSIS FACTO, P189; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LANDRY J, 1992, J BIOL CHEM, V267, P794; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MARINO MW, 1989, P NATL ACAD SCI USA, V86, P8417, DOI 10.1073/pnas.86.21.8417; MEGGIO F, 1981, J BIOL CHEM, V256, P1958; MUNRO J, 1990, BIOCHIM BIOPHYS ACTA, V1054, P225, DOI 10.1016/0167-4889(90)90245-9; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1987, BIOCHEMISTRY-US, V26, P7960, DOI 10.1021/bi00398a062; ROBAYE B, 1989, BIOCHEM BIOPH RES CO, V163, P301, DOI 10.1016/0006-291X(89)92135-9; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SPRAGUE GF, 1991, TRENDS GENET, V7, P393, DOI 10.1016/0168-9525(91)90262-O; SPRANG SR, 1990, TRENDS BIOCHEM SCI, V15, P366, DOI 10.1016/0968-0004(90)90228-4; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUFFYS P, 1987, BIOCHEM BIOPH RES CO, V149, P735, DOI 10.1016/0006-291X(87)90429-3; TUNG HYL, 1984, EUR J BIOCHEM, V138, P635, DOI 10.1111/j.1432-1033.1984.tb07962.x; VILCEK J, 1991, J BIOL CHEM, V266, P7313; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802	51	83	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25916	25921						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1281478				2022-12-27	WOS:A1992KD07300050
J	POU, S; POU, WS; BREDT, DS; SNYDER, SH; ROSEN, GM				POU, S; POU, WS; BREDT, DS; SNYDER, SH; ROSEN, GM			GENERATION OF SUPEROXIDE BY PURIFIED BRAIN NITRIC-OXIDE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							L-ARGININE; BIOLOGICAL-SYSTEMS; ENDOTHELIAL-CELLS; NITROGEN-OXIDES; RELAXING FACTOR; INHIBITION; BIOPTERIN; COFACTOR; RADICALS; RELEASE	Brain nitric oxide synthase (NOS), which utilizes NADPH and calcium/calmodulin as cofactors for metabolizing L-arginine to nitric oxide (NO) and L-citrulline, contains recognition sites for the flavins FAD and FMN. Using a spin-trapping technique combined with electron spin resonance spectroscopy, we report that brain NOS generates superoxide O2 radical-anion in a calcium/calmodulin-dependent manner. The "specific inhibitors" of NOS, N(G)-monomethyl L-arginine (L-NMMA), and N(G)-nitro-L-arginine methyl ester (L-NAME), have different effects on O2 radical-anion generation. For L-NMMA, O2 radical-anion production is unaffected, while for L-NAME, inhibition of this free radical is concentration-dependent.	JOHNS HOPKINS MED INST,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205; VET ADM MED CTR,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA)	POU, S (corresponding author), UNIV MARYLAND,SCH PHARM,DEPT PHARMACOL & TOXICOL,20 N PINE ST,BALTIMORE,MD 21201, USA.		Bredt, David/J-4872-2012		NHLBI NIH HHS [HL-33550] Funding Source: Medline; NIDA NIH HHS [DA-271-90-7408] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033550] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH018501, R37MH018501] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BILLIAR TR, 1989, J EXP MED, V169, P1467, DOI 10.1084/jem.169.4.1467; BONNETT R, 1956, J CHEM SOC, P2094; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CURRAN RD, 1989, J EXP MED, V170, P1769, DOI 10.1084/jem.170.5.1769; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FINKELSTEIN E, 1982, MOL PHARMACOL, V21, P262; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; HIBBS JB, 1987, J IMMUNOL, V138, P550; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; JANZEN EG, 1971, ACCOUNTS CHEM RES, V4, P31, DOI 10.1021/ar50037a005; KUTHAN H, 1982, BIOCHEM J, V203, P551, DOI 10.1042/bj2030551; KWON NS, 1989, J BIOL CHEM, V264, P20496; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MAYER B, 1989, FEBS LETT, V256, P211, DOI 10.1016/0014-5793(89)81750-8; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MONCADA S, 1991, PHARMACOL REV, V43, P109; MONTELLANO PRO, 1986, CYTOCHROME P450 STRU, P217; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; PALACIOS M, 1989, BIOCHEM BIOPH RES CO, V165, P802, DOI 10.1016/S0006-291X(89)80037-3; PALMER RMJ, 1989, BIOCHEM BIOPH RES CO, V158, P348, DOI 10.1016/S0006-291X(89)80219-0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; POU S, 1989, ANAL BIOCHEM, V177, P1, DOI 10.1016/0003-2697(89)90002-X; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P5193, DOI 10.1073/pnas.87.13.5193; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; THOMAS G, 1992, J PHARMACOL EXP THER, V260, P676; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; YUI Y, 1991, J BIOL CHEM, V266, P3369	34	711	738	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24173	24176						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1280257				2022-12-27	WOS:A1992KA26300007
J	GOTTLIEB, PA; WU, S; ZHANG, XL; TECKLENBURG, M; KUEMPEL, P; HILL, TM				GOTTLIEB, PA; WU, S; ZHANG, XL; TECKLENBURG, M; KUEMPEL, P; HILL, TM			EQUILIBRIUM, KINETIC, AND FOOTPRINTING STUDIES OF THE TUS-TERPROTEIN-DNA INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; REPRESSOR-OPERATOR INTERACTION; EXHIBIT POLAR INHIBITION; REPLICATION TERMINUS; BINDING-PROTEIN; PLASMID R6K; TERMINATION; SEQUENCE; REGION; SITES	Arrest of DNA replication in the terminus region of the Escherichia coli chromosome is mediated by protein-DNA complexes composed of the Tus protein and 23 base pair sequences generically called Ter sites. We have characterized the in vitro binding of purified Tus protein to a 37-base pair oligodeoxyribonucleotide containing the TerB sequence. The measured equilibrium binding constant (K(D)) for the chromosomal TerB site in KG buffer (50 mM Tris-Cl, 150 mM potassium glutamate, 25-degrees-C, pH 7.5, 0.1 mM dithiothreitol, 0.1 mM EDTA, and 100-mu-g/ml bovine serum albumin) was 3.4 x 10(-13) M. Kinetic measurements in the same buffer revealed that the Tus-TerB complex was very stable, with a half-life of 550 min, a dissociation rate constant of 2.1 x 10(-5) s-1, and an association rate constant of 1.4 x 10(8) M-1 s-1. Similar measurements of Tus protein binding to the TerR2 site of the plasmid R6K showed an affinity 30-fold lower than the Tus-TerB interaction. This difference was due primarily to a more rapid dissociation of the Tus-TerR2 complex. Using standard chemical modification techniques, we also examined the DNA-protein contacts of the Tus-TerB interaction. Extensive contacts between the Tus protein and the TerB sequence were observed in the highly conserved 11 base-pair "core" sequence common to all identified Ter sites. In addition, protein-DNA contact sites were observed in the region of the Ter site where DNA replication is arrested. Projection of the footprinting data onto B-form DNA indicated that the majority of the alkylation interference and hydroxyl radical-protected sites were arranged on one face of the DNA helix. We also observed dimethyl sulfate protection of 2 guanine residues on the opposite side of the helix, suggesting that part of the Tus protein extends around the double helix. The distribution of contacts along the TerB sequence was consistent with the functional polarity of the Tus-Ter complex and suggested possible mechanisms for the impediment of protein translocation along DNA.	DREXEL UNIV,DEPT BIOSCI & BIOTECHNOL,PHILADELPHIA,PA 19104; UNIV DELAWARE,DEPT CHEM & BIOCHEM,NEWARK,DE 19716; UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309	Drexel University; University of Delaware; University of Colorado System; University of Colorado Boulder			Gottlieb, Philip/C-3113-2019	Gottlieb, Philip/0000-0003-3764-9885	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043193, R01GM032968, R29GM043193] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43193, GM32968] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHMANN BJ, 1990, MICROBIOL REV, V54, P130, DOI 10.1128/MMBR.54.2.130-197.1990; BASTIA D, 1981, GENE, V14, P81, DOI 10.1016/0378-1119(81)90150-5; BERG OG, 1981, BIOCHEMISTRY-US, V20, P6929, DOI 10.1021/bi00527a028; Berg OG, 1990, BIOL NONSPECIFIC DNA, P71; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURKHOFF AM, 1987, CELL, V48, P935, DOI 10.1016/0092-8674(87)90702-1; DEMASSY B, 1987, P NATL ACAD SCI USA, V84, P1759; FRANCOIS V, 1989, MOL MICROBIOL, V3, P995, DOI 10.1111/j.1365-2958.1989.tb00250.x; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P248; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GRIEP MA, 1989, J BIOL CHEM, V264, P11294; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; HIDAKA M, 1989, J BIOL CHEM, V264, P21031; HIDAKA M, 1988, CELL, V55, P467, DOI 10.1016/0092-8674(88)90033-5; HIDAKA M, 1991, J BACTERIOL, V173, P391, DOI 10.1128/jb.173.1.391-393.1991; HILL TM, 1988, J BACTERIOL, V170, P662, DOI 10.1128/jb.170.2.662-668.1988; HILL TM, 1987, P NATL ACAD SCI USA, V84, P1754, DOI 10.1073/pnas.84.7.1754; HILL TM, 1989, P NATL ACAD SCI USA, V86, P1593, DOI 10.1073/pnas.86.5.1593; HILL TM, 1990, P NATL ACAD SCI USA, V87, P2481, DOI 10.1073/pnas.87.7.2481; HILL TM, 1988, CELL, V55, P459, DOI 10.1016/0092-8674(88)90032-3; HORIUCHI T, 1988, CELL, V54, P515, DOI 10.1016/0092-8674(88)90073-6; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; KHOURY AM, 1990, BIOCHIM BIOPHYS ACTA, V1087, P55, DOI 10.1016/0167-4781(90)90120-Q; KOBAYASHI T, 1989, EMBO J, V8, P2435, DOI 10.1002/j.1460-2075.1989.tb08374.x; KOLTER R, 1978, J MOL BIOL, V124, P425, DOI 10.1016/0022-2836(78)90180-8; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; LEIRMO S, 1987, BIOCHEMISTRY-US, V26, P2095, DOI 10.1021/bi00382a006; LEWIS PJ, 1990, J MOL BIOL, V214, P72; LI SF, 1987, J BACTERIOL, V169, P4614, DOI 10.1128/jb.169.10.4614-4620.1987; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACALLISTER T, 1990, P NATL ACAD SCI USA, V87, P2828, DOI 10.1073/pnas.87.7.2828; MAJUMDAR A, 1989, J MOL BIOL, V208, P217, DOI 10.1016/0022-2836(89)90383-5; OGATA RT, 1979, J MOL BIOL, V132, P709, DOI 10.1016/0022-2836(79)90384-X; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; PELLETIER AJ, 1989, J BACTERIOL, V171, P1739, DOI 10.1128/jb.171.3.1739-1741.1989; Record Jr M. T., 1990, BIOL NONSPECIFIC DNA, P33; RECORD MT, 1981, ANNU REV BIOCHEM, V50, P997, DOI 10.1146/annurev.bi.50.070181.005025; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; REVZIN A, 1990, BIOL NONSPECIFIC DNA, P89; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; ROECKLEIN B, 1991, RES MICROBIOL, V142, P169, DOI 10.1016/0923-2508(91)90026-7; Sambrook J, 1989, MOL CLONING LABORATO; SCHLEIF R, 1988, SCIENCE, V241, P1182, DOI 10.1126/science.2842864; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SISTA PR, 1991, GENE DEV, V5, P74, DOI 10.1101/gad.5.1.74; SISTA PR, 1989, P NATL ACAD SCI USA, V86, P3026, DOI 10.1073/pnas.86.9.3026; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; WEISS AS, 1984, J MOL BIOL, V179, P745, DOI 10.1016/0022-2836(84)90165-7	50	56	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7434	7443						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1313800				2022-12-27	WOS:A1992HN48500036
J	BLANPAIN, JP; RONJAT, M; SUPPLY, P; DUFOUR, JP; GOFFEAU, A; DUPONT, Y				BLANPAIN, JP; RONJAT, M; SUPPLY, P; DUFOUR, JP; GOFFEAU, A; DUPONT, Y			THE YEAST PLASMA-MEMBRANE H+-ATPASE - AN ESSENTIAL CHANGE OF CONFORMATION TRIGGERED BY H+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA-2+-ATPASE; SCHIZOSACCHAROMYCES-POMBE; BINDING-SITE; FORMYCIN TRIPHOSPHATE; FLUORESCENCE; VANADATE; INHIBITION; PHOSPHATE; HYDROLYSIS; EXCHANGE	The plasma membrane of Schizosaccharomyces pombe contains an H+-ATPase similar to the cation transport ATPases of other eukaryotic organisms. The fluorescence excitation and emission spectra of the purified H+-ATPase are characteristic of tryptophan residues. pH reduction from 7.5 to 5.7 produces a 4% decrease in fluorescence intensity, while a further reduction to pH 5.0 leads to an increase of fluorescence. A close correlation is observed between the pH dependence of the intrinsic fluorescence and the pH dependence of (i) ATPase activity, (ii) the fluorescence of Tb-formycin triphosphate bound to the active site, and (iii) inhibition by vanadate of ATPase activity. It is proposed that the effect of pH on intrinsic fluorescence reveals the existence of an H+ induced conformational change of the H+-ATPase similar to the E1 <--> E2 transition of the other plasma membrane cation transport ATPases.	CATHOLIC UNIV LOUVAIN, SCI & TECHN BRASSICOLES LAB, B-1348 LOUVAIN, BELGIUM; CEN, DEPT BIOL MOLEC & STRUCT, BIOPHYS MOLEC & CELLULAIRE,CNRS, UA 520, F-38041 GRENOBLE, FRANCE	Universite Catholique Louvain; Centre National de la Recherche Scientifique (CNRS)	BLANPAIN, JP (corresponding author), CATHOLIC UNIV LOUVAIN, UNITE BIOCHIM PHYSIOL, B-1348 LOUVAIN, BELGIUM.		Supply, Philip/A-9580-2019	Supply, Philip/0000-0003-3690-3853; Ronjat, Michel/0000-0002-9728-6425				ADDISON R, 1982, J BIOL CHEM, V257, P421; AMORY A, 1982, J BIOL CHEM, V257, P4723; AMORY A, 1982, J BIOL CHEM, V257, P2509; BORSTPAUWELS GWFH, 1981, BIOCHIM BIOPHYS ACTA, V642, P173, DOI 10.1016/0005-2736(81)90147-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDOLIN G, 1981, BIOCHEM BIOPH RES CO, V98, P28, DOI 10.1016/0006-291X(81)91865-9; CHAMPEIL P, 1986, FEBS LETT, V206, P93, DOI 10.1016/0014-5793(86)81347-3; DELHEZ J, 1977, EUR J BIOCHEM, V79, P319, DOI 10.1111/j.1432-1033.1977.tb11812.x; DEMEIS L, 1987, FEBS LETT, V212, P323, DOI 10.1016/0014-5793(87)81369-8; DUFOUR JP, 1980, J BIOL CHEM, V255, P591; DUFOUR JP, 1980, EUR J BIOCHEM, V105, P145, DOI 10.1111/j.1432-1033.1980.tb04484.x; DUFOUR JP, 1988, METHOD ENZYMOL, V157, P513; DUPONT Y, 1982, FEBS LETT, V139, P237, DOI 10.1016/0014-5793(82)80860-0; DUPONT Y, 1976, BIOCHEM BIOPH RES CO, V71, P544, DOI 10.1016/0006-291X(76)90821-4; DUPONT Y, 1988, METHOD ENZYMOL, V157, P206; FERSHT A, 1985, ENZYME STRUCTURE MEC, P161; Fiske CH, 1925, J BIOL CHEM, V66, P375; GIRARDET JL, 1989, EUR J BIOCHEM, V184, P131, DOI 10.1111/j.1432-1033.1989.tb14999.x; GUILLAIN F, 1982, J BIOL CHEM, V257, P7366; KARLISH SJD, 1978, BIOCHIM BIOPHYS ACTA, V527, P115, DOI 10.1016/0005-2744(78)90261-9; KARLISH SJD, 1979, NATURE, V282, P333, DOI 10.1038/282333a0; Karlish SJD, 1979, NA K ATPASE STRUCTUR, P115; LOPEZ V, 1976, ARCH BIOCHEM BIOPHYS, V175, P31, DOI 10.1016/0003-9861(76)90482-3; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PICK U, 1982, J BIOL CHEM, V257, P6111; PICK U, 1981, FEBS LETT, V123, P127, DOI 10.1016/0014-5793(81)80035-X; RONJAT M, 1987, J BIOL CHEM, V262, P3146; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; VERJOVSKIALMEIDA S, 1981, J BIOL CHEM, V256, P2662; WACH A, 1990, EUR J BIOCHEM, V189, P675, DOI 10.1111/j.1432-1033.1990.tb15536.x	30	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3735	3740						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1310980				2022-12-27	WOS:A1992HE60700032
J	LIEBERMAN, AP; PITHA, PM; SHIN, ML				LIEBERMAN, AP; PITHA, PM; SHIN, ML			POLY(A) REMOVAL IS THE KINASE-REGULATED STEP IN TUMOR-NECROSIS-FACTOR MESSENGER-RNA DECAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-KINASE; BINDING-PROTEIN; RICH SEQUENCES; STABILITY; VIRUS; ASTROCYTES	Tumor necrosis factor (TNF) is a pleiotropic biomodulator and an important inducer of certain pathophysiologic immune reactions such as granuloma formation, cachexia, and septic shock. The production of TNF by astrocytes, which may figure prominently in the development of immune responses within the central nervous system, is subject to post-transcriptional regulation. We have previously shown that in virus-stimulated astrocytes, inhibition of protein kinase C results in a specific, 10-fold decrease in TNF mRNA half-life. Here we show that the decay of TNF messages induced in the macrophage-like cell line RAW 264.7 by either virus or lipopolysaccharide was subject to similar regulation, and that this pathway influenced the amount of TNF protein released by stimulated cells. Using a modified RNase protection assay, we demonstrate that inhibition of protein kinase C significantly enhanced the rate of poly(A) removal from TNF mRNA, thus facilitating an early event in the process of mRNA degradation.	UNIV MARYLAND,SCH MED,DEPT PATHOL,10 S PINE ST,BALTIMORE,MD 21201; JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015662, P50NS020022] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI-19737] Funding Source: Medline; NINDS NIH HHS [R01-NS-15662, NS-20022] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; ESPEVIK T, 1986, J IMMUNOL METHODS, V95, P99, DOI 10.1016/0022-1759(86)90322-4; GILMAN M, 1991, CURRENT PROTOCOLS MO; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOFMAN FM, 1989, J EXP MED, V170, P607, DOI 10.1084/jem.170.2.607; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; LIEBERMAN AP, 1990, J EXP MED, V172, P989, DOI 10.1084/jem.172.3.989; LIEBERMAN AP, 1989, P NATL ACAD SCI USA, V86, P6348, DOI 10.1073/pnas.86.16.6348; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; SELMAJ K, 1991, J CLIN INVEST, V87, P949, DOI 10.1172/JCI115102; STOECKLE MY, 1989, MOL CELL BIOL, V9, P4738, DOI 10.1128/MCB.9.11.4738; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0	21	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2123	2126						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1310308				2022-12-27	WOS:A1992HB53200003
J	HE, F; BECKERICH, JM; GAILLARDIN, C				HE, F; BECKERICH, JM; GAILLARDIN, C			A MUTANT OF 7SL RNA IN YARROWIA-LIPOLYTICA AFFECTING THE SYNTHESIS OF A SECRETED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; COLI 4.5S RNA; SCHIZOSACCHAROMYCES-POMBE; ENDOPLASMIC-RETICULUM; NASCENT PREPROLACTIN; ELONGATION ARREST; SRP RNA; TRANSLOCATION; DOMAIN; MEMBRANE	The yeast Yarrowia lipolytica contains two genes, SCR1 and SCR2, encoding a 7SL RNA associated with a signal recognition particle (SRP). To study 7SL RNA function in vivo we have systematically substituted the two conserved nucleotides G128 and A130 in loop 1 of SCR2-encoded 7SL RNA. All single mutations in either nucleotide have no effect. All double mutations are lethal except for one which results in temperature-sensitive growth. We have studied the synthesis and secretion of an alkaline extracellular protease (AEP) in both wild-type and temperature-sensitive mutant strains. Pulse-chase labeling and immunoprecipitation of this protein show that: 1) total protein synthesis is not affected in the mutant strain; 2) levels of AEP precursors in the mutant strain are 60% less than in the wild-type strain; 3) for both strains there is no accumulation of the AEP precursors in the cytoplasm; 4) the kinetics of secretion is similar. These results suggest that mutated SRP is deficient in membrane targeting but still performs translational arrest. This is consistent with the functions of SRP observed in vitro and represents the first demonstration of such roles in vivo.	INRA, CNRS, INST NATL AGRON, GENET LAB, F-78850 THIVERVAL GRIGNON, FRANCE	AgroParisTech; Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Universite Paris Saclay								BARTH G, 1985, A VAN LEEUW J MICROB, V51, P167, DOI 10.1007/BF02310010; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BOORSTEIN WR, 1989, METHOD ENZYMOL, V180, P347; BRENNWALD P, 1988, MOL CELL BIOL, V8, P1580, DOI 10.1128/MCB.8.4.1580; FABRE E, 1991, J BIOL CHEM, V266, P3782; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; HE F, 1990, CURR GENET, V17, P289, DOI 10.1007/BF00314874; HE F, 1989, CURR GENET, V16, P347, DOI 10.1007/BF00340713; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN N, 1991, NUCLEIC ACIDS RES, V19, P209, DOI 10.1093/nar/19.2.209; LIAO XB, 1989, P NATL ACAD SCI USA, V86, P4137, DOI 10.1073/pnas.86.11.4137; MATOBA S, 1988, MOL CELL BIOL, V8, P4904, DOI 10.1128/MCB.8.11.4904; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; PORITZ MA, 1988, P NATL ACAD SCI USA, V85, P4315, DOI 10.1073/pnas.85.12.4315; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; RIBES V, 1988, EMBO J, V7, P231, DOI 10.1002/j.1460-2075.1988.tb02804.x; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROMISCH K, 1990, J CELL BIOL, V111, P1793, DOI 10.1083/jcb.111.5.1793; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOULICA E, 1987, EUR J BIOCHEM, V163, P519, DOI 10.1111/j.1432-1033.1987.tb10899.x; SIEGEL V, 1988, CELL, V52, P39, DOI 10.1016/0092-8674(88)90529-6; SIEGEL V, 1988, TRENDS BIOCHEM SCI, V13, P314, DOI 10.1016/0968-0004(88)90127-2; SIEGEL V, 1988, P NATL ACAD SCI USA, V85, P1801, DOI 10.1073/pnas.85.6.1801; SIEGEL V, 1985, J CELL BIOL, V100, P1913, DOI 10.1083/jcb.100.6.1913; STRUCK JCR, 1988, NUCLEIC ACIDS RES, V16, P7740, DOI 10.1093/nar/16.15.7740; TOLLERVEY D, 1985, EMBO J, V4, P3873, DOI 10.1002/j.1460-2075.1985.tb04160.x; TOLLERVEY D, 1987, EMBO J, V6, P469, DOI 10.1002/j.1460-2075.1987.tb04777.x; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WOLIN SL, 1989, J CELL BIOL, V109, P2617, DOI 10.1083/jcb.109.6.2617; XUAN JW, 1988, CURR GENET, V14, P15, DOI 10.1007/BF00405848; ZOPF D, 1990, EMBO J, V9, P4511, DOI 10.1002/j.1460-2075.1990.tb07902.x	38	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1932	1937						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1309803				2022-12-27	WOS:A1992HA48500082
J	KHACHIGIAN, LM; OWENSBY, DA; CHESTERMAN, CN				KHACHIGIAN, LM; OWENSBY, DA; CHESTERMAN, CN			A TYROSINATED PEPTIDE REPRESENTING THE ALTERNATIVELY SPLICED EXON OF THE PLATELET-DERIVED GROWTH FACTOR-A-CHAIN BINDS SPECIFICALLY TO CULTURED-CELLS AND INTERFERES WITH BINDING OF SEVERAL GROWTH-FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; DIFFERENT DIMERIC FORMS; HUMAN-ENDOTHELIAL CELLS; HUMAN-FIBROBLASTS; RECEPTOR; HEPARIN; EXPRESSION; PDGF; IDENTIFICATION; LINES	Platelet-derived growth factor (PDGF) is a potent mitogen for cells of mesenchymal origin. Alternative exon splicing is responsible for two forms of the PDGF A-chain which differ at the carboxyl terminus by a highly basic region consisting of 18 amino acids. To clarify the function of the region, we synthesized an octadecapeptide corresponding to this extension (A194-211), incorporated a tyrosine residue at the amino terminus, and used the radioiodinated construct in binding studies with Balb/c3T3 cells and a variety of human cell lines. I-125-(Y)A194-211 bound specifically, reversibly, saturably, and with low affinity to a large population of binding sites on these cells. In addition, (Y)A194-211 markedly reduced the binding of its parent protein, I-125-PDGF-AA(L), to its receptor. (Y)A194-211 also attenuated the binding of epidermal growth factor and several other isoforms of PDGF, but did not interfere with the binding of transferrin to its receptor. These observations were not due to competitive binding of peptide directly to known receptors for the respective growth factors, but was likely due to interaction of (Y)A194-211 with extracellular glycosaminoglycan. Thus, A194-211 may represent an additional heparin binding domain on mature PDGF-AA(L), and as an isolate, is capable of modulating interactions between several potent growth factors and their respective receptors.	UNIV NEW S WALES, PRINCE WALES HOSP, DEPT HAEMATOL, HIGH ST, RANDWICK, NSW 2031, AUSTRALIA; UNIV NEW S WALES, PRINCE WALES HOSP, DEPT CARIOVASC MED, RANDWICK, NSW 2031, AUSTRALIA	University of New South Wales Sydney; University of New South Wales Sydney			Khachigian, Levon/AAZ-7458-2020	Khachigian, Levon/0000-0003-3446-0323				ADLER S, 1990, AM J PATHOL, V136, P557; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; BOWENPOPE DF, 1982, J BIOL CHEM, V257, P5161; BROOKS G, 1990, CARCINOGENESIS, V11, P1223, DOI 10.1093/carcin/11.7.1223; BYWATER M, 1988, MOL CELL BIOL, V8, P2753, DOI 10.1128/MCB.8.7.2753; COLLINS T, 1987, NATURE, V328, P621, DOI 10.1038/328621a0; DAVIS RJ, 1987, J BIOL CHEM, V262, P16041; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; GUO XJ, 1990, CANCER RES, V50, P5164; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HART CE, 1990, BIOCHEMISTRY-US, V29, P166, DOI 10.1021/bi00453a022; HELDIN CH, 1987, J CELL PHYSIOL, P31; HELDIN CH, 1981, P NATL ACAD SCI-BIOL, V78, P3664, DOI 10.1073/pnas.78.6.3664; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1988, BRIT J CANCER, V57, P591, DOI 10.1038/bjc.1988.134; HOSANG M, 1985, J CELL BIOCHEM, V29, P265, DOI 10.1002/jcb.240290310; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KATSUURA M, 1989, J BIOCHEM-TOKYO, V106, P87, DOI 10.1093/oxfordjournals.jbchem.a122826; KLOCZEWIAK M, 1989, BIOCHEMISTRY-US, V28, P2915, DOI 10.1021/bi00433a025; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOBB R, 1986, J BIOL CHEM, V261, P1924; MACIAG T, 1979, P NATL ACAD SCI USA, V76, P5674, DOI 10.1073/pnas.76.11.5674; MATOSKOVA B, 1989, MOL CELL BIOL, V9, P3148, DOI 10.1128/MCB.9.7.3148; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NISTER M, 1988, CANCER RES, V48, P3910; PENGO V, 1987, BLOOD, V70, P69; POGGI A, 1988, HAEMOSTASIS, V18, P18; RAKOWICZSZULCZYNSKA EM, 1986, P NATL ACAD SCI USA, V83, P3728, DOI 10.1073/pnas.83.11.3728; RORSMAN F, 1988, MOL CELL BIOL, V8, P571, DOI 10.1128/MCB.8.2.571; ROSS R, 1987, ANNU REV MED, V38, P71, DOI 10.1146/annurev.med.38.1.71; RYAN J, 1989, J BIOL CHEM, V264, P20283; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SARIBAN E, 1988, J CLIN INVEST, V82, P1157, DOI 10.1172/JCI113712; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHREIBER AB, 1985, P NATL ACAD SCI USA, V82, P6138, DOI 10.1073/pnas.82.18.6138; SJOLUND M, 1989, CELL TISSUE RES, V256, P35; STADDON JM, 1990, J BIOL CHEM, V265, P11841; STURANI E, 1989, FEBS LETT, V255, P191, DOI 10.1016/0014-5793(89)81089-0; SUDHALTER J, 1989, J BIOL CHEM, V264, P6892; TANNER LI, 1987, J BIOL CHEM, V262, P8975; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; TONG BD, 1987, NATURE, V328, P619, DOI 10.1038/328619a0; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YEH HJ, 1987, P NATL ACAD SCI USA, V84, P2317, DOI 10.1073/pnas.84.8.2317	47	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1660	1666						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1309790				2022-12-27	WOS:A1992HA48500042
J	JIANG, H; COLBRAN, JL; FRANCIS, SH; CORBIN, JD				JIANG, H; COLBRAN, JL; FRANCIS, SH; CORBIN, JD			DIRECT EVIDENCE FOR CROSS-ACTIVATION OF CGMP-DEPENDENT PROTEIN-KINASE BY CAMP IN PIG CORONARY-ARTERIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; ATRIAL NATRIURETIC FACTOR; PARTICULATE GUANYLATE-CYCLASE; CYCLIC-NUCLEOTIDE ANALOGS; SODIUM-NITROPRUSSIDE; NITRIC-OXIDE; BOVINE LUNG; GMP; RELAXATION; CELLS	Elevation of either cAMP or cGMP causes smooth muscle relaxation. Whether these effects are mediated through cAMP-dependent protein kinase (cAK), cGMP-dependent protein kinase (cGK), or both is unknown. Pig coronary arteries were treated with sodium nitroprusside (SNP) or atrial natriuretic factor (ANF), relaxants which elevate cGMP, and with isoproterenol or forskolin, relaxants which elevate cAMP. Incubation of the arteries with 10-mu-m SNP produced a 3.3-fold increase in cGMP without altering cAMP; the cGK activity ratio (-cGMP/+cGMP) in these extracts was increased by 2.6-fold as determined by a newly developed assay, while the cAK activity ratio (-cAMP/+cAMP) was unchanged. The increase in cGK activity ratio by SNP was concentration-dependent and was nearly maximal at 30 s. Treatment of the tissue with 10 nM ANF also increased the cGK activity ratio (2.3-fold), but not that of cAK. 100-mu-M isoproterenol caused a 2.9-fold elevation of cAMP with no change in cGMP, but both cAK and cGK activity ratios were increased (2.3- and 1.6-fold, respectively). The increase in the cGK activity ratio could be mimicked by cAMP addition to control tissue extracts at the concentration measured in extracts of the isoproterenol-treated tissue. Forskolin (1 and 10-mu-M) also increased the cGK activity ratio (1.9- and 4.9-fold). The increases in cGK activity observed in extracts suggest that moderate elevation of either cGMP or cAMP causes intracellular cGK activation, thus producing relaxation of vascular smooth muscle.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Vanderbilt University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041269] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-40029] Funding Source: Medline; NIGMS NIH HHS [GM-41269] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINSON JL, 1991, FASEB J, V5, pA800; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Corbin J D, 1975, Adv Cyclic Nucleotide Res, V5, P265; CORBIN JD, 1988, METHOD ENZYMOL, V159, P74; CORBIN JD, 1983, METHOD ENZYMOL, V99, P227; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; FISCUS RR, 1984, BIOCHIM BIOPHYS ACTA, V805, P382, DOI 10.1016/0167-4889(84)90022-3; FORTE LR, 1991, IN PRESS N AM CYSTIC; FOSTER JL, 1981, J BIOL CHEM, V256, P5029; FRANCIS SH, 1988, MOL PHARMACOL, V34, P506; GERZER R, 1981, FEBS LETT, V132, P71, DOI 10.1016/0014-5793(81)80429-2; GRUETTER CA, 1979, J CYCLIC NUCL PROT, V5, P211; HARDMAN JG, 1984, J CARDIOVASC PHARM, V6, P5639; HEASLIP RJ, 1987, J PHARMACOL EXP THER, V243, P1018; HEI YJ, 1991, MOL PHARMACOL, V39, P233; IGNARRO LJ, 1985, ANNU REV PHARMACOL, V25, P171, DOI 10.1146/annurev.pharmtox.25.1.171; KATSUKI S, 1977, J CYCLIC NUCL PROT, V3, P23; KUBOVETZ WR, 1979, N-S ARCH PHARMACOL, V310, P129; LANDGRAF W, 1986, EUR J BIOCHEM, V154, P113, DOI 10.1111/j.1432-1033.1986.tb09365.x; LINCOLN TM, 1983, ADV CYCL NUCL RES<D>, V15, P139; LINCOLN TM, 1984, ADV CYCLIC NUCL PROT, V17, P285; LINCOLN TM, 1977, J BIOL CHEM, V252, P4269; LINCOLN TM, 1990, AM J PHYSIOL, V258, pC399, DOI 10.1152/ajpcell.1990.258.3.C399; LINCOLN TM, 1983, EUR J PHARMACOL, V101, P17; MURAD F, 1986, J CLIN INVEST, V78, P1, DOI 10.1172/JCI112536; MURAD F, 1987, AM J MED SCI, V294, P139, DOI 10.1097/00000441-198709000-00003; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SCHULTZ KD, 1977, NATURE, V265, P750, DOI 10.1038/265750a0; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; SHABB JB, 1990, J BIOL CHEM, V265, P16031; SILVER PJ, 1982, AM J PHYSIOL, V242, P177; THOMAS MK, 1990, J BIOL CHEM, V265, P14971; TORPHY TJ, 1982, J BIOL CHEM, V257, P1609; TRINER L, 1971, ANN NY ACAD SCI, V185, P458; WALDMAN SA, 1984, J BIOL CHEM, V259, P4332; WINQUIST RJ, 1984, P NATL ACAD SCI-BIOL, V81, P7661, DOI 10.1073/pnas.81.23.7661; WOLFE L, 1987, J BIOL CHEM, V262, P16906; WOLFE L, 1989, J BIOL CHEM, V264, P4157	38	258	262	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1015	1019						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1309758				2022-12-27	WOS:A1992GY96000055
J	KITAJIMA, I; SHINOHARA, T; MINOR, T; BIBBS, L; BILAKOVICS, J; NERENBERG, M				KITAJIMA, I; SHINOHARA, T; MINOR, T; BIBBS, L; BILAKOVICS, J; NERENBERG, M			HUMAN T-CELL LEUKEMIA-VIRUS TYPE-I TAX TRANSFORMATION IS ASSOCIATED WITH INCREASED UPTAKE OF OLIGODEOXYNUCLEOTIDES INVITRO AND INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HTLV-I; TRANSCRIPTIONAL REGULATION; TRANSGENIC MICE; GENE-EXPRESSION; PHORBOL ESTER; IDENTIFICATION; ENDOCYTOSIS; INHIBITION; ACTIVATION; DNA	We have utilized antisense oligodeoxynucleotides (ODNs) to modulate transcriptional activation by the human T-cell leukemia virus type I (HTLV-I) tax gene, the major transcriptional regulator of this virus. 3'-Terminal phosphorothioate-modified antisense ODNs were shown to efficiently inhibit Tax protein expression both in vitro and in vivo. Terminal substitution did not affect the affinity of ODNs for their target sequence but conferred a 9-fold increase in tax inhibition in vitro. When delivered into mice by intraperitoneal injection, ODNs inhibited tax expression in established tumors by 90%. Unmanipulated tax-transformed mouse fibroblasts, or HTLV-I-transformed human lymphocytes, showed at least 5-fold higher ODN binding and uptake over control cells. Balb/3T3 cell binding was induced to similar levels by cellular activators. This suggests that constitutive activation by tax transformation may increase susceptibility of HTLV-I-transformed cells to antisense therapy, providing a rationale for the use of antisense ODN therapeutics in HTLV-I-associated diseases.	Scripps Res Inst, DEPT NEUROPHARMACOL, CVN 10, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, CORE FACIL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	NERENBERG, M (corresponding author), SCRIPPS RES INST, DEPT NEUROPHARMACOL, CVN 10, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R01CA050234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH047680] Funding Source: NIH RePORTER; NCI NIH HHS [CA50234] Funding Source: Medline; NIMH NIH HHS [MH47680] Funding Source: Medline; NINDS NIH HHS [NS01330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BISCHOFBERGER N, 1992, SEMIN VIROL, V3, P57; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY JE, 1988, BIOTECHNIQUES, V6, P114; CALABRETTA B, 1991, CANCER RES, V51, P4505; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; COLLINS JF, 1992, J CLIN INVEST, V89, P1523, DOI 10.1172/JCI115744; COZZA EN, 1990, MOL CELL ENDOCRINOL, V70, P155, DOI 10.1016/0303-7207(90)90155-2; FROEHLER B, 1988, NUCLEIC ACIDS RES, V16, P4831, DOI 10.1093/nar/16.11.4831; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; GOODARZI G, 1991, BIOCHEM BIOPH RES CO, V181, P1343, DOI 10.1016/0006-291X(91)92086-Y; JACOBSON S, 1990, NATURE, V348, P245, DOI 10.1038/348245a0; KINOSHITA T, 1989, P NATL ACAD SCI USA, V86, P5620, DOI 10.1073/pnas.86.14.5620; KITAJIMA I, 1991, J CLIN INVEST, V88, P1315, DOI 10.1172/JCI115436; KITAJIMA I, 1992, IN PRESS SCIENCE; KLAUSNER RD, 1984, P NATL ACAD SCI-BIOL, V81, P3005, DOI 10.1073/pnas.81.10.3005; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; MACGREGOR GR, 1989, METHOD MOL BIOL, P217; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MATSUKURA M, 1987, P NATL ACAD SCI USA, V84, P7706, DOI 10.1073/pnas.84.21.7706; MILLER PS, 1980, J BIOL CHEM, V255, P9659; MIYATA Y, 1989, EXP CELL RES, V181, P454, DOI 10.1016/0014-4827(89)90102-X; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NERENBERG MI, 1991, J VIROL, V65, P3349, DOI 10.1128/JVI.65.6.3349-3353.1991; NERENBERG MI, 1989, AM J PATHOL, V135, P1025; NILSEN T, 1991, BIOCHIM BIOPHYS ACTA, V1095, P39, DOI 10.1016/0167-4889(91)90042-V; NILSSON M, 1989, EXP CELL RES, V181, P551, DOI 10.1016/0014-4827(89)90111-0; POTTER BVL, 1983, J BIOL CHEM, V258, P1758; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; Sambrook J, 1989, MOL CLONING; SANDVIG K, 1988, J CELL BIOCHEM, V36, P73, DOI 10.1002/jcb.240360108; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHAW JP, 1991, NUCLEIC ACIDS RES, V19, P747, DOI 10.1093/nar/19.4.747; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; STEIN CA, 1988, CANCER RES, V48, P2659; WILEY CA, 1989, NEW ENGL J MED, V320, P992, DOI 10.1056/NEJM198904133201507; YOKUBOV LA, 1989, P NATL ACAD SCI USA, V86, P6454; ZAMECNIK PC, 1986, P NATL ACAD SCI USA, V83, P4143, DOI 10.1073/pnas.83.12.4143	41	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25881	25888						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1281476				2022-12-27	WOS:A1992KD07300046
J	HSU, D; OLEFSKY, JM				HSU, D; OLEFSKY, JM			CHARACTERIZATION OF INSULIN-LIKE GROWTH-FACTOR (IGF) BINDING-PROTEINS AND THEIR ROLE IN MODULATING IGF-I ACTION IN BHK CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLASTS	We have found that over one-half of the total cell surface I-125-insulin-like growth factor I (IGF-I) binding to BHK cells represents binding to IGF binding proteins (IGFBPs) rather than to the IGF-I receptor. In addition to a number of secreted IGFBPs, we have now characterized two cell-associated IGFBPs with unique characteristics. The cell-associated IGFBPs have molecular weights of 30,000 (30K) and 25,000 (25K), as determined by the Western ligand blot technique. IGFBP-30K is located at the cell surface and can be readily labeled by affinity cross-linking with I-125-IGF-I. Surface expression of IGFBP-30K increases 5.4 +/- 1.2-fold (n = 11) with serum starvation. This induction is fully evident by 4 h, plateauing by 24 h, and is completely inhibitable by cycloheximide. The fasting-induced increase in IGFBP-30K is inhibited by IGF-I and by des-IGF-I and, to a lesser extent, by insulin. Unlike cell-associated IGFBP-30K, secretion of IGFBP was stimulated (6.8 +/- 0.5-fold, n = 2) by IGF-I, whereas IGFBP secretion was inhibited 54% by insulin. These results demonstrate coordinate regulation of IGFBP by serum starvation and IGF-I, such that at low concentrations of IGF-I, cell surface binding protein increases whereas binding protein secretion decreases. At high concentrations of IGF-I, IGFBP secretion increases and cell surface IGF-I receptor, as well as IGFBP, decreases. Taken together, these regulatory events regulate the availability of IGF-I for biologic signalling.	VET ADM MED CTR,SAN DIEGO,CA 92161	US Department of Veterans Affairs; Veterans Health Administration (VHA)	HSU, D (corresponding author), UNIV CALIF SAN DIEGO,DEPT MED,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008682, R01DK033651, R37DK033651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK08682, DK 33651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAR RS, 1990, ENDOCRINOLOGY, V127, P1078, DOI 10.1210/endo-127-3-1078; BICSAK TA, 1990, ENDOCRINOLOGY, V126, P2184, DOI 10.1210/endo-126-4-2184; BLAT C, 1989, J BIOL CHEM, V264, P12449; BLUM WF, 1989, ENDOCRINOLOGY, V125, P766, DOI 10.1210/endo-125-2-766; BUSBY WH, 1988, J BIOL CHEM, V263; CLEMMONS DR, 1991, J DEV PHYSIOL, V15, P105; CLEMMONS DR, 1991, ADV EXP MED BIOL, V293, P113; CLEMMONS DR, 1986, J CLIN INVEST, V77, P1548, DOI 10.1172/JCI112470; CONOVER CA, 1991, J CLIN INVEST, V88, P1354, DOI 10.1172/JCI115441; CONOVER CA, 1990, ENDOCRINOLOGY, V127, P2795, DOI 10.1210/endo-127-6-2795; CONOVER CA, 1991, ENDOCRINOLOGY, V129, P710, DOI 10.1210/endo-129-2-710; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; DEVROEDE MA, 1986, J CLIN INVEST, V77, P602, DOI 10.1172/JCI112343; ELGIN RG, 1987, P NATL ACAD SCI USA, V84, P3254, DOI 10.1073/pnas.84.10.3254; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; RITVOS O, 1988, ENDOCRINOLOGY, V122, P2150, DOI 10.1210/endo-122-5-2150; ROSS M, 1989, BIOCHEM J, V258, P267, DOI 10.1042/bj2580267; SHIMASAKI S, 1991, MOL ENDOCRINOL, V5, P938, DOI 10.1210/mend-5-7-938; STOKER M, 1964, NATURE, V203, P1355, DOI 10.1038/2031355a0	19	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25576	25582						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1281161				2022-12-27	WOS:A1992KB60300099
J	WONG, I; CHAO, KL; BUJALOWSKI, W; LOHMAN, TM				WONG, I; CHAO, KL; BUJALOWSKI, W; LOHMAN, TM			DNA-INDUCED DIMERIZATION OF THE ESCHERICHIA-COLI REP HELICASE - ALLOSTERIC EFFECTS OF SINGLE-STRANDED AND DUPLEX DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPRESSOR-OPERATOR INTERACTION; FILTER-BINDING ASSAY; NUCLEIC-ACIDS; EQUILIBRIUM BINDING; GENE-PRODUCT; CIRCULAR DNA; PROTEIN; REPLICATION; SPECIFICITY; ATP	The Escherichia coli Rep helicase is a stable monomer (M(r) = 72,802) in the absence of DNA; however, binding of single-stranded (ss) or duplex (ds) DNA induces Rep monomers to dimerize. Furthermore, a chemically cross-linked Rep dimer retains both its DNA-dependent ATPase and helicase activities, suggesting that the functionally active Rep helicase is a dimer (Chao, K., and Lohman, T. M. (1991) J. Mol. Biol. 221, 1165-1181). Using a modified "double-filter" nitrocellulose filter binding assay, we have examined quantitatively the equilibrium binding of Rep to a series of ss-oligodeoxynucleotides, d(pN)n (8 less-than-or-equal-to n less-than-or-equal-to 20) and two 16-base pair duplex oligodeoxynucleotides, which are short enough so that only a single Rep monomer can bind to each oligonucleotide. This strategy has enabled us to examine the linkage between DNA binding and dimerization. We also present a statistical thermodynamic model to describe the DNA-induced Rep dimerization in the presence of ss- and/or ds-oligodeoxynucleotides. We observe quantitative agreement between this model and the experimental binding isotherms and have analyzed these isotherms to obtain the seven independent interaction constants that describe Rep-DNA binding and Rep dimerization. We find that Rep monomers (P) can bind either ss-DNA (S) or ds-DNA (D) to form PS or PD, respectively, which can then dimerize to form P2S or P2D. Furthermore, both protomers of the DNA-induced Rep dimer can bind DNA to form either P2S2, P2D2 or the mixed dimer species P2SD and ss- and ds-DNA compete for the same sites on the Rep protein. When bound to DNA, the Rep dimerization constants are approximately 1-2 x 10(8) M-1 (6 mM NaCl, pH 7.5, 4-degrees-C), which are greater than the dimerization constant for free Rep monomers by at least 10(4)-fold. The Rep-ss-DNA interaction constants are independent of base composition and sequence, consistent with its role as a nonspecific DNA-binding protein. Allosteric effects are associated with ss- and ds-DNA binding to the half-saturated Rep dimers, i.e. the affinity of either ss- or ds-DNA to the free protomer of a half-saturated Rep dimer is clearly influenced by the conformation of DNA bound to the first protomer. These allosteric effects further support the proposal that the Rep dimer is functionally important and that the Rep-DNA species P2S2 and P2SD may serve as useful models for intermediates that occur during DNA unwinding. The ability of Rep to form the ternary complexes P2S2 and P2SD has important implications for how a Rep dimer may interact with a DNA replication fork and unwind DNA.	WASHINGTON UNIV, SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,BOX 8231, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA	Washington University (WUSTL)					NIGMS NIH HHS [GM45948, R01 GM045948] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045948] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI N, 1981, J BIOL CHEM, V256, P5287; ARAI N, 1981, J BIOL CHEM, V256, P5294; BARKLEY MD, 1981, BIOCHEMISTRY-US, V20, P3842, DOI 10.1021/bi00516a027; BRIDGES BA, 1981, MUTAT RES, V82, P229, DOI 10.1016/0027-5107(81)90152-4; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; CALENDAR R, 1970, VIROLOGY, V40, P72, DOI 10.1016/0042-6822(70)90380-6; CANTOR CR, 1970, BIOPOLYMERS, V9, P1059, DOI 10.1002/bip.1970.360090909; CHAO K, 1991, THESIS TEXAS A M U; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; CLORE GM, 1982, J MOL BIOL, V155, P447, DOI 10.1016/0022-2836(82)90481-8; COLASANTI J, 1987, MOL GEN GENET, V209, P382, DOI 10.1007/BF00329669; DENHARDT DT, 1967, P NATL ACAD SCI USA, V57, P813, DOI 10.1073/pnas.57.3.813; DRAPER DE, 1978, J MOL BIOL, V122, P339; DYKSTRA CC, 1984, COLD SPRING HARB SYM, V49, P463, DOI 10.1101/SQB.1984.049.01.052; FASSLER JS, 1985, J BACTERIOL, V161, P609, DOI 10.1128/JB.161.2.609-614.1985; FINGER LR, 1982, J MOL BIOL, V156, P203, DOI 10.1016/0022-2836(82)90467-3; GIEDROC DP, 1991, BIOCHEMISTRY-US, V30, P8230, DOI 10.1021/bi00247a020; GILCHRIST CA, 1987, NUCLEIC ACIDS RES, V15, P465, DOI 10.1093/nar/15.2.465; HAGERMAN PJ, 1988, ANNU REV BIOPHYS BIO, V17, P265; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; KELLY RC, 1976, J BIOL CHEM, V251, P7240; KORNBERG A, 1978, J BIOL CHEM, V253, P3298; LANE HED, 1974, J BACTERIOL, V120, P805, DOI 10.1128/JB.120.2.805-814.1974; LANE HED, 1975, J MOL BIOL, V97, P99; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE EH, 1991, P NATL ACAD SCI USA, V88, P3029, DOI 10.1073/pnas.88.8.3029; LIU CC, 1981, J BIOL CHEM, V256, P2813; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; LOHMAN TM, 1988, BIOCHEMISTRY-US, V27, P2260, DOI 10.1021/bi00407a002; LOHMAN TM, 1989, J BIOL CHEM, V264, P10139; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MATSON SW, 1991, PROG NUCLEIC ACID RE, V40, P289; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; NEWPORT JW, 1981, J MOL BIOL, V145, P105, DOI 10.1016/0022-2836(81)90336-3; OVERMAN LB, 1988, BIOCHEMISTRY-US, V27, P456, DOI 10.1021/bi00401a067; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4043; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2873, DOI 10.1021/bi00433a019; RUNYON GT, 1989, J BIOL CHEM, V264, P17502; SANG BC, 1989, J BIOMOL STRUCT DYN, V7, P693, DOI 10.1080/07391102.1989.10508514; SCOTT JF, 1977, P NATL ACAD SCI USA, V74, P193, DOI 10.1073/pnas.74.1.193; SENIOR MM, 1988, P NATL ACAD SCI USA, V85, P6242, DOI 10.1073/pnas.85.17.6242; SEO YS, 1991, J BIOL CHEM, V266, P13161; SMITH GR, 1990, NUCLEIC ACIDS MOL BI, V4, P78; SMOLARSKY M, 1979, BIOCHIM BIOPHYS ACTA, V199, P447; TAUCHERSCHOLZ G, 1983, UCLA S MOL CELL BIOL, V10, P65; THOMMES P, 1990, FEBS LETT, V268, P325, DOI 10.1016/0014-5793(90)81279-W; WASHBURN BK, 1991, J BACTERIOL, V173, P2569, DOI 10.1128/jb.173.8.2569-2575.1991; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6948, DOI 10.1021/bi00527a029; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; WOODBURY CP, 1983, BIOCHEMISTRY-US, V22, P4730, DOI 10.1021/bi00289a018; YARRANTON GT, 1979, J BIOL CHEM, V254, P2002; YARRANTON GT, 1979, P NATL ACAD SCI USA, V76, P1658, DOI 10.1073/pnas.76.4.1658	54	113	113	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7596	7610						15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1313807				2022-12-27	WOS:A1992HN48500058
J	DING, JB; BADWEY, JA				DING, JB; BADWEY, JA			EFFECTS OF ANTAGONISTS OF PROTEIN PHOSPHATASES ON SUPEROXIDE RELEASE BY NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; 2 CYTOSOLIC COMPONENTS; KINASE-C; PHORBOL ESTERS; PLASMA-MEMBRANE; NADPH OXIDASE; PHOSPHORYLATION; ACTIVATION; CALCIUM	Neutrophils stimulated with 4-beta-phorbol 12-myristate 13-acetate (PMA) release large quantities of superoxide (O2-) and exhibit phosphorylation of two proteins with molecular masses of 47(p47) and 49 kDa (p49). Addition of inhibitors of protein kinases (e.g. 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine (H-7)) to these cells after stimulation with PMA results in the loss of P-32 from these proteins and a rapid cessation of O2- release (e.g. Heyworth, P. G., and Badwey, J. A. (1990) Biochim. Biophys. Acta 1052, 299-305). In this paper we report that antagonists of type 1 and 2A protein phosphatases (okadaic acid, calyculin A) prevented both the loss of P-32 from p47 and the termination of O2- release in stimulated neutrophils treated with H-7. Calyculin A also caused a remarkable hyperphosphorylation of a number of proteins in neutrophils and increased O2- release from these cells in response to a suboptimal amount of PMA. Enzymes present in both the soluble and particulate fractions of neutrophils catalyzed the near complete dephosphorylation of P-32-labeled p47 and p49 bound to Immobilon-P membranes. Dephosphorylation of these blotted phosphoproteins occurred at physiological rates and was inhibited by okadaic acid and calyculin A. These data strongly suggest that p47 undergoes a continual cycle of phosphorylation and dephosphorylation throughout the period of O2- release when PMA is the stimulus. Moreover, we show that antagonists of type 1 and 2A protein phosphatases block dephosphorylation of p47 both in vivo and in vitro, indicating that these enzymes may modulate O2- release under certain circumstances.	BOSTON BIOMED RES INST, DEPT CELL & MOLEC BIOL, 20 STANIFORD ST, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	Boston Biomedical Research Institute; Harvard University; Harvard Medical School					NIAID NIH HHS [AI28342, AI23323] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023323, R01AI028342] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Badwey J A, 1986, Methods Enzymol, V132, P365; BADWEY JA, 1989, BIOCHEM BIOPH RES CO, V158, P1029, DOI 10.1016/0006-291X(89)92825-8; BADWEY JA, 1988, J BIOL CHEM, V263, P2779; BADWEY JA, 1989, J BIOL CHEM, V264, P14947; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHAN JRA, 1986, J BIOL CHEM, V261, P7635; CLARK RA, 1989, NEW ENGL J MED, V321, P647, DOI 10.1056/NEJM198909073211005; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; COHEN P, 1989, J BIOL CHEM, V264, P21435; CURNUTTE JT, 1984, J BIOL CHEM, V259, P1851; CURNUTTE JT, 1987, ADV HUM GENET, V16, P229; DEPIERRE JW, 1974, J BIOL CHEM, V249, P7111; DING J, 1992, IN PRESS BIOCH BIOPH; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; HAYAKAWA T, 1986, J BIOL CHEM, V261, P9109; HEYWORTH PG, 1986, BIOCHEM J, V239, P723, DOI 10.1042/bj2390723; HEYWORTH PG, 1990, BIOCHIM BIOPHYS ACTA, V1052, P299, DOI 10.1016/0167-4889(90)90225-3; HEYWORTH PG, 1990, J BIOENERG BIOMEMBR, V22, P1, DOI 10.1007/BF00762842; HEYWORTH PG, 1989, BIOCHEM J, V260, P243, DOI 10.1042/bj2600243; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HONKANEN RE, 1990, J BIOL CHEM, V265, P19401; HONKANEN RE, 1991, J BIOL CHEM, V266, P6614; ISHIHARA H, 1989, J PHARMACOL EXP THER, V250, P388; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEREA KM, 1989, BIOCHEMISTRY-US, V28, P9286, DOI 10.1021/bi00450a008; LIU Y, 1989, J BIOL CHEM, V264, P12800; LOMAX KJ, 1989, SCIENCE, V246, P987, DOI 10.1126/science.2587992; MAZON MJ, 1982, J BIOL CHEM, V257, P1128; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; OFLAHERTY JT, 1990, J BIOL CHEM, V265, P21619; OKAMURA N, 1988, J BIOL CHEM, V263, P6777; PHILLIPS WA, 1989, J BIOL CHEM, V264, P8361; PONTREMOLI S, 1987, P NATL ACAD SCI USA, V84, P398, DOI 10.1073/pnas.84.2.398; QUINN MT, 1989, BIOCHIM BIOPHYS ACTA, V987, P83, DOI 10.1016/0005-2736(89)90458-6; ROBINSON JM, 1987, J CELL BIOL, V105, P417, DOI 10.1083/jcb.105.1.417; ROBINSON JM, 1990, BIOCHIM BIOPHYS ACTA, V1055, P55, DOI 10.1016/0167-4889(90)90090-Z; ROBINSON JM, 1985, J CELL BIOL, V101, P1052, DOI 10.1083/jcb.101.3.1052; ROSEN J, 1991, J BIOL CHEM, V266, P3827; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P9563	44	72	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6442	6448						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1313435				2022-12-27	WOS:A1992HK31800108
J	WASER, M; HESSBIENZ, D; DAVIES, K; SOLIOZ, M				WASER, M; HESSBIENZ, D; DAVIES, K; SOLIOZ, M			CLONING AND DISRUPTION OF A PUTATIVE NAH-ANTIPORTER GENE OF ENTEROCOCCUS-HIRAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOCOCCUS-FAECALIS; ESCHERICHIA-COLI; K+-ATPASE; PROTEIN; ANT; DNA	When growing in a sodium-rich environment, wild-type Enterococcus hirae extrudes sodium by two mechanisms, ATP-driven sodium extrusion, and NaH-antiport. Mutant 7683 is unable to grow on sodium-rich media. This is due to two mutations, one inactivating ATP-driven sodium transport and a second rendering NaH-antiport inoperative. 7683 was transformed by electroporation with a gene bank, derived from E. hirae, in an Escherichia coli-E. hirae shuttle vector. Transformants which had regained the ability to grow on sodium-rich media were selected for and the transforming plasmids analyzed. A gene able to restore NaH-antiport activity in 7683 was identified. This gene was named napA. It codes for an extremely hydrophobic protein of 383 amino acids. Hydropathy analysis of this protein indicates that it probably forms 12 transmembraneous helices. In a mutant, possessing only the NaH-antiporter, the napA gene was disrupted by homologous recombination. The resultant strain failed to grow in sodium-rich media, and vesicles isolated from these cells exhibited a defect in sodium proton antiport activity. We conclude that the napA gene codes for a NaH-antiporter. The NapA protein does not exhibit significant homology to any protein in the EMBL genetic data bank.	UNIV BERN,DEPT CLIN PHARMACOL,MURTENSTR 35,CH-3010 BERN,SWITZERLAND	University of Bern			Solioz, Marc/I-3162-2013	Solioz, Marc/0000-0002-7989-6721; Davies, Kelvin/0000-0001-7790-3003				ANDERSON DG, 1983, APPL ENVIRON MICROB, V46, P549, DOI 10.1128/AEM.46.3.549-552.1983; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIBROV PA, 1991, BIOCHIM BIOPHYS ACTA, V1056, P209, DOI 10.1016/S0005-2728(05)80052-0; FERRETTI JJ, 1987, STREPTOCOCCAL GENETI; GRINSTEIN S, 1988, NAPLUS HPLUS EXCHANG; HAROLD FM, 1970, J BACTERIOL, V101, P152, DOI 10.1128/JB.101.1.152-159.1970; HEEFNER DL, 1980, J BIOL CHEM, V255, P1403; HEEFNER DL, 1982, P NATL ACAD SCI-BIOL, V79, P2798, DOI 10.1073/pnas.79.9.2798; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HUGENTOBLER G, 1983, J BIOL CHEM, V258, P7611; KAKINUMA Y, 1990, FEBS LETT, V261, P135, DOI 10.1016/0014-5793(90)80654-2; KAKINUMA Y, 1989, J BIOENERG BIOMEMBR, V21, P679, DOI 10.1007/BF00762686; KAKINUMA Y, 1987, J BACTERIOL, V169, P3886, DOI 10.1128/jb.169.9.3886-3890.1987; KAKINUMA Y, 1985, J BIOL CHEM, V260, P2086; KAKINUMA Y, 1990, FEBS LETT, V271, P97, DOI 10.1016/0014-5793(90)80381-R; KAKINUMA Y, 1990, FEBS LETT, V271, P102, DOI 10.1016/0014-5793(90)80382-S; KARPEL R, 1988, J BIOL CHEM, V263, P10408; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Maniatis T., 1982, MOL CLONING; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; PADAN E, 1989, J BIOL CHEM, V264, P20297; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOLIOZ M, 1990, BIOCHIMIE, V72, P279, DOI 10.1016/0300-9084(90)90084-T; SOLIOZ M, 1987, J BIOL CHEM, V262, P7358; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289	27	102	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5396	5400						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1312090				2022-12-27	WOS:A1992HH74700061
J	JONGES, GN; VANNOORDEN, CJF; LAMERS, WH				JONGES, GN; VANNOORDEN, CJF; LAMERS, WH			INSITU KINETIC-PARAMETERS OF GLUCOSE-6-PHOSPHATASE IN THE RAT-LIVER LOBULUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC-MICROSOMAL GLUCOSE-6-PHOSPHATASE; GLYCOGEN-STORAGE-DISEASE; GLUCOSE 6-PHOSPHATASE; TRANSPORT-SYSTEM; EXCLUDED VOLUME; PHOSPHATE; PROTEIN; ASSOCIATION; INVOLVEMENT; HEPATOCYTES	Glucose-6-phosphatase activity has been determined in periportal and pericentral zones of the rat liver lobule using a quantitative histochemical method. The study was performed on unfixed cryostat sections of livers from fasted and fed female and male rats. Highest activity was found in periportal zones, and starvation caused a 2-3-fold increase of glucose-6-phosphatase activity in periportal and pericentral zones of both sexes. Unexpectedly, K(M) values were also significantly different in periportal and pericentral zones and were found to increase linearly with V(max) values, irrespective of sex and feeding condition. Because the cryofixation procedure was shown to permeabilize the biomembranes in the tissue sections, it can be concluded that the rise in K(M) and V(max) values has to be attributed to the catalytic unit of the glucose-6-phosphatase system. It is suggested that the enzyme exists in a high affinity configuration at low enzyme concentrations but that at high enzyme concentrations a hysteretic mechanism, as proposed by Berteloot et al. (Berteloot, A., Vidal, H., and Van de Werve, G. (1991) J. Biol. Chem. 266, 5497-5507), transforms the enzyme from a high to a low affinity configuration. The present study indicates that the concept of functional heterogeneity of liver parenchyma may be more complex than thus far assumed.	UNIV AMSTERDAM,ACAD MED CTR,DEPT ANAT & EMBRYOL,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam	JONGES, GN (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,CELL BIOL & HISTOL LAB,MEIBERGDREEF 15,1105 AZ AMSTERDAM,NETHERLANDS.		Lamers, Wouter H./D-2965-2012					ARION WJ, 1980, J BIOL CHEM, V255, P396; ARION WJ, 1976, J BIOL CHEM, V251, P6784; ARION WJ, 1975, MOL CELL BIOCHEM, V6, P75, DOI 10.1007/BF01732001; ASHMORE J, 1959, VITAM HORM, V17, P91, DOI 10.1016/S0083-6729(08)60269-1; BERTELOOT A, 1991, J BIOL CHEM, V266, P5497; BURCHELL A, 1990, FASEB J, V4, P2978, DOI 10.1096/fasebj.4.12.2168325; BURCHELL A, 1985, BIOCHEM J, V230, P489, DOI 10.1042/bj2300489; BURCHELL A, 1990, J INHERIT METAB DIS, V13, P247, DOI 10.1007/BF01799362; BUTCHER RG, 1971, HISTOCHEMISTRY, V28, P131; CANFIELD WK, 1988, J BIOL CHEM, V263, P7458; FRASCH ACC, 1978, J HISTOCHEM CYTOCHEM, V26, P157, DOI 10.1177/26.3.204704; FULTON AB, 1982, CELL, V30, P345, DOI 10.1016/0092-8674(82)90231-8; GOLD G, 1976, J BIOL CHEM, V251, P1035; GUNDERSON HM, 1975, J BIOL CHEM, V250, P3552; IYER SL, 1983, ARCH BIOCHEM BIOPHYS, V223, P173, DOI 10.1016/0003-9861(83)90583-0; JONGES GN, 1990, J HISTOCHEM CYTOCHEM, V38, P1413, DOI 10.1177/38.10.2169492; JONGES GN, 1989, I PHYS C SER, V98, P755; JUNGERMANN K, 1982, EUR J BIOCHEM, V123, P429, DOI 10.1111/j.1432-1033.1982.tb19786.x; KALICHARAN D, 1985, HISTOCHEMISTRY, V82, P287, DOI 10.1007/BF00501407; KATZ N, 1976, H-S Z PHYSIOL CHEM, V357, P359, DOI 10.1515/bchm2.1976.357.1.359; LANGE AJ, 1980, J BIOL CHEM, V255, P8381; LI CY, 1987, J HISTOCHEM CYTOCHEM, V35, P1457, DOI 10.1177/35.12.2824601; MINTON AP, 1981, BIOCHEMISTRY-US, V20, P4821, DOI 10.1021/bi00520a003; MINTON AP, 1981, BIOPOLYMERS, V20, P2093, DOI 10.1002/bip.1981.360201006; MINTON AP, 1983, MOL CELL BIOCHEM, V55, P119, DOI 10.1007/BF00673707; NORDLIE RC, 1983, J BIOL CHEM, V258, P9739; NORDLIE RC, 1979, LIFE SCI, V24, P2397, DOI 10.1016/0024-3205(79)90447-8; NORDLIE RC, 1981, J BIOL CHEM, V256, P4768; NORDLIE RC, 1983, BIOCH METABOLIC PROC, P125; PAGLIARO L, 1988, J CELL BIOL, V107, P981, DOI 10.1083/jcb.107.3.981; PEARS J, 1989, BIOCHIM BIOPHYS ACTA, V993, P224, DOI 10.1016/0304-4165(89)90168-2; PEARSE AGE, 1980, HISTOCHEMISTRY THEOR, V1, P15; SASSE D, 1975, FEBS LETT, V57, P83, DOI 10.1016/0014-5793(75)80157-8; SCHULZE HU, 1986, J BIOL CHEM, V261, P6571; SCHULZE HU, 1980, EUR J BIOCHEM, V106, P505, DOI 10.1111/j.1432-1033.1980.tb04597.x; STETTEN MR, 1967, BIOCHIM BIOPHYS ACTA, V132, P138; STOWARD PJ, 1980, CIBA F S, V73, P11; SWEZEY RR, 1986, J CELL BIOL, V103, P1509, DOI 10.1083/jcb.103.4.1509; TRAXINGER RR, 1990, BIOCHEM CELL BIOL, V68, P454, DOI 10.1139/o90-064; Van Noorden CJF, 1991, HISTOCHEMISTRY THEOR, V3, P355; VANDEWERVE G, 1989, J BIOL CHEM, V264, P6033; VANNOORDEN CJF, 1986, HISTOCHEM J, V18, P397, DOI 10.1007/BF01675221; VANNOORDEN CJF, 1991, IN PRESS; WADDELL ID, 1987, BIOCHEM SOC T, V15, P1126, DOI 10.1042/bst0151126; WEBER G, 1955, CANCER RES, V15, P105; WILF J, 1981, BIOCHIM BIOPHYS ACTA, V670, P316, DOI 10.1016/0005-2795(81)90103-3; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324	47	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4878	4881						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1311322				2022-12-27	WOS:A1992HF64200087
J	MOURA, I; TAVARES, P; MOURA, JJG; RAVI, N; HUYNH, BH; LIU, MY; LEGALL, J				MOURA, I; TAVARES, P; MOURA, JJG; RAVI, N; HUYNH, BH; LIU, MY; LEGALL, J			DIRECT SPECTROSCOPIC EVIDENCE FOR THE PRESENCE OF A 6FE CLUSTER IN AN IRON-SULFUR PROTEIN ISOLATED FROM DESULFOVIBRIO-DESULFURICANS (ATCC-27774)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RES; GIGAS FERREDOXIN-II; AZOTOBACTER-VINELANDII; MOFE PROTEIN; CLOSTRIDIUM-PASTEURIANUM; RESONANCE SPECTROSCOPY; MOSSBAUER-SPECTROSCOPY; 2<4FE-4SE>+ FERREDOXIN; SPIN STATES; P-CLUSTER	A novel iron-sulfur protein was purified from the extract of Desulfovibrio desulfuricans (ATCC 27774) to homogeneity as judged by polyacrylamide gel electrophoresis. The purified protein is a monomer of 57 kDa molecular mass. It contains comparable amounts of iron and inorganic labile sulfur atoms and exhibits an optical spectrum typical of iron-sulfur proteins with maxima at 400, 305, and 280 nm. Mossbauer data of the as-isolated protein show two spectral components, a paramagnetic and a diamagnetic, of equal intensity. Detailed analysis of the paramagnetic component reveals six distinct antiferromagnetically coupled iron sites, providing direct spectroscopic evidence for the presence of a 6Fe cluster in this newly purified protein. One of the iron sites exhibits parameters (DELTA-E(Q) = 2.67 +/- 0.03 mm/s and delta = 1.09 +/- 0.02 mm/s at 140 K) typical for high spin ferrous ion; the observed large isomer shift indicates an iron environment that is distinct from the tetrahedral sulfur coordination commonly observed for the iron atoms in iron-sulfur clusters and is consistent with a penta- or hexacoordination containing N and/or O ligands. The other five iron sites are most probably high spin ferric. Three of them show parameters characteristic for tetrahedral sulfur coordination. In correlation with the EPR spectrum of the as-purified protein which shows a resonance signal at g = 15.3 and a group of signals between g = 9.8 and 5.4, this 6Fe cluster is assigned to an unusual spin state of 9/2 with zero field splitting parameters D = -1.3 cm-1 and E/D = 0.062. Other EPR signals attributable to minor impurities are also observed at the g = 4.3 and 2.0 regions. The diamagnetic Mossbauer component represents a second iron cluster, which, upon reduction with dithionite, displays an intense S = 1/2 EPR signal with g values at 2.00, 1.83, and 1.31. In addition, an EPR signal of the S = 3/2 type is also observed for the dithionite-reduced protein.	EMORY UNIV, DEPT PHYS, ATLANTA, GA 30322 USA; UNIV NOVA LISBOA, CTR TECNOL QUIM & BIOL, P-2780 OEIRAS, PORTUGAL; UNIV GEORGIA, DEPT BIOCHEM, ATHENS, GA 30602 USA	Emory University; Universidade Nova de Lisboa; University System of Georgia; University of Georgia			Moura, José J G/D-6426-2013; Tavares, Pedro/B-3654-2008; Moura, Isabel/D-6339-2013	Moura, José J G/0000-0002-4726-2388; Tavares, Pedro/0000-0002-7398-2661; Moura, Isabel/0000-0003-0971-4977	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032187, R01GM041482] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 41482, GM 32187] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MWW, 1989, P NATL ACAD SCI USA, V86, P4932, DOI 10.1073/pnas.86.13.4932; AURIC P, 1987, BIOCHEM J, V242, P525, DOI 10.1042/bj2420525; BACKES G, 1991, J AM CHEM SOC, V113, P2055, DOI 10.1021/ja00006a027; BECK JL, 1988, J AM CHEM SOC, V110, P3317, DOI 10.1021/ja00218a061; BEINERT H, 1990, FASEB J, V4, P2483, DOI 10.1096/fasebj.4.8.2185975; BEINERT H, 1989, EUR J BIOCHEM, V186, P5, DOI 10.1111/j.1432-1033.1989.tb15170.x; BERTINI I, 1991, J AM CHEM SOC, V113, P1237, DOI 10.1021/ja00004a025; BREWER JM, 1969, J CHEM EDUC, V46, P41, DOI 10.1021/ed046p41; CAMMACK R, 1985, BIOCHEM SOC T, V13, P572, DOI 10.1042/bst0130572; Carter Jr C. W., 1977, IRON SULFUR PROTEINS, V3, P157; CLINE JF, 1985, J BIOL CHEM, V260, P3251; CONOVER RC, 1990, J AM CHEM SOC, V112, P4562, DOI 10.1021/ja00167a074; DUNHAM WR, 1971, BIOCHIM BIOPHYS ACTA, V253, P134, DOI 10.1016/0005-2728(71)90240-4; EMPTAGE MH, 1980, J BIOL CHEM, V255, P1793; FEE JA, 1984, J BIOL CHEM, V259, P124; FISCHER DS, 1964, CLIN CHEM, V10, P21, DOI 10.1016/0009-8981(64)90210-4; FOGO JK, 1949, ANAL CHEM, V21, P732, DOI 10.1021/ac60030a028; FREY M, 1987, J MOL BIOL, V197, P525, DOI 10.1016/0022-2836(87)90562-6; FUKUYAMA K, 1989, J MOL BIOL, V210, P383, DOI 10.1016/0022-2836(89)90338-0; FUKUYAMA K, 1980, NATURE, V286, P522, DOI 10.1038/286522a0; GAILLARD J, 1986, BIOCHEMISTRY-US, V25, P464, DOI 10.1021/bi00350a028; GEORGE SJ, 1989, BIOCHEM J, V264, P275, DOI 10.1042/bj2640275; GOLBECK JH, 1987, BIOCHIM BIOPHYS ACTA, V895, P167, DOI 10.1016/S0304-4173(87)80002-2; HAGEN WR, 1989, J CHEM SOC FARAD T 1, V85, P4083, DOI 10.1039/f19898504083; HAGEN WR, 1986, FEBS LETT, V203, P59, DOI 10.1016/0014-5793(86)81436-3; HAGEN WR, 1987, EUR J BIOCHEM, V169, P457, DOI 10.1111/j.1432-1033.1987.tb13633.x; HIRS CHW, 1986, METHOD ENZYMOL, V11, P167; HOLMES S, 1990, COMPOS SCI TECHNOL, V38, P1, DOI 10.1016/0266-3538(90)90068-G; HUYNH BH, 1984, P NATL ACAD SCI-BIOL, V81, P3728, DOI 10.1073/pnas.81.12.3728; HUYNH BH, 1980, BIOCHIM BIOPHYS ACTA, V623, P124, DOI 10.1016/0005-2795(80)90015-X; HUYNH BH, 1979, BIOCHIM BIOPHYS ACTA, V576, P192, DOI 10.1016/0005-2795(79)90497-5; HUYNH BH, 1980, J BIOL CHEM, V255, P3242; JORDANOV J, 1990, INORG CHEM, V29, P4288, DOI 10.1021/ic00346a025; KANATZIDIS MG, 1985, J AM CHEM SOC, V107, P953, DOI 10.1021/ja00290a034; KENNEDY MC, 1987, P NATL ACAD SCI USA, V84, P8854, DOI 10.1073/pnas.84.24.8854; KENT TA, 1985, J BIOL CHEM, V260, P6871; KENT TA, 1982, P NATL ACAD SCI-BIOL, V79, P1096, DOI 10.1073/pnas.79.4.1096; KENT TA, 1980, P NATL ACAD SCI-BIOL, V77, P6574, DOI 10.1073/pnas.77.11.6574; KISSINGER CR, 1989, FEBS LETT, V244, P447, DOI 10.1016/0014-5793(89)80580-0; LINDAHL PA, 1987, J BIOL CHEM, V262, P14945; LINDAHL PA, 1988, J BIOL CHEM, V263, P19412; LIU MC, 1981, J BIOL CHEM, V256, P3159; LOVENBERG W, 1963, J BIOL CHEM, V238, P3899; Lovenberg W, 1973, IRON SULFUR PROTEINS, VI; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCLEAN PA, 1987, J BIOL CHEM, V262, P12900; MOORE S, 1963, METHOD ENZYMOL, V6, P819, DOI 10.1016/0076-6879(63)06257-1; MOULIS JM, 1984, J BIOL CHEM, V259, P1396; MOURA I, 1980, J BIOL CHEM, V255, P2493; MOURA I, 1986, J AM CHEM SOC, V108, P349, DOI 10.1021/ja00262a057; Moura I., 1989, ADV EPR APPLICATIONS, P813; MOURA JJG, 1982, J BIOL CHEM, V257, P6259; MUNCK E, 1986, HYPERFINE INTERACT, V27, P161, DOI 10.1007/BF02354752; MUNCK E, 1972, BIOCHEMISTRY-US, V11, P855; NOODLEMAN L, 1991, INORG CHEM, V30, P246, DOI 10.1021/ic00002a019; NOODLEMAN L, 1991, INORG CHEM, V30, P256, DOI 10.1021/ic00002a020; OHNISHI T, 1987, CURR TOP BIOENERG, V15, P37; PAPAEFTHYMIOU V, 1987, J AM CHEM SOC, V109, P4703, DOI 10.1021/ja00249a037; ROBINSON AE, 1984, BIOCHEM J, V219, P495, DOI 10.1042/bj2190495; SMITH JP, 1982, J BIOL CHEM, V257, P2310; SPIRO TG, 1982, IRON SULFUR PROTEINS, V4; STOUT CD, 1989, J MOL BIOL, V205, P545, DOI 10.1016/0022-2836(89)90225-8; STOUT GH, 1988, P NATL ACAD SCI USA, V85, P1020, DOI 10.1073/pnas.85.4.1020; SURERUS KK, 1987, J AM CHEM SOC, V109, P3805, DOI 10.1021/ja00246a062; TEIXEIRA M, 1989, J BIOL CHEM, V264, P16435; VANDERZWAAN JW, 1987, EUR J BIOCHEM, V169, P377; WHITAKER JR, 1963, ANAL CHEM, V35, P1950, DOI 10.1021/ac60205a048; ZIMMERMANN R, 1978, BIOCHIM BIOPHYS ACTA, V537, P185, DOI 10.1016/0005-2795(78)90504-4	68	44	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4489	4496						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1311311				2022-12-27	WOS:A1992HF64200034
J	KORANGY, F; JULIN, DA				KORANGY, F; JULIN, DA			ENZYMATIC EFFECTS OF A LYSINE-TO-GLUTAMINE MUTATION IN THE ATP-BINDING CONSENSUS SEQUENCE IN THE RECD SUBUNIT OF THE RECBCD ENZYME FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXONUCLEASE-V; DEOXYRIBONUCLEASE; K-12; DNA; RECONSTITUTION; SPECIFICITY; HYDROLYSIS; MECHANISM; PROTEINS	The RecBCD-K177Q enzyme has a lysine-to-glutamine mutation in the putative ATP-binding sequence of the RecD protein (Korangy, F., and Julin, D. A. (1992) J. Biol. Chem. 267,1727-1732). We have compared the enzymatic properties of the RecBCD-K177Q enzyme with those of the wild-type RecBCD enzyme from Escherichia coli. The purified RecBCD-K177Q enzyme has ATP-dependent nuclease activity on double-stranded or denatured DNA which is reduced (4-14-fold less) compared with the wild type. The k(cat) and K(m)(ATP) for ATP hydrolysis stimulated by double-stranded DNA are both reduced in RecBCD-K177Q, so that k(cat)/K(m)(ATP) is relatively unaffected. The mutant enzyme is impaired in its ability to unwind DNA in an assay where single-stranded DNA is trapped by the single-stranded DNA binding protein and subsequently degraded by S1 nuclease. The mutant enzyme also produces fewer acid-soluble DNA nucleotides per ATP hydrolyzed than does the wild type, at low ATP concentrations (< 20-mu-M).	UNIV MARYLAND,DEPT CHEM & BIOCHEM,COLLEGE PK,MD 20742	University System of Maryland; University of Maryland College Park					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039777, R29GM039777] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39777] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMUNDSEN SK, 1986, P NATL ACAD SCI USA, V83, P5558, DOI 10.1073/pnas.83.15.5558; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; CHA TA, 1988, CANCER CELL, V6, P1; CHAUDHURY AM, 1984, P NATL ACAD SCI-BIOL, V81, P7850, DOI 10.1073/pnas.81.24.7850; CLEAVER JE, 1972, BIOCHIM BIOPHYS ACTA, V262, P116, DOI 10.1016/0005-2787(72)90224-9; DAVIS RW, 1980, ADV BACTERIAL GENET, P116; EICHLER DC, 1977, J BIOL CHEM, V252, P499; GOLDMARK PJ, 1972, J BIOL CHEM, V247, P1849; HICKSON ID, 1985, J BIOL CHEM, V260, P1224; JULIN DA, 1987, J BIOL CHEM, V262, P9044; KARU AE, 1973, J BIOL CHEM, V248, P4874; KORANGY F, 1992, J BIOL CHEM, V267, P1727; LIEBERMAN RP, 1974, P NATL ACAD SCI USA, V71, P4816, DOI 10.1073/pnas.71.12.4816; MACKAY V, 1974, J BIOL CHEM, V249, P4286; Maniatis T., 1982, MOL CLONING; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; Muskavitch K. M. T., 1981, ENZYMES, V14, P233; MYLES GM, 1991, BIOCHEMISTRY-US, V30, P3824, DOI 10.1021/bi00230a004; PALAS KM, 1990, J BIOL CHEM, V265, P3447; PARSONAGE D, 1988, J BIOL CHEM, V263, P4740; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2873, DOI 10.1021/bi00433a019; ROSAMOND J, 1979, J BIOL CHEM, V254, P8646; SMITH GR, 1990, NUCLEIC ACIDS MOL BI, V4, P78; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; TIAN G, 1990, BIOCHEMISTRY-US, V29, P4296, DOI 10.1021/bi00470a006; UGURBIL K, 1982, BIOCHEMISTRY-US, V21, P1068, DOI 10.1021/bi00534a038; WALSH C, 1979, ENZYMATIC REACTION M, P71; WIEGAND RC, 1975, J BIOL CHEM, V250, P8848; WRIGHT M, 1971, J BIOL CHEM, V246, P6543	30	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1733	1740						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1309793				2022-12-27	WOS:A1992HA48500053
J	PEREZ, HD; KELLY, E; HOLMES, R				PEREZ, HD; KELLY, E; HOLMES, R			REGULATION OF FORMYL PEPTIDE RECEPTOR EXPRESSION AND ITS MESSENGER-RNA LEVELS DURING DIFFERENTIATION OF HL-60 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOID-LEUKEMIA CELLS; NUCLEAR FACTOR CREB; PROTEIN-KINASE-C; CYCLIC-AMP; GRANULOCYTIC DIFFERENTIATION; TRANSCRIPTIONAL REGULATION; BINDING-SITES; CAMP; JUN; STAUROSPORINE	When incubated with N6-2'-O-dibutyryladenosine 3',5'-cyclic monophosphate (dbcAMP), HL-60 cells expressed formyl peptide receptor (FPR) (as assessed by ligand binding) and FPR transcripts in a time- and concentration-dependent fashion. Experiments using dbcAMP analogs modified at either the C-6 or C-8 position indicated that the process was mediated by a protein kinase A type I, and protein kinase A type I activity was isolated from undifferentiated HL-60 cells by DEAE-Sephacel chromatography. Forskolin mimicked the effects of dbcAMP. Forskolin and dbcAMP-dependent expression of FPR and FPR transcript was inhibited by staurosporine. Retinoic acid (but not retinal or retinol) was capable of inhibiting dbcAMP-dependent expression of FPR and FPR transcripts without affecting FPR mRNA half-life. Dexamethasone enhanced the effects of dbcAMP and blocked the inhibitory effect of retinoic acid on expression of FPR and FPR transcripts. Phorbol 12-myristate 13-acetate (PMA) alone (1.5-15 nM) failed to induce HL-60 to express FPR and FPR transcripts. Low concentrations (1.5 nM) of PMA enhanced the ability of dbcAMP to induce HL-60 cells to express FPR and FPR transcript, whereas high (15 nM) concentrations of PMA inhibited dbcAMP effects. These results indicate that expression of FPR and FPR transcripts by HL-60 cells can be up- and down-regulated by agents that induce HL-60 cells to differentiate and that a "cross-talk" effect exists between protein kinase A and protein kinase C that modulates FPR gene transcription (and receptor expression) by these cells.	UNIV CALIF SAN FRANCISCO,ROSALIND RUSSELL ARTHRITIS RES LAB,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	PEREZ, HD (corresponding author), SAN FRANCISCO GEN HOSP,MED SERV,BLDG 30,ROOM 3300,1001 POTRERO AVE,SAN FRANCISCO,CA 94110, USA.				NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM028566] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028290] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM-28566] Funding Source: Medline; NIAID NIH HHS [AI-28290] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON R, 1984, J BIOL CHEM, V259, P3309; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BEEBE SJ, 1984, J BIOL CHEM, V259, P3539; BLUMBERG PM, 1988, CANCER RES, V48, P1; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; COLLINS S, 1989, P NATL ACAD SCI USA, V86, P4853, DOI 10.1073/pnas.86.13.4853; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; Corbin J D, 1975, Adv Cyclic Nucleotide Res, V5, P265; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V171, P189, DOI 10.1016/0006-291X(90)91375-3; HICKSTEIN DD, 1988, J BIOL CHEM, V263, P13863; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; LOBO E, 1990, BIOCHIM BIOPHYS ACTA, V1055, P193, DOI 10.1016/0167-4889(90)90122-T; LUBBERT M, 1991, BLOOD, V77, P909; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAKAMURA T, 1990, J BIOL CHEM, V265, P22011; NISHIZUKA Y, 1984, SCIENCE, V245, P371; PEREZ HD, 1989, J CLIN INVEST, V83, P1963, DOI 10.1172/JCI114105; PEREZ HD, 1991, J CLIN INVEST, V87, P971, DOI 10.1172/JCI115105; POLAKIS PG, 1988, J BIOL CHEM, V263, P4969; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SKUBITZ KM, 1982, BLOOD, V59, P586; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TASKEN K, 1990, BIOCHEM BIOPH RES CO, V172, P409, DOI 10.1016/0006-291X(90)90688-J; VALLARI DS, 1990, J BIOL CHEM, V265, P4261; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	28	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					358	363						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1309742				2022-12-27	WOS:A1992GY43900059
J	IIDA, S; OHSHIMA, H; OGUCHI, S; HATA, T; SUZUKI, H; KAWASAKI, H; ESUMI, H				IIDA, S; OHSHIMA, H; OGUCHI, S; HATA, T; SUZUKI, H; KAWASAKI, H; ESUMI, H			IDENTIFICATION OF INDUCIBLE CALMODULIN-DEPENDENT NITRIC-OXIDE SYNTHASE IN THE LIVER OF RATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ARGININE; CYTOSOLIC ENZYME; RELAXING FACTOR; PURIFICATION; MACROPHAGES; CYCLASE	A calmodulin-dependent nitric oxide synthase was significantly induced in the liver of rats treated intravenously with heat-killed Propionibacterium acnes and 5 days later with Escherichia coli lipopolysaccharide. The apparent calmodulin-dependent and -independent isozymes were separated by Mono Q column chromatography after their partial purification by 2',5'-ADP-agarose affinity chromatography. Both enzymes had a molecular weight of 125,000 as determined by SDS-polyacrylamide gel electrophoresis and required NADPH, tetrahydrobiopterin, and dithiothreitol as cofactors. Their activities were completely inhibited by the specific nitric oxide synthase inhibitors N(G)-monomethyl-L-arginine and N(omega)-nitro-L-arginine at 80 and 800 muM, respectively. The peptide maps of these two isozymes with lysylendopeptidase and their reverse-phase column chromatographic profiles were indistinguishable. In the presence of bovine calmodulin, the purified calmodulin-dependent isozyme behaved as a calmodulin-independent isozyme on Mono Q column chromatography. The purified calmodulin-independent isozyme was converted to a calmodulin-dependent isozyme by EDTA and EGTA. Calmodulin blot analysis using I-125-calmodulin showed that the two isozymes bound calmodulin equally efficiently.	NATL CANC CTR,RES INST,DIV BIOCHEM,5-1-1 TSUKIJI,CHUO KU,TOKYO 104,JAPAN; SAITAMA MED SCH,FAC MED,DEPT OBSTET & GYNECOL,MOROYAMA,SAITAMA 35004,JAPAN; TOKYO METROPOLITAN INST MED SCI,DEPT MOLEC BIOL,BUNKYO KU,TOKYO 113,JAPAN	National Cancer Center - Japan; Saitama Medical University; Tokyo Metropolitan Institute of Medical Science			Kawasaki, Hiroshi/C-3048-2011; Ohshima, Hiroshi/E-8044-2010	Kawasaki, Hiroshi/0000-0002-2517-159X; 				BILLIAR TR, 1990, BIOCHEM BIOPH RES CO, V168, P1034, DOI 10.1016/0006-291X(90)91133-D; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; GEISER JR, 1991, CELL, V65, P949, DOI 10.1016/0092-8674(91)90547-C; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; MAYER B, 1989, BIOCHEM BIOPH RES CO, V164, P678, DOI 10.1016/0006-291X(89)91513-1; MONCADA S, 1991, PHARMACOL REV, V43, P109; OGUCHI S, 1992, FEBS LETT, V308, P22, DOI 10.1016/0014-5793(92)81041-J; OHSHIMA H, 1991, CARCINOGENESIS, V12, P1217, DOI 10.1093/carcin/12.7.1217; OHSHIMA H, 1992, BIOCHEM BIOPH RES CO, V183, P238, DOI 10.1016/0006-291X(92)91634-3; OHSHIMA H, 1992, IN PRESS BIOCH BIOPH; PALACIOS M, 1989, BIOCHEM BIOPH RES CO, V165, P802, DOI 10.1016/S0006-291X(89)80037-3; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P5193, DOI 10.1073/pnas.87.13.5193; SALTER M, 1991, FEBS LETT, V291, P145, DOI 10.1016/0014-5793(91)81123-P; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; YUI Y, 1991, J BIOL CHEM, V266, P12544	20	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25385	25388						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1281157				2022-12-27	WOS:A1992KB60300072
J	SANCHEZYAGUE, J; RODRIGUEZ, MC; SEGALOFF, DL; ASCOLI, M				SANCHEZYAGUE, J; RODRIGUEZ, MC; SEGALOFF, DL; ASCOLI, M			TRUNCATION OF THE CYTOPLASMIC TAIL OF THE LUTROPIN/CHORIOGONADOTROPIN RECEPTOR PREVENTS AGONIST-INDUCED UNCOUPLING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LEYDIG TUMOR-CELLS; HUMAN CHORIO-GONADOTROPIN; LUTROPIN-CHORIOGONADOTROPIN RECEPTOR; RESPONSIVE ADENYLATE-CYCLASE; EPIDERMAL GROWTH-FACTOR; LUTEINIZING-HORMONE; BETA-2-ADRENERGIC RECEPTOR; INDUCED DESENSITIZATION; PHOSPHORYLATION SITES; MECHANISM	An agonist-induced change in the functional properties of a constant number of receptors seems to be a ubiquitous phenomenon involved in the regulation of cell surface receptors. Although the mechanisms responsible for this phenomenon (called uncoupling or desensitization) have been studied in detail using beta-2-adrenergic receptors it is unclear if the models derived from these studies are applicable to other members of the family of G protein-coupled receptors. Since it has been shown previously that truncation of the C-terminal cytoplasmic tail of the beta-2-adrenergic receptor results in a delay in the onset of agonist-induced uncoupling (Bouvier, M., Hausdorff, W. P., De Blasi, A., O'Dowd, B. F., Kobilka, B. K., Caron, M. G., and Lefkowitz, R. J. (1988) Nature 333, 370-373), we now present experiments designed to test the effects of a similar truncation of the lutropin/choriogonadotropin (LH/CG) receptor on its functional properties. The results presented herein show that (i) clonal lines of human embryonic kidney cells stably transfected with cDNAs encoding for the wild-type (rLHR-wt) or a mutant receptor truncated at amino acid residue 631 (rLHR-t631) express functional LH/CG receptors as judged by their ability to bind hCG and to respond to it with increased cAMP accumulation; (ii) a preincubation of the cells expressing rLHR-wt with hCG leads to a reduction in the ability of hCG to activate adenylylcyclase; and (iii) this reduction is severely blunted in cells expressing rLHR-t631. These results demonstrate that the C-terminal cytoplasmic tail of the LH/CG receptor is necessary for agonist-induced uncoupling.	UNIV IOWA,COLL MED,DEPT PHARMACOL,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Iowa; University of Iowa			Yague, Jesus Sanchez/B-7792-2008	Sanchez-Yague, Jesus/0000-0003-0409-3198	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD022196] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022196] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA040629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NCI NIH HHS [CA-40629] Funding Source: Medline; NICHD NIH HHS [HD-22196] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASCOLI M, 1984, J CELL BIOL, V99, P1242, DOI 10.1083/jcb.99.4.1242; ASCOLI M, 1982, J BIOL CHEM, V257, P13306; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; Bradford M. M., 1976, ANAL BIOCHEM, V53, P304; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EKSTROM RC, 1989, ENDOCRINOLOGY, V125, P2470, DOI 10.1210/endo-125-5-2470; EKSTROM RC, 1989, ENDOCRINOLOGY, V124, P956, DOI 10.1210/endo-124-2-956; EZRA E, 1980, J BIOL CHEM, V255, P653; EZRA E, 1981, J BIOL CHEM, V256, P5377; FREEMAN DA, 1982, P NATL ACAD SCI-BIOL, V79, P7796, DOI 10.1073/pnas.79.24.7796; FREEMAN DA, 1981, P NATL ACAD SCI-BIOL, V78, P6309, DOI 10.1073/pnas.78.10.6309; HAFEZ MM, 1990, ENDOCRINOLOGY, V127, P394, DOI 10.1210/endo-127-1-394; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HUNZICKERDUNN M, 1981, ENDOCRINOLOGY, V109, P345, DOI 10.1210/endo-109-2-345; INOUE Y, 1989, J BIOL CHEM, V264, P8504; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; LAMPRECHT SA, 1977, J CYCLIC NUCL PROT, V3, P69; LEFKOWITZ RJ, 1990, TRENDS PHARMACOL SCI, V11, P190, DOI 10.1016/0165-6147(90)90113-M; LLOYD CE, 1983, J CELL BIOL, V96, P521, DOI 10.1083/jcb.96.2.521; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MINEGISH T, 1990, BIOCHEM BIOPH RES CO, V172, P1049, DOI 10.1016/0006-291X(90)91552-4; MINEGISHI T, 1989, P NATL ACAD SCI USA, V86, P1470, DOI 10.1073/pnas.86.5.1470; NAMBI P, 1984, J BIOL CHEM, V259, P4629; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; REBOIS RV, 1986, ENDOCRINOLOGY, V118, P2340, DOI 10.1210/endo-118-6-2340; REBOIS RV, 1985, J BIOL CHEM, V260, P8026; RODRIGUEZ MC, 1990, ENDOCRINOLOGY, V127, P674, DOI 10.1210/endo-127-2-674; RODRIGUEZ MC, 1992, IN PRESS MOL ENDOCRI; ROSEMBLIT N, 1988, ENDOCRINOLOGY, V123, P2284, DOI 10.1210/endo-123-5-2284; SEGALOFF DL, 1981, J BIOL CHEM, V256, P1420; WANG H, 1991, J BIOL CHEM, V266, P780	34	56	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7217	7220						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1313793				2022-12-27	WOS:A1992HN48500007
J	GOLDBERG, GI; STRONGIN, A; COLLIER, IE; GENRICH, LT; MARMER, BL				GOLDBERG, GI; STRONGIN, A; COLLIER, IE; GENRICH, LT; MARMER, BL			INTERACTION OF 92-KDA TYPE-IV COLLAGENASE WITH THE TISSUE INHIBITOR OF METALLOPROTEINASES PREVENTS DIMERIZATION, COMPLEX-FORMATION WITH INTERSTITIAL COLLAGENASE, AND ACTIVATION OF THE PROENZYME WITH STROMELYSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST COLLAGENASE; ERYTHROID-POTENTIATING ACTIVITY; HUMAN-SKIN; SEQUENCE IDENTIFICATION; MESSENGER-RNA; CDNA CLONING; EXPRESSION; CELLS; PROCOLLAGENASE; TIMP-2	Secreted metalloproteases initiating proteolytic degradation of collagens and proteoglycans play a critical role in remodeling of the connective tissue. Activation of the secreted proenzymes and interaction with their specific inhibitors TIMP and TIMP-2 are responsible for regulation of enzyme activity in extracellular space. We have previously demonstrated that 92- and 72-kDa Type IV procollagenases, in contrast to interstitial collagenase (ClI), form specific complexes with TIMP and the related inhibitor TIMP-2, respectively. The physiologic significance of the proenzyme-inhibitor complex and the mechanism of activation of Type IV collagenases remained unclear. Here, we demonstrate that in the absence of TIMP, 92-kDa Type IV procollagenase (92T4Cl) can form a covalent homodimer and a novel complex with ClI. In the presence of TIMP, the formation of a 92T4Cl proenzyme complex with TIMP prevents dimerization, formation of the complex with ClI, and activation of the 92T4Cl proenzyme by stromelysin, a related metalloprotease. The proenzyme homodimer is unable to form a complex with TIMP. All TIMP-free forms of the proenzyme can be activated by stromelysin. The 92T4Cl-ClI complex can be activated to yield a complex active against both gelatin and fibrillar Type I collagen, suggesting a mechanism for cooperative action of two enzymes in reducing collagen fibrils to small peptides under physiologic conditions.			GOLDBERG, GI (corresponding author), WASHINGTON UNIV,SCH MED,DIV DERMATOL,ST LOUIS,MO 63110, USA.		Strongin, Alex/R-6609-2019	Strongin, Alex/0000-0003-3765-3016	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007284, R01AR039472] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39472, T32 AR07284] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBINI A, 1991, J NATL CANCER I, V83, P775, DOI 10.1093/jnci/83.11.775; BLAIR HC, 1986, J CELL PHYSIOL, V129, P111, DOI 10.1002/jcp.1041290116; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; CAMPBELL EJ, 1991, J IMMUNOL, V146, P1286; CARMICHAEL DF, 1986, P NATL ACAD SCI USA, V83, P2407, DOI 10.1073/pnas.83.8.2407; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; DECLERCK YA, 1989, J BIOL CHEM, V264, P17445; DELAISSE JM, 1985, BIOCHEM BIOPH RES CO, V133, P483, DOI 10.1016/0006-291X(85)90932-5; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; EISEN AZ, 1969, J INVEST DERMATOL, V52, P442, DOI 10.1038/jid.1969.76; FRISCH SM, 1990, ONCOGENE, V5, P75; GASSON JC, 1985, NATURE, V315, P768, DOI 10.1038/315768a0; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; GOLDBERG GI, 1991, REGULATORY MECHANISM, P421; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GRANT GA, 1987, J BIOL CHEM, V262, P5886; GRILLO HC, 1967, DEV BIOL, V15, P300, DOI 10.1016/0012-1606(67)90029-2; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; Reddi A. H., 1984, EXTRACELLULAR MATRIX, P375; RUOSLAHTI E, 1984, CANCER METAST REV, V3, P43, DOI 10.1007/BF00047692; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SELTZER JL, 1981, J BIOL CHEM, V256, P4662; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P1353; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WELGUS HG, 1985, COLLAGEN REL RES, V5, P167; WELGUS HG, 1983, J BIOL CHEM, V258, P2259; WELGUS HG, 1979, J BIOL CHEM, V254, P1938; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WILHELM SM, 1986, P NATL ACAD SCI USA, V83, P3756, DOI 10.1073/pnas.83.11.3756	48	507	518	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4583	4591						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1311314				2022-12-27	WOS:A1992HF64200048
J	SHUTTLEWORTH, TJ				SHUTTLEWORTH, TJ			CA2+ RELEASE FROM INOSITOL TRISPHOSPHATE-SENSITIVE STORES IS NOT MODULATED BY INTRALUMINAL [CA2+]	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CALCIUM RELEASE; ENDOPLASMIC-RETICULUM; INTRACELLULAR CALCIUM; POSSIBLE MECHANISM; TUMOR PROMOTER; CA-2+ STORES; GLAND-CELLS; 1,4,5-TRISPHOSPHATE; PHOSPHATES; ENTRY	In a recent model developed to explain the apparent "quantal" nature of inositol 1,4,5-trisphosphate (Ins(1,4,5)P3)-induced Ca2+ release from specific intracellular stores, it was proposed that Ca2+ release from the stores may itself be modulated by intraluminal levels of Ca2+, possibly via an action at a binding site on the Ins(1,4,5)P3 receptor/Ca2+ channel complex. Essential predictions of this model include a specific effect of intraluminal Ca2+ levels on the sensitivity of Ins(1,4,5)P3-induced Ca2+ release and a non-exponential decay of passive Ca2+ loss from the store following inhibition of the Ca2+ pump on the store. However, in measurements of Ins(1,4,5)P3-induced Ca2+ release and passive Ca2+ loss in permeabilized preparations of a model exocrine cell under conditions of thapsigargin-induced store depletion, we found that neither of these predicted behaviors could be demonstrated.			SHUTTLEWORTH, TJ (corresponding author), UNIV ROCHESTER, MED CTR,SCH MED & DENT,DEPT PHYSIOL,BOX 642, 601 ELMWOOD AVE, ROCHESTER, NY 14642 USA.				NIGMS NIH HHS [GM-40457] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRIDGE M J, 1986, P25; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BORUT A, 1963, AM J PHYSIOL, V204, P573, DOI 10.1152/ajplegacy.1963.204.4.573; CHUEH SH, 1986, J BIOL CHEM, V261, P13883; COOKE AM, 1987, J CHEM SOC CHEM COMM, P1525, DOI 10.1039/c39870001525; CRAWFORD KM, 1991, AM J PHYSIOL, V261, pC177, DOI 10.1152/ajpcell.1991.261.1.C177; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HILDEBRANDT JP, 1991, AM J PHYSIOL, V261, pC210, DOI 10.1152/ajpcell.1991.261.2.C210; HOOTMAN SR, 1981, AM J PHYSIOL, V241, pR77, DOI 10.1152/ajpregu.1981.241.1.R77; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IRVINE RF, 1991, BIOESSAYS, V13, P419, DOI 10.1002/bies.950130810; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MUALLEM S, 1989, J BIOL CHEM, V264, P205; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PIETRI F, 1990, J BIOL CHEM, V265, P17478; SHUTTLEWORTH TJ, 1990, BIOCHEM J, V266, P719, DOI 10.1042/bj2660719; SHUTTLEWORTH TJ, 1989, AM J PHYSIOL 1, V257, pC1020; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189; TAYLOR CW, 1989, BIOCHEM J, V259, P645, DOI 10.1042/bj2590645; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TREGEAR RT, 1991, P ROY SOC B-BIOL SCI, V243, P263, DOI 10.1098/rspb.1991.0040	25	64	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3573	3576						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1310975				2022-12-27	WOS:A1992HE60700006
J	VOCKLEY, J; NAGAO, M; PARIMOO, B; TANAKA, K				VOCKLEY, J; NAGAO, M; PARIMOO, B; TANAKA, K			THE VARIANT HUMAN ISOVALERYL-COA DEHYDROGENASE GENE RESPONSIBLE FOR TYPE-II ISOVALERIC ACIDEMIA DETERMINES AN RNA SPLICING ERROR, LEADING TO THE DELETION OF THE ENTIRE 2ND CODING EXON AND THE PRODUCTION OF A TRUNCATED PRECURSOR PROTEIN THAT INTERACTS POORLY WITH MITOCHONDRIAL IMPORT RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; MESSENGER-RNA; PROTEOLYTIC CLEAVAGE; NUCLEOTIDE-SEQUENCE; LEADER SEQUENCE; POINT MUTATION; COENZYME-A; FIBROBLASTS; DEFICIENCY; DNA	Isovaleryl-CoA dehydrogenase (IVD) is a mitochondrial enzyme involved in leucine metabolism. Previous studies of fibroblasts from patients with isovaleric acidemia (IVA), an inherited defect in IVD, have revealed that IVD precursor protein produced by type II IVA cells is 3 kDa smaller than normal and is processed inefficiently to a mature form which is also 3 kDa smaller than normal. Using the polymerase chain reaction, we have identified a 90-base pair deletion encompassing bases 145-234 in type II IVD cDNA. This deletion is caused by an error in RNA splicing and predicts the in-frame deletion of 30 amino acids beginning with leucine 20 of the mature IVD. The rate of leader peptide cleavage by purified mitochondrial leader peptidases was similar for the variant and normal precursor IVDs expressed in vitro, and radio-sequencing confirmed that both mature proteins contain identical amino termini. In vitro import studies showed that the efficiency of overall mitochondrial import of type II variant IVD precursor was approximately 30% of normal, as was its binding to the mitochondrial surface. Unlike its normal counterpart, the bound variant IVD precursor was readily released. These data suggest that binding of the variant protein to mitochondrial membrane receptors per se is hindered, resulting in the inefficient mitochondrial processing.	YALE UNIV,SCH MED,DEPT GENET,333 CEDAR ST,POB 3333,NEW HAVEN,CT 06510	Yale University			Vockley, Jerry/AAF-8523-2020; Vockley, Jerry/B-5210-2016	Vockley, Jerry/0000-0002-8180-6457; Vockley, Jerry/0000-0002-8180-6457	NIDDK NIH HHS [DK 17453] Funding Source: Medline; NIGMS NIH HHS [GM 13125, GM 07439] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK017453, R01DK017453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013125] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; CONBOY JG, 1981, P NATL ACAD SCI-BIOL, V78, P3073, DOI 10.1073/pnas.78.5.3073; DALESSIO M, 1989, EMBO J, V8, P1705; FENTON WA, 1987, P NATL ACAD SCI USA, V84, P1421, DOI 10.1073/pnas.84.5.1421; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HIGASHI Y, 1988, P NATL ACAD SCI USA, V85, P7486, DOI 10.1073/pnas.85.20.7486; HORWICH AL, 1985, P NATL ACAD SCI USA, V82, P4930, DOI 10.1073/pnas.82.15.4930; HORWICH AL, 1985, EMBO J, V4, P1129, DOI 10.1002/j.1460-2075.1985.tb03750.x; IKEDA Y, 1985, P NATL ACAD SCI USA, V82, P7081, DOI 10.1073/pnas.82.20.7081; IKEDA Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P662, DOI 10.1016/0003-9861(87)90072-5; IKEDA Y, 1983, J BIOL CHEM, V258, P1077; INANA G, 1989, J BIOL CHEM, V264, P17432; KALOUSEK F, 1988, P NATL ACAD SCI USA, V85, P7536, DOI 10.1073/pnas.85.20.7536; KAZAZIAN HH, 1988, MOL GENETICS MED, P43; LEDLEY FD, 1990, P NATL ACAD SCI USA, V87, P3147, DOI 10.1073/pnas.87.8.3147; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; MATSUBARA Y, 1990, J CLIN INVEST, V85, P1058, DOI 10.1172/JCI114536; MATSUBARA Y, 1989, J BIOL CHEM, V264, P16321; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAKANO T, 1989, J BIOL CHEM, V264, P5155; OHNO K, 1988, BIOCHEM BIOPH RES CO, V153, P463, DOI 10.1016/S0006-291X(88)81247-6; RHEAD WJ, 1980, P NATL ACAD SCI-BIOL, V77, P580, DOI 10.1073/pnas.77.1.580; RUFFNER DE, 1988, P NATL ACAD SCI USA, V85, P2125, DOI 10.1073/pnas.85.7.2125; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; TANAKA K, 1966, P NATL ACAD SCI USA, V56, P236, DOI 10.1073/pnas.56.1.236; TROMP G, 1988, P NATL ACAD SCI USA, V85, P5245; VASSAROTTI A, 1987, J BIOL CHEM, V262, P411; VOCKLEY J, 1991, AM J HUM GENET, V40, P147; WEIL D, 1988, J BIOL CHEM, V263, P8561; Youssoufian H, 1988, GENOMICS, V2, P32, DOI 10.1016/0888-7543(88)90106-1	37	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2494	2501						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1310317				2022-12-27	WOS:A1992HB53200059
J	MINAGAWA, J; MOGI, T; GENNIS, RB; ANRAKU, Y				MINAGAWA, J; MOGI, T; GENNIS, RB; ANRAKU, Y			IDENTIFICATION OF HEME AND COPPER LIGANDS IN SUBUNIT-I OF THE CYTOCHROME-BO COMPLEX IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AEROBIC RESPIRATORY-CHAIN; COMPLETE NUCLEOTIDE-SEQUENCE; O TERMINAL OXIDASE; C-OXIDASE; MITOCHONDRIAL GENOME; RHODOBACTER-SPHAEROIDES; PROTON TRANSLOCATION; ACID SUBSTITUTIONS; GENETIC-CODE; DNA	The cytochrome bo complex is a terminal ubiquinol oxidase in the aerobic respiratory chain of Escherichia coli (Kita, K., Konishi, K., and Anraku, Y. (1984) J. Biol. Chem. 259, 3368-3374) and functions as a proton pump. It belongs to the heme-copper oxidase super-family with the aa3-type cytochrome c oxidases in mitochondria and aerobic bacteria. In order to identify ligands of hemes and copper, we have substituted eight conserved histidines in subunit I by alanine and, in addition, His-106, -284, and -421 by glutamine and methionine. Western immunoblotting analysis showed that all the mutations do not affect the expression level of subunit I in the cytoplasmic membrane, indicating that these histidines are not crucial for its stability. A single copy expression vector carrying a single mutation at the invariant histidines, His-106, His-284, His333, His-334, His-419, and His-421, of subunit I was unable to support the aerobic growth of a strain in which the chromosomal terminal oxidase genes (the cyo and cyd operons) have been deleted. The same mutations caused a complete loss of ubiquinol oxidase activity of the partially purified enzymes. Spectroscopic analysis of mutant oxidases in the cytoplasmic membrane revealed that substitutions of His-106 and -421 specifically eliminated a 563.5 nm peak of the low spin heme and that replacements of His-106, -284, and -419 reduced the extent of the CO-binding high spin heme. These spectroscopic properties of mutant oxidases were further confirmed with partially purified preparations. Atomic absorption analysis showed that substitutions of His-106, -333, -334, and -419 eliminated Cu(B) almost completely. Based on these findings, we conclude that His-106 and -421 function as the axial ligands of the low spin heme and His-284 is a possible ligand of the high spin heme. His-333, -334, and -419 residues are attributed to the ligands of CU(B). We present a helical wheel model of the redox center in subunit I, which consists of the membrane-spanning regions II, VI, VII, and X, and discuss the implications of the model.	UNIV TOKYO,FAC SCI,DEPT BIOL,HONGO,BUNKYO KU,TOKYO 113,JAPAN; UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801; UNIV ILLINOIS,DEPT CHEM,URBANA,IL 61801	University of Tokyo; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign				Minagawa, Jun/0000-0002-3028-3203				ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ANDERSON S, 1982, J MOL BIOL, V156, P683, DOI 10.1016/0022-2836(82)90137-1; ANRAKU Y, 1987, TRENDS BIOCHEM SCI, V12, P262, DOI 10.1016/0968-0004(87)90131-9; ANRAKU Y, 1988, ANNU REV BIOCHEM, V57, P101, DOI 10.1146/annurev.bi.57.070188.000533; AU DCT, 1985, J BACTERIOL, V161, P123, DOI 10.1128/JB.161.1.123-127.1985; BABCOCK GT, 1981, BIOCHEMISTRY-US, V20, P959, DOI 10.1021/bi00507a049; Bachmann B.J., 1987, ESCHERICHIA COLI SAL, P1190; BLOKZIJLHOMAN MF, 1971, BIOCHIM BIOPHYS ACTA, V234, P493, DOI 10.1016/0005-2728(71)90215-5; BOER PH, 1985, P NATL ACAD SCI USA, V82, P3340, DOI 10.1073/pnas.82.10.3340; BONITZ SG, 1980, J BIOL CHEM, V255, P1927; BOTT M, 1990, MOL MICROBIOL, V4, P2147, DOI 10.1111/j.1365-2958.1990.tb00576.x; BURGER G, 1982, EMBO J, V1, P1385, DOI 10.1002/j.1460-2075.1982.tb01327.x; BUSHNELL GW, 1990, J MOL BIOL, V214, P585, DOI 10.1016/0022-2836(90)90200-6; CANTATORE P, 1989, J BIOL CHEM, V264, P10965; CAPALDI RA, 1990, ARCH BIOCHEM BIOPHYS, V280, P252, DOI 10.1016/0003-9861(90)90327-U; CHANG CH, 1991, BIOCHEMISTRY-US, V30, P5352, DOI 10.1021/bi00236a005; CHEPURI V, 1990, J BIOL CHEM, V265, P11185; CHEPURI V, 1990, J BIOL CHEM, V265, P12978; CLINE J, 1983, J BIOL CHEM, V258, P5124; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; DEBRUIJN MHL, 1983, NATURE, V304, P234, DOI 10.1038/304234a0; EGLINTON DG, 1984, J INORG BIOCHEM, V21, P1, DOI 10.1016/0162-0134(84)85034-5; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FINKELE U, 1990, BIOCHEMISTRY-US, V29, P8517, DOI 10.1021/bi00489a002; GENNIS RB, 1991, BIOCHIM BIOPHYS ACTA, V1058, P21, DOI 10.1016/S0005-2728(05)80260-9; GEORGIOU CD, 1988, J BACTERIOL, V170, P961, DOI 10.1128/jb.170.2.961-966.1988; GILSON MK, 1989, P NATL ACAD SCI USA, V86, P1624; GRABAU EA, 1986, PLANT MOL BIOL, V7, P377, DOI 10.1007/BF00032567; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HATA A, 1985, BIOCHIM BIOPHYS ACTA, V810, P62, DOI 10.1016/0005-2728(85)90206-3; HENSGENS LAM, 1984, NUCLEIC ACIDS RES, V12, P7327, DOI 10.1093/nar/12.19.7327; HOLM L, 1987, EMBO J, V6, P2819, DOI 10.1002/j.1460-2075.1987.tb02578.x; ISAAC PG, 1985, EMBO J, V4, P1617, DOI 10.1002/j.1460-2075.1985.tb03828.x; ISHIZUKA M, 1990, J BIOCHEM-TOKYO, V108, P866, DOI 10.1093/oxfordjournals.jbchem.a123294; KITA K, 1982, J BIOL CHEM, V257, P7933; KITA K, 1984, J BIOL CHEM, V259, P3368; KITA K, 1984, J BIOL CHEM, V259, P3375; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDERER F, 1981, J MOL BIOL, V148, P427, DOI 10.1016/0022-2836(81)90185-6; LEMIEUX LJ, 1992, J BIOL CHEM, V267, P2105; LI PM, 1987, BIOCHEMISTRY-US, V26, P2091, DOI 10.1021/bi00382a005; LO KM, 1984, P NATL ACAD SCI-BIOL, V81, P2285, DOI 10.1073/pnas.81.8.2285; Miller JH, 1972, EXPT MOL GENETICS, P201; MINAGAWA J, 1990, J BIOL CHEM, V265, P11198; MOGI T, 1988, P NATL ACAD SCI USA, V85, P4148, DOI 10.1073/pnas.85.12.4148; MOGI T, 1989, J BIOL CHEM, V264, P14197; MOGI T, 1990, INT S BIOENERGETICS, P96; MURAKAMI H, 1984, MOL GEN GENET, V196, P1, DOI 10.1007/BF00334084; NAGARAJAN V, 1990, P NATL ACAD SCI USA, V87, P7888, DOI 10.1073/pnas.87.20.7888; NAKAMURA H, 1990, J BIOL CHEM, V265, P11193; ODEN KL, 1990, GENE, V96, P29, DOI 10.1016/0378-1119(90)90337-Q; PRITCHARD AE, 1986, GENE, V44, P243, DOI 10.1016/0378-1119(86)90188-5; PUUSTINEN A, 1989, FEBS LETT, V249, P163, DOI 10.1016/0014-5793(89)80616-7; PUUSTINEN A, 1991, BIOCHEMISTRY-US, V30, P3936, DOI 10.1021/bi00230a019; ROE BA, 1985, J BIOL CHEM, V260, P9759; SALERNO JC, 1990, J BIOL CHEM, V265, P4364; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1991, EUR J BIOCHEM, V195, P517, DOI 10.1111/j.1432-1033.1991.tb15732.x; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SCOTT RA, 1988, ANN NY ACAD SCI, V550, P207; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STERN LJ, 1989, J BIOL CHEM, V264, P14202; STEVENS TH, 1981, J BIOL CHEM, V256, P1069; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UNO T, 1985, J BIOL CHEM, V260, P6755; WARING RB, 1984, EMBO J, V3, P2121, DOI 10.1002/j.1460-2075.1984.tb02100.x; WEBER PC, 1980, NATURE, V287, P82, DOI 10.1038/287082a0; YAMATO I, 1975, J BIOCHEM, V77, P705, DOI 10.1093/oxfordjournals.jbchem.a130774; ZHANG H, 1988, NUCLEIC ACIDS RES, V16, P1220, DOI 10.1093/nar/16.3.1220	73	117	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					2096	2104						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1309808				2022-12-27	WOS:A1992HA48500103
J	DAVID, P; MAYAN, H; COHEN, H; TAL, DM; KARLISH, SJD				DAVID, P; MAYAN, H; COHEN, H; TAL, DM; KARLISH, SJD			GUANIDINIUM DERIVATIVES ACT AS HIGH-AFFINITY ANTAGONISTS OF NA+ IONS IN OCCLUSION SITES OF NA+,K+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA-2+-ATPASE; CONFORMATIONAL TRANSITIONS; PHOSPHOLIPID-VESICLES; RB+-OCCLUSION; NA/K-ATPASE; TRANSPORT; SODIUM; MEMBRANE; CATIONS; PROBE	We have screened various alkyl- and arylguanidinium derivatives as possible competitors of Na+ or Rb+ for the cation sites on renal Na+,K+-ATPase. Alkylmonoguanidinium or alkylbisguanidinium (BisG) compounds (chain lengths of C3 to C-10) competitively inhibit the occlusion of Rb+ and Na+ with an order of affinities C-10 > C-8 > C6 > C4 > C3. BisG compounds are approximately twice as effective as the equivalent alkylmonoguanidinium compounds. In media of high ionic strength, affinities of tens of micromolar are observed, e.g. 26-mu-M for BisG 8. m-(mXBG)- and p-xylylenebisguanidinium were synthesized and were found to compete with Rb+ or Na+ with intrinsic affinities of 7.7 and 8.2-mu-M, respectively. The hydrophobicity rather than the degree of proximity of the guanidinium groups in all BisG compounds appears to determine the binding affinity. A systematic search has been made of conditions in occlusion assays for which the inhibitor affinities are highest. When the pH is raised from 7.0 to 8.5, a 5-fold increase in affinity is observed, suggesting that the guanidinium derivatives compete with protons at sites of pK(a) almost-equal-to 7.5. Replacing Tris-HCl with choline chloride-containing media raised apparent affinities approximately 2-fold. All guanidinium derivatives stabilize the E1 conformation of fluorescein-labeled Na+,K+-ATPase, acting as competitive Na+ analogues. In media containing only 1 mM Tris-HCl, pH 8.55, very high affinities were observed for binding to the fluorescein-labeled enzyme (e.g. 0.08-mu-M for mXBG). In very low ionic strength medium, the inhibition was still competitive with Rb+ ions. However, there was also evidence for nonspecific adsorption to the membranes. The following findings show that mXBG, a typical guanidinium derivative, behaves as a Na+-like antagonist. (a) It inhibits Na+,K+-ATPase activity, competing strongly with Na+ but only weakly with K+ ions. (b) It inhibits phosphorylation from ATP, competing with Na+ ions. (c) Like Na+ ions, it blocks phosphorylation from inorganic phosphate. Based on these results, we propose that the guanidinium group binds to a relatively wide vestibule at the cytoplasmic surface; but, unlike Na+ or K+ ions, it cannot pass into a narrower region of the cation transport path within the membrane. Therefore, it blocks the occlusion and active transport of cations. In the future, high affinity guanidinium derivatives may serve the purpose of locating cation-binding domains of the pump protein after being converted to reactive affinity or photoaffinity covalent labels.	WEIZMANN INST SCI,DEPT BIOCHEM,IL-76100 REHOVOT,ISRAEL; SHEBA HOSP,DEPT INTERNAL MED E,IL-52621 TEL HASHOMER,ISRAEL	Weizmann Institute of Science								BENOS DJ, 1982, AM J PHYSIOL, V242, pC131, DOI 10.1152/ajpcell.1982.242.3.C131; DAVID P, 1991, J BIOL CHEM, V266, P14896; ELLORY JC, 1979, NA K ATPASE STRUCTUR, P453; ELSLAGER EF, 1968, J HETEROCYCLIC CHEM, V5, P609, DOI 10.1002/jhet.5570050504; ESMANN M, 1985, BIOCHEM BIOPH RES CO, V127, P857, DOI 10.1016/S0006-291X(85)80022-X; FORBUSH B, 1988, J BIOL CHEM, V263, P7979; FUKUSHIMA Y, 1987, J BIOL CHEM, V262, P11000; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GOLDSHLEGER R, 1990, J MEMBRANE BIOL, V113, P139, DOI 10.1007/BF01872888; GOLDSHLEGGER R, 1987, J PHYSIOL-LONDON, V387, P331, DOI 10.1113/jphysiol.1987.sp016576; HILLE B, 1984, IONIC CHANNELS EXCIT, P60; Jorgensen P L, 1974, Methods Enzymol, V32, P277; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P35; Karlish S J, 1991, Soc Gen Physiol Ser, V46, P129; KARLISH SJD, 1985, J PHYSIOL-LONDON, V359, P119, DOI 10.1113/jphysiol.1985.sp015578; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KIRSCH GE, 1980, J GEN PHYSIOL, V76, P315, DOI 10.1085/jgp.76.3.315; KLEMENS MR, 1986, J BIOL CHEM, V261, P1495; KLEMENS MR, 1988, FEBS LETT, V237, P4, DOI 10.1016/0014-5793(88)80160-1; KROPP DL, 1977, J PHYSIOL-LONDON, V264, P471, DOI 10.1113/jphysiol.1977.sp011678; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTIN RB, 1979, Q REV BIOPHYS, V12, P181, DOI 10.1017/S0033583500002754; MARTIN RB, 1984, METAL IONS BIOL, V17, P2; OVCHINNIKOV YA, 1987, TRENDS BIOCHEM SCI, V12, P434, DOI 10.1016/0968-0004(87)90210-6; REPHAELI A, 1986, J BIOL CHEM, V261, P6248; SHANI M, 1987, BIOCHIM BIOPHYS ACTA, V904, P13, DOI 10.1016/0005-2736(87)90081-2; SHANISEKLER M, 1988, J BIOL CHEM, V263, P19331; SKOU JC, 1980, BIOCHIM BIOPHYS ACTA, V601, P386, DOI 10.1016/0005-2736(80)90543-X; STEKHOVEN FMAHS, 1989, BIOCHIM BIOPHYS ACTA, V982, P103, DOI 10.1016/0005-2736(89)90180-6; STEKHOVEN FMAHS, 1988, BIOCHIM BIOPHYS ACTA, V937, P161, DOI 10.1016/0005-2736(88)90238-6; STURMER W, 1991, J MEMBRANE BIOL, V121, P163, DOI 10.1007/BF01870530; TAKADA J, 1990, BIOCHIM BIOPHYS ACTA, V1037, P373, DOI 10.1016/0167-4838(90)90039-I	35	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1141	1149						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1309763				2022-12-27	WOS:A1992GY96000074
J	FERRIS, CD; CAMERON, AM; BREDT, DS; HUGANIR, RL; SNYDER, SH				FERRIS, CD; CAMERON, AM; BREDT, DS; HUGANIR, RL; SNYDER, SH			AUTOPHOSPHORYLATION OF INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; RECONSTITUTED LIPID VESICLES; CALCIUM-RELEASE CHANNEL; PROTEIN-KINASE-C; TRISPHOSPHATE RECEPTOR; SKELETAL-MUSCLE; RYANODINE RECEPTOR; ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEIN; BRAIN	Inositol 1,4,5-trisphosphate (IP3) releases internal stores of calcium by binding to a specific membrane receptor which includes both the IP3 recognition site as well as the associated calcium channel. The IP3 receptor is regulated by ATP, calcium, and phosphorylation by protein kinase A, protein kinase C, and calcium/calmodulin-dependent protein kinase II. Its cDNA sequence predicts at least two consensus sequences where nucleotides might bind, and direct binding of ATP to the IP3 receptor has been demonstrated. In the present study, we demonstrate autophosphorylation of the purified and reconstituted IP3 receptor on serine and find serine protein kinase activity of the IP3 receptor toward a specific peptide substrate. Several independent purification procedures do not separate the IP3 receptor protein from the phosphorylating activity, and many different protein kinase activators and inhibitors do not identify protein kinases as contaminants. Also, renaturation experiments reveal autophosphorylation of the monomeric receptor on polyvinylidene difluoride membranes.	JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHARMACOL & MOLEC SCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PSYCHIAT & BEHAV SCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University			Bredt, David/J-4872-2012		NIDA NIH HHS [DA-00074] Funding Source: Medline; NIGMS NIH HHS [GM-07309] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH018501, R37MH018501] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; DANOFF SK, 1988, BIOCHEM J, V254, P701, DOI 10.1042/bj2540701; EHRLICH BE, 1988, NATURE, V336, P583, DOI 10.1038/336583a0; FERRELL JE, 1989, J BIOL CHEM, V264, P20723; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; FERRIS CD, 1991, IN PRESS ANN REV PHY; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEILMANN C, 1989, CELL CALCIUM, V10, P275, DOI 10.1016/0143-4160(89)90054-7; HUGANIR RL, 1984, P NATL ACAD SCI-BIOL, V81, P6968, DOI 10.1073/pnas.81.22.6968; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; JOSEPH SK, 1989, MOL PHARMACOL, V35, P355; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1989, J BIOL CHEM, V264, P16776; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PRESTWICH GD, 1991, J AM CHEM SOC, V113, P1822, DOI 10.1021/ja00005a055; REHM H, 1989, BIOCHEMISTRY-US, V28, P6455, DOI 10.1021/bi00441a044; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; ROSS CA, 1991, IN PRESS NEUR ABSTR; SMITH JS, 1986, J GEN PHYSIOL, V88, P573, DOI 10.1085/jgp.88.5.573; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; UCHIDA T, 1984, J BIOL CHEM, V259, P2311; WORLEY PF, 1987, J BIOL CHEM, V262, P12132	43	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					7036	7041						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1313030				2022-12-27	WOS:A1992HM05300088
J	WING, SS; DUMAS, F; BANVILLE, D				WING, SS; DUMAS, F; BANVILLE, D			A RABBIT RETICULOCYTE UBIQUITIN CARRIER PROTEIN THAT SUPPORTS UBIQUITIN-DEPENDENT PROTEOLYSIS (E2(14K) IS HOMOLOGOUS TO THE YEAST DNA-REPAIR GENE RAD6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONJUGATING ENZYME; ACTIVATING ENZYME; MECHANISM; ATP; PURIFICATION; POLYPEPTIDE; BREAKDOWN; E2; DEGRADATION; RESOLUTION	The two isoforms of the 14-kDa ubiquitin carrier protein (E2(14k)) are unique among rabbit E2s in efficiently supporting ubiquitin-protein ligase (E3)-mediated ubiquitination of proteins destined for degradation. To begin determining the structural basis for this property, we have isolated a cDNA encoding the predominant reticulocyte isoform of the E2 from a rabbit skeletal muscle library. The sequence predicts a protein of 152 amino acids with a molecular weight of 17,293. Expression of the cDNA in Escherichia coli and purification of the recombinant protein revealed an E2 with high affinity for E3 and ubiquitin activating enzyme (E1). The latter high affinity interaction appears to be between the ubiquitin charged form of E1 and the uncharged form of E2 and does not result in a stable complex between these two enzymes. The predicted sequence shows regions of strong homology with other sequenced E2s, suggesting that these regions may be involved in binding to E1 and/or in ubiquitin transfer from E1, functions common to all E2s. Surprisingly, the E2(14k) sequence is markedly more similar to Saccharomyces cerevisiae RAD6 (69% identity) than to its proposed homologs UBC4/UBC5 (38% identity). The sequence is identical to that recently reported for a human 17-kDa E2 which can complement rad6 mutants thereby identifying rabbit E2(14k) as a RAD6 homologue. The biochemical properties of this previously uncharacterized human 17-kDa E2 are now defined and its misassignment as a homologue of rabbit E2(17k) is corrected. Our findings resolve current confusion regarding relationships among E2s and define yeast RAD6, rabbit E2(14k), and the human 17-kDa E2 as a subclass of E2s which biochemically support E3-mediated conjugation and ubiquitin-dependent proteolysis and physiologically play a role in DNA repair.			WING, SS (corresponding author), NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,MOLEC BIOL SECTOR,MONTREAL H4P 2R2,QUEBEC,CANADA.							BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CHARBONNEAU H, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P15; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; CIECHANOVER A, 1980, P NATL ACAD SCI-BIOL, V77, P1365, DOI 10.1073/pnas.77.3.1365; CIECHANOVER A, 1981, P NATL ACAD SCI-BIOL, V78, P761, DOI 10.1073/pnas.78.2.761; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1982, J BIOL CHEM, V257, P329; HAAS AL, 1991, J BIOL CHEM, V266, P5104; HAAS AL, 1988, J BIOL CHEM, V263, P13268; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HOUGH R, 1987, J BIOL CHEM, V262, P8303; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1990, TRENDS BIOCHEM SCI, V15, P195, DOI 10.1016/0968-0004(90)90161-4; KLEMPERER NS, 1989, BIOCHEMISTRY-US, V28, P6035, DOI 10.1021/bi00440a047; KOKEN MHM, 1991, P NATL ACAD SCI USA, V88, P8865, DOI 10.1073/pnas.88.20.8865; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOOS M, 1988, J BIOL CHEM, V263, P6005; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PICKART CM, 1988, J BIOL CHEM, V263, P15076; PICKART CM, 1988, J BIOL CHEM, V263, P12028; PICOLOGLOU S, 1990, MOL CELL BIOL, V10, P1017, DOI 10.1128/MCB.10.3.1017; RABINOVITZ M, 1964, BIOCHIM BIOPHYS ACTA, V91, P313, DOI 10.1016/0926-6550(64)90255-5; Rechsteiner M., 1988, UBIQUITIN; REISS Y, 1989, J BIOL CHEM, V264, P10378; REYNOLDS P, 1990, EMBO J, V9, P1423, DOI 10.1002/j.1460-2075.1990.tb08258.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDER R, 1990, EMBO J, V9, P1431, DOI 10.1002/j.1460-2075.1990.tb08259.x; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SUNG P, 1991, EMBO J, V10, P2187, DOI 10.1002/j.1460-2075.1991.tb07754.x; WOLFFENDIN C, 1991, BIOCHIM BIOPHYS ACTA, V1090, P81	36	42	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6495	6501						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1313008				2022-12-27	WOS:A1992HM05300011
J	HARRISON, SA; CLANCY, BM; PESSINO, A; CZECH, MP				HARRISON, SA; CLANCY, BM; PESSINO, A; CZECH, MP			ACTIVATION OF CELL-SURFACE GLUCOSE TRANSPORTERS MEASURED BY PHOTOAFFINITY-LABELING OF INSULIN-SENSITIVE 3T3-L1 ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-CELLS; PLASMA-MEMBRANE; HEXOSE TRANSPORTERS; SUGAR TRANSPORTER; PHORBOL ESTER; TRANSLOCATION; ERYTHROCYTE; STIMULATION; ISOPROTERENOL; MODULATION	Several studies have demonstrated that the intrinsic catalytic activity of cell surface glucose transporters is highly regulated in 3T3-L1 adipocytes expressing GLUT1 (erythrocyte/brain) and GLUT4 (adipocyte/skeletal muscle) glucose transporter isoforms. For example, inhibition of protein synthesis in these cells by anisomycin or cycloheximide leads to marked increases in hexose transport without a change in the levels of cell surface glucose transporter proteins (Clancy, B. M., Harrison, S. A., Buxton, J. M., and Czech, M. P. (1991) J. Biol. Chem. 266,10122-10130). In the present work the exofacial hexose binding sites on GLUT1 and GLUT4 in anisomycin-treated 3T3-L1 adipocytes were labeled with the cell-impermeant photoaffinity reagent [2-H-3]2-N-[4-(1-azitrifluoroethyl)benzoyl]1, 3-bis-(D-mannos-4-yloxy)-2-propylamine ([2-H-3] ATB-BMPA) to determine which isoform is activated by protein synthetic blockade. As expected, a 15-fold increase in 2-deoxyglucose uptake in response to insulin was associated with 1.7- and 2.6-fold elevations in plasma membrane GLUT1 and GLUT4 protein levels, respectively. Anisomycin treatment of cultured adipocytes for 5 h produced an 8-fold stimulation of hexose transport but no increase in the content of glucose transporters in the plasma membrane fraction as measured by protein immunoblot analysis. Cell surface GLUT1 levels were also shown to be unaffected on 3T3-L1 adipocytes in response to anisomycin using an independent method, the binding of an antiexofacial GLUT1 antibody to intact cells. In contrast, anisomycin fully mimicked the action of insulin to stimulate (about 4-fold) the radiolabeling of GLUT1 transporters specifically immunoprecipitated from intact 3T3-L1 adipocytes irradiated after incubation with [2-H-3] ATB-BMPA. Photolabeling of GLUT4 under these conditions was also significantly enhanced (1.8-fold) by anisomycin treatment, but this effect was only 15% of that caused by insulin. These results suggest that: 1) the photoaffinity reagent [2-H-3]ATB-BMPA labels those cell surface glucose transporters present in a catalytically active state rather than total cell surface transporters as assumed previously and 2) inhibition of protein synthesis in 3T3-L1 adipocytes stimulates sugar transport primarily by enhancing the intrinsic catalytic activity of cell surface GLUT1, and to a lesser extent, GLUT4 proteins.	UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester	HARRISON, SA (corresponding author), UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030898, R37DK030898] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 30898] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BLOK J, 1988, J CELL BIOL, V106, P69, DOI 10.1083/jcb.106.1.69; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CALDERHEAD DM, 1988, J BIOL CHEM, V263, P12171; CARRUTHERS A, 1989, BIOCHEMISTRY-US, V28, P8337, DOI 10.1021/bi00447a011; CARRUTHERS A, 1986, BIOCHEMISTRY-US, V25, P3592, DOI 10.1021/bi00360a018; CARRUTHERS A, 1986, J BIOL CHEM, V261, P1028; CLANCY BM, 1991, J BIOL CHEM, V266, P10122; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; CLARK AE, 1990, BIOCHEM J, V269, P615, DOI 10.1042/bj2690615; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; GOULD GW, 1990, TRENDS BIOCHEM SCI, V15, P18, DOI 10.1016/0968-0004(90)90125-U; HARRISON SA, 1991, P NATL ACAD SCI USA, V88, P7839, DOI 10.1073/pnas.88.17.7839; HARRISON SA, 1990, J BIOL CHEM, V265, P5793; HARRISON SA, 1991, J BIOL CHEM, V266, P19438; HARRISON SA, 1990, J BIOL CHEM, V265, P20106; HEBERT DN, 1986, J BIOL CHEM, V261, P93; HOLMAN GD, 1988, BIOCHIM BIOPHYS ACTA, V946, P75, DOI 10.1016/0005-2736(88)90459-2; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JOOST HG, 1986, J BIOL CHEM, V261, P33; JOOST HG, 1987, J BIOL CHEM, V262, P11261; KOZKA IJ, 1991, J BIOL CHEM, V266, P11726; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; OKA Y, 1984, J BIOL CHEM, V259, P8125; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	30	61	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3783	3788						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1310982				2022-12-27	WOS:A1992HE60700039
J	MORTON, KA; JONES, BJ; SOHN, MH; SCHAEFER, AE; PHELPS, RC; DATZ, FL; LYNCH, RE				MORTON, KA; JONES, BJ; SOHN, MH; SCHAEFER, AE; PHELPS, RC; DATZ, FL; LYNCH, RE			UPTAKE OF CADMIUM IS DIMINISHED IN TRANSFECTED MOUSE NIH 3T3 CELLS ENRICHED FOR METALLOTHIONEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MESSENGER-RNA; EXPRESSION; ZINC; GENE; DNA; DEXAMETHASONE; ACCUMULATION; REPLICATION; SEQUENCES; PROTEINS	To determine the relationship between cellular uptake of cadmium and content of metallothionein, we measured uptake of Cd-109 in cells that differed in content of metallothionein (MT). MT cells were derived from NIH/3T3 cells by transfection with a plasmid containing the genome of bovine papilloma virus and the mouse metallothionein-I gene, driven by the promoter for the glucose-regulated protein of 78 kDa. Control cells were similarly transfected with bovine papilloma virus-based plasmids with the gene for metallothionein inverted and thus separated from the promoter (TM), or deleted, along with the promoter (BPA). The number of copies of bovine papilloma virus-based plasmids was similar in MT, TM, and BPA cells, approximately 100 per cell. MT cells were more than 10 times more resistant to the lethal effect of cadmium than were the control cells. Synthesis of metallothionein was 15-fold greater in the MT cells than in the TM or BPA cells. The uptake of Cd-109 by the cells enriched in metallothionein was 4-fold less than by the control cells. These data suggest that an increased content of metallothionein may protect some cells from the toxic effects of cadmium, in part, by diminishing uptake of the metal.	VET ADM MED CTR,RES SERV,SALT LAKE CITY,UT 84148; UNIV UTAH,SCH MED,DEPT RADIOL,SALT LAKE CITY,UT 84132; UNIV UTAH,SCH MED,DEPT PATHOL,SALT LAKE CITY,UT 84132; CHONBUK NATL UNIV,SCH MED,DEPT RADIOL,CHONJU 560182,SOUTH KOREA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Jeonbuk National University	MORTON, KA (corresponding author), VET ADM MED CTR,NUCL MED SERV,500 FOOTHILL BLVD,SALT LAKE CITY,UT 84148, USA.				NATIONAL CANCER INSTITUTE [R29CA049275] Funding Source: NIH RePORTER; NCI NIH HHS [CA 49275] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM., 2006, ENZYMATIC MANIPULATI; BREMNER I, 1990, ANNU REV NUTR, V10, P63, DOI 10.1146/annurev.nu.10.070190.000431; CHANG SC, 1987, P NATL ACAD SCI USA, V84, P680, DOI 10.1073/pnas.84.3.680; CHEN EY, 1982, NATURE, V299, P529, DOI 10.1038/299529a0; COLBEREGARAPIN F, 1981, J MOL BIOL, V150, P1, DOI 10.1016/0022-2836(81)90321-1; CORRIGAN AJ, 1982, BIOLT RACE ELEMENT R, V5, P25; DISILVESTRO RA, 1984, LIFE SCI, V35, P2113, DOI 10.1016/0024-3205(84)90510-1; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; FUKUSHIMA T, 1988, BIOCHEM BIOPH RES CO, V152, P874, DOI 10.1016/S0006-291X(88)80120-7; GLANVILLE N, 1981, NATURE, V292, P267, DOI 10.1038/292267a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; KARIN M, 1985, CELL, V41, P9, DOI 10.1016/0092-8674(85)90051-0; KARIN M, 1979, SCIENCE, V204, P176, DOI 10.1126/science.432639; KARIN M, 1981, EUR J BIOCHEM, V118, P527, DOI 10.1111/j.1432-1033.1981.tb05551.x; KRALL J, 1988, J BIOL CHEM, V263, P1910; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHE R, 1984, DNA-J MOLEC CELL BIO, V3, P173, DOI 10.1089/dna.1984.3.173; LUSKY M, 1981, NATURE, V293, P79, DOI 10.1038/293079a0; MORRIS S, 1989, EXP CELL RES, V185, P166, DOI 10.1016/0014-4827(89)90046-3; MROCZKOWSKI B, 1988, P NATL ACAD SCI USA, V85, P126, DOI 10.1073/pnas.85.1.126; RESENDEZ E, 1985, MOL CELL BIOL, V5, P1212, DOI 10.1128/MCB.5.6.1212; ROOS DS, 1987, P NATL ACAD SCI USA, V84, P4860, DOI 10.1073/pnas.84.14.4860; SARVER N, 1982, P NATL ACAD SCI-BIOL, V79, P7147, DOI 10.1073/pnas.79.23.7147; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; UDOM AO, 1980, BIOCHEM J, V187, P329, DOI 10.1042/bj1870329; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237	27	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					2880	2883						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1310676				2022-12-27	WOS:A1992HD15400012
J	KNAUS, HG; MOSHAMMER, T; KANG, HC; HAUGLAND, RP; GLOSSMANN, H				KNAUS, HG; MOSHAMMER, T; KANG, HC; HAUGLAND, RP; GLOSSMANN, H			A UNIQUE FLUORESCENT PHENYLALKYLAMINE PROBE FOR L-TYPE CA2+ CHANNELS - COUPLING OF PHENYLALKYLAMINE RECEPTORS TO CA2+ AND DIHYDROPYRIDINE BINDING-SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNEL; RABBIT SKELETAL-MUSCLE; TARGET SIZE ANALYSIS; CA-2+ CHANNELS; HIGH-AFFINITY; SODIUM-CHANNEL; (-)-<H-3> DESMETHOXYVERAPAMIL; MEMBRANE-VESICLES; ALPHA-1 SUBUNIT; DRUG RECEPTORS	The first fluorescently labeled phenylalkylamine, DMBODIPY-PAA (5-{3-[3-(4,4-difluoro-5,7-dimethyl-3a,4a-diaza-4-bora-indacen-3-yl)propionamido] phenethyl-N-methylamino}-2-isopropyl-2-(3,4,5-trimethoxyphenyl)-valeronitrile) has been introduced for L-type Ca2+ channel research. DMBODIPY-PAA binds reversibly to L-type Ca2+ channels purified from rabbit skeletal muscle microsomes by wheat germ agglutinin-Sepharose chromatography. In this preparation DMBODIPY-PAA labels 412 pmol of phenylalkylamine receptors/mg of protein with a K(d) of 6.82 nM and a favorable signal-to-noise ratio. Therefore DMBODIPY-PAA has a higher affinity for purified Ca2+ channels than the commonly employed radioligands and consequently has assisted in channel purification after prelabeling by simply monitoring receptor-bound fluorescence. (+)-PN200-110 (which is stimulatory for (-)-[H-3]desmethoxyverapamil binding to purified Ca2+ channels) inhibits DMBODIPY-PAA labeling. Since these drug interactions are reciprocal, the phenylalkylamine and dihydropyridine binding sites of the alpha-1-subunit are tightly coupled. Kinetic and equilibrium binding studies with (-)-[H-3]desmethoxyverapamil and DMBODIPY-PAA show that phenylalkylamine binding to L-type Ca2+ channels is dependent on Ca2+. Chelation of divalent metal ions converts phenylalkylamine receptors into a very low affinity state. This conversion is temperature- and time-dependent and completely reversible (K0.5 for free Ca2+ = 58 nM). This study demonstrates the utility of fluorescent ligands for binding studies with L-type Ca2+ channels and provides evidence for coupling between Ca2+ binding sites and phenylalkylamine receptors.	INST BIOCHEM PHARMACOL, PETER MAYR STR 1, A-6020 INNSBRUCK, AUSTRIA; MOLEC PROBES INC, EUGENE, OR 97402 USA				Glossmann, Hartmut/AAL-9790-2020	glossmann, hartmut h./0000-0002-7392-3266	NIGMS NIH HHS [GM-37347] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R43GM037347, R44GM037347] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMERS W, 1984, J PHYSIOL-LONDON, V353, P585, DOI 10.1113/jphysiol.1984.sp015352; ANGELIDES KJ, 1981, BIOCHEMISTRY-US, V20, P4107, DOI 10.1021/bi00517a025; ANGELIDES KJ, 1983, J BIOL CHEM, V258, P1948; AXELROD D, 1980, P NATL ACAD SCI-BIOL, V77, P4823, DOI 10.1073/pnas.77.8.4823; BABITCH J, 1990, NATURE, V346, P321, DOI 10.1038/346321b0; BARHANIN J, 1987, EUR J BIOCHEM, V164, P525, DOI 10.1111/j.1432-1033.1987.tb11158.x; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; BOER R, 1989, EUR J PHARM-MOLEC PH, V172, P131, DOI 10.1016/0922-4106(89)90004-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CURTIS BM, 1984, BIOCHEMISTRY-US, V23, P2113, DOI 10.1021/bi00305a001; DARBON H, 1984, J BIOL CHEM, V259, P6074; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; EBATA H, 1990, J BIOL CHEM, V265, P177; FERRY DR, 1984, N-S ARCH PHARMACOL, V327, P183, DOI 10.1007/BF00500915; FLOCKERZI V, 1986, NATURE, V323, P66, DOI 10.1038/323066a0; FLOCKERZI V, 1986, EUR J BIOCHEM, V161, P217, DOI 10.1111/j.1432-1033.1986.tb10145.x; GALIZZI JP, 1984, EUR J BIOCHEM, V144, P211, DOI 10.1111/j.1432-1033.1984.tb08451.x; GARCIA ML, 1984, J BIOL CHEM, V259, P5013; GARCIA ML, 1986, J BIOL CHEM, V261, P8146; GARCIA ML, 1990, J BIOL CHEM, V265, P3763; GLOSSMANN H, 1990, REV PHYSIOL BIOCH P, V114, P1; GLOSSMANN H, 1988, VITAM HORM, V44, P155; GLOSSMANN H, 1991, BRIT J PHARMACOL, V102, P446, DOI 10.1111/j.1476-5381.1991.tb12193.x; GLOSSMANN H, 1985, METHOD ENZYMOL, V109, P513; GLOSSMANN H, 1982, N-S ARCH PHARMACOL, V321, P7, DOI 10.1007/BF00586341; Glossmann H., 1988, CALCIUM CHANNEL STRU, P168, DOI [10.1007/978-3-642-73914-9_15, DOI 10.1007/978-3-642-73914-9_15]; GOLL A, 1984, FEBS LETT, V176, P371, DOI 10.1016/0014-5793(84)81199-0; GOLL A, 1984, EUR J BIOCHEM, V141, P177, DOI 10.1111/j.1432-1033.1984.tb08172.x; GRABNER M, 1991, P NATL ACAD SCI USA, V88, P727, DOI 10.1073/pnas.88.3.727; HEITHIER H, 1988, BIOCHIMIE, V70, P687, DOI 10.1016/0300-9084(88)90254-4; HOSEY MM, 1988, J MEMBRANE BIOL, V104, P81, DOI 10.1007/BF01870922; Janis RA, 1987, ADV DRUG RES, V16, P309; JONES OT, 1989, SCIENCE, V244, P1189, DOI 10.1126/science.2543080; KASS RS, 1989, AM J CARDIOL, V64, pI35, DOI 10.1016/0002-9149(89)90958-2; KING VF, 1989, J BIOL CHEM, V264, P5633; KNAUS HG, 1990, J BIOL CHEM, V265, P11156; KOSTYUK PG, 1983, J MEMBRANE BIOL, V76, P83, DOI 10.1007/BF01871455; LANSMAN JB, 1986, J GEN PHYSIOL, V88, P321, DOI 10.1085/jgp.88.3.321; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTTGAU HC, 1992, EXCITATION CONTRACTI; NAKAYAMA H, 1991, P NATL ACAD SCI USA, V88, P9203, DOI 10.1073/pnas.88.20.9203; PIZARRO G, 1989, J GEN PHYSIOL, V94, P405, DOI 10.1085/jgp.94.3.405; QAR J, 1988, MOL PHARMACOL, V33, P363; REYNOLDS IJ, 1986, J PHARMACOL EXP THER, V237, P731; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; SCHILLING WP, 1988, BIOCHIM BIOPHYS ACTA, V943, P220, DOI 10.1016/0005-2736(88)90554-8; SRINIVASAN Y, 1990, J NEUROSCI, V10, P985; STAUDINGER R, 1991, J BIOL CHEM, V266, P10787; STRIESSNIG J, 1986, FEBS LETT, V197, P204, DOI 10.1016/0014-5793(86)80327-1; STRIESSNIG J, 1990, P NATL ACAD SCI USA, V87, P9108, DOI 10.1073/pnas.87.23.9108; STRIESSNIG J, 1987, FEBS LETT, V212, P247, DOI 10.1016/0014-5793(87)81354-6; STRIESSNIG J, 1988, BIOCHEM J, V253, P39, DOI 10.1042/bj2530039; STRIESSNIG J, 1991, METHODS NEUROSCI, V4, P210; TAKAHASHI M, 1987, P NATL ACAD SCI USA, V84, P5478, DOI 10.1073/pnas.84.15.5478; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TSIEN RW, 1987, ANNU REV BIOPHYS BIO, V16, P265; VAGHY PL, 1987, J BIOL CHEM, V262, P14337	59	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2179	2189						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1310311				2022-12-27	WOS:A1992HB53200013
J	BRION, C; MILLER, SG; MOORE, HPH				BRION, C; MILLER, SG; MOORE, HPH			REGULATED AND CONSTITUTIVE SECRETION - DIFFERENTIAL-EFFECTS OF PROTEIN-SYNTHESIS ARREST ON TRANSPORT OF GLYCOSAMINOGLYCAN CHAINS TO THE 2 SECRETORY PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PITUITARY-TUMOR CELLS; MEMBRANE-PROTEINS; GRANULES; LINE; ADRENOCORTICOTROPIN; CONTAIN; SURFACE; ATT-20	Many neural and endocrine cells possess two pathways of secretion: a regulated pathway and a constitutive pathway. Peptide hormones are stored in granules which undergo regulated release whereas other surface-bound proteins are externalized constitutively via a distinct set of vesicles. An important issue is whether proper function of these pathways requires continuous protein synthesis. Wieland et al. (Wieland, F. T., Gleason, M. L., Serafini, T. A., and Rothman, J. E. (1987) Cell 50, 289-300) have shown that a tripeptide containing the sequence Asn-Tyr-Thr can be glycosylated in intracellular compartments and secreted efficiently from Chinese hamster ovary and HepG2 cells, presumably via the constitutive secretory pathway. Secretion is not affected by cycloheximide, suggesting that operation of this pathway does not require components supplied by new protein synthesis. In this report we determined the effects of protein synthesis inhibitor on membrane traffic to the regulated secretory pathway in the mouse pituitary AtT-20 cells. We examined transport of glycosaminoglycan chains since previous studies have shown that these chains enter the regulated secretory pathways and are packaged along with the hormone adrenocorticotropin (ACTH). We found that cycloheximide treatment severely impairs the cell's ability to store and secrete glycosaminoglycan chains by the regulated secretory pathway. In marked contrast, constitutive secretion of glycosaminoglycan chains remains unhindered in the absence of protein synthesis. The differential requirements for protein synthesis indicate differences in the mechanisms for sorting and/or transport of molecules through the constitutive and the regulated secretory pathways. We discuss the possible mechanisms by which protein synthesis may influence trafficking of glycosaminoglycan chains to the regulated secretory pathway.			BRION, C (corresponding author), UNIV CALIF BERKELEY, DEPT CELL & MOLEC BIOL, DIV CELL & DEV BIOL, BERKELEY, CA 94720 USA.				NIGMS NIH HHS [GM 35239] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035239] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROWN MS, 1983, CELL, V32, P663, DOI 10.1016/0092-8674(83)90052-1; BURGESS TL, 1984, J CELL BIOL, V99, P2223, DOI 10.1083/jcb.99.6.2223; GUMBINER B, 1982, CELL, V28, P51, DOI 10.1016/0092-8674(82)90374-9; GUMBINER B, 1981, P NATL ACAD SCI-BIOL, V78, P318, DOI 10.1073/pnas.78.1.318; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; MATSUUCHI L, 1991, J CELL BIOL, V112, P843, DOI 10.1083/jcb.112.5.843; MILLER SG, 1991, J CELL BIOL, V112, P39, DOI 10.1083/jcb.112.1.39; MOORE HH, 1988, PROTEIN TRANSFER ORG, P521; MOORE HP, 1983, J CELL BIOL, V97, P810, DOI 10.1083/jcb.97.3.810; MOORE HPH, 1986, NATURE, V321, P443, DOI 10.1038/321443a0; MOORE HPH, 1987, ANN NY ACAD SCI, V493, P50, DOI 10.1111/j.1749-6632.1987.tb27180.x; MOORE HPH, 1985, J CELL BIOL, V101, P1773, DOI 10.1083/jcb.101.5.1773; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; POWELL SK, 1988, J CELL BIOL, V106, P1843, DOI 10.1083/jcb.106.6.1843; ROSA P, 1989, J CELL BIOL, V109, P17, DOI 10.1083/jcb.109.1.17; SIMONS K, 1987, BIOL ORG MACROMOLECU, P139; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8	19	58	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1477	1483						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1309785				2022-12-27	WOS:A1992HA48500016
J	HADARI, T; WARMS, JVB; ROSE, IA; HERSHKO, A				HADARI, T; WARMS, JVB; ROSE, IA; HERSHKO, A			A UBIQUITIN C-TERMINAL ISOPEPTIDASE THAT ACTS ON POLYUBIQUITIN CHAINS - ROLE IN PROTEIN-DEGRADATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY PURIFICATION; LIGASE SYSTEM; ATP; ENZYME; RESOLUTION; BREAKDOWN; IDENTIFICATION; PROTEOLYSIS; CONJUGATION; POLYPEPTIDE	In the ubiquitin (Ub) pathway, proteins are ligated with polyUb chains and then are degraded by a 26 S protease complex. We describe an enzyme, called isopeptidase T, that acts on polyUb chains. It is a monomeric Ub-binding protein abundant in erythrocytes and reticulocytes. The activity of the isopeptidase is inhibited by iodoacetamide and Ub aldehyde. Treatment of the enzyme with Ub aldehyde increased its affinity for free Ub, indicating the existence of two different Ub-binding sites and cooperativity between the two sites. Isopeptidase T acts on polyUb protein conjugates, but not on conjugates in which the formation of polyUb chains was prevented by the use of reductively methylated Ub or on abnormal polyUb chains formed with a mutant Ub that contains a Lys --> Arg substitution at residue 48. The enzyme converts high molecular mass polyUb-protein conjugates to lower molecular mass forms with the release of free Ub, but not of free protein substrate. The lower molecular mass Ub-protein conjugate products are resistant to further action of the enzyme. Isopeptidase T stimulates protein degradation in a system reconstituted from purified enzyme components. The enzyme also stimulates the degradation of proteins ligated to polyUb chains by the 26 S protease complex. Preincubation of polyUb-protein conjugates with the isopeptidase did not much increase their susceptibility to proteolysis by the 26 S complex. On the other hand, preincubation of conjugates with the 26 S protease complex and ATP increased the release of free Ub upon further incubation with the isopeptidase. It thus seems that a role of this isopeptidase in protein breakdown is to remove polyUb chain remnants following the degradation of the protein substrate moiety by the 26 S complex.	TECHNION ISRAEL INST TECHNOL,RAPPAPORT INST RES MED SCI,IL-31096 HAIFA,ISRAEL; FOX CHASE CANC INST,INST CANC RES,PHILADELPHIA,PA 19111	Technion Israel Institute of Technology; Fox Chase Cancer Center	HADARI, T (corresponding author), TECHNION ISRAEL INST TECHNOL,FAC MED,BIOCHEM UNIT,IL-31096 HAIFA,ISRAEL.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025614] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25614] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGELL N, 1991, BIOCHEM J, V273, P615, DOI 10.1042/bj2730615; ANDERSEN MW, 1981, BIOCHEMISTRY-US, V20, P1100, DOI 10.1021/bi00508a009; ANDERSEN MW, 1981, FEBS LETT, V132, P210, DOI 10.1016/0014-5793(81)81162-3; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; CIECHANOVER A, 1980, P NATL ACAD SCI-BIOL, V77, P1365, DOI 10.1073/pnas.77.3.1365; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; GANOTH D, 1988, J BIOL CHEM, V263, P12412; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; HERSHKO A, 1986, PROG NUCLEIC ACID RE, V33, P19, DOI 10.1016/S0079-6603(08)60019-7; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; HOUGH R, 1986, J BIOL CHEM, V261, P2400; JONNALAGADDA S, 1989, J BIOL CHEM, V264, P10637; KANDA F, 1986, BIOCHIM BIOPHYS ACTA, V870, P64, DOI 10.1016/0167-4838(86)90009-9; MATSUI SI, 1982, P NATL ACAD SCI-BIOL, V79, P1535, DOI 10.1073/pnas.79.5.1535; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; MILLER HI, 1989, BIO-TECHNOL, V7, P698, DOI 10.1038/nbt0789-698; OZKAYNAK E, 1987, EMBO J, V6, P1429, DOI 10.1002/j.1460-2075.1987.tb02384.x; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PICKART CM, 1985, J BIOL CHEM, V260, P7903; PICKART CM, 1986, J BIOL CHEM, V261, P210; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; REDMAN KL, 1989, NATURE, V338, P438, DOI 10.1038/338438a0; REISS Y, 1990, J BIOL CHEM, V265, P3685; ROSE IA, 1987, P NATL ACAD SCI USA, V84, P1477, DOI 10.1073/pnas.84.6.1477; ROSE IA, 1983, BIOCHEMISTRY-US, V22, P4234, DOI 10.1021/bi00287a012; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630	33	151	154	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					719	727						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1309773				2022-12-27	WOS:A1992GY96000010
J	MIAO, CH; LEYTUS, SP; CHUNG, DW; DAVIE, EW				MIAO, CH; LEYTUS, SP; CHUNG, DW; DAVIE, EW			LIVER-SPECIFIC EXPRESSION OF THE GENE CODING FOR HUMAN FACTOR-X, A BLOOD-COAGULATION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE REGULATORY ELEMENTS; BETA-HYDROXYASPARTIC ACID; FACTOR-IX GENE; FACTOR-VII; TRANSCRIPTION FACTORS; NUCLEOTIDE-SEQUENCE; HORMONE RECEPTORS; ACTING ELEMENTS; CHOROID-PLEXUS; HEMOPHILIA-B	Factor X is a vitamin K-dependent glycoprotein that plays an essential role in both the intrinsic and extrinsic pathways of blood coagulation. Studies on a recombinant lambda-phage containing the 5'-flanking region of the human factor X gene showed that the factor X gene was linked to and was located at the 3' end of the factor VII gene: the initiation codon of the factor X gene was 2823 base pairs (bp) downstream from the polyadenylation site of the factor VII gene. This 2.8-kilobase intergenic region, and progressively deleted fragments of it, was fused to the chloramphenicol acetyltransferase gene, and transient expressions in HepG2 cells, human fibroblasts, and Chinese hamster ovary cells were measured. A liver-specific promoter element, FXP1-binding site, essential for hepatocyte-specific transcription was identified. This promoter sequence, further localized to -63 to -42 bp in DNase I footprint studies, was homologous to LF-A1 or hepatic nuclear factor-4 recognition sequence and was equally functional in the normal and inverse orientations. FXP1 site bound to nuclear protein(s) from HepG2 cells and complex formation was partially abolished by the presence of duplex oligonucleotides containing liver factor-A1 or hepatic nuclear factor-4-binding sequences. Two additional positive elements located upstream of the promoter region, spanning from -215 to -149 bp (FXP2 site), and -457 to -351 bp (FXP3 site), were also established by reporter gene assays.	UNIV WASHINGTON,DEPT BIOCHEM SJ-70,SEATTLE,WA 98195	University of Washington; University of Washington Seattle			Sessum, Rachel/F-7312-2015	Sessum, Rachel/0000-0002-2444-7056	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016919] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16919] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAARENDS WM, 1990, MOL CELL ENDOCRINOL, V74, P75, DOI 10.1016/0303-7207(90)90207-O; BANCROFT JD, 1990, GENE, V95, P253, DOI 10.1016/0378-1119(90)90368-2; BLANCHART RA, 1985, BLOOD S, V66, P331; BRIET E, 1985, ANN INTERN MED, V103, P225, DOI 10.7326/0003-4819-103-2-225; BUCKINGHAM LE, 1990, P NATL ACAD SCI USA, V87, P9406, DOI 10.1073/pnas.87.23.9406; CHOW BKC, 1991, J BIOL CHEM, V266, P18927; COSTA RH, 1990, P NATL ACAD SCI USA, V87, P6589, DOI 10.1073/pnas.87.17.6589; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; CROSSLEY M, 1990, NATURE, V345, P444, DOI 10.1038/345444a0; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DESIMONE V, 1987, EMBO J, V6, P2759, DOI 10.1002/j.1460-2075.1987.tb02570.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P5253, DOI 10.1021/bi00643a015; ELSHOURBAGY NA, 1987, J BIOL CHEM, V262, P7973; FERNLUND P, 1983, J BIOL CHEM, V258, P2509; FLANAGAN JR, 1991, P NATL ACAD SCI USA, V88, P3145, DOI 10.1073/pnas.88.8.3145; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FRAIN M, 1990, MOL CELL BIOL, V10, P991, DOI 10.1128/MCB.10.3.991; FUNG MR, 1985, P NATL ACAD SCI USA, V82, P3591, DOI 10.1073/pnas.82.11.3591; GILGENKRANTZ S, 1986, ANN GENET-PARIS, V29, P32; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HADDAD IA, 1986, J BIOL CHEM, V261, P3268; HAMMER RE, 1987, SCIENCE, V235, P53, DOI 10.1126/science.2432657; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HERBST RS, 1989, P NATL ACAD SCI USA, V86, P1553, DOI 10.1073/pnas.86.5.1553; HIROSAWA S, 1990, P NATL ACAD SCI USA, V87, P4421, DOI 10.1073/pnas.87.12.4421; HUDSON LG, 1990, P NATL ACAD SCI USA, V87, P7536, DOI 10.1073/pnas.87.19.7536; JAGADEESWARAN P, 1989, GENE, V84, P517, DOI 10.1016/0378-1119(89)90529-5; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KAUSHANSKY K, 1989, J IMMUNOL, V143, P2525; LECHLER E, 1965, AM J MED SCI, V249, P291, DOI 10.1097/00000441-196503000-00006; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P5098, DOI 10.1021/bi00366a018; LEYTUS SP, 1984, P NATL ACAD SCI-BIOL, V81, P3699, DOI 10.1073/pnas.81.12.3699; LUCERO MA, 1989, NUCLEIC ACIDS RES, V6, P2283; MACGILLIVRAY RTA, 1991, THROMB HAEMOSTASIS, V65, P612; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MCMULLEN BA, 1983, BIOCHEMISTRY-US, V22, P2875, DOI 10.1021/bi00281a016; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MONACI P, 1988, EMBO J, V7, P2075, DOI 10.1002/j.1460-2075.1988.tb03047.x; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; OHARA PJ, 1987, P NATL ACAD SCI USA, V84, P5158, DOI 10.1073/pnas.84.15.5158; OLIVIERO S, 1987, EMBO J, V6, P1905, DOI 10.1002/j.1460-2075.1987.tb02450.x; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; PFEIFFER RA, 1982, HUM GENET, V62, P358, DOI 10.1007/BF00304557; RAMJI DP, 1991, NUCLEIC ACIDS RES, V19, P1139, DOI 10.1093/nar/19.5.1139; REUE K, 1988, J BIOL CHEM, V263, P6857; ROYLE NJ, 1987, SOMAT CELL MOLEC GEN, V13, P285, DOI 10.1007/BF01535211; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SALIER JP, 1990, J BIOL CHEM, V265, P7062; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; VAULONT S, 1989, MOL CELL BIOL, V9, P4409, DOI 10.1128/MCB.9.10.4409; WASYLYK B, 1988, BIOCHIM BIOPHYS ACTA, V951, P17, DOI 10.1016/0167-4781(88)90021-8; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x	61	67	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7395	7401						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1313796				2022-12-27	WOS:A1992HN48500030
J	SEETHARAM, S; RAMANUJAM, KS; SEETHARAM, B				SEETHARAM, S; RAMANUJAM, KS; SEETHARAM, B			SYNTHESIS AND BRUSH-BORDER EXPRESSION OF INTRINSIC FACTOR-COBALAMIN RECEPTOR FROM RAT RENAL-CORTEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTASE-PHLORIZIN HYDROLASE; INTESTINAL EPITHELIAL-CELLS; BASOLATERAL PLASMA-MEMBRANES; MICROVILLAR PROTEINS; BIOSYNTHESIS; CACO-2; LOCALIZATION; MATURATION; TRANSPORT; PATHWAYS	The main objective of the current study was to investigate the factors that affect brush border membrane expression of intrinsic factor-cobalamin receptor (IFCR). Because of high levels of IFCR expression (Seetharam, B., Levine, J. S., Ramasamy, M., and Alpers, D. H. (1988) J. Biol. Chem. 263, 4443-4449) in the rat kidney, we have studied the synthesis and expression of IFCR using rat cortical slices in culture. The IFCR activity in the renal apical brush border was maximum from rats between the age of 20-24 days and about 75% of the activity was lost from the isolated apical surface membranes following culture of cortical slices with nonradioactive intrinsic factor-cobalamin. However, the membrane IFCR activity recovered to 100 or 75%, respectively, when the slices were cultured with intrinsic factor-cobalamin mixed with either leupeptin or chloroquine. When these lysosomotropic agents were added during the metabolic labeling of the cortical slices with trans-S-35-label neither the synthesis nor the amount of [S-35]IFCR transported to the apical membrane was inhibited. However, with the addition of colchicine, the apical membrane expression of [S-35]IFCR was inhibited by 75-80%. Metabolic labeling of cortical slices with trans-S-35-label and immunoprecipitation of the Triton X-100 extract from the total, internal, and apical membranes revealed the presence of a 230-kDa band following sodium dodecyl sulfate-polyacrylamide gel electrophoresis. With either continuous or pulse-chase labeling of the cortical slices, the amount of 230-kDa [S-35]IFCR recovered in the apical membrane did not exceed 10-15% of the total labeled receptor synthesized. Based on these and our recent studies (Seetharam, S., Dahms, N., Li, N., Ramanujam, K. S., and Seetharam, B. (1991) Biochem. Biophys. Res. Commun. 177, 751-756), we propose that rat renal IFCR is synthesized as a single polypeptide chain of 220 kDa and is transported slowly to the apical membrane during which four or five N-linked oligosaccharides are processed to the complex type. Moreover, the brush border expression of IFCR is regulated by the biosynthetic and not by the endocytic pathway.	MED COLL WISCONSIN,MACC FUND CTR,DEPT MED,DIV GI,RM 6061,8701 WATERTOWN PLANK RD,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT BIOCHEM,MILWAUKEE,WI 53226	Medical College of Wisconsin; Medical College of Wisconsin					NIDDK NIH HHS [NIDDK-26638] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026638] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHNEN DJ, 1983, J BIOL CHEM, V258, P5960; BULLER HA, 1987, J BIOL CHEM, V262, P17206; BURNETTE WN, 1981, ANAL BIOCHEM, V63, P414; CAPLAN MJ, 1986, CELL, V46, P623, DOI 10.1016/0092-8674(86)90888-3; DANIELSEN EM, 1990, BIOCHEMISTRY-US, V29, P305, DOI 10.1021/bi00453a042; DANIELSEN EM, 1984, BIOCHEM J, V221, P1; DANIELSEN EM, 1984, BIOCHEM BIOPH RES CO, V122, P82; DIECKGRAEFE BK, 1988, AM J PHYSIOL, V17, P913; ELLINGER A, 1983, J ULTRA MOL STRUCT R, V85, P260, DOI 10.1016/S0022-5320(83)90038-2; FERACCI H, 1986, J MEMBRANE BIOL, V83, P139; FYFE JC, 1991, PEDIATR RES, V29, P24, DOI 10.1203/00006450-199101000-00006; FYFE JC, 1991, J BIOL CHEM, V266, P489; HAGEDORN CH, 1977, GASTROENTEROLOGY, V73, P1019; HERBERT V, 1961, J CLIN INVEST, V40, P1978, DOI 10.1172/JCI104423; HOOPER DC, 1973, J CLIN INVEST, V52, P3074, DOI 10.1172/JCI107506; KAPADIA CR, 1983, J CLIN INVEST, V71, P440, DOI 10.1172/JCI110788; KENNY JA, 1976, BIOCHEM SOC T, V4, P1011; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; LEVINE JS, 1984, J CELL BIOL, V98, P1111, DOI 10.1083/jcb.98.3.1111; LIBBY P, 1978, SCIENCE, V199, P534, DOI 10.1126/science.622552; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALATHI P, 1979, BIOCHIM BIOPHYS ACTA, V554, P259, DOI 10.1016/0005-2736(79)90023-3; MATTER K, 1990, J BIOL CHEM, V265, P3503; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MOLITORIS BA, 1985, J MEMBRANE BIOL, V83, P207, DOI 10.1007/BF01868695; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; NASH B, 1982, J BIOL CHEM, V257, P585; RAMANUJAM KS, 1991, J BIOL CHEM, V266, P13135; RAMANUJAM KS, 1991, AM J PHYSIOL, V260, pG416, DOI 10.1152/ajpgi.1991.260.3.G416; RAMANUJAM KS, 1990, BIOCHIM BIOPHYS ACTA, V1030, P157, DOI 10.1016/0005-2736(90)90251-I; SCALERA V, 1980, BIOCHEM J, V186, P177, DOI 10.1042/bj1860177; SEETHARAM B, 1981, J BIOL CHEM, V256, P3785; SEETHARAM B, 1983, BIOCHEM BIOPH RES CO, V115, P238, DOI 10.1016/0006-291X(83)90995-6; SEETHARAM B, 1988, J BIOL CHEM, V263, P4443; SEETHARAM S, 1991, BIOCHEM BIOPH RES CO, V177, P751, DOI 10.1016/0006-291X(91)91852-4; VANDENBOSCH L, 1990, BIOCHEM J, V265, P609, DOI 10.1042/bj2650609	38	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7421	7427						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1313799				2022-12-27	WOS:A1992HN48500034
J	ZHENG, L; KENNEDY, MC; BEINRT, H; ZALKIN, H				ZHENG, L; KENNEDY, MC; BEINRT, H; ZALKIN, H			MUTATIONAL ANALYSIS OF ACTIVE-SITE RESIDUES IN PIG-HEART ACONITASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-RESONANCE CHARACTERIZATION; ELECTRON-PARAMAGNETIC-RES; IRON-SULFUR CLUSTERS; <4FE-4S>+ CLUSTER; INHIBITOR BINDING; 4FE-4S CLUSTER; SUBSTRATE; MOSSBAUER; STATE; O-17	A cDNA encoding mature porcine heart aconitase was over-expressed in Escherichia coli under the control of a phage T7 promoter. Recombinant aconitase purified from E. coli was identical to the enzyme from pig and beef heart in size, [3Fe-4S] and [4Fe-4S] cluster structure and enzymatic activity. Nine amino acid residues in close proximity to the Fe-S cluster and bound substrate (Lauble, H., Kennedy, M. C., Beinert, H., and Stout, C. D. (1992) Biochemistry, in press) were replaced by site-directed mutagenesis. Fe-S cluster environment as indicated by the EPR spectrum, tight binding of substrate, and enzymatic activity were compared for the mutant and wild type enzymes. Significant perturbations were detected for all of the mutant enzymes. Replacements for Asp100, His101, Asp165, Arg580, and Ser642 result in a 10(3)-10(5)-fold drop in activity, which suggests that these residues are involved in critical aspects of the reaction. Arg580 appears to be a key residue for substrate binding, as shown by a 30-fold increased K(m) and loss of tight substrate binding. Results of mutagenesis support the interpretation of the x-ray model, namely that Asp100 and His101 form an ion pair for elimination of the substrate hydroxyl and Ser642 may function as a general base for proton abstraction from citrate or isocitrate in the dehydration step and protonation of cis-aconitate in the hydration step. Asp165 appears to play a critical role in the interaction of Fe(a) with substrate.	MED COLL WISCONSIN,NATL BIOMED ESR CTR,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT BIOCHEM,MILWAUKEE,WI 53226	Medical College of Wisconsin; Medical College of Wisconsin	ZHENG, L (corresponding author), PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024658, R01GM034812, R37GM024658] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01008] Funding Source: Medline; NIGMS NIH HHS [GM34812, GM24658] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEINERT H, 1983, P NATL ACAD SCI-BIOL, V80, P393, DOI 10.1073/pnas.80.2.393; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; DINGMAN DW, 1987, J BACTERIOL, V169, P3062, DOI 10.1128/jb.169.7.3062-3067.1987; EMPTAGE MH, 1983, J BIOL CHEM, V258, P1106; EMPTAGE MH, 1988, ACS SYM SER, V372, P343; EMPTAGE MH, 1983, P NATL ACAD SCI-BIOL, V80, P4674, DOI 10.1073/pnas.80.15.4674; Fansler B., 1969, METHODS ENZYMOL, V13, P26; GAWRON O, 1958, J AM CHEM SOC, V80, P5856, DOI 10.1021/ja01554a069; GOUY M, 1982, NUCLEIC ACIDS RES, V10, P7055, DOI 10.1093/nar/10.22.7055; KENNEDY MC, 1987, P NATL ACAD SCI USA, V84, P8854, DOI 10.1073/pnas.84.24.8854; KENNEDY MC, 1988, J BIOL CHEM, V263, P8194; KENNEDY MC, 1984, J BIOL CHEM, V259, P4463; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; KENT TA, 1985, J BIOL CHEM, V260, P6871; KENT TA, 1982, P NATL ACAD SCI-BIOL, V79, P1096, DOI 10.1073/pnas.79.4.1096; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUO DJ, 1987, BIOCHEMISTRY-US, V26, P7589, DOI 10.1021/bi00398a009; LAUBLE H, 1992, IN PRESS BIOCHEMISTR; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; Miller J. H., 1972, EXPT MOL GENETICS, P431; MILLER RE, 1972, J BIOL CHEM, V247, P7407; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; ROBBINS AH, 1989, P NATL ACAD SCI USA, V86, P3639, DOI 10.1073/pnas.86.10.3639; ROBBINS AH, 1989, PROTEINS, V5, P289, DOI 10.1002/prot.340050406; ROSE IA, 1967, J BIOL CHEM, V242, P1870; RYDEN L, 1984, J BIOL CHEM, V259, P3141; SCHLOSS JV, 1980, BIOCHEMISTRY-US, V19, P2358, DOI 10.1021/bi00552a012; SCHOLZE H, 1983, BIOCHIM BIOPHYS ACTA, V746, P133, DOI 10.1016/0167-4838(83)90066-3; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TELSER J, 1986, J BIOL CHEM, V261, P4840; THOMSON JF, 1966, ARCH BIOCHEM BIOPHYS, V117, P65, DOI 10.1016/0003-9861(66)90126-3; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WERST MM, 1990, BIOCHEMISTRY-US, V29, P10526, DOI 10.1021/bi00498a015; ZHENG LM, 1990, J BIOL CHEM, V265, P2814	35	51	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7895	7903						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1313811				2022-12-27	WOS:A1992HN48500097
J	SEEFELDT, LC; MORGAN, TV; DEAN, DR; MORTENSON, LE				SEEFELDT, LC; MORGAN, TV; DEAN, DR; MORTENSON, LE			MAPPING THE SITE(S) OF MGATP AND MGADP INTERACTION WITH THE NITROGENASE OF AZOTOBACTER-VINELANDII - LYSINE 15 OF THE IRON PROTEIN PLAYS A MAJOR ROLE IN MGATP INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; AMINO-ACID-SEQUENCE; MAGNESIUM ADENOSINE 5'-TRIPHOSPHATE; NUCLEOTIDE-BINDING DOMAIN; CLOSTRIDIUM-PASTEURIANUM; KLEBSIELLA-PNEUMONIAE; ESCHERICHIA-COLI; ADENYLATE KINASE; AZOFERREDOXIN; MECHANISM	Nitrogenase binds and hydrolyzes 2MgATP yielding 2MgADP and 2P(i) for each electron that is transferred from the iron protein to the MoFe protein. The iron protein alone binds but does not hydrolyze 2MgATP or 2MgADP and the binding of these nucleotides is competitive. Iron protein amino acid sequences all contain a putative mononucleotide-binding region similar to a region found in other mononucleotide-binding proteins. To examine the role of this region in MgATP interaction, we have substituted glutamine and proline for conserved lysine 15. The amino acid substitutions, K15Q and K15P, both yielded a non-N2-fixing phenotype when the genes coding for them were substituted into the Azotobacter vinelandii chromosome in place of the wild-type gene. The iron protein from the K15Q mutant was purified to homogeneity, whereas the protein from the K15P mutant could not be purified in its native form. Unlike wild-type iron protein, the purified K15Q iron protein showed no acetylene reduction, H-2 evolution, or ATP hydrolysis activities when complemented with wild-type MoFe protein. The K15Q iron protein and the normal iron protein had a similar total iron content and both proteins showed the characteristic rhombic EPR signal resulting from the reduced state of the single 4Fe-4S cluster bridging the two subunits. Unlike the wild-type iron protein, addition of MgATP to the K15Q iron protein did not result in the perturbation necessary to change the EPR signal of its 4Fe-4S center from a rhombic to an axial line shape. Also unlike the wild-type iron protein, addition of MgATP to K15Q iron protein in the presence of the iron chelator, alpha,alpha'-dipyridyl, did not result in a time-dependent transfer of iron to the chelator. Thus, even though the K15Q iron protein contains a normal 4Fe-4S center, it does not respond to MgATP like the wild-type protein. Examination of the ability of the K15Q iron protein to bind MgADP showed no change from the wild-type iron protein, but its ability to bind MgATP decreased to 35% of the wild-type protein. Thus, in A. vinelandii iron protein, lysine 15 is not needed for interaction with MgADP but is involved in the binding of ATP, presumably through charge-charge interaction with the gamma-phosphate. Based on the above data, this lysine appears to be essential for the MgATP induced conformational change of wild-type iron protein that is required for activity. This is supported additionally by our finding that the K15Q iron protein did not compete with wild-type iron protein for interaction with the MoFe protein in activity assays. In spite of this, like the wild-type iron protein, the K15Q iron protein still formed the reported 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) cross-linked complex with the beta subunit of the MoFe protein. These results suggest that only a specific interaction of iron protein with MgATP forms a catalytically relevant complex with the MoFe protein and that the sites reported to be involved in EDC cross-linking are not relevant to this catalytically competent interaction.	UNIV GEORGIA,DEPT BIOCHEM,CTR METALLOENZYME STUDIES,ATHENS,GA 30602; VIRGINIA POLYTECH INST & STATE UNIV,DEPT ANAEROB MICROBIOL,BLACKSBURG,VA 24061	University System of Georgia; University of Georgia; Virginia Polytechnic Institute & State University				Seefeldt, Lance/0000-0002-6457-9504	NIGMS NIH HHS [R01-GM40067] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040067] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOLIN JT, 1990, 8TH P INT C NITR FIX, P117; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; BUI PT, 1968, P NATL ACAD SCI USA, V61, P1021, DOI 10.1073/pnas.61.3.1021; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DILWORTH MJ, 1966, BIOCHIM BIOPHYS ACTA, V127, P285, DOI 10.1016/0304-4165(66)90383-7; GEORGIADIS MM, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P111; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HAGEMAN RV, 1978, P NATL ACAD SCI USA, V75, P2699, DOI 10.1073/pnas.75.6.2699; Hathaway G M, 1979, Methods Enzymol, V60, P495; HAUSINGER RP, 1982, J BIOL CHEM, V257, P2483; HOOVER TR, 1989, BIOCHEMISTRY-US, V28, P2768, DOI 10.1021/bi00433a004; HOWARD JB, 1989, J BIOL CHEM, V264, P11270; JACOBSON MR, 1989, J BACTERIOL, V171, P1017, DOI 10.1128/jb.171.2.1017-1027.1989; JACOBSON MR, 1989, MOL GEN GENET, V219, P49, DOI 10.1007/BF00261156; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOVENBERG W, 1963, J BIOL CHEM, V238, P3899; LOWE DJ, 1984, BIOCHEM J, V224, P895, DOI 10.1042/bj2240895; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MORGAN TV, 1986, FEBS LETT, V206, P4, DOI 10.1016/0014-5793(86)81329-1; MORGAN TV, 1990, BIOCHEMISTRY-US, V29, P3077, DOI 10.1021/bi00464a026; NORMAND P, 1989, J MOL EVOL, V29, P436, DOI 10.1007/BF02602914; ORMEJOHNSON WH, 1972, P NATL ACAD SCI USA, V69, P3142, DOI 10.1073/pnas.69.11.3142; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PARSONAGE D, 1988, J BIOL CHEM, V263, P4740; RAMIREZ F, 1980, BIOCHIM BIOPHYS ACTA, V589, P21, DOI 10.1016/0005-2728(80)90129-2; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7451, DOI 10.1021/bi00484a014; ROBSON RL, 1984, FEBS LETT, V173, P394, DOI 10.1016/0014-5793(84)80812-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SEEFELDT LC, 1987, BIOCHIM BIOPHYS ACTA, V914, P299, DOI 10.1016/0167-4838(87)90290-1; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; SMITH BE, 1973, BIOCHEM J, V135, P331, DOI 10.1042/bj1350331; STEPHENS PJ, 1979, P NATL ACAD SCI USA, V76, P2585, DOI 10.1073/pnas.76.6.2585; STRANDBERG GW, 1968, CAN J MICROBIOL, V14, P25, DOI 10.1139/m68-005; TIAN G, 1990, BIOCHEMISTRY-US, V29, P4296, DOI 10.1021/bi00470a006; WALKER GA, 1973, BIOCHEM BIOPH RES CO, V53, P904, DOI 10.1016/0006-291X(73)90177-0; WALKER GA, 1974, BIOCHEMISTRY-US, V13, P2382, DOI 10.1021/bi00708a023; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WILLING AH, 1989, J BIOL CHEM, V264, P8499; ZUMFT WG, 1974, EUR J BIOCHEM, V46, P525, DOI 10.1111/j.1432-1033.1974.tb03646.x; ZUMFT WG, 1972, BIOCHEM BIOPH RES CO, V48, P1525, DOI 10.1016/0006-291X(72)90887-X; 1990, PROMEGA PROTOCOLS AP, P76	46	70	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6680	6688						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1313018				2022-12-27	WOS:A1992HM05300036
J	BUHR, A; DANIELS, GA; ERNI, B				BUHR, A; DANIELS, GA; ERNI, B			THE GLUCOSE TRANSPORTER OF ESCHERICHIA-COLI - MUTANTS WITH IMPAIRED TRANSLOCATION ACTIVITY THAT RETAIN PHOSPHORYLATION ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL PHOSPHOTRANSFERASE SYSTEM; SALMONELLA-TYPHIMURIUM; ENZYME-II; SUGAR-TRANSPORT; STREPTOCOCCUS-LACTIS; MANNITOL PERMEASE; PHOSPHOENOLPYRUVATE; IIGLC; MUTATIONS; SEQUENCE	The glucose transporter of the bacterial phosphotransferase system couples translocation with phosphorylation of the substrate in a 1:1 stoichiometry. It is a complex consisting of a transmembrane subunit (II(Glc)) and a hydrophilic subunit (III(Glc)). Both subunits are transiently phosphorylated. III(Glc) is phosphorylated at a histidyl residue by the cytoplasmic phosphoryl carrier protein phospho-heat-stable phosphoryl carrier protein; II(Glc) is phosphorylated at a cysteinyl residue by phospho-III(Glc). The II(Glc) subunit consists of two domains. The N-terminal hydrophobic domain is presumed to span the membrane several times; the C-terminal cytoplasmic domain includes the phosphorylation site. II(Glc) phosphorylates glucose and methyl-alpha-D-glucopyranoside in transit across the inner membrane but can also phosphorylate intracellular glucose. Ten mutants resistant against extracellular toxic methyl-alpha-D-glucopyranoside yet capable of phosphorylating intracellular glucose were isolated. Strong impairment of transport activity in these mutants was accompanied by only a slight decrease of phosphorylation activity. Amino acid substitutions occurred at six sites that are clustered in three presumably hydrophilic loops in the transmembrane domain of II(Glc): M17T, M17I, G149S, K150E, S157F, H339Y, and D343G. We presume that the three polypeptide segments are directly involved in sugar translocation and/or binding but are of little importance for phosphorylation activity, folding, and membrane localization of II(Glc).	UNIV MARBURG, DEPT BIOL, W-3550 MARBURG, GERMANY; UNIV BASEL, BIOCTR, DEPT MICROBIOL, CH-4056 BASEL, SWITZERLAND	Philipps University Marburg; University of Basel								AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BOTFIELD MC, 1988, J BIOL CHEM, V263, P12909; CURTIS SJ, 1975, J BACTERIOL, V122, P1189, DOI 10.1128/JB.122.3.1189-1199.1975; DORSCHUG M, 1984, EUR J BIOCHEM, V144, P113, DOI 10.1111/j.1432-1033.1984.tb08438.x; ERNI B, 1989, FEMS MICROBIOL LETT, V63, P13, DOI 10.1016/0168-6445(89)90004-1; ERNI B, 1986, J BIOL CHEM, V261, P6398; ERNI B, 1982, J BIOL CHEM, V257, P13726; ERNI B, 1986, BIOCHEMISTRY-US, V25, P305, DOI 10.1021/bi00350a004; ERNI B, 1992, IN PRESS INT REV CYT; FOWLER RG, 1974, MOL GEN GENET, V133, P179, DOI 10.1007/BF00267667; GERHARDT P, 1981, MANUAL METHODS GENER, P504; GRISAFI PL, 1989, J BACTERIOL, V171, P2719, DOI 10.1128/jb.171.5.2719-2727.1989; HAZELBAUER GL, 1983, INT REV CYTOL, V81, P33, DOI 10.1016/S0074-7696(08)62334-7; KUNDIG W, 1971, J BIOL CHEM, V246, P1407; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE CA, 1983, J BIOL CHEM, V258, P761; LOLKEMA JS, 1990, BIOCHEMISTRY-US, V29, P10659, DOI 10.1021/bi00499a012; MANAYAN R, 1988, J BACTERIOL, V170, P1290, DOI 10.1128/jb.170.3.1290-1296.1988; Maniatis T., 1982, MOL CLONING; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MEINS M, 1988, J BIOL CHEM, V263, P12986; NUOFFER C, 1988, J BIOL CHEM, V263, P6647; PAS HH, 1988, BIOCHEMISTRY-US, V27, P5835, DOI 10.1021/bi00416a002; PAS HH, 1991, J BIOL CHEM, V266, P6690; PERI KG, 1988, BIOCHEMISTRY-US, V27, P6054, DOI 10.1021/bi00416a034; POSTMA PW, 1985, MICROBIOL REV, V49, P232, DOI 10.1128/MMBR.49.3.232-269.1985; POSTMA PW, 1981, J BACTERIOL, V147, P382, DOI 10.1128/JB.147.2.382-389.1981; POSTMA PW, 1987, ESCHERICHIA COLI SAL, V1, P127; REIDL J, 1991, J BACTERIOL, V173, P4862, DOI 10.1128/jb.173.15.4862-4876.1991; ROBILLARD GT, 1988, BIOCHIM BIOPHYS ACTA, V947, P493, DOI 10.1016/0304-4157(88)90005-6; RUIJTER GJG, 1990, J BACTERIOL, V172, P4783, DOI 10.1128/jb.172.9.4783-4789.1990; Saier Jr MH, 1990, BACTERIA, VXII, P273; SAIER MH, 1989, MICROBIOL REV, V53, P109, DOI 10.1128/MMBR.53.1.109-120.1989; SAIER MH, 1988, J BACTERIOL, V170, P2296, DOI 10.1128/jb.170.5.2296-2300.1988; SAIER MH, 1988, BIOCHIMIE, V70, P1743, DOI 10.1016/0300-9084(88)90033-8; SCHNETZ K, 1990, J BIOL CHEM, V265, P13464; SCHWARTZ M, 1987, ESCHERICHIA COLI SAL, V2, P1482; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; STOCK JB, 1982, J BIOL CHEM, V257, P4543; THOMPSON J, 1985, J BACTERIOL, V162, P224, DOI 10.1128/JB.162.1.224-234.1985; THOMPSON J, 1985, J BACTERIOL, V162, P217, DOI 10.1128/JB.162.1.217-223.1985; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	43	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3847	3851						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1310984				2022-12-27	WOS:A1992HE60700048
J	VANHOLDE, KE; LOHR, DE; ROBERT, C				VANHOLDE, KE; LOHR, DE; ROBERT, C			WHAT HAPPENS TO NUCLEOSOMES DURING TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ORGANOMERCURIAL-AGAROSE COLUMNS; ACTIVE MAMMALIAN NUCLEOSOMES; RNA POLYMERASE-II; CORE PARTICLE; HISTONE HYPERACETYLATION; CHROMATIN STRUCTURE; AFFINITY-CHROMATOGRAPHY; CONTRASTING BEHAVIOR; YEAST NUCLEOSOMES; 2 MODES		ARIZONA STATE UNIV,DEPT CHEM,TEMPE,AZ 85281	Arizona State University; Arizona State University-Tempe	VANHOLDE, KE (corresponding author), OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,WENIGER 535,CORVALLIS,OR 97331, USA.			Robert, Charles/0000-0003-0337-1504				ALLAN J, 1982, J CELL BIOL, V93, P285, DOI 10.1083/jcb.93.2.285; ANNUNZIATO AT, 1982, J BIOL CHEM, V257, P8507; AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1421, DOI 10.1021/bi00354a035; BAER BW, 1983, NATURE, V301, P482, DOI 10.1038/301482a0; BODE J, 1983, EUR J BIOCHEM, V130, P437, DOI 10.1111/j.1432-1033.1983.tb07170.x; BOFFA LC, 1990, EUR J BIOCHEM, V194, P811, DOI 10.1111/j.1432-1033.1990.tb19474.x; BRILL SJ, 1988, CELL, V54, P403, DOI 10.1016/0092-8674(88)90203-6; CHEN TA, 1990, J MOL BIOL, V212, P481, DOI 10.1016/0022-2836(90)90327-I; CLARK DJ, 1991, EMBO J, V10, P387, DOI 10.1002/j.1460-2075.1991.tb07960.x; DAVIE JR, 1990, BIOCHEMISTRY-US, V29, P4752, DOI 10.1021/bi00472a002; DEBERNARDIN W, 1986, J MOL BIOL, V191, P469, DOI 10.1016/0022-2836(86)90142-7; DONG F, 1991, P NATL ACAD SCI USA, V88, P10596, DOI 10.1073/pnas.88.23.10596; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FOE VE, 1976, CELL, V9, P131, DOI 10.1016/0092-8674(76)90059-3; GARRARD WT, 1991, BIOESSAYS, V13, P87, DOI 10.1002/bies.950130208; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; GODFREY JE, 1980, BIOCHEMISTRY-US, V19, P1339, DOI 10.1021/bi00548a012; GONZALEZ PJ, 1989, J BIOL CHEM, V264, P18457; GOULET I, 1988, J MOL BIOL, V200, P253, DOI 10.1016/0022-2836(88)90238-0; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HANSEN J, 1990, J BIL CHEM, V256, P4276; HANSEN J, 1992, IN PRESS TRENDS BIOL; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; HUANG SY, 1986, P NATL ACAD SCI USA, V83, P3738, DOI 10.1073/pnas.83.11.3738; IMAI BS, 1986, J BIOL CHEM, V261, P8784; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; JACKSON V, 1990, BIOCHEMISTRY-US, V29, P719, DOI 10.1021/bi00455a019; LEE MS, 1991, EMBO J, V10, P607, DOI 10.1002/j.1460-2075.1991.tb07988.x; LIBERTINI LJ, 1988, BIOPHYS J, V53, P477, DOI 10.1016/S0006-3495(88)83126-6; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LOHR D, 1983, NUCLEIC ACIDS RES, V11, P6755, DOI 10.1093/nar/11.19.6755; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; LORCH Y, 1988, CELL, V55, P743, DOI 10.1016/0092-8674(88)90128-6; LOSA R, 1987, CELL, V50, P501; MARVIN KW, 1990, J BIOL CHEM, V265, P19839; McKnight S L, 1978, Cold Spring Harb Symp Quant Biol, V42 Pt 2, P741; MCMURRAY CT, 1991, BIOCHEMISTRY-US, V30, P5631, DOI 10.1021/bi00237a001; MCMURRAY CT, 1986, P NATL ACAD SCI USA, V83, P8472, DOI 10.1073/pnas.83.22.8472; MORSE R, 1992, IN PRESS TRENDS BIOL; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; OLIVA R, 1990, NUCLEIC ACIDS RES, V18, P2739, DOI 10.1093/nar/18.9.2739; PFAFFLE P, 1990, J BIOL CHEM, V265, P16830; PFAFFLE P, 1990, J BIOL CHEM, V265, P16821; PRIOR CP, 1983, CELL, V34, P1033, DOI 10.1016/0092-8674(83)90561-5; REEVES R, 1984, BIOCHIM BIOPHYS ACTA, V782, P343, DOI 10.1016/0167-4781(84)90044-7; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; SCHICK VV, 1980, J MOL BIOL, V139, P491; SOLOMON MJ, 1988, CELL, V53, P937, DOI 10.1016/S0092-8674(88)90469-2; STEIN A, 1985, BIOCHEMISTRY-US, V24, P1783, DOI 10.1021/bi00328a032; SZENTGYORGYI C, 1987, J MOL BIOL, V193, P71, DOI 10.1016/0022-2836(87)90628-0; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; THOMA F, 1991, TRENDS GENET, V7, P175, DOI 10.1016/0168-9525(91)90429-T; TURNER BM, 1990, J CELL SCI, V96, P335; TURNER BM, 1991, J CELL SCI, V99, P13; van Holde K.E., 1988, CHROMATIN; VOORDOUW G, 1978, NATURE, V273, P446, DOI 10.1038/273446a0; WALKER J, 1990, J BIOL CHEM, V265, P5736; WASYLYK B, 1980, EUR J BIOCHEM, V103, P219, DOI 10.1111/j.1432-1033.1980.tb04306.x; WEINTRAUB H, 1976, CELL, V9, P409, DOI 10.1016/0092-8674(76)90085-4; WIDMER RM, 1984, EMBO J, V3, P1635, DOI 10.1002/j.1460-2075.1984.tb02022.x; WILLIAMSON P, 1978, BIOCHEMISTRY-US, V17, P5695, DOI 10.1021/bi00619a015; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8; YAO J, 1990, P NATL ACAD SCI USA, V87, P7603, DOI 10.1073/pnas.87.19.7603; ZLATANOVA J, 1990, TRENDS BIOCHEM SCI, V15, P273, DOI 10.1016/0968-0004(90)90053-E	67	149	150	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					2837	2840						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1310672				2022-12-27	WOS:A1992HD15400001
J	ROMERO, FJ; ORDONEZ, I; ARDUINI, A; CADENAS, E				ROMERO, FJ; ORDONEZ, I; ARDUINI, A; CADENAS, E			THE REACTIVITY OF THIOLS AND DISULFIDES WITH DIFFERENT REDOX STATES OF MYOGLOBIN - REDOX AND ADDITION-REACTIONS AND FORMATION OF THIYL RADICAL INTERMEDIATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTENTIAL PROTECTIVE MECHANISM; SULFHEME PROTEINS; LIPID-PEROXIDATION; FERRYL-MYOGLOBIN; ACTIVATED METMYOGLOBIN; REDUCTION; OXIDATION; GLUTATHIONE; FERRYLMYOGLOBIN; SULFMYOGLOBIN	The reactivity of several thiols, including glutathione, dihydrolipoic acid, cysteine, N-acetyl cysteine, and ergothioneine, as well as several disulfides, toward different redox states of myoglobin, mainly met-myoglobin (HX-Fe(III)) and ferrylmyoglobin (HX-Fe(IV) = O), was evaluated by optical spectral analysis, product formation, and thiyl free radical generation. Only dihydrolipoic acid reduced met-myoglobin to oxy-myoglobin, whereas all the other thiols tested did not interact with met-myoglobin. Although the redox transitions involved in the former reduction were expected to yield the dihydrolipoate thiyl radical, the reaction was EPR silent. Conversely, all thiols interacted to different extent with the high oxidation state of myoglobin, i.e. ferrylmyoglobin, via two processes. First, direct electron transfer to heme iron in ferrylmyoglobin (HX-Fe(IV) = O) with formation of met-myoglobin (HX-Fe(III)) or oxymyoglobin (HX-Fe(II)O2); the former transition was effected by all thiols except dihydrolipoate, which facilitated the latter, i.e. the formation of the two-electron reduction product of ferrylmyoglobin. Second, nucleophilic addition onto a pyrrole in ferrylmyoglobin with subsequent formation of sulfmyoglobin. The contribution of either direct electron transfer to the heme iron or nucleophilic addition depended on the physicochemical properties of the thiol involved and on the availability of H2O2 to reoxidize met-myoglobin to ferrylmyoglobin. The thiyl radicals of glutathione, cysteine, and N-acetylcysteine were formed during the interaction of the corresponding thiols with ferrylmyoglobin and detected by EPR in conjunction with the spin trap 5,5'-dimethyl-1-pyroline-N-oxide. The intensity of the EPR signal was insensitive to superoxide dismutase and it was decreased, but not suppressed, by catalase. The disulfides of glutathione and cysteine did not react with ferrylmyoglobin, but the disulfide bridge in lipoic acid interacted efficiently with the ferryl species by either reducing directly the heme iron to form metmyoglobin or adding onto a pyrrole ring to form sulfmyoglobin; either process depended on the presence or absence of catalase (to eliminate the excess of H2O2) in the reaction mixture, respectively. The biological significance of the above results is discussed in terms of the occurrence and distribution of high oxidation states of myoglobin, its specific participation in cellular injury, and its potential interaction with biologically important thiols leading to either recovery of myoglobin or generation of nonfunctional forms of the hemoprotein as sulfmyoglobin.	UNIV SO CALIF, INST TOXICOL, LOS ANGELES, CA 90089 USA; UNIV G DANNUNZIO, IST SCI BIOCHIM, I-66100 CHIETI, ITALY	University of Southern California; G d'Annunzio University of Chieti-Pescara			Arduini, Arduino/ABH-5284-2020	Romero, Francisco J/0000-0001-8701-5907	NIEHS NIH HHS [ES05423] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMES BN, 1981, P NATL ACAD SCI-BIOL, V78, P6858, DOI 10.1073/pnas.78.11.6858; ARDUINI A, 1990, ARCH BIOCHEM BIOPHYS, V281, P41, DOI 10.1016/0003-9861(90)90410-Z; ARDUINI A, 1990, FREE RADICAL BIO MED, V9, P511, DOI 10.1016/0891-5849(90)90130-B; BERZOFSKY JA, 1972, J BIOL CHEM, V247, P3783; BERZOFSKY JA, 1971, J BIOL CHEM, V246, P7366; BERZOFSKY JA, 1972, J BIOL CHEM, V247, P3774; BERZOFSKY JA, 1971, J BIOL CHEM, V246, P3367; BUFFINTON G, 1988, CHEM-BIOL INTERACT, V66, P205, DOI 10.1016/0009-2797(88)90072-5; BUFFINTON G, 1988, CHEM-BIOL INTERACT, V66, P233, DOI 10.1016/0009-2797(88)90074-9; CATALANO CE, 1989, J BIOL CHEM, V264, P10534; CAUGHEY WS, 1985, HDB METHODS OXYGEN R, P95; CHANCE M, 1986, BIOCHEMISTRY-US, V25, P1259, DOI 10.1021/bi00354a010; DEMONTELLANO PRO, 1985, J BIOL CHEM, V260, P9265; EDDY L, 1990, AM J PHYSIOL, V259, pC995, DOI 10.1152/ajpcell.1990.259.6.C995; EDDY L, 1990, J APPL CARDIOL, V5, P409; GALARIS D, 1990, ARCH BIOCHEM BIOPHYS, V281, P163, DOI 10.1016/0003-9861(90)90427-Z; GALARIS D, 1989, ARCH BIOCHEM BIOPHYS, V273, P497, DOI 10.1016/0003-9861(89)90509-2; GALARIS D, 1989, BIOCHEM BIOPH RES CO, V160, P1162, DOI 10.1016/S0006-291X(89)80125-1; GALARIS D, 1989, FREE RADICAL BIO MED, V6, P473, DOI 10.1016/0891-5849(89)90039-7; GALARIS D, 1988, ARCH BIOCHEM BIOPHYS, V262, P221, DOI 10.1016/0003-9861(88)90184-1; GEORGE P, 1952, BIOCHEM J, V52, P511, DOI 10.1042/bj0520511; GIULIVI C, 1990, J BIOL CHEM, V265, P19453; GLARIS D, 1990, MEMBRANE LIPID OXIDA, V1, P269; GRISHAM M B, 1985, Journal of Free Radicals in Biology and Medicine, V1, P227, DOI 10.1016/0748-5514(85)90122-9; HAENEN GRMM, 1990, MOL PHARMACOL, V37, P412; HARADA K, 1986, J BIOCHEM, V100, P499, DOI 10.1093/oxfordjournals.jbchem.a121739; HARMAN LS, 1986, J BIOL CHEM, V261, P1642; HARMAN LS, 1984, J BIOL CHEM, V259, P5606; HOLLER TP, 1988, J AM CHEM SOC, V110, P4837, DOI 10.1021/ja00222a057; JANIG GR, 1984, BIOCHIM BIOPHYS ACTA, V787, P8, DOI 10.1016/0167-4838(84)90102-X; JOCELYN PC, 1972, BIOCH SH GROUP; KANNER J, 1985, LIPIDS, V20, P625, DOI 10.1007/BF02534290; KANNER J, 1985, ARCH BIOCHEM BIOPHYS, V237, P314, DOI 10.1016/0003-9861(85)90282-6; KING NK, 1963, J BIOL CHEM, V238, P1520; KNECHT KT, 1986, ADV EXP MED BIOL, V197, P75; MASON RP, 1990, METHOD ENZYMOL, V186, P318; MIKI H, 1989, ARCH BIOCHEM BIOPHYS, V275, P354, DOI 10.1016/0003-9861(89)90382-2; NICHOLLS P, 1961, BIOCHEM J, V81, P374, DOI 10.1042/bj0810374; PEISACH J, 1968, J BIOL CHEM, V243, P1871; PEISACH J, 1975, BIOCHIM BIOPHYS ACTA, V393, P404, DOI 10.1016/0005-2795(75)90069-0; ROSS D, 1985, J BIOL CHEM, V260, P5028; SCHMIDT U, 1969, ADV ENZYMOL RAMB, V32, P423; SCHOLICH H, 1989, BIOCHIM BIOPHYS ACTA, V1001, P256, DOI 10.1016/0005-2760(89)90108-2; SUZUKI Y, 1991, IN PRESS FREE RAD RE; TAJIMA G, 1987, J BIOL CHEM, V262, P12603; TAMURA M, 1978, ARCH BIOCHEM BIOPHYS, V191, P8, DOI 10.1016/0003-9861(78)90062-0; TEW D, 1988, J BIOL CHEM, V263, P17880; UYEDA M, 1981, BIOCHEMISTRY-US, V20, P2028, DOI 10.1021/bi00510a045; WALTERS FP, 1983, FEBS LETT, V163, P292, DOI 10.1016/0014-5793(83)80838-2; WARDMAN P, 1988, GLUTATHIONE CONJUGAT, P44; WINTERBOURN CC, 1985, HDB METHODS OXYGEN R, P137; YONETANI T, 1967, J BIOL CHEM, V242, P1974; YUSA K, 1987, BIOCHEMISTRY-US, V26, P6684, DOI 10.1021/bi00395a018	53	101	109	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1680	1688						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1309791				2022-12-27	WOS:A1992HA48500045
J	ELFERINK, MGL; DEWIT, JG; DEMEL, R; DRIESSEN, AJM; KONINGS, WN				ELFERINK, MGL; DEWIT, JG; DEMEL, R; DRIESSEN, AJM; KONINGS, WN			FUNCTIONAL RECONSTITUTION OF MEMBRANE-PROTEINS IN MONOLAYER LIPOSOMES FROM BIPOLAR LIPIDS OF SULFOLOBUS-ACIDOCALDARIUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-MOTIVE FORCE; THERMOPHILIC ARCHAEBACTERIA; STREPTOCOCCUS-CREMORIS; BLACK MEMBRANES; ETHER LIPIDS; CYTOCHROME-C; VESICLES; OXIDASE; PURIFICATION; TEMPERATURE	Membranes of Sulfolobus acidocaldarius, an extreme thermophilic archaebacterium, are composed of unusual bipolar lipids. They consist of macrocyclic tetraethers with two polar heads linked by two hydrophobic C40 phytanyl chains which are thought to be arranged as a monolayer in the cytoplasmic membrane. Fractionation of a total lipid-extract from S. acidocaldarius yielded a lipid fraction which forms closed and stable unilamellar liposomes in aqueous media. Beef heart cytochrome c-oxidase could be functionally reconstituted in these liposomes. In the presence of reduced cytochrome c, a protonmotive force (DELTA-p) across the liposomal membrane was generated of up to -92 mV. Upon fusion of these proteoliposomes with membrane vesicles of Lactococcus lactis, the DELTA-p generated by cytochrome c-oxidase activity was capable to drive uphill transport of leucine. Electron microscopic analysis indicated that the tetraether lipids form a single monolayer liposome. The results demonstrate that tetraether lipids of archaebacteria can form a suitable matrix for the function of exogenous membrane proteins originating from a regular lipid bilayer.	UNIV UTRECHT, CTR BIOMEMBRANES & LIPID ENZYMOL, 3584 CH UTRECHT, NETHERLANDS; UNIV UTRECHT, INST MOLEC BIOL & MED BIOTECHNOL, 3584 CH UTRECHT, NETHERLANDS	Utrecht University; Utrecht University	ELFERINK, MGL (corresponding author), UNIV GRONINGEN, DEPT MICROBIOL, 9751 NN HAREN, NETHERLANDS.		Driessen, Arnold J.M./D-1876-2012; Konings, Wilhelmus N./C-7063-2013	Driessen, Arnold J.M./0000-0001-9258-9104				ANEMULLER S, 1990, EUR J BIOCHEM, V191, P297, DOI 10.1111/j.1432-1033.1990.tb19123.x; AUER J, 1991, BIOCHIMIE, V73, P683, DOI 10.1016/0300-9084(91)90048-6; De Rosa M., 1991, LIFE EXTREME CONDITI, P61, DOI [10.1007/978-3-642-76056-3_5, DOI 10.1007/978-3-642-76056-3_5]; Demel R A, 1974, Methods Enzymol, V32, P539; DEMEL RA, 1982, MEMBRANES TRANSPORT, V1, P159; DEROSA M, 1988, PROG LIPID RES, V27, P153, DOI 10.1016/0163-7827(88)90011-2; DEROSA M, 1983, J MEMBRANE SCI, V16, P287, DOI 10.1016/S0376-7388(00)81316-2; DEROSA M, 1986, MICROBIOL REV, V50, P70, DOI 10.1128/MMBR.50.1.70-80.1986; DRIESSEN AJM, 1987, MICROBIOL SCI, V4, P173; DRIESSEN AJM, 1988, BIOCHEMISTRY-US, V27, P865, DOI 10.1021/bi00403a005; DRIESSEN AJM, 1985, P NATL ACAD SCI USA, V82, P7555, DOI 10.1073/pnas.82.22.7555; DRIESSEN AJM, 1991, IN PRESS METHODS ENZ; GLIOZZI A, 1982, BIOPHYS J, V37, P563, DOI 10.1016/S0006-3495(82)84702-4; GLIOZZI A, 1983, J MEMBRANE BIOL, V75, P45, DOI 10.1007/BF01870798; GLIOZZI A, 1983, BIOCHIM BIOPHYS ACTA, V735, P234, DOI 10.1016/0005-2736(83)90298-5; Gliozzi A., 1982, TRANSPORT BIOMEMBRAN, P39; LANGWORTHY TA, 1977, BIOCHIM BIOPHYS ACTA, V487, P37, DOI 10.1016/0005-2760(77)90042-X; LANGWORTHY TA, 1985, BACTERIA, V8; LELKES PI, 1983, BIOCHIM BIOPHYS ACTA, V732, P714, DOI 10.1016/0005-2736(83)90252-3; LO SL, 1990, BIOCHEM BIOPH RES CO, V167, P238, DOI 10.1016/0006-291X(90)91756-I; LOLKEMA JS, 1983, EUR J BIOCHEM, V130, P287, DOI 10.1111/j.1432-1033.1983.tb07149.x; LOLKEMA JS, 1982, BIOCHIM BIOPHYS ACTA, V681, P85, DOI 10.1016/0005-2728(82)90281-X; OTTO R, 1982, J BACTERIOL, V149, P733, DOI 10.1128/JB.149.2.733-738.1982; ROLANDI R, 1986, EUR BIOPHYS J BIOPHY, V14, P19, DOI 10.1007/BF00260399; SCHAFER G, 1990, FEMS MICROBIOL LETT, V75, P335, DOI 10.1016/0378-1097(90)90543-Y; VELD GI, 1991, BIOCHIM BIOPHYS ACTA, V1065, P203, DOI 10.1016/0005-2736(91)90231-V; VERGER R, 1982, CHEM PHYS LIPIDS, V30, P189, DOI 10.1016/0009-3084(82)90052-4; VIITANEN P, 1986, METHOD ENZYMOL, V125, P429; YU CA, 1975, J BIOL CHEM, V250, P1383	29	103	106	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1375	1381						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1309769				2022-12-27	WOS:A1992GY96000108
J	RAMOS, CL; POU, S; BRITIGAN, BE; COHEN, MS; ROSEN, GM				RAMOS, CL; POU, S; BRITIGAN, BE; COHEN, MS; ROSEN, GM			SPIN TRAPPING EVIDENCE FOR MYELOPEROXIDASE-DEPENDENT HYDROXYL RADICAL FORMATION BY HUMAN NEUTROPHILS AND MONOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOLOGICAL-SYSTEMS; BACTERICIDAL ACTIVITY; HYDROGEN-PEROXIDE; SUPEROXIDE; IRON; LACTOFERRIN; LEUKOCYTES; GENERATION; OXYGEN; GRANULOCYTES	Using the electron spin resonance/spin trapping system, 4-pyridyl 1-oxide N-tert-butylnitrone (4-POBN)/ethanol, hydroxyl radical was detected as the alpha-hydroxyethyl spin trapped adduct of 4-POBN, 4-POBN-CH(CH3)OH, from phorbol 12-myristate 13-acetate-stimulated human neutrophils and monocytes without the addition of supplemental iron. 4-POBN-CH(CH3)OH was stable in the presence of a neutrophil-derived superoxide flux. Hydroxyl radical formation was inhibited by treatment with superoxide dismutase, catalase, and azide. Treatment with a series of transition metal chelators did not appreciably alter 4-POBN-CH(CH3)OH, which suggested that hydroxyl radical generation was mediated by a mechanism independent of the transition metal-catalyzed Haber-Weiss reaction. Kinetic differences between transition metal-dependent and -independent mechanisms of hydroxyl radical generation by stimulated neutrophils were demonstrated by a greater rate of 4-POBN-CH(CH3)OH accumulation in the presence of supplemental iron. Detection of hydroxyl radical from stimulated monocyte-derived macrophages, which lack myeloperoxidase, required the addition of supplemental iron. The addition of purified myeloperoxidase to an enzymatic superoxide generating system resulted in the detection of hydroxyl radical that was dependent upon the presence of chloride and was inhibited by superoxide dismutase, catalase, and azide. These findings implicated the reaction of hypochlorous acid and superoxide to produce hydroxyl radical. 4-POBN-CH(CH3)OH was not observed upon stimulation of myeloperoxidase-deficient neutrophils, whereas addition of myeloperoxidase to the reaction mixture resulted in the detection of hydroxyl radical. These results support the ability of human neutrophils and monocytes to generate hydroxyl radical through a myeloperoxidase-dependent mechanism.	UNIV MARYLAND, SCH PHARM, DEPT PHARMACOL & TOXICOL, 20 N PINE ST, BALTIMORE, MD 21201 USA; VET ADM MED CTR, DEPT INTERNAL MED, IOWA CITY, IA 52246 USA; VET ADM MED CTR, RES SERV, IOWA CITY, IA 52246 USA; UNIV IOWA, COLL MED, DEPT INTERNAL MED, IOWA CITY, IA 52242 USA; UNIV N CAROLINA, DEPT MED, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT MICROBIOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT IMMUNOL, CHAPEL HILL, NC 27599 USA; VET ADM MED CTR, BALTIMORE, MD 21218 USA	University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Iowa; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NHLBI NIH HHS [HL-44275, HL-33550] Funding Source: Medline; NIAID NIH HHS [AI-28412] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL044275, R01HL033550] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI028412] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARUOMA OI, 1987, BIOCHEM J, V241, P273, DOI 10.1042/bj2410273; AUGUSTO O, 1982, J BIOL CHEM, V257, P1288; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BALDWIN DA, 1984, J BIOL CHEM, V259, P3391; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BRITIGAN BE, 1988, J EXP MED, V168, P2367, DOI 10.1084/jem.168.6.2367; BRITIGAN BE, 1989, BIOCHEM J, V264, P447, DOI 10.1042/bj2640447; BRITIGAN BE, 1986, J BIOL CHEM, V261, P7026; BRITIGAN BE, 1987, J LEUKOCYTE BIOL, V41, P349, DOI 10.1002/jlb.41.4.349; BRITIGAN BE, 1990, J BIOL CHEM, V265, P17533; BRITIGAN BE, 1990, J BIOL CHEM, V265, P2650; BRITIGAN BE, 1986, J BIOL CHEM, V261, P4426; BUETTNER GR, 1988, J BIOCHEM BIOPH METH, V16, P27, DOI 10.1016/0165-022X(88)90100-5; COHEN MS, 1988, FREE RADICAL BIO MED, V5, P81, DOI 10.1016/0891-5849(88)90033-0; FINKELSTEIN E, 1982, MOL PHARMACOL, V21, P262; FINKELSTEIN E, 1980, ARCH BIOCHEM BIOPHYS, V200, P1, DOI 10.1016/0003-9861(80)90323-9; GUTTERIDGE JMC, 1981, BIOCHEM J, V199, P259, DOI 10.1042/bj1990259; Haber F., 1934, P R SOC LOND A, V147, P332, DOI [10.1098/rspa.1934.0221, DOI 10.1098/RSPA.1934.0221, DOI 10.1098/rspa.1934.0221]; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; ISOGAI Y, 1991, J BIOL CHEM, V266, P13481; Janzen E G, 1987, Free Radic Res Commun, V4, P115; JOHNSON WD, 1977, J EXP MED, V146, P1613, DOI 10.1084/jem.146.6.1613; JOHNSTON RB, 1975, J CLIN INVEST, V55, P1357, DOI 10.1172/JCI108055; KENNEDY CH, 1990, J BIOL CHEM, V265, P11425; KLEBANOFF SJ, 1978, J EXP MED, V148, P490, DOI 10.1084/jem.148.2.490; KLEBANOFF SJ, 1972, J RETICULOENDOTH SOC, V12, P170; KUTHAN H, 1982, BIOCHEM J, V203, P551, DOI 10.1042/bj2030551; LONG CA, 1980, J PHYS CHEM-US, V84, P555, DOI 10.1021/j100442a023; MANDELL GL, 1970, P SOC EXP BIOL MED, V134, P447; MOREHOUSE KM, 1988, J BIOL CHEM, V263, P1204; NAUSEEF WM, 1986, BLOOD, V67, P865; NAUSEEF WM, 1983, BLOOD, V61, P483; OEHLER UM, 1982, CAN J CHEM, V60, P1542, DOI 10.1139/v82-501; POU S, 1989, J BIOL CHEM, V264, P12299; ROOT RK, 1981, REV INFECT DIS, V3, P565; ROOT RK, 1975, J CLIN INVEST, V55, P945, DOI 10.1172/JCI108024; Rosen G.M., 1985, ADV FREE RADIC BIOL, V1, P345, DOI [10.1016/8755-9668(85)90012-2, DOI 10.1016/8755-9668(85)90012-2]; ROSEN GM, 1988, BIOCHIM BIOPHYS ACTA, V969, P236, DOI 10.1016/0167-4889(88)90057-2; ROSEN GM, 1990, FREE RADICAL RES COM, V9, P187, DOI 10.3109/10715769009145676; ROSEN H, 1979, J EXP MED, V149, P27, DOI 10.1084/jem.149.1.27; SAGONE AL, 1987, J IMMUNOL, V138, P2177; SAGONE AL, 1980, BIOCHIM BIOPHYS ACTA, V628, P90, DOI 10.1016/0304-4165(80)90354-2; SAMUNI A, 1988, J BIOL CHEM, V263, P13797; SAMUNI A, 1989, FREE RADICAL BIO MED, V6, P141, DOI 10.1016/0891-5849(89)90111-1; TAUBER AI, 1977, J CLIN INVEST, V60, P374, DOI 10.1172/JCI108786; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEISS SJ, 1986, ACTA PHYSIOL SCAND, V126, P9; WEISS SJ, 1978, J EXP MED, V147, P316, DOI 10.1084/jem.147.2.316; WINTERBOURN CC, 1986, J CLIN INVEST, V78, P545, DOI 10.1172/JCI112607; WINTERBOURN CC, 1983, BIOCHEM J, V210, P15, DOI 10.1042/bj2100015; WINTERBOURN CC, 1991, FREE RADICAL BIO MED, V11, P353, DOI 10.1016/0891-5849(91)90151-R	51	212	215	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8307	8312						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1314821				2022-12-27	WOS:A1992HQ18500054
J	WASSALL, SR; MCCABE, RCY; EHRINGER, WD; STILLWELL, W				WASSALL, SR; MCCABE, RCY; EHRINGER, WD; STILLWELL, W			EFFECTS OF DIETARY FISH OIL ON PLASMA HIGH-DENSITY-LIPOPROTEIN - ELECTRON-SPIN-RESONANCE AND FLUORESCENCE POLARIZATION STUDIES OF LIPID ORDERING AND DYNAMICS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM-LIPOPROTEINS; FLUIDITY; PARAMETERS; FAT; BILAYERS; STATE; ACIDS; HEART; MEN; NMR	Dietary fish oils are implicated in reducing the incidence of coronary heart disease, perhaps by altering the properties of plasma lipoproteins. The hypothesis that omega-3 polyunsaturated fatty acids (PUFA) in fish oils produce changes in lipid ordering and dynamics within high density lipoprotein (HDL), thereby potentially modifying cholesterol transport, is investigated here. Rabbits were fed a diet supplemented with either 10% (by weight) menhaden oil (MO), a fish oil rich in omega-3 PUFAs, or hydrogenated cottonseed oil for a period of 12 weeks. HDL was isolated by sequential flotation ultracentrifugation from plasma drawn every 2 weeks. Gas chromatography confirmed that the predominant omega-3 PUFAs of fish oils, eicosapentaenoic 20:5 and docosahexaenoic 22:6 acids, were only incorporated into the triglyceride, phospholipid, and cholesteryl ester constituents of lipoproteins from rabbits on the MO diet. ESR of 5- and 16-doxyl stearic acids demonstrates that molecular order and dynamics within the outer monolayer of HDL is virtually unaffected. In contrast, ESR of cholesteryl 12-doxyl stearate indicates order is less within the inner apolar core of the lipoprotein for the MO diet than for the hydrogenated cottonseed oil diet. Fluorescence polarization of 1,6-diphenyl-1,3,5-hexatriene supports this finding. The greater disorder detected within HDL from rabbits fed fish oil may result in an enhancement of cholesterol exchange between lipoproteins and between lipoproteins and cells, which may have anti-atherogenic ramifications.	INDIANA UNIV PURDUE UNIV,DEPT BIOL,INDIANAPOLIS,IN 46205	Indiana University System; Indiana University-Purdue University Indianapolis	WASSALL, SR (corresponding author), INDIANA UNIV PURDUE UNIV,DEPT PHYS,INDIANAPOLIS,IN 46205, USA.							AMES BN, 1960, J BIOL CHEM, V235, P769; BELCHER D, 1988, BIOCHEM BIOPH RES CO, V150, P1063, DOI 10.1016/0006-291X(88)90737-1; BERLIN E, 1991, ATHEROSCLEROSIS, V86, P95, DOI 10.1016/0021-9150(91)90206-I; BERLIN E, 1983, ATHEROSCLEROSIS, V48, P15, DOI 10.1016/0021-9150(83)90014-X; BERLIN E, 1984, BIOCHIM BIOPHYS ACTA, V794, P49, DOI 10.1016/0005-2760(84)90296-0; BERLIN E, 1987, ATHEROSCLEROSIS, V66, P215, DOI 10.1016/0021-9150(87)90065-7; BOERRESEN AL, 1976, J IMMUNOGENET, V3, P73; Brainard J R, 1980, Ann N Y Acad Sci, V348, P299, DOI 10.1111/j.1749-6632.1980.tb21309.x; Connor W. E., 1986, Health effects of polyunsaturated fatty acids in seafoods, P173; EDELSTEIN C, 1986, METHOD ENZYMOL, V128, P151; EHRINGER W, 1990, CHEM PHYS LIPIDS, V54, P79, DOI 10.1016/0009-3084(90)90063-W; FENSKE DB, 1988, BIOCHEMISTRY-US, V27, P4491, DOI 10.1021/bi00412a041; HAMILTON JA, 1979, J BIOL CHEM, V254, P5435; HARRIS WS, 1989, J LIPID RES, V30, P785; KEITH AD, 1973, CHEM PHYS LIPIDS, V10, P223, DOI 10.1016/0009-3084(73)90003-0; LAGGNER P, 1978, Q REV BIOPHYS, V11, P371, DOI 10.1017/S0033583500002304; Lands WEM., 1986, FISH HUMAN HLTH; MORRISETT JD, 1984, BIOCHEMISTRY-US, V23, P5343, DOI 10.1021/bi00317a037; MORRISETT JD, 1977, POLYUNSATURATED FATT, P139; PAUL R, 1980, ADV LIPID RES, V17, P155; RHOADS GG, 1976, NEW ENGL J MED, V294, P293, DOI 10.1056/NEJM197602052940601; SACNU AM, 1979, BIOCH ATHEROSCLEROSI, P3; SALMON A, 1987, J AM CHEM SOC, V109, P2600, DOI 10.1021/ja00243a010; SCANU A, 1966, J LIPID RES, V7, P295; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; SHEPHERD J, 1980, BRIT J NUTR, V44, P265, DOI 10.1079/BJN19800040; SHINITZKY M, 1978, BIOCHIM BIOPHYS ACTA, V515, P367, DOI 10.1016/0304-4157(78)90010-2; SKLAR LA, 1980, BIOCHEMISTRY-US, V19, P1294, DOI 10.1021/bi00548a005; SMALL DM, 1988, ARTERIOSCLEROSIS, V8, P103, DOI 10.1161/01.ATV.8.2.103; SOLA R, 1990, BIOCHIM BIOPHYS ACTA, V1043, P43, DOI 10.1016/0005-2760(90)90108-A; SOLERARGILAGA C, 1976, J LIPID RES, V17, P139; SOUTAR A, 1978, NATURE, V273, P11, DOI 10.1038/273011a0; Stansby M. E., 1986, Health effects of polyunsaturated fatty acids in seafoods, P389; SWANSON JE, 1988, BRIT J NUTR, V59, P535, DOI 10.1079/BJN19880062; VANBLITTERSWIJK WJ, 1981, BIOCHIM BIOPHYS ACTA, V644, P323, DOI 10.1016/0005-2736(81)90390-4; WASSALL SR, 1982, BIOCHEM BIOPH RES CO, V107, P429, DOI 10.1016/0006-291X(82)91509-1; WASSALL SR, 1990, METHOD ENZYMOL, V189, P383; WASSALL SR, 1988, BIOCHIM BIOPHYS ACTA, V939, P393, DOI 10.1016/0005-2736(88)90085-5	38	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8168	8174						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1314819				2022-12-27	WOS:A1992HQ18500033
J	KALYANARAMAN, B; DARLEYUSMAR, VM; WOOD, J; JOSEPH, J; PARTHASARATHY, S				KALYANARAMAN, B; DARLEYUSMAR, VM; WOOD, J; JOSEPH, J; PARTHASARATHY, S			SYNERGISTIC INTERACTION BETWEEN THE PROBUCOL PHENOXYL RADICAL AND ASCORBIC-ACID IN INHIBITING THE OXIDATION OF LOW-DENSITY-LIPOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERITABLE HYPERLIPIDEMIC RABBIT; VITAMIN-E; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; DEGRADATION; PEROXIDATION; PROGRESSION; LDL	Chain-breaking antioxidants such as butylated hydroxytoluene, alpha-tocopherol, and probucol have been shown to decrease markedly the oxidative modification of low density lipoprotein (LDL). Their mechanism of action appears to involve scavenging of LDL-lipid peroxyl radicals. The purpose of this study was to investigate the occurrence of radical reactions produced during oxidation of LDL and LDL-containing probucol initiated by lipoxygenase or copper. In addition, we have investigated the possibility of a synergistic interaction between ascorbate and probucol in inhibiting the oxidation of LDL. Incubation of LDL-containing probucol and lipoxygenase produced a composite electron spin resonance (ESR) spectrum due to the endogenous alpha-tocopheroxyl radical and probucol-derived phenoxyl radical. The spectral assignment was further verified by chemical oxidation of alpha-tocopherol and probucol. In the presence of ascorbic acid, these radicals in the LDL particle were reduced to their parent compounds with concomitant formation of the ascorbate radical. In both the peroxidation of linoleic acid and the copper-initiated peroxidation of LDL, the antioxidant activity of probucol was significantly increased by low (3-6-mu-M) concentrations of ascorbate. The probucol-dependent inhibition of LDL oxidation was enhanced in the presence of ascorbic acid. We conclude that the reaction between the phenoxyl radical of probucol and ascorbate results in a synergistic enhancement of the antioxidant capacity of these two compounds and speculate that such reactions could play a role in maintaining the antioxidant status of LDL during oxidative stress in vivo.	WELLCOME RES LABS, BECKENHAM BR3 3BS, KENT, ENGLAND; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA	GlaxoSmithKline; Wellcome Research Laboratories; University of California System; University of California San Diego	KALYANARAMAN, B (corresponding author), MED COLL WISCONSIN, DEPT RADIOL, BIOPHYS SECT, MILWAUKEE, WI 53226 USA.		Darley-Usmar, Victor/F-7656-2010; Parthasarathy, Sampath/AAP-3361-2020; Parthasarathy, Sampath/G-5602-2011	Darley-Usmar, Victor/0000-0001-8921-7086	NCRR NIH HHS [RR01008] Funding Source: Medline; NHLBI NIH HHS [HL47250, HL14197] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047250, P50HL014197] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARUOMA OI, 1990, FREE RADICAL RES COM, V10, P143, DOI 10.3109/10715769009149883; BARNHART RL, 1989, J LIPID RES, V30, P1703; BENDICH A, 1986, ADV FREE RADICAL BIO, V2, P419, DOI 10.1016/S8755-9668(86)80021-7; BJORKHEM I, 1991, ARTERIOSCLER THROMB, V11, P15, DOI 10.1161/01.ATV.11.1.15; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; DARLEYUSMAR VM, 1989, BIOCHEM PHARMACOL, V38, P1465, DOI 10.1016/0006-2952(89)90186-X; DILIBERTO EJ, 1982, J NEUROCHEM, V39, P563, DOI 10.1111/j.1471-4159.1982.tb03982.x; DOBA T, 1985, BIOCHIM BIOPHYS ACTA, V835, P298, DOI 10.1016/0005-2760(85)90285-1; ESTERBAUER H, 1990, BIOCHEM SOC T, V18, P1059, DOI 10.1042/bst0181059; ESTERBAUER H, 1990, CHEM RES TOXICOL, V3, P77, DOI 10.1021/tx00014a001; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; JESSUP W, 1991, BIOCHEM J, V278, P163, DOI 10.1042/bj2780163; JIALAL I, 1991, J CLIN INVEST, V87, P597, DOI 10.1172/JCI115035; KAGAN VE, 1990, ARCH BIOCHEM BIOPHYS, V280, P33, DOI 10.1016/0003-9861(90)90514-Y; KALYANARAMAN B, 1991, FEBS LETT, V280, P17, DOI 10.1016/0014-5793(91)80194-8; KALYANARAMAN B, 1990, BIOCHIM BIOPHYS ACTA, V1035, P286, DOI 10.1016/0304-4165(90)90090-J; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; MAO SJT, 1991, J MED CHEM, V34, P298, DOI 10.1021/jm00105a046; MCCAY PB, 1985, ANNU REV NUTR, V5, P323, DOI 10.1146/annurev.nu.05.070185.001543; MCLEAN LR, 1989, BIOCHEMISTRY-US, V28, P321, DOI 10.1021/bi00427a043; NIKI E, 1984, J BIOL CHEM, V259, P4177; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; PARTHASARATHY S, 1986, J CLIN INVEST, V77, P641, DOI 10.1172/JCI112349; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4; STEINBRECHER UP, 1987, ARTERIOSCLEROSIS, V7, P135, DOI 10.1161/01.ATV.7.2.135; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; TAPPEL AL, 1962, VITAM HORM, V20, P493, DOI 10.1016/S0083-6729(08)60732-3	28	65	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6789	6795						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1313022				2022-12-27	WOS:A1992HM05300051
J	PELUFFO, RD; GARRAHAN, PJ; REGA, AF				PELUFFO, RD; GARRAHAN, PJ; REGA, AF			LOW AFFINITY SUPERPHOSPHORYLATION OF THE NA,K-ATPASE BY ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; (NA++K+)-ACTIVATED ATPASE; CALCIUM-ION; SODIUM; POTASSIUM; (NA++K+)-ATPASE; PHOSPHORYLATION; SITE; PURIFICATION; MEMBRANES	Pre-steady-state phosphorylation of purified Na,K-ATPase from red outer medulla of pig kidney was studied at 25-degrees-C and an ample range of [tau-P-32]ATP concentrations. At 10-mu-M ATP phosphorylation followed simple exponential kinetics reaching after 40 ms a steady level of 0.76 +/- 0.04 nmol of P/mg of protein with k(app) = 73.0 +/- 6.5 s-1. At 500-mu-M ATP the time course of phosphorylation changed drastically, since the phosphoenzyme reached a level two to four times higher at a much higher rate (k(app) greater-than-or-equal-to 370 s-1) and in about 40 ms dropped to the same steady level as with 10-mu-M ATP. This superphosphorylation was not observed in Na,K-ATPase undergoing turnover in a medium with Mg2+, Na+, and ATP, suggesting that it required the enzyme to be at rest. Superphosphorylation depended on Mg2+ and Na+ and was fully inhibited by ouabain and FITC. After denaturation the phosphoenzyme made by superphosphorylation had the electrophoretic mobility of the alpha-subunit of the Na,K-ATPase, and its hydrolysis was accelerated by hydroxylamine. On a molar basis, the stoichiometry of phosphate per ouabain bound was 2.40 +/- 0.60 after phosphorylation with 1000-mu-M ATP. The results are consistent with the idea that under proper conditions every functional Na,K-ATPase unit can accept two, or more, phosphates of rapid turnover from ATP.			PELUFFO, RD (corresponding author), FAC FARM & BIOQUIM BUENOS AIRES, INST QUIM & FISICOQUIM BIOL, JUNIN 956, RA-1113 BUENOS AIRES, ARGENTINA.							BUXBAUM E, 1991, EUR J BIOCHEM, V195, P407, DOI 10.1111/j.1432-1033.1991.tb15720.x; CHOI YR, 1978, BIOCHIM BIOPHYS ACTA, V508, P313, DOI 10.1016/0005-2736(78)90334-6; Dawson R. M. C., 1991, DATA BIOCH RES, V3rd, P363; FROEHLICH JP, 1976, J BIOL CHEM, V251, P2307; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; HASTINGS DF, 1979, BIOCHEMISTRY-US, V18, P817, DOI 10.1021/bi00572a012; HAYASHI Y, 1985, SODIUM PUMP, P51; JENSEN J, 1984, J PHYSIOL-LONDON, V346, P219, DOI 10.1113/jphysiol.1984.sp015018; JENSEN J, 1985, SODIUM PUMP, P77; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; KAKAR SS, 1985, BIOCHEM INT, V11, P611; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARDH S, 1977, J BIOL CHEM, V252, P633; MOCZYDLOWSKI EG, 1981, J BIOL CHEM, V256, P2357; NORBY JG, 1989, J BIOL CHEM, V264, P19548; OTTOLENGHI P, 1986, BIOCHEM BIOPH RES CO, V135, P1008, DOI 10.1016/0006-291X(86)91028-4; PELUFFO RD, 1991, IN PRESS SODIUM PUMP, P379; REGA AF, 1975, J MEMBRANE BIOL, V22, P313, DOI 10.1007/BF01868177; RICHARDS DE, 1978, BIOCHIM BIOPHYS ACTA, V511, P194, DOI 10.1016/0005-2736(78)90313-9; ROSSI RC, 1989, BIOCHIM BIOPHYS ACTA, V981, P85, DOI 10.1016/0005-2736(89)90085-0; SEGEL IH, 1975, ENZYME KINETICS, P57; SHULL GE, 1988, J BIOL CHEM, V263, P8646; STEKHOVEN FMAHS, 1985, BIOCHIM BIOPHYS ACTA, V815, P16, DOI 10.1016/0005-2736(85)90468-7; STEKHOVEN FMAHS, 1983, BIOCHIM BIOPHYS ACTA, V732, P607; TANIGUCHI K, 1975, J BIOL CHEM, V250, P3010	27	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6596	6601						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1313015				2022-12-27	WOS:A1992HM05300025
J	CAFFREY, MS; BARTSCH, RG; CUSANOVICH, MA				CAFFREY, MS; BARTSCH, RG; CUSANOVICH, MA			STUDY OF THE CYTOCHROME-C2-REACTION CENTER INTERACTION BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE CYTOCHROMES; RHODOSPIRILLUM-RUBRUM CYTOCHROME-C2; RHODOBACTER-SPHAEROIDES R-26; ELECTRON-TRANSFER; BINDING; PROTEIN; COMPLEX; DOMAIN	Photooxidation of Rhodobacter capsulatus cytochrome c2 and four site-directed mutants by detergent solubilized Rhodobacter sphaeroides reaction centers was studied as a function of ionic strength at pH 8.0. Mutants of cytochrome c2 included K12D (lysine 12 substituted by aspartate), K14E (lysine 14 substituted by glutamate), K32E (lysine 32 substituted by glutamate), and K14E/K32E (lysines 14 and 32 substituted by glutamates). With respect to the wild-type, the mutants exhibited decreased second-order rate constants, indicating perturbation of their electrostatic interaction with the reaction center. In the transient complex, the interaction domain charges of the reaction center and wild-type cytochrome c2 were estimated to be -4.8 and +4.8, respectively. In contrast, the interaction domain charges of mutants K12D, K14E, K32E, and K14E/K32E were estimated to be +2.8, +3.7, +3.6 and +1.3, respectively. At infinite ionic strength, the second-order rate constant of the wild-type cytochrome c2 photooxidation (k(infinity)) was estimated to be 8.7 x 10(6) M-1 s-1. In the case of K32E, k(infinity) was not changed significantly (8.2 x 10(6) m-1 s-1), suggesting that the electrostatic perturbation of this mutant was largely overcome at high ionic strength. In contrast, the k(infinity) for K12D, K14E, and K14E/K32E were estimated to be decreased 2-7-fold. Consequently, mutations to R. capsulatus lysines 12 and 14 appear to perturb the distance and/or orientation of the cytochrome c2 relative to the reaction center in the reactive complex, as well as alter electrostatic interactions. Based upon the kinetic results presented here, the cytochrome c2-reaction center transient complex has been modeled.	UNIV ARIZONA, DEPT BIOCHEM, TUCSON, AZ 85721 USA	University of Arizona					NIGMS NIH HHS [GM 21277] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021277] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P5730, DOI 10.1073/pnas.84.16.5730; ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P6162, DOI 10.1073/pnas.84.17.6162; BENNING MM, 1991, J MOL BIOL, V220, P673, DOI 10.1016/0022-2836(91)90109-J; BOSSHARD HR, 1987, BIOCHEMISTRY-US, V26, P7688, DOI 10.1021/bi00398a023; CAFFREY M, 1991, IN PRESS ARCH BIOCH; CAFFREY MS, 1991, BIOCHEMISTRY-US, V30, P9238, DOI 10.1021/bi00102a015; CAFFREY MS, 1991, BIOCHEMISTRY-US, V30, P4119, DOI 10.1021/bi00231a002; CAFFREY MS, 1991, ARCH BIOCHEM BIOPHYS, V285, P227, DOI 10.1016/0003-9861(91)90353-K; CUSANOVICH MA, 1988, ADV INORG BIOCHEM, V7, P37; CUSANOVICH MA, 1991, BIOCHIM BIOPHYS ACTA, V1058, P67, DOI 10.1016/S0005-2728(05)80271-3; GOOLEY PR, 1990, BIOCHEMISTRY-US, V29, P2278, DOI 10.1021/bi00461a011; HALL J, 1987, J BIOL CHEM, V262, P14005; HALL J, 1987, BIOCHEMISTRY-US, V26, P4494, DOI 10.1021/bi00388a048; LONG JE, 1989, BIOCHEMISTRY-US, V28, P6970, DOI 10.1021/bi00443a029; MEYER TE, 1982, ADV PROTEIN CHEM, V35, P105, DOI 10.1016/S0065-3233(08)60469-6; MOSER CC, 1988, BIOCHEMISTRY-US, V27, P2450, DOI 10.1021/bi00407a031; OVERFIELD RE, 1986, PHOTOSYNTH RES, V9, P167, DOI 10.1007/BF00029742; RICKLE GK, 1979, ARCH BIOCHEM BIOPHYS, V197, P589, DOI 10.1016/0003-9861(79)90283-2; SALEMME FR, 1973, J BIOL CHEM, V248, P7701; TAKANO T, 1973, J BIOL CHEM, V248, P5234; TOLLIN G, 1984, BIOCHEMISTRY-US, V23, P6345, DOI 10.1021/bi00321a009; WATKINS A, 1966, THESIS U ARIZONA TUC	22	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6317	6321						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1313433				2022-12-27	WOS:A1992HK31800090
J	CAMPBELL, GS; PANG, L; MIYASAKA, T; SALTIEL, AR; CARTERSU, C				CAMPBELL, GS; PANG, L; MIYASAKA, T; SALTIEL, AR; CARTERSU, C			STIMULATION BY GROWTH-HORMONE OF MAP KINASE-ACTIVITY IN 3T3-F442A FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN-2; SERINE-THREONINE KINASE; MYELIN BASIC-PROTEIN; TYROSINE KINASE; POSSIBLE INVOLVEMENT; MONOCLONAL-ANTIBODY; RAT ADIPOCYTES; PC12 CELLS; PHOSPHORYLATION; INSULIN	We have previously demonstrated that growth hormone (GH) promotes an increase in tyrosine kinase activity associated with the GH receptor. To gain insight into the role of GH-dependent tyrosine kinase activity in signaling by GH, we investigated the possibility that GH might stimulate MAP kinase, a serine/threonine/tyrosine kinase thought to be a common element in tyrosine kinase-initiated response cascades. Treatment of 3T3-F442A fibroblasts with 100 ng/ml GH results in a 3-6-fold increase in the ability of cell-free extracts to phosphorylate MAP-2 and myelin basic protein. GH-stimulated kinase activity is unaffected by heparin, H7, or cAMP-dependent protein kinase inhibitor peptide, partially reduced by staurosporine and inhibited by fluoride and calcium ions, indicating that the kinase is not protein kinase C or A, casein kinase, or a calcium/calmodulin-dependent protein kinase. Based on gel permeation chromatography, the molecular mass of the GH-stimulated MAP kinase is approximately 40 kDa. Furthermore, anti-phosphotyrosine antibodies revealed the GH-dependent appearance of two phosphotyrosine-containing proteins in cell-free lysates of GH-treated cells that co-migrate with proteins recognized by anti-MAP kinase antibodies. The GH-dependent increase in MAP kinase activity displays a biphasic time course and is dependent on the concentration of GH applied to the cells. GH-dependent MAP kinase activity, partially purified by Mono-Q chromatography, is inactivated by treatment with alkaline phosphatase. Addition of H7 to the cells prior to the addition of GH has no effect, whereas addition of H8 increases MAP kinase activity in control cells with no effect in GH-treated cells, indicating that protein kinase C is unlikely to be an intermediary in the GH-dependent stimulation of MAP kinase activity. These findings indicate that signaling by GH in 3T3-F443A cells may, at least in part, utilize a kinase cascade similar to those that have been proposed for other membrane receptors with associated tyrosine kinase activity.	PARKE DAVIS & CO,DEPT SIGNAL TRANSDUCT,ANN ARBOR,MI 48105	Pfizer	CAMPBELL, GS (corresponding author), UNIV MICHIGAN,DEPT PHYSIOL,ANN ARBOR,MI 48109, USA.		Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828	NIDDK NIH HHS [DK-33804, R01 DK034171, DK-34171] Funding Source: Medline; NIGMS NIH HHS [GM-14099] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R23DK033804, R01DK033804, R01DK034171, R37DK034171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014099] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11495; AKIYAMA T, 1986, J BIOL CHEM, V261, P4797; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BORISY GG, 1975, ANN NY ACAD SCI, V253, P107, DOI 10.1111/j.1749-6632.1975.tb19196.x; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTERSU C, 1989, J BIOL CHEM, V264, P18654; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; DAVIDSON MB, 1987, ENDOCR REV, V8, P115, DOI 10.1210/edrv-8-2-115; EDEN S, 1979, ENDOCRINOLOGY, V105, P555, DOI 10.1210/endo-105-2-555; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GORIN E, 1990, ENDOCRINOLOGY, V126, P2973; GULLER S, 1991, ENDOCRINOLOGY, V129, P527, DOI 10.1210/endo-129-1-527; GURLAND G, 1990, ENDOCRINOLOGY, V127, P3187, DOI 10.1210/endo-127-6-3187; HANEKOM C, 1989, BIOCHEM J, V262, P449, DOI 10.1042/bj2620449; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; ISAKSSON OGP, 1987, ENDOCR REV, V8, P426, DOI 10.1210/edrv-8-4-426; ISAO H, 1990, J BIOL CHEM, V265, P15471; KAMPS MP, 1988, ONCOGENE RES, V3, P105; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRETH GE, 1990, J NEUROCHEM, V55, P514, DOI 10.1111/j.1471-4159.1990.tb04165.x; LEWIS SA, 1986, J CELL BIOL, V102, P2098, DOI 10.1083/jcb.102.6.2098; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MIYASAKA T, 1991, P NATL ACAD SCI USA, V88, P2653, DOI 10.1073/pnas.88.7.2653; MORIKAWA M, 1982, CELL, V29, P783, DOI 10.1016/0092-8674(82)90440-8; NAKANO H, 1987, J ANTIBIOT, V40, P706, DOI 10.7164/antibiotics.40.706; NEL AE, 1990, J IMMUNOL, V145, P971; NEL AE, 1990, J IMMUNOL, V144, P2683; NIXON T, 1984, ENDOCRINOLOGY, V114, P527, DOI 10.1210/endo-114-2-527; PRESS M, 1988, DIABETES METAB REV, V4, P391, DOI 10.1002/dmr.5610040406; RAY LB, 1988, ARCH BIOCHEM BIOPHYS, V262, P307, DOI 10.1016/0003-9861(88)90193-2; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SANO M, 1990, J NEUROCHEM, V55, P427, DOI 10.1111/j.1471-4159.1990.tb04154.x; SCHULMAN H, 1984, J CELL BIOL, V99, P11, DOI 10.1083/jcb.99.1.11; SECRIST JP, 1990, J BIOL CHEM, V265, P20394; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SLOBODA RD, 1975, P NATL ACAD SCI USA, V72, P177, DOI 10.1073/pnas.72.1.177; SMAL J, 1989, P NATL ACAD SCI USA, V86, P4705, DOI 10.1073/pnas.86.12.4705; SMAL J, 1987, BIOCHEM BIOPH RES CO, V147, P1232, DOI 10.1016/S0006-291X(87)80202-4; STRED SE, 1990, ENDOCRINOLOGY, V127, P2506, DOI 10.1210/endo-127-5-2506; STRED SE, 1992, ENDOCRINOLOGY, V130; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUZUKI K, 1990, J BIOL CHEM, V265, P11320; VALLEE R, 1980, P NATL ACAD SCI-BIOL, V77, P3206, DOI 10.1073/pnas.77.6.3206; YAMAMOTO H, 1983, J NEUROCHEM, V41, P1119, DOI 10.1111/j.1471-4159.1983.tb09060.x	55	170	170	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6074	6080						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1313428				2022-12-27	WOS:A1992HK31800055
J	THOMAS, L; CLARKE, PR; PAGANO, M; GRUENBERG, J				THOMAS, L; CLARKE, PR; PAGANO, M; GRUENBERG, J			INHIBITION OF MEMBRANE-FUSION INVITRO VIA CYCLIN-B BUT NOT CYCLIN-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEINS; CELL-FREE-EXTRACTS; XENOPUS EGGS; PHOSPHORYLATION SITES; NUCLEAR LAMINA; FREE SYSTEM; M-PHASE; CDC2; KINASE; ACTIVATION	It is now clear that complexes of cdc2 kinase with "mitotic" cyclins regulate the transition between the G2 phase of the cell cycle and mitosis and that membrane traffic in mammalian cells is arrested during mitosis. Using a cell-free assay, we have previously reported that the fusion of early endosomes is, in fact, inhibited via the cdc2 kinase (Tuomikoski, T., Felix, M.-A., Doree, M., and Gruenberg, J. (1989) Nature 342, 942-945). In the present paper, we show that this in vitro inhibition occurs efficiently only when the kinase activity is specifically evoked by a cyclin of the B-type but not by cyclins of the A-type. In addition, high resolution two-dimensional gel analysis revealed that the kinases associated with A- and B-type cyclins exhibit different substrate preferences. These data suggest that the complexes of the cdc2 kinase with different cyclins may control specific events of the cell cycle.	EUROPEAN MOLEC BIOL LAB,POSTFACH 102209,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Clarke, Paul R./AAA-6803-2020; Clarke, Paul/B-1684-2009	Clarke, Paul/0000-0003-3525-2622				BAILLY E, 1991, NATURE, V350, P715, DOI 10.1038/350715a0; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BRAVO R, 1984, 2 DIMENSIONAL GEL EL, P3; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; FELIX MA, 1989, EMBO J, V8, P3059, DOI 10.1002/j.1460-2075.1989.tb08457.x; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRUENBERG J, 1987, P NATL ACAD SCI USA, V84, P5758, DOI 10.1073/pnas.84.16.5758; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; GRUENBERG J, 1992, PROTEIN TARGETING PR, P187; GRUENBERG JE, 1986, EMBO J, V5, P3091, DOI 10.1002/j.1460-2075.1986.tb04615.x; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HOWELL KE, 1989, METHODS CELL BIOL A, V31, P264; HUNT T, 1991, NATURE, V349, P100, DOI 10.1038/349100a0; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; KARSENTI E, 1987, DEV BIOL, V119, P442, DOI 10.1016/0012-1606(87)90048-0; KARSENTI E, 1991, ADV PROTEIN PHOSPHAT, V6, P453; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; LOHKA MJ, 1984, DEV BIOL, V103, P434, DOI 10.1016/0012-1606(84)90331-2; MIAKELYE R, 1985, CELL, V41, P165, DOI 10.1016/0092-8674(85)90071-6; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAGANO M, 1992, IN PRESS EMBO J, V11; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; ROY LM, 1991, J CELL BIOL, V113, P507, DOI 10.1083/jcb.113.3.507; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; TUOMIKOSKI T, 1989, NATURE, V342, P945; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WARREN G, 1989, NATURE, V342, P857, DOI 10.1038/342857a0; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	45	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6183	6187						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1313431				2022-12-27	WOS:A1992HK31800071
J	BECKER, MA; KIM, M; HUSAIN, K; KANG, T				BECKER, MA; KIM, M; HUSAIN, K; KANG, T			REGULATION OF PURINE NUCLEOTIDE SYNTHESIS IN HUMAN B-LYMPHOBLASTS WITH BOTH HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY AND PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE SUPERACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LESCH-NYHAN SYNDROME; CULTURED HUMAN-FIBROBLASTS; TUMOR-CELLS; OVERPRODUCTION; BIOSYNTHESIS; ACID; METABOLISM; DENOVO; GOUT; AMIDOTRANSFERASE	Human B lymphoblast lines severely deficient in hypoxanthine-guanine phosphoribosyltransferase (HGPRT) were selected for resistance to 6-thioguanine from cloned normal and phosphoribosylpyrophosphate (PP-Rib-P) synthetase-superactive cell lines and were compared with their respective parental cell lines with regard to growth and PP-Rib-P and purine nucleotide metabolism. During blockade of purine synthesis de novo with 6-methylthioinosine or aminopterin, inhibition of growth of all HGPRT-deficient cell lines was refractory to addition of Ade at concentrations which restored substantial growth to parental cell lines. Ade-resistant inhibition of growth of parental lines by 6-methylthioinosine, however, occurred during Ado deaminase inhibition. Insufficient generation of IMP (and ultimately guanylates) to support growth of lymphoblasts lacking HGPRT activity and blocked in purine synthesis de novo best explained these findings, implying that a major route of interconversion of AMP to IMP involves the reaction sequence: AMP --> Ado --> Ino --> Hyp --> IMP. PP-Rib-P generation and purine nucleoside triphosphate pools were unchanged by introduction of HGPRT deficiency into normal lymphoblast lines, in agreement with the view that accelerated purine synthesis de novo in this deficiency results from increased availability of PP-Rib-P for the pathway. Cell lines with dual enzyme defects did not differ from PP-Rib-P synthetase-superactive parental lines in rates of PP-Rib-P and purine synthesis despite 5-6-fold increases in PP-Rib-P concentrations, excretion of nearly 50% of newly synthesized purines, and diminished GTP concentrations. Fixed rates of purine synthesis de novo in PP-Rib-P synthetase-superactive cells appeared to reflect saturation of the rate-limiting amidophosphoribosyltransferase reaction for PP-Rib-P. In combination with accelerated purine excretion, increased channeling of newly formed purines into adenylates, and impaired conversion of AMP to IMP, fixed rates of purine synthesis de novo may condition cell lines with defects in HGPRT and PP-Rib-P synthetase to depletion of GTP with consequent growth retardation.			BECKER, MA (corresponding author), UNIV CHICAGO, PRITZKER SCH MED,MED CTR,DEPT MED,RHEUMATOL SECT, BOX 74, 5841 S MARYLAND AVE, CHICAGO, IL 60637 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028554] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-28554] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAGNARA AS, 1974, BIOCHIM BIOPHYS ACTA, V374, P259, DOI 10.1016/0005-2787(74)90247-0; BARANKIEWICZ J, 1977, CAN J BIOCHEM CELL B, V55, P257, DOI 10.1139/o77-036; BECKER MA, 1989, ADV EXP MED BIOL, V253, P13; BECKER MA, 1976, J CLIN INVEST, V57, P308, DOI 10.1172/JCI108282; BECKER MA, 1980, J CLIN INVEST, V65, P109, DOI 10.1172/JCI109640; BECKER MA, 1987, J BIOL CHEM, V262, P5596; BECKER MA, 1986, BIOCHIM BIOPHYS ACTA, V882, P168, DOI 10.1016/0304-4165(86)90151-0; BECKER MA, 1982, J LAB CLIN MED, V99, P495; BECKER MA, 1975, J BIOL CHEM, V250, P6822; BECKER MA, 1976, BIOCHIM BIOPHYS ACTA, V435, P132, DOI 10.1016/0005-2787(76)90244-6; BECKER MA, 1986, ARTHRITIS RHEUM, V29, P880, DOI 10.1002/art.1780290710; BECKER MA, 1987, J BIOL CHEM, V262, P14531; BECKER MA, 1973, SCIENCE, V179, P1123, DOI 10.1126/science.179.4078.1123; BENNETT LL, 1970, BIOCHEM PHARMACOL, V19, P2172, DOI 10.1016/0006-2952(70)90318-7; BOSS GR, 1984, J BIOL CHEM, V259, P2936; BOYLE JA, 1972, BIOCHIM BIOPHYS ACTA, V269, P179, DOI 10.1016/0005-2787(72)90424-8; BRENTON DP, 1977, BIOCHEM MED METAB B, V17, P231, DOI 10.1016/0006-2944(77)90029-1; CRABTREE GW, 1971, CANCER RES, V31, P985; GORDON RB, 1979, BIOCHIM BIOPHYS ACTA, V562, P162, DOI 10.1016/0005-2787(79)90135-7; GREEN CD, 1973, P NATL ACAD SCI USA, V70, P3698, DOI 10.1073/pnas.70.12.3698; Hershfield M S, 1977, Adv Exp Med Biol, V76A, P303; HERSHFIELD MS, 1977, J BIOL CHEM, V252, P6002; HERSHFIELD MS, 1977, SCIENCE, V197, P1284, DOI 10.1126/science.197600; HERSHFIELD MS, 1976, J BIOL CHEM, V251, P7348; HILL DL, 1969, BIOCHEMISTRY-US, V8, P122, DOI 10.1021/bi00829a017; HOLMES EW, 1973, J BIOL CHEM, V248, P6035; HOLMES EW, 1973, J BIOL CHEM, V248, P144; KELLEY W N, 1970, Metabolism Clinical and Experimental, V19, P1025, DOI 10.1016/0026-0495(70)90026-0; KELLEY WN, 1970, BIOCHIM BIOPHYS ACTA, V215, P512, DOI 10.1016/0304-4165(70)90101-7; KHYM JX, 1975, CLIN CHEM, V21, P1245; LESCH M, 1964, AM J MED, V36, P561, DOI 10.1016/0002-9343(64)90104-4; LEVER JE, 1974, P NATL ACAD SCI USA, V71, P2679, DOI 10.1073/pnas.71.7.2679; LOSMAN MJ, 1984, J LAB CLIN MED, V103, P932; LOSMAN MJ, 1985, J CLIN INVEST, V76, P1657, DOI 10.1172/JCI112151; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTIN DW, 1976, SCIENCE, V193, P408, DOI 10.1126/science.180603; MIGEON BR, 1968, SCIENCE, V160, P425, DOI 10.1126/science.160.3826.425; MITCHELL BS, 1978, P NATL ACAD SCI USA, V75, P5011, DOI 10.1073/pnas.75.10.5011; NUKI G, 1974, ADV EXP MED BIOL   A, V41, P255; RAIVIO KO, 1973, BIOCHIM BIOPHYS ACTA, V299, P273, DOI 10.1016/0005-2787(73)90350-X; RAIVIO KO, 1973, BIOCHIM BIOPHYS ACTA, V299, P283, DOI 10.1016/0005-2787(73)90351-1; REEM GH, 1975, SCIENCE, V190, P1098, DOI 10.1126/science.171772; ROSENBLOOM FM, 1968, J BIOL CHEM, V243, P1166; SEEGMILLER JE, 1967, SCIENCE, V155, P1682, DOI 10.1126/science.155.3770.1682; SKAPER SD, 1976, SCIENCE, V193, P587, DOI 10.1126/science.959817; SPERLING O, 1972, REV EUR ETUD CL BIOL, V17, P703; SZYBALSKI WACLAW, 1962, NATL CANCER INST MONOGR, V7, P75; TAY BS, 1969, BIOCHEM PHARMACOL, V18, P934, DOI 10.1016/0006-2952(69)90069-0; THOMPSON LF, 1978, P NATL ACAD SCI USA, V75, P3722, DOI 10.1073/pnas.75.8.3722; ULLMAN B, 1983, MOL CELL BIOL, V3, P1187, DOI 10.1128/MCB.3.7.1187; WEBER G, 1983, CANCER RES, V43, P3466; WOOD AW, 1973, BIOCHEM GENET, V9, P261, DOI 10.1007/BF00485739; YEN RCK, 1981, J BIOL CHEM, V256, P1839; YEN RCK, 1978, P NATL ACAD SCI USA, V75, P482, DOI 10.1073/pnas.75.1.482; ZOREF E, 1976, NATURE, V260, P786, DOI 10.1038/260786a0; ZOREF E, 1975, J CLIN INVEST, V56, P1093, DOI 10.1172/JCI108183; ZOREFSHANI E, 1980, BIOCHIM BIOPHYS ACTA, V607, P503, DOI 10.1016/0005-2787(80)90160-4	57	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4317	4321						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1311306				2022-12-27	WOS:A1992HF64200011
J	YANAGISAWA, J; SEKI, M; KOHDA, T; ENOMOTO, T; UI, M				YANAGISAWA, J; SEKI, M; KOHDA, T; ENOMOTO, T; UI, M			DNA-DEPENDENT ADENOSINE-TRIPHOSPHATASE-C1 FROM MOUSE FM3A CELLS HAS DNA HELICASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; LARGE TUMOR-ANTIGEN; ADENOSINE-TRIPHOSPHATASE; ESCHERICHIA-COLI; CALF-THYMUS; SACCHAROMYCES-CEREVISIAE; UNWINDING ACTIVITY; ATPASE; PURIFICATION; REPLICATION	In our previous study, we identified four chromatographically distinct DNA-dependent ATPases, B, C1, C2, and C3, in mouse FM3A cells (Tawaragi, Y., Enomoto, T., Watanabe, Y., Hanaoka, F., and Yamada, M. (1984) Biochemistry 23, 529-533). The DNA-dependent ATPase C1 has been purified and characterized in detail. A divalent cation and a polynucleotide cofactor were required for the ATPase activity. Poly(dT), single-stranded circular DNA, and heat-denatured DNA were very effective. Almost no ATPase activity was observed with S1 nuclease-treated native DNA. ATPase C1 hydrolyzed ATP only among the ribo- and deoxyribonucleoside triphosphates tested, and this fact distinguished ATPase C1 from ATPases B, C2, and C3, because the latter enzymes are capable of hydrolyzing both ATP and dATP. The purified DNA-dependent ATPase C1 fraction was shown to have a DNA helicase activity that was dependent on hydrolysis of ATP. The helicase activity and DNA-dependent ATPase activity cosedimented at 5.2 S on glycerol gradient centrifugation. Both activities showed similar preferences for nucleoside 5'-triphosphates and similar requirements for divalent cations. The DNA helicase activity was inhibited by the addition of single-stranded DNAs that served as cofactor for the ATPase activity. The efficiency of a single-stranded DNA to inhibit DNA helicase activity correlated well with the capacity of the DNA to serve as cofactor for DNA-dependent ATPase activity. The helicase was shown to migrate along the DNA strand in the 5' to 3' direction, which is the same direction of migration of the mouse DNA helicase B (Seki, M., Enomoto, T., Yanagisawa, J., Hanaoka, F., and Ui, M. (1988) Biochemistry 27, 1766-1771).	UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								APOSHIAN HV, 1962, J BIOL CHEM, V237, P519; ASSAIRI LM, 1979, EUR J BIOCHEM, V99, P71, DOI 10.1111/j.1432-1033.1979.tb13232.x; BOXER LM, 1980, BIOCHEMISTRY-US, V19, P2623, DOI 10.1021/bi00553a014; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; CRUTE JJ, 1988, NUCLEIC ACIDS RES, V16, P6585, DOI 10.1093/nar/16.14.6585; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DEJONG PJ, 1981, EUR J BIOCHEM, V117, P179; GOETZ GS, 1988, J BIOL CHEM, V263, P383; HACHMANN HJ, 1976, EUR J BIOCHEM, V61, P325, DOI 10.1111/j.1432-1033.1976.tb10025.x; HANAOKA F, 1981, CELL STRUCT FUNCT, V6, P357, DOI 10.1247/csf.6.357; HAROSH I, 1989, J BIOL CHEM, V264, P20532; HOCKENSMITH JW, 1986, BIOCHEMISTRY-US, V25, P7812, DOI 10.1021/bi00372a005; HOTTA Y, 1978, BIOCHEMISTRY-US, V17, P1872, DOI 10.1021/bi00603a011; HUBSCHER U, 1985, NUCLEIC ACIDS RES, V13, P5471, DOI 10.1093/nar/13.15.5471; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; KELLY TJ, 1988, J BIOL CHEM, V263, P17889; KORN LJ, 1976, J MOL BIOL, V106, P231, DOI 10.1016/0022-2836(76)90082-6; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1986, J BIOL CHEM, V261, P169; MESSING J, 1983, METHOD ENZYMOL, V101, P20; PLEVANI P, 1980, J BIOL CHEM, V255, P4957; POLL EHA, 1988, BIOCHEMISTRY-US, V27, P8701, DOI 10.1021/bi00424a002; SEKI M, 1990, BIOCHEMISTRY-US, V29, P1003, DOI 10.1021/bi00456a024; SEKI M, 1986, BIOCHEMISTRY-US, V25, P3239, DOI 10.1021/bi00359a024; SEKI M, 1987, BIOCHEMISTRY-US, V26, P2924, DOI 10.1021/bi00384a038; SEKI M, 1988, BIOCHEMISTRY-US, V27, P1766, DOI 10.1021/bi00405a057; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; SUGINO A, 1986, J BIOL CHEM, V261, P1744; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; TANUMA SI, 1980, CELL STRUCT FUNCT, V5, P27, DOI 10.1247/csf.5.27; TAWARAGI Y, 1984, BIOCHEMISTRY-US, V23, P529, DOI 10.1021/bi00298a020; THOMAS DC, 1982, BIOCHEMISTRY-US, V21, P5060, DOI 10.1021/bi00263a033; THOMMES P, 1990, J BIOL CHEM, V265, P14347; TUTEJA N, 1990, NUCLEIC ACIDS RES, V18, P6785, DOI 10.1093/nar/18.23.6785; TUTEJA N, 1991, NUCLEIC ACIDS RES, V19, P3613, DOI 10.1093/nar/19.13.3613; WATANABE Y, 1981, BIOCHEM INT, V3, P407; WIEKOWSKI M, 1988, J BIOL CHEM, V263, P436; YAGINUMA K, 1981, NUCLEIC ACIDS RES, V9, P1949, DOI 10.1093/nar/9.8.1949; YARRANTON GT, 1979, P NATL ACAD SCI USA, V76, P1658, DOI 10.1073/pnas.76.4.1658	42	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3644	3649						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1310978				2022-12-27	WOS:A1992HE60700018
J	BUEHRER, BM; BELL, RM				BUEHRER, BM; BELL, RM			INHIBITION OF SPHINGOSINE KINASE INVITRO AND IN PLATELETS - IMPLICATIONS FOR SIGNAL TRANSDUCTION PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-CHAIN BASES; CELL-DIFFERENTIATION; HL-60 CELLS; ACTIVATION; SERINE; LOWRY; BOND	Sphingosine kinase was partially purified and characterized from rat brain microsomes. A new assay, utilizing octyl-beta-D-glucopyranoside and sphingosine mixed micelles, was developed to quantitate formation of the sphingosine-1-phosphate product. The assay was proportional with respect to time and protein, displayed Michaelis-Menten kinetics, and was subject to surface dilution in regard to the sphingosine substrate. Investigations into substrate specificity showed that the enzyme is specific for the erythro-enantiomers of sphingosine and dihydrosphingosine. Neither of the threo-enantiomers were phosphorylated in this system, but both were found to be potent competitive inhibitors of sphingosine kinase activity. Human platelet sphingosine kinase activity displayed substrate and inhibitor specificities similar to the rat brain enzyme. A mixture of DL-threo-dihydrosphingosine competitively inhibited sphingosine kinase activity in a dose dependent manner in isolated platelets. DL-Threo-dihydrosphingosine caused a prolongation of the inhibition of thrombin- induced protein kinase C-dependent 40 (47)-kDa protein phosphorylation in platelets. D-, L-, or DL-Threo-dihydrosphingosine may be useful as a tool to investigate D-Erythrosphingosine metabolism and the function of sphingosine-1-phosphate in signal transduction processes.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University				Buehrer, Benjamin/0000-0001-6654-4367	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK020205, R01DK020205] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 20205] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P115, DOI 10.1021/bi00375a017; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; HALL FL, 1988, J BIOL CHEM, V263, P4460; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HIRSCHBERG CB, 1970, J BIOL CHEM, V245, P3084; KEENAN RW, 1972, BIOCHIM BIOPHYS ACTA, V270, P383, DOI 10.1016/0005-2760(72)90201-9; KEENAN RW, 1969, BIOCHIM BIOPHYS ACTA, V176, P348, DOI 10.1016/0005-2760(69)90193-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOCKNEY MW, 1984, BIOCHIM BIOPHYS ACTA, V796, P384, DOI 10.1016/0005-2760(84)90141-3; LOUIE DD, 1976, J BIOL CHEM, V251, P4557; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MERRILL A, 1991, FASEB J, V5, pA1065; MERRILL AH, 1986, J BIOL CHEM, V261, P2610; MERRILL AH, 1989, BIOCHEMISTRY-US, V28, P3138, DOI 10.1021/bi00434a004; MERRILL AH, 1983, BIOCHIM BIOPHYS ACTA, V754, P284, DOI 10.1016/0005-2760(83)90144-3; MERRILL AH, 1986, J BIOL CHEM, V261, P3764; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; ONG DE, 1973, J BIOL CHEM, V248, P3884; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SEISS W, 1983, J BIOL CHEM, V258, P11236; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P169, DOI 10.1515/bchm2.1973.354.1.169; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P1311, DOI 10.1515/bchm2.1973.354.2.1311; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P562, DOI 10.1515/bchm2.1973.354.1.562; STOFFEL W, 1968, H-S Z PHYSIOL CHEM, V349, P1149, DOI 10.1515/bchm2.1968.349.2.1149; STOFFEL W, 1968, H-S Z PHYSIOL CHEM, V349, P1745, DOI 10.1515/bchm2.1968.349.2.1745; STOFFEL W, 1970, H-S Z PHYSIOL CHEM, V351, P1041, DOI 10.1515/bchm2.1970.351.2.1041; STOFFEL W, 1974, H-S Z PHYSIOL CHEM, V355, P61, DOI 10.1515/bchm2.1974.355.1.61; STOFFEL W, 1969, H-S Z PHYSIOL CHEM, V350, P1233, DOI 10.1515/bchm2.1969.350.2.1233; VANVELDHOVEN PP, 1991, J BIOL CHEM, V266, P12502; WALSH JP, 1986, J BIOL CHEM, V261, P6239; WILSON E, 1986, J BIOL CHEM, V261, P2616; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	37	178	186	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3154	3159						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1310683				2022-12-27	WOS:A1992HD15400053
J	WU, D; ARONSON, AI				WU, D; ARONSON, AI			LOCALIZED MUTAGENESIS DEFINES REGIONS OF THE BACILLUS-THURINGIENSIS DELTA-ENDOTOXIN INVOLVED IN TOXICITY AND SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; INSECTICIDAL CRYSTAL PROTEINS; PIERIS-BRASSICAE; BINDING-SITES; VAR KURSTAKI; MIDGUT; DOMAIN; GENES; INHIBITION; EXPRESSION	Bacillus thuringiensis produces a variety of delta-endotoxins which bind to specific receptors in insect larval midguts. Following insertion into the membrane there is an alteration of ion flux culminating in osmotic lysis. Mutagenic oligonucleotides were used to define regions in one of these toxins involved in specificity and toxicity. One region is highly conserved among all toxins sequenced to date and many mutations resulted in loss of toxicity for three test Lepidoptera. The mutant toxins had lost the capacity to inhibit K+-dependent amino acid transport into larval midgut vesicles, but there was no effect on their ability to compete with wild type toxin for binding. The results are consistent with this amphiphilic helical region of the toxin being essential for toxicity. A second mutagenized region overlapped a portion of another potential amphiphilic helix. Mutations of only 2 residues, Ala-92 and Arg-93, resulted in loss of toxicity for two lepidopteran larvae but some activity remained for a third. The A92D mutant toxin competed with the wild type toxin for binding to vesicles prepared from midguts from the sensitive but not from the insensitive larvae. Decreased toxicity was also found when this mutation was transferred to two other related protoxin genes. A number of mutations of each of these residues was analyzed and selective loss of toxicity correlated with the absence of a positive charge. Despite being distal from the presumptive specificity domain, 1 or both of these residues must have an important role in the specific binding of toxins.			WU, D (corresponding author), PURDUE UNIV, DEPT BIOL SCI, W LAFAYETTE, IN 47907 USA.				NIGMS NIH HHS [GM 34035] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034035] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], PATHOGENSIS INVERTEB; ARONSON AI, 1986, MICROBIOL REV, V50, P1; ARVIDSON H, 1989, MOL MICROBIOL, V3, P1533, DOI 10.1111/j.1365-2958.1989.tb00139.x; BIETLOT H, 1989, BIOCHEM J, V260, P87, DOI 10.1042/bj2600087; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARAMORI T, 1991, GENE, V98, P37, DOI 10.1016/0378-1119(91)90101-G; CONVENTS D, 1990, J BIOL CHEM, V265, P1369; CONVENTS D, 1991, EUR J BIOCHEM, V195, P631, DOI 10.1111/j.1432-1033.1991.tb15747.x; CRAWFORD DN, 1988, J EXP BIOL, V137, P277; GE AZ, 1989, P NATL ACAD SCI USA, V86, P4037, DOI 10.1073/pnas.86.11.4037; GEISER M, 1986, GENE, V48, P109, DOI 10.1016/0378-1119(86)90357-4; GOTHAM SM, 1988, ANAL BIOCHEM, V173, P353, DOI 10.1016/0003-2697(88)90199-6; HAIDER MZ, 1986, EUR J BIOCHEM, V156, P531, DOI 10.1111/j.1432-1033.1986.tb09612.x; HAIDER MZ, 1987, MOL MICROBIOL, V1, P59, DOI 10.1111/j.1365-2958.1987.tb00527.x; HAIDER MZ, 1989, J MOL BIOL, V208, P183, DOI 10.1016/0022-2836(89)90094-6; Hodgman T C, 1990, DNA Seq, V1, P97, DOI 10.3109/10425179009016037; HOFMANN C, 1988, P NATL ACAD SCI USA, V85, P7844, DOI 10.1073/pnas.85.21.7844; HOFTE H, 1989, MICROBIOL REV, V53, P242; KNOWLES BH, 1987, BIOCHIM BIOPHYS ACTA, V924, P509, DOI 10.1016/0304-4165(87)90167-X; KONDO S, 1987, AGR BIOL CHEM TOKYO, V51, P455, DOI 10.1080/00021369.1987.10868034; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESZCZYNSKI JF, 1986, SCIENCE, V234, P849, DOI 10.1126/science.3775366; METTUS AM, 1990, APPL ENVIRON MICROB, V56, P1128, DOI 10.1128/AEM.56.4.1128-1134.1990; NER SS, 1988, BIOTECHNIQUES, V6, P408; NER SS, 1988, DNA-J MOLEC CELL BIO, V7, P127, DOI 10.1089/dna.1988.7.127; POPOT JL, 1990, ANNU REV BIOPHYS BIO, V19, P369; SACCHI VF, 1986, FEBS LETT, V204, P213, DOI 10.1016/0014-5793(86)80814-6; SCHEIN CH, 1990, BIO-TECHNOL, V8, P308, DOI 10.1038/nbt0490-308; SCHNEPF HE, 1990, J BIOL CHEM, V265, P20923; SCHNEPF HE, 1981, P NATL ACAD SCI-BIOL, V78, P2893, DOI 10.1073/pnas.78.5.2893; SCHURTER W, 1989, MOL GEN GENET, V218, P177, DOI 10.1007/BF00330581; SIEGALL CB, 1989, J BIOL CHEM, V264, P14256; STRAUSS EC, 1986, ANAL BIOCHEM, V154, P353, DOI 10.1016/0003-2697(86)90536-1; VANRIE J, 1990, SCIENCE, V247, P72, DOI 10.1126/science.2294593; VANRIE J, 1989, EUR J BIOCHEM, V186, P239, DOI 10.1111/j.1432-1033.1989.tb15201.x; VANRIE J, 1990, APPL ENVIRON MICROB, V56, P1378, DOI 10.1128/AEM.56.5.1378-1385.1990; WIDNER WR, 1989, J BACTERIOL, V171, P965, DOI 10.1128/jb.171.2.965-974.1989; WOLFERSBERGER M, 1987, COMP BIOCHEM PHYS A, V86, P301, DOI 10.1016/0300-9629(87)90334-3; WOLFERSBERGER MG, 1989, ARCH INSECT BIOCHEM, V12, P267, DOI 10.1002/arch.940120406; WOLFERSBERGER MG, 1990, EXPERIENTIA, V46, P475; WOLFERSBERGER MG, 1986, ZENTRALBL BAKTERIO S, V15, P237; WU D, 1991, FEMS MICROBIOL LETT, V81, P31, DOI 10.1016/0378-1097(91)90466-N; WU D, 1990, GENETICS BIOTECHNOLO, V3, P211	44	111	136	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2311	2317						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1310313				2022-12-27	WOS:A1992HB53200032
J	WATSON, AJM; LEVINE, S; DONOWITZ, M; MONTROSE, MH				WATSON, AJM; LEVINE, S; DONOWITZ, M; MONTROSE, MH			SERUM REGULATES NA+/H+ EXCHANGE IN CACO-2 CELLS BY A MECHANISM WHICH IS DEPENDENT ON F-ACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ILEAL BRUSH-BORDER; OPOSSUM KIDNEY-CELLS; H+ EXCHANGE; INTRACELLULAR PH; APICAL MEMBRANE; CYTOCHALASIN-B; GROWTH-FACTORS; CYTOPLASMIC PH; LLC-PK1 CELLS; CYCLIC-AMP	Regulation of Na+/H+ exchange by fetal bovine serum was studied in Caco-2 cells, an established cell line derived from a human colon carcinoma. Cells were grown as polarized monolayers on collagen-coated filters and intracellular pH measured fluorometrically with 2',7'-bis(2-carboxymethyl)-5,6-carboxyfluorescein. Na+/H+ exchange was reduced 64% when cells were deprived of serum for 4 h. In contrast to other cell types, readdition of serum for 10 min did not activate Na+/H+ exchange; however, readdition of serum for 4 h restored Na+/H+ exchange to control values. This long-term effect of serum on Na+/H+ exchange activity could not be explained by changes in intracellular buffering capacity or intracellular [Na+]. 4-h serum deprivation reduced the K(t) of the exchanger for external Na+ from 21 to 6 mm, and reduced the V(max) by 57%, but did not alter the IC50 for amiloride in the presence of 140 mm Na+. Inhibition of protein synthesis with cycloheximide (5-mu-M) did not alter the effect of serum removal or readdition on Na+/H+ exchange. Low temperature (13-degrees-C) completely prevented the inhibition of Na+/H+ exchange caused by the removal of serum. In addition, once Na+/H+ exchange was inhibited by serum removal at 37-degrees-C, maintaining cells at 13-degrees-C also blocked the recovery of Na+/H+ exchange caused by serum readdition. Conversely, cytochalasin D (0.1-20-mu-M) blocked the reduction of Na+/H+ exchange which occurred due to 4-h serum deprivation, but did not block the restoration of Na+/H+ exchange when the cells were re-exposed to serum for a further 4 h. Colchicine (20-mu-M) did not alter the effect of serum removal or readdition. These data suggest that serum regulates Na+/H+ exchange activity by a posttranslational mechanism which is dependent on F-actin.	JOHNS HOPKINS UNIV, SCH MED,DEPT PHYSIOL,HUNTERIAN 515,725 N WOLFE ST, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042457, R01DK026523] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK42457, R01-DK26523] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHLER C, 1989, J CELL BIOL, V109, P179, DOI 10.1083/jcb.109.1.179; BENNETT G, 1984, AM J ANAT, V170, P545, DOI 10.1002/aja.1001700404; BLOK J, 1982, CELL TISSUE RES, V222, P113; BONDER EM, 1986, J CELL BIOL, V102, P282, DOI 10.1083/jcb.102.1.282; BRETT JG, 1984, TISSUE CELL, V16, P325, DOI 10.1016/0040-8166(84)90052-1; CASAVOLA V, 1989, BIOCHEM BIOPH RES CO, V165, P833, DOI 10.1016/S0006-291X(89)80041-5; CASAVOLA V, 1991, PFLUG ARCH EUR J PHY, V418, P276, DOI 10.1007/BF00370527; COHEN ME, 1991, J CLIN INVEST, V88, P855, DOI 10.1172/JCI115387; COHEN ME, 1990, P NATL ACAD SCI USA, V87, P8990, DOI 10.1073/pnas.87.22.8990; DUNN WA, 1980, J BIOL CHEM, V255, P5971; GREEN J, 1989, FASEB J, V3, P2408, DOI 10.1096/fasebj.3.12.2551762; GRINSTEIN S, 1985, J GEN PHYSIOL, V85, P765, DOI 10.1085/jgp.85.5.765; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; HAGGERTY JG, 1988, P NATL ACAD SCI USA, V85, P6797, DOI 10.1073/pnas.85.18.6797; HELMLEKOLB C, 1990, PFLUG ARCH EUR J PHY, V415, P461, DOI 10.1007/BF00373624; KINSELLA J, 1984, J BIOL CHEM, V259, P3224; KINSELLA JL, 1986, J MEMBRANE BIOL, V91, P183, DOI 10.1007/BF01925795; KINSELLA JL, 1985, AM J PHYSIOL, V248, pF233, DOI 10.1152/ajprenal.1985.248.2.F233; KNICKELBEIN R, 1983, AM J PHYSIOL, V245, pG504, DOI 10.1152/ajpgi.1983.245.4.G504; KNICKELBEIN RG, 1988, J CLIN INVEST, V82, P2158, DOI 10.1172/JCI113838; MACLEANFLETCHER S, 1980, CELL, V20, P329, DOI 10.1016/0092-8674(80)90619-4; MATTHEWS J B, 1991, Gastroenterology, V100, pA697; MONTROSE MH, 1986, J MEMBRANE BIOL, V93, P33, DOI 10.1007/BF01871016; MONTROSE MH, 1989, J MEMBRANE BIOL, V108, P31, DOI 10.1007/BF01870423; MONTROSE MH, 1988, AM J PHYSIOL, V255, pC76, DOI 10.1152/ajpcell.1988.255.1.C76; MONTROSE MH, 1990, AM J PHYSIOL, V259, pC121, DOI 10.1152/ajpcell.1990.259.1.C121; MONTROSE MH, 1987, J MEMBRANE BIOL, V97, P63, DOI 10.1007/BF01869615; MOOLENAAR WH, 1983, NATURE, V304, P645, DOI 10.1038/304645a0; MUELLER SC, 1986, J CELL BIOL, V102, P932, DOI 10.1083/jcb.102.3.932; PARIS S, 1984, J BIOL CHEM, V259, P989; PEARL M, 1985, BIOL CELL, V55, P163, DOI 10.1111/j.1768-322X.1985.tb00421.x; PRAT AG, 1991, FASEB J, V5, pA690; PRATTEN MK, 1979, BIOCHEM J, V180, P567, DOI 10.1042/bj1800567; RAMASWAMY K, 1989, BIOCHIM BIOPHYS ACTA, V981, P193, DOI 10.1016/0005-2736(89)90028-X; REUSS L, 1985, J GEN PHYSIOL, V85, P409, DOI 10.1085/jgp.85.3.409; RINDLER MJ, 1987, J CELL BIOL, V104, P231, DOI 10.1083/jcb.104.2.231; RINK TJ, 1982, J CELL BIOL, V95, P189, DOI 10.1083/jcb.95.1.189; ROOD RP, 1988, J CLIN INVEST, V82, P1091, DOI 10.1172/JCI113665; ROTHENBERG P, 1983, J BIOL CHEM, V258, P2644; SACKTOR B, 1987, BIOCHEM ACTION HORM, V14, P141; SALAS PJI, 1986, J CELL BIOL, V102, P1853, DOI 10.1083/jcb.102.5.1853; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SCHLIWA M, 1982, J CELL BIOL, V92, P79, DOI 10.1083/jcb.92.1.79; STANTON RC, 1988, AM J PHYSIOL, V254, pC267, DOI 10.1152/ajpcell.1988.254.2.C267; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; WADE JB, 1989, AM J PHYSIOL, V257, pR998, DOI 10.1152/ajpregu.1989.257.5.R998; WATSON AJM, 1991, AM J PHYSIOL, V261, pG229, DOI 10.1152/ajpgi.1991.261.2.G229	47	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					956	962						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1309780				2022-12-27	WOS:A1992GY96000045
J	PETANCESKA, S; DEVI, L				PETANCESKA, S; DEVI, L			SEQUENCE-ANALYSIS, TISSUE DISTRIBUTION, AND EXPRESSION OF RAT CATHEPSIN-S	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; CYSTEINE PROTEINASE; MOLECULAR-CLONING; BOVINE SPLEEN; PROTEASES; DEGRADATION; PAPAIN; SUSCEPTIBILITY; LOCALIZATION; PROHORMONE	Cysteine proteases are involved in many diverse cellular processes ranging from processing of precursor proteins to intracellular degradation. In an effort to identify novel cysteine proteases, we used the polymerase chain reaction and primers directed against the catalytic sites of previously cloned cysteine proteases. From rat brain mRNA, a 600-base pair band was amplified; cloning and partial sequence analysis of this band resulted in the identification of cathepsins B and L and five novel sequences. The novel cDNAs contained a number of residues conserved in lysosomal cysteine proteases, including the active site residue His"' (papain numbering). In addition, the amino acid homology between the novel sequences and either cathepsins B, L, or H ranged from 63 to 32%. The insert with highest homology was used to screen a rat brain cDNA library; a 1334-base pair cDNA was isolated and the nucleotide sequence determined. This sequence encodes an open reading frame of 330 amino acids which is 82% homologous to human cathepsin S, suggesting that this sequence represents rat cathepsin S. Northern blot analysis for rat cathepsin S revealed tissue-specific expression distinct from the distribution of cathepsin B and L. The regulation of expression of rat cathepsin S mRNA in response to thyroid-stimulating hormone was studied in a rat thyroid cell line FRTL-5. The level of cathepsin S mRNA was substantially increased in response to thyroid-stimulating hormone, whereas cathepsin B and cathepsin L mRNA levels were not altered by this treatment. A portion of cDNA encoding the predicted mature protein of rat cathepsin S was expressed as a glutathione S-transferase-fusion protein. The affinity-purified protein exhibited proteolytic activity with properties similar to bovine cathepsin S. Taken together, these results imply highly specific functions for cathepsin S.	NYU HOSP, DEPT PHARMACOL, 550 1ST AVE, NEW YORK, NY 10016 USA	New York University	DEVI, L (corresponding author), NYU HOSP, DEPT PHARMACOL, 550 1ST AVE, NEW YORK, NY 10016 USA.							Ausubel FA, 1990, CURRENT PROTOCOLS MO; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; Battey, 1986, BASIC METHODS MOL BI; BEJANNET S, 1991, P NATIONAL ACAD SCI, V88, P3564; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; BROMME D, 1989, BIOCHEM J, V264, P475; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; CATALDO AM, 1991, P NATL ACAD SCI USA, V88, P10998, DOI 10.1073/pnas.88.24.10998; CATALDO AM, 1990, P NATL ACAD SCI USA, V87, P3861, DOI 10.1073/pnas.87.10.3861; CHAUHAN SS, 1991, CANCER RES, V51, P1478; DENHARDT DT, 1987, ONCOGENE, V2, P55; DUNN AD, 1991, J BIOL CHEM, V266, P20198; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; ISHIDOH K, 1987, FEBS LETT, V223, P69, DOI 10.1016/0014-5793(87)80511-2; ISHIURA S, 1991, J NEUROCHEM, V56, P363, DOI 10.1111/j.1471-4159.1991.tb08160.x; JAFFE RC, 1989, MOL ENDOCRINOL, V3, P1807, DOI 10.1210/mend-3-11-1807; KAMPHUIS IG, 1985, J MOL BIOL, V182, P317, DOI 10.1016/0022-2836(85)90348-1; KATUNUMA N, 1983, CURR TOP CELL REGUL, V22, P71; KEPPLER D, 1988, BIOL CHEM H-S, V369, P185; KIRSCHKE H, 1989, BIOCHEM J, V264, P467, DOI 10.1042/bj2640467; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LINDBERG I, 1991, MOL ENDOCRINOL, V5, P1361, DOI 10.1210/mend-5-10-1361; MACIEWICZ RA, 1988, BIOCHEM J, V256, P433, DOI 10.1042/bj2560433; MACIEWICZ RA, 1989, INT J CANCER, V43, P478, DOI 10.1002/ijc.2910430323; MACIEWICZ RA, 1990, FEBS LETT, V269, P189, DOI 10.1016/0014-5793(90)81151-D; MITCHEL REJ, 1970, J BIOL CHEM, V245, P3485; MURNANE MJ, 1991, CANCER RES, V51, P1137; PONTREMOLI S, 1982, ARCH BIOCHEM BIOPHYS, V214, P376, DOI 10.1016/0003-9861(82)90042-X; PORTNOY DA, 1986, J BIOL CHEM, V261, P4697; QIAN F, 1989, CANCER RES, V49, P4870; QIAN F, 1990, INT J BIOCHEM, V22, P1457, DOI 10.1016/0020-711X(90)90237-W; RITONJA A, 1991, FEBS LETT, V283, P329, DOI 10.1016/0014-5793(91)80620-I; ROUGHLEY PJ, 1977, BIOCHEM J, V167, P629, DOI 10.1042/bj1670629; SAKANARI JA, 1989, P NATL ACAD SCI USA, V86, P4863, DOI 10.1073/pnas.86.13.4863; Sambrook J, 1989, MOL CLONING LABORATO; SEGUNDO BS, 1985, P NATL ACAD SCI USA, V82, P2320, DOI 10.1073/pnas.82.8.2320; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SHI GP, 1992, J BIOL CHEM, V267, P7258; Steiner D. F., 1991, PEPTIDE BIOSYNTHESIS, P1; TAKIO K, 1983, P NATL ACAD SCI-BIOL, V80, P3666, DOI 10.1073/pnas.80.12.3666; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; TRYGGVASON K, 1987, BIOCHIM BIOPHYS ACTA, V907, P191, DOI 10.1016/0304-419X(87)90006-0; UCHIYAMA Y, 1989, J HISTOCHEM CYTOCHEM, V37, P691, DOI 10.1177/37.5.2703704; [No title captured]	44	85	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					26038	26043						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1281481				2022-12-27	WOS:A1992KD07300068
J	TAIPALE, J; KOLI, K; KESKIOJA, J				TAIPALE, J; KOLI, K; KESKIOJA, J			RELEASE OF TRANSFORMING GROWTH FACTOR-BETA-1 FROM THE PERICELLULAR MATRIX OF CULTURED FIBROBLASTS AND FIBROSARCOMA CELLS BY PLASMIN AND THROMBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT COMPLEX; SMOOTH-MUSCLE CELLS; FACTOR-BETA; ACTIVATOR INHIBITOR; ENDOTHELIAL-CELLS; CARCINOMA-CELLS; HUMAN-PLATELETS; TGF-BETA; TGF-BETA-1; EXPRESSION	A sensitive immunoblotting assay was developed for the detection of transforming growth factor (TGF)-beta1 from cell extracts and culture medium. HT-1080 human fibrosarcoma cells and human fibroblasts were used as models for the secretion and proteolytic release of pericellular matrix-associated TGF-beta1. Analysis of the pericellular matrices of the cells indicated that the majority of cell-layer associated TGF-beta1 was associated with the pericellular matrix. Treatment of the cells with plasmin or thrombin released the matrix-associated TGF-beta1 to the culture medium. Assays for the biological activity of plasmin-released TGF-beta1 by Mv1Lu cell growth inhibition assays indicated that the majority was in the latent form. Northern hybridization analyses indicated that the mRNA levels of TGF-beta1 were not elevated during the proteinase treatment. Experiments using radiolabeled TGF-beta1 indicated that exogenous active TGF-beta1 associates mainly with the presumed TGF-beta1 receptors that were not retained in the extracellular matrix preparations. These results indicate that a major fraction of latent TGF-beta1 that is produced by the cells is deposited to and remains associated with the pericellular matrices of cultured fibroblasts and fibrosarcoma cells, and that matrix-associated TGF-beta1 is very susceptible to release by various proteolytic enzymes.	UNIV HELSINKI, DEPT VIROL, HAARTMANINKATU 3, SF-00290 HELSINKI 29, FINLAND; UNIV HELSINKI, DEPT DERMATOL & VENEREOL, SF-00290 HELSINKI 29, FINLAND	University of Helsinki; University of Helsinki								ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; ANTONELLIORLIDGE A, 1989, P NATL ACAD SCI USA, V86, P4544, DOI 10.1073/pnas.86.12.4544; BASCOM CC, 1989, MOL CELL BIOL, V9, P5508, DOI 10.1128/MCB.9.12.5508; Brownh PD, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037500; DANIELPOUR D, 1989, J CELL PHYSIOL, V138, P79, DOI 10.1002/jcp.1041380112; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; FAVA RA, 1987, J CELL PHYSIOL, V131, P184, DOI 10.1002/jcp.1041310207; HEDMAN K, 1979, J CELL BIOL, V81, P83, DOI 10.1083/jcb.81.1.83; HEINE UI, 1990, DEVELOPMENT, V109, P29; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; KESKIOJA J, 1988, J BIOL CHEM, V263, P3111; KESKIOJA J, 1987, CANCER RES, V47, P6451; KESKIOJA J, 1991, SEMIN THROMB HEMOST, V17, P231, DOI 10.1055/s-2007-1002614; KESKIOJA J, 1988, J CELL BIOL, V106, P451, DOI 10.1083/jcb.106.2.451; LAIHO M, 1987, J BIOL CHEM, V262, P17467; LAIHO M, 1992, Critical Reviews in Oncogenesis, V3, P1; LAWRENCE D, 1985, BIOCHEM BIOPH RES CO, V133, P1026, DOI 10.1016/0006-291X(85)91239-2; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; Maniatis T., 1982, MOL CLONING; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MIYAZONO K, 1989, NATURE, V338, P158, DOI 10.1038/338158a0; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; PARALKAR VM, 1991, DEV BIOL, V143, P303, DOI 10.1016/0012-1606(91)90081-D; PELTON RW, 1991, J CELL BIOL, V115, P1091, DOI 10.1083/jcb.115.4.1091; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SPORN MB, 1990, CELL REGUL, V1, P875, DOI 10.1091/mbc.1.12.875; TAIPALE J, 1992, FIBRINOLYSIS S2, V6, P25; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; WAKEFIELD LM, 1988, J BIOL CHEM, V263, P7646; Yamada KM, 1989, FIBRONECTIN, P47; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	40	191	192	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25378	25384						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1281156				2022-12-27	WOS:A1992KB60300071
J	CHIESA, G; HOBBS, HH; KOSCHINSKY, ML; LAWN, RM; MAIKA, SD; HAMMER, RE				CHIESA, G; HOBBS, HH; KOSCHINSKY, ML; LAWN, RM; MAIKA, SD; HAMMER, RE			RECONSTITUTION OF LIPOPROTEIN(A) BY INFUSION OF HUMAN LOW-DENSITY-LIPOPROTEIN INTO TRANSGENIC MICE EXPRESSING HUMAN APOLIPOPROTEIN(A)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA; LP(A) LIPOPROTEIN; BINDING; SEQUENCE; PROMOTER; GENE; OVEREXPRESSION; HETEROGENEITY; RECEPTORS; PROTEIN	Lipoprotein(a) (Lp(a)) is an atherosclerosis-causing lipoprotein that circulates in human plasma as a complex of low density lipoprotein (LDL) and apolipoprotein(a) (apo(a)). It is not known whether apo(a) attaches to LDL within hepatocytes prior to secretion or in plasma subsequent to secretion. Here we describe the development of a line of mice expressing the human apo(a) transgene under the control of the murine transferrin promoter. The apo(a) was secreted into the plasma, but circulated free of lipoproteins. When human (h)-LDL was injected intravenously, the circulating apo(a) rapidly associated with the lipoproteins, as determined by nondenaturing gel electrophoresis. Human HDL and mouse LDL had no such effect. When h-VLDL was injected, there was a delayed association of apo(a) with the lipoprotein fraction which suggests that apo(a) preferentially associated with a metabolic product of VLDL. The complex of apo(a) with LDL formed both in vivo and in vitro was resistant to boiling in the presence of detergents and denaturants, but was resolved upon disulfide reduction. These studies suggest that apo(a) fails to associate with mouse lipoproteins due to structural differences between human and mouse LDL, and that Lp(a) formation can occur in plasma through the association of apo(a) with circulating LDL.	UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DEPT BIOCHEM, DALLAS, TX 75235 USA; QUEENS UNIV, DEPT BIOCHEM, KINGSTON K7L 3N6, ONTARIO, CANADA; STANFORD UNIV, DEPT INTERNAL MED, STANFORD, CA 94305 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Queens University - Canada; Stanford University			Chiesa, Giulia/G-8987-2012	Chiesa, Giulia/0000-0001-5553-1210; Hammer, Robert E./0000-0001-5487-7551; Koschinsky, Marlys/0000-0002-2643-2288	NHLBI NIH HHS [HL-20948, HL-47619] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, R01HL047619] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FLESS GM, 1984, J BIOL CHEM, V259, P1470; FLESS GM, 1985, J LIPID RES, V26, P1224; GAUBATZ JW, 1983, J BIOL CHEM, V258, P4582; GUO HC, 1991, ARTERIOSCLER THROMB, V11, P1030, DOI 10.1161/01.ATV.11.4.1030; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; HARPEL PC, 1989, P NATL ACAD SCI USA, V86, P3847, DOI 10.1073/pnas.86.10.3847; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOFMANN SL, 1990, J CLIN INVEST, V85, P1542, DOI 10.1172/JCI114602; IDZERDA RL, 1989, MOL CELL BIOL, V9, P5154, DOI 10.1128/MCB.9.11.5154; KANE JP, 1975, J CLIN INVEST, V56, P1622, DOI 10.1172/JCI108245; KOSCHINSKY ML, 1991, BIOCHEMISTRY-US, V30, P5044, DOI 10.1021/bi00234a029; KREMPLER F, 1979, BIOCHIM BIOPHYS ACTA, V575, P63, DOI 10.1016/0005-2760(79)90131-0; LACKNER C, 1991, J CLIN INVEST, V87, P2153, DOI 10.1172/JCI115248; LAPLAUD PM, 1988, J LIPID RES, V29, P1157; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAKINO K, 1989, ATHEROSCLEROSIS, V78, P81, DOI 10.1016/0021-9150(89)90161-5; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MENZEL HJ, 1990, J BIOL CHEM, V265, P981; NAKANE PK, 1974, J HISTOCHEM CYTOCHEM, V22, P1084, DOI 10.1177/22.12.1084; PALMITER RD, 1991, P NATL ACAD SCI USA, V88, P478, DOI 10.1073/pnas.88.2.478; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; PFAFFINGER D, 1991, J LIPID RES, V32, P679; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; SCANU AM, 1972, ANNU REV BIOCHEM, V41, P703, DOI 10.1146/annurev.bi.41.070172.003415; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SHENG J, 1990, METABOLISM, V39, P155, DOI 10.1016/0026-0495(90)90069-O; SIMONET WS, 1990, J BIOL CHEM, V265, P10809; SMITH TJ, 1990, GENE, V87, P309, DOI 10.1016/0378-1119(90)90319-M; SOMMER A, 1991, BIOCHEMISTRY-US, V30, P11245, DOI 10.1021/bi00111a008; THOMSEN DR, 1984, P NATL ACAD SCI-BIOL, V81, P659, DOI 10.1073/pnas.81.3.659; TOMLINSON JE, 1989, J BIOL CHEM, V264, P5957; TRIEU VN, 1990, BIOCHEMISTRY-US, V29, P5919, DOI 10.1021/bi00477a006; UTERMANN G, 1983, FEBS LETT, V154, P357, DOI 10.1016/0014-5793(83)80182-3; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; WEISGRABER KH, 1991, J BIOL CHEM, V266, P12029; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210	39	168	175	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24369	24374						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1280258				2022-12-27	WOS:A1992KA26300037
J	ELMAGHRABI, MR; AUSTIN, LR; CORREIA, JJ; PILKIS, SJ				ELMAGHRABI, MR; AUSTIN, LR; CORREIA, JJ; PILKIS, SJ			LYSINE-274 IS ESSENTIAL FOR FRUCTOSE 2,6-BISPHOSPHATE INHIBITION OF FRUCTOSE-1,6-BISPHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER FRUCTOSE-1,6-BISPHOSPHATASE; AMINO-ACID-SEQUENCE; ACTIVE-SITE; 1,6-BISPHOSPHATASE; PHOSPHOFRUCTOKINASE; MUTAGENESIS; CDNA; AMP	Lysine 274 is conserved in all known fructose-1,6-bisphosphatase sequences. It has been implicated in substrate binding and/or catalysis on the basis of reactivity with pyridoxal phosphate as well as by x-ray crystallographic analysis. Lys274 of rat liver fructose-1,6-bisphosphatase was mutated to alanine by the polymerase chain reaction, and the T7-RNA polymerase-transcribed construct containing the mutant sequence was expressed in Escherichia coli. The mutant and wild-type forms of the enzyme were purified to homogeneity, and their specific activity, substrate dependence, and inhibition by fructose 2,6-bisphosphate and AMP were compared. While the mutant exhibited no change in maximal velocity, its K(m) for fructose 1,6-bisphosphate was 20-fold higher than that of the wild-type, and its K(i) for fructose 2,6-bisphosphate was increased 1000-fold. Consistent with the unaltered maximal velocity, there were no apparent difference between the secondary structure of the wild-type and mutant enzyme forms, as measured by circular dichroism and ultraviolet difference spectroscopy. The K(i) for the allosteric inhibitor AMP was only slightly increased, indicating that Lys274 is not directly involved in AMP inhibition. Fructose 2,6-bisphosphate potentiated AMP inhibition of both forms, but 500-fold higher concentrations of fructose 2,6-bisphosphate were needed to reduce the K(i) for AMP for the mutant compared to the wild-type. However, potentiation of AMP inhibition of the Lys274 --> Ala mutant was evident at fructose 2,6-bisphosphate concentrations (approximately 100-mu-M) well below those that inhibited the enzyme, which suggests that fructose 2,6-bisphosphate interacts either with the AMP site directly or with other residues involved in the active site-AMP synergy. The results also demonstrate that although Lys274 is an important binding site determinant for sugar bisphosphates, it plays a more significant role in binding fructose 2,6-bisphosphate than fructose 1,6-bisphosphate, probably because it binds the 2-phospho group of the former while other residues bind the 1-phospho group of the substrate. It is concluded that the enzyme utilizes Lys274 to discriminate between its substrate and fructose 2,6-bisphosphate.	UNIV MISSISSIPPI,MED CTR,DEPT BIOCHEM,JACKSON,MS 39216	University of Mississippi; University of Mississippi Medical Center	ELMAGHRABI, MR (corresponding author), SUNY STONY BROOK,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038354, R37DK038354] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041117] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 38354] Funding Source: Medline; NIGMS NIH HHS [GM 41117] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COLOMBO G, 1974, BIOCHEMISTRY-US, V13, P3085, DOI 10.1021/bi00712a014; ELMAGHRABI MR, 1988, P NATL ACAD SCI USA, V85, P8430, DOI 10.1073/pnas.85.22.8430; ELMAGHRABI MR, 1991, J BIOL CHEM, V266, P2115; ELMAGHRABI MR, 1991, BIOCHEM BIOPH RES CO, V176, P137, DOI 10.1016/0006-291X(91)90900-R; GANSON NJ, 1985, J BIOL CHEM, V260, P2837; GIBSON JL, 1990, BIOCHEMISTRY-US, V29, P8085, DOI 10.1021/bi00487a014; HORECKER BL, 1975, ADV ENZYMOL RAMB, V42, P193; KE H, 1989, J MOL BIOL, V212, P513; KEMP RG, 1990, FRUCTOSE 2 6 BISPHOS, P17; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU F, 1989, BIOCHEM BIOPH RES CO, V161, P689, DOI 10.1016/0006-291X(89)92654-5; LIU F, 1990, FRUCTOSE 2 6 BISPHOS, P39; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCUS F, 1981, REGULATION CARBOHYDR, P269; MCGRANE MM, 1983, J BIOL CHEM, V258, P445; MEEK DW, 1984, BIOCHEM J, V222, P131, DOI 10.1042/bj2220131; PILKIS SJ, 1981, J BIOL CHEM, V256, P3619; PONTREMO.S, 1966, BIOCHEMISTRY-US, V5, P3072, DOI 10.1021/bi00873a042; POORMAN RA, 1984, NATURE, V309, P467, DOI 10.1038/309467a0; PURICH DL, 1973, ADV ENZYMOL, V35, P249; RITTENHOUSE J, 1983, J BIOL CHEM, V258, P7648; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHWAB DA, 1988, J BIOL CHEM, V263, P3220; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; SUDA H, 1982, ARCH BIOCHEM BIOPHYS, V217, P10, DOI 10.1016/0003-9861(82)90473-8; VANSCHAFTINGEN E, 1981, P NATL ACAD SCI-BIOL, V78, P2861; XU GJ, 1981, ARCH BIOCHEM BIOPHYS, V210, P98, DOI 10.1016/0003-9861(81)90168-5	27	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6526	6530						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1313010				2022-12-27	WOS:A1992HM05300015
J	LIN, K; LI, L; CORREIA, JJ; PILKIS, SJ				LIN, K; LI, L; CORREIA, JJ; PILKIS, SJ			GLU(327) IS PART OF A CATALYTIC TRIAD IN RAT-LIVER FRUCTOSE-2,6-BISPHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE 2,6-BISPHOSPHATASE; AMINO-ACID-SEQUENCE; HEPATIC FRUCTOSE-2,6-BISPHOSPHATASE; PHOSPHOGLYCERATE MUTASE; ESCHERICHIA-COLI; MESSENGER-RNA; CDNA CLONE; SITE; EXPRESSION; 6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE	The fructose-2,6-bisphosphatase domain of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase has been shown to be structurally and functionally homologous to phosphoglycerate mutase. Both enzymes catalyze their reactions via phosphoenzyme intermediates which utilize an active site histidine as a nucleophilic phosphoacceptor and another histidine as a proton donor to the leaving group. Glu327 in the bisphosphatase domain of the rat liver bifunctional enzyme is conserved in all phosphoglycerate mutase structures and is postulated, by modelling studies, to be located in the active site. Glu327 was mutated to Ala, Gln, or Asp. The mutant and wild-type enzymes were expressed in Escherichia coli with a T-7 RNA polymerase-based expression system and purified to homogeneity by substrate elution from phosphocellulose. The Glu327 mutants had apparent molecular weights of 110,000 by gel filtration and had unaltered 6-phosphofructo-2-kinase activity. Circular dichroism showed that the secondary structure of the Glu327 mutant enzyme forms was the same as the wild-type enzyme. The maximal velocity of the fructose-2,6-bisphosphatase of the Glu327 --> Ala, Glu327 --> Gln, and Glu327 --> Asp mutants was 4, 2, and 20%, respectively, that of the wild-type enzyme, but the rate of phosphoenzyme formation of the mutants was reduced by at least a factor of 1000. In addition, the rate constants of phosphoenzyme hydrolysis for the Glu372 --> Ala and Glu327 --> Gln mutants were 2.7 and 1.3%, respectively, of the wild type, whereas the rate constant for the Glu327 --> Asp mutant was 60% of the wild-type value. Glu327 was not a substrate or product binding site determinant since the K(m) for fructose-2-6-bisphosphate and K(i) for fructose-6-phosphate of the mutants were not appreciably changed. The results implicate Glu327 as part of a catalytic triad in fructose-2,6-bisphosphatase and suggest that it influences the protonation state of the active site histidine residues during phosphoenzyme formation and/or acts as a base catalyst to enhance the nucleophilic attack of water on the phosphoenzyme intermediate.	UNIV MISSISSIPPI,MED CTR,DEPT BIOCHEM,JACKSON,MS 39216	University of Mississippi; University of Mississippi Medical Center	LIN, K (corresponding author), SUNY STONY BROOK,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794, USA.				NIDDK NIH HHS [DK38354] Funding Source: Medline; NIGMS NIH HHS [GM41117] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK038354, R01DK038354] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041117] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAZAN JF, 1989, P NATL ACAD SCI USA, V86, P9642, DOI 10.1073/pnas.86.24.9642; COLOSIA AD, 1988, J BIOL CHEM, V263, P18669; COLOSIA AD, 1987, BIOCHEM BIOPH RES CO, V143, P1092, DOI 10.1016/0006-291X(87)90364-0; CREPIN KM, 1989, BIOCHEM J, V264, P151, DOI 10.1042/bj2640151; CREPIN KM, 1989, EUR J BIOCHEM, V183, P433, DOI 10.1111/j.1432-1033.1989.tb14946.x; DARVILLE MI, 1987, FEBS LETT, V224, P317, DOI 10.1016/0014-5793(87)80476-3; DARVILLE MI, 1991, FEBS LETT, V288, P91, DOI 10.1016/0014-5793(91)81009-W; ELMAGHRABI MR, 1986, P NATL ACAD SCI USA, V83, P5005, DOI 10.1073/pnas.83.14.5005; ELMAGHRABI MR, 1984, J BIOL CHEM, V259, P3096; KITAJIMA S, 1984, J BIOL CHEM, V259, P6896; KOUNTZ PD, 1985, ARCH BIOCHEM BIOPHYS, V238, P531, DOI 10.1016/0003-9861(85)90197-3; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; KRETSCHMER M, 1991, BIOCHEMISTRY-US, V30, P10663, DOI 10.1021/bi00108a009; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANGE AJ, 1991, ARCH BIOCHEM BIOPHYS, V290, P258, DOI 10.1016/0003-9861(91)90617-R; LANGE AJ, 1989, BIOCHEM BIOPH RES CO, V162, P753, DOI 10.1016/0006-291X(89)92374-7; LI L, 1992, J BIOL CHEM, V267, P4386; Lin K, 1990, Protein Expr Purif, V1, P169, DOI 10.1016/1046-5928(90)90012-N; LIVELY MO, 1988, J BIOL CHEM, V263, P839; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAINATIS T, 1982, MOL CLONING LABORATO; MURRAY KJ, 1984, J BIOL CHEM, V259, P7673; PILKIS SJ, 1983, J BIOL CHEM, V258, P6135; PILKIS SJ, 1984, J BIOL CHEM, V259, P949; PILKIS SJ, 1982, MOL CELL ENDOCRINOL, V25, P245, DOI 10.1016/0303-7207(82)90082-X; PILKIS SJ, 1991, ANNU REV NUTR, V11, P465, DOI 10.1146/annurev.nu.11.070191.002341; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; PILKIS SJ, 1990, DIABETES CARE, V13, P582, DOI 10.2337/diacare.13.6.582; PILKIS SJ, 1987, J BIOL CHEM, V262, P12672; PILKIS SJ, 1990, FRUCTOSE 2 6 BISPHOS; SAKATA J, 1990, P NATL ACAD SCI USA, V87, P4951, DOI 10.1073/pnas.87.13.4951; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEWART HB, 1985, J BIOL CHEM, V260, P2935; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAULER A, 1989, P NATL ACAD SCI USA, V86, P7316, DOI 10.1073/pnas.86.19.7316; TAULER A, 1990, J BIOL CHEM, V265, P15617; WINN SI, 1981, PHILOS T ROY SOC B, V293, P121, DOI 10.1098/rstb.1981.0066	39	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6556	6562						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1313012				2022-12-27	WOS:A1992HM05300019
J	WATKINS, JD; KENT, C				WATKINS, JD; KENT, C			IMMUNOLOCALIZATION OF MEMBRANE-ASSOCIATED CTP - PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE IN PHOSPHATIDYLCHOLINE-DEFICIENT CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTALLOID ENDOPLASMIC-RETICULUM; PHOSPHOLIPASE-C TREATMENT; RAT-LIVER; MAMMALIAN-CELLS; PHOSPHORYLCHOLINE CYTIDYLYLTRANSFERASE; ENZYME TRANSLOCATION; BIOSYNTHESIS; PHOSPHORYLATION; STIMULATION; FIBROBLASTS	The location of CTP:phosphocholine cytidylyltransferase in Chinese hamster ovary (CHO) cells made deficient in phosphatidylcholine was determined by immunofluorescence techniques. A rabbit polyclonal antibody was raised against a synthetic peptide corresponding to the amino-terminal 17 amino acid residues of rat liver cytidylyltransferase. The antibody recognized both native and denatured cytidylyltransferase from both rat liver and CHO cells. CHO cells were treated with phospholipase C to alter the lipid composition of the plasma membrane and to elicit translocation of cytidylyltransferase from the less active soluble pool to an activated membrane fraction. Visualization of cytidylyltransferase by indirect immunofluorescence revealed staining of the nuclear envelope in phospholipase C-treated cells but not in untreated cells. CHO cells were also starved for choline and supplemented with a choline analogue to provide an alternative technique of rendering the cells phosphatidylcholine-deficient. Although this treatment should affect different cellular membranes than those affected by phospholipase C treatment, cytidylyltransferase still translocated to the nuclear envelope, as shown by indirect immunofluorescence. These results indicate that activated, membrane-bound cytidylyltransferase is associated with the nuclear membrane and suggest that the nuclear membrane may be a site of de novo phosphatidylcholine synthesis.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD010580] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 10580] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CHIN DJ, 1982, P NATL ACAD SCI-BIOL, V79, P1185, DOI 10.1073/pnas.79.4.1185; CORNELL R, 1989, J BIOL CHEM, V264, P9077; CORNELL R, 1989, PHOSPHATIDYLCHOLINE, P47; DAWSON DB, 1987, BIOCHIM BIOPHYS ACTA, V923, P389; EXTON JH, 1990, J BIOL CHEM, V265, P1; FELDMAN DA, 1987, J BIOL CHEM, V262, P9075; FISKUM G, 1980, P NATL ACAD SCI-BIOL, V77, P3430, DOI 10.1073/pnas.77.6.3430; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; HENRY SM, 1983, J CELL BIOL, V97, P166, DOI 10.1083/jcb.97.1.166; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; KOLESNICK RN, 1987, J BIOL CHEM, V262, P14525; KRUG EL, 1984, ARCH BIOCHEM BIOPHYS, V231, P400, DOI 10.1016/0003-9861(84)90403-X; KRUG EL, 1979, ANAL BIOCHEM, V97, P43, DOI 10.1016/0003-2697(79)90324-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACKALL J, 1979, ANAL BIOCHEM, V95, P270, DOI 10.1016/0003-2697(79)90216-1; MORAND JN, 1989, J BIOL CHEM, V264, P13785; MORRE DJ, 1970, PLANT PHYSIOL, V45, P800, DOI 10.1104/pp.45.6.800; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; PATHAK RK, 1986, J CELL BIOL, V102, P2158, DOI 10.1083/jcb.102.6.2158; PELECH SL, 1982, J BIOL CHEM, V257, P4198; SCHROEDER F, 1976, J BIOL CHEM, V251, P5015; SLEIGHT R, 1980, J BIOL CHEM, V255, P644; SLEIGHT R, 1983, J BIOL CHEM, V258, P831; SLEIGHT R, 1983, J BIOL CHEM, V258, P836; SLEIGHT R, 1983, J BIOL CHEM, V258, P824; TERCE F, 1988, J BIOL CHEM, V263, P3142; VANCE DE, 1984, TRENDS BIOCHEM SCI, V9, P17, DOI 10.1016/0968-0004(84)90041-0; VANCE JE, 1988, J BIOL CHEM, V263, P5898; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WATKINS JD, 1990, J BIOL CHEM, V265, P2190; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; WILGRAM GF, 1963, J BIOL CHEM, V238, P2615; WILLINGHAM MC, 1985, ATLAS IMMUNOFLUROESC; WRIGHT PS, 1985, J BIOL CHEM, V260, P7919	36	78	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5686	5692						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1312094				2022-12-27	WOS:A1992HH74700103
J	GUERRA, M; STEINBERG, M; DUNHAM, PB				GUERRA, M; STEINBERG, M; DUNHAM, PB			ORTHOPHOSPHATE-PROMOTED OUABAIN BINDING TO NA/K PUMPS OF RESEALED RED-CELL GHOSTS - EVIDENCE FOR E-STAR-P PREFERENTIALLY BINDING OUABAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+)-DEPENDENT ADENOSINE-TRIPHOSPHATASE; INORGANIC-PHOSPHATE; BLOOD-CELLS; SODIUM-PUMP; K PUMP; NA,K-ATPASE PROTEOLIPOSOMES; HUMAN-ERYTHROCYTES; POTASSIUM; NA+; TRANSPORT	Modulation of phosphoenzyme forms of the Na/K pump by Na+ and K+ was studied by measuring the rate of P(i)-promoted ouabain binding to resealed ghosts made from human red cells. This system permits distinguishing the effects of the ions at intracellular and external binding sites. Internal K+, K(i), inhibited the rate of P(i)-promoted ouabain binding, contrary to a prediction based on a current model of the pump. External K+, K(o), failed to inhibit ouabain binding in the absence of K(i). However, K(o) enhanced the inhibition by K(i). Na(i) also inhibited ouabain binding; this inhibition was much less affected by K(o) than was inhibition by K(i), suggesting that K(i) and Na(i) affect ouabain binding at different internal sites. Na(o) inhibited ouabain binding in the absence of K(i) or K(o), so Na(o) and K(o) also act at different sites. With Na(o) present, K(i) stimulated ouabain binding. Thus a condition was found in which the predicted stimulation of binding by K(i) was observed. The results of this study are interpreted in terms of three phosphoenzyme forms of the pump: E1P, E*P, and E2P. E*P is the form binding ouabain with highest affinity. K(i) promotes E*P --> E2P, thereby inhibiting ouabain binding. K(o) binds only to E2P, therefore K(i) is required for inhibition by K(o), and there is little E2P present with no K(i). Na(o) inhibits binding by stabilizing E1P whereas Na(i) inhibits by stabilizing E1. The stimulation by K(i) with Na(o) present means that K(i) and Na(o) together favor formation of E*P. Furthermore, K(i) and Na(o) may bind to the pump simultaneously. K(i) may play a role in the normal pump cycle, binding at allosteric sites to promote E*P --> E2P.	SYRACUSE UNIV, DEPT BIOL, 130 COLL PL, SYRACUSE, NY 13244 USA; SUNY HLTH SCI CTR, DEPT PHARMACOL, SYRACUSE, NY 13210 USA	Syracuse University; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033640, R37DK033640] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 33640] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERS RW, 1968, MOL PHARMACOL, V4, P324; ALBERS RW, 1967, ANNU REV BIOCHEM, V36, P727, DOI 10.1146/annurev.bi.36.070167.003455; ASKARI A, 1984, J BIOL CHEM, V259, P4169; ASKARI A, 1983, J BIOL CHEM, V258, P3453; BODEMANN HH, 1976, J GEN PHYSIOL, V67, P497, DOI 10.1085/jgp.67.5.497; BODEMANN HH, 1976, J GEN PHYSIOL, V67, P527, DOI 10.1085/jgp.67.5.527; BRAUER M, 1985, J BIOL CHEM, V260, P1643; CABANTCHIK ZI, 1972, J MEMBRANE BIOL, V10, P311, DOI 10.1007/BF01867863; DODGE JT, 1963, ARCH BIOCHEM BIOPHYS, V100, P119, DOI 10.1016/0003-9861(63)90042-0; ERDMANN E, 1973, BIOCHIM BIOPHYS ACTA, V330, P302, DOI 10.1016/0005-2736(73)90235-6; FORBUSH B, 1983, CURR TOP MEMBR TRANS, V19, P167; GARAY RP, 1973, J PHYSIOL-LONDON, V231, P297, DOI 10.1113/jphysiol.1973.sp010234; GARRAHAN PJ, 1967, J PHYSIOL-LONDON, V192, P159, DOI 10.1113/jphysiol.1967.sp008294; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GLYNN IM, 1957, J PHYSIOL-LONDON, V136, P148, DOI 10.1113/jphysiol.1957.sp005749; GLYNN IM, 1970, J PHYSIOL-LONDON, V207, P371, DOI 10.1113/jphysiol.1970.sp009067; HANSEN O, 1973, BIOCHIM BIOPHYS ACTA, V311, P51, DOI 10.1016/0005-2736(73)90254-X; HOBBS AS, 1978, J GEN PHYSIOL, V72, P381, DOI 10.1085/jgp.72.3.381; HOFFMAN JF, 1962, J GEN PHYSIOL, V45, P837, DOI 10.1085/jgp.45.5.837; HOFFMAN JF, 1958, J GEN PHYSIOL, V42, P9, DOI 10.1085/jgp.42.1.9; JOINER CH, 1978, J PHYSIOL-LONDON, V283, P155, DOI 10.1113/jphysiol.1978.sp012494; JOINER CH, 1978, J PHYSIOL-LONDON, V283, P177, DOI 10.1113/jphysiol.1978.sp012495; JORGENSEN PL, 1988, ION PUMPS STRUCTURE, P25; KAPLAN JH, 1982, J GEN PHYSIOL, V80, P915, DOI 10.1085/jgp.80.6.915; KARLISH SJD, 1985, J PHYSIOL-LONDON, V359, P119, DOI 10.1113/jphysiol.1985.sp015578; LEE JA, 1985, SODIUM PUMP, P277; LEPKE S, 1976, J MEMBRANE BIOL, V29, P147, DOI 10.1007/BF01868957; MATSUI H, 1968, BIOCHIM BIOPHYS ACTA, V151, P655, DOI 10.1016/0005-2744(68)90013-2; MERCER RW, 1981, J GEN PHYSIOL, V78, P547, DOI 10.1085/jgp.78.5.547; NORBY JG, 1983, J GEN PHYSIOL, V82, P725, DOI 10.1085/jgp.82.6.725; NORBY JG, 1988, NA PLUS K PLUS PUM A, P249; POST RL, 1975, J BIOL CHEM, V250, P691; POST RL, 1969, J GEN PHYSIOL, V54, pS306, DOI 10.1085/jgp.54.1.306; PRATAP PR, 1991, BIOCHIM BIOPHYS ACTA, V1069, P288, DOI 10.1016/0005-2736(91)90137-W; PROVERBIO F, 1988, NA K PUMP B, P561; ROBINSON JD, 1988, NA PLUS K PLUS PUM A, P341; SACHS JR, 1981, J PHYSIOL-LONDON, V319, P515, DOI 10.1113/jphysiol.1981.sp013923; SACHS JR, 1974, J GEN PHYSIOL, V63, P389, DOI 10.1085/jgp.63.4.389; SACHS JR, 1988, J GEN PHYSIOL, V92, P685, DOI 10.1085/jgp.92.5.685; SEN AK, 1969, J BIOL CHEM, V244, P6596; STEINBERG M, 1989, J BIOL CHEM, V264, P2726; TANIGUCHI K, 1986, J BIOL CHEM, V261, P3272; WOOD PG, 1984, EUR J BIOCHEM, V141, P91, DOI 10.1111/j.1432-1033.1984.tb08161.x; YODA A, 1988, J BIOL CHEM, V263, P10320; YODA S, 1986, J BIOL CHEM, V261, P1147; YODA S, 1987, J BIOL CHEM, V262, P103	47	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1596	1602						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1309788				2022-12-27	WOS:A1992HA48500033
J	COFFEY, M; PETERSGOLDEN, M; FANTONE, JC; SPORN, PHS				COFFEY, M; PETERSGOLDEN, M; FANTONE, JC; SPORN, PHS			MEMBRANE ASSOCIATION OF ACTIVE 5-LIPOXYGENASE IN RESTING CELLS - EVIDENCE FOR NOVEL REGULATION OF THE ENZYME IN THE RAT ALVEOLAR MACROPHAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONATE METABOLISM; PERITONEAL-MACROPHAGES; HUMAN-LEUKOCYTES; MONOCYTES; PROTEIN; BIOSYNTHESIS; LUNG; DIFFERENTIATION; LEUKOTRIENE-B4; LIPOXYGENASE	The enzyme 5-lipoxygenase (5-LO) catalyzes the first two steps in the metabolism of arachidonic acid to leukotrienes, substances which play pivotal roles both in normal host defense and in pathologic states of inflammation. Recent studies in granulocytic cells have shown that activation of 5-LO involves its Ca2+-dependent translocation from cytosol to membrane compartments. However, little information exists about the molecular regulation of 5-LO in macrophages, even though these cells comprise the resident effector cell population of most organs. We therefore examined the levels of 5-LO activity and immunoreactive protein in cytosol and membrane fractions of resident rat alveolar (AM) and peritoneal macrophages (PM) and compared them with the well studied human neutrophil (polymorphonuclear leukocyte). In the resting state, PM resembled polymorphonuclear leukocyte in that most of their cell-free 5-LO activity, as well as protein content, were localized to the cytosol fraction. By contrast, resting AM contained most of their activity and almost half of their immunoreactive protein in the crude membrane fraction. The inability of the drug MK-886 to reverse this membrane association suggested that the 5-LO-activating protein was not the site of binding in the resting cell; however, this drug completely inhibited leukotriene B, synthesis in ionophore A23187-stimulated AM, indicating that an interaction between 5-LO and 5-LO-activating protein was nonetheless required for product synthesis upon stimulation. Translocation of cytosolic 5-LO protein could not be convincingly demonstrated in A23187-stimulated AM, suggesting that the pool of 5-LO enzyme responsible for product formation originated in the membrane rather than the cytosol fraction of the resting cell. The AM therefore represents the first mammalian cell in which 5-LO has been recovered from the membrane fraction (a) of a resting cell and (b) in active form. These novel findings extend our understanding of the molecular regulation of 5-LO and may be Of importance in designing strategies to limit inflammation in the lung and other sites.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; VET AFFAIRS MED CTR,MED SERV,ANN ARBOR,MI 48105	University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA)	COFFEY, M (corresponding author), UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48109, USA.			Sporn, Peter/0000-0002-1006-9437	NHLBI NIH HHS [HL-01638, HL-02407] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALTER MS, 1989, J IMMUNOL, V142, P602; BIGBY TD, 1987, J IMMUNOL, V138, P1546; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; DOIG MV, 1980, PROSTAGLANDINS, V20, P1007, DOI 10.1016/0090-6980(80)90055-6; FELS AOS, 1982, P NATL ACAD SCI-BIOL, V79, P7866, DOI 10.1073/pnas.79.24.7866; GILLARD J, 1989, CAN J PHYSIOL PHARM, V67, P456, DOI 10.1139/y89-073; HOFFMAN T, 1991, J IMMUNOL, V146, P692; HOLTZMAN MJ, 1991, AM REV RESPIR DIS, V143, P188, DOI 10.1164/ajrccm/143.1.188; JOHNSTON RB, 1988, NEW ENGL J MED, V318, P747, DOI 10.1056/NEJM198803243181205; KARGMAN S, 1989, J BIOL CHEM, V264, P13313; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; MENARD L, 1990, BRIT J PHARMACOL, V100, P15, DOI 10.1111/j.1476-5381.1990.tb12044.x; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; PETERSGOLDEN M, 1990, J IMMUNOL, V144, P263; PETERSGOLDEN M, 1990, J IMMUNOL, V144, P4320; PETERSGOLDEN M, 1991, AM J PHYSIOL, V261, pL462, DOI 10.1152/ajplung.1991.261.6.L462; PUUSTINEN T, 1988, BIOCHIM BIOPHYS ACTA, V960, P261, DOI 10.1016/0005-2760(88)90033-1; REDDANNA P, 1988, BIOCHEM BIOPH RES CO, V157, P1348, DOI 10.1016/S0006-291X(88)81023-4; ROUZER CA, 1985, P NATL ACAD SCI USA, V82, P6040, DOI 10.1073/pnas.82.18.6040; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; ROUZER CA, 1990, J BIOL CHEM, V265, P1436; ROUZER CA, 1980, P NATL ACAD SCI-BIOL, V77, P4928, DOI 10.1073/pnas.77.8.4928; SAMUELSSON B, 1989, J BIOL CHEM, V264, P19469; SCOTT WA, 1982, J EXP MED, V155, P535, DOI 10.1084/jem.155.2.535; TODD JF, 1990, PLANT PHYSIOL, V94, P1225, DOI 10.1104/pp.94.3.1225; WILLIAMS JD, 1984, J IMMUNOL, V132, P3034; WONG A, 1988, BIOCHEMISTRY-US, V27, P6763, DOI 10.1021/bi00418a018	29	82	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					570	576						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1309754				2022-12-27	WOS:A1992GY43900089
J	CORCORAN, ML; STETLERSTEVENSON, WG; BROWN, PD; WAHL, LM				CORCORAN, ML; STETLERSTEVENSON, WG; BROWN, PD; WAHL, LM			INTERLEUKIN-4 INHIBITION OF PROSTAGLANDIN-E2 SYNTHESIS BLOCKS INTERSTITIAL COLLAGENASE AND 92-KDA TYPE-IV COLLAGENASE GELATINASE PRODUCTION BY HUMAN MONOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MONONUCLEAR PHAGOCYTES; HUMAN PERIPHERAL-BLOOD; MACROPHAGE COLLAGENASE; GENE-EXPRESSION; SYNOVIAL-CELLS; IFN-GAMMA; IDENTIFICATION; METALLOPROTEINASES	Activation of human monocytes results in the production of interstitial collagenase through a prostaglandin E2 (PGE2)-cAMP-dependent pathway. Inasmuch as interleukin 4 (IL-4) has been shown to inhibit PGE2 synthesis by monocytes, we examined the effect of IL-4 on the production of human monocyte interstitial collagenase. Additionally, we also assessed the effect of IL-4 on the production of 92-kDa type IV collagenase/gelatinase and tissue inhibitor of metalloproteinase-1 (TIMP-1) by monocytes. The inhibition of PGE2 synthesis by IL-4 resulted in decreased interstitial collagenase protein and activity that could be restored by exogenous PGE2 or dibutyryl cyclic AMP (Bt2cAMP). IL-4 also suppressed ConA-stimulated 92-kDa type IV collagenase/gelatinase protein and zymogram enzyme activity that could be reversed by exogenous PGE2 or Bt2cAMP. Moreover, indomethacin suppressed the ConA-induced production of 92-kDa type IV collagenase/gelatinase. These data demonstrate that, like monocyte interstitial collagenase, the ConA-inducible monocyte 92-kDa type IV collagenase/gelatinase is regulated through a PGE2-mediated cAMP-dependent pathway. In contrast to ConA stimulation, unstimulated monocytes released low levels of 92-kDa type IV collagenase/gelatinase that were not affected by IL-4, PGE2, or Bt2cAMP, indicating that basal production of this enzyme is PGE2-cAMP independent. IL-4 inhibition of both collagenases was not a result of increased TIMP expression since Western analysis of 28.5-kDa TIMP-1 revealed that IL-4 did not alter the increased TIMP-1 protein in response to ConA. These data indicate that IL-4 may function in natural host regulation of connective tissue damage by monocytes.	NIDR,CELLULAR IMMUNOL SECT,IMMUNOL LAB,BLDG 30,RM 325,BETHESDA,MD 20892; NCI,TUMOR INVAS & METASTASIS SECT,PATHOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Stetler-Stevenson, William/AAE-3501-2020; Stetler-Stevenson, William G/H-6956-2012	Stetler-Stevenson, William/0000-0002-5500-5808; Stetler-Stevenson, William G/0000-0002-5500-5808				ABRAMSON SL, 1990, J IMMUNOL, V144, P625; CAMPBELL EJ, 1991, J IMMUNOL, V146, P1286; CAMPBELL EJ, 1987, J BIOL CHEM, V262, P15862; DAYER JM, 1986, J CLIN INVEST, V77, P645, DOI 10.1172/JCI112350; ESSNER R, 1989, J IMMUNOL, V142, P3857; EVANS CH, 1981, BIOCHIM BIOPHYS ACTA, V677, P287, DOI 10.1016/0304-4165(81)90098-2; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; HART PH, 1989, P NATL ACAD SCI USA, V86, P3803, DOI 10.1073/pnas.86.10.3803; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914; LEHN M, 1989, J IMMUNOL, V143, P3020; LOUIE JS, 1984, ARTHRITIS RHEUM-US, V27, P1397, DOI 10.1002/art.1780271210; MIZEL SB, 1989, FASEB J, V3, P2379, DOI 10.1096/fasebj.3.12.2676681; PAUL WE, 1987, ANNU REV IMMUNOL, V5, P429, DOI 10.1146/annurev.iy.05.040187.002241; SIMPSON JW, 1980, J DENT RES, V59, P2, DOI 10.1177/00220345800590010301; STANDIFORD TJ, 1990, J IMMUNOL, V145, P1435; Velde AA, 1990, BLOOD, V76, P1392; WACHER MP, 1990, J IMMUNOL METHODS, V126, P239, DOI 10.1016/0022-1759(90)90156-P; WAHL LM, 1984, CELL IMMUNOL, V85, P373, DOI 10.1016/0008-8749(84)90251-X; WAHL LM, 1984, ARCH BIOCHEM BIOPHYS, V230, P661, DOI 10.1016/0003-9861(84)90447-8; WAHL LM, 1988, J ORAL PATHOL MED, V17, P452, DOI 10.1111/j.1600-0714.1988.tb01314.x; WAHL LM, 1974, P NATL ACAD SCI USA, V71, P3598, DOI 10.1073/pnas.71.9.3598; WAHL LM, 1990, J IMMUNOL, V144, P3518; WAHL LM, 1987, CELL IMMUNOL, V105, P411, DOI 10.1016/0008-8749(87)90088-8; WAHL LM, 1977, P NATL ACAD SCI USA, V74, P4955, DOI 10.1073/pnas.74.11.4955; WAHL LM, 1981, MANUAL MACROPHAGE ME, P423; WAHL LM, 1984, J DENT RES, V63, pA338; WAHL SM, 1987, J IMMUNOL, V139, P1342; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WILHELM SM, 1989, J BIOL CHEM, V264, P17213	30	192	195	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					515	519						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1309751				2022-12-27	WOS:A1992GY43900082
J	SCHEPERS, TM; BRIER, ME; MCLEISH, KR				SCHEPERS, TM; BRIER, ME; MCLEISH, KR			QUANTITATIVE AND QUALITATIVE DIFFERENCES IN GUANINE-NUCLEOTIDE BINDING-PROTEIN ACTIVATION BY FORMYL PEPTIDE AND LEUKOTRIENE-B4 RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; PERTUSSIS-TOXIN; HUMAN-NEUTROPHILS; CHEMOTACTIC PEPTIDE; RABBIT NEUTROPHILS; PHOSPHOLIPASE-A2 ACTIVATION; CALCIUM MOBILIZATION; MUSCARINIC RECEPTOR; ADENYLATE-CYCLASE; DIACYLGLYCEROL PRODUCTION	Formyl peptides and leukotriene B4 (LTB4) stimulate disparate neutrophil functional responses and second messenger generation. The hypothesis that differences in receptor-guanine nucleotide-binding proteins (G protein) interaction account for the disparate responses was examined using HL-60 granulocyte plasma membranes. The quantity of receptor-coupled G proteins was determined by guanosine 5'-(gamma-thio)triphosphate (GTP-gamma-S) equilibrium binding in the presence or absence of f-Met-Leu-Phe and/or LTB4. About one-third of the total GTP-gamma-S binding sites were coupled to f-Met-Leu-Phe receptors, to LTB4 receptors, and to receptors when both ligands were added simultaneously. The dissociation constant of GTP-gamma-S-binding sites in the presence of LTB4 was significantly greater than that in the presence of f-Met-Leu-Phe. f-Met-Leu-Phe shifted the GDP dose-inhibition curve for GTP-gamma-S binding further to the right than did LTB4. The apparent initial rate of GTP hydrolysis and GTP-gamma-S binding stimulated by f-Met-Leu-Phe was significantly greater than that stimulated by LTB4. There were significantly more formyl peptide receptors than LTB4 receptors, however, formyl peptide and LTB4 receptor density did not differ under GTP-gamma-S binding assay conditions. The rate of GTP hydrolysis stimulated by LTB4 was not increased in membranes containing twice the LTB4 receptor density. We conclude that formyl peptide receptors stimulate more rapid activation of a common pool of G proteins than LTB4 receptors because of a significantly reduced affinity of formyl peptide receptor-activated G proteins for GDP.	UNIV LOUISVILLE,HLTH SCI CTR,SCH MED,DEPT MED,LOUISVILLE,KY 40202; VET ADM MED CTR,LOUISVILLE,KY 40292; UNIV LOUISVILLE,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,LOUISVILLE,KY 40202	University of Louisville; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Louisville			McLeish, Kenneth R./B-9819-2013; Brier, Michael/B-9805-2013	McLeish, Kenneth R./0000-0002-7816-3286; Brier, Michael/0000-0002-5952-9561				AKTORIES K, 1982, MOL PHARMACOL, V21, P336; ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BAULDRY SA, 1988, J BIOL CHEM, V263, P16787; BECKER EL, 1985, J CELL BIOL, V100, P1641, DOI 10.1083/jcb.100.5.1641; BENNETT JP, 1982, BIOCHEM J, V108, P801; BILLAH MM, 1987, BIOCHEM BIOPH RES CO, V144, P683, DOI 10.1016/S0006-291X(87)80019-0; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BOKOCH GM, 1984, CELL, V39, P301, DOI 10.1016/0092-8674(84)90008-4; BORMANN BJ, 1984, P NATL ACAD SCI-BIOL, V81, P767, DOI 10.1073/pnas.81.3.767; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; FALCONE RC, 1990, J PHARMACOL EXP THER, V255, P565; FELTNER DE, 1986, J IMMUNOL, V137, P1961; FUNG BKK, 1980, P NATL ACAD SCI-BIOL, V77, P2500, DOI 10.1073/pnas.77.5.2500; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GIERSCHIK P, 1987, EUR J BIOCHEM, V165, P185, DOI 10.1111/j.1432-1033.1987.tb11210.x; GIERSCHIK P, 1991, EUR J BIOCHEM, V197, P725, DOI 10.1111/j.1432-1033.1991.tb15964.x; GIERSCHIK P, 1989, EUR J PHARM-MOLEC PH, V172, P481, DOI 10.1016/0922-4106(89)90031-X; GIERSCHIK P, 1987, FEBS LETT, V224, P219, DOI 10.1016/0014-5793(87)80451-9; GIERSCHIK P, 1989, EUR J BIOCHEM, V183, P97, DOI 10.1111/j.1432-1033.1989.tb14901.x; GOLDMAN DW, 1985, J EXP MED, V162, P145, DOI 10.1084/jem.162.1.145; GOLDMAN DW, 1984, J EXP MED, V159, P1027, DOI 10.1084/jem.159.4.1027; HARTIALA KT, 1987, BIOCHEM BIOPH RES CO, V144, P794, DOI 10.1016/S0006-291X(87)80034-7; HEKMAN M, 1984, EMBO J, V8, P3339; KANAHO Y, 1991, J IMMUNOL, V146, P3536; KOO C, 1983, J CLIN INVEST, V72, P748, DOI 10.1172/JCI111045; MCLEISH KR, 1991, BIOCHEM J, V279, P455, DOI 10.1042/bj2790455; MCLEISH KR, 1989, BIOCHEM J, V260, P427, DOI 10.1042/bj2600427; MCLEISH KR, 1989, MOL PHARMACOL, V36, P384; MEI L, 1989, J PHARMACOL EXP THER, V251, P90; MOLSKI TFP, 1984, BIOCHEM BIOPH RES CO, V124, P644, DOI 10.1016/0006-291X(84)91603-6; NAKASHIMA S, 1988, ARCH BIOCHEM BIOPHYS, V261, P375, DOI 10.1016/0003-9861(88)90353-0; OMANN GM, 1987, J IMMUNOL, V138, P2626; PAI JK, 1988, BIOCHEM BIOPH RES CO, V150, P355, DOI 10.1016/0006-291X(88)90528-1; PAI JK, 1988, J BIOL CHEM, V263, P12472; PALMBLAD J, 1988, BIOCHIM BIOPHYS ACTA, V970, P92; PEDERSEN SE, 1982, P NATL ACAD SCI-BIOL, V79, P7228, DOI 10.1073/pnas.79.23.7228; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; REIBMAN J, 1988, J BIOL CHEM, V263, P6322; RODBARD D, 1976, CLIN CHEM, V22, P350; ROLLINS TE, 1983, PROSTAGLANDINS, V25, P281, DOI 10.1016/0090-6980(83)90110-7; SERHAN CN, 1982, BIOCHEM BIOPH RES CO, V107, P1006, DOI 10.1016/0006-291X(82)90622-2; SHEFCYK J, 1985, BIOCHEM BIOPH RES CO, V126, P1174, DOI 10.1016/0006-291X(85)90309-2; SKLAR LA, 1989, J BIOL CHEM, V264, P8483; SMITH CD, 1985, J BIOL CHEM, V260, P5875; TOLKOVSKY AM, 1978, BIOCHEMISTRY-US, V17, P3795, DOI 10.1021/bi00611a020; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; TRUETT AP, 1989, BIOCHEM J, V260, P909, DOI 10.1042/bj2600909; TRUETT AP, 1988, P NATL ACAD SCI USA, V85, P1549, DOI 10.1073/pnas.85.5.1549; VERGHESE MW, 1987, J IMMUNOL, V138, P4374; VERGHESE MW, 1985, BIOCHEM BIOPH RES CO, V127, P450, DOI 10.1016/S0006-291X(85)80181-9; VOLPI M, 1985, P NATL ACAD SCI USA, V82, P2708, DOI 10.1073/pnas.82.9.2708; VOTTA B, 1990, BIOCHEM J, V265, P841, DOI 10.1042/bj2650841	53	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					159	165						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1309732				2022-12-27	WOS:A1992GY43900030
J	HEERZE, LD; CHONG, PCS; ARMSTRONG, GD				HEERZE, LD; CHONG, PCS; ARMSTRONG, GD			INVESTIGATION OF THE LECTIN-LIKE BINDING DOMAINS IN PERTUSSIS TOXIN USING SYNTHETIC PEPTIDE SEQUENCES - IDENTIFICATION OF A SIALIC-ACID BINDING-SITE IN THE S2-SUBUNIT OF THE TOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISLET-ACTIVATING PROTEIN; WHEAT-GERM-AGGLUTININ; S2 SUBUNIT; CELLS; DETERMINANTS; ANTIBODIES; GENE	Synthetic peptides corresponding to selected sequences in the S2 and S3 subunits of pertussis toxin were prepared and evaluated for their ability to inhibit the binding of biotinylated pertussis toxin and three biotinylated sialic acid specific plant lectins to fetuin and asialofetuin. The screening results indicated that two regions in the S2 subunit corresponding to amino acids 78-98 and 123-154 inhibited pertussis toxin binding to fetuin at submillimolar concentrations, while S3 sequences corresponding to amino acids 87-108 and 134-154 inhibited pertussis toxin-biotin binding to asialofetuin albeit with lower affinity. These results confirm earlier findings, which suggest that the S2 subunit is responsible for binding sialylated glycoconjugates. This was further confirmed by the ability of S2 peptides to inhibit the binding of the lectins from Maackia amurensis and wheat germ to fetuin. Two additional peptides from the S2 subunit of pertussis toxin corresponding to sequences 9-23 and 1-23 were found to contain within their sequences a 6-amino acid fragment which has strong homology with a sequence in wheat germ agglutinin that has been shown to be a component of the sialic acid binding site as determined by x-ray crystallography. One of these sequences from S2 (9-23) was biotinylated and evaluated for its ability to bind to carbohydrate. Through a series of experiments using fetuin, asialofetuin, asialoagalactofetuin, and simple saccharides, the biotinylated peptide was shown to bind with high affinity to sialic acid-containing glycoconjugates indicating that these sequences within the S2 subunit of pertussis toxin also play an important role in binding sialic acid.	CONNAUGHT CTR BIOTECHNOL RES,N YORK M2R 3T4,ONTARIO,CANADA		HEERZE, LD (corresponding author), UNIV ALBERTA,DEPT MED MICROBIOL & INFECT DIS,EDMONTON T6G 2H7,ALBERTA,CANADA.		Chong, Pele/E-3855-2010					ARMSTRONG GD, 1987, INFECT IMMUN, V55, P1294, DOI 10.1128/IAI.55.5.1294-1299.1987; ARMSTRONG GD, 1988, J BIOL CHEM, V263, P8677; BHAVANANDAN VP, 1979, J BIOL CHEM, V254, P4000; BRENNAN MJ, 1988, J BIOL CHEM, V263, P4895; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; Francotte M., 1989, VACCINES 89, P243; HEERZE LD, 1991, BIOCHEM BIOPH RES CO, V179, P1464, DOI 10.1016/0006-291X(91)91737-W; HEERZE LD, 1990, BIOCHEM BIOPH RES CO, V172, P1224, DOI 10.1016/0006-291X(90)91579-H; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; LOCHT C, 1986, SCIENCE, V232, P1258, DOI 10.1126/science.3704651; NICOSIA A, 1986, P NATL ACAD SCI USA, V83, P4631, DOI 10.1073/pnas.83.13.4631; NOGIMORI K, 1986, BIOCHEMISTRY-US, V25, P1355, DOI 10.1021/bi00354a025; SATO H, 1984, INFECT IMMUN, V46, P415, DOI 10.1128/IAI.46.2.415-421.1984; SAUKKONEN K, 1992, P NATL ACAD SCI USA, V89, P118, DOI 10.1073/pnas.89.1.118; SCHMIDT MA, 1991, INFECT IMMUN, V59, P1402, DOI 10.1128/IAI.59.4.1402-1408.1991; SCHMIDT MA, 1989, INFECT IMMUN, V57, P3828, DOI 10.1128/IAI.57.12.3828-3833.1989; SCHMIDT W, 1989, INFECT IMMUN, V57, P438, DOI 10.1128/IAI.57.2.438-445.1989; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; TAMURA M, 1983, J BIOL CHEM, V258, P6756; TUOMANEN E, 1988, J EXP MED, V168, P267, DOI 10.1084/jem.168.1.267; TYRRELL GJ, 1989, INFECT IMMUN, V57, P1854, DOI 10.1128/IAI.57.6.1854-1857.1989; WANG WC, 1988, J BIOL CHEM, V263, P4576; WITVLIET MH, 1989, INFECT IMMUN, V57, P3324, DOI 10.1128/IAI.57.11.3324-3330.1989; WRIGHT CS, 1990, J MOL BIOL, V215, P635, DOI 10.1016/S0022-2836(05)80174-3	25	29	29	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25810	25815						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1281475				2022-12-27	WOS:A1992KD07300037
J	SCOTTCRAIG, JS; PANACCIONE, DG; POCARD, JA; WALTON, JD				SCOTTCRAIG, JS; PANACCIONE, DG; POCARD, JA; WALTON, JD			THE CYCLIC PEPTIDE SYNTHETASE CATALYZING HC-TOXIN PRODUCTION IN THE FILAMENTOUS FUNGUS COCHLIOBOLUS-CARBONUM IS ENCODED BY A 15.7-KILOBASE OPEN READING FRAME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINYL-VALINE SYNTHETASE; GRAMICIDIN-S SYNTHETASE; HOST-SPECIFIC TOXIN; BIOSYNTHETIC GENES; HELMINTHOSPORIUM-CARBONUM; PENICILLIUM-CHRYSOGENUM; NUCLEOTIDE-SEQUENCE; BACILLUS-BREVIS; PCBAB; ORGANIZATION	Race 1 of Cochliobolus carbonum, a fungal plant pathogen, owes its exceptional virulence on certain genotypes of maize to the production of HC-toxin, a cyclic tetrapeptide. Production of HC-toxin is controlled by a single known gene, TOX2. Race 1, but not races that do not make HC-toxin, contains two copies of a 22-kilobase (kb) region of chromosomal DNA that is required for HC-toxin biosynthesis and hence virulence. We have sequenced this 22-kb region and here show that it contains an open reading frame of 15.7 kb that encodes a multifunctional cyclic peptide synthetase of potential M(r) 574,620. This gene, called HTS1, apparently contains no introns. The predicted gene product, HC-toxin synthetase (HTS), contains four amino acid-binding (adenylate-forming) domains that are highly similar to those found in other cyclic peptide synthetases and other adenylate-binding enzymes. The DNA sequence encodes tryptic peptides derived from two HC-toxin biosynthetic enzymes, HC-toxin synthetase 1 (HTS-1) and HC-toxin synthetase 2 (HTS-2), indicating that these two enzymes exist in vivo as part of a single polypeptide. Consistent with this, in some enzyme preparations antibodies against the enzyme HTS-2, which was originally purified as a protein with a subunit M(r) of 160,000, recognize a protein with an estimated subunit M(r) greater than 480,000.			SCOTTCRAIG, JS (corresponding author), MICHIGAN STATE UNIV,DEPT ENERGY,PLANT RES LAB,E LANSING,MI 48824, USA.							AMY CM, 1992, P NATL ACAD SCI USA, V89, P1105, DOI 10.1073/pnas.89.3.1105; Ballance DJ, 1991, MOL IND MYCOLOGY SYS, P1; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; BRONSON CR, 1991, EXPERIENTIA, V47, P771, DOI 10.1007/BF01922456; COQUE JJR, 1991, MOL MICROBIOL, V5, P1125, DOI 10.1111/j.1365-2958.1991.tb01885.x; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIEZ B, 1990, J BIOL CHEM, V265, P16358; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; GUTIERREZ S, 1991, J BACTERIOL, V173, P2354; HAMES BD., 1981, GEL ELECTROPHORESIS, P1; HARLOW E, 1988, ANTIBODIES LABORATOR; HORI K, 1989, J BIOCHEM-TOKYO, V106, P639, DOI 10.1093/oxfordjournals.jbchem.a122909; KAWAI M, 1983, TETRAHEDRON LETT, V24, P5309, DOI 10.1016/S0040-4039(00)87855-7; KLEINKAUF H, 1987, ANNU REV MICROBIOL, V41, P259, DOI 10.1146/annurev.mi.41.100187.001355; KOHMOTO K, 1991, EXPERIENTIA, V47, P755, DOI 10.1007/BF01922454; KRATZSCHMAR J, 1989, J BACTERIOL, V171, P5422; MACCABE AP, 1991, J BIOL CHEM, V266, P12646; MEELEY RB, 1992, PLANT CELL, V4, P71, DOI 10.1105/tpc.4.1.71; PANACCIONE DG, 1992, P NATL ACAD SCI USA, V89, P6590, DOI 10.1073/pnas.89.14.6590; POPE MR, 1983, BIOCHEMISTRY-US, V22, P3502, DOI 10.1021/bi00283a030; PWALTON JD, 1988, MOL PLANT MICROBE IN, V2, P128; Sambrook J, 1989, MOL CLONING LABORATO; SCHLUMBOHM W, 1991, J BIOL CHEM, V266, P23135; SCOTTCRAIG JS, 1990, PLANT CELL, V2, P1191, DOI 10.1105/tpc.2.12.1191; SKARPEID HJ, 1990, EUR J BIOCHEM, V187, P627, DOI 10.1111/j.1432-1033.1990.tb15346.x; SMITH DJ, 1990, EMBO J, V9, P2743, DOI 10.1002/j.1460-2075.1990.tb07461.x; TURGAY K, 1992, MOL MICROBIOL, V6, P529, DOI 10.1111/j.1365-2958.1992.tb01498.x; WALTON JD, 1982, BIOCHEM BIOPH RES CO, V107, P785, DOI 10.1016/0006-291X(82)90592-7; WALTON JD, 1987, P NATL ACAD SCI USA, V84, P8444, DOI 10.1073/pnas.84.23.8444; WECKERMANN R, 1988, NUCLEIC ACIDS RES, V16, P11841, DOI 10.1093/nar/16.24.11841; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359	32	127	132	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					26044	26049						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1281482				2022-12-27	WOS:A1992KD07300069
J	LAROSA, GJ; THOMAS, KM; KAUFMANN, ME; MARK, R; WHITE, M; TAYLOR, L; GRAY, G; WITT, D; NAVARRO, J				LAROSA, GJ; THOMAS, KM; KAUFMANN, ME; MARK, R; WHITE, M; TAYLOR, L; GRAY, G; WITT, D; NAVARRO, J			AMINO TERMINUS OF THE INTERLEUKIN-8 RECEPTOR IS A MAJOR DETERMINANT OF RECEPTOR SUBTYPE SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMYELOCYTIC LEUKEMIA-CELLS; GROWTH-STIMULATORY ACTIVITY; ADRENERGIC-RECEPTOR; HUMAN NEUTROPHILS; BINDING; NAP-2; CHORIOGONADOTROPIN; RESIDUES; CLONING	Interleukin-8 (IL-8) is a key mediator in the migration of neutrophils from the circulation to the site of inflammation in the tissue. IL-8 is secreted by many cell types in response to proinflammatory stimuli such as interleukin 1, tumor necrosis factor, and lipopolysaccharide and is a potent chemoattractant and activator of neutrophils. Neutrophil activating peptide-2 (NAP-2) and melanoma growth-stimulatory activity (MGSA/GRO) are structurally and functionally related to IL-8 and, like IL-8, bind to specific G protein-coupled receptors on neutrophils. In the present study two closely related cloned IL-8 receptor subtypes are characterized by expression of the cDNA clones in monkey kidney cells (COS-7) or chinese hamster ovary cells and analysis of their ligand binding profiles. Both receptor subtypes bind I-125-labeled IL-8 with similar high affinity, however, the F3R receptor binds IL-8 exclusively, while the 4Ab receptor binds both IL-8 and MGSA/GRO with high affinity and NAP-2 with lesser affinity. Furthermore, we demonstrate with the use of intersubtype chimeric receptors that the specificity of ligand binding to both IL-8 receptor subtypes is dictated by the heterogeneous NH2-terminal domain. The F3R receptor is representative of a restricted IL-8 receptor subtype, and 4Ab represents a nonrestricted receptor subtype. It is proposed that these subtypes be named IL-8 receptors alpha and beta, respectively.	BOSTON UNIV,SCH MED,DEPT PHYSIOL,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	Boston University; Boston University	LAROSA, GJ (corresponding author), REPLIGEN CORP,DEPT MOLEC BIOL,1 KENDALL SQ,CAMBRIDGE,MA 02139, USA.			Navarro, Javier/0000-0001-7098-4373	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039602, K04AR001810] Funding Source: NIH RePORTER; NIAMS NIH HHS [K04 AR 01810, R01 AR 39602] Funding Source: Medline; NIA NIH HHS [AG00115] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BECKMANN MP, 1991, BIOCHEM BIOPH RES CO, V179, P784, DOI 10.1016/0006-291X(91)91885-G; CHAPLINSKI TJ, 1982, J CLIN INVEST, V70, P953, DOI 10.1172/JCI110707; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; COLLINS SJ, 1979, J EXP MED, V149, P969, DOI 10.1084/jem.149.4.969; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIXON RAF, 1988, COLD SPRING HARB SYM, V53, P487, DOI 10.1101/SQB.1988.053.01.056; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FERRANTE A, 1980, J IMMUNOL METHODS, V36, P109, DOI 10.1016/0022-1759(80)90036-8; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HOFFMAN BB, 1979, LIFE SCI, V24, P1739, DOI 10.1016/0024-3205(79)90061-4; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; JI I, 1991, J BIOL CHEM, V266, P13076; KUNKEL SL, 1991, EXP LUNG RES, V17, P17, DOI 10.3109/01902149109063278; LEONARD EJ, 1991, J LEUKOCYTE BIOL, V49, P258, DOI 10.1002/jlb.49.3.258; Maniatis T, 1989, DECONTAMINATION DILU; MCPHERSON GA, 1985, KINETIC EBDA LIGAND; MOSER B, 1990, J EXP MED, V171, P1797, DOI 10.1084/jem.171.5.1797; MOSER B, 1991, J BIOL CHEM, V266, P10666; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; THOMAS KM, 1991, J BIOL CHEM, V266, P14839; THOMAS KM, 1990, J BIOL CHEM, V265, P20061; URLAUB G, 1986, SOMAT CELL MOLEC GEN, V12, P555, DOI 10.1007/BF01671941; WALZ A, 1990, J EXP MED, V171, P449, DOI 10.1084/jem.171.2.449; WALZ A, 1991, J LEUKOCYTE BIOL, V50, P279, DOI 10.1002/jlb.50.3.279; XIE YB, 1990, J BIOL CHEM, V265, P21411	29	168	179	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25402	25406						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1281158				2022-12-27	WOS:A1992KB60300075
J	VEDIA, LM; MCDONALD, B; REEP, B; BRUNE, B; DISILVIO, M; BILLIAR, TR; LAPETINA, EG				VEDIA, LM; MCDONALD, B; REEP, B; BRUNE, B; DISILVIO, M; BILLIAR, TR; LAPETINA, EG			NITRIC OXIDE-INDUCED S-NITROSYLATION OF GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE INHIBITS ENZYMATIC-ACTIVITY AND INCREASES ENDOGENOUS ADP-RIBOSYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HEPATOCYTE PROTEIN-SYNTHESIS; L-ARGININE; NITROGEN-OXIDES; PLASMA-MEMBRANE; RELAXING FACTOR; CELL; RIBOSYLTRANSFERASE; ACTIVATION; MODULATION; NITRATE	Using conditions that produced chronic inflammation in rat liver, we were able to find a correlation between induction of nitric oxide production and inhibition of glyceraldehyde-3-phosphate dehydrogenase (GAPDH; EC 1.2.1.12). This enzyme is a tetramer composed of identical M(r) 37,000 subunits. The tetramer contains 16 thiol groups, four of which are essential for enzymatic activity. Our information indicates that four thiol groups are S-nitrosylated by exposure to authentic nitric oxide (NO) gas. Furthermore, NO decreased GAPDH activity while increasing its auto-ADP-ribosylation. Reduced nicotinamide adenine dinucleotide and dithiothreitol are required for the S-nitrosylation of GAPDH caused by the NO-generating compound sodium nitroprusside. Our results suggests that a new and important action of nitric oxide on cells is the S-nitrosylation and inactivation of GAPDH. S-Nitrosylation of GAPDH may be a key covalent modification of multiple regulatory consequences in chronic liver inflammation.	UNIV PITTSBURGH,DEPT SURG,PITTSBURGH,PA 15261; UNIV CONSTANCE,FAK BIOL,W-7750 CONSTANCE,GERMANY	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Konstanz	VEDIA, LM (corresponding author), WELLCOME RES LABS,3030 CORNWALLIS RD,RES TRIANGLE PK,NC 27709, USA.		DI SILVIO, MAURICIO/AGE-5993-2022	DI SILVIO, MAURICIO/0000-0002-9543-0366				ALLEN RW, 1987, J BIOL CHEM, V262, P649; BANAS T, 1976, EUR J BIOCHEM, V68, P313, DOI 10.1111/j.1432-1033.1976.tb10790.x; BILLIAR TR, 1990, BIOCHEM BIOPH RES CO, V168, P1034, DOI 10.1016/0006-291X(90)91133-D; BILLIAR TR, 1989, J EXP MED, V169, P1467, DOI 10.1084/jem.169.4.1467; BILLIAR TR, 1990, J LEUKOCYTE BIOL, V48, P565, DOI 10.1002/jlb.48.6.565; BILLIAR TR, 1992, AM J PHYSIOL, V262, pC1077, DOI 10.1152/ajpcell.1992.262.4.C1077; BLOUGH NV, 1985, INORG CHEM, V24, P3504; BRUNE B, 1989, J BIOL CHEM, V264, P8455; BRUNE B, 1990, ARCH BIOCHEM BIOPHYS, V279, P286, DOI 10.1016/0003-9861(90)90493-I; BUNTON CA, 1957, RECENT ASPECTS INORG, V10, P113; CONSTANTINIDES SM, 1969, J BIOL CHEM, V244, P5695; CONWAY A, 1968, BIOCHEMISTRY-US, V7, P4011, DOI 10.1021/bi00851a031; CURRAN RD, 1991, FASEB J, V5, P2085, DOI 10.1096/fasebj.5.7.1707021; CURRAN RD, 1989, J EXP MED, V170, P1769, DOI 10.1084/jem.170.5.1769; DEVIJLDER JJ, 1968, BIOCHIM BIOPHYS ACTA, V167, P23, DOI 10.1016/0005-2744(68)90274-X; DIMMELER S, 1992, J BIOL CHEM, V267, P16771; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HARRIS I, 1963, BIOCHEM J, V89, pP60; HARTMANN S, 1978, FEBS LETT, V93, P339, DOI 10.1016/0014-5793(78)81135-1; HSU SC, 1990, J BIOL CHEM, V265, P13308; HUITOREL P, 1985, EUR J BIOCHEM, V150, P265, DOI 10.1111/j.1432-1033.1985.tb09016.x; IGNARRO LJ, 1980, BIOCHIM BIOPHYS ACTA, V631, P221, DOI 10.1016/0304-4165(80)90297-4; KAWAMOTO RM, 1986, BIOCHEMISTRY-US, V25, P656, DOI 10.1021/bi00351a022; KELM M, 1990, CIRC RES, V66, P1561, DOI 10.1161/01.RES.66.6.1561; KOTS AY, 1992, FEBS LETT, V300, P9, DOI 10.1016/0014-5793(92)80153-8; KRIMSKY I, 1963, BIOCHEMISTRY-US, V2, P512, DOI 10.1021/bi00903a021; KUZMINSKAYA EV, 1991, BIOCHIM BIOPHYS ACTA, V1075, P123, DOI 10.1016/0304-4165(91)90241-8; LI YK, 1991, BIOCHEM J, V275, P767, DOI 10.1042/bj2750767; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; MIZOGUCHI Y, 1987, HEPATOLOGY, V7, P1184, DOI 10.1002/hep.1840070603; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; ROGALSKI AA, 1989, J BIOL CHEM, V264, P6438; SAVILLE B, 1958, ANALYST, V83, P670, DOI 10.1039/an9588300670; STADLER J, 1991, AM J PHYSIOL, V260, pC910, DOI 10.1152/ajpcell.1991.260.5.C910; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; VEDIA LMY, 1988, BIOCHEM BIOPH RES CO, V157, P1323, DOI 10.1016/S0006-291X(88)81019-2	37	319	323	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					24929	24932						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1281150				2022-12-27	WOS:A1992KB60300005
J	VAZQUEZ, SR; KUO, DZ; BOSITIS, CM; HARDY, LW; LEW, RA; HUMPHREYS, RE				VAZQUEZ, SR; KUO, DZ; BOSITIS, CM; HARDY, LW; LEW, RA; HUMPHREYS, RE			RESIDUES IN THE LONGITUDINAL, HYDROPHOBIC STRIP-OF-HELIX RELATE TO TERMINATIONS AND CROSSINGS OF ALPHA-HELICES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PACKING; PROTEINS; SEQUENCES; PEPTIDES; DESIGN; CORE	An alpha-helix terminates when the virtual extension of its most hydrophobic, longitudinal strip containing Leu, Ile, Val, Phe, and Met lacks those residues. In each of 247 helices a template (square circle circle circle square circle circle square circle circle circle square circle circle square circle circle circle) was fitted to maximize the mean hydrophobicity of square positions forming a longitudinal strip-of-helix. The template was then extended into sequences beyond the ends of the helices. Leu, Ile, Val, Phe, and Met occurred in square positions in the longitudinal strip-of-helix at an increased frequency (p < 0.001), but in the first and second square positions beyond either end of each true helix, they occurred at the same frequency as for their empirical distribution over all the proteins. Excesses of Asp and Glu were found in the N-terminal loop, and of Arg, His, and Lys in specific positions about the C terminus of helices. The longitudinal hydrophobic strip, the smallest amino acid in that strip, and charged amino acids in that strip, related to rotational and longitudinal orientation of alpha-helices in 15 proteins. Adjacent helices generally crossed through their longitudinal hydrophobic strips. They usually crossed through the smallest residue in the strip. Charged residues, when they occurred in the strips, were excluded from the crossing regions.	UNIV MASSACHUSETTS,SCH MED,DEPT PHARMACOL,55 LAKE AVE N,WORCESTER,MA 01655; UNIV MASSACHUSETTS,SCH MED,DEPT MED,WORCESTER,MA 01655; UNIV MASSACHUSETTS,SCH MED,PROGRAM MOLEC MED,WORCESTER,MA 01655	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester					NCI NIH HHS [CA39802] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BOWIE JU, 1990, PROTEINS, V7, P257, DOI 10.1002/prot.340070307; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; CHOTHIA C, 1975, NATURE, V254, P304, DOI 10.1038/254304a0; CHOTHIA C, 1981, J MOL BIOL, V145, P215, DOI 10.1016/0022-2836(81)90341-7; CHOU KC, 1983, J PHYS CHEM-US, V87, P2869, DOI 10.1021/j100238a033; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; EFIMOV AV, 1979, J MOL BIOL, V134, P23, DOI 10.1016/0022-2836(79)90412-1; HOL WGJ, 1981, NATURE, V294, P532, DOI 10.1038/294532a0; KAISER ET, 1987, METHOD ENZYMOL, V154, P473; KELLIS JT, 1989, BIOCHEMISTRY-US, V28, P4914, DOI 10.1021/bi00437a058; LESK AM, 1980, J MOL BIOL, V136, P225, DOI 10.1016/0022-2836(80)90373-3; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; LU S, 1992, VACCINE, V10, P3, DOI 10.1016/0264-410X(92)90410-L; MATOUSCHEK A, 1990, NATURE, V346, P440, DOI 10.1038/346440a0; MINAKATA H, 1989, J BIOL CHEM, V264, P7907; OSTERMAN DG, 1985, J CELL BIOCHEM, V29, P57, DOI 10.1002/jcb.240290202; PERUTZ MF, 1965, J MOL BIOL, V13, P669, DOI 10.1016/S0022-2836(65)80134-6; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; REYES VE, 1989, J BIOL CHEM, V264, P12854; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; RICHMOND TJ, 1978, J MOL BIOL, V119, P537, DOI 10.1016/0022-2836(78)90201-2; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; TORGERSON RR, 1991, J BIOL CHEM, V266, P5521	25	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7406	7410						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1313798				2022-12-27	WOS:A1992HN48500032
J	WANG, CP; FRANCO, R; MOURA, JJG; MOURA, I; DAY, EP				WANG, CP; FRANCO, R; MOURA, JJG; MOURA, I; DAY, EP			THE NICKEL SITE IN ACTIVE DESULFOVIBRIO-BACULATUS [NIFESE] HYDROGENASE IS DIAMAGNETIC - MULTIFIELD SATURATION MAGNETIZATION MEASUREMENT OF THE SPIN STATE OF NI(II)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTERS; EPR; GIGAS	The magnetic properties of the nickel(II) site in active Desulfovibrio baculatus (DSM 1743) [NiFeSe] hydrogenase have been measured using the multifield saturation magnetization technique. The periplasmic [NiFeSe] hydrogenase was isolated from bacteria grown in excess selenium in the presence of Fe-57. Saturation magnetization data were collected at three fixed fields (1.375, 2.75, 5.5 tesla) over the temperature range from 2 to 100 K. Mossbauer and EPR spectroscopies were used to characterize the magnetic state of the two [4Fe-4S] clusters of the enzyme and to quantitate the small amounts of iron impurities present in the sample. The nickel(II) site was found to be diamagnetic (low spin, S = 0). In combination with recent results from extended x-ray absorption fine structure studies, this magnetic state indicates that the nickel(II) site of active D. baculatus [NiFeSe] hydrogenase is five-coordinate.	EMORY UNIV,DEPT PHYS,ATLANTA,GA 30322; UNIV NOVA LISBOA,P-2780 OEIRAS,PORTUGAL; CTR TECNOL QUIM & BIOL,OEIRAS,PORTUGAL	Emory University; Universidade Nova de Lisboa			Moura, Isabel/D-6339-2013; Franco, Ricardo/C-5247-2008; Moura, José J G/D-6426-2013	Moura, Isabel/0000-0003-0971-4977; Franco, Ricardo/0000-0002-5139-2871; Moura, José J G/0000-0002-4726-2388	NIGMS NIH HHS [GM32394] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032394] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; ADAMS MWW, 1990, BIOCHIM BIOPHYS ACTA, V1020, P115, DOI 10.1016/0005-2728(90)90044-5; Cammack R, 1988, BIOINORGANIC CHEM NI, P167; COTTON FA, 1988, ADV INORG CHEM RAD, P741; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DAY EP, 1987, BIOPHYS J, V52, P837, DOI 10.1016/S0006-3495(87)83277-0; EIDSNESS MK, 1989, P NATL ACAD SCI USA, V86, P147, DOI 10.1073/pnas.86.1.147; FAUQUE G, 1988, FEMS MICROBIOL LETT, V54, P299, DOI 10.1111/j.1574-6968.1988.tb02748.x; HE SH, 1989, J BIOL CHEM, V264, P2678; HUYNH BH, 1980, J BIOL CHEM, V255, P3242; LAMPREIA J, 1990, EUR J BIOCHEM, V188, P653, DOI 10.1111/j.1432-1033.1990.tb15447.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARONEY MJ, 1991, J AM CHEM SOC, V113, P3962, DOI 10.1021/ja00010a044; MOURA JJG, 1988, BIOINORGANIC CHEM NI, P191; NELDER JA, 1965, COMPUT J, V7, P308, DOI 10.1093/comjnl/7.4.308; PECK HD, 1956, J BACTERIOL, V71, P70, DOI 10.1128/JB.71.1.70-80.1956; Sacconi L., 1968, TRANSITION METAL CHE, V4, P199; TEIXEIRA M, 1987, EUR J BIOCHEM, V167, P47, DOI 10.1111/j.1432-1033.1987.tb13302.x; TEIXEIRA M, 1990, EUR J BIOCHEM, V189, P381, DOI 10.1111/j.1432-1033.1990.tb15499.x; VANDERZWAAN JW, 1985, FEBS LETT, V179, P271, DOI 10.1016/0014-5793(85)80533-0	20	54	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7378	7380						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1313795				2022-12-27	WOS:A1992HN48500027
J	BEGUM, N; SUSSMAN, KE; DRAZNIN, B				BEGUM, N; SUSSMAN, KE; DRAZNIN, B			CALCIUM-INDUCED INHIBITION OF PHOSPHOSERINE PHOSPHATASE IN INSULIN TARGET-CELLS IS MEDIATED BY THE PHOSPHORYLATION AND ACTIVATION OF INHIBITOR-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; CYTOSOLIC FREE CALCIUM; PROTEIN PHOSPHATASES; GLYCOGEN-METABOLISM; RAT ADIPOCYTES; GLUCOSE-TRANSPORT; CELLULAR-REGULATION; HORMONAL-CONTROL; DEPHOSPHORYLATION; ENZYME	In this study, we examined the mechanism of inhibition of phosphoserine phosphatase (PSPase) activity by elevated [Ca2+]i in insulin target cells. In in vitro studies, isolated rat adipocytes were incubated with either 40 mM K+ or parathyroid hormone (PTH) (20 ng/ml) for 1 h. In in vivo studies, rats were injected with PTH (three hourly injections of 40-mu-g intraperitoneally) prior to isolation of either adipocytes or skeletal muscle. Under these conditions, intracellular [Ca2+]i changed from 100 +/- 8.7 to 263 +/- 10.5 nM. There was a concomitant 30% decrease in adipocyte PSPase activity and a 35% decrease in skeletal muscle PSPase activity, assayed using P-32-labeled phosphorylase "a" as a substrate. The inhibition of PSPase was accompanied by a 60% increase in adipocytes (p < 0.05) and a 118% increase (p < 0.01) in skeletal muscle inhibitor 1 (I1) activities, respectively. Since Il is active only in the phosphorylated state, we studied the effect of [Ca2+]i on I1 phosphorylation. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of heat treated extracts immunoprecipitated with I1 antibody revealed significant increase in P-32 incorporation (45-60%, p < 0.05) into I1 protein in cells with elevated [Ca2+]i. Nitrendipine, a calcium channel blocker, completely prevented increases in I1 phosphorylation and activity in cells exposed to K+ but was only partially effective in the PTH-treated cells. In contrast, a cyclic AMP antagonist, RpcAMP, prevented both the K+- and the PTH-induced increases in I1 phosphorylation and activity, even though it failed to block the elevations in [Ca2+]i in these cells. We conclude that [Ca2+]i-induced and cAMP-mediated phosphorylation and activation of I1 results in inhibition of PSPase activity in insulin target cells. The inhibition of PSPases may cause inappropriate serine dephosphorylation of substrates of insulin action resulting in insulin resistance.	VET AFFAIRS MED CTR,MED RES SERV,ENDOCRINOL SECT 111H,1055 CLERMONT ST,DENVER,CO 80220; UNIV COLORADO,HLTH SCI CTR,DEPT MED,DENVER,CO 80262	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								ALEMANY S, 1986, EUR J BIOCHEM, V156, P101, DOI 10.1111/j.1432-1033.1986.tb09554.x; ALEMANY S, 1986, FEBS LETT, V198, P194, DOI 10.1016/0014-5793(86)80404-5; ANTONIW JF, 1977, BIOCHEM J, V162, P423, DOI 10.1042/bj1620423; BEGUM N, 1991, CELL CALCIUM, V12, P423, DOI 10.1016/0143-4160(91)90068-P; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COHEN P, 1985, EUR J BIOCHEM, V151, P439, DOI 10.1111/j.1432-1033.1985.tb09121.x; COHEN P, 1988, PROC R SOC SER B-BIO, V234, P115, DOI 10.1098/rspb.1988.0040; COHEN P, 1989, J BIOL CHEM, V264, P21435; CORVERA S, 1991, J BIOL CHEM, V266, P9271; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DRAZNIN B, 1989, ENDOCRINOLOGY, V125, P2341, DOI 10.1210/endo-125-5-2341; DRAZNIN B, 1988, J CLIN INVEST, V82, P1848, DOI 10.1172/JCI113801; DRAZNIN B, 1987, J BIOL CHEM, V262, P14385; DRAZNIN B, 1988, AM J MED, V85, P44, DOI 10.1016/0002-9343(88)90397-X; FOULKES JG, 1980, EUR J BIOCHEM, V105, P195, DOI 10.1111/j.1432-1033.1980.tb04489.x; FOULKES JG, 1979, EUR J BIOCHEM, V97, P251, DOI 10.1111/j.1432-1033.1979.tb13109.x; GINTY DD, 1991, J BIOL CHEM, V266, P17454; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P263, DOI 10.1111/j.1432-1033.1983.tb07358.x; KATO K, 1972, J BIOL CHEM, V247, P7420; KING MJ, 1988, BIOCHEM J, V256, P893, DOI 10.1042/bj2560893; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE JC, 1990, J BIOL CHEM, V265, P19768; LAWRENCE JC, 1984, J BIOL CHEM, V259, P7975; NEMENOFF RA, 1983, J BIOL CHEM, V258, P9437; REUSCH JEB, 1991, ENDOCRINOLOGY, V129, P3269, DOI 10.1210/endo-129-6-3269; RODBELL M, 1964, J BIOL CHEM, V239, P375; SHENOLIKAR S, 1984, METHOD ENZYMOL, V107, P102; SHENOLIKAR S, 1988, FASEB J, V2, P2753, DOI 10.1096/fasebj.2.12.2842213; SUIDAN HS, 1991, CELL REGUL, V2, P13, DOI 10.1091/mbc.2.1.13; TANTI JF, 1991, J BIOL CHEM, V266, P2099; VOLKER TT, 1985, ANAL BIOCHEM, V144, P347, DOI 10.1016/0003-2697(85)90127-7	31	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5959	5963						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1313423				2022-12-27	WOS:A1992HK31800040
J	DESROCHERS, PE; MOOKHTIAR, K; VANWART, HE; HASTY, KA; WEISS, SJ				DESROCHERS, PE; MOOKHTIAR, K; VANWART, HE; HASTY, KA; WEISS, SJ			PROTEOLYTIC INACTIVATION OF ALPHA-1-PROTEINASE INHIBITOR AND ALPHA-1-ANTICHYMOTRYPSIN BY OXIDATIVELY ACTIVATED HUMAN NEUTROPHIL METALLOPROTEINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-DISTRESS SYNDROME; HUMAN FIBROBLAST COLLAGENASE; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; GLOMERULAR BASEMENT-MEMBRANE; SERINE PROTEINASES; RHEUMATOID-ARTHRITIS; SYNOVIAL FIBROBLASTS; MACROPHAGE ELASTASE; TISSUE INHIBITOR; CYSTEINE SWITCH	Human neutrophils use the H2O2-myeloperoxidase-chloride system to generate chlorinated oxidants capable of activating metalloproteinase zymogens that hydrolyze not only native and denatured collagens, but also the serine proteinase inhibitor (serpin) alpha-1-proteinase inhibitor (alpha-1PI). To identify the metalloenzyme that hydrolyzes and inactivates alpha-1PI, neutrophil releasates were chromatographed over gelatin-Sepharose and divided into fractions containing either progelatinase or procollagenase. The gelatinase-containing fraction cleaved alpha-1PI in a manner inhibitable by native type V, but not type I, collagen. Conversely, while the collagenase-containing fraction also cleaved alpha-1PI, this activity was inhibited by type I, but not type V, collagen. Because type I and V collagens are competitive substrates for collagenase and gelatinase, respectively, each of the metalloproteinase zymogens were purified to apparent homogeneity and examined for alpha-1PI-hydrolytic activities. Both purified gelatinase and collagenase inactivated alpha-1PI by hydrolyzing the serpin within its active-site loop at the Phe352-Leu353 and Pro357-Met358 bonds, albeit with distinct kinetic properties. Furthermore, purified collagenase, but not gelatinase, cleaved a second serpin, alpha-1-antichymotrypsin, by hydrolyzing the Ala362-Leu363 bond within its active-site loop. These data demonstrate that human neutrophils use chlorinated oxidants to activate collagenolytic metalloproteinases whose substrate specificities can be extended to members of the serpin superfamily.	UNIV MICHIGAN, MED CTR, DEPT MED, ANN ARBOR, MI 48109 USA; UNIV TENNESSEE CTR HLTH SCI, DEPT ANAT & NEUROBIOL, MEMPHIS, TN 38104 USA; FLORIDA STATE UNIV, DEPT CHEM, TALLAHASSEE, FL 32306 USA; FLORIDA STATE UNIV, INST MOLEC BIOPHYS, TALLAHASSEE, FL 32306 USA	University of Michigan System; University of Michigan; University of Tennessee System; University of Tennessee Health Science Center; State University System of Florida; Florida State University; State University System of Florida; Florida State University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023876] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-28024] Funding Source: Medline; NIAID NIH HHS [AI-23876] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AZZO W, 1986, J BIOL CHEM, V261, P5434; BABIOR BM, 1984, BLOOD, V64, P959; BANDA MJ, 1985, J CLIN INVEST, V75, P1758, DOI 10.1172/JCI111887; BANDA MJ, 1988, J BIOL CHEM, V263, P4481; BANDA MJ, 1987, J CLIN INVEST, V79, P1314, DOI 10.1172/JCI112955; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BEATTY K, 1980, J BIOL CHEM, V255, P3931; BIRKEDALHANSEN H, 1987, METHOD ENZYMOL, V144, P140; CAPODICI C, 1989, AGENTS ACTIONS, V27, P481, DOI 10.1007/BF01972858; CARP H, 1980, J CLIN INVEST, V66, P987, DOI 10.1172/JCI109968; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; CHANDRA T, 1983, BIOCHEMISTRY-US, V22, P5055, DOI 10.1021/bi00291a001; CHIN JR, 1985, J BIOL CHEM, V260, P2367; CLARK RA, 1981, J BIOL CHEM, V256, P3348; COCHRANE CG, 1983, J CLIN INVEST, V71, P754, DOI 10.1172/JCI110823; DESROCHERS PE, 1988, J CLIN INVEST, V81, P1646, DOI 10.1172/JCI113500; DESROCHERS PE, 1991, J CLIN INVEST, V87, P2258, DOI 10.1172/JCI115262; DOCHERTY AJP, 1990, ANN RHEUM DIS, P469; EDWARDS SW, 1988, BIOCHEM J, V250, P81, DOI 10.1042/bj2500081; GADEK JE, 1979, NEW ENGL J MED, V301, P737, DOI 10.1056/NEJM197910043011401; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; HARRIS ED, 1972, BIOCHIM BIOPHYS ACTA, V258, P566, DOI 10.1016/0005-2744(72)90249-5; HASTY KA, 1987, J BIOL CHEM, V262, P10048; HASTY KA, 1986, J BIOL CHEM, V261, P5645; HASTY KA, 1990, J BIOL CHEM, V265, P11421; HENSON PM, 1987, J CLIN INVEST, V79, P669, DOI 10.1172/JCI112869; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HIBBS MS, 1984, COLLAGEN REL RES, V4, P467; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JANOFF A, 1985, ANNU REV MED, V36, P207; KNAUPER V, 1990, FEBS LETT, V263, P355, DOI 10.1016/0014-5793(90)81412-H; KURDOWSKA A, 1990, J BIOL CHEM, V265, P21023; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDMARK B, 1989, BIOCHIM BIOPHYS ACTA, V997, P90, DOI 10.1016/0167-4838(89)90139-8; MALLYA SK, 1990, BIOCHEMISTRY-US, V29, P10628, DOI 10.1021/bi00499a008; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MCGUIRE WW, 1982, J CLIN INVEST, V69, P543, DOI 10.1172/JCI110480; MICHAELIS J, 1990, BIOCHEM J, V270, P809, DOI 10.1042/bj2700809; MOOKHTIAR KA, 1990, BIOCHEMISTRY-US, V29, P10620, DOI 10.1021/bi00499a007; NAKAJIMA K, 1979, J BIOL CHEM, V254, P4027; NETZELARNETT S, 1991, J BIOL CHEM, V266, P6747; OKADA Y, 1988, FEBS LETT, V229, P157, DOI 10.1016/0014-5793(88)80817-2; OKADA Y, 1986, J BIOL CHEM, V261, P14245; OSSANNA PJ, 1986, J CLIN INVEST, V77, P1939, DOI 10.1172/JCI112523; PEPPIN GJ, 1986, P NATL ACAD SCI USA, V83, P4322, DOI 10.1073/pnas.83.12.4322; PERLMUTTER DH, 1990, J BIOL CHEM, V265, P16713; RANTALARYHANEN S, 1983, EUR J BIOCHEM, V134, P129, DOI 10.1111/j.1432-1033.1983.tb07541.x; REDDY VY, 1989, J BIOL CHEM, V264, P13801; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P152; SHAH SV, 1987, J CLIN INVEST, V79, P25, DOI 10.1172/JCI112790; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STRICKLIN GP, 1990, CLIN RES, V38, pA74; TEST ST, 1984, J BIOL CHEM, V259, P399; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; TYAGI SC, 1991, J BIOL CHEM, V266, P5279; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; VISSERS MCM, 1988, J CLIN INVEST, V82, P706, DOI 10.1172/JCI113651; VISSERS MCM, 1988, COLLAGEN REL RES, V8, P113; VISSERS MCM, 1988, BIOCHEM J, V249, P327, DOI 10.1042/bj2490327; VISSERS MCM, 1987, BIOCHEM J, V245, P277, DOI 10.1042/bj2450277; WEILAND JE, 1986, AM REV RESPIR DIS, V133, P218; WEILAND JE, 1987, J APPL PHYSIOL, V62, P628, DOI 10.1152/jappl.1987.62.2.628; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEISS SJ, 1986, BIOCHEM PHARMACOL, V35, P3189, DOI 10.1016/0006-2952(86)90412-0; WEISS SJ, 1986, ACTA PHYSIOL SCAND, V126, P9; WEISS SJ, 1985, SCIENCE, V227, P747, DOI 10.1126/science.2982211; WELGUS HG, 1982, J BIOL CHEM, V257, P1534; Werb Z., 1989, TXB RHEUMATOLOGY, P300; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WINYARD PG, 1991, FEBS LETT, V279, P91, DOI 10.1016/0014-5793(91)80258-5; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; ZHANG Z, 1990, BIOCHEM SOC T, V18, P898, DOI 10.1042/bst0180898	73	104	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					5005	5012						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1311327				2022-12-27	WOS:A1992HF64200106
J	DEWEILLE, JR; MULLER, M; LAZDUNSKI, M				DEWEILLE, JR; MULLER, M; LAZDUNSKI, M			ACTIVATION AND INHIBITION OF ATP-SENSITIVE K+ CHANNELS BY FLUORESCEIN DERIVATIVES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; PANCREATIC-B-CELLS; REGULATED POTASSIUM CHANNELS; RAT VENTRICULAR MYOCYTES; INSULIN-SECRETING CELLS; ARTERIAL SMOOTH-MUSCLE; SKELETAL-MUSCLE; BETA-CELLS; SARCOPLASMIC-RETICULUM; INTRACELLULAR ATP	Fluorescein derivatives are known to bind to nucleotide-binding sites on transport ATPases. In this study, they have been used as ligands to nucleotide-binding sites on ATP-sensitive K+ channels in insulinoma cells. Their effect on channel activity has been studied using Rb-86(+) efflux and patch-clamp techniques. Fluorescein derivatives have two opposite effects. First, like ATP, they can inhibit active ATP-sensitive K+ channels. Second, they are able to reactivate ATP-sensitive K+ channels subjected to inactivation or "run-down" in the absence of cytoplasmic ATP. Therefore reactivation of the inactivated ATP-sensitive K+ channel clearly does not require channel phosphorylation as is commonly believed. The results indicate the existence of two binding sites for nucleotides, one activator site and one inhibitor site. Irreversible binding at either the inhibitor or the activator site on the channel was obtained with eosin-5-maleimide, resulting in irreversible inhibition or activation of the ATP-sensitive K+ channel respectively. The irreversibly activated channel could still be inhibited by 2 mM ATP. After activation by fluorescein derivatives, ATP-sensitive K+ channels become resistant to the classical blocker of this channel, the sulfonylurea glibenclamide. Negative allosteric interactions between fluorescein/nucleotide receptors and sulfonylurea-binding sites were suggested by results obtained in [H-3]glibenclamide-binding experiments.	SOPHIA ANTIPOLIS, INST PHARMACOL MOLEC & CELLULAIRE, 660 ROUTE LUCIOLES, F-06560 VALBONNE, FRANCE				de Weille, Jan R/F-8103-2014	de Weille, Jan R/0000-0002-0505-3166				ABBOTT AJ, 1991, BIOCHEMISTRY-US, V30, P1692, DOI 10.1021/bi00220a035; ARKHAMMAR P, 1987, J BIOL CHEM, V262, P5448; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; ASHFORD MLJ, 1988, PFLUG ARCH EUR J PHY, V412, P297, DOI 10.1007/BF00582512; BERNARDI H, 1988, P NATL ACAD SCI USA, V85, P9816, DOI 10.1073/pnas.85.24.9816; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; de Weille J R, 1990, Ion Channels, V2, P205; DUNN WJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P67; DUNNE MJ, 1986, FEBS LETT, V208, P59, DOI 10.1016/0014-5793(86)81532-0; DUNNE MJ, 1988, J MEMBRANE BIOL, V102, P205, DOI 10.1007/BF01925714; DUNNE MJ, 1986, PFLUG ARCH EUR J PHY, V407, P564, DOI 10.1007/BF00657518; FAN Z, 1990, J PHYSIOL-LONDON, V430, P273, DOI 10.1113/jphysiol.1990.sp018291; FARLEY RA, 1984, J BIOL CHEM, V259, P9532; FARLEY RA, 1985, J BIOL CHEM, V260, P3899; FINDLAY I, 1988, PFLUG ARCH EUR J PHY, V412, P37, DOI 10.1007/BF00583729; FINDLAY I, 1986, PFLUG ARCH EUR J PHY, V407, P238, DOI 10.1007/BF00580683; FINDLAY I, 1988, J MEMBRANE BIOL, V101, P83, DOI 10.1007/BF01872823; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; KAKEI M, 1985, J PHYSIOL-LONDON, V363, P441, DOI 10.1113/jphysiol.1985.sp015721; KAKEI M, 1986, FEBS LETT, V208, P63, DOI 10.1016/0014-5793(86)81533-2; KARLISH SJD, 1979, NATURE, V282, P333, DOI 10.1038/282333a0; KIRLEY TL, 1984, BIOCHEM BIOPH RES CO, V125, P767, DOI 10.1016/0006-291X(84)90605-3; LEDERER WJ, 1989, J PHYSIOL-LONDON, V419, P193, DOI 10.1113/jphysiol.1989.sp017869; MILLER RJ, 1990, TRENDS NEUROSCI, V13, P197, DOI 10.1016/0166-2236(90)90158-7; MISLER S, 1986, P NATL ACAD SCI USA, V83, P7119, DOI 10.1073/pnas.83.18.7119; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; MUALLEM S, 1983, J BIOL CHEM, V258, P169; NELSON MT, 1990, AM J PHYSIOL, V259, pC3; NELSON TY, 1987, J BIOL CHEM, V262, P2608; NIKI I, 1990, BIOCHEM J, V268, P713, DOI 10.1042/bj2680713; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; OHNOSHOSAKU T, 1987, PFLUG ARCH EUR J PHY, V408, P133, DOI 10.1007/BF00581342; PAL PK, 1990, J BIOL CHEM, V265, P14996; PETERSEN O H, 1989, Pfluegers Archiv European Journal of Physiology, V414, pS115, DOI 10.1007/BF00582259; POWELL T, 1980, J PHYSIOL-LONDON, V302, P131; RIBALET B, 1987, P NATL ACAD SCI USA, V84, P1721, DOI 10.1073/pnas.84.6.1721; RORSMAN P, 1989, POTASSIUM CHANNELS S, P96; SCHMIDANTOMARCHI H, 1987, BIOCHEM BIOPH RES CO, V146, P21, DOI 10.1016/0006-291X(87)90684-X; SCOTT TL, 1985, J BIOL CHEM, V260, P4421; SKOU JC, 1981, BIOCHIM BIOPHYS ACTA, V647, P232, DOI 10.1016/0005-2736(81)90251-0; SPRUCE AE, 1985, NATURE, V316, P736, DOI 10.1038/316736a0; SPRUCE AE, 1987, J PHYSIOL-LONDON, V382, P213, DOI 10.1113/jphysiol.1987.sp016364; STANDEN NB, 1989, SCIENCE, V245, P177, DOI 10.1126/science.2501869; STEKHOVEN FS, 1981, PHYSIOL REV, V61, P1; STURGESS NC, 1985, LANCET, V2, P474; TRUBE G, 1984, PFLUG ARCH EUR J PHY, V401, P178, DOI 10.1007/BF00583879; TSENG GN, 1990, PFLUG ARCH EUR J PHY, V415, P414, DOI 10.1007/BF00373618; WEIK R, 1989, J MEMBRANE BIOL, V110, P217, DOI 10.1007/BF01869152	48	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4557	4563						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1311312				2022-12-27	WOS:A1992HF64200044
J	ZHAO, GP; SOMERVILLE, RL				ZHAO, GP; SOMERVILLE, RL			GENETIC AND BIOCHEMICAL-CHARACTERIZATION OF THE TRPB8-MUTATION OF ESCHERICHIA-COLI TRYPTOPHAN SYNTHASE - AN AMINO-ACID SWITCH AT THE SHARP TURN OF THE TRYPSIN-SENSITIVE HINGE REGION DIMINISHES SUBSTRATE BINDING AND ALTERS SOLUBILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; SALMONELLA-TYPHIMURIUM; BACTERIOPHAGE-LAMBDA; MULTIENZYME COMPLEX; BETA-2 SUBUNIT; TRP REPRESSOR; SYNTHETASE; CLONING; OPERON; DNA	The trpB8 mutation of Escherichia coli tryptophan synthase is unique in that the cells bearing this lesion are not only capable of utilizing indole for growth, but they also accumulate indole, under conditions of tryptophan limitation. The lesion was shown by DNA sequencing to be a G to C transversion at nucleotide 5528 of the trp operon, resulting in a Gly to Arg switch at codon 281. Gly-281, within the trypsin-sensitive "hinge" region, is invariant among all known beta-polypeptides. The catalytic activity of the mutant beta-2(B8) protein is dramatically stimulated by alpha-subunit, both in vivo and in vitro. In the absence of alpha-subunit, ammonium ion effectively stimulated the activity in an apparently cooperative manner. The pH optimum for the mutant subunit was 9.8, which is 2 units higher than that of wild type. In contrast to the wild-type subunit, beta(B8) partially aggregated within cells upon overexpression. At the optimal concentration of ammonium ions (2.25 M), the beta-2(B8) mutant enzyme displayed lower affinity than wild-type enzyme toward indole and L-serine, but the V(max) was almost unchanged. The physicochemical behavior of beta-2(B8) is supported by computer graphic modeling studies. An open versus closed model of conformational change within the beta-2 protein is proposed. A plausible role for the hinge region is discussed.			ZHAO, GP (corresponding author), PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022131] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22131] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED SA, 1986, BIOCHEMISTRY-US, V25, P3118, DOI 10.1021/bi00359a008; BERLYN MB, 1989, P NATL ACAD SCI USA, V86, P4604, DOI 10.1073/pnas.86.12.4604; BLATTNER FR, 1977, SCIENCE, V196, P161, DOI 10.1126/science.847462; BOGOSIAN G, 1981, J MOL BIOL, V149, P821, DOI 10.1016/0022-2836(81)90361-2; BOGOSIAN G, 1984, MOL GEN GENET, V193, P110, DOI 10.1007/BF00327423; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNS DM, 1989, J BIOL CHEM, V264, P3840; Carmody W. R., 1961, J CHEM EDUC, V38, P559, DOI DOI 10.1021/ED038P559; CHUNG CT, 1988, NUCLEIC ACIDS RES, V16, P3580, DOI 10.1093/nar/16.8.3580; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; CRAWFORD I, 1975, SUBUNIT ENZYMES BIOC, V2, P223; CRAWFORD IP, 1980, J MOL BIOL, V142, P489, DOI 10.1016/0022-2836(80)90259-4; CRAWFORD IP, 1989, BIOCHIMIE, V71, P521, DOI 10.1016/0300-9084(89)90183-1; CRAWFORD IP, 1970, GENETICS, V65, P201; CRAWFORD IP, 1970, GENETICS, V66, P607; CRAWFORD IP, 1964, GENETICS, V49, P267; CRAWFORD IP, 1963, GENETICS, V48, P725; CRAWFORD IP, 1978, BIOCHEM BIOPH RES CO, V85, P309, DOI 10.1016/S0006-291X(78)80044-8; CREIGHTON TE, 1970, METHODS ENZYMOLOGY A, V17, P365, DOI DOI 10.1021/ACS.BIOCHEM.8B00167; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; GIBSON F, 1961, J GEN MICROBIOL, V24, P301, DOI 10.1099/00221287-24-2-301; GOTTESMAN ME, 1968, J MOL BIOL, V31, P487, DOI 10.1016/0022-2836(68)90423-3; HADERO A, 1986, MOL BIOL EVOL, V3, P191; HATANAKA M, 1962, ARCH BIOCHEM BIOPHYS, V97, P596, DOI 10.1016/0003-9861(62)90129-7; HAYDOCK PV, 1983, J MOL BIOL, V170, P1019, DOI 10.1016/S0022-2836(83)80201-0; HENNER DJ, 1985, GENE, V34, P169, DOI 10.1016/0378-1119(85)90125-8; HENNING U, 1962, J BIOL CHEM, V237, P1523; HERSCHMAN HR, 1967, J BACTERIOL, V94, P691, DOI 10.1128/JB.94.3.691-699.1967; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HOGBERGRAIBAUD A, 1977, P NATL ACAD SCI USA, V74, P442, DOI 10.1073/pnas.74.2.442; HYDE CC, 1990, BIO-TECHNOL, V8, P27, DOI 10.1038/nbt0190-27; HYDE CC, 1988, J BIOL CHEM, V263, P17857; ISHIWATA K, 1989, AGR BIOL CHEM TOKYO, V53, P2941, DOI 10.1080/00021369.1989.10869796; KAUFMANN M, 1991, BIOCHEMISTRY-US, V30, P4173, DOI 10.1021/bi00231a010; KAYASTHA AM, 1991, J BIOL CHEM, V266, P7618; KIDA S, 1974, J BACTERIOL, V118, P551, DOI 10.1128/JB.118.2.551-559.1974; KOYAMA Y, 1990, J BACTERIOL, V172, P3490, DOI 10.1128/jb.172.6.3490-3495.1990; KRUEGER JK, 1989, PROTEIN FOLDING DECI, P136; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAM WL, 1990, P NATL ACAD SCI USA, V87, P6614, DOI 10.1073/pnas.87.17.6614; LENNOX ES, 1955, VIROLOGY, V1, P190, DOI 10.1016/0042-6822(55)90016-7; LIM WK, 1989, APPL ENVIRON MICROB, V55, P1106, DOI 10.1128/AEM.55.5.1106-1111.1989; Maniatis T., 1982, MOL CLONING; MATSUI K, 1986, NUCLEIC ACIDS RES, V14, P10113, DOI 10.1093/nar/14.24.10113; MCKITRICK JC, 1980, J BACTERIOL, V141, P235, DOI 10.1128/JB.141.1.235-245.1980; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MOSTELLER RD, 1977, J BIOL CHEM, V252, P4527; NAGATA S, 1989, J BIOL CHEM, V264, P6288; RAVNIKAR PD, 1987, J BACTERIOL, V169, P4716, DOI 10.1128/jb.169.10.4716-4721.1987; ROEDER W, 1979, MOL GEN GENET, V176, P361, DOI 10.1007/BF00333098; ROSS CM, 1988, J BACTERIOL, V170, P757, DOI 10.1128/jb.170.2.757-768.1988; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHIMADA K, 1973, J MOL BIOL, V80, P297, DOI 10.1016/0022-2836(73)90174-5; SIBOLD L, 1988, MOL GEN GENET, V214, P439, DOI 10.1007/BF00330478; SKRZYNIA C, 1989, GENE, V81, P73, DOI 10.1016/0378-1119(89)90338-7; SMITH OH, 1962, METHOD ENZYMOL, V5, P794, DOI 10.1016/S0076-6879(62)05315-X; SNELL EE, 1975, ADV ENZYMOL RAMB, V42, P287; UZAN M, 1976, BIOCHEM BIOPH RES CO, V69, P751, DOI 10.1016/0006-291X(76)90939-6; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; YANOFSKY C, 1957, J BIOL CHEM, V224, P783; YANOFSKY C, 1981, NUCLEIC ACIDS RES, V9, P6647, DOI 10.1093/nar/9.24.6647; YANOFSKY C, 1960, BACTERIOL REV, V24, P221, DOI 10.1128/MMBR.24.2.221-245.1960; YANOFSKY C, 1971, GENETICS, V69, P409; YANOFSKY C, 1958, P NATL ACAD SCI USA, V44, P245, DOI 10.1073/pnas.44.3.245; YANOFSKY C, 1972, ENZYMES, V7, P1; ZALKIN H, 1982, J BIOL CHEM, V257, P1491; ZHAO GP, 1990, THESIS PURDUE U	71	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					526	541						16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1309752				2022-12-27	WOS:A1992GY43900084
J	KAHARI, VM; CHEN, YQ; BASHIR, MM; ROSENBLOOM, J; UITTO, J				KAHARI, VM; CHEN, YQ; BASHIR, MM; ROSENBLOOM, J; UITTO, J			TUMOR-NECROSIS-FACTOR-ALPHA DOWN-REGULATES HUMAN ELASTIN GENE-EXPRESSION - EVIDENCE FOR THE ROLE OF AP-1 IN THE SUPPRESSION OF PROMOTER ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; HUMAN DERMAL FIBROBLASTS; MESSENGER-RNA; C-JUN; 5'-FLANKING REGION; CONNECTIVE-TISSUE; RECOMBINANT INTERLEUKIN-1-BETA; FUNCTIONAL PROMOTER; INHIBITS COLLAGEN; SKIN FIBROBLASTS	Cytokine modulation of elastin gene expression was examined by assay of elastin mRNA abundance and by transient transfections of cultured human skin fibroblasts and rat aortic smooth muscle cells with elastin promoter/reporter gene (chloramphenicol acetyltransferase, CAT) constructs. Incubation of cells with human recombinant tumor necrosis factor-alpha (TNF-alpha) markedly suppressed the elastin mRNA levels in a time- and dose-dependent manner by up to 91%. TNF-alpha also suppressed the expression of the elastin promoter/CAT construct by up to 70% in transiently transfected cells, indicating regulation at the transcriptional level. This suppression was temporally preceded by rapid and transient up-regulation of c-jun and c-fos genes. The down-regulatory effect of TNF-alpha on elastin promoter activity was abolished by co-transfections with a synthetic double-stranded AP-1 oligomer. Furthermore, co-transfection of the elastin promoter construct with c-jun and c-fos expression plasmids resulted in a marked decrease in the promoter activity. Elucidation of the cis-regulatory elements in the elastin promoter by 5' deletion construct analysis implicated a region -290 to -198 containing one AP-1 binding site. The functional role of this AP-1 site was further tested by gel retardation assays which indicated formation of a DNA-protein complex specific for TNF-alpha treated cells. This complex could be partially dissociated by a competing oligomer containing the consensus AP-1 binding site. These observations suggest that the inhibitory effects of TNF-alpha on elastin gene expression involve the transcription factor AP-1. Interferon-gamma also suppressed the elastin gene expression at the mRNA level by approximately 52%, but it had no effect on the elastin promoter activity, suggesting post-transcriptional mechanisms. These results indicate that mediators released from inflammatory cells can modulate elastin gene expression, and such modulation may play a role in diseases characterized by altered accumulation of elastic fibers in tissues.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL,DEPT DERMATOL,233 S 10TH ST, BLSB 450, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, DEPT MOLEC BIOL, PHILADELPHIA, PA 19107 USA; UNIV PENN, SCH DENT MED, DEPT ANAT & HISTOL, PHILADELPHIA, PA 19104 USA; THOMAS JEFFERSON UNIV, JEFFERSON INST MOLEC MED, MOLEC DERMATOL SECT, PHILADELPHIA, PA 19107 USA	Jefferson University; Jefferson University; University of Pennsylvania; Jefferson University	UITTO, J (corresponding author), THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, DEPT DERMATOL, 233 S 10TH ST, BLSB 450, PHILADELPHIA, PA 19107 USA.		Kahari, Veli-Matti/E-5144-2011	Kahari, Veli-Matti/0000-0003-2421-9368	NIAMS NIH HHS [AR28450, T32-AR 7685, AR20553] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR020553, R01AR028450] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABERGEL RP, 1985, J INVEST DERMATOL, V84, P384, DOI 10.1111/1523-1747.ep12265471; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BADESCH DB, 1989, BIOCHEM BIOPH RES CO, V160, P382, DOI 10.1016/0006-291X(89)91667-7; BASHIR MM, 1989, J BIOL CHEM, V264, P8887; BERK JL, 1991, J BIOL CHEM, V266, P3192; BEUTLER B, 1985, J EXP MED, V161, P984, DOI 10.1084/jem.161.5.984; BIETH J, 1978, FRONTIERS MATRIX BIO, V6, P1; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOOTH BA, 1980, BIOCHIM BIOPHYS ACTA, V607, P145, DOI 10.1016/0005-2787(80)90228-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER DA, 1989, NUCLEIC ACIDS RES, V17, P6055, DOI 10.1093/nar/17.15.6055; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; Burke J M, 1979, Int Rev Connect Tissue Res, V8, P119; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CONCA W, 1989, J CLIN INVEST, V83, P1753, DOI 10.1172/JCI114077; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FARIS B, 1976, BIOCHIM BIOPHYS ACTA, V418, P93, DOI 10.1016/0005-2787(76)90330-0; FAZIO MJ, 1988, J INVEST DERMATOL, V91, P458, DOI 10.1111/1523-1747.ep12476591; FAZIO MJ, 1990, J INVEST DERMATOL, V94, P191, DOI 10.1111/1523-1747.ep12874495; FAZIO MJ, 1991, AM J HUM GENET, V48, P696; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GIRO MG, 1985, J CLIN INVEST, V75, P672, DOI 10.1172/JCI111746; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; INDIK Z, 1987, P NATL ACAD SCI USA, V84, P5680, DOI 10.1073/pnas.84.16.5680; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; KAHARI VM, 1990, J BIOL CHEM, V265, P9485; KAHARI VM, 1992, LAB INVEST, V66, P580; KRANE SM, 1990, ANN NY ACAD SCI, V580, P340, DOI 10.1111/j.1749-6632.1990.tb17943.x; Lavker R M, 1989, Clin Geriatr Med, V5, P53; LEVER WF, 1983, HISTOPATHOLOGY SKIN, P604; LIU JM, 1988, BIOCHEM BIOPH RES CO, V154, P895, DOI 10.1016/0006-291X(88)90224-0; MAUVIEL A, 1988, FEBS LETT, V236, P47, DOI 10.1016/0014-5793(88)80283-7; MAUVIEL A, 1991, J INVEST DERMATOL, V96, P243, DOI 10.1111/1523-1747.ep12462185; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; OAKES BW, 1982, EUR J CELL BIOL, V27, P34; OWEN TA, 1990, P NATL ACAD SCI USA, V87, P9990, DOI 10.1073/pnas.87.24.9990; ROSENBLOOM J, 1991, ANN NY ACAD SCI, V624, P116, DOI 10.1111/j.1749-6632.1991.tb17012.x; ROSENBLOOM J, 1984, LAB INVEST, V51, P605; Sambrook J, 1989, MOL CLONING LABORATO; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SEPHEL GC, 1987, J INVEST DERMATOL, V88, P732, DOI 10.1111/1523-1747.ep12470403; SOLISHERRUZO JA, 1988, J BIOL CHEM, V263, P5841; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; UITTO J, 1988, J CUTANEOUS AGING CO, V1, P13; UITTO J, 1991, PHYSL BIOCH MOL BIOL, P533; WERB Z, 1982, J INVEST DERMATOL, V79, pS154, DOI 10.1111/1523-1747.ep12546056; WRENN DS, 1987, J BIOL CHEM, V262, P2244	54	111	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					26134	26141						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1281483				2022-12-27	WOS:A1992KD07300082
J	HUTTENHOFER, A; HUDSON, S; NOLLER, HF; MASCHARAK, PK				HUTTENHOFER, A; HUDSON, S; NOLLER, HF; MASCHARAK, PK			CLEAVAGE OF TRANSFER-RNA BY FE(II)-BLEOMYCIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED BLEOMYCIN; DNA; BINDING; MECHANISM	We have investigated the action of the chemotherapeutic agent Fe(II)-bleomycin on yeast tRNA(Phe), an RNA of known three-dimensional structure. In the absence of Mg2+ ions, the RNA is cleaved preferentially at two major positions, A31 and G53, both of which are located at the terminal base pairs of hairpin loops, and coincide with the location of tight Mg2+ binding sites. A fragment of the tRNA (residues 47-76) containing the T stem-loop is also cleaved specifically at G53. Cleavage of both the intact tRNA and the tRNA fragment is abolished in the presence of physiological concentrations of Mg2+ (>0.5 mM). Since Fe(II) is not displaced from bleomycin under these conditions, we infer that tight binding of Mg2+ to tRNA excludes productive interactions between Fe(II)-bleomycin and the RNA. These results also show that loss of cleavage is not due to Mg2+-dependent formation of tertiary interactions between the D and T loops. In contrast, cleavage of synthetic DNA analogs of the anticodon and T stem-loops is not detectably inhibited by Mg2+, even at concentrations as high as 50 mM. In addition, the site specificities observed in cleavage of RNA and DNA differ significantly. From these results, and from similar findings with other representative RNA molecules, we suggest that the cleavage of RNA by Fe(II)-bleomycin is unlikely to be important for its therapeutic action.	UNIV CALIF SANTA CRUZ,SINSHEIMER LABS,SANTA CRUZ,CA 95064	University of California System; University of California Santa Cruz					NATIONAL CANCER INSTITUTE [R29CA053076] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017129, R37GM017129] Funding Source: NIH RePORTER; NCI NIH HHS [CA 53076, CA 53076-01] Funding Source: Medline; NIGMS NIH HHS [GM-17129] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUM RH, 1973, CANCER, V31, P903, DOI 10.1002/1097-0142(197304)31:4<903::AID-CNCR2820310422>3.0.CO;2-N; CARTER BJ, 1990, P NATL ACAD SCI USA, V87, P9373, DOI 10.1073/pnas.87.23.9373; CIESIOLKA J, 1989, EUR J BIOCHEM, V186, P71, DOI 10.1111/j.1432-1033.1989.tb15179.x; DABROWIAK JC, 1983, ADV INORG BIOCHEM, V4, P69; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; England T E, 1980, Methods Enzymol, V65, P65; HECHT SM, 1986, ACCOUNTS CHEM RES, V19, P383, DOI 10.1021/ar00132a002; HEERSCHAP A, 1983, NUCLEIC ACIDS RES, V11, P4501, DOI 10.1093/nar/11.13.4501; Kim S-H, 1979, TRANSFER RNA STRUCTU, P83; MAGLIOZZO RS, 1989, MOL PHARMACOL, V35, P428; MANIATIS T, 1982, MOL CLONING LABORATO, P124; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; PETERING DH, 1990, CHEM-BIOL INTERACT, V73, P133, DOI 10.1016/0009-2797(90)90001-4; SCHIMMEL PR, 1980, ANNU REV BIOPHYS BIO, V9, P181, DOI 10.1146/annurev.bb.09.060180.001145; STUBBE J, 1987, CHEM REV, V87, P1107, DOI 10.1021/cr00081a011; SUGIURA Y, 1985, MET IONS BIOL SYST, V19, P81; SUZUKI H, 1970, J ANTIBIOT, V23, P473, DOI 10.7164/antibiotics.23.473; TEETER MM, 1980, NUCLEIC ACID METAL I, P145; TULLIUS TD, 1985, SCIENCE, V230, P679, DOI 10.1126/science.2996145; UMEZAWA H, 1984, TETRAHEDRON, V40, P501, DOI 10.1016/0040-4020(84)85055-3; ZUEVA VS, 1985, EUR J BIOCHEM, V146, P679, DOI 10.1111/j.1432-1033.1985.tb08704.x	21	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24471	24475						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1280260				2022-12-27	WOS:A1992KA26300052
J	KETTLE, AJ; WINTERBOURN, CC				KETTLE, AJ; WINTERBOURN, CC			OXIDATION OF HYDROQUINONE BY MYELOPEROXIDASE - MECHANISM OF STIMULATION BY BENZOQUINONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-DISMUTASE; HYDROGEN-PEROXIDE; ELECTRON-TRANSFER; RADICALS; CARCINOGENS; REACTIVITY; LEUKOCYTES; CHLORIDE; PHENOLS; REDOX	Myeloperoxidase (MPO) is a prime candidate for mediating the inflammatory tissue damage of neutrophils because it converts Cl- to the potent oxidant hypochlorous acid. It also oxidizes xenobiotics to reactive free radicals. We have found that the kinetics of oxidation of hydroquinone by myeloperoxidase are inadequately explained by the classical peroxidase mechanism. Peroxidation of hydroquinone displayed a distinct lag phase, which was practically abolished by excluding O2 and was eliminated by adding benzoquinone at the start of the reaction. Superoxide dismutase increased the rate of peroxidation by 40% but did not eliminate the lag phase. Spectral investigations revealed that during the initial phase of the reaction, MPO was converted to oxy-MPO, or compound III, by a mechanism that was not reliant on superoxide. Benzosemiquinone, however, was able to convert ferric-MPO to compound III. Both compound III and ferro-MPO reacted with benzoquinone to regenerate ferric-MPO. We propose that the lag phase occurs because benzosemiquinone reduces ferric-MPO to ferro-MPO, which rapidly binds O2 to form compound III. Since compound III is outside the peroxidation cycle, conversion of hydroquinone to benzoquinone is retarded. However, as benzoquinone accumulates, it oxidizes ferro-MPO and compound III to ferric-MPO, thereby increasing the rate of peroxidation. There is a minimal lag phase under an atmosphere of N2 because ferro-MPO would be rapidly oxidized by benzoquinone, without formation of compound III. We conclude that when substrates produce radicals capable of reducing ferric-MPO, they will be peroxidized efficiently only if oxy-MPO is readily recycled. Furthermore, these radicals will prevent MP3+ from reacting with H2O2, and thereby prevent the enzyme from oxidizing Cl- to hypochlorous acid. Thus, this mechanism could be exploited to prevent hypochlorous acid-mediated inflammatory tissue damage.			KETTLE, AJ (corresponding author), CHRISTCHURCH SCH MED,DEPT PATHOL,FREE RAD RES UNIT,CHRISTCHURCH,NEW ZEALAND.		Kettle, Anthony J/A-8520-2008	Kettle, Anthony J/0000-0002-8218-7766				BEERS RF, 1952, J BIOL CHEM, V195, P133; ELING TE, 1990, ANNU REV PHARMACOL, V30, P1, DOI 10.1146/annurev.pa.30.040190.000245; HALLIWELL B, 1980, OXIDASES RELATED RED, P733; HOOGLAND H, 1988, BIOCHIM BIOPHYS ACTA, V955, P337, DOI 10.1016/0167-4838(88)90213-0; HUANG J, 1991, ARCH BIOCHEM BIOPHYS, V287, P257, DOI 10.1016/0003-9861(91)90476-Y; IKEDASAITO M, 1985, J BIOL CHEM, V260, P8301; ILAN YA, 1976, BIOCHIM BIOPHYS ACTA, V430, P209, DOI 10.1016/0005-2728(76)90080-3; James TH, 1938, J AM CHEM SOC, V60, P2084, DOI 10.1021/ja01276a020; KETTLE AJ, 1991, BIOCHEM PHARMACOL, V41, P1485, DOI 10.1016/0006-2952(91)90565-M; KETTLE AJ, 1988, BIOCHEM J, V252, P529, DOI 10.1042/bj2520529; KETTLE AJ, 1988, BIOCHIM BIOPHYS ACTA, V956, P58, DOI 10.1016/0167-4838(88)90297-X; KLEBANOFF SJ, 1967, J CLIN INVEST, V46, P1078; KOBAYASHI K, 1990, BIOCHEMISTRY-US, V29, P2080, DOI 10.1021/bi00460a017; LEE TT, 1982, PHYTOCHEMISTRY, V21, P517, DOI 10.1016/0031-9422(82)83132-4; MEISEL D, 1975, CHEM PHYS LETT, V34, P263, DOI 10.1016/0009-2614(75)85269-9; NAKAJIMA R, 1979, J BIOL CHEM, V254, P872; NAKAMURA M, 1985, J BIOL CHEM, V260, P3546; OBRIEN PJ, 1988, FREE RADICAL BIO MED, V4, P169, DOI 10.1016/0891-5849(88)90025-1; ODAJIMA T, 1972, BIOCHIM BIOPHYS ACTA, V284, P355, DOI 10.1016/0005-2744(72)90130-1; OHLSSON PI, 1982, DEV BIOCHEM, V23, P805; SAWADA Y, 1975, BIOCHEMISTRY-US, V17, P3761; SMITH MT, 1990, PROG CLIN BIOL RES, V340, P125; SUBRAHMANYAM VV, 1991, ARCH BIOCHEM BIOPHYS, V286, P76, DOI 10.1016/0003-9861(91)90010-G; SUTTON HC, 1975, J CHEM SOC F1, V78, P695; SUZUKI K, 1986, ARCH BIOCHEM BIOPHYS, V245, P167, DOI 10.1016/0003-9861(86)90201-8; TSURUTA Y, 1985, CHEM-BIOL INTERACT, V53, P25, DOI 10.1016/S0009-2797(85)80081-8; WEITZMAN SA, 1990, BLOOD, V76, P655; WINTERBOURN CC, 1981, ARCH BIOCHEM BIOPHYS, V209, P159, DOI 10.1016/0003-9861(81)90268-X; WINTERBOURN CC, 1979, BIOCHEM J, V179, P665, DOI 10.1042/bj1790665; WINTERBOURN CC, 1985, BIOCHEM J, V228, P583, DOI 10.1042/bj2280583; WINTERBOURN CC, 1989, OXYGEN RADICALS SYST, P31; YAMADA H, 1975, ARCH BIOCHEM BIOPHYS, V169, P334; YAMAZAKI I, 1963, BIOCHIM BIOPHYS ACTA, V77, P47, DOI 10.1016/0006-3002(63)90468-2; YOKOTA K, 1965, BIOCHEM BIOPH RES CO, V18, P48, DOI 10.1016/0006-291X(65)90880-6	34	58	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8319	8324						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1314822				2022-12-27	WOS:A1992HQ18500056
J	COLLIER, IE; KRASNOV, PA; STRONGIN, AY; BIRKEDALHANSEN, H; GOLDBERG, GI				COLLIER, IE; KRASNOV, PA; STRONGIN, AY; BIRKEDALHANSEN, H; GOLDBERG, GI			ALANINE SCANNING MUTAGENESIS AND FUNCTIONAL-ANALYSIS OF THE FIBRONECTIN-LIKE COLLAGEN-BINDING DOMAIN FROM HUMAN 92-KDA TYPE-IV COLLAGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST COLLAGENASE; BOVINE SEMINAL PLASMA; AMINO-ACID SEQUENCE; HUMAN-SKIN; ESCHERICHIA-COLI; PROTEIN; SITE; GELATIN; GENE; FRAGMENTS	The human 72-kDa (CLG4A) and 92-kDa (CLG4B) type IV collagenases contain a domain consisting of three contiguous copies of the fibronectin (FN)-derived type II homology unit (T2HU), T2HU-1, T2HU-2, and T2HU-3. To investigate the functional role of this domain, we have constructed plasmids expressing beta-galactosidase fusion proteins with one or more of the CLG4B-derived T2HU. The gelatin binding assays demonstrate that a single copy of T2HU-2 renders beta-galactosidase capable of binding gelatin. The three repeats, however, differ dramatically in their capacity to bind gelatin, with T2HU-1 and T2HU-3 having significantly less binding activity than T2HU-2. Using alanine scanning mutagenesis we have defined the amino acid residues (Arg307, Asp309, Asn319, Tyr320, Asp323) that are critical for gelatin binding of T2HU-2. The low gelatin binding of T2HU-1 compared to T2HU-2 was traced to the non-conserved residues Ala228-Ala and Leu253-Pro. The results suggest that the gelatin binding of the type IV collagenase proenzyme is mediated by the FN-like domain, although the presence of another gelatin-binding site cannot be excluded. The FN domain-mediated binding, however, is not a rate-limiting step in the hydrolysis of gelatin by the enzyme.	UNIV ALABAMA,DEPT ORAL BIOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham	COLLIER, IE (corresponding author), WASHINGTON UNIV,SCH MED,DIV DERMATOL,ST LOUIS,MO 63110, USA.		Strongin, Alex/R-6609-2019	Strongin, Alex/0000-0003-3765-3016	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007284, R01AR039472] Funding Source: NIH RePORTER; NIAMS NIH HHS [5R01 AR39472, 5 T32 AR07284-13] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBER T, 1987, BIOCHEMISTRY-US, V26, P3754, DOI 10.1021/bi00387a002; BANYAI L, 1990, EUR J BIOCHEM, V193, P801, DOI 10.1111/j.1432-1033.1990.tb19403.x; BASSET P, 1990, NATURE, V348, P20; CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; COLLIER IE, 1988, J BIOL CHEM, V263, P10711; COLLIER IE, 1991, GENOMICS, V9, P429, DOI 10.1016/0888-7543(91)90408-7; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CONSTANTINE KL, 1991, BIOCHEMISTRY-US, V30, P1663, DOI 10.1021/bi00220a032; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; ESCH FS, 1983, BIOCHEM BIOPH RES CO, V113, P861, DOI 10.1016/0006-291X(83)91078-1; FALOONA F, 1987, METHOD ENZYMOL, V155, P335; FIELDS GB, 1987, J BIOL CHEM, V262, P6221; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GOLDBERG GI, 1991, REGULATORY MECHANISM, P421; GRANT GA, 1987, J BIOL CHEM, V262, P5886; HASTY KA, 1990, J BIOL CHEM, V265, P11421; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HECHT MH, 1983, P NATL ACAD SCI-BIOL, V80, P2676, DOI 10.1073/pnas.80.9.2676; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOLLAND SK, 1987, EMBO J, V6, P1875, DOI 10.1002/j.1460-2075.1987.tb02446.x; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; HYNES RO, 1990, FIBRONECTINS, P119; INGHAM KC, 1989, J BIOL CHEM, V264, P16977; ISAACS BS, 1989, BIOCHEMISTRY-US, V28, P842, DOI 10.1021/bi00428a065; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MCKERROW JH, 1987, J BIOL CHEM, V262, P5943; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; OWENS RJ, 1986, EMBO J, V5, P2825, DOI 10.1002/j.1460-2075.1986.tb04575.x; PARK AJ, 1991, J BIOL CHEM, V266, P1584; REIDHAAROLSON JF, 1988, SCIENCE, V241, P53, DOI 10.1126/science.3388019; RUOSLAHTI E, 1988, ANN REV BIOCH, V57, P775; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SEIDAH NG, 1987, BIOCHEM J, V243, P195, DOI 10.1042/bj2430195; SELTZER JL, 1981, J BIOL CHEM, V256, P4662; SELTZER JL, 1989, J BIOL CHEM, V264, P19583; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; VALLEE BL, 1990, P NATL ACAD SCI USA, V87, P220, DOI 10.1073/pnas.87.1.220; VUENTO M, 1982, BIOCHEM J, V201, P1; VUENTO M, 1983, MOL IMMUNOL, V20, P149, DOI 10.1016/0161-5890(83)90125-6; WEINGARTEN H, 1985, BIOCHEMISTRY-US, V24, P6730, DOI 10.1021/bi00344a064; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WILHELM SM, 1986, P NATL ACAD SCI USA, V83, P3756, DOI 10.1073/pnas.83.11.3756; WINDSOR LJ, 1991, BIOCHEMISTRY-US, V30, P641, DOI 10.1021/bi00217a008	45	134	137	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6776	6781						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1313021				2022-12-27	WOS:A1992HM05300049
J	TSIANG, M; LENTZ, SR; SADLER, JE				TSIANG, M; LENTZ, SR; SADLER, JE			FUNCTIONAL DOMAINS OF MEMBRANE-BOUND HUMAN THROMBOMODULIN - EGF-LIKE DOMAIN-4 TO DOMAIN-6 AND THE SERINE THREONINE-RICH DOMAIN ARE REQUIRED FOR COFACTOR ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN THROMBOMODULIN; PROTEIN-C ACTIVATION; THROMBIN BINDING; HOMOLOGY DOMAIN; DNA; LOCALIZATION; INHIBITORS; SEQUENCE; COMPLEX; PLASMA	Thrombomodulin is an endothelial cell thrombin receptor that serves as a cofactor for thrombin-catalyzed activation of protein C. Structural requirements for thrombin binding and cofactor activity were studied by mutagenesis of recombinant human thrombomodulin expressed on COS-7 and CV-1 cells. Deletion of the fourth epidermal growth factor (EGF)-like domain abolished cofactor activity but did not affect thrombin binding. Deletion of either the fifth or the sixth EGF-like domain markedly reduced both thrombin binding affinity and cofactor activity. Thrombin binding sequences were also localized by assaying the ability of synthetic peptides derived from thrombomodulin to compete with diisopropyl fluorophosphate-inactivated I-125-thrombin binding to thrombomodulin. The two most active peptides corresponded to (a) the entire third loop of the fifth EGF-like domain (K(p) = 85 +/- 6-mu-M) and (b) parts of the second and third loops of the sixth EGF-like domain (K(p) = 117 +/- 9-mu-M). These data suggest that thrombin interacts with two discrete elements in thrombomodulin. Deletion of the Ser/Thr-rich domain dramatically decreased both thrombin binding affinity and cofactor activity and also prevented the formation of a high molecular weight thrombomodulin species containing chondroitin sulfate. Substitutions of this domain with polypeptide segments of decreasing length and devoid of glycosylation sites progressively decreased both cofactor activity and thrombin binding affinity. This correlation suggests that increased proximity of the membrane surface to the thrombin binding site may hinder efficient thrombin binding and the subsequent activation of protein C. Membrane-bound thrombomodulin therefore requires the Ser/Thr-rich domain as an important spacer, in addition to EGF-like domains 4-6, for efficient protein C activation.	WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,660 S EUCLID,BOX 8045,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,DIV HEMATOL ONCOL,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)			Sadler, Evan/D-8556-2011	Lentz, Steven/0000-0002-8885-4718; Sadler, J. Evan/0000-0001-5705-469X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007088, P50HL014147] Funding Source: NIH RePORTER; NHLBI NIH HHS [HLBI 14147, T32 HLBI 07088] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; CAMPBELL ID, 1990, BIOCHEM PHARMACOL, V40, P35, DOI 10.1016/0006-2952(90)90175-K; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CRIMMINS DL, 1988, J CHROMATOGR, V443, P63, DOI 10.1016/S0021-9673(00)94783-6; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; ESMON NL, 1983, J BIOL CHEM, V258, P2238; ESMON NL, 1982, J BIOL CHEM, V257, P859; ESMON NL, 1987, SEMIN THROMB HEMOST, V13, P454, DOI 10.1055/s-2007-1003522; GREGORY H, 1977, INT J PEPT PROT RES, V9, P107; HAYASHI T, 1990, J BIOL CHEM, V265, P20156; HORTIN GL, 1990, BIOCHEM BIOPH RES CO, V169, P437, DOI 10.1016/0006-291X(90)90350-V; ISHII H, 1985, J CLIN INVEST, V76, P2178, DOI 10.1172/JCI112225; JACKMAN RW, 1987, P NATL ACAD SCI USA, V84, P6425, DOI 10.1073/pnas.84.18.6425; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLINE TP, 1990, BIOCHEMISTRY-US, V29, P7805, DOI 10.1021/bi00486a005; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; LENTZ SR, 1991, J CLIN INVEST, V88, P1906, DOI 10.1172/JCI115514; LENTZ SR, 1991, BLOOD, V77, P542; LU RL, 1989, J BIOL CHEM, V264, P12956; MARUYAMA I, 1985, J BIOL CHEM, V260, P5432; NAWA K, 1990, BIOCHEM BIOPH RES CO, V171, P729, DOI 10.1016/0006-291X(90)91207-9; PARKINSON JF, 1990, J BIOL CHEM, V265, P12602; PARKINSON JF, 1991, THROMB HAEMOSTASIS, V65; Richardson J.S., 1990, PREDICTION PROTEIN S, P1; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEARNS DJ, 1989, J BIOL CHEM, V264, P3352; SUZUKI K, 1989, J BIOL CHEM, V264, P4872; SUZUKI K, 1987, EMBO J, V6, P1897; TAKANO S, 1990, BLOOD, V76, P2024; TOMIC M, 1990, NUCLEIC ACIDS RES, V18, P1656, DOI 10.1093/nar/18.6.1656; TSIANG M, 1990, BIOCHEMISTRY-US, V29, P10602, DOI 10.1021/bi00499a005; WEN DZ, 1987, BIOCHEMISTRY-US, V26, P4350, DOI 10.1021/bi00388a025; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; ZUSHI M, 1989, J BIOL CHEM, V264, P10351	35	99	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6164	6170						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1313430				2022-12-27	WOS:A1992HK31800068
J	TARTAGLIA, LA; GOEDDEL, DV				TARTAGLIA, LA; GOEDDEL, DV			TUMOR-NECROSIS-FACTOR RECEPTOR SIGNALING - A DOMINANT NEGATIVE MUTATION SUPPRESSES THE ACTIVATION OF THE 55-KDA TUMOR-NECROSIS-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MONOCLONAL-ANTIBODIES; FACTOR TNF; MOLECULAR-CLONING; CELL-LINES; BINDING; EXPRESSION; TRANSDUCTION; PROTEINS; ALPHA	To investigate the signaling mechanism of the 55-kDa tumor necrosis factor (TNF) receptor a functional transfection based assay was developed. The human 55-kDa TNF receptor, stably expressed in mouse L929 cells, was demonstrated to be activated specifically by agonist antibodies and to initiate a signal for cellular cytotoxicity. A deletion mutant of the human TNF receptor lacking most of the cytoplasmic domain was found to be completely defective in generating the signal for cytotoxicity. Additionally, expression of the truncated receptor substantially suppressed signaling by endogenous mouse TNF receptors in response to TNF, but not in response to specific anti-murine TNF receptor antibodies. These results suggest that aggregation of 55-kDa TNF receptor intracellular domains, which are not associated in the absence of ligand, is an important component of the signal for cellular toxicity. This work also provides an example of a dominant negative mutation in a transmembrane receptor that lacks a tyrosine kinase domain, and suggests a more general utility of dominant negative mutations in the investigation of cytokine receptor function.			TARTAGLIA, LA (corresponding author), GENENTECH INC,DEPT MOLEC BIOL,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080, USA.							AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BAGLIONI C, 1985, J BIOL CHEM, V260, P3395; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CAMERINI D, 1991, J IMMUNOL, V147, P3165; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; DECKER T, 1987, J IMMUNOL, V138, P957; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; GOEDDEL DV, 1986, COLD SPRING HARB SYM, V51, P597, DOI 10.1101/SQB.1986.051.01.072; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KULL FC, 1985, P NATL ACAD SCI USA, V82, P5756, DOI 10.1073/pnas.82.17.5756; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOETSCHER H, 1991, J BIOL CHEM, V266, P18324; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; OLD LJ, 1988, SCI AM, V258, P59, DOI 10.1038/scientificamerican0588-59; PENNICA D, 1992, IN PRESS BIOCHEMISTR; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SHALABY MR, 1990, J EXP MED, V172, P1517, DOI 10.1084/jem.172.5.1517; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SPRIGGS DR, 1988, J CLIN INVEST, V81, P455, DOI 10.1172/JCI113341; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; TURNER M, 1987, EUR J IMMUNOL, V17, P1807, DOI 10.1002/eji.1830171220; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	35	136	147	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4304	4307						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1311304				2022-12-27	WOS:A1992HF64200008
J	HOMMA, Y; EMORI, Y; TAKENAWA, T				HOMMA, Y; EMORI, Y; TAKENAWA, T			ISOLATION AND CHARACTERIZATION OF RAT 3Y1 FIBROBLAST CLONES OVEREXPRESSING THE SRC HOMOLOGY REGION OF PHOSPHOLIPASE-C-GAMMA-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; C-GAMMA; SIGNAL TRANSDUCTION; FACTOR RECEPTOR; PROTEIN; PHOSPHORYLATION; ASSOCIATION; ONCOGENE; DOMAINS	To examine the regulatory function of the src-related SH2 and SH3 (SH2/SH3) region of phospholipase C-gamma-2 (PLC-gamma-2), we expressed this region of rat PLC-gamma-2 cDNA in rat 3Y1 fibroblasts and isolated and characterized a number of clones (approximately 20 clones). An increase of endogenous tyrosine kinase activity was observed in all cell clones that highly expressed a translational product of the SH2/SH3 domain. Moreover, endogenous phosphatidylinositol 4,5-bisphosphate hydrolyzing activity was also enhanced in these clones, and PLC-gamma-1 seemed to be preferentially activated among endogenous PLC isozymes. Genistein, an inhibitor of tyrosine kinase, inhibited this activation of PLC-gamma-1, and tyrosine phosphorylation was observed on PLC-gamma-1 molecules, indicating the involvement of tyrosine kinases in the PLC-gamma-1 activation. These results suggest that the SH2/SH3 region of PLC-gamma would function as a multidirectional regulator which controls at least two major signaling pathways: tyrosine kinase and phosphatidylinositol 4,5-bisphosphate hydrolysis.	UNIV TOKYO, FAC SCI, DEPT BIOPHYS & BIOCHEM, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo	HOMMA, Y (corresponding author), TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL, DEPT BIOSIGNAL RES, 35-2 SAKAE, TOKYO 173, JAPAN.							ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; EMORI Y, 1989, J BIOL CHEM, V264, P21885; EMORI Y, 1988, J BIOL CHEM, V263, P2364; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HOMMA Y, 1988, J BIOL CHEM, V263, P6592; HOMMA Y, 1989, BIOCHEM BIOPH RES CO, V164, P406, DOI 10.1016/0006-291X(89)91734-8; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KRIZ R, 1990, CIBA F SYMP, V150, P112; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MATUDA M, 1990, SCIENCE, V248, P1537; MATUDA M, 1990, J BIOL CHEM, V265, P12000; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; NISHIBE S, 1990, P NATL ACAD SCI USA, V87, P424, DOI 10.1073/pnas.87.1.424; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; Sambrook J, 1989, MOL CLONING LABORATO; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934	34	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3778	3782						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1310981				2022-12-27	WOS:A1992HE60700038
J	NOVOKHATNY, V; MEDVED, L; MAZAR, A; MARCOTTE, P; HENKIN, J; INGHAM, K				NOVOKHATNY, V; MEDVED, L; MAZAR, A; MARCOTTE, P; HENKIN, J; INGHAM, K			DOMAIN-STRUCTURE AND INTERACTIONS OF RECOMBINANT UROKINASE-TYPE PLASMINOGEN-ACTIVATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; MOLECULAR WEIGHT FORM; AMINO-ACIDS 1; BLOOD-COAGULATION; FUSION PROTEIN; T-PA; STABILITY; DIFFERENTIATION; MACROMOLECULES; PURIFICATION	Urokinase-type plasminogen activator (uPA) is a mosaic glycoprotein composed of an epidermal growth factor-like (EGF), a kringle and a serine protease (SP) module. It exists in single and two-chain forms designated HMW pro-uPA and HMW uPA, respectively. A low molecular weight form, LMW uPA, lacks the EGF and kringle modules and is composed of the SP module alone. Recombinant-expressed proteins representing both HMW forms exhibit four reversible unfolding transitions that are resolved by deconvolution of melting curves obtained by differential scanning calorimetry at pH 4.5; no differences in the melting properties of the single and two-chain forms were found. The proteolytic fragment Ser1-Lys135 (EGF-kringle) exhibits two transitions, while the isolated EGF and kringle modules each exhibit a single two-state transition. Thus, both of these modules retain an independently folded compact structure when isolated. The isolated SP module (LMW uPA) exhibits two closely spaced transitions at low pH indicating the melting of two domains of similar stability. Fluorescence-detected melting curves of LMW uPA reveal increasing cooperativity with increasing pH, suggesting an increase in the interaction between the two SP domains. Treatment of both HMW and LMW uPA with the tripeptide inhibitor Glu-Gly-Arg-chloromethylketone dramatically increased the stability of both domains of the SP module which now melt together in a single two-state transition, even at low pH, with no effect on the EGF and kringle modules. From these data one concludes that UK consists of four independently folded domains. Two are formed by the EGF and kringle modules which do not interact with each other or with the SP module. The SP module contains two domains that are independent at low pH but exhibit a tendency to merge into a single cooperative unit at neutral pH or after treatment with the tripeptide inhibitor.	AMER RED CROSS, BIOCHEM LAB, 15601 CRABBS BRANCH WAY, ROCKVILLE, MD 20855 USA; ABBOTT LABS, ABBOTT PK, IL 60064 USA	American Red Cross; Abbott Laboratories				Medved, Leonid/0000-0002-3665-9849	NHLBI NIH HHS [HL21791] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021791] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APPELLA E, 1987, J BIOL CHEM, V262, P4437; APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; BAKSHY AKC, 1974, PREP BIOCHEM, V4, P315, DOI 10.1080/00327487408068207; BARLOW GH, 1981, THROMB RES, V23, P541, DOI 10.1016/0049-3848(81)90177-8; BILTONEN RL, 1978, CRC CR REV BIOCH MOL, V5, P85, DOI 10.3109/07388557809148191; BIRKTOFT JJ, 1972, J MOL BIOL, V68, P187, DOI 10.1016/0022-2836(72)90210-0; BLAKE CCF, 1978, NATURE, V273, P267, DOI 10.1038/273267a0; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BOGUSKY MJ, 1989, BIOCHEMISTRY-US, V28, P6728, DOI 10.1021/bi00442a028; CASTELLINO FJ, 1981, J BIOL CHEM, V256, P4778; COLLEN D, 1986, PROG HEMOST THROMB, V8, P1; COOKE RM, 1990, EUR J BIOCHEM, V193, P807, DOI 10.1111/j.1432-1033.1990.tb19404.x; DEVRIES C, 1988, BIOCHEMISTRY-US, V27, P2565, DOI 10.1021/bi00407a044; ENGEL J, 1989, FEBS LETT, V251, P1, DOI 10.1016/0014-5793(89)81417-6; FREIRE E, 1978, BIOPOLYMERS, V17, P463, DOI 10.1002/bip.1978.360170212; GHELIS C, 1978, BIOCHEM BIOPH RES CO, V84, P31, DOI 10.1016/0006-291X(78)90258-9; GHEYSEN D, 1987, J BIOL CHEM, V262, P11779; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; HIGAKI JN, 1986, J BIOL CHEM, V261, P606; HOLMBERG L, 1976, BIOCHIM BIOPHYS ACTA, V445, P215, DOI 10.1016/0005-2744(76)90174-1; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; HUSAIN SS, 1991, BIOCHEMISTRY-US, V30, P5797, DOI 10.1021/bi00237a024; JACKSON WM, 1970, BIOCHEMISTRY-US, V9, P2294, DOI 10.1021/bi00813a011; KELLEY RF, 1989, BIOCHEMISTRY-US, V28, P4047, DOI 10.1021/bi00435a062; LEE SG, 1988, J BIOL CHEM, V263, P2917; LIJNEN HR, 1988, THROMB RES, V52, P431, DOI 10.1016/0049-3848(88)90027-8; LIJNEN HR, 1988, J BIOL CHEM, V263, P19083; LIJNEN HR, 1987, SEMIN THROMB HEMOST, V13, P152, DOI 10.1055/s-2007-1003486; LITVINOVICH SV, 1991, J MOL BIOL, V217, P563, DOI 10.1016/0022-2836(91)90758-X; LO KM, 1991, BIOCHIM BIOPHYS ACTA, V1088, P217; MANGEL WF, 1991, J BIOL CHEM, V266, P9408; MAYER M, 1990, CLIN BIOCHEM, V23, P197, DOI 10.1016/0009-9120(90)90601-P; MAZAR A, 1991, IN PRESS FIBRINOLYSI; MUNK GAW, 1990, FIBRINOLYSIS, V4, P1; NELLES L, 1987, J BIOL CHEM, V262, P10855; NOVOKHATNY VV, 1984, J MOL BIOL, V179, P215, DOI 10.1016/0022-2836(84)90466-2; NOVOKHATNY VV, 1991, J BIOL CHEM, V266, P12994; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; PATTHY L, 1990, SEMIN THROMB HEMOST, V16, P245, DOI 10.1055/s-2007-1002677; PETERSEN LC, 1988, J BIOL CHEM, V263, P11189; PETERSEN LC, 1987, J CELL BIOL, V111, P801; PIERARD L, 1987, J BIOL CHEM, V262, P11771; PLOPLIS VA, 1981, BIOCHEMISTRY-US, V20, P15, DOI 10.1021/bi00504a003; Privalov P L, 1986, Methods Enzymol, V131, P4; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4; PRIVALOV PL, 1990, CRIT REV BIOCHEM MOL, V25, P281, DOI 10.3109/10409239009090612; RAMAKRISHNAN V, 1991, BIOCHEMISTRY-US, V30, P3963, DOI 10.1021/bi00230a023; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SAWYER L, 1978, J MOL BIOL, V118, P137, DOI 10.1016/0022-2836(78)90412-6; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; STROUD RM, 1971, COLD SPRING HARB SYM, V36, P125, DOI 10.1101/SQB.1972.036.01.018; STUMP DC, 1986, J BIOL CHEM, V261, P7120; PHARM FINE CHEM AFFI, P11	55	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3878	3885						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1310986				2022-12-27	WOS:A1992HE60700053
J	YANAGISAWA, J; SEKI, M; UI, M; ENOMOTO, T				YANAGISAWA, J; SEKI, M; UI, M; ENOMOTO, T			ALTERATION OF A DNA-DEPENDENT ATPASE ACTIVITY IN XERODERMA-PIGMENTOSUM COMPLEMENTATION GROUP-C CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SACCHAROMYCES-CEREVISIAE; CALF-THYMUS; ADENOSINE-TRIPHOSPHATASES; REPAIR; HELICASE; RAD3; PURIFICATION; PREFERS; GENE	DNA-dependent ATPase activities in crude extracts prepared from HeLa cells were separated into five peaks by fast protein liquid chromatography Mono Q column chromatography. Similar elution profiles were observed with the extracts from human cells normal in repair and xeroderma pigmentosum cells belonging to complementation groups A through G except for group C. An alteration in elution of one of the five ATPases, designated DNA-dependent ATPase Q1, was observed with a cell line of complementation group C. This alteration was observed with all tested cell lines that belonged to group C. ATPase Q1 in HeLa cell extracts exhibited about 2-fold higher activity with ultraviolet light-irradiated DNA as compared to that with non-irradiated DNA, whereas little difference in the effects of two DNAs was observed with the ATPase activities in the extract from group C cells.	UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								ARLETT CF, 1978, ANNU REV GENET, V12, P95, DOI 10.1146/annurev.ge.12.120178.000523; ASSAIRI LM, 1979, EUR J BIOCHEM, V99, P71, DOI 10.1111/j.1432-1033.1979.tb13232.x; DEJONG PJ, 1981, EUR J BIOCHEM, V117, P179; FRIEDBERG EC, 1988, MICROBIOL REV, V52, P70, DOI 10.1128/MMBR.52.1.70-102.1988; FRIEDBERG EC, 1985, DNA REPAIR, P213; GROSSMAN L, 1988, FASEB J, V2, P2696, DOI 10.1096/fasebj.2.11.3294078; HOCKENSMITH JW, 1986, BIOCHEMISTRY-US, V25, P7812, DOI 10.1021/bi00372a005; KORN LJ, 1976, J MOL BIOL, V106, P231, DOI 10.1016/0022-2836(76)90082-6; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SEKI M, 1988, BIOCHEMISTRY-US, V27, P1766, DOI 10.1021/bi00405a057; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; TAWARAGI Y, 1984, BIOCHEMISTRY-US, V23, P529, DOI 10.1021/bi00298a020; THOMAS DC, 1982, BIOCHEMISTRY-US, V21, P5060, DOI 10.1021/bi00263a033; WATANABE Y, 1981, BIOCHEM INT, V3, P407; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U	17	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3585	3588						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1310977				2022-12-27	WOS:A1992HE60700009
J	LUTZ, W; LONDOWSKI, JM; SANDERS, M; SALISBURY, J; KUMAR, R				LUTZ, W; LONDOWSKI, JM; SANDERS, M; SALISBURY, J; KUMAR, R			A VASOPRESSIN ANALOG THAT BINDS BUT DOES NOT ACTIVATE V1 OR V2 VASOPRESSIN RECEPTORS IS NOT INTERNALIZED INTO CELLS THAT EXPRESS V1 OR V2 RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PROTEIN-TYROSINE KINASE; SMOOTH-MUSCLE CELLS; MEDIATED ENDOCYTOSIS; EGF RECEPTOR; CYTOPLASMIC DOMAIN; DESENSITIZATION; MECHANISMS; LLC-PK1; KIDNEY	To assess whether receptor binding is sufficient to initiate vasopressin receptor endocytosis in cells expressing the vasopressin V1 or V2 receptors, we synthesized a novel fluorescent-labeled vasopressin analog, [1-(beta-mercapto-beta,beta-cyclopentamethylene propionic acid), 2-(O-ethyl)-D-tyrosine, 4-valine, 8-lysine-N6-carboxytetramethylrhodamine] vasopressin (R-CLVP), that binds to vasopressin receptors but does not activate intracellular events such as the mobilization of intracellular calcium or the activation of adenylate cyclase. We compared the manner in which this analog was endocytosed in cells expressing V1 (A-10, rat smooth muscle cells) or V2 (LLC-PK1, porcine kidney cells) receptors with that of a full agonist, [1-(beta-mercaptopropionic acid), 8-lysine-N6-carboxytetramethylrhodamine] vasopressin (R-MLVP) [Lutz et al. (1990) J. Biol. Chem. 265, 4657-4663; Lutz et al. (1990) Proc.Natl.Acad.Sci. U.S.A. 87,6507-6511]. We showed that R-CLVP bound to both types of receptors with good affinity. It failed to increase cyclic AMP concentrations in LLC-PK1 cells and did not increase the mobilization of intracellular calcium in A-10 cells. It bound to the surface of both these cell types in a diffuse manner and it did not undergo receptor endocytosis in either cell type. In contrast, R-MLVP, an agonist that bound to both receptor subtypes and elicited changes in intracellular cyclic AMP and calcium, bound to the surface of these cells in a diffuse manner at early times after exposure, and rapidly underwent endocytosis. We conclude that binding of vasopressin to its receptors alone is insufficient to cause receptor endocytosis, and other events distal to the receptor are required to initiate endocytosis. R-CLVP should be a useful analog in determining the factors responsible for initiating receptor endocytosis.	MAYO CLIN & MAYO FDN, DEPT MED, NEPHROL RES UNIT, 911A GUGGENHEIM BLDG, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT BIOCHEM & MOLEC BIOL, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic				Salisbury, Jeffrey/0000-0001-9257-4578; Kumar, Rajiv/0000-0003-3497-3057	NIDDK NIH HHS [R01 DK058546, R01 DK025409] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058546, R01DK025409] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1990, J BIOL CHEM, V265, P16450; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN RD, 1984, J BIOL CHEM, V259, P7554; CANTAU B, 1988, J BIOL CHEM, V263, P10443; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COLLINS MKL, 1984, J CELL PHYSIOL, V118, P133, DOI 10.1002/jcp.1041180205; COWLEY JF, 1985, VASOPRESSIN CELLULAR; DAUTRYVARSAT A, 1986, BIOCHIMIE, V68, P375, DOI 10.1016/S0300-9084(86)80004-9; DRIPPS DJ, 1991, J BIOL CHEM, V266, P10331; EGGENA P, 1990, AM J PHYSIOL, V259, pC462, DOI 10.1152/ajpcell.1990.259.3.C462; FISHMAN JB, 1985, J BIOL CHEM, V260, P2641; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GRIER CE, 1989, J BIOL CHEM, V264, P5384; HELIN K, 1991, J BIOL CHEM, V266, P8363; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; IACOPETTA BJ, 1988, CELL, V54, P485, DOI 10.1016/0092-8674(88)90069-4; JANS DA, 1989, EMBO J, V8, P2481, DOI 10.1002/j.1460-2075.1989.tb08384.x; JARD S, 1983, CURR TOP MEMBR TRANS, V18, P255; KIMES BW, 1976, EXP CELL RES, V98, P349, DOI 10.1016/0014-4827(76)90446-8; KIRK KL, 1988, AM J PHYSIOL, V255, pC622, DOI 10.1152/ajpcell.1988.255.5.C622; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LEHRMAN MA, 1985, CELL, V41, P735, DOI 10.1016/S0092-8674(85)80054-4; LESTER BR, 1985, MOL CELL ENDOCRINOL, V40, P193, DOI 10.1016/0303-7207(85)90175-3; LUTZ W, 1990, P NATL ACAD SCI USA, V87, P6507, DOI 10.1073/pnas.87.17.6507; LUTZ WH, 1990, J BIOL CHEM, V265, P4657; MANNING M, 1989, J MED CHEM, V32, P382, DOI 10.1021/jm00122a016; MCCLAIN DA, 1990, J BIOL CHEM, V265, P21363; Michell R H, 1979, Biochem Soc Trans, V7, P861; MOTULSKY HJ, 1984, RECEPTOR SCI CARDIOL, P1; NAMBI P, 1989, CELL SIGNAL, V1, P241, DOI 10.1016/0898-6568(89)90041-7; Pastan I., 1985, ENDOCYTOSIS, V1-44; RODRIGUEZ J, 1960, VIROLOGY, V12, P316, DOI 10.1016/0042-6822(60)90205-1; ROY C, 1981, J BIOL CHEM, V256, P3423; ROY C, 1985, AM J PHYSIOL, V248, pC425, DOI 10.1152/ajpcell.1985.248.5.C425; RYAN KL, 1989, AM J PHYSIOL, V256, pH486, DOI 10.1152/ajpheart.1989.256.2.H486; SCHRIER RW, 1985, VASOPRESSIN; SHEPHERD VL, 1989, TRENDS PHARMACOL SCI, V10, P458, DOI 10.1016/S0165-6147(89)80011-2; SORKIN A, 1991, J BIOL CHEM, V266, P8355; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; STASSEN FL, 1987, MOL PHARMACOL, V31, P259; THIES RS, 1990, J BIOL CHEM, V265, P10132; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263	46	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1109	1115						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1309761				2022-12-27	WOS:A1992GY96000070
J	MUNOZ, CM; LEEBLUNDBERG, LMF				MUNOZ, CM; LEEBLUNDBERG, LMF			RECEPTOR-MEDIATED INTERNALIZATION OF BRADYKININ - DDT1 MF-2 SMOOTH-MUSCLE CELLS PROCESS INTERNALIZED BRADYKININ VIA MULTIPLE DEGRADATIVE PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLIOMA HYBRID-CELLS; NEURO-BLASTOMA; HUMAN-FIBROBLASTS; BINDING; BOMBESIN; LINE; STIMULATION; ENDOCYTOSIS; MECHANISMS; KINETICS	This study was undertaken to evaluate the role of internalization in the action of the peptide autacoid bradykinin (BK). At 4-degrees-C [H-3]BK binds to an apparently single class of B2 kinin receptors on DDT1 MF-2 smooth muscle cells (C. M. Munoz, S. Cotecchia, and L. M. F. Leeb-Lundberg, manuscript submitted). At this temperature the [H-3]BK binding was confined exclusively to the cell surface. On the other hand, at 37-degrees-C the B2 receptor-specific cell surface [H-3]BK binding was rapidly followed by a receptor-specific internalization of [H-3]BK (t1/2 approximately 9 min). The internalization reached a steady-state level after 30-40 min that was 80-100% of the level of specifically bound [H-3]BK on the cell surface at 4-degrees-C, and this level was maintained for greater-than-or-equal-to 2 h. Internalized [H-3]BK was routed via at least two intracellular degradative pathways which were distinguished primarily based on subcellular localization but also on a small but significant difference in the rate of [H-3]BK degradation. One pathway was localized in a plasma membrane-enriched fraction and had a relatively high degradative capacity. Another pathway was localized in a microsomal fraction and had a relatively low degradative capacity. The internalized [H-3]BK activity was rapidly released into the media (t1/2 approximately 24 min). Following a single round of internalization, the released activity consisted almost exclusively of small [H-3]BK fragments (<[H-3]BK(1-5)). In contrast, at steady-state [H-3]BK represented 30-40% of the released activity. While chloroquine (100-mu-M) did not alter the rate of [H-3]BK internalization or release or the intracellular distribution of [H-3]BK, this agent significantly decreased the rate of [H-3]BK degradation in both pathways. In all, these results show that B2 kinin receptor-mediated internalization of BK is a process integral to the interaction of BK with DDT1 MF-2 smooth muscle cells and may be a mechanism for terminating BK actions by rapidly removing extracellular free and receptor-bound BK and accessing various intracellular BK degradative path ways.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041659, R29GM041659] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41659] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASCOLI M, 1982, J BIOL CHEM, V257, P13306; AVRUCH J, 1971, BIOCHIM BIOPHYS ACTA, V233, P334, DOI 10.1016/0005-2736(71)90331-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN KD, 1988, BIOCHEM J, V252, P227, DOI 10.1042/bj2520227; BROWN MS, 1979, P NATL ACAD SCI USA, V76, P3330, DOI 10.1073/pnas.76.7.3330; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; CIECHANOVER A, 1983, J BIOL CHEM, V258, P9681; CROZAT A, 1986, ENDOCRINOLOGY, V118, P2312, DOI 10.1210/endo-118-6-2312; DERIAN CK, 1986, J BIOL CHEM, V261, P3831; ERDOS EG, 1990, J CARDIOVASC PHARM, V15, pS20; ERDOS EG, 1966, HYPOTENSIVE PEPTIDES, P235; FISHMAN JB, 1985, J BIOL CHEM, V260, P2641; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; HIGASHIDA H, 1986, P NATL ACAD SCI USA, V83, P942, DOI 10.1073/pnas.83.4.942; HONG SL, 1978, J BIOL CHEM, V251, P5814; LEEBLUNDBERG LMF, 1987, J BIOL CHEM, V262, P3098; LOFFLER BM, 1984, ANAL BIOCHEM, V142, P312, DOI 10.1016/0003-2697(84)90470-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNING DC, 1986, J PHARMACOL EXP THER, V237, P504; MARGOLIUS HS, 1989, ANNU REV PHARMACOL, V29, P343; MCNAMEE MG, 1989, BIOTECHNIQUES, V7, P466; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49, DOI 10.1146/annurev.iy.06.040188.000405; REGOLI D, 1980, PHARMACOL REV, V32, P1; REISER G, 1982, BRAIN RES, V239, P191, DOI 10.1016/0006-8993(82)90841-1; ROBERTS RA, 1989, J CELL SCI, V94, P527; ROSCHER AA, 1984, J CLIN INVEST, V74, P552, DOI 10.1172/JCI111452; ROSCHER AA, 1983, J CLIN INVEST, V72, P626, DOI 10.1172/JCI111012; SCHWARTZ AL, 1982, J BIOL CHEM, V257, P4230; SHEPHERD VL, 1989, TRENDS PHARMACOL SCI, V10, P458, DOI 10.1016/S0165-6147(89)80011-2; TILLY BC, 1987, BIOCHEM J, V244, P129, DOI 10.1042/bj2440129; WESTENDORF JM, 1983, J BIOL CHEM, V258, P7527; YANO K, 1984, J BIOL CHEM, V259, P201; ZACHARY I, 1987, EMBO J, V6, P2233, DOI 10.1002/j.1460-2075.1987.tb02495.x	33	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					303	309						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1309739				2022-12-27	WOS:A1992GY43900051
J	HINKLE, PM; SHANSHALA, ED; NELSON, EJ				HINKLE, PM; SHANSHALA, ED; NELSON, EJ			MEASUREMENT OF INTRACELLULAR CADMIUM WITH FLUORESCENT DYES - FURTHER EVIDENCE FOR THE ROLE OF CALCIUM CHANNELS IN CADMIUM UPTAKE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS; MECHANISMS; KIDNEY; METALS; CA-2+	Cellular uptake of Cd2+ has been monitored using intracellularly trapped dyes, Fura 2 and Quin 2, which bind Cd2+ with extremely high affinity, and digital fluorescence imaging has been used to visualize intracellular free Cd2+. The excitation spectrum of the Cd2+ complex of Fura 2 is similar to that of the Ca2+ complex, whereas Cd2+ displaces Ca2+ from Quin 2 and reduces fluorescence. Fluorescence of Fura 2-loaded cells increased when 50 muM extracellular Cd2+ was added and fluorescence of Quin 2-loaded cells decreased. Cd2+ uptake by GH-3 pituitary cells, which occurs in part via voltage-sensitive L-type calcium channels, was increased by BAY K8644 and depolarization and decreased by nimodipine. When Fura 2 and Quin 2 were used to measure Cd2+ uptake by glial C6 cells, which have no L-channel activity, high K+ and BAY K8644 did not change the apparent rate of Cd2+ uptake. GH3 and C6 cells were incubated with Cd2+ for 24 h and loaded with Fura 2, and fluorescence was measured before and after addition of tetrakis-(2-pyridylmethyl)ethylenediamine (TPEN), a membrane permeant chelator with extremely high affinity for metals. TPEN had little effect on fluorescence of Fura 2-loaded GH-3 and C6 cells not exposed to Cd2+ but decreased fluorescence of cells that had been incubated with 1-10 muM Cd2+. Fluorescence ratio imaging of Fura 2-loaded cells was used to image intracellular free Cd2+ for both GH3 and C6 cells. Cd2+ uptake over 30-180 min could be followed by the increase in 340/380 fluorescence ratio and the increase in fluorescence ratio was reversed within 5 min by TPEN. The results provide further evidence for the importance of voltage-gated calcium channels to Cd2+ uptake of certain cells.	UNIV ROCHESTER,SCH MED & DENT,CTR CANC,ROCHESTER,NY 14642	University of Rochester	HINKLE, PM (corresponding author), UNIV ROCHESTER,SCH MED & DENT,DEPT PHARMACOL,ROCHESTER,NY 14642, USA.				NCI NIH HHS [CA 11198] Funding Source: Medline; NIDDK NIH HHS [DK 19974] Funding Source: Medline; NIEHS NIH HHS [ES 05855] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019974] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDEREGG G, 1971, HELV CHIM ACTA, V60, P123; ARSLAN P, 1985, J BIOL CHEM, V260, P2719; BLAZKA ME, 1991, TOXICOL APPL PHARM, V110, P355, DOI 10.1016/S0041-008X(05)80018-3; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; COSTA M, 1980, METAL CARCINOGENESIS; FLANAGAN JL, 1991, TOXICOL APPL PHARM, V109, P241, DOI 10.1016/0041-008X(91)90172-B; FRIBERG L, 1984, ENVIRON HEALTH PERSP, V54, P1; GOYER RA, 1989, TOXICOL LETT, V46, P153, DOI 10.1016/0378-4274(89)90124-0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HASKETH TR, 1983, J BIOL CHEM, V258, P4876; HINKLE PM, 1987, J BIOL CHEM, V262, P16333; HOLMQUIST B, 1988, METHOD ENZYMOL, V158, P6, DOI 10.1016/0076-6879(88)58042-4; JONES SG, 1990, TOXICOLOGY, V61, P73, DOI 10.1016/0300-483X(90)90008-5; KWAN CY, 1990, J BIOL CHEM, V265, P678; LI P, 1992, IN PRESS MOL ENDOCRI; Martell A. E., 1974, CRITICAL STABILITY C; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; NORDBERG M, 1978, ENVIRON RES, V15, P381, DOI 10.1016/0013-9351(78)90120-2; Shaikh Z A, 1986, Experientia Suppl, V50, P124; TEMPLETON DM, 1990, J BIOL CHEM, V265, P21764; TOMSIG JL, 1990, AM J PHYSIOL, V259, pC762, DOI 10.1152/ajpcell.1990.259.5.C762; TSIEN RW, 1987, ANNU REV BIOPHYS BIO, V16, P265; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TSIEN RW, 1983, ANNU REV PHYSIOL, V45, P341, DOI 10.1146/annurev.ph.45.030183.002013	24	119	123	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25553	25559						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1281160				2022-12-27	WOS:A1992KB60300096
J	CHENG, H; GROHMANN, K; SWEENEY, W				CHENG, H; GROHMANN, K; SWEENEY, W			NMR-STUDIES OF AZOTOBACTER-VINELANDII AND PSEUDOMONAS-PUTIDA 7-IRON FERREDOXINS - DIRECT ASSIGNMENT OF BETA-CYSTEINYL CARBON NMR RESONANCES AND FURTHER PROTON NMR ASSIGNMENTS OF CYSTEINYL AND AROMATIC RESONANCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE-QUANTUM COHERENCE; MAGNETIC-RESONANCE; CLOSTRIDIUM-PASTEURIANUM; CORRELATION SPECTROSCOPY; CHEMICAL-SHIFTS; ROTATING FRAME; SPECTRA; H-1-NMR; OVALIS; N-15	Ferredoxins are proteins which contain iron and inorganic sulfide and are capable of electron transport. They are found in a wide range of organisms, from anaerobic bacteria, to plants and mammals. Although NMR spectroscopy has been used to study ferredoxins since the 1970s, little important structural or biochemical information has resulted from these investigations. The major difficulty has been the effect of the paramagnetic iron-sulfur clusters on the peptide resonances, hindering nuclear Overhauser effect (NOE) studies and causing broad line widths. These effects are most pronounced on resonances arising from the nuclei closest to the iron-sulfur center. Unfortunately, these are likely to be the most interesting nuclei, as they report the events and geometry in the vicinity of the active sites. In this paper, the first direct assignment of beta-cysteinyl C-13 resonances for any iron-sulfur protein is reported for the spectrum of Pseudomonas putida ferredoxin. These resonances are of special significance, as they arise from the atoms on the protein closest to the iron centers, with the exception of the directly bound cysteinyl sulfur atoms. In addition, cysteinyl and ring system H-1 NMR resonance assignments are made for the spectra of P. putida ferredoxin and Azotobacter vinelandii ferredoxin I.	CUNY HUNTER COLL,DEPT CHEM,NEW YORK,NY 10021	City University of New York (CUNY) System; Hunter College (CUNY)								BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; BAX A, 1983, J AM CHEM SOC, V105, P7188, DOI 10.1021/ja00362a038; BENDALL MR, 1983, J MAGN RESON, V52, P81, DOI 10.1016/0022-2364(83)90264-0; BERTINI I, 1990, INORG CHEM, V29, P1874, DOI 10.1021/ic00335a023; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; CALHOUN DH, 1969, J BACTERIOL, V97, P210, DOI 10.1128/JB.97.1.210-216.1969; CHENG H, 1990, J BIOL CHEM, V265, P12388; HASE T, 1978, FEBS LETT, V91, P315, DOI 10.1016/0014-5793(78)81200-9; HELLER C, 1960, J CHEM PHYS, V32, P1535, DOI 10.1063/1.1730955; HO FFL, 1969, ANAL CHEM, V41, P1835, DOI 10.1021/ac60282a008; JARDETZKY O, 1981, NMR MOL BIOL, P153; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; MARION D, 1988, J MAGN RESON, V79, P352, DOI 10.1016/0022-2364(88)90230-2; MARKLEY JL, 1973, BIOCHEMISTRY-US, V12, P2245, DOI 10.1021/bi00736a010; MULLER L, 1979, MOL PHYS, V38, P963, DOI 10.1080/00268977900102161; MULLER L, 1979, J AM CHEM SOC, V101, P4481; OH BH, 1990, BIOCHEMISTRY-US, V29, P3993, DOI 10.1021/bi00468a029; OHMORI D, 1976, BIOCHEM BIOPH RES CO, V72, P566, DOI 10.1016/S0006-291X(76)80078-2; OTTING G, 1986, J MAGN RESON, V66, P187, DOI 10.1016/0022-2364(86)90122-8; PACKER EL, 1978, J BIOL CHEM, V253, P7722; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; POE M, 1970, P NATL ACAD SCI USA, V65, P797, DOI 10.1073/pnas.65.4.797; RUDNER R, 1981, MUTAT RES, V83, P339, DOI 10.1016/0027-5107(81)90016-6; SHAKA AJ, 1983, J MAGN RESON, V51, P169, DOI 10.1016/0022-2364(83)90117-8; SHETHNA YI, 1970, BIOCHIM BIOPHYS ACTA, V205, P58, DOI 10.1016/0005-2728(70)90061-7; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; STONE EW, 1962, J CHEM PHYS, V37, P1326, DOI 10.1063/1.1733281; STOUT CD, 1988, J BIOL CHEM, V263, P9256; STOUT CD, 1989, J MOL BIOL, V205, P545, DOI 10.1016/0022-2836(89)90225-8; STOUT GH, 1988, P NATL ACAD SCI USA, V85, P1020, DOI 10.1073/pnas.85.4.1020; SWEENEY WV, 1981, J BIOL CHEM, V256, P2222; Wood JL, 1939, J BIOL CHEM, V131, P267; Wuthrich K., 1986, NMR PROTEINS NUCL AC	35	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8073	8080						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1314816				2022-12-27	WOS:A1992HQ18500020
J	STEPHENS, JM; CARTER, BZ; PEKALA, PH; MALTER, JS				STEPHENS, JM; CARTER, BZ; PEKALA, PH; MALTER, JS			TUMOR-NECROSIS-FACTOR ALPHA-INDUCED GLUCOSE TRANSPORTER (GLUT-1) MESSENGER-RNA STABILIZATION IN 3T3-L1 PREADIPOCYTES - REGULATION BY THE ADENOSINE-URIDINE BINDING-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GENE-EXPRESSION; POSTTRANSCRIPTIONAL REGULATION; PHORBOL ESTER; CELLS; SEQUENCE; IDENTIFICATION; INDUCTION; TURNOVER; REGION	Tumor necrosis factor-alpha (TNF-alpha), 12-O-tetradecanoylphorbol-13-acetate and cAMP stimulate hexose transport in quiescent 3T3-L1 preadipocytes by stabilizing the relatively labile mRNA coding for the basal glucose transporter, GLUT-1. The 3'-UTR of GLUT-1 mRNA contains a single copy of the destabilizing AUUUA motif in the context of an AU-rich region. The adenosine-uridine binding factor (AUBF) is a cytosolic protein which interacts with similar AU-rich regions in a variety of labile cytokine and oncogene mRNAs. Here, we demonstrate that AUBF complexes in vitro with GLUT-1 mRNA through the AU-rich portion of the 3'-UTR. AUBF activity is very low in quiescent preadipocytes, but can be up-regulated by agonists such as TPA, TNF-alpha, cAMP, and okadaic acid, all of which stabilize GLUT-1 mRNA. The time courses of TNF-alpha- and TPA-mediated AUBF up-regulation and GLUT-1 mRNA stabilization are coincident, suggesting a cause and effect relationship.	UNIV WISCONSIN,DEPT PATHOL & LAB MED,MADISON,WI 53792; E CAROLINA UNIV,SCH MED,DEPT BIOCHEM,GREENVILLE,NC 27858	University of Wisconsin System; University of Wisconsin Madison; University of North Carolina; East Carolina University			Stephens, Jacqueline M/R-5217-2018		NIDDK NIH HHS [DK 44213] Funding Source: Medline; NIGMS NIH HHS [GM 32892] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032892] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRD TA, 1990, J BIOL CHEM, V265, P13578; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BRACH MA, 1990, FEBS LETT, V263, P349, DOI 10.1016/0014-5793(90)81411-G; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORNELIUS P, 1991, J CELL PHYSIOL, V146, P298, DOI 10.1002/jcp.1041460215; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; CORNELIUS P, 1988, BIOCHEM J, V249, P765, DOI 10.1042/bj2490765; CROSSMAN DC, 1990, J BIOL CHEM, V265, P9782; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GOULD GW, 1990, TRENDS BIOCHEM SCI, V15, P18, DOI 10.1016/0968-0004(90)90125-U; HIRAKI Y, 1989, P NATL ACAD SCI USA, V86, P8252, DOI 10.1073/pnas.86.21.8252; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; JOOST HG, 1989, DIABETOLOGIA, V32, P831, DOI 10.1007/BF00297447; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MALTER JS, 1990, ENZYME, V44, P203, DOI 10.1159/000468758; Maniatis T., 1982, MOL CLONING; MOUNTJOY KG, 1989, MOL ENDOCRINOL, V3, P2018, DOI 10.1210/mend-3-12-2018; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; PEPPEL K, 1991, J BIOL CHEM, V266, P6663; PILCH PF, 1990, ENDOCRINOLOGY, V126, P3, DOI 10.1210/endo-126-1-3; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; RAGHOW R, 1987, TRENDS BIOCHEM SCI, V12, P358, DOI 10.1016/0968-0004(87)90165-4; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777	33	123	124	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8336	8341						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1314824				2022-12-27	WOS:A1992HQ18500059
J	SCHUSTER, MG; ENRIQUEZ, PM; CURRAN, P; COOPERMAN, BS; RUBIN, H				SCHUSTER, MG; ENRIQUEZ, PM; CURRAN, P; COOPERMAN, BS; RUBIN, H			REGULATION OF NEUTROPHIL SUPEROXIDE BY ANTICHYMOTRYPSIN-CHYMOTRYPSIN COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADPH OXIDASE ACTIVATION; RESPIRATORY BURST; HUMAN-DISEASE; PROTEIN; INVOLVEMENT; PHAGOCYTES; RADICALS; SYSTEM	The ability of neutrophils to generate free radicals is a crucial component of host defense (Babior, B. M. (1978) N. Engl. J. Med. 298, 659-668, 721-725. Neutrophil oxidants, however, can cause significant host tissue destruction (Weiss, S. J. (1989) N. Engl. J. Med. 320, 365-376), and the regulation of free radical production is not well understood. We have previously shown that recombinant antichymotrypsin (rACT), a serine protease inhibitor, inhibits superoxide production in intact neutrophils (Kilpatrick, L., Johnson, J. L., Nickbarg, E. B., Wang, Z., Clifford, T. F., Banach, M., Cooperman, B. S., Douglas, S. D., and Rubin, H. (1991) J. Immunol. 146, 2388-2393). Using a cell-free NADPH oxidase preparation, we now demonstrate that rACT alone has no effect on superoxide production and that antichymotrypsin-chymotrypsin (rACT.CT) complexes are required to inhibit superoxide, suggesting that neutrophil chymotrypsin-like proteases produce conformational changes in ACT, allowing it to become active in regulating superoxide production. Additionally, we have identified NADPH oxidase itself as the target for rACT.CT and have demonstrated that rACT.CT interferes specifically with activation of the NADPH oxidase without changing the K(m) for NADPH or the rate constant describing the rate-limiting step in activation. These observations suggest an important role for antichymotrypsin in the regulation of NADPH-oxidase activation, which is a prerequisite for neutrophil superoxide production, and predict possible therapeutic uses for rACT in conditions where unregulated neutrophil-free radical production has been implicated in the mechanism of tissue destruction.	UNIV PENN,SCH MED,DEPT MED,DIV INFECT DIS,536 JOHNSON PAVILION,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT CHEM,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania								AKARD LP, 1988, BLOOD, V72, P322; BABIOR BM, 1978, NEW ENGL J MED, V298, P721, DOI 10.1056/NEJM197803302981305; BABIOR BM, 1988, J BIOL CHEM, V263, P1713; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BANDA MJ, 1988, J EXP MED, V167, P1608, DOI 10.1084/jem.167.5.1608; CROSS CE, 1987, ANN INTERN MED, V107, P526, DOI 10.7326/0003-4819-107-4-526; GABIG TG, 1987, J BIOL CHEM, V262, P1685; GABIG TG, 1990, J IMMUNOL, V145, P945; GABIG TG, 1986, METHOD ENZYMOL, V132, P335; HENSON PM, 1987, J CLIN INVEST, V79, P669, DOI 10.1172/JCI112869; JOHNSTON RB, 1971, PEDIATRICS, V48, P730; KILPATRICK L, 1991, J IMMUNOL, V146, P2388; KURDOWSKA A, 1990, J BIOL CHEM, V265, P21023; KUSNER DJ, 1989, J IMMUNOL, V143, P1696; MALECH HL, 1987, NEW ENGL J MED, V317, P687, DOI 10.1056/NEJM198709103171107; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOUTHORN PA, 1988, MAYO CLIN PROC, V63, P390, DOI 10.1016/S0025-6196(12)64862-9; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; WEISS SJ, 1989, NEW ENGL J MED, V320, P365	21	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5056	5059						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1312083				2022-12-27	WOS:A1992HH74700011
J	LOIRAND, G; FAIDERBE, S; BARON, A; GEFFARD, M; MIRONNEAU, J				LOIRAND, G; FAIDERBE, S; BARON, A; GEFFARD, M; MIRONNEAU, J			AUTOANTI-PHOSPHATIDYLINOSITIDE ANTIBODIES SPECIFICALLY INHIBIT NORADRENALINE EFFECTS ON CA2+ AND CL- CHANNELS IN RAT PORTAL-VEIN MYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; INOSITOL PHOSPHATES; POLYPHOSPHOINOSITIDE PHOSPHODIESTERASE; CALCIUM; CURRENTS; ACTIVATION; ANTISERUM; PROTEINS; INCREASE	High levels of circulating autoantibodies (auto-Ab) directed against phosphatidylinositides have been identified in the sera of patients with malignant tumors. These polyclonal autoantibodies had higher avidity and specificity for phosphatidylinositol (PtdIns) than for the other phosphatidylinositides. Effects of the auto-Ab were studied in smooth muscle myocytes in the PtdIns-involving transduction mechanism triggered by activation of alpha-1-adrenoceptors. Noradrenaline activated a Ca2+-dependent Cl- current through the Ca2+-releasing action of inositol 1,4,5-trisphosphate (InsP3) and enhanced the Ca2+ channel current through a diacylglycerol and protein kinase C-dependent mechanism. External applications of auto-Ab (0.03-0.3 mg/ml) were without effect on noradrenaline-induced responses whereas intracellular applications (0.0004-0.012 mg/ml) inhibited both Cl- current activation and Ca2+ channel current stimulation. Intracellular applications of IgG from healthy donors had no effect on noradrenaline-induced responses. When anti-PtdIns Ab were preincubated with PtdIns the inhibition of the noradrenaline-induced responses on Ca2+ and Cl- channels was not observed. Autoanti-PtdIns Ab inhibited also the acetylcholine-activated Cl- current, confirming that the acetylcholine response was mediated through the phosphatidylinositol breakdown. In contrast, the autoanti-PtdIns Ab were ineffective against the transduction pathway after beta-adrenoceptor activation. Therefore, these results suggest that the biological effect of autoanti-PtdIns Ab results from a specific binding to membrane PtdIns or PtdIns metabolites and thereby prevented InsP3 and diacylglycerol production. These autoanti-PtdIns Ab appear to be a new specific tool to identify the role of phosphatidylinositides in intracellular transduction processes.	UNIV BORDEAUX 2, PHYSIOL CELLULAIRE & PHARMACOL MOLEC LAB, CJF 88-13, F-33076 BORDEAUX, FRANCE; UNIV BORDEAUX 2, INSERM, IMMUNOL & PATHOL LAB, F-33076 BORDEAUX, FRANCE	UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux			BARON, Anne/N-5691-2016; Loirand, Gervaise/K-1834-2014	BARON, Anne/0000-0002-8026-6380; Loirand, Gervaise/0000-0002-2306-3931				ABDELLATIF AA, 1986, PHARMACOL REV, V38, P227; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1987, PHILOS T ROY SOC B, V317, P525, DOI 10.1098/rstb.1987.0079; BURLET AJ, 1987, EXP BRAIN RES, V65, P629; COCKCROFT S, 1985, NATURE, V314, P534, DOI 10.1038/314534a0; DANGUIR J, 1988, BRAIN RES BULL, V20, P9, DOI 10.1016/0361-9230(88)90003-2; DOWNES CP, 1981, BIOCHEM J, V198, P133, DOI 10.1042/bj1980133; FAIDERBE S, 1990, CR ACAD SCI III-VIE, V310, P49; FAIDERBE S, 1991, CANCER LETT, V57, P15, DOI 10.1016/0304-3835(91)90057-O; FAIDERBE S, 1991, CANCER DETECT PREV, V15, P199; FUKAMI K, 1988, P NATL ACAD SCI USA, V85, P9057, DOI 10.1073/pnas.85.23.9057; FUKUMITSU T, 1990, BRIT J PHARMACOL, V100, P593, DOI 10.1111/j.1476-5381.1990.tb15852.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HERRMANN E, 1989, EUR J BIOCHEM, V185, P677, DOI 10.1111/j.1432-1033.1989.tb15165.x; HUANG CL, 1991, J BIOL CHEM, V266, P4045; HUGHES BP, 1988, BIOCHEM PHARMACOL, V37, P1357, DOI 10.1016/0006-2952(88)90794-0; KOMORI S, 1990, J PHYSIOL-LONDON, V427, P395, DOI 10.1113/jphysiol.1990.sp018178; KOVACS GL, 1982, PHYSIOL BEHAV, V28, P45, DOI 10.1016/0031-9384(82)90099-3; LECCESE AP, 1983, PEPTIDES, V4, P265, DOI 10.1016/0196-9781(83)90125-0; LOIRAND G, 1986, PFLUG ARCH EUR J PHY, V407, P566, DOI 10.1007/BF00657519; LOIRAND G, 1990, J PHYSIOL-LONDON, V428, P517, DOI 10.1113/jphysiol.1990.sp018225; LOIRAND G, 1989, J PHYSIOL-LONDON, V412, P333, DOI 10.1113/jphysiol.1989.sp017619; MAJERUS PW, 1988, J BIOL CHEM, V263, P3051; OTANI H, 1988, CIRC RES, V62, P8, DOI 10.1161/01.RES.62.1.8; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; SHEARS SB, 1989, BIOCHEM J, V260, P313, DOI 10.1042/bj2600313; TARRABHAZDAI R, 1980, EXP NEUROL, V67, P670, DOI 10.1016/0014-4886(80)90135-1; WELLING A, 1991, BLOOD VESSELS, V28, P154	28	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4312	4316						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1311305				2022-12-27	WOS:A1992HF64200010
J	MAYOR, S; MENON, AK; CROSS, GAM				MAYOR, S; MENON, AK; CROSS, GAM			GALACTOSE-CONTAINING GLYCOSYLPHOSPHATIDYLINOSITOLS IN TRYPANOSOMA-BRUCEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; LEISHMANIA-MAJOR; PHOSPHOLIPASE-C; STRUCTURAL CHARACTERIZATION; LINKED OLIGOSACCHARIDES; GLYCOLIPID PRECURSORS; RESISTANT GLYCOLIPIDS; BIOSYNTHESIS	Many eukaryotic surface glycoproteins, including the variant surface glycoproteins (VSGs) of Trypanosoma brucei, are synthesized with a carboxyl-terminal hydrophobic peptide extension that is cleaved and replaced by a complex glycosylphosphatidylinositol (GPI) membrane anchor within 1-5 min of the completion of polypeptide synthesis. We have reported the purification and partial characterization of candidate precursor glycolipids (P2 and P3) from T. brucei. P2 and P3 contain ethanolamine-phosphate-Man-alpha-1-2Man-alpha-1-6Man-alpha-1GlcN linked glycosidically to an inositol residue, as do all the GPI anchors that have been structurally characterized. The anchors on mature VSGs contain a heterogenously branched galactose structure attached alpha-1-3 to the mannose residue adjacent to the glucosamine. We report the identification of free GPIs that appear to be similarly galactosylated. These glycolipids contain diacylglycerol and alpha-galactosidase-sensitive glycan structures which are indistinguishable from the glycans derived from galactosylated VSG GPI anchors. We discuss the relevance of these galactosylated GPIs to the biosynthesis of VSG GPI anchors.	ROCKEFELLER UNIV,NEW YORK,NY 10021	Rockefeller University			Cross, George A M/B-7444-2011	Cross, George A M/0000-0003-1374-6955; Menon, Anant Kumar/0000-0001-6924-2698	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021531] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21531] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANGS JD, 1988, J BIOL CHEM, V263, P17697; BANGS JD, 1986, J CELL BIOL, V103, P255, DOI 10.1083/jcb.103.1.255; BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3207, DOI 10.1073/pnas.82.10.3207; CONZELMANN A, 1988, EMBO J, V7, P2233, DOI 10.1002/j.1460-2075.1988.tb03063.x; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DAVITZ MA, 1987, SCIENCE, V238, P81, DOI 10.1126/science.2443973; DOERING TL, 1989, J BIOL CHEM, V264, P11168; FERGUSON MAJ, 1988, PARASITE IMMUNOL, V10, P465, DOI 10.1111/j.1365-3024.1988.tb00236.x; FERGUSON MAJ, 1986, J BIOL CHEM, V261, P356; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FERGUSON MAJ, 1988, BIOCHEM SOC T, V16, P265, DOI 10.1042/bst0160265; FIELD MC, 1991, J BIOL CHEM, V266, P8392; GRAB DJ, 1984, J CELL BIOL, V99, P569, DOI 10.1083/jcb.99.2.569; HOLDER AA, 1985, CURR TOP MICROBIOL, V117, P57; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; KRAKOW JL, 1989, MOL BIOCHEM PARASIT, V36, P263, DOI 10.1016/0166-6851(89)90174-6; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; LOW MG, 1988, P NATL ACAD SCI USA, V85, P980, DOI 10.1073/pnas.85.4.980; LOW P, 1991, J BIOL CHEM, V266, P19250; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MAYOR S, 1990, J BIOL CHEM, V265, P6164; MAYOR S, 1990, Methods (Orlando), V1, P297, DOI 10.1016/S1046-2023(05)80331-7; MAYOR S, 1991, J CELL BIOL, V114, P61, DOI 10.1083/jcb.114.1.61; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P7385; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MENON AK, 1988, BIOCHEM SOC T, V16, P996, DOI 10.1042/bst0160996; MENON AK, 1988, J BIOL CHEM, V263, P1970; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; PREVIATO JO, 1990, J BIOL CHEM, V265, P2518; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; ROSEN G, 1989, J BIOL CHEM, V264, P10457; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; SCHWARZ RT, 1988, BIOCH SOC T LOND, V17, P746; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; TURCO SJ, 1989, J BIOL CHEM, V264, P6711; TURCO SJ, 1977, P NATL ACAD SCI USA, V74, P4411, DOI 10.1073/pnas.74.10.4411	43	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					754	761						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1309774				2022-12-27	WOS:A1992GY96000015
J	SOKOLIK, CW; COHEN, RE				SOKOLIK, CW; COHEN, RE			UBIQUITIN CONJUGATION TO CYTOCHROMES-C - STRUCTURE OF THE YEAST ISO-1 CONJUGATE AND POSSIBLE RECOGNITION DETERMINANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LIGASE SYSTEM; CONFORMATION CHANGE; FERRICYTOCHROME-C; CARRIER PROTEINS; RESOLUTION; BREAKDOWN; ISO-1-CYTOCHROME-C; POLYPEPTIDE; REPLACEMENT; REFINEMENT	Saccharomyces cerevisiae iso-1-cytochrome c was conjugated with ubiquitin (Ub) in vitro in a rabbit reticulocyte extract (Fraction II). By N-terminal protein sequencing, it was found for both the mono- and diubiquitinated products that the major Ub attachment site is on Lys4 (residue 9) of the cytochrome c. Thus, the residue ubiquitinated in iso-1-cytochrome c is identical with that previously determined for the yeast iso-2 form (Sokolik, C. W., and Cohen, R. E. (1991) J. Biol. Chem. 266, 9100-9107). For both cytochromes c, the proportions of diubiquitinated and higher order conjugates are drastically reduced when Ub is replaced with a Lys48 --> Arg variant, suggesting that the Ub-Ub moieties are linked predominantly through Lys48. Despite close similarities in structure and ubiquitination sites, conjugation to iso-2-cytochrome c is approximately 5-fold faster than for the iso-1 form; vertebrate cytochromes c are even poorer substrates, being ubiquitinated at only approximately 5% of the rate of the iso-2 protein. Comparison of several cytochrome c variants excludes alpha-N-acetylation or the identity of the N-terminal amino acid as the important recognition determinants in these reactions. The results, which include the finding that ferro and ferri-iso-2-cytochromes c are ubiquitinated equally, also are evidence against a simple correlation between ubiquitination efficiency and thermodynamic stability. Rather, the presence of a pair of lysines (Lys4-Lys5) within the relatively unstructured N-terminal extension of the yeast cytochromes c may be responsible for their preferential ubiquitination.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,405 HILGARD AVE,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NCRR NIH HHS [1 S10RR05554-01] Funding Source: Medline; NIGMS NIH HHS [GM07185, GM37666] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR005554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007185, R01GM037666] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BHUYAN AK, 1991, J CELL BIOCH G, V15, P188; BUSCH H, 1981, MOL CELL BIOCHEM, V40, P173; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1980, P NATL ACAD SCI-BIOL, V77, P1365, DOI 10.1073/pnas.77.3.1365; CLEMENTS JM, 1989, GENE, V83, P1, DOI 10.1016/0378-1119(89)90398-3; DICKERSON RE, 1971, J BIOL CHEM, V246, P1511; DUNTEN RL, 1989, J BIOL CHEM, V264, P16739; DUNTEN RL, 1991, J BIOL CHEM, V266, P3260; ENOSAWA S, 1987, ANAL BIOCHEM, V160, P211, DOI 10.1016/0003-2697(87)90632-4; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; FUSAUCHI Y, 1985, J BIOCHEM-TOKYO, V97, P1467, DOI 10.1093/oxfordjournals.jbchem.a135201; GONDA DK, 1989, J BIOL CHEM, V264, P16700; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; HERSHKO A, 1984, P NATL ACAD SCI-BIOL, V81, P7021, DOI 10.1073/pnas.81.22.7021; JENTSCH S, 1990, TRENDS BIOCHEM SCI, V15, P195, DOI 10.1016/0968-0004(90)90161-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOUIE GV, 1990, J MOL BIOL, V214, P527, DOI 10.1016/0022-2836(90)90197-T; MARGOLIASH E., 1966, ADVANCE PROTEIN CHEM, V21, P113, DOI 10.1016/S0065-3233(08)60128-X; MARGOLIASH E, 1959, BIOCHEM J, V71, P570, DOI 10.1042/bj0710570; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PICKART CM, 1988, J BIOL CHEM, V263, P12028; RAMDAS L, 1986, BIOCHEMISTRY-US, V25, P6952, DOI 10.1021/bi00370a032; Rechsteiner M., 1988, UBIQUITIN; REISS Y, 1988, J BIOL CHEM, V263, P2693; SILVESTRI I, 1988, J BIOL CHEM, V263, P18702; SOKOLIK CW, 1991, J BIOL CHEM, V266, P9100; TAKANO T, 1981, J MOL BIOL, V153, P95, DOI 10.1016/0022-2836(81)90529-5; TAKANO T, 1981, J MOL BIOL, V153, P79, DOI 10.1016/0022-2836(81)90528-3; WHITE TB, 1987, BIOCHEMISTRY-US, V26, P4358, DOI 10.1021/bi00388a026	34	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1067	1071						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1309759				2022-12-27	WOS:A1992GY96000063
J	JAUNIN, P; HORISBERGER, JD; RICHTER, K; GOOD, PJ; ROSSIER, BC; GEERING, K				JAUNIN, P; HORISBERGER, JD; RICHTER, K; GOOD, PJ; ROSSIER, BC; GEERING, K			PROCESSING, INTRACELLULAR-TRANSPORT, AND FUNCTIONAL EXPRESSION OF ENDOGENOUS AND EXOGENOUS ALPHA-BETA-3 NA,K-ATPASE COMPLEXES IN XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT; ENDOPLASMIC-RETICULUM; ALPHA-SUBUNITS; K+-ATPASE; MEMBRANE; NA+; NA+,K+-ATPASE; ALDOSTERONE; MATURATION; CELLS	The minimal functional Na,K-ATPase unit is composed of a catalytic alpha-subunit and a glycosylated beta-subunit. So far three putative beta-isoforms have been described, but only beta-1-isoforms have been identified clearly as part of a purified active enzyme complex. In this study we provide evidence that a putative beta-3-isoform might be the functional component of Xenopus oocyte Na,K-ATPase. Beta-3-isoforms are expressed in the oocyte plasma membrane together with alpha-subunits, but beta-3-isoforms are synthesized to a lesser extent than alpha-subunits. The unassembled oocyte alpha-subunits accumulate in an immature trypsin-sensitive form most likely in the endoplasmic reticulum (ER). Injection of both beta-1- and beta-3-cRNA into oocytes abolishes the transport constraint of the oocyte alpha-subunit, renders it trypsin-resistant, and finally leads to an increased number of functional pumps at the plasma membrane. In addition, beta-3-isoforms as beta-1-isoforms depend on the concomitant synthesis of alpha-subunits to be able to leave the ER and to become fully glycosylated. Finally, alpha-beta-1 and alpha-beta-3 complexes expressed at the plasma membrane appear to have similar transport properties as assessed by ouabain binding, rubidium uptake, and electrophysiological measurements in oocytes coexpressing exogenous alpha-1- and beta-1- or beta-3-isoforms. Thus our data indicate that beta-3-isoforms have functional qualities similar to beta-1-isoforms. They can assemble and impose a structural reorganization to newly synthesized alpha-subunits which permits the exit from the ER and the expression of functional Na,K-pumps at the plasma membrane.	UNIV LAUSANNE, INST PHARMACOL & TOXICOL, RUE DU BUGNON 27, CH-1005 LAUSANNE, SWITZERLAND; SALZBURG UNIV, DEPT GENET, A-5020 SALZBURG, AUSTRIA; NICHHD, MOLEC GENET LAB, BETHESDA, MD 20892 USA	University of Lausanne; Salzburg University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Horisberger, Jean-Daniel/A-2538-2009					ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; GEERING K, 1990, J MEMBRANE BIOL, V115, P109, DOI 10.1007/BF01869450; GEERING K, 1982, J BIOL CHEM, V257, P338; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; GEERING K, 1987, J CELL BIOL, V105, P2613, DOI 10.1083/jcb.105.6.2613; GEERING K, 1985, J BIOL CHEM, V260, P5154; GIRARDET M, 1981, BIOCHEMISTRY-US, V20, P6684, DOI 10.1021/bi00526a025; GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165; GOOD PJ, 1988, J VIROL, V62, P944, DOI 10.1128/JVI.62.3.944-953.1988; GOOD PJ, 1990, P NATL ACAD SCI USA, V87, P9088, DOI 10.1073/pnas.87.23.9088; HORISBERGER JD, 1991, IN PRESS P NATL ACAD; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; SCHMALZING G, 1991, BIOCHEM J, V279, P329, DOI 10.1042/bj2790329; SEPULVEDA FV, 1984, J CELL PHYSIOL, V118, P211, DOI 10.1002/jcp.1041180214; SKOU JC, 1990, FEBS LETT, V268, P314, DOI 10.1016/0014-5793(90)81278-V; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; VERREY F, 1987, J CELL BIOL, V104, P1231, DOI 10.1083/jcb.104.5.1231	27	101	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					577	585						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1309755				2022-12-27	WOS:A1992GY43900090
J	BARSONY, J; MCKOY, W				BARSONY, J; MCKOY, W			MOLYBDATE INCREASES INTRACELLULAR 3',5'-GUANOSINE CYCLIC MONOPHOSPHATE AND STABILIZES VITAMIN-D RECEPTOR ASSOCIATION WITH TUBULIN-CONTAINING FILAMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GINGIVAL FIBROBLASTS; GUANYLATE-CYCLASE ACTIVITY; HEAT-SHOCK PROTEIN; GLUCOCORTICOID-RECEPTOR; CYTOPLASMIC MICROTUBULES; CILIARY MOTILITY; DNA-BINDING; CELLS; COMPLEX; CGMP	With a recently developed method we detected rapid and sequential reorganization of vitamin D receptors (VDR), including their temporary association with fibers, and we showed that calcitriol induces cGMP accumulation around reorganizing VDRs. In this report we first identified the VDR-associated fibers as microtubules: they showed immunoreactivity with tubulin antisera and were sensitive to tubulin-disruptive agents. Tubulin-disruptive agents also prevented calcitriol-induced alignment and intranuclear accumulation of VDR and cGMP, but did not prevent the initial cGMP accumulation in the cytoplasm. Then we studied the effect of molybdate on VDR reorganization and on cGMP accumulation. Sodium molybdate inhibits steroid receptor transformation into a DNA binding form through interaction with the steroid binding region of the receptor. The mechanism of molybdate effect on steroid receptors is not well understood and the interaction of molybdate with guanylate cyclase has not been investigated. We found in cells pretreated with molybdate that the addition of calcitriol resulted in a prolonged and accentuated association of VDR and cGMP with the microtubules. Furthermore, both immunocytology and radioimmunoassay demonstrated that molybdate is a highly potent inducer of guanylate cyclase. Neither calcitriol nor molybdate effect on guanylate cyclase were prevented by methylene blue pretreatment, suggesting that they activate particulate guanylate cyclase. Pretreatment of cells with dibutyryl-cGMP mimicked molybdate effect on VDR reorganization. The effect of molybdate on cGMP may participate in molybdate stabilization of steroid receptors. We suggest that rapid cGMP accumulation after steroid exposure plays a role in facilitation of intracellular transport of the steroid receptor through interaction with microtubules.			BARSONY, J (corresponding author), NIDDKD, MINERAL METAB SECT, BETHESDA, MD 20892 USA.							AKNER G, 1991, J STEROID BIOCHEM, V39, P419, DOI 10.1016/0960-0760(91)90235-W; AKNER G, 1990, EUR J CELL BIOL, V53, P390; BARSONY J, 1990, J CELL BIOL, V111, P2385, DOI 10.1083/jcb.111.6.2385; BARSONY J, 1991, P NATL ACAD SCI USA, V88, P1436, DOI 10.1073/pnas.88.4.1436; BARSONY J, 1990, P NATL ACAD SCI USA, V87, P1188, DOI 10.1073/pnas.87.3.1188; BARSONY J, 1988, P NATL ACAD SCI USA, V85, P1223, DOI 10.1073/pnas.85.4.1223; BECKER EL, 1977, ARCH PATHOL LAB MED, V101, P509; BODINE PV, 1990, MOL CELL ENDOCRINOL, V74, pC77, DOI 10.1016/0303-7207(90)90199-I; BODINE PV, 1988, P NATL ACAD SCI USA, V85, P1462, DOI 10.1073/pnas.85.5.1462; BODINE PV, 1990, J BIOL CHEM, V265, P9544; BONINI NM, 1988, J CELL BIOL, V106, P1615, DOI 10.1083/jcb.106.5.1615; BONINI NM, 1990, J CELL SCI, V95, P219; BRESNICK EH, 1990, CANCER RES, V49, pS2222; Brooker G, 1979, Adv Cyclic Nucleotide Res, V10, P1; CAKE MH, 1976, BIOCHEM BIOPH RES CO, V71, P45, DOI 10.1016/0006-291X(76)90247-3; CHONG MT, 1982, J RECEPTOR RES, V2, P575, DOI 10.3109/107998981809038886; DAHMER MK, 1984, ANNU REV PHYSIOL, V46, P67; DAVIDOFF M, 1989, ACTA HISTOCHEM, V85, P109, DOI 10.1016/S0065-1281(89)80106-0; FLEISCHMAN D, 1980, BIOCHIM BIOPHYS ACTA, V630, P176, DOI 10.1016/0304-4165(80)90419-5; FLEMING H, 1982, ENDOCRINOLOGY, V111, P1671, DOI 10.1210/endo-111-5-1671; FLEMING H, 1983, P NATL ACAD SCI-BIOL, V80, P2486, DOI 10.1073/pnas.80.9.2486; GARBERS DL, 1989, J BIOL CHEM, V264, P9103; GIBBONS IR, 1988, J BIOL CHEM, V263, P15837; HSU TC, 1991, J BIOL CHEM, V266, P17573; Jensen E V, 1991, Curr Top Pathol, V83, P365; LAD PM, 1985, MOL IMMUNOL, V22, P731, DOI 10.1016/0161-5890(85)90138-5; LARSSON H, 1977, J NEUROCHEM, V29, P115, DOI 10.1111/j.1471-4159.1977.tb03932.x; MESHINCHI S, 1988, J BIOL CHEM, V263, P16809; MESHINCHI S, 1990, J BIOL CHEM, V265, P4863; MIYATA Y, 1991, J BIOL CHEM, V266, P8779; MURAKAMI N, 1982, ARCH BIOCHEM BIOPHYS, V214, P326, DOI 10.1016/0003-9861(82)90037-6; NISHIGORI H, 1980, BIOCHEMISTRY-US, V19, P77, DOI 10.1021/bi00542a012; OLAH Z, 1988, J NEUROCHEM, V51, P49, DOI 10.1111/j.1471-4159.1988.tb04834.x; OLIVER JM, 1978, AM J PATHOL, V93, P221; PRATT WB, 1988, J BIOL CHEM, V263, P267; RAAKA BM, 1985, J BIOL CHEM, V260, P4009; RICHARDS JM, 1979, J BIOL CHEM, V254, P6857; SANCHEZ ER, 1988, MOL ENDOCRINOL, V2, P756, DOI 10.1210/mend-2-8-756; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SATO B, 1980, ENDOCRINOLOGY, V106, P1142, DOI 10.1210/endo-106-4-1142; SCHNAPP BJ, 1989, P NATL ACAD SCI USA, V86, P1548, DOI 10.1073/pnas.86.5.1548; SHEETZ MP, 1989, TRENDS NEUROSCI, V12, P474, DOI 10.1016/0166-2236(89)90099-4; VESELY DL, 1980, J PHARMACOL EXP THER, V214, P561; WALDMAN SA, 1986, INFECT IMMUN, V51, P320, DOI 10.1128/IAI.51.1.320-326.1986; WESCOTT SL, 1985, J CYCLIC NUCL PROT, V10, P189; WIKSTROM AC, 1987, ENDOCRINOLOGY, V120, P1232, DOI 10.1210/endo-120-4-1232; YAMASHITA K, 1972, J BIOL CHEM, V247, P7062	47	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24457	24465						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1280259				2022-12-27	WOS:A1992KA26300050
J	ESTIVARIZ, FE; FRIEDMAN, TC; CHIKUMA, T; LOH, YP				ESTIVARIZ, FE; FRIEDMAN, TC; CHIKUMA, T; LOH, YP			PROCESSING OF ADRENOCORTICOTROPIN BY 2 PROTEASES IN BOVINE INTERMEDIATE LOBE SECRETORY VESICLE MEMBRANES - A DISTINCT ACIDIC, TETRABASIC RESIDUE-SPECIFIC CALCIUM-ACTIVATED SERINE PROTEASE AND A PC2-LIKE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPIOMELANOCORTIN-CONVERTING ENZYME; MELANOCYTE STIMULATING HORMONE; PRO-OPIOMELANOCORTIN; GENE-PRODUCT; PITUITARY; KEX2; RAT; CARBOXYPEPTIDASE; PURIFICATION; PROTEOLYSIS	Adrenocorticotropin (ACTH) is cleaved at the tetrabasic residue site, in pituitary intermediate lobe secretory vesicles, to yield ACTH1-17 and corticotropin-like intermediate lobe peptide (CLIP). ACTH1-17 is then converted to alpha-melanocyte-stimulating hormone (N-AcACTH1-13NH2) by first removing the Lys15-Lys16-Arg17 residues, followed by amidation of the COOH terminus and acetylation of the NH2 terminus. Bovine intermediate lobe secretory vesicle membranes were screened for proteolytic enzyme activity that will cleave the tetrabasic residues of ACTH. Two activities with pH optima of 5.0-6.0 and 7.5-8.0 were detected. The acidic, ACTH-converting enzyme cleaved ACTH1-39 at the tetrabasic residues between the Arg17-Arg18 bond to yield ACTH1-17 and CLIP, but did not cleave paired basic residues of pro-opiomelanocortin. This enzyme activity was characterized as a Ca2+-activated serine protease with unique specificity for the tetrabasic residues of ACTH1-39. The neutral activity preferentially generated ACTH1-17 and to a small extent ACTH1-16 from ACTH1-39 and ACTH1-24. This enzyme activity was Ca2+-dependent but was not inhibited by serine or aspartic protease inhibitors. The neutral activity was significantly immunodepleted by anti-serum raised against bovine PC2/PC3, and together with specificity studies, suggests that the enzyme is a PC2-like serine protease. The pH optimum, distinct specificity for tetrabasic residues, and subcellular localization of the acidic ACTH-converting enzyme indicate a function of this enzyme in the in vivo conversion of ACTH1-39 to alpha-melanocyte-stimulating hormone in intermediate lobe secretory vesicles which have an acidic internal pH.	NICHHD,CELLULAR NEUROBIOL SECT,DEV NEUROBIOL LAB,BLDG 36,RM 2A21,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENNETT HPJ, 1982, J BIOL CHEM, V257, P96; BIRCH NP, 1991, EUR J BIOCHEM, V201, P85, DOI 10.1111/j.1432-1033.1991.tb16259.x; BIRCH NP, 1991, BIOCHEM BIOPH RES CO, V179, P1311, DOI 10.1016/0006-291X(91)91716-P; BRESHNAHAN PA, 1991, J CELL BIOL, V111, P2851; BRUBAKER PL, 1980, BIOCHEM BIOPH RES CO, V96, P1441, DOI 10.1016/0006-291X(80)90112-6; CHRISTIE DL, 1991, J BIOL CHEM, V266, P15679; COATES PJ, 1989, J ENDOCRINOL, V130, P525; COHEN P, 1987, BIOCHIMIE, V69, P87, DOI 10.1016/0300-9084(87)90239-2; DARBY NJ, 1990, BIOSCIENCE REP, V10, P1, DOI 10.1007/BF01116845; DAVIDSON HW, 1987, BIOCHEM J, V245, P575, DOI 10.1042/bj2450575; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; Eipper B A, 1980, Endocr Rev, V1, P1; ESTIVARIZ FE, 1989, J BIOL CHEM, V264, P17796; ESTIVARIZ FE, 1988, J ENDOCRINOL, V116, P207, DOI 10.1677/joe.0.1160207; EVANS CJ, 1982, BIOCHEM BIOPH RES CO, V106, P910, DOI 10.1016/0006-291X(82)91797-1; FENGER M, 1988, ACTA ENDOCRINOL-COP, V118, P119, DOI 10.1530/acta.0.1180119; FRICKER LD, 1983, J BIOL CHEM, V258, P950; FULLER R, 1986, MICROBIOLOGY 1986, P273; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; HAKES DJ, 1991, ENDOCRINOLOGY, V129, P3053, DOI 10.1210/endo-129-6-3053; HOOK VYH, 1984, P NATL ACAD SCI-BIOL, V81, P2776, DOI 10.1073/pnas.81.9.2776; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; LOH YP, 1984, ANNU REV NEUROSCI, V7, P189, DOI 10.1146/annurev.ne.07.030184.001201; LOH YP, 1986, J BIOL CHEM, V261, P1949; LOH YP, 1984, J BIOL CHEM, V259, P8238; LOH YP, 1985, J BIOL CHEM, V260, P7194; LOH YP, 1988, MOL MECHANISMS SECRE, P525; MAINS RE, 1990, FRONT NEUROENDOCRIN, V11, P52; RIUS RA, 1991, DEV BRAIN RES, V60, P179, DOI 10.1016/0165-3806(91)90046-L; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; SCOTT AP, 1973, NATURE-NEW BIOL, V244, P65, DOI 10.1038/newbio244065a0; SEGER MA, 1986, J STEROID BIOCHEM, V25, P703, DOI 10.1016/0022-4731(86)90298-0; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHENNAN KIJ, 1991, FEBS LETT, V284, P277, DOI 10.1016/0014-5793(91)80703-6; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; STOECKEL ME, 1985, CELL TISSUE RES, V242, P365; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VASICEK TJ, 1983, P NATL ACAD SCI-BIOL, V80, P2127, DOI 10.1073/pnas.80.8.2127	44	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7456	7463						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1313803				2022-12-27	WOS:A1992HN48500039
J	YAMAGUCHI, A; AKASAKA, T; ONO, N; SOMEYA, Y; NAKATANI, M; SAWAI, T				YAMAGUCHI, A; AKASAKA, T; ONO, N; SOMEYA, Y; NAKATANI, M; SAWAI, T			METAL-TETRACYCLINE/H+ ANTIPORTER OF ESCHERICHIA-COLI ENCODED BY TRANSPOSON TN10 - ROLES OF THE ASPARTYL RESIDUES LOCATED IN THE PUTATIVE TRANSMEMBRANE HELICES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANCE DETERMINANTS; NUCLEOTIDE-SEQUENCE; LACTOSE CARRIER; INNER MEMBRANE; LAC PERMEASE; PROTEIN; GENE; BACTERIORHODOPSIN; MUTANTS; HISTIDINE-322	Three conserved aspartyl residues located in the putative transmembrane helices in the Tn10-encoded metal-tetracycline/H+ antiporter were replaced by Asn, Lys, or Glu with oligonucleotide-directed site-specific mutagenesis. Replacement of Asp84 or Asp15 by Asn or Lys caused a severe defect in tetracycline transport activity, however, the Glu84 and Glu15 mutants retained 150 and 40% of the wild type activity, respectively, indicating the critical role of the negative charge. The increase in the activity of the Glu84 mutant was due to an increase in the affinity for the substrate. H+/tetracycline coupling was intact in these mutants, including Asn and Lys mutants. On the other hand, all of the Asp285-substitution mutants showed a severe defect in tetracycline transport activity and a complete lack of tetracycline-coupled H+ transport. However, since in vivo tests showed the tetracycline resistance for the Glu285 mutant, a negative charge in position 285 plays some role in maintaining the possible downhill and/or low affinity efflux of accumulated tetracycline from intact cells. Similar work was done for Asp365, and here the Asn and Glu mutants showed decreased but high activity, while the Lys mutant was only marginally active (5%), indicating that a negative charge is not so demanding in position 365, possibly because it is not in the membrane.			YAMAGUCHI, A (corresponding author), CHIBA UNIV,FAC PHARMACEUT SCI,DIV MICROBIAL CHEM,CHIBA 260,JAPAN.							BROOKER RJ, 1991, J BIOL CHEM, V266, P4131; CAIN BD, 1988, J BIOL CHEM, V263, P6606; CARRASCO N, 1989, BIOCHEMISTRY-US, V28, P2533, DOI 10.1021/bi00432a028; CARRASCO N, 1986, BIOCHEMISTRY-US, V25, P4486, DOI 10.1021/bi00364a004; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; ECKERT B, 1989, J BIOL CHEM, V264, P11663; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FRANCO PJ, 1991, J BIOL CHEM, V266, P6693; HENDERSON PJF, 1990, J BIOENERG BIOMEMBR, V22, P525, DOI 10.1007/BF00762961; HICKMAN RK, 1990, MOL MICROBIOL, V4, P1241, DOI 10.1111/j.1365-2958.1990.tb00703.x; HILLEN W, 1983, NUCLEIC ACIDS RES, V11, P525, DOI 10.1093/nar/11.2.525; HOPPE J, 1984, BIOCHIM BIOPHYS ACTA, V768, P1, DOI 10.1016/0304-4173(84)90005-3; KING SC, 1989, J BIOL CHEM, V264, P7390; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; KING SC, 1990, J BIOL CHEM, V265, P9645; KOBAYASHI H, 1978, J BIOL CHEM, V253, P2085; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEVY SB, 1989, J ANTIMICROB CHEMOTH, V24, P1, DOI 10.1093/jac/24.1.1; LEVY SB, 1984, ANTIMICROBIAL DRUG R, P191; MARINETTI T, 1989, P NATL ACAD SCI USA, V86, P529, DOI 10.1073/pnas.86.2.529; MCMURRY L, 1980, P NATL ACAD SCI-BIOL, V77, P3974, DOI 10.1073/pnas.77.7.3974; MOGI T, 1988, P NATL ACAD SCI USA, V85, P4148, DOI 10.1073/pnas.85.12.4148; MOYED HS, 1983, J BACTERIOL, V155, P549, DOI 10.1128/JB.155.2.549-556.1983; NGUYEN TT, 1983, GENE, V25, P83, DOI 10.1016/0378-1119(83)90170-1; OTTO H, 1989, P NATL ACAD SCI USA, V86, P9228, DOI 10.1073/pnas.86.23.9228; RUBIN RA, 1990, GENE, V87, P7, DOI 10.1016/0378-1119(90)90489-E; STOKER NG, 1982, GENE, V18, P335, DOI 10.1016/0378-1119(82)90172-X; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WATERS SH, 1983, NUCLEIC ACIDS RES, V11, P6089, DOI 10.1093/nar/11.17.6089; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P4809; YAMAGUCHI A, 1991, FEBS LETT, V282, P415, DOI 10.1016/0014-5793(91)80527-A; YAMAGUCHI A, 1991, J BIOL CHEM, V266, P6045; YAMAGUCHI A, 1990, FEBS LETT, V265, P17, DOI 10.1016/0014-5793(90)80872-G; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P15525; YAMAGUCHI A, 1991, ANTIMICROB AGENTS CH, V35, P53, DOI 10.1128/AAC.35.1.53; YAMAMOTO T, 1981, J BACTERIOL, V145, P808, DOI 10.1128/JB.145.2.808-813.1981	38	84	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7490	7498						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1313805				2022-12-27	WOS:A1992HN48500044
J	ARAKAKI, N; HIRONO, S; ISHII, T; KIMOTO, M; KAWAKAMI, S; NAKAYAMA, H; TSUBOUCHI, H; HISHIDA, T; DAIKUHARA, Y				ARAKAKI, N; HIRONO, S; ISHII, T; KIMOTO, M; KAWAKAMI, S; NAKAYAMA, H; TSUBOUCHI, H; HISHIDA, T; DAIKUHARA, Y			IDENTIFICATION AND PARTIAL CHARACTERIZATION OF 2 CLASSES OF RECEPTORS FOR HUMAN HEPATOCYTE GROWTH-FACTOR ON ADULT-RAT HEPATOCYTES IN PRIMARY CULTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FULMINANT HEPATIC-FAILURE; PLASMINOGEN-ACTIVATOR; HEPATOPOIETIN-A; SCATTER FACTOR; MESSENGER-RNA; MOLECULAR-CLONING; ESCHERICHIA-COLI; EXPRESSION; CDNA; PURIFICATION	To characterize the receptor(s) for human hepatocyte growth factor (hHGF), a physiological hepatotrophic factor involved in liver regeneration following hepatic injury, recombinant hHGF (rhHGF) was radioiodinated. The labeled rhHGF retained its full biological activity on adult rat hepatocytes in primary culture. The specific binding of [I-125]iodo-rhHGF to hepatocytes reached a plateau within 240 min at 4-degrees-C. Scatchard plot analysis of the binding data suggested the presence of two classes of high affinity binding sites for [I-125]iodo-rhHGF. One of the sites had a dissociation constant (K(d)) of about 4.6 pM with 300 sites/cell and the other has a K(d) of about 275 pM with 15,160 sites/cell. Unlabeled rhHGF displaced cell surface-bound [I-125]iodo-rhHGF in a dose-dependent manner as did native hHGF purified from plasma of patients with fulminant hepatic failure. However, other growth factors to rat hepatocytes in primary culture such as insulin and human epidermal growth factor, and proteins which have high amino acid sequence-homology to hHGF such as plasminogen and prothrombin, did not compete with [I-125]iodo-rhHGF in the binding, which suggests the binding was specific to hHGF. Covalent cross-linking experiment of [I-125]iodo-rhHGF to cell surface receptor(s) on hepatocytes showed there were two macromolecular species with apparent molecular weights of 330,000 and 230,000. Unlabeled rhHGF and native hHGF competed for the binding of [I-125]iodo-rhHGF to the two macromolecular species, but insulin, human epidermal growth factor, plasminogen, and prothrombin did not. Based upon our estimated molecular weight of rhHGF = 84,000, these results suggest that hHGF specifically binds to two polypeptides of 246,000 and 146,000 daltons which are likely to represent the hHGF receptors of primary cultured rat hepatocytes.	KAGOSHIMA UNIV,SCH DENT,DEPT BIOCHEM,35-1 SAKURAGAOKA-8,KAGOSHIMA 890,JAPAN; MITSUBISHI KASEI CORP,RES CTR,MIDORI KU,YOKOHAMA 227,JAPAN; KAGOSHIMA UNIV,FAC MED,DEPT INTERNAL MED 2,KAGOSHIMA 890,JAPAN	Kagoshima University; Kagoshima University								BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; COOL DE, 1985, J BIOL CHEM, V260, P3666; Cuatrecasas P, 1976, Adv Protein Chem, V30, P251, DOI 10.1016/S0065-3233(08)60481-7; DEGAN SJF, 1983, BIOCHEMISTRY-US, V22, P2087; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GOHDA E, 1990, LIFE SCI, V46, P1801; GOHDA E, 1990, BIOCHIM BIOPHYS ACTA, V1053, P21, DOI 10.1016/0167-4889(90)90020-E; GOHDA E, 1986, EXP CELL RES, V166, P139, DOI 10.1016/0014-4827(86)90514-8; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; HIGASHIO K, 1990, BIOCHEM BIOPH RES CO, V170, P397, DOI 10.1016/0006-291X(90)91287-3; HOLMES WE, 1985, BIO-TECHNOL, V3, P923, DOI 10.1038/nbt1085-923; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; ICHINOSE A, 1986, J CLIN INVEST, V78, P163, DOI 10.1172/JCI112546; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KINOSHITA T, 1989, BIOCHEM BIOPH RES CO, V165, P1229, DOI 10.1016/0006-291X(89)92733-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERCH PG, 1980, EUR J BIOCHEM, V107, P7, DOI 10.1111/j.1432-1033.1980.tb04617.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALINOWSKI DP, 1984, BIOCHEMISTRY-US, V23, P4243, DOI 10.1021/bi00313a035; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAKAMURA T, 1983, J BIOCHEM-TOKYO, V94, P1029, DOI 10.1093/oxfordjournals.jbchem.a134444; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1983, P NATL ACAD SCI-BIOL, V80, P7229, DOI 10.1073/pnas.80.23.7229; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NAKAYAMA H, 1985, BIOMED RES-TOKYO, V6, P231; OKAJIMA A, 1990, EUR J BIOCHEM, V193, P375, DOI 10.1111/j.1432-1033.1990.tb19349.x; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; ROSE SP, 1975, J CELL PHYSIOL, V86, P593, DOI 10.1002/jcp.1040860504; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SEKI T, 1990, BIOCHEM BIOPH RES CO, V172, P321, DOI 10.1016/S0006-291X(05)80212-8; STOKER M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P81, DOI 10.1016/0304-419X(91)90008-9; STRAIN AJ, 1991, J CLIN INVEST, V87, P1853, DOI 10.1172/JCI115207; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; TSUBOUCHI H, 1989, HEPATOLOGY, V9, P875, DOI 10.1002/hep.1840090615; TSUBOUCHI H, 1991, HEPATOLOGY, V13, P1; VANZONNEVELD AJ, 1986, P NATL ACAD SCI USA, V83, P4670; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WRAY W, 1981, ANAL BIOCHEM, V105, P361; YOSHIYAMA Y, 1991, BIOCHEM BIOPH RES CO, V175, P660, DOI 10.1016/0006-291X(91)91616-K; ZARNEGAR R, 1989, BIOCHEM BIOPH RES CO, V163, P1370, DOI 10.1016/0006-291X(89)91130-3; ZARNEGAR R, 1990, P NATL ACAD SCI USA, V87, P1252, DOI 10.1073/pnas.87.3.1252; ZARNEGAR R, 1990, BIOCHEM BIOPH RES CO, V173, P1179, DOI 10.1016/S0006-291X(05)80910-6; ZARNEGAR R, 1989, CANCER RES, V49, P3314	49	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					7101	7107						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1313034				2022-12-27	WOS:A1992HM05300099
J	KANEMATSU, T; TAKEYA, H; WATANABE, Y; OZAKI, S; YOSHIDA, M; KOGA, T; IWANAGA, S; HIRATA, M				KANEMATSU, T; TAKEYA, H; WATANABE, Y; OZAKI, S; YOSHIDA, M; KOGA, T; IWANAGA, S; HIRATA, M			PUTATIVE INOSITOL 1,4,5-TRISPHOSPHATE BINDING-PROTEINS IN RAT-BRAIN CYTOSOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRISPHOSPHATE RECEPTOR; CA-2+ RELEASE; SMOOTH-MUSCLE; PURIFICATION; EXPRESSION; PHOSPHATES; 3-KINASE; ANALOGS; CLONING; TETRAKISPHOSPHATE	In previous works, we synthesized a series of inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) analogs, with a substituent on the second carbon of the inositol ring. Using these analogs, the Ins(1,4,5)P3 affinity media were also synthesized (Hirata, M., Watanabe, Y., Ishimatsu, T., Yanaga, F., Koga, T., and Ozaki, S. (1990) Biochem. Biophys. Res. Commun. 168 379-386). When the cytosol fraction from the rat brain was applied to an Ins(1,4,5)P3 affinity column, an eluate with a 2 M NaCl solution was found to have remarkable Ins(1,4,5)P3-binding activity. The active fraction was further fractionated with gel filtration chromatography, and two proteins with an apparent molecular mass of 130 or 85 kDa were found to be Ins(1,4,5)P3-binding proteins but with no Ins(1,4,5)P3 metabolizing activities. Partial amino acid sequences determined after proteolysis and reversed-phase chromatography revealed that the protein with an apparent molecular mass of 85 kDa is the delta-isozyme of phospholipase C and that of 130 kDa has no sequence the same as the Ins(1,4,5)P3-recognizing proteins hitherto examined. Ins(1,4,5)P3 at concentrations greater than 1-mu-M strongly inhibited 85-kDa phospholipase C-delta activity, without changing its dependence on the concentrations of free Ca2+ and H+. Among inositol phosphates examined, Ins(3,4,5,6)P4 inhibited the binding of [H-3]Ins(1,4,5)P3 to the 130-kDa protein at much the same concentrations as seen with Ins(1,4,5)P3. This report seems to be the first evidence for the presence of soluble Ins(1,4,5)P3-binding proteins in the rat brain, one of which is the delta isozyme of phospholipase C.	KYUSHU UNIV, FAC DENT, DEPT BIOCHEM, FUKUOKA 812, JAPAN; KYUSHU UNIV, FAC SCI, DEPT BIOL, FUKUOKA 812, JAPAN; EHIME UNIV, FAC ENGN, DEPT APPL CHEM, MATSUYAMA, EHIME 790, JAPAN	Kyushu University; Kyushu University; Ehime University								BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; CHOI KY, 1990, SCIENCE, V248, P64, DOI 10.1126/science.2157285; ERNEUX C, 1989, EUR J BIOCHEM, V181, P317, DOI 10.1111/j.1432-1033.1989.tb14726.x; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; HANSEN CA, 1987, J BIOL CHEM, V262, P17319; HENNE V, 1988, EUR J BIOCHEM, V174, P95, DOI 10.1111/j.1432-1033.1988.tb14067.x; HIRATA M, 1985, NATURE, V317, P723, DOI 10.1038/317723a0; HIRATA M, 1990, BIOCHEM BIOPH RES CO, V168, P379, DOI 10.1016/0006-291X(90)91719-9; HIRATA M, 1989, J BIOL CHEM, V264, P20303; HIRATA M, 1990, J BIOL CHEM, V265, P8404; IRVINE RF, 1986, NATURE, V320, P631, DOI 10.1038/320631a0; IRVINE RF, 1986, BIOCHEM J, V240, P917, DOI 10.1042/bj2400917; IRVINE RF, 1984, BIOCHEM J, V222, P269, DOI 10.1042/bj2220269; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MARKS AR, 1990, J BIOL CHEM, V265, P20719; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; OZAKI S, 1991, ACS SYM SER, V463, P43; PALMER S, 1989, CELL SIGNAL, V1, P147, DOI 10.1016/0898-6568(89)90004-1; POLOKOFF MA, 1988, J BIOL CHEM, V263, P11922; PRESTWICH GD, 1991, J AM CHEM SOC, V113, P1822, DOI 10.1021/ja00005a055; SHEARS SB, 1989, BIOCHEM J, V260, P313, DOI 10.1042/bj2600313; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRUPISH J, 1988, BIOCHEM J, V253, P901, DOI 10.1042/bj2530901; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAKAZAWA K, 1990, BIOCHEM J, V272, P107, DOI 10.1042/bj2720107; TAKIMOTO K, 1989, J BIOCHEM-TOKYO, V106, P684, DOI 10.1093/oxfordjournals.jbchem.a122917; VARNEY MA, 1990, BIOCHEM J, V269, P211, DOI 10.1042/bj2690211; WATANABE Y, 1988, TETRAHEDRON LETT, V29, P5259, DOI 10.1016/S0040-4039(00)80731-5; Youngburg GE, 1930, J LAB CLIN MED, V16, P158	37	129	132	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6518	6525						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1313009				2022-12-27	WOS:A1992HM05300014
J	KELADA, ASM; MACAULAY, SL; PROIETTO, J				KELADA, ASM; MACAULAY, SL; PROIETTO, J			CYCLIC-AMP ACUTELY STIMULATES TRANSLOCATION OF THE MAJOR INSULIN-REGULATABLE GLUCOSE TRANSPORTER GLUT4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT ADIPOCYTES; ELECTROPHORETIC TRANSFER; POLYACRYLAMIDE GELS; ADIPOSE-CELLS; FAT-CELLS; PROTEIN; CATECHOLAMINES; NITROCELLULOSE; MECHANISMS; ADENOSINE	Facilitated glucose transport across plasma membranes is mediated by a family of transporters (GLUT1-GLUT5) that have different tissue distributions and K(m) values for transport. It has been shown that insulin stimulates glucose transport in fat and muscle tissues by causing the redistribution of one of these proteins (GLUT4) from inside the cell to the plasma membrane. Previous studies have shown that agents that change cAMP levels are able to modulate glucose transport in fat cells. The aim of this study was to investigate the mechanisms responsible for modulation of glucose transport by cAMP. 2-Deoxyglucose transport and insulin-regulatable glucose transporter (GLUT4) immunoreactivity in plasma and low density microsomal membranes were measured in adipocytes incubated for 30 min with insulin or dibutyryl-cAMP (Bt2cAMP). Low concentrations of Bt2cAMP (10-mu-M) increased 2-deoxyglucose uptake by translocating GLUT4 from low density microsomal membranes to the plasma membranes. Bt2cAMP at 1000-mu-M inhibited glucose transport below basal but further increased translocation of GLUT4. The effect of Bt2cAMP on translocation was additive to that of 7 nM insulin. We conclude that in rat adipocytes, Bt2cAMP acutely translocates GLUT4 but inhibits its activity to transport glucose.	CSIRO,DIV BIOMOLEC ENGN,PARKVILLE,VIC 3050,AUSTRALIA	Commonwealth Scientific & Industrial Research Organisation (CSIRO)	KELADA, ASM (corresponding author), UNIV MELBOURNE,ROYAL MELBOURNE HOSP,DEPT MED,MELBOURNE,VIC 3050,AUSTRALIA.		Macaulay, Stuart Lance/A-6086-2008; Proietto, Joe/B-3780-2012	Macaulay, Stuart Lance/0000-0001-5069-9516; 				AVRUCH J, 1971, BIOCHIM BIOPHYS ACTA, V233, P344; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; Fleischer B, 1974, Methods Enzymol, V31, P180; GREEN A, 1983, FEBS LETT, V152, P261, DOI 10.1016/0014-5793(83)80392-5; GUERREMILLO M, 1985, J BIOL CHEM, V260, P2197; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JOOST HG, 1984, FEBS LETT, V167, P5, DOI 10.1016/0014-5793(84)80821-2; KASHIWAGI A, 1983, J BIOL CHEM, V258, P3685; KIRSCH DM, 1983, BIOCHEM J, V216, P737, DOI 10.1042/bj2160737; KONO T, 1981, J BIOL CHEM, V256, P6400; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE JC, 1990, J BIOL CHEM, V265, P2324; LUDVIGSEN C, 1980, ENDOCRINOLOGY, V106, P786, DOI 10.1210/endo-106-3-786; OKA Y, 1988, J BIOL CHEM, V263, P13432; OLEFSKY JM, 1978, BIOCHEM J, V172, P137, DOI 10.1042/bj1720137; RODBELL M, 1964, J BIOL CHEM, V239, P375; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMITH MM, 1984, BIOCHIM BIOPHYS ACTA, V775, P121, DOI 10.1016/0005-2736(84)90162-7; SMITH U, 1984, J BIOL CHEM, V259, P8758; Stanley KK, 1979, BIOCHEM SOC T, V7, P361, DOI 10.1042/bst0070361; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TAYLOR WM, 1979, BIOCHEM J, V178, P381, DOI 10.1042/bj1780381; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	28	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					7021	7025						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1313029				2022-12-27	WOS:A1992HM05300086
J	ZAVITZ, KH; MARIANS, KJ				ZAVITZ, KH; MARIANS, KJ			ATPASE-DEFICIENT MUTANTS OF THE ESCHERICHIA-COLI DNA-REPLICATION PROTEIN PRIA ARE CAPABLE OF CATALYZING THE ASSEMBLY OF ACTIVE PRIMOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-Y; PHI-X174 DNA; ENZYMATIC REPLICATION; INITIATION SIGNALS; DEPENDENT ATPASE; ADENYLATE KINASE; PBR322 DNA; CHROMOSOME; HELICASE; STRAND	The PriA replication protein of Escherichia coli (formerly replication factor Y or protein n') is multifunctional. It is a site-specific, single-stranded DNA-dependent ATPase (dATPase), a 3' --> 5' DNA helicase, and guides the ordered assembly of the primosome, a mobile, multiprotein DNA replication priming/helicase complex. Although PriA is not absolutely required for viability, priA null mutant cells grow very slowly, have poor viability, and form extensive filaments. In order to assess which of the multiple activities of PriA are required for normal replication and growth, site-directed mutagenesis was employed to introduce single amino acid substitutions for the invariant lysine within the consensus nucleotide-binding motif found in PriA. Biochemical characterization of the representative purified mutant PriA proteins revealed them to be completely deficient in nucleotide hydrolysis, incapable of translocation along a single-stranded DNA binding protein-coated single-stranded DNA template, and unable to manifest the 3' --> 5' DNA helicase activity of wild-type PriA. These mutant proteins were, however, capable of catalyzing the assembly of active primosomes in vitro. Furthermore, when supplied in trans to insertionally inactivated priA cells, plasmids containing a copy of these mutant priA genes restored the wild-type growth rate, viability, and cell morphology. Based on these results, a model for PriA function in vivo is discussed.	CORNELL UNIV,GRAD SCH MED SCI,GRAD PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Cornell University	ZAVITZ, KH (corresponding author), MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034557, R01GM034557] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34557] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAZUA P, 1984, J BIOL CHEM, V259, P14286; ALLEN GC, 1991, J BIOL CHEM, V266, P11610; ARAI K, 1981, P NATL ACAD SCI-BIOL, V78, P69, DOI 10.1073/pnas.78.1.69; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; CONWAY TW, 1964, P NATL ACAD SCI USA, V52, P1462, DOI 10.1073/pnas.52.6.1462; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GREENBAUM JH, 1984, J BIOL CHEM, V259, P2594; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; HEITMAN J, 1989, P NATL ACAD SCI USA, V86, P2281, DOI 10.1073/pnas.86.7.2281; HIASA H, 1989, FEBS LETT, V246, P21, DOI 10.1016/0014-5793(89)80245-5; KORNBERG A, 1982, DNA REPLICATION; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LASKEN RS, 1988, J BIOL CHEM, V263, P5512; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE EH, 1990, P NATL ACAD SCI USA, V87, P4620, DOI 10.1073/pnas.87.12.4620; LEE EH, 1991, P NATL ACAD SCI USA, V88, P3029, DOI 10.1073/pnas.88.8.3029; LEE MS, 1989, J BIOL CHEM, V264, P14531; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; MANIATIS T, 1982, MOL CLONING LABORATO, P249; MARIANS KJ, 1990, UCLA SYM BI, V127, P289; MARIANS KJ, 1984, CRC CR REV BIOCH MOL, V17, P153, DOI 10.3109/10409238409113604; MARIANS KJ, 1982, J BIOL CHEM, V257, P5656; MCMACKEN R, 1978, J BIOL CHEM, V253, P3313; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MODEL P, 1974, J MOL BIOL, V83, P231, DOI 10.1016/0022-2836(74)90389-1; NURSE P, 1990, P NATL ACAD SCI USA, V87, P4615, DOI 10.1073/pnas.87.12.4615; NURSE P, 1991, J BACTERIOL, V173, P6686, DOI 10.1128/jb.173.21.6686-6693.1991; PARSONAGE D, 1988, J BIOL CHEM, V263, P4740; REINSTEIN J, 1988, BIOCHEMISTRY-US, V27, P4712, DOI 10.1021/bi00413a020; SASSANFAR M, 1990, J MOL BIOL, V212, P79, DOI 10.1016/0022-2836(90)90306-7; SEELEY TW, 1989, P NATL ACAD SCI USA, V86, P6577, DOI 10.1073/pnas.86.17.6577; SEUFERT W, 1986, EMBO J, V5, P3401, DOI 10.1002/j.1460-2075.1986.tb04656.x; SHLOMAI J, 1980, J BIOL CHEM, V255, P6789; SHLOMAI J, 1980, P NATL ACAD SCI-BIOL, V77, P799, DOI 10.1073/pnas.77.2.799; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; STUITJE AR, 1984, NUCLEIC ACIDS RES, V12, P3321, DOI 10.1093/nar/12.7.3321; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; THIAGALINGAM S, 1991, J BIOL CHEM, V266, P11395; VANDERENDE A, 1985, P NATL ACAD SCI USA, V82, P3954; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEINER JH, 1976, P NATL ACAD SCI USA, V73, P752, DOI 10.1073/pnas.73.3.752; WICKNER S, 1974, P NATL ACAD SCI USA, V71, P783, DOI 10.1073/pnas.71.3.783; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P3342, DOI 10.1073/pnas.72.9.3342; WICKNER S, 1975, P NATL ACAD SCI USA, V71, P4120; ZAVITZ KH, 1991, J BIOL CHEM, V266, P13988; ZECHNER EJ, 1992, IN PRESS J BIOL CHEM, V267	47	118	127	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6933	6940						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1313026				2022-12-27	WOS:A1992HM05300074
J	PELTON, PD; GANZHORN, AJ				PELTON, PD; GANZHORN, AJ			THE EFFECT OF HISTIDINE MODIFICATION ON THE ACTIVITY OF MYOINOSITOL MONOPHOSPHATASE FROM BOVINE BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOINOSITOL MONOPHOSPHATASE; ACID-PHOSPHATASE; PURIFICATION; LITHIUM; MYO-INOSITOL-1-PHOSPHATASE; PHOSPHOHISTIDINE; INTERMEDIATE; LIVER	The pH dependence of myo-inositol monophosphatase may indicate a role for histidine residues in the catalytic mechanism (Ganzhorn, A. J., and Chanal, M. C. (1990) Biochemistry 29, 6065-6071). This possibility was investigated by chemical modification. At pH 6.0 and 25-degrees-C, the enzyme was inactivated by diethylpyrocarbonate in a pseudo-first order reaction with a bimolecular rate constant of 0.37 M-1 s-1. Two histidines were modified rapidly with no effect on enzyme activity, while 3 residues were modified at a slower rate corresponding to the rate of inactivation. No noticeable changes in the secondary structure of the enzyme were observed by comparison of circular dichroic spectra before and after modification. Treatment of myo-inositol monophosphatase with diethylpyrocarbonate in the presence of inositol 1-phosphate, Mg2+, and Li+ protected 2 residues from modification and decreased the inactivation rate by about 5-fold. Spectrophotometric analysis, the restoration of enzyme activity by hydroxylamine, and the lack of any inhibitory effect with alkylating agents suggest that inactivation is due solely to modification of histidine. We conclude that a histidine residue is essential for activity and may act as a base catalyst during hydrolysis of the substrate.	MARION MERRELL DOW RES INST,16 RUE ANKARA,F-67009 STRASBOURG,FRANCE									ALLISON JH, 1976, BIOCHEM BIOPH RES CO, V71, P664, DOI 10.1016/0006-291X(76)90839-1; ATTWOOD PV, 1988, BIOCHEM J, V253, P387, DOI 10.1042/bj2530387; BAKER GR, 1991, BIOORG MED CHEM LETT, V1, P193, DOI 10.1016/S0960-894X(00)80250-4; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; DEGROOT H, 1985, BIOCHEM J, V230, P255, DOI 10.1042/bj2300255; DIEHL RE, 1990, J BIOL CHEM, V265, P5946; DUMAS DP, 1990, J BIOL CHEM, V265, P21498; FELDMAN F, 1969, BIOCHEM BIOPH RES CO, V36, P119, DOI 10.1016/0006-291X(69)90657-3; Fersht A., 1985, ENZYME STRUCTURE MEC; GANZHORN AJ, 1990, BIOCHEMISTRY-US, V29, P6065, DOI 10.1021/bi00477a026; GEE NS, 1988, BIOCHEM J, V249, P883, DOI 10.1042/bj2490883; GEE NS, 1991, FEBS LETT, V284, P95, DOI 10.1016/0014-5793(91)80770-4; GOMI T, 1983, BIOCHEMISTRY-US, V22, P137, DOI 10.1021/bi00270a020; HALLCHER LM, 1980, J BIOL CHEM, V255, P896; HENNECKE M, 1983, BIOCHEMISTRY-US, V22, P3721, DOI 10.1021/bi00285a001; JACKSON RG, 1989, BIOCHEM J, V264, P419, DOI 10.1042/bj2640419; LEVY HM, 1963, J BIOL CHEM, V238, P3654; MAJERUS PW, 1988, J BIOL CHEM, V263, P3051; MEEK JL, 1988, BIOCHEM BIOPH RES CO, V156, P143, DOI 10.1016/S0006-291X(88)80816-7; MELCHIOR WB, 1970, BIOCHEMISTRY-US, V9, P251, DOI 10.1021/bi00804a010; Miles E W, 1977, Methods Enzymol, V47, P431; MUHLRAD A., 1967, ACTA BIOCHIM BIOPHYS ACAD SCI HUNG, V2, P19; OVADI J, 1967, Acta Biochimica et Biophysica Academiae Scientiarum Hungaricae, V2, P455; PUTNEY JW, 1989, FASEB J, V3, P1899, DOI 10.1096/fasebj.3.8.2542110; RAY WJ, 1961, J BIOL CHEM, V236, P1973; ROSE ZB, 1970, ARCH BIOCHEM BIOPHYS, V140, P508, DOI 10.1016/0003-9861(70)90095-0; Schowen R. L., 1977, ISOTOPE EFFECTS ENZY, P64; SHUTE JK, 1988, J CHEM SOC CHEM COMM, V9, P626; VANETTEN RL, 1977, BIOCHIM BIOPHYS ACTA, V484, P386, DOI 10.1016/0005-2744(77)90094-8; VANETTEN RL, 1977, ARCH BIOCHEM BIOPHYS, V183, P250, DOI 10.1016/0003-9861(77)90438-6	31	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5916	5920						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1313422				2022-12-27	WOS:A1992HK31800033
J	THOMMES, P; FERRARI, E; JESSBERGER, R; HUBSCHER, U				THOMMES, P; FERRARI, E; JESSBERGER, R; HUBSCHER, U			4 DIFFERENT DNA HELICASES FROM CALF THYMUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; SINGLE-STRANDED-DNA; LARGE TUMOR-ANTIGEN; ESCHERICHIA-COLI; POLYMERASE-ALPHA; SACCHAROMYCES-CEREVISIAE; POLYACRYLAMIDE GELS; REPLICATION INVITRO; DEPENDENT ATPASE; BINDING-PROTEIN	Using a strand displacement assay we have followed DNA helicase activities during the simultaneous isolation of several enzymes from calf thymus such as DNA polymerases alpha, delta, and epsilon, proliferating cell nuclear antigen, and replication factor A. Thus we were able to discriminate and isolate four different DNA helicases called A, B, C, and D. DNA helicase A is identical with the enzyme described earlier (Thommes, P., and Hubscher, U. (1990) J. Biol. Chem. 265, 1434714354). The four enzymes can be distinguished by (i) their putative molecular weights after sodium dodecyl sulfate-polyacrylamide gel electrophoresis, (ii) glycerol gradient sedimentation under low and high salt conditions, (iii) sensitivity to salt, (iv) binding to DNA, (v) nucleoside- and deoxynucleoside 5'-triphosphate requirements, and (vi) by their direction of movement. DNA helicase A unwinds in the 3' --> 5' direction on the DNA it was bound to, while DNA helicases B, C, and D do so in the 5' --> 3' direction. DNA helicase D, and to some extent DNA helicases B and C, are able to unwind long substrates of more than 400 nucleotides. Replication factor A, a single-stranded heterotrimeric DNA binding protein involved in cellular DNA replication and DNA repair stimulates the DNA helicases. The stimulatory effect is most pronounced on DNA helicase A, where replication factor A enables this helicase to unwind longer substrates. DNA helicases B, C, and D are also stimulated by replication factor A. The effect of replication factor A appears to be specific since corresponding single-stranded DNA binding proteins from Escherichia coli and bacteriophage T4 have no or even a negative effect on the four DNA helicases. Heterologous human replication factor A has no stimulatory effect on any of the four DNA helicases suggesting a species specificity of these interactions. Thus it appears that mammalian cells possess, as does E. coli, a variety of different enzymes that can transiently abolish the double helical DNA structure in the cell.	STANFORD UNIV, MED CTR, SCH MED, DEPT BIOCHEM, STANFORD, CA 94305 USA	Stanford University	THOMMES, P (corresponding author), UNIV ZURICH, DEPT PHARMACOL & BIOCHEM, WINTERTHURERSTR 190, CH-8057 ZURICH, SWITZERLAND.							ACUTO O, 1983, CELL, V34, P717, DOI 10.1016/0092-8674(83)90528-7; AREZZO F, 1987, ANAL BIOCHEM, V167, P387, DOI 10.1016/0003-2697(87)90181-3; BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BEEN MD, 1983, METHOD ENZYMOL, V101, P90; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; CHALLBERG MD, 1986, P NATL ACAD SCI USA, V83, P9094, DOI 10.1073/pnas.83.23.9094; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DOWNEY KM, 1990, UCLA SYM BI, V127, P141; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; GOETZ GS, 1988, J BIOL CHEM, V263, P383; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; HUBSCHER U, 1985, NUCLEIC ACIDS RES, V13, P5471, DOI 10.1093/nar/13.15.5471; JONGENEEL CV, 1984, J BIOL CHEM, V259, P2925; KENNY MK, 1990, J BIOL CHEM, V265, P769; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KORNBERG A, 1978, J BIOL CHEM, V253, P3298; Kornberg A., 1991, DNA REPLICATION; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHUE EE, 1988, J BIOL CHEM, V263, P3208; LASKEN RS, 1988, J BIOL CHEM, V263, P5512; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE EH, 1990, P NATL ACAD SCI USA, V87, P4620, DOI 10.1073/pnas.87.12.4620; MATSON SW, 1985, J BIOL CHEM, V260, P2281; MATSON SW, 1991, PROG NUCLEIC ACID RE, V40, P289; MATSON SW, 1986, J BIOL CHEM, V261, P169; MATSUMOTO T, 1990, P NATL ACAD SCI USA, V87, P9712, DOI 10.1073/pnas.87.24.9712; OH EY, 1987, P NATL ACAD SCI USA, V84, P3638, DOI 10.1073/pnas.84.11.3638; POLL EHA, 1988, BIOCHEMISTRY-US, V27, P8701, DOI 10.1021/bi00424a002; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; Sambrook J, 1989, MOL CLONING LABORATO; SEKI M, 1990, BIOCHEMISTRY-US, V29, P1003, DOI 10.1021/bi00456a024; SEKI M, 1988, BIOCHEMISTRY-US, V27, P1766, DOI 10.1021/bi00405a057; SEO YS, 1991, J BIOL CHEM, V266, P13161; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SMALE ST, 1986, MOL CELL BIOL, V6, P4077, DOI 10.1128/MCB.6.11.4077; STAHL H, 1987, BIOCHIM BIOPHYS ACTA, V910, P1, DOI 10.1016/0167-4781(87)90088-1; SUGINO A, 1986, J BIOL CHEM, V261, P1744; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; THOMMES P, 1990, J BIOL CHEM, V265, P14347; THOMMES P, 1990, FEBS LETT, V268, P325, DOI 10.1016/0014-5793(90)81279-W; THOMMES P, 1986, BIOCHEMISTRY-US, V25, P1308; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUTEJA N, 1990, NUCLEIC ACIDS RES, V18, P6785, DOI 10.1093/nar/18.23.6785; TUTEJA N, 1991, NUCLEIC ACIDS RES, V19, P3613, DOI 10.1093/nar/19.13.3613; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; VIRSHUP DM, 1989, P NATL ACAD SCI USA, V86, P3584, DOI 10.1073/pnas.86.10.3584; WEISER T, 1991, J BIOL CHEM, V266, P10420; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1989, J BIOL CHEM, V264, P2801; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; WOOD ER, 1987, J BIOL CHEM, V262, P15269; ZHANG SS, 1991, J BIOL CHEM, V266, P20483	56	61	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6063	6073						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1313427				2022-12-27	WOS:A1992HK31800054
J	ABLER, A; SMITH, JA; RANDAZZO, PA; ROTHENBERG, PL; JARETT, L				ABLER, A; SMITH, JA; RANDAZZO, PA; ROTHENBERG, PL; JARETT, L			GENISTEIN DIFFERENTIALLY INHIBITS POSTRECEPTOR EFFECTS OF INSULIN IN RAT ADIPOCYTES WITHOUT INHIBITING THE INSULIN-RECEPTOR KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-KINASE; PHOSPHOLIPASE-C; MONOCLONAL-ANTIBODIES; TOPOISOMERASE-II; PROTEIN-KINASES; GLUCOSE-UPTAKE; NIH-3T3 CELLS; DNA-SYNTHESIS; PHOSPHORYLATION; ACTIVATION	Genistein, an isoflavone putative tyrosine kinase inhibitor, was used to investigate the coupling of insulin receptor tyrosine kinase activation to four metabolic effects of insulin in the isolated rat adipocyte. Genistein inhibited insulin-stimulated glucose oxidation in a concentration-dependent manner with an ID50 of 25-mu-g/ml and complete inhibition at 100-mu-g/ml. Genistein also prevented insulin's (10(-9) M) inhibition of isoproterenol-stimulated lipolysis with an ID50 of 15-mu-g/ml and a complete effect at 50-mu-g/ml. The effect of genistein (25-mu-g/ml) was not reversed by supraphysiological (10(-7) M) insulin levels. In contrast, genistein up to 100-mu-g/ml had no effect on insulin's (10(-9) M) stimulation of either pyruvate dehydrogenase or glycogen synthase activity. We determined whether genistein influenced insulin receptor beta-subunit autophosphorylation or tyrosine kinase substrate phosphorylation either in vivo or in vitro by anti-phosphotyrosine immunoblotting. Genistein at 100-mu-g/ml did not inhibit insulin's (10(-7) M) stimulation of insulin receptor tyrosine autophosphorylation or tyrosine phosphorylation of the cellular substrates pp185 and pp60. Also, genistein did not prevent insulin-stimulated autophosphorylation of partially purified human insulin receptors from NIH 3T3/HIR 3.5 cells or the phosphorylation of histones by the activated receptor tyrosine kinase. In control experiments using either NIH 3T3 fibroblasts or partially purified membranes from these cells, genistein did inhibit platelet-derived growth factor's stimulation of its receptor autophosphorylation. These findings indicate the following: (a) Genistein can inhibit certain responses to insulin without blocking insulin's stimulation of its receptor tyrosine autophosphorylation or of the receptor kinase substrate tyrosine phosphorylation. (b) In adipocytes genistein must block the stimulation of glucose oxidation and the antilipolytic effects of insulin at site(s) downstream from the insulin receptor tyrosine kinase. (c) The inhibitory effects of genistein on hormonal signal transduction cannot necessarily be attributed to inhibition of tyrosine kinase activity, unless specifically demonstrated.	UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,3400 SPRUCE ST,6 GATES,PHILADELPHIA,PA 19104	University of Pennsylvania					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028144] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 28144, DK 08484] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ATLURU S, 1991, TRANSPLANTATION, V51, P448, DOI 10.1097/00007890-199102000-00035; BESTERMAN B, 1990, J EXP ZOOL, V256, P44, DOI 10.1002/jez.1402560107; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COYNE DW, 1990, BIOCHEM BIOPH RES CO, V173, P718, DOI 10.1016/S0006-291X(05)80094-4; Cuatrecasas P, 1974, Methods Enzymol, V34, P653; DEAN NM, 1989, BIOCHEM BIOPH RES CO, V165, P795, DOI 10.1016/S0006-291X(89)80036-1; DEBANT A, 1989, BIOCHEMISTRY-US, V28, P14, DOI 10.1021/bi00427a003; DHAR A, 1990, MOL PHARMACOL, V37, P519; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FAALAND CA, 1991, MOL CELL BIOL, V11, P2697, DOI 10.1128/MCB.11.5.2697; FILVAROFF E, 1990, MOL CELL BIOL, V10, P1164, DOI 10.1128/MCB.10.3.1164; FUJITAYAMAGUCHI Y, 1988, BIOCHEM BIOPH RES CO, V157, P955, DOI 10.1016/S0006-291X(88)80967-7; GAUDETTE DC, 1990, BIOCHEM BIOPH RES CO, V170, P238, DOI 10.1016/0006-291X(90)91265-T; GOTTSCHALK WK, 1991, J BIOL CHEM, V266, P8814; HAWLEY DM, 1989, J BIOL CHEM, V264, P2438; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JARETT L, 1985, SCIENCE, V227, P533, DOI 10.1126/science.3917578; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE PJL, 1991, J IMMUNOL, V146, P715; LINASSIER C, 1990, BIOCHEM PHARMACOL, V39, P187, DOI 10.1016/0006-2952(90)90664-7; MADDUX BA, 1991, J BIOL CHEM, V266, P6731; MAJUMDAR APN, 1990, AM J PHYSIOL, V259, pG626, DOI 10.1152/ajpgi.1990.259.4.G626; MARKOVITS J, 1989, CANCER RES, V49, P5111; MOLLER DE, 1991, J BIOL CHEM, V266, P10995; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; OGAWARA H, 1989, J ANTIBIOT, V42, P340, DOI 10.7164/antibiotics.42.340; OKURA A, 1988, BIOCHEM BIOPH RES CO, V157, P183, DOI 10.1016/S0006-291X(88)80030-5; OLEFSKY JM, 1990, DIABETES, V39, P1009, DOI 10.2337/diabetes.39.9.1009; PERLMAN R, 1989, J BIOL CHEM, V264, P8946; RANDAZZO PA, 1990, EXP CELL RES, V190, P31, DOI 10.1016/0014-4827(90)90140-6; RODBELL M, 1964, J BIOL CHEM, V239, P375; ROSEN OM, 1989, DIABETES, V38, P1508, DOI 10.2337/diabetes.38.12.1508; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; SAPERSTEIN R, 1989, BIOCHEMISTRY-US, V28, P5694, DOI 10.1021/bi00439a053; SCHECHTER Y, 1989, EMBO J, V8, P1671, DOI 10.1002/j.1460-2075.1989.tb03558.x; SMITH RM, 1988, LAB INVEST, V58, P613; SOLER AP, 1989, P NATL ACAD SCI USA, V86, P6640, DOI 10.1073/pnas.86.17.6640; SUNG CK, 1989, J BIOL CHEM, V264, P18951; WATANABE T, 1991, CANCER RES, V51, P764; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; YAMASHITA Y, 1990, BIOCHEM PHARMACOL, V39, P737; ZWILLER J, 1991, ONCOGENE, V6, P219	48	107	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3946	3951						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1310987				2022-12-27	WOS:A1992HE60700062
J	ALLGOOD, VE; CIDLOWSKI, JA				ALLGOOD, VE; CIDLOWSKI, JA			VITAMIN-B6 MODULATES TRANSCRIPTIONAL ACTIVATION BY MULTIPLE MEMBERS OF THE STEROID-HORMONE RECEPTOR SUPERFAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GLUCOCORTICOID RECEPTOR; MAMMARY-TUMOR VIRUS; AVIAN PROGESTERONE RECEPTOR; ESTROGEN-RESPONSIVE ELEMENT; HELA S3 CELLS; PYRIDOXAL-PHOSPHATE; GENE-EXPRESSION; FUNCTIONAL DOMAINS; BINDING-SITE; CHEMICAL MODIFICATION	Recent studies have shown that vitamin B-6 modulates transcriptional activation by the human glucocorticoid receptor in HeLa S3 cells. We have now examined the possibility that vitamin B-6 might similarly influence transcriptional activation by the glucocorticoid receptor in other cell types, as well as gene expression mediated by other members of the steroid hormone receptor superfamily. We show that elevated vitamin B-6 concentrations suppress by 40-65% the level of transcription mediated through the endogenous murine L cell glucocorticoid receptor, as well as the human receptor transfected into E8.2 and T47D cells. In contrast, glucocorticoid receptor-mediated transcription was enhanced 60-110% in mild vitamin deficiency. The level of hormone-independent constitutive gene expression was not affected by these same alterations in vitamin B-6 concentration. These studies indicated that the transcriptional modulatory effects of the vitamin were neither restricted to specific cell types nor limited to the human form of the glucocorticoid receptor. We next determined if hormone-induced transcription by several other steroid receptors (androgen, progesterone, and estrogen receptors) was analogously affected by alterations in vitamin B-6 concentration. Analysis of gene expression mediated through the mouse mammary tumor virus promoter revealed that transcriptional activation of both the androgen and progesterone receptors was reduced by 35-40% under conditions of elevated vitamin B-6 and enhanced by 60-90% in deficiency, again under conditions where constitutive expression was unaffected. Using a different promoter, the estrogen-regulated vitellogenin promoter, we found that transcriptional activation of the estrogen receptor was similarly affected. Estrogen-induced gene expression was reduced by 30% under conditions of elevated intracellular vitamin B-6 and enhanced by 85% in vitamin deficiency. Thus, vitamin B-6 modulates transcriptional activation by multiple classes of steroid hormone receptors. The similarities in vitamin B-6 effects on transcription mediated through different promoters, the mouse mammary tumor virus and vitellogenin promoters, suggest that this vitamin may modulate the expression of a diverse array of hormonally responsive genes. These observations together support the hypothesis that vitamin B-6 represents a physiological modulator of steroid hormone action.	UNIV N CAROLINA, DEPT PHYSIOL, 460 MED SCI RES BLDG, CB 7545, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, INST NUTR, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Cidlowski, John A/G-2548-2019	Cidlowski, John A/0000-0003-1420-0516	NIDDK NIH HHS [DK 32459] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032459] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLGOOD VE, 1990, ANN NY ACAD SCI, V585, P452, DOI 10.1111/j.1749-6632.1990.tb28076.x; ALLGOOD VE, 1990, J BIOL CHEM, V265, P12424; ALLGOOD VE, 1991, J NUTR BIOCH, V2, P641; ARONICA SM, 1991, ENDOCRINOLOGY, V128, P2045, DOI 10.1210/endo-128-4-2045; Ballard P L, 1979, Monogr Endocrinol, V12, P493; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BELLINGHAM D L, 1988, P97; BOWDEN JF, 1986, J STEROID BIOCHEM, V25, P359, DOI 10.1016/0022-4731(86)90248-7; BUNCE GE, 1987, J STEROID BIOCHEM, V26, P303, DOI 10.1016/0022-4731(87)90093-8; BURNSTEIN KL, 1989, ANNU REV PHYSIOL, V51, P683, DOI 10.1146/annurev.ph.51.030189.003343; BURNSTEIN KL, 1991, STEROIDS, V56, P52, DOI 10.1016/0039-128X(91)90124-E; BURNSTEIN KL, 1990, J BIOL CHEM, V265, P7284; CAKE MH, 1978, J BIOL CHEM, V253, P4886; CATO ACB, 1988, EMBO J, V7, P1403, DOI 10.1002/j.1460-2075.1988.tb02957.x; CHANDLER VL, 1983, CELL, V33, P489, DOI 10.1016/0092-8674(83)90430-0; CIDLOWSKI JA, 1990, MOL ENDOCRINOL, V4, P1427, DOI 10.1210/mend-4-10-1427; CIDLOWSKI JA, 1978, BIOCHEM BIOPH RES CO, V82, P1140, DOI 10.1016/0006-291X(78)90305-4; CIDLOWSKI JA, 1980, BIOCHEMISTRY-US, V19, P6162, DOI 10.1021/bi00567a033; CIDLOWSKI JA, 1977, NATURE, V266, P643, DOI 10.1038/266643a0; COBURN SP, 1981, J NUTR, V111, P391, DOI 10.1093/jn/111.2.391; COMPTON MM, 1986, ENDOCR REV, V7, P140, DOI 10.1210/edrv-7-2-140; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; DEFRANCO D, 1986, MOL CELL BIOL, V6, P993, DOI 10.1128/MCB.6.4.993; DEFRANCO D, 1985, UCLA S MOL CELL BIOL, V20, P305; DISORBO DM, 1981, BIOCHEM BIOPH RES CO, V99, P1203, DOI 10.1016/0006-291X(81)90747-6; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GEHRING U, 1984, MOL CELL ENDOCRINOL, V36, P107, DOI 10.1016/0303-7207(84)90089-3; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GRAHAM ML, 1990, CANCER RES, V50, P6208; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; GREEN S, 1988, EMBO J, V7, P3037, DOI 10.1002/j.1460-2075.1988.tb03168.x; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRONEMEYER H, 1988, P153; GROUL DJ, 1989, GENE REGULATION STER, V4, P41; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; HIIPAKKA RA, 1980, J STEROID BIOCHEM, V13, P841, DOI 10.1016/0022-4731(80)90156-9; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HOLLEY J, 1983, J STEROID BIOCHEM, V18, P161, DOI 10.1016/0022-4731(83)90082-1; HOUSLEY PR, 1989, BIOCHEM BIOPH RES CO, V164, P480, DOI 10.1016/0006-291X(89)91745-2; KALINYAK JE, 1989, J CLIN INVEST, V84, P1843, DOI 10.1172/JCI114370; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KLOCK G, 1987, NATURE, V329, P734, DOI 10.1038/329734a0; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LACROIX A, 1984, J STEROID BIOCHEM, V21, P73, DOI 10.1016/0022-4731(84)90062-1; LEKLEM JE, 1988, CLIN PHYSL APPL VITA, P3; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LITTLEFIELD BA, 1984, ENDOCRINOLOGY, V114, P566, DOI 10.1210/endo-114-2-566; LITTLEFIELD BA, 1980, ARCH BIOCHEM BIOPHYS, V201, P174, DOI 10.1016/0003-9861(80)90500-7; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAJUMDER PK, 1983, J BIOL CHEM, V258, P6793; MCCORMICK D, 1961, J BIOL CHEM, V236, P2085; MCKNIGHT GS, 1980, CELL, V22, P469; MERRILL AH, 1984, J NUTR, V114, P1664, DOI 10.1093/jn/114.9.1664; MIESFELD R, 1987, SCIENCE, V236, P423, DOI 10.1126/science.3563519; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; MORINO Y, 1984, METHOD ENZYMOL, V106, P116; MULDOON TG, 1980, J BIOL CHEM, V255, P3100; NG KW, 1989, MOL ENDOCRINOL, V3, P2079, DOI 10.1210/mend-3-12-2079; NISHIGORI H, 1979, J BIOL CHEM, V254, P9155; OBRIEN JM, 1981, J STEROID BIOCHEM, V14, P9, DOI 10.1016/0022-4731(81)90186-2; ROBERTS AB, 1984, CANCER RES, V44, P1635; RUSH MG, 1991, ENDOCRINOLOGY, V129, P705, DOI 10.1210/endo-129-2-705; SILVA CM, 1987, P NATL ACAD SCI USA, V84, P1744, DOI 10.1073/pnas.84.7.1744; SYMES EK, 1984, J STEROID BIOCHEM, V20, P1089, DOI 10.1016/0022-4731(84)90348-0; VANDERBILT JN, 1987, MOL ENDOCRINOL, V1, P68, DOI 10.1210/mend-1-1-68; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YONEDA T, 1982, TERATOLOGY, V26, P255, DOI 10.1002/tera.1420260306	73	59	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3819	3824						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1310983				2022-12-27	WOS:A1992HE60700044
J	VENEMA, VJ; SWIDEREK, KM; LEE, TD; HATHAWAY, GM; ADAMS, ME				VENEMA, VJ; SWIDEREK, KM; LEE, TD; HATHAWAY, GM; ADAMS, ME			ANTAGONISM OF SYNAPTOSOMAL CALCIUM CHANNELS BY SUBTYPES OF OMEGA-AGATOXINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNNEL-WEB SPIDER; CONOTOXIN GVIA; AGELENOPSIS-APERTA; VENOM; NEURONS; BRAIN; NEUROTOXINS; SENSITIVITY; CURRENTS; IDENTIFICATION	Venom of the funnel web spider Agelenopsis aperta inhibits the binding of I-125-omega-conotoxin GVIA (omega-CgTx) to calcium channels in chick brain synaptosomal membranes. Fractionation of the venom by liquid chromatography shows that this inhibitory activity is associated primarily with a diverse class of peptide toxins called omega-agatoxins (omega-Aga). Using binding inhibition as an assay, we purified and identified the novel, 76-amino acid toxin, omega-Aga-IIIA. Inhibition of I-125-omega-CgTx binding to chick synaptosomal membranes by omega-Aga-IIIA and omega-Aga-IIA is correlated with block of potassium-stimulated Ca-45 entry into synaptosomes; omega-Aga-IA neither inhibits I-125-omega-CgTx binding nor Ca-45 entry under identical conditions. Omega-Aga-IIA and omega-Aga-IIIA are 20-30-fold more potent than omega-CgTx as antagonists of synaptosomal calcium channels. However, whereas omega-CgTx completely blocks Ca-45 entry into synaptosomes at saturating concentrations, the omega-agatoxins maximally block only 60-70% of Ca-45 entry. Pretreatment of synaptosomes with omega-Aga-IIIA occludes block of Ca-45 entry by omega-CgTx. The results indicate that, while the omega-agatoxins bind to the entire population of omega-CgTx-sensitive calcium channels in chick synaptosomal membranes, they exert only a partial block of Ca-45 flux. Such block could occur via two distinct mechanisms. Toxin binding may alter the kinetics of a homogeneous population of channels, resulting in lower overall conductance upon depolarization. Alternatively, the omega-agatoxins may bind to two distinct channel subtypes, only one of which is blocked as a result of toxin occupation.	UNIV CALIF RIVERSIDE,DEPT ENTOMOL,RIVERSIDE,CA 92521; BECKMAN RES INST,DIV IMMUNOL,DUARTE,CA 91010; UNIV CALIF RIVERSIDE,BIOTECHNOL INSTRUMENTAT FACIL,RIVERSIDE,CA 92521	University of California System; University of California Riverside; City of Hope; Beckman Research Institute of City of Hope; University of California System; University of California Riverside			Adams, Michael/ABF-6728-2020	Adams, Michael/0000-0003-0519-6113	NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR007010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024472] Funding Source: NIH RePORTER; NCRR NIH HHS [2 S07 RR07010-22] Funding Source: Medline; NINDS NIH HHS [NS24472] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS ME, 1989, J COMP PHYSIOL A, V164, P333, DOI 10.1007/BF00612993; ADAMS ME, 1990, J BIOL CHEM, V265, P861; AOSAKI T, 1989, PFLUG ARCH EUR J PHY, V414, P150, DOI 10.1007/BF00580957; BINDOKAS VP, 1989, J NEUROBIOL, V20, P171, DOI 10.1002/neu.480200402; BINDOKAS VP, 1991, J NEUROPHYSIOL, V66, P590, DOI 10.1152/jn.1991.66.2.590; BOWERS CW, 1987, P NATL ACAD SCI USA, V84, P3506, DOI 10.1073/pnas.84.10.3506; BRANTON WD, 1987, J NEUROSCI, V7, P4195; COTMAN CW, 1971, BIOCHIM BIOPHYS ACTA, V249, P380, DOI 10.1016/0005-2736(71)90117-9; FEIGENBAUM P, 1988, BIOCHEM BIOPH RES CO, V154, P298, DOI 10.1016/0006-291X(88)90684-5; GORNALL AG, 1949, J BIOL CHEM, V177, P751; KASAI H, 1987, Neuroscience Research, V4, P228, DOI 10.1016/0168-0102(87)90014-9; KERR LM, 1984, NATURE, V308, P282, DOI 10.1038/308282a0; LINDGREN CA, 1989, J PHYSIOL-LONDON, V414, P201, DOI 10.1113/jphysiol.1989.sp017684; LLINAS R, 1989, P NATL ACAD SCI USA, V86, P1689, DOI 10.1073/pnas.86.5.1689; MANN M, 1989, ANAL CHEM, V61, P1702, DOI 10.1021/ac00190a023; MCCLESKEY EW, 1987, P NATL ACAD SCI USA, V84, P4327, DOI 10.1073/pnas.84.12.4327; MINTZ IM, 1991, P NATL ACAD SCI USA, V88, P6628, DOI 10.1073/pnas.88.15.6628; OLIVERA BM, 1985, SCIENCE, V230, P1338, DOI 10.1126/science.4071055; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; REGAN LJ, 1991, J NEUROSCI, V11, P2259; REGAN LJ, 1991, NEURON, V6, P260; REYNOLDS IJ, 1986, P NATL ACAD SCI USA, V83, P8804, DOI 10.1073/pnas.83.22.8804; RIVIER J, 1987, J BIOL CHEM, V262, P1194; SCOTT RH, 1990, MOL PHARMACOL, V38, P711; SKINNER WS, 1989, J BIOL CHEM, V264, P2150; SUN XP, 1987, COMP BIOCHEM PHYS C, V87, P363; SUSZKIW JB, 1987, BIOCHEM BIOPH RES CO, V145, P1283, DOI 10.1016/0006-291X(87)91576-2; WAGNER JA, 1988, J NEUROSCI, V8, P3354	28	71	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2610	2615						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1310319				2022-12-27	WOS:A1992HB53200078
J	CHELBIALIX, MK; CHOUSTERMAN, S				CHELBIALIX, MK; CHOUSTERMAN, S			ETHANOL INDUCES 2',5'-OLIGOADENYLATE SYNTHETASE AND ANTIVIRAL ACTIVITIES THROUGH INTERFERON-BETA PRODUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; 2'5' OLIGOADENYLATE SYNTHETASE; GROWTH-FACTOR; CELLS; INDUCTION; STRESS; GENES; THERMOTOLERANCE; DIFFERENTIATION; INTERNALIZATION	We demonstrate here that ethanol, in contrast to heat shock (Chousterman, S., Chelbi-Alix, M. K., and Thang, M. N. (1987) J. Biol. Chem. 262, 4806-4811), induces interferon (IFN) synthesis and its related activities in Madin-Darby bovine kidney (MDBK) cells. The induced IFN is secreted maximally at 6 h, whereas the induction of 2',5'-oligoadenylate synthetase mRNA peaks between 9 and 12 h and its activity at 15 h. The appearance of both 2',5'-oligoadenylate synthetase activity and the antiviral state upon ethanol treatment is prevented by anti-bovine recombinant IFN-beta antibodies. Bovine diarrhea virus infection-free MDBK cells cultured in medium supplemented with serum substitute also gave similar results, thus indicating that IFN synthesis induced by ethanol is not mediated by the activation of bovine diarrhea virus. Together, these results show that: 1) ethanol induces the 2',5'-oligoadenylate synthetase and antiviral activities through IFN-beta production; and 2) the IFN produced does not act directly from inside the cells, but has to be first secreted to bind to its receptor. In MDBK cells, ethanol induces the synthesis of the 70-kDa protein, which precedes the expression of 2',5'-oligoadenylate synthetase; moreover, the transient nature of the synthesis of the hsp 70 in these cells is similar after both heat shock and ethanol treatment.			CHELBIALIX, MK (corresponding author), CTR INST NATL SANTE & RECH MED ST ANTOINE, INSERM, U245, 184 RUE FG ST ANTOINE, F-75571 PARIS 12, FRANCE.							AGUET M, 1984, INTERFERON, P1; Ashburner M., 1982, HEAT SHOCK BACTERIA, P1; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AYME A, 1985, J MOL BIOL, V182, P469, DOI 10.1016/0022-2836(85)90233-5; BAKER JC, 1986, P NATL ACAD SCI USA, V83, P2350, DOI 10.1073/pnas.83.8.2350; BALL LA, 1982, ENZYMES, V15, P281; BENECH P, 1985, EMBO J, V4, P2249, DOI 10.1002/j.1460-2075.1985.tb03922.x; BESANCON F, 1981, BIOCHEM BIOPH RES CO, V103, P16, DOI 10.1016/0006-291X(81)91654-5; BURDON RH, 1986, BIOCHEM J, V240, P313, DOI 10.1042/bj2400313; CAPON DJ, 1985, MOL CELL BIOL, V5, P768, DOI 10.1128/MCB.5.4.768; CHOUSTERMAN S, 1987, J BIOL CHEM, V262, P4806; CHOUSTERMAN S, 1987, BIOL ITNERFERON SYST, P557; CHOUSTERMAN S, 1985, 2 5A SYSTEM, P67; DUNCAN R, 1984, J BIOL CHEM, V259, P1882; FALTYNEK CR, 1988, J BIOL CHEM, V263, P7112; GUEDON G, 1985, EMBO J, V4, P3743, DOI 10.1002/j.1460-2075.1985.tb04143.x; HOVANESSIAN AG, 1980, J INTERFERON RES, V1, P125, DOI 10.1089/jir.1980.1.125; JUSTESEN J, 1980, NUCLEIC ACIDS RES, V8, P3073, DOI 10.1093/nar/8.14.3073; KRISHNAN I, 1980, P NATL ACAD SCI-BIOL, V77, P6506, DOI 10.1073/pnas.77.11.6506; LEE PC, 1983, P NATL ACAD SCI-BIOL, V80, P7496, DOI 10.1073/pnas.80.24.7496; LENGYEL P, 1982, ANNU REV BIOCHEM, V51, P251, DOI 10.1146/annurev.bi.51.070182.001343; LI GC, 1983, J CELL PHYSIOL, V115, P116, DOI 10.1002/jcp.1041150203; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; MADIN SH, 1958, P SOC EXP BIOL MED, V98, P574, DOI 10.3181/00379727-98-24111; Maniatis T., 1982, MOL CLONING; MAYTIN EV, 1985, J BIOL CHEM, V260, P2384; NEIDHARDT FC, 1984, ANNU REV GENET, V18, P295, DOI 10.1146/annurev.ge.18.120184.001455; NOVER L, 1984, HEAT SHOCK RESPONSE; PLESSET J, 1982, BIOCHEM BIOPH RES CO, V108, P1340, DOI 10.1016/0006-291X(82)92147-7; RANDERATH E, 1967, J CHROMATOGR, V31, P485, DOI 10.1016/S0021-9673(01)86099-4; ROCCHERI MC, 1981, DEV BIOL, V83, P173, DOI 10.1016/S0012-1606(81)80020-6; SAARMA M, 1986, EXP CELL RES, V166, P229, DOI 10.1016/0014-4827(86)90522-7; SCHLESINGER MJ, 1982, TRENDS BIOCHEM SCI, V7, P222, DOI 10.1016/0968-0004(82)90096-2; SPECTOR T, 1978, ANAL BIOCHEM, V86, P142, DOI 10.1016/0003-2697(78)90327-5; TAYLOR MW, 1984, P NATL ACAD SCI-BIOL, V81, P4033, DOI 10.1073/pnas.81.13.4033; TORRENCE PF, 1982, INTERFERONS, P123; VENGRIS VE, 1975, VIROLOGY, V65, P410, DOI 10.1016/0042-6822(75)90046-X; YONEHARA S, 1983, J GEN VIROL, V64, P2409, DOI 10.1099/0022-1317-64-11-2409; ZEUTHEN ML, 1988, J GEN MICROBIOL, V134, P1375; ZOON KC, 1984, PHARMACOL THERAPEUT, V24, P259, DOI 10.1016/0163-7258(84)90037-8; ZULLO JN, 1985, CELL, V43, P793, DOI 10.1016/0092-8674(85)90252-1	41	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1741	1745						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1309794				2022-12-27	WOS:A1992HA48500054
J	UENO, H; GUNN, M; DELL, K; TSENG, A; WILLIAMS, L				UENO, H; GUNN, M; DELL, K; TSENG, A; WILLIAMS, L			A TRUNCATED FORM OF FIBROBLAST GROWTH-FACTOR RECEPTOR-1 INHIBITS SIGNAL TRANSDUCTION BY MULTIPLE TYPES OF FIBROBLAST GROWTH-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; ALTERED AUTOPHOSPHORYLATION SITES; EARLY XENOPUS EMBRYOS; FACTOR-I RECEPTOR; CELL-GROWTH; NUCLEOTIDE-SEQUENCE; FACTOR CDNA; EXPRESSION; GENE; PHOSPHORYLATION	A truncated form of the type 1 fibroblast growth factor receptor (FGFR1) lacking most of its cytoplasmic domain was tested for its ability to inhibit signal transduction by each of three different wild-type FGFRs (FGFR1, 2, and 3). When the truncated FGFR1 was expressed in Xenopus oocytes in excess of each wild-type FGFR, mobilization of intracellular calcium mediated by the wild-type FGFRs was completely blocked. The truncated FGFR did not inhibit signal transduction by the co-expressed platelet-derived growth factor beta-receptor. A form of truncated FGFR1 which lacked the first immunoglobulin-like domain also inhibited signal transduction by wild-type FGFRs. Truncated FGFR formed complexes with wild-type FGFR in the presence of basic FGF in intact cells. These observations were consistent with the hypothesis that the truncated FGFR interacted with wild-type FGFRs to form nonfunctional heterodimers, thus eliminating the signaling by the wild-type FGFRs. The observation that signaling by multiple types of FGFR can be blocked by a single type of truncated FGFR suggests that the different types of FGFR can interact with each other in ligand-mediated complexes. These findings provide a molecular basis for inhibiting the actions of FGFs in vivo.	UNIV CALIF SAN FRANCISCO, INST CARDIOVASC RES, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco				Gunn, Michael/0000-0003-4602-0667	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032898, P01HL043821] Funding Source: NIH RePORTER; NHLBI NIH HHS [R0-1-HL-32898, P01 HL-43821] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ANDERSON KJ, 1988, NATURE, V332, P360, DOI 10.1038/332360a0; BISHAYEE S, 1988, MOL CELL BIOL, V8, P3696, DOI 10.1128/MCB.8.9.3696; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; HONEGGER A, 1988, EMBO J, V7, P3045, DOI 10.1002/j.1460-2075.1988.tb03169.x; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KEATING MT, 1988, J BIOL CHEM, V263, P12805; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LINKHART TA, 1981, DEV BIOL, V86, P19, DOI 10.1016/0012-1606(81)90311-0; MARICS I, 1989, ONCOGENE, V4, P335; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; MORRISON RS, 1986, P NATL ACAD SCI USA, V83, P7537, DOI 10.1073/pnas.83.19.7537; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; NEUFELD G, 1988, J CELL BIOL, V106, P1385, DOI 10.1083/jcb.106.4.1385; OHTSUKA M, 1990, MOL CELL BIOL, V10, P1664, DOI 10.1128/MCB.10.4.1664; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROREIJ S, 1988, NATURE, V331, P173; RUTA M, 1988, ONCOGENE, V3, P9; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; WALICKE P, 1986, P NATL ACAD SCI USA, V83, P3012, DOI 10.1073/pnas.83.9.3012; WILLIAMS JA, 1988, P NATL ACAD SCI USA, V85, P4939, DOI 10.1073/pnas.85.13.4939; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	54	252	264	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1470	1476						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1309784				2022-12-27	WOS:A1992HA48500015
J	SWEADNER, KJ; MCGRAIL, KM; KHAW, BA				SWEADNER, KJ; MCGRAIL, KM; KHAW, BA			DISCOORDINATE REGULATION OF ISOFORMS OF NA,K-ATPASE AND MYOSIN HEAVY-CHAIN IN THE HYPOTHYROID POSTNATAL RAT-HEART AND SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-K+-ATPASE; THYROID-HORMONE; NEONATAL RAT; BETA-SUBUNIT; ALPHA-MYOSIN; CATALYTIC SUBUNIT; MESSENGER-RNAS; ANTIMYOSIN FAB; EXPRESSION; ISOZYME	During postnatal life, many contractile and electrophysiological properties of the rat heart undergo changes. Among the changes is a switch in the expression of Na,K-ATPase catalytic subunit isoforms. Thyroid hormone has been postulated to play an important role in the postnatal transformation of the heart, and its effect on myosin heavy chain isoform gene transcription is well documented. To test whether it controls Na,K-ATPase gene switching in vivo, we made neonatal rats hypothyroid by maternal treatment with methimazole. The expression of Na,K-ATPase catalytic subunit isoforms in cardiac and skeletal muscle membranes was measured with specific antibodies at time points from birth to 4 weeks of age. Postnatal changes in Na,K-ATPase isoform expression in cardiac ventricle and hind limb skeletal muscle were similar in control and hypothyroid animals. In the same hypothyroid animals, the postnatal switch from the V3 (beta) isoform of myosin heavy chain to the V1 (alpha) isoform was blocked. The conclusion is that thyroid hormone may have a modulatory role in Na,K-ATPase gene expression, but it is not the developmental signal that dominates gene switching.	MASSACHUSETTS GEN HOSP, DEPT NUCL MED, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, BOSTON, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	SWEADNER, KJ (corresponding author), MASSACHUSETTS GEN HOSP, DEPT NEUROSURG RES, WELLMAN 4, FRUIT ST, BOSTON, MA 02114 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036271] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 36271] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHIZZONITE RA, 1984, J BIOL CHEM, V259, P2628; CURFMAN GD, 1977, J CLIN INVEST, V59, P586, DOI 10.1172/JCI108675; DILLMANN WH, 1990, AM J MED, V88, P626, DOI 10.1016/0002-9343(90)90530-Q; DUSSAULT JH, 1975, ENDOCRINOLOGY, V97, P1321, DOI 10.1210/endo-97-5-1321; EVERTS ME, 1990, AM J PHYSIOL, V259, pE278, DOI 10.1152/ajpendo.1990.259.2.E278; FELSENFELD DP, 1988, J BIOL CHEM, V263, P10932; FLINK IL, 1990, J BIOL CHEM, V265, P11233; FRIST W, 1987, CIRCULATION, V76, P81; GICK GG, 1990, J MEMBRANE BIOL, V115, P273, DOI 10.1007/BF01868642; GUSTAFSON TA, 1987, P NATL ACAD SCI USA, V84, P3122, DOI 10.1073/pnas.84.10.3122; GUSTAFSON TA, 1987, J BIOL CHEM, V262, P13316; HABER RS, 1988, AM J PHYSIOL, V255, pE912, DOI 10.1152/ajpendo.1988.255.6.E912; HENNING SJ, 1978, AM J PHYSIOL, V235, pE451, DOI 10.1152/ajpendo.1978.235.5.E451; HERRERA VLM, 1987, J CELL BIOL, V105, P1855, DOI 10.1083/jcb.105.4.1855; HOPKINS SF, 1973, CIRC RES, V32, P685, DOI 10.1161/01.RES.32.6.685; HOROWITZ B, 1990, J BIOL CHEM, V265, P14308; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; KHAW BA, 1984, HYBRIDOMA, V3, P11, DOI 10.1089/hyb.1984.3.11; KHAW BA, 1987, J NUCL MED, V28, P1671; KHAW BA, 1988, NEW CONCEPTS VIRAL H, P363; KJELDSEN K, 1986, PFLUG ARCH EUR J PHY, V406, P529, DOI 10.1007/BF00583377; KLEIN LE, 1984, AM J PHYSIOL, V247, pH570, DOI 10.1152/ajpheart.1984.247.4.H570; LARSEN PR, 1976, HORMONES HUMAN BLOOD, P679; LIN MH, 1978, J BIOL CHEM, V253, P723; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LO CS, 1976, J BIOL CHEM, V251, P7834; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; LUCCHESI PA, 1991, J BIOL CHEM, V266, P9327; LYTTON J, 1985, J BIOL CHEM, V260, P1177; MORROW DH, 1963, J PHARMACOL EXP THER, V140, P324; NG YC, 1989, AM J PHYSIOL, V257, pH534, DOI 10.1152/ajpheart.1989.257.2.H534; NORGAARD A, 1985, EUR J PHARMACOL, V113, P373, DOI 10.1016/0014-2999(85)90085-8; ORLOWSKI J, 1988, J BIOL CHEM, V263, P17817; ORLOWSKI J, 1990, J BIOL CHEM, V265, P3462; ORLOWSKI J, 1988, J BIOL CHEM, V263, P10436; PHILIPSON KD, 1977, AM J PHYSIOL, V232, pC196, DOI 10.1152/ajpcell.1977.232.5.C196; REZKALLA S, 1987, CLIN RES, V35, pA319; SHARMA VK, 1978, MOL PHARMACOL, V14, P122; SILVA JE, 1982, J CLIN INVEST, V70, P1110, DOI 10.1172/JCI110699; SWEADNER KJ, 1987, P NATL ACAD SCI USA, V84, P8404, DOI 10.1073/pnas.84.23.8404; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; URAYAMA O, 1989, J BIOL CHEM, V264, P8271; URAYAMA O, 1988, BIOCHEM BIOPH RES CO, V156, P796, DOI 10.1016/S0006-291X(88)80914-8; WALKER P, 1980, PEDIATR RES, V14, P247, DOI 10.1203/00006450-198003000-00014; YASUDA T, 1987, CIRCULATION, V76, P306, DOI 10.1161/01.CIR.76.2.306; YOUNG RM, 1987, BIOCHEM BIOPH RES CO, V145, P52, DOI 10.1016/0006-291X(87)91286-1	46	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					769	773						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1309775				2022-12-27	WOS:A1992GY96000017
J	ISHIMI, Y; SUGASAWA, K; HANAOKA, F; EKI, T; HURWITZ, J				ISHIMI, Y; SUGASAWA, K; HANAOKA, F; EKI, T; HURWITZ, J			TOPOISOMERASE-II PLAYS AN ESSENTIAL ROLE AS A SWIVELASE IN THE LATE STAGE OF SV40 CHROMOSOME-REPLICATION INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELA-CELL NUCLEI; DNA TOPOISOMERASE; SACCHAROMYCES-CEREVISIAE; INHIBITOR; ORIGIN; SEGREGATION; TERMINATION; SEPARATION; MOLECULES; BREAKAGE	The effects of topoisomerases I and II on the replication of SV40 DNA were examined using an in vitro replication system of purified proteins that constitutes the monopolymerase system. In the presence of the two topoisomerases, two distinct nascent DNAs were formed. One product arising from the replication of the leading template strand was approximately half the size of the template DNA, whereas the other product derived from the lagging template strand consisted of short DNAs. These products were synthesized from both SV40 naked DNA and SV40 chromosomes. For the replication of SV40 naked DNA, either topoisomerase I or II maintained replication fork movement and supported complete leading strand synthesis. When SV40 chromosomes were replicated with the same proteins, reactions containing only topoisomerase I produced shorter leading strands. However, mature size DNA products accumulated in reactions supplemented with topoisomerase II, as well as in reactions containing only topoisomerase II. In the presence of crude extracts of HeLa cells, VP-16, a specific inhibitor of topoisomerase II, blocked elongation of the nascent DNA during the replication of SV40 chromosomes. These results indicate that topoisomerase II plays a crucial role as a swivelase in the late stage of SV40 chromosome replication in vitro.	INST PHYS & CHEM RES RIKEN,CELLULAR PHYSIOL LAB,WAKO,SAITAMA 35101,JAPAN; MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021	RIKEN; Memorial Sloan Kettering Cancer Center	ISHIMI, Y (corresponding author), MITSUBISHI KASEI INST LIFE SCI,11 MINAMIOOYA,MACHIDA,TOKYO 194,JAPAN.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034559, R01GM034559] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-34559-06] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; AVEMANN K, 1988, MOL CELL BIOL, V8, P3026, DOI 10.1128/MCB.8.8.3026; BRILL SJ, 1987, NATURE, V326, P414, DOI 10.1038/326414a0; CAIRNS J, 1963, J MOL BIOL, V6, P208, DOI 10.1016/S0022-2836(63)80070-4; Champoux JJ, 1980, MECH STUDIES DNA REP, P809; CHEN GL, 1984, J BIOL CHEM, V259, P3560; DECKER RS, 1987, J BIOL CHEM, V262, P10863; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; ISHIMI Y, 1991, J BIOL CHEM, V266, P16141; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KIM RA, 1989, J MOL BIOL, V208, P257, DOI 10.1016/0022-2836(89)90387-2; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; MILLER KG, 1981, J BIOL CHEM, V256, P9334; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; RICHTER A, 1987, NUCLEIC ACIDS RES, V15, P3455, DOI 10.1093/nar/15.8.3455; RICHTER A, 1988, NUCLEIC ACIDS RES, V16, P10119, DOI 10.1093/nar/16.21.10119; SNAPKA RM, 1988, MOL CELL BIOL, V8, P515, DOI 10.1128/MCB.8.2.515; SUGASAWA K, 1990, J VIROL, V64, P4820, DOI 10.1128/JVI.64.10.4820-4829.1990; SUNDIN O, 1981, CELL, V25, P659, DOI 10.1016/0092-8674(81)90173-2; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; VARSHAVSKY A, 1983, MECHANISMS DNA REPLI, P463; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WEAVER DT, 1985, CELL, V41, P565, DOI 10.1016/S0092-8674(85)80029-5; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; YANAGIDA M, 1987, NUCLEIC ACIDS MOL BI, V1, P196; YANG L, 1987, P NATL ACAD SCI USA, V84, P950, DOI 10.1073/pnas.84.4.950	31	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					462	466						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1309747				2022-12-27	WOS:A1992GY43900074
J	KATO, M; TOKUDA, H; MIZUSHIMA, S				KATO, M; TOKUDA, H; MIZUSHIMA, S			INVITRO TRANSLOCATION OF SECRETORY PROTEINS POSSESSING NO CHARGES AT THE MATURE DOMAIN TAKES PLACE EFFICIENTLY IN A PROTONMOTIVE FORCE-DEPENDENT MANNER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI MEMBRANE-VESICLES; M13 PROCOAT PROTEIN; ESCHERICHIA-COLI; MOTIVE FORCE; SIGNAL SEQUENCE; CYTOPLASMIC MEMBRANE; POSITIVE CHARGE; BETA-LACTAMASE; AMINO TERMINUS; SECA PROTEIN	The effect of charges existing on the mature domain of secretory proteins on the efficiency and protonmotive force dependence of translocation into everted membrane vesicles of Escherichia coli was studied. Model secretory proteins devoid of charges on the mature domain were constructed at the DNA level using proOmpF-Lpp as the starting protein. The chargeless presecretory proteins thus constructed were translocated and processed for the signal peptide much faster than proOmpF-Lpp and the rate of translocation was appreciably enhanced by imposition of the protonmotive force. Not only the membrane potential but also DELTA-pH were effective in stimulating the rate of translocation of the chargeless proteins. The results indicate that the mature domain does not have to be charged for the secretory translocation and that the major requirement of the protonmotive force for the secretory translocation is not for the movement, including an electrophoretic one, of charged regions of the mature domain. All of the proOmpF-Lpp derivatives thus constructed were translocated efficiently into everted membrane vesicles in a SecA-dependent manner, irrespective of their size. The mature domain of the smallest one was 45 amino acid residues in length. Contrary to the views previously presented by other workers, these results suggest that there is no sharp boundary at the reported regions for the translocation of presecretory proteins across the cytoplasmic membrane or for the requirement of SecA.	UNIV TOKYO, INST APPL MICROBIOL, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo			Kato, Masashi/AAG-3755-2021	Kato, Masashi/0000-0002-8951-3640				AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; AKITA M, 1990, J BIOL CHEM, V265, P8164; BAKKER EP, 1984, EMBO J, V3, P895, DOI 10.1002/j.1460-2075.1984.tb01902.x; BASSFORD P, 1979, NATURE, V277, P538, DOI 10.1038/277538a0; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CHEN LL, 1985, P NATL ACAD SCI USA, V82, P4384, DOI 10.1073/pnas.82.13.4384; COBET WWE, 1989, J BIOL CHEM, V264, P10169; DANIELS CJ, 1981, P NATL ACAD SCI-BIOL, V78, P5396, DOI 10.1073/pnas.78.9.5396; DAVIS NG, 1985, CELL, V41, P607, DOI 10.1016/S0092-8674(85)80033-7; DRIESSEN AJM, 1991, P NATL ACAD SCI USA, V88, P2471, DOI 10.1073/pnas.88.6.2471; FANDL JP, 1988, P NATL ACAD SCI USA, V85, P8953, DOI 10.1073/pnas.85.23.8953; FREUDL R, 1989, J MOL BIOL, V205, P771, DOI 10.1016/0022-2836(89)90321-5; GELLER BL, 1989, J BIOL CHEM, V264, P16465; GELLER BL, 1986, P NATL ACAD SCI USA, V83, P4219, DOI 10.1073/pnas.83.12.4219; GENNITY J, 1990, J BIOENERG BIOMEMBR, V22, P233, DOI 10.1007/BF00763167; KAWASAKI H, 1989, FEBS LETT, V242, P431, DOI 10.1016/0014-5793(89)80516-2; KUHN A, 1988, EUR J BIOCHEM, V177, P267, DOI 10.1111/j.1432-1033.1988.tb14372.x; KUHN A, 1990, EMBO J, V9, P2385, DOI 10.1002/j.1460-2075.1990.tb07413.x; KUHN A, 1986, NATURE, V322, P335, DOI 10.1038/322335a0; LI P, 1988, P NATL ACAD SCI USA, V85, P7685, DOI 10.1073/pnas.85.20.7685; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; LINGAPPA VR, 1984, P NATL ACAD SCI-BIOL, V81, P456, DOI 10.1073/pnas.81.2.456; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIZUSHIMA S, 1987, BACTERIAL OUTER MEMB, P163; MIZUSHIMA S, 1991, METHOD CELL BIOL, V34, P107; MORENO F, 1980, NATURE, V286, P356, DOI 10.1038/286356a0; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; SASAKI S, 1990, J BIOL CHEM, V265, P4358; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SHIOZUKA K, 1990, J BIOL CHEM, V265, P18843; TAN K, 1989, J BIOL CHEM, V264, P18582; TANI K, 1990, J BIOL CHEM, V265, P17341; TOKUDA H, 1990, FEBS LETT, V264, P10, DOI 10.1016/0014-5793(90)80751-4; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1986, J MOL BIOL, V192, P287, DOI 10.1016/0022-2836(86)90365-7; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P347; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WOLFE PB, 1985, J BIOL CHEM, V260, P1836; YAMADA H, 1989, J BIOL CHEM, V264, P1723; YAMADA H, 1989, J BIOL CHEM, V264, P18577; YAMANE K, 1988, J BIOL CHEM, V263, P19690; YAMANE K, 1987, J BIOL CHEM, V262, P2358	46	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					413	418						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1309745				2022-12-27	WOS:A1992GY43900067
J	SANCHEZ, LM; FREIJE, JP; MERINO, AM; VIZOSO, F; FOLTMANN, B; LOPEZOTIN, C				SANCHEZ, LM; FREIJE, JP; MERINO, AM; VIZOSO, F; FOLTMANN, B; LOPEZOTIN, C			ISOLATION AND CHARACTERIZATION OF A PEPSIN-C ZYMOGEN PRODUCED BY HUMAN BREAST TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROSS CYSTIC-DISEASE; CANCER-CELLS; EXTRACELLULAR-MATRIX; GENE-EXPRESSION; ACID PROTEINASE; SEMINAL FLUID; CATHEPSIN-B; PROTEASES; INVASION; DEGRADATION	An aspartic proteinase present in cyst fluid from women with gross cystic breast disease was purified by a procedure involving affinity chromatography on pepstatin-agarose and size-exclusion high performance liquid chromatography. The amino-terminal sequence of the purified breast proteinase was identical to that corresponding to gastric pepsinogen C. Additional data on cleavage specificity, pH optimum, and immunological properties supported the close relationship between both molecules. Northern blot analysis and polymerase chain reaction amplification studies performed on RNAs obtained from normal and pathological breast tissues demonstrated that the protein is produced by mammary carcinomas and cysts, but not by the normal resting mammary gland. Immunohistochemical staining of paraffin-embedded tissue sections confirmed the existence of a subset of tumors that have the ability to synthesize and secrete this pepsin zymogen. On the basis of these results, we suggest that pepsinogen C expression by human mammary epithelium may be involved in the development of breast diseases, being also of potential interest as a biochemical marker of the hormonal imbalance underlying these pathologies.	HOSP JOVE, SERV CIRUGIA, GIJON, SPAIN; UNIV COPENHAGEN, INST BIOCHEM GENET, DK-1353 COPENHAGEN, DENMARK; HOSP JOV, SERV ANAT PATOL, GIJON, SPAIN	University of Copenhagen	SANCHEZ, LM (corresponding author), UNIV OVIEDO, DEPT BIOL FUNC, E-33006 OVIEDO, SPAIN.		Freije, José M.P./A-6535-2008; Lopez-Otin, Carlos/AAB-2106-2020	Freije, José M.P./0000-0002-4688-8266; Lopez-Otin, Carlos/0000-0001-6964-1904				BALBIN M, 1990, BIOCHEM J, V271, P803, DOI 10.1042/bj2710803; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BRADLOW HL, 1990, ANN NY ACAD SCI, V586, P12, DOI 10.1111/j.1749-6632.1990.tb17784.x; BRIOZZO P, 1988, CANCER RES, V48, P3688; CHALBOS D, 1987, CANCER RES, V47, P2787; CHAUHAN SS, 1991, CANCER RES, V51, P1478; CHIANG L, 1981, ARCH BIOCHEM BIOPHYS, V210, P14, DOI 10.1016/0003-9861(81)90158-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DILLEY WG, 1983, J NATL CANCER I, V70, P69; DUFFY MJ, 1987, EUR J CANCER CLIN ON, V23, P583, DOI 10.1016/0277-5379(87)90326-9; FIOCCA R, 1988, CANCER, V61, P956, DOI 10.1002/1097-0142(19880301)61:5<956::AID-CNCR2820610517>3.0.CO;2-C; FOLTMANN B, 1981, ESSAYS BIOCHEM, V17, P52; FOLTMANN B, 1982, EUR J BIOCHEM, V128, P63; GAL S, 1986, J BIOL CHEM, V261, P1760; Gottesman M., 1990, SEMIN CANCER BIOL, V1, P97; HAAGENSEN CD, 1981, BREAST CARCINOMA RIS, P55; HAYANO T, 1988, J BIOL CHEM, V263, P1382; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; JAMES MNG, 1986, NATURE, V319, P33, DOI 10.1038/319033a0; KAGEYAMA T, 1990, J BIOL CHEM, V265, P17031; KESNER L, 1988, CANCER RES, V48, P6379; LIOTTA LA, 1988, BREAST CANCER RES TR, V11, P113, DOI 10.1007/BF01805835; LIPPMAN ME, 1988, DIAGNOSIS MANAGEMENT, P1; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCOY K, 1988, J CELL BIOL, V106, P1879, DOI 10.1083/jcb.106.6.1879; MONTEAGUDO C, 1990, AM J PATHOL, V136, P585; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RECKLIES AD, 1982, BIOCHEM J, V207, P633, DOI 10.1042/bj2070633; REESE JH, 1986, J UROLOGY, V136, P1148, DOI 10.1016/S0022-5347(17)45242-6; REID WA, 1984, CELL TISSUE RES, V236, P597; ROCHEFORT H, 1987, J CELL BIOCHEM, V35, P17, DOI 10.1002/jcb.240350103; Sambrook J, 1989, MOL CLONING LABORATO; SAMLOFF IM, 1989, GASTROENTEROLOGY, V96, P586, DOI 10.1016/S0016-5085(89)80054-X; SANCHEZ LM, 1992, EUR J CANCER, V28A, P828, DOI 10.1016/0959-8049(92)90124-K; SAPPINO AP, 1987, CANCER RES, V47, P4043; SCHER W, 1987, LAB INVEST, V57, P607; SIMARD J, 1989, MOL ENDOCRINOL, V3, P694, DOI 10.1210/mend-3-4-694; SIMARD J, 1990, ENDOCRINOLOGY, V126, P3223, DOI 10.1210/endo-126-6-3223; SLOANE BF, 1981, SCIENCE, V212, P1151, DOI 10.1126/science.7233209; SPYRATOS F, 1989, LANCET, V2, P1115; SZECSI PB, 1988, FEBS LETT, V238, P101, DOI 10.1016/0014-5793(88)80234-5; TAGGART RT, 1989, J BIOL CHEM, V264, P375; TANDON AK, 1990, NEW ENGL J MED, V322, P297, DOI 10.1056/NEJM199002013220504; TRYGGVASON K, 1987, BIOCHIM BIOPHYS ACTA, V907, P191, DOI 10.1016/0304-419X(87)90006-0; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; VIGNON F, 1986, ENDOCRINOLOGY, V118, P1537, DOI 10.1210/endo-118-4-1537; WARD PH, 1982, J UROLOGY, V127, P1027, DOI 10.1016/S0022-5347(17)54181-6	49	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24725	24731						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1280267				2022-12-27	WOS:A1992KA26300086
J	VIVAT, V; COHEN-TANNOUDJI, J; REVELLI, JP; MUZZIN, P; GIACOBINO, JP; MALTIER, JP; LEGRAND, C				VIVAT, V; COHEN-TANNOUDJI, J; REVELLI, JP; MUZZIN, P; GIACOBINO, JP; MALTIER, JP; LEGRAND, C			PROGESTERONE TRANSCRIPTIONALLY REGULATES THE BETA-2-ADRENERGIC RECEPTOR GENE IN PREGNANT RAT MYOMETRIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BETA-ADRENERGIC RECEPTORS; MESSENGER-RNA; GLUCOCORTICOIDS; CELLS; AGONISTS; HORMONES; CLONING; OVIDUCT; INVIVO; LUNG	Administration of 5 mg of progesterone to late pregnant rats induced an increase in myometrial beta-adrenergic receptors density detected by I-125-cyanopindolol binding. This increase was significant after 24 h (1.4-fold; p < 0.05) and reached 1.6-fold (p < 0.05) after 36 h. The antiprogestin RU 486 or cycloheximide completely suppressed the effect of progesterone injection. Quantification of the beta-1- and beta-2-receptor subtypes revealed that progesterone selectively up-regulated the beta-2-subtype. The increase in beta-2-adrenoreceptors was preceded by an elevation of their mRNA (2.3 kilobases) levels as determined by Northern blot hybridization with a rat heart beta-2-adrenoreceptor cDNA probe. This increase was significant after 18 h of exposure to progesterone (2.1-fold; p < 0.05) and reached a maximum after 24 h (3.4-fold; p < 0.01). The rate of beta-2-adrenergic gene transcription evaluated by nuclear run-on transcription assays, increased by 2.5-fold in myometria exposed for 4 h to progesterone. This study indicates that progesterone regulates myometrial beta-2-adrenergic receptor expression by controlling the rate of transcription of the gene.	UNIV PARIS 06, NEUROENDOCRINOL GRP, PHYSIOL REPROD LAB, 4 PL JUSSIEU, F-75252 PARIS 05, FRANCE; CTR MED UNIV GENEVA, DEPT BIOCHIM MED, CH-1211 GENEVA 4, SWITZERLAND	UDICE-French Research Universities; Sorbonne Universite; University of Geneva								ANDERSSON RGG, 1980, GYNECOL OBSTET INVES, V11, P286, DOI 10.1159/000299848; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; COHEN-TANNOUDJI J, 1991, J MOL ENDOCRINOL, V6, P137, DOI 10.1677/jme.0.0060137; COLLINS S, 1988, J BIOL CHEM, V263, P9067; COLLINS S, 1988, FEBS LETT, V233, P173, DOI 10.1016/0014-5793(88)81378-4; CSAPO A, 1956, AM J ANAT, V98, P273, DOI 10.1002/aja.1000980206; DAVIES AO, 1980, J CLIN ENDOCR METAB, V51, P599, DOI 10.1210/jcem-51-3-599; FRASER CM, 1980, BIOCHEM BIOPH RES CO, V94, P390, DOI 10.1016/S0006-291X(80)80233-6; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; GOCAYNE J, 1987, P NATL ACAD SCI USA, V84, P8296, DOI 10.1073/pnas.84.23.8296; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P8415, DOI 10.1073/pnas.85.22.8415; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; HOMBURGER V, 1984, J CELL PHYSIOL, V121, P589, DOI 10.1002/jcp.1041210318; JOHANSSON SRM, 1980, ACTA PHARMACOL TOX, V47, P5; LEGRAND C, 1986, J REPROD FERTIL, V76, P415, DOI 10.1530/jrf.0.0760415; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MALTIER JP, 1989, BIOL REPROD, V40, P531, DOI 10.1095/biolreprod40.3.531; MARSHALL JM, 1981, AM J PHYSIOL, V240, pC165, DOI 10.1152/ajpcell.1981.240.5.C165; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; NEVE KA, 1986, MOL PHARMACOL, V30, P104; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; SCARPACE PJ, 1982, DRUG DEVELOP RES, V2, P91, DOI 10.1002/ddr.430020113; SCHACTERLE GR, 1973, ANAL BIOCHEM, V51, P654, DOI 10.1016/0003-2697(73)90523-X; STRASSER RH, 1984, ENDOCRINOLOGY, V115, P1392, DOI 10.1210/endo-115-4-1392; WEILAND NG, 1989, NEUROENDOCRINOLOGY, V50, P655, DOI 10.1159/000125295	25	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					7975	7978						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1314813				2022-12-27	WOS:A1992HQ18500005
J	HASHIMOTO, M; NAKAMURA, T; INOUE, S; KONDO, T; YAMADA, R; ETO, Y; SUGINO, H; MURAMATSU, M				HASHIMOTO, M; NAKAMURA, T; INOUE, S; KONDO, T; YAMADA, R; ETO, Y; SUGINO, H; MURAMATSU, M			FOLLISTATIN IS A DEVELOPMENTALLY REGULATED CYTOKINE IN NEURAL DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RAT FOLLISTATIN; ACTIVIN-A; MESODERM; PROTEIN; PURIFICATION; EXPRESSION; INDUCTION; INHIBIN; CHAIN; OVARY	Activin acts mitogenically on P19 cells as well as being inhibitory of the differentiation of retinoic acid-treated P19 cells and some neuroblastoma cell lines. Here, we show some lines of evidence that follistatin, an activin-binding protein, is also involved in neural differentiation. Counteracting the activity of activin, addition of follistatin suppresses the anchorage-independent growth of P19 cells in soft agar and stimulates neurite outgrowth of a neuroblastoma cell line, IMR-32 cells. While activin does not seem to be expressed significantly, follistatin is demonstrated in the conditioned medium of these cells. Furthermore, the expression of follistatin in P19 cells is subject to dynamic fluctuations in response to retinoic acid treatment. These neural cells may produce follistatin in a cell stage-specific manner in order to interact with exogenously derived activin.	UNIV TOKYO,FAC MED,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; INST PHYS & CHEM RES,FRONTIER RES PROGRAM,WAKO,SAITAMA 35101,JAPAN; AJINOMOTO CO INC,CENT RES LABS,KAWASAKI KU,KAWASAKI 210,JAPAN	University of Tokyo; RIKEN; Ajinomoto Co Inc								ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; CHO KWY, 1990, GENE DEV, V4, P1910, DOI 10.1101/gad.4.11.1910; ETO Y, 1987, BIOCHEM BIOPH RES CO, V142, P1095, DOI 10.1016/0006-291X(87)91528-2; HASHIMOTO M, 1990, BIOCHEM BIOPH RES CO, V173, P193, DOI 10.1016/S0006-291X(05)81040-X; JEREMY B, 1990, NATUER, V347, P391; KAISER M, 1990, ENDOCRINOLOGY, V126, P2768, DOI 10.1210/endo-126-5-2768; KOGAWA K, 1991, ENDOCRINOLOGY, V128, P1434, DOI 10.1210/endo-128-3-1434; KONDO S, 1989, BIOCHEM BIOPH RES CO, V161, P1267, DOI 10.1016/0006-291X(89)91379-X; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MICHEL U, 1990, BIOCHEM BIOPH RES CO, V173, P401, DOI 10.1016/S0006-291X(05)81072-1; MURATA M, 1988, P NATL ACAD SCI USA, V85, P2434, DOI 10.1073/pnas.85.8.2434; NAKAMURA T, 1991, J BIOL CHEM, V266, P19432; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SAITO S, 1991, BIOCHEM BIOPH RES CO, V176, P413, DOI 10.1016/0006-291X(91)90940-9; SAITO S, 1991, ENDOCRINOL JAPON, V38, P377; SCHUBERT D, 1990, NATURE, V344, P868, DOI 10.1038/344868a0; SCHUBERT D, 1991, J CELL BIOL, V114, P841, DOI 10.1083/jcb.114.4.841; SHIMASAKI S, 1989, MOL ENDOCRINOL, V3, P651, DOI 10.1210/mend-3-4-651; SHIMASAKI S, 1988, P NATL ACAD SCI USA, V85, P4218, DOI 10.1073/pnas.85.12.4218; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; TASHIRO K, 1991, BIOCHEM BIOPH RES CO, V174, P1022, DOI 10.1016/0006-291X(91)91521-D; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; UENO N, 1987, P NATL ACAD SCI USA, V84, P8282, DOI 10.1073/pnas.84.23.8282; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0; VANDENEIJNDENVANRAAIJ AJM, 1991, MECH DEVELOP, V33, P157, DOI 10.1016/0925-4773(91)90082-H	29	56	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7203	7206						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1313791				2022-12-27	WOS:A1992HN48500003
J	URAKAZE, M; KAMITANI, T; DEGASPERI, R; SUGIYAMA, E; CHANG, HM; WARREN, CD; YEH, ETH				URAKAZE, M; KAMITANI, T; DEGASPERI, R; SUGIYAMA, E; CHANG, HM; WARREN, CD; YEH, ETH			IDENTIFICATION OF A MISSING LINK IN GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR BIOSYNTHESIS IN MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							VARIANT SURFACE GLYCOPROTEINS; PHOSPHOLIPID MEMBRANE ANCHOR; GLYCOSYL-PHOSPHATIDYLINOSITOL; GLYCOLIPID PRECURSORS; RESISTANT GLYCOLIPIDS; PROTEIN; ACTIVATION; HYDROLYSIS; MOLECULES	A large number of mammalian proteins are anchored to the cell membrane by a glycosylphosphatidylinositol (GPI) anchor. Biosynthetic intermediates of the GPI anchor have been identified in mammalian cells. The early GPI precursors are sensitive to phosphatidylinositol (PI)-specific phospholipase C (PLC). However, all of the later GPI precursors, which contain 1 or more mannose residues, are PI-PLC-resistant, suggesting that there is another unidentified precursor. Here, we report the identification of this missing link. This GPI precursor can only be labeled with glucosamine and inositol, and is resistant to PI-PLC but sensitive to GPI-phospholipase D. It accumulates in large quantity only in mutants which are defective in the addition of the first mannose residue to the elongating GPI core. Thus, fatty acylation of glucosaminylphosphatidylinositol, to render it PI-PLC-resistant, is an obligatory step in the biosynthesis of mammalian GPI anchor precursors.	HARVARD UNIV, MASSACHUSETTS GEN HOSP,SCH MED,DEPT MED, ARTHRIT UNIT, BOSTON, MA 02114 USA; HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02114 USA; HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, DEPT ANESTHESIA, BOSTON, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital				Kamitani, Tetsu/0000-0002-3257-9630; Chang, Hui-Ming/0000-0002-5856-3397	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR003564] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040930] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45851] Funding Source: Medline; NIAMS NIH HHS [AR-03564] Funding Source: Medline; NIDDK NIH HHS [DK-40930] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGER J, 1988, J BIOL CHEM, V263, P10016; CARAS IW, 1987, SCIENCE, V238, P1280, DOI 10.1126/science.2446389; CHAN BL, 1989, P NATL ACAD SCI USA, V86, P1756, DOI 10.1073/pnas.86.6.1756; DEGASPERI R, 1990, SCIENCE, V250, P988, DOI 10.1126/science.1978413; DOERING TL, 1990, J BIOL CHEM, V265, P611; EARDLEY DD, 1991, SCIENCE, V251, P78, DOI 10.1126/science.1824727; FERGUSON MAJ, 1986, J BIOL CHEM, V261, P356; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GAULTON GN, 1988, CELL, V53, P963, DOI 10.1016/S0092-8674(88)90509-0; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HUANG KS, 1990, J BIOL CHEM, V265, P17738; HYMAN R, 1988, TRENDS GENET, V4, P5, DOI 10.1016/0168-9525(88)90120-5; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MAYOR S, 1990, J BIOL CHEM, V265, P6164; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MENON AK, 1990, J BIOL CHEM, V265, P9033; MERIDA I, 1990, P NATL ACAD SCI USA, V87, P9421, DOI 10.1073/pnas.87.23.9421; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; SALTIEL AR, 1986, SCIENCE, V233, P967, DOI 10.1126/science.3016898; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; WANECK GL, 1988, SCIENCE, V241, P697, DOI 10.1126/science.3399901; YEH ETH, 1988, CELL, V52, P665, DOI 10.1016/0092-8674(88)90404-7	24	73	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6459	6462						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1313004				2022-12-27	WOS:A1992HM05300003
J	XING, MZ; THEVENOD, F; MATTERA, R				XING, MZ; THEVENOD, F; MATTERA, R			DUAL REGULATION OF ARACHIDONIC-ACID RELEASE BY P(2U) PURINERGIC RECEPTORS IN DIBUTYRYL CYCLIC AMP-DIFFERENTIATED HL-60 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED DESENSITIZATION; ISOLATED RAT HEPATOCYTES; HUMAN-NEUTROPHILS; PHOSPHOLIPASE-C; PERTUSSIS TOXIN; P2-PURINERGIC RECEPTORS; P2Y-PURINERGIC RECEPTOR; INSENSITIVE MECHANISMS; CALCIUM MOBILIZATION; NADPH OXIDASE	ATP promoted biphasic effects on both basal and fMLP-stimulated arachidonic acid (AA) release in neutrophil-like HL60 cells: stimulation in the micromolar range (EC50 = 3.2 +/- 0.9-mu-M) and inhibition at higher concentrations (EC50 = 90 +/- 11-mu-M). ATP also inhibited UTP- and platelet activating factor-stimulated AA release. Only stimulatory effects of ATP on basal or fMLP-stimulated phospholipase C were observed. The inhibitory effect of ATP on AA release was not due to reacylation of released AA, chelation of extracellular Ca2+, cell permeabilization, or changes in the rise of [Ca2+]i induced by agonist. The inhibition was rapid, being detected within 5-15 s. The inhibitory effect of ATP on fMLP-stimulated AA release could be desensitized by pretreatment of the cells with 2 mM ATP, but not 20-mu-M ATP, the concentration that resulted in maximal release of AA and inositol phosphates. The inhibition by ATP was neither dependent on generation of adenosine by ATP hydrolysis nor the result of direct interaction of ATP with P1 purinergic receptors. Among other nucleotides tested (CTP, GTP, ITP, TTP, XTP, adenosine 5'-(beta,gamma-methylene)triphosphate (AMP-PCP), adenyl-5'-yl imidodiphosphate (AMP-P(NH)P, ADP, adenosine 5'-O-(3-thiotriphosphate) (ATP(gamma)S), and UTP), only UTP and ATP(gamma)S displayed biphasic effects with potencies and efficacies almost identical to those of ATP. The other nucleotides only exhibited stimulatory effects (EC50 = 60-300-mu-M). The results are consistent with a model of dual regulation of AA release by two distinct subtypes of P2U receptors in HL60 cells.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,2109 ADELBERT RD,CLEVELAND,OH 44106	Case Western Reserve University					NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005410] Funding Source: NIH RePORTER; NCRR NIH HHS [SO7RR-05410-28] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BIZZARRI C, 1990, P NATL ACAD SCI USA, V87, P4889, DOI 10.1073/pnas.87.12.4889; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOKOCH GM, 1984, CELL, V39, P301, DOI 10.1016/0092-8674(84)90008-4; BROOKS RC, 1989, J BIOL CHEM, V264, P20147; BRUNER G, 1990, J NEUROCHEM, V55, P1569, DOI 10.1111/j.1471-4159.1990.tb04940.x; BURNSTOCK G, 1985, GEN PHARMACOL, V16, P433, DOI 10.1016/0306-3623(85)90001-1; Burnstock G., 1978, CELL MEMBRANE RECEPT, Vpp, P107; CHAREST R, 1985, J BIOL CHEM, V260, P5789; COCKCROFT S, 1989, BIOCHEM J, V263, P715, DOI 10.1042/bj2630715; COCKCROFT S, 1979, J PHYSIOL-LONDON, V296, P229, DOI 10.1113/jphysiol.1979.sp013002; COCKCROFT S, 1989, FEBS LETT, V245, P25, DOI 10.1016/0014-5793(89)80184-X; COWEN DS, 1989, J CLIN INVEST, V83, P1651, DOI 10.1172/JCI114064; COWEN DS, 1990, BIOCHIM BIOPHYS ACTA, V1053, P195, DOI 10.1016/0167-4889(90)90014-5; CRONSTEIN BN, 1990, J CLIN INVEST, V85, P1150, DOI 10.1172/JCI114547; DUBYAK GR, 1988, J BIOL CHEM, V263, P18108; DUBYAK GR, 1991, AM J RESP CELL MOL, V4, P295, DOI 10.1165/ajrcmb/4.4.295; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FEDAN JS, 1982, EUR J PHARMACOL, V81, P193, DOI 10.1016/0014-2999(82)90437-X; GLENDE EA, 1986, BIOCHEM PHARMACOL, V35, P3301, DOI 10.1016/0006-2952(86)90427-2; GONZALEZ FA, 1989, BIOCHEM BIOPH RES CO, V164, P706, DOI 10.1016/0006-291X(89)91517-9; GONZALEZ FA, 1988, BIOCHEM BIOPH RES CO, V151, P1205, DOI 10.1016/S0006-291X(88)80494-7; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; GREENBERG S, 1988, J BIOL CHEM, V263, P10337; GRIFFIN HD, 1978, BIOCHEM J, V176, P541, DOI 10.1042/bj1760541; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; HARDEN TK, 1983, PHARMACOL REV, V35, P5; HENDERSON LM, 1989, BIOCHEM J, V264, P249, DOI 10.1042/bj2640249; HEPPEL LA, 1985, J MEMBRANE BIOL, V86, P189, DOI 10.1007/BF01870597; KENAKIN TP, 1989, MOL PHARMACOL, V35, P214; KUHNS DB, 1988, LAB INVEST, V58, P448; KUROKI M, 1989, BIOCHIM BIOPHYS ACTA, V1012, P103, DOI 10.1016/0167-4889(89)90017-7; MARTIN MW, 1989, J BIOL CHEM, V264, P19535; MORRIS AJ, 1990, J BIOL CHEM, V265, P13501; MURPHY PM, 1990, J BIOL CHEM, V265, P11615; NAKASHIMA S, 1989, BIOCHEM J, V259, P139, DOI 10.1042/bj2590139; NAUM CC, 1991, J LEUKOCYTE BIOL, V49, P83, DOI 10.1002/jlb.49.1.83; OCONNOR SE, 1991, TRENDS PHARMACOL SCI, V12, P137, DOI 10.1016/0165-6147(91)90530-6; OETGEN E, 1990, BIOCHEM J, V271, P337; OKAJIMA F, 1990, J BIOL CHEM, V265, P21741; OKAJIMA F, 1987, J BIOL CHEM, V262, P13483; RUBIN RP, 1979, BIOCHEM BIOPH RES CO, V90, P1364, DOI 10.1016/0006-291X(79)91186-0; SEIFERT R, 1989, TRENDS PHARMACOL SCI, V10, P365, DOI 10.1016/0165-6147(89)90009-6; SEIFERT R, 1989, EUR J BIOCHEM, V181, P277, DOI 10.1111/j.1432-1033.1989.tb14722.x; SLIVKA SR, 1988, J BIOL CHEM, V263, P14640; STEINBERG TH, 1987, J BIOL CHEM, V262, P8884; TAKENAWA T, 1986, J BIOL CHEM, V261, P1092; TARAPCHAK S, 1991, FASEB J, V5, P5695; WALSH CE, 1981, J BIOL CHEM, V256, P7228; Weksler BB, 1988, INFLAMMATION BASIC P, P543; WOLFF J, 1978, ARCH BIOCHEM BIOPHYS, V191, P161, DOI 10.1016/0003-9861(78)90078-4; XIE MS, 1991, BIOCHEM J, V278, P81, DOI 10.1042/bj2780081; YOSS EB, 1990, AM J RESP CELL MOL, V2, P69, DOI 10.1165/ajrcmb/2.1.69	54	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6602	6610						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1313016				2022-12-27	WOS:A1992HM05300026
J	GALINDO, E; MENDEZ, M; CALVO, S; GONZALEZGARCIA, C; CENA, V; HUBERT, P; BADER, MF; AUNIS, D				GALINDO, E; MENDEZ, M; CALVO, S; GONZALEZGARCIA, C; CENA, V; HUBERT, P; BADER, MF; AUNIS, D			CHROMOSTATIN RECEPTORS CONTROL CALCIUM-CHANNEL ACTIVITY IN ADRENAL CHROMAFFIN CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE CHROMOGRANIN-A; MESSENGER-RNA; PANCREASTATIN; SECRETION; CURRENTS; HORMONE; PEPTIDE; RELEASE; ACTIVATION; ENDOCRINE	One of the functions of chromogranin A (CGA), the major soluble component of secretory granules in both adrenal medullary chromaffin cells and many other endocrine cell types appears to be that of a prohormone. CGA is the precursor of several peptides including pancreastatin, a 49-residue peptide, and a 20-residue peptide, chromostatin, which have been identified as biologically active peptides. Chromostatin produces a dose-dependent inhibition (ID50 of 5 nM) of the secretagogue-evoked catecholamine secretion from chromaffin cells. Here we report that chromostatin potently inhibits L-type calcium currents recorded with the nystatin-perforated patch technique in cultured chromaffin cells. This inhibitory effect of chromostatin on calcium currents was not observed in experiments using the classical patch-clamp whole-cell approach which induces the leakage of cytoplasmic components. Using I-125-chromostatin, we show that chromostatin exhibits a fully reversible and saturable binding to the plasma membrane of cultured chromaffin cells. Analysis of binding experiments at equilibrium indicates the existence of one class of binding sites with a B(max) of 2.7 pmol/mg of chromaffin cell proteins and an apparent K(d) of 6.5 nM. This high affinity is in good correlation with the half-maximal concentration (ID50 5 nM) of chromostatin inhibiting catecholamine secretion from chromaffin cells. Specificity of the chromostatin binding was further assessed by displacement experiments with unlabeled CGA-related or -unrelated peptides. We found an excellent quantitative correlation between the affinities of the various peptides determined by binding assays and their functional potency tested on catecholamine secretion: bovine chromostatin > human chromostatin > CGA >> rat chromostatin, pancreastatin, CAP-14, substance P, and Leu-enkephalin, Cross-linking experiments reveal that chromostatin associates specifically with an 80-kDa plasma membrane protein. These results together with the patch-clamp experiments support the idea that chromaffin cells possess specific chromostatin receptors and that activation of such receptors leads to the inhibition of L-type voltage-sensitive calcium channels through an intracellular second messenger pathway.	INSERM,U338,UNITE BIOL COMMUN CELLULAIRE,5 RUE BLAISE PASCAL,F-67084 STRASBOURG,FRANCE; UNIV ALICANTE,DEPT NEUROQUIM,DIV FARMACOL,E-03080 ALICANTE,SPAIN; UNIV ALICANTE,INST NEUROCIENCIAS,E-03080 ALICANTE,SPAIN	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universitat d'Alacant; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN); Universitat d'Alacant			Hubert, Pierre/C-6678-2013; Dominique, Aunis/W-1419-2019; Cena, Valentin/L-1751-2017; Bader, Marie-France/O-2098-2016	Hubert, Pierre/0000-0002-7549-8910; Cena, Valentin/0000-0001-8928-3681; 				ARMSTRONG CM, 1974, J GEN PHYSIOL, V63, P533, DOI 10.1085/jgp.63.5.533; ARTALEJO CR, 1987, J BIOL CHEM, V262, P915; BADER MF, 1986, J BIOL CHEM, V261, P5777; BENEDUM UM, 1986, EMBO J, V5, P1495, DOI 10.1002/j.1460-2075.1986.tb04388.x; BLASCHKO H, 1967, NATURE, V215, P58, DOI 10.1038/215058a0; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CENA V, 1989, J MEMBRANE BIOL, V112, P255, DOI 10.1007/BF01870956; DEFTOS LJ, 1990, J BONE MINER RES, V5, P989; EFENDIC S, 1987, P NATL ACAD SCI USA, V84, P7257, DOI 10.1073/pnas.84.20.7257; FASCIOTTO BH, 1988, J CELL BIOL, V107, P2730; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P599, DOI 10.1113/jphysiol.1982.sp014394; GALINDO E, 1991, P NATL ACAD SCI USA, V88, P1426, DOI 10.1073/pnas.88.4.1426; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HELLE KB, 1990, J PHYSIOL-LONDON, V430, pP40; HELLE KB, 1966, MOL PHARMACOL, V2, P298; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; IACANGELO A, 1986, NATURE, V323, P82, DOI 10.1038/323082a0; IACANGELO AL, 1988, ENDOCRINOLOGY, V122, P2339, DOI 10.1210/endo-122-5-2339; ISHIZUKA J, 1989, PANCREAS, V4, P277, DOI 10.1097/00006676-198906000-00001; LEWIS JJ, 1989, BIOCHEM BIOPH RES CO, V163, P667, DOI 10.1016/0006-291X(89)92275-4; LORINET AM, 1989, EUR J PHARMACOL, V160, P405, DOI 10.1016/0014-2999(89)90097-6; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; SIMON JP, 1988, P NATL ACAD SCI USA, V85, P1712, DOI 10.1073/pnas.85.5.1712; SIMON JP, 1989, BIOCHEM J, V262, P1; SONTAG JM, 1990, J PHYSIOL-LONDON, V427, P495, DOI 10.1113/jphysiol.1990.sp018184; TANIUCHI M, 1986, P NATL ACAD SCI USA, V83, P4094, DOI 10.1073/pnas.83.11.4094; TATEMOTO K, 1986, NATURE, V324, P476, DOI 10.1038/324476a0; UNSICKER K, 1981, J NEUROSCI METH, V4, P227, DOI 10.1016/0165-0270(81)90034-0; VANREGENMORTEL MHV, 1988, LABORATORY TECHNIQUE, P1; WAND GS, 1991, ENDOCRINOLOGY, V128, P1345, DOI 10.1210/endo-128-3-1345	31	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					407	412						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1309744				2022-12-27	WOS:A1992GY43900066
J	STOOPS, JK; BAKER, TS; SCHROETER, JP; KOLODZIEJ, SJ; NIU, XD; REED, LJ				STOOPS, JK; BAKER, TS; SCHROETER, JP; KOLODZIEJ, SJ; NIU, XD; REED, LJ			3-DIMENSIONAL STRUCTURE OF THE TRUNCATED CORE OF THE SACCHAROMYCES-CEREVISIAE PYRUVATE-DEHYDROGENASE COMPLEX DETERMINED FROM NEGATIVE STAIN AND CRYOELECTRON MICROSCOPY IMAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOME; PROTEIN-X; DIHYDROLIPOAMIDE ACETYLTRANSFERASE; ELECTRON MICROGRAPHS; RECONSTRUCTION; MUTAGENESIS; DOMAINS; SUBUNIT; VIEWS; VIRUS	Dihydrolipoamide acyltransferase (E2), a catalytic and structural component of the three functional classes of multienzyme complexes that catalyze the oxidative decarboxylation of alpha-keto acids, forms the central core to which the other components are attached. We have imaged by negative stain and cryoelectron microscopy the truncated dihydrolipoamide acetyltransferase core (60 subunits; M(r) = 2.7 x 10(6)) of the Saccharomyces cerevisiae pyruvate dehydrogenase complex. Using icosahedral particle reconstruction techniques, we determined its structure to 25 angstrom resolution. Although the model derived from the negative stain reconstruction was approximately 20% smaller than the model derived from the frozen-hydrated data, when corrected for the effects of the electron microscope contrast transfer functions, the reconstructions showed excellent correspondence. The pentagonal do-decahedron-shaped macromolecule has a maximum diameter, as measured along the 3-fold axis, of approximately 226 angstrom (frozen-hydrated value), and 12 large openings (approximately 63 angstrom in diameter) on the 5-fold axes that lead into a large solvent-accessible cavity (approximately 76-140 angstrom diameter). The 20 vertices consist of cone-shaped trimers, each with a flattened base on the outside of the structure and an apex directed toward the center. The trimers are interconnected by 20 angstrom thick "bridges" on the 2-fold axes. These studies also show that the highest resolution features apparent in the frozen-hydrated reconstruction are revealed in a filtered reconstruction of the stained molecule.	PURDUE UNIV, DEPT BIOL SCI, W LAFAYETTE, IN 47907 USA; UNIV TEXAS, CLAYTON FDN, INST BIOCHEM, AUSTIN, TX 78712 USA; UNIV TEXAS, DEPT CHEM & BIOCHEM, AUSTIN, TX 78712 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	STOOPS, JK (corresponding author), UNIV TEXAS, HLTH SCI CTR, DEPT PATHOL & LAB MED, HOUSTON, TX 77030 USA.			, Timothy/0000-0001-6543-8968	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042886] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039536, R01GM046278, R01GM033050, R37GM033050] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42886] Funding Source: Medline; NIGMS NIH HHS [GM46278, R01 GM033050, GM39536, R37 GM033050] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER TS, 1991, BIOPHYS J, V60, P1445, DOI 10.1016/S0006-3495(91)82181-6; BOSMA HJ, 1984, EUR J BIOCHEM, V142, P541, DOI 10.1111/j.1432-1033.1984.tb08320.x; CARAZO JM, 1989, BIOPHYS J, V55, P465, DOI 10.1016/S0006-3495(89)82840-1; CROWTHER RA, 1971, PHILOS T R SOC B, V261, P221, DOI 10.1098/rstb.1971.0054; DEROSIER DJ, 1971, P NATL ACAD SCI USA, V68, P1135, DOI 10.1073/pnas.68.6.1135; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; ERICKSON HP, 1971, PHILOS T ROY SOC B, V261, P105, DOI 10.1098/rstb.1971.0040; FRANK J, 1991, J CELL BIOL, V115, P597, DOI 10.1083/jcb.115.3.597; FULLER CC, 1979, BIOCHEM BIOPH RES CO, V90, P431, DOI 10.1016/0006-291X(79)91253-1; GOPALAKRISHNAN S, 1989, BIOCHEM BIOPH RES CO, V160, P715, DOI 10.1016/0006-291X(89)92492-3; GUEST JR, 1989, ANN N Y ACAD SCI, V573, P76; HESSLER D, 1992, MICROSCOPY KEY RES T, P73; JUNGER E, 1971, BIOCHIM BIOPHYS ACTA, V250, P478, DOI 10.1016/0005-2744(71)90248-8; LAWSON JE, 1991, BIOCHEMISTRY-US, V30, P11249, DOI 10.1021/bi00111a009; LAWSON JE, 1991, BIOCHEMISTRY-US, V30, P2834, DOI 10.1021/bi00225a015; MATTEVI A, 1992, SCIENCE, V255, P1544, DOI 10.1126/science.1549782; NEAGLE JC, 1991, BIOCHEM J, V278, P423, DOI 10.1042/bj2780423; NIU XD, 1990, BIOCHEMISTRY-US, V29, P8614, DOI 10.1021/bi00489a017; OLIVER RM, 1982, ELECTRON MICROS, V2, P1; OLSON NH, 1990, J STRUCT BIOL, V105, P111, DOI 10.1016/1047-8477(90)90105-L; OLSON NH, 1989, ULTRAMICROSCOPY, V30, P281, DOI 10.1016/0304-3991(89)90057-0; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; REED LJ, 1990, J BIOL CHEM, V265, P8971; STOOPS JK, 1991, J STRUCT BIOL, V106, P172, DOI 10.1016/1047-8477(91)90086-C; STOOPS JK, 1992, P NATL ACAD SCI USA, V89, P6585, DOI 10.1073/pnas.89.14.6585; STOOPS JK, 1991, J ELECTRON MICR TECH, V18, P157, DOI 10.1002/jemt.1060180210; TOYOSHIMA C, 1988, ULTRAMICROSCOPY, V25, P279, DOI 10.1016/0304-3991(88)90003-4; WAGENKNECHT T, 1989, BIOPHYS J, V55, P455, DOI 10.1016/S0006-3495(89)82839-5; WAGENKNECHT T, 1991, J BIOL CHEM, V266, P24650	29	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24769	24775						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1280269				2022-12-27	WOS:A1992KA26300092
J	MORIYAMA, K; YONEZAWA, N; SAKAI, H; YAHARA, I; NISHIDA, E				MORIYAMA, K; YONEZAWA, N; SAKAI, H; YAHARA, I; NISHIDA, E			MUTATIONAL ANALYSIS OF AN ACTIN-BINDING SITE OF COFILIN AND CHARACTERIZATION OF CHIMERIC PROTEINS BETWEEN COFILIN AND DESTRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE BRAIN; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; DEPOLYMERIZING FACTOR; MYOSIN SUBFRAGMENT-1; NUCLEOTIDE-SEQUENCE; SKELETAL-MUSCLE; GELSOLIN; TROPOMYOSIN; CDNA; IDENTIFICATION	Cofilin and destrin are two related low molecular weight mammalian actin-binding proteins. Cofilin is an F-actin side-binding and pH-dependent actin-depolymerizing protein, and destrin is a pH-independent actin-depolymerizing protein. We have introduced a few point mutations within an actin-binding sequence of cofilin. Biochemical analyses of these mutant proteins have clearly shown that Lys112 and Lys114 of cofilin,are crucially but differently involved in its interaction with actin and phosphatidylinositol 4,5-bisphosphate. This is the first example among actin-binding proteins whose point mutations inactivate their interaction with actin in vitro. We have also made and characterized a series of chimeric proteins between cofilin and destrin to identify the regions responsible for the pH dependence and the F-actin side binding activity of cofilin. Our results suggest that a central region consisting of 42 amino acid residues and a carboxyl-terminal quarter of cofilin are both involved in regulation of the pH-dependent actin depolymerizing activity and the activity to bind along F-actin.	UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN INST MED SCI,DEPT CELL BIOL,TOKYO 113,JAPAN	University of Tokyo; Tokyo Metropolitan Institute of Medical Science			Yonezawa, Naoto/F-8300-2011					ABE H, 1990, BIOCHEMISTRY-US, V29, P7420, DOI 10.1021/bi00484a010; ADAMS ME, 1990, BIOCHEMISTRY-US, V29, P7414, DOI 10.1021/bi00484a009; HEISS SG, 1991, BIOCHEMISTRY-US, V30, P8753, DOI 10.1021/bi00100a006; JANMEY PA, 1988, J BIOL CHEM, V263, P16738; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; MAEKAWA S, 1990, J BIOL CHEM, V265, P10940; Maniatis T., 1982, MOL CLONING; MATSUZAKI F, 1988, J BIOL CHEM, V263, P11564; MORIYAMA K, 1990, NUCLEIC ACIDS RES, V18, P3053, DOI 10.1093/nar/18.10.3053; MORIYAMA K, 1990, J BIOL CHEM, V265, P5771; MUNEYUKI F, 1985, J BIOCHEM-TOKYO, V97, P563, DOI 10.1093/oxfordjournals.jbchem.a135091; NISHIDA E, 1984, J BIOCHEM-TOKYO, V95, P387, DOI 10.1093/oxfordjournals.jbchem.a134619; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P6624, DOI 10.1021/bi00344a049; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P1160, DOI 10.1021/bi00326a015; NISHIDA E, 1987, P NATL ACAD SCI USA, V84, P5262, DOI 10.1073/pnas.84.15.5262; OGAWA K, 1990, NUCLEIC ACIDS RES, V18, P7169, DOI 10.1093/nar/18.23.7169; OHTA Y, 1989, J BIOL CHEM, V264, P16143; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUTOH K, 1989, BIOCHEMISTRY-US, V28, P102, DOI 10.1021/bi00427a015; SUTOH K, 1983, BIOCHEMISTRY-US, V22, P1579, DOI 10.1021/bi00276a009; VANCOMPERNOLLE K, 1991, J BIOL CHEM, V266, P15427; VANDEKERCKHOVE JS, 1989, J CELL BIOL, V109, P619, DOI 10.1083/jcb.109.2.619; YAMAMOTO K, 1989, BIOCHEMISTRY-US, V28, P5573, DOI 10.1021/bi00439a035; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218; YONEZAWA N, 1989, EUR J BIOCHEM, V183, P235, DOI 10.1111/j.1432-1033.1989.tb14918.x; YONEZAWA N, 1985, J BIOL CHEM, V260, P4410; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382; YONEZAWA N, 1987, CELL STRUCT FUNCT, V12, P443, DOI 10.1247/csf.12.443; YONEZAWA N, 1988, BIOCHEM J, V251, P121, DOI 10.1042/bj2510121; YONEZAWA N, 1991, J BIOL CHEM, V266, P10485	36	71	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7240	7244						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1313794				2022-12-27	WOS:A1992HN48500010
J	DASHTI, N				DASHTI, N			THE EFFECT OF LOW-DENSITY LIPOPROTEINS, CHOLESTEROL, AND 25-HYDROXYCHOLESTEROL ON APOLIPOPROTEIN-B GENE-EXPRESSION IN HEPG2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A REDUCTASE-ACTIVITY; 3-HYDROXY-3-METHYLGLUTARYL COENZYME; MESSENGER-RNA; LINE HEPG2; DIETARY-CHOLESTEROL; PLASMA-LIPOPROTEINS; RECEPTOR ACTIVITY; RAT HEPATOCYTES; FATTY-ACIDS; OLEIC-ACID	The purpose of the present study was to examine the effects of exogenous cholesterol on the apolipoprotein (Apo) B gene expression in HepG2 cells. Pure cholesterol had no significant effect on either the cellular content of cholesteryl esters or the net accumulation of neutral lipids and ApoB in the culture medium. By contrast, addition of 25-hydroxycholesterol increased the net accumulation of cholesteryl esters in cells and medium by 2-3 fold and decreased that of unesterified cholesterol by 50% in both compartments. A 33% reduction in the cellular content of triglycerides was commensurate with a 40% increase in their accumulation in the medium. A significant 3-fold increase in the net accumulation of ApoB in the medium was predominantly due to enhanced secretion of newly synthesized ApoB as established by pulse-chase studies. The stimulation in ApoB secretion was accompanied by a 55% increase in cellular ApoB mRNA. Under these experimental conditions, the low density lipoprotein receptor activity was decreased by only 12-20%. Addition of progesteron prevented the effects of 25-hydroxycholesterol. The changes in the concentration of neutral lipids and ApoB were reflected in the composition of secreted "low-density" lipoproteins. These particles had increased percentage contents of cholesteryl esters and ApoB and a decreased percentage content of unesterified cholesterol in comparison with lipoproteins produced by control cells. The rate of ApoB production was not correlated with the triglyceride mass in the cells but was positively correlated with the cellular and secreted cholesteryl esters and secreted triglycerides. With the exception of unchanged cellular unesterified cholesterol and ApoB mRNA levels, plasma low density lipoprotein had similar, although less pronounced, effects on the production of neutral lipids and ApoB. These results demonstrate that in HepG2 cells the synthesis and secretion of ApoB and cholesteryl esters are tightly coupled and that 25-hydroxycholesterol increased the concentration of ApoB-containing lipoproteins primarily by stimulating their production rather than reducing their catabolism.			DASHTI, N (corresponding author), OKLAHOMA MED RES FDN,LIPOPROT & ATHEROSCLEROSIS RES PROGRAM,825 NE 13TH ST,OKLAHOMA CITY,OK 73104, USA.				NHLBI NIH HHS [HL-23181] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELL JJ, 1976, J BIOL CHEM, V251, P1745; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; BRESLOW JL, 1982, P NATL ACAD SCI-BIOL, V79, P6861, DOI 10.1073/pnas.79.22.6861; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1974, J BIOL CHEM, V249, P7306; BRUNZELL JD, 1984, ARTERIOSCLEROSIS, V4, P79, DOI 10.1161/01.ATV.4.2.79; CARLSON TL, 1989, BIOCHEM J, V264, P241, DOI 10.1042/bj2640241; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIANFLONE KM, 1990, J LIPID RES, V31, P2045; CRAIG WY, 1988, J BIOL CHEM, V263, P13880; DASHTI N, 1986, BIOCHEM BIOPH RES CO, V137, P493, DOI 10.1016/0006-291X(86)91237-4; DASHTI N, 1989, BIOCHEM BIOPH RES CO, V163, P574, DOI 10.1016/0006-291X(89)92176-1; DASHTI N, 1989, J LIPID RES, V30, P1365; DASHTI N, 1990, J LIPID RES, V31, P113; DASHTI N, 1987, BIOCHEMISTRY-US, V26, P4837, DOI 10.1021/bi00389a035; DASHTI N, 1986, BIOCHIM BIOPHYS ACTA, V875, P473, DOI 10.1016/0005-2760(86)90067-6; DASHTI N, 1987, J LIPID RES, V28, P423; DASHTI N, 1984, BIOCHIM BIOPHYS ACTA, V794, P373, DOI 10.1016/0005-2760(84)90003-1; DASHTI N, 1990, ARTERIOSCLEROSIS, V10, P777; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DOLPHIN PJ, 1985, CAN J BIOCHEM CELL B, V63, P850, DOI 10.1139/o85-107; DREVON CA, 1980, J BIOL CHEM, V255, P9128; ERICKSON SK, 1978, J BIOL CHEM, V253, P4159; FIELD FJ, 1983, J LIPID RES, V24, P1049; GOFMAN JW, 1966, CIRCULATION, V34, P679, DOI 10.1161/01.CIR.34.4.679; GOODNIGHT SH, 1982, ARTERIOSCLEROSIS, V2, P87, DOI 10.1161/01.ATV.2.2.87; GRUNDY SM, 1990, J LIPID RES, V31, P1149; HAVEKES LM, 1987, BIOCHEM J, V247, P739, DOI 10.1042/bj2470739; HUANG LS, 1985, P NATL ACAD SCI USA, V82, P6825, DOI 10.1073/pnas.82.20.6825; JOHNSON FL, 1983, J CLIN INVEST, V72, P221, DOI 10.1172/JCI110961; KANDUTSCH AA, 1974, J BIOL CHEM, V249, P6057; KANE JP, 1983, ANNU REV PHYSIOL, V45, P637, DOI 10.1146/annurev.ph.45.030183.003225; KUKSIS A, 1975, J CHROMATOGR SCI, V13, P423, DOI 10.1093/chromsci/13.9.423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY R W, 1978, P181; MAHLEY RW, 1984, J LIPID RES, V25, P1277; Maniatis T, 1982, MOL CLONING LABORATO; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MCCONATHY WJ, 1985, J CHROMATOGR, V342, P47, DOI 10.1016/S0378-4347(00)84488-6; MISTRY P, 1981, J CLIN INVEST, V67, P493, DOI 10.1172/JCI110058; PACKARD CJ, 1983, J CLIN INVEST, V72, P45, DOI 10.1172/JCI110983; PROTTER AA, 1986, P NATL ACAD SCI USA, V83, P1467, DOI 10.1073/pnas.83.5.1467; SATO R, 1990, J BIOL CHEM, V265, P11880; SCHONFELD G, 1982, J CLIN INVEST, V69, P1072, DOI 10.1172/JCI110542; SORCITHOMAS M, 1988, J BIOL CHEM, V263, P5183; SORCITHOMAS M, 1989, J BIOL CHEM, V264, P9039; SPARKS JD, 1990, J BIOL CHEM, V265, P8854; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WILLIAMS DL, 1986, METHOD ENZYMOL, V128, P671; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	51	133	135	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					7160	7169						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1313035				2022-12-27	WOS:A1992HM05300108
J	BARRETT, CB; ERIKSON, E; MALLER, JL				BARRETT, CB; ERIKSON, E; MALLER, JL			A PURIFIED S6 KINASE KINASE FROM XENOPUS EGGS ACTIVATES S6 KINASE-II AND AUTOPHOSPHORYLATES ON SERINE, THREONINE, AND TYROSINE RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-PROTEIN S6; MICROTUBULE-ASSOCIATED PROTEIN-2; MYELIN BASIC-PROTEIN; SWISS 3T3-CELLS; PHOSPHORYLATION; INSULIN; CELLS; IDENTIFICATION; PURIFICATION; MATURATION	S6 kinases I and II have been purified previously from Xenopus eggs and shown to be activated by phosphorylation on serine and threonine residues. An S6 kinase clone, closely related to S6 kinase II, was subsequently identified and the protein product was expressed in a baculovirus system. Using this protein, termed "rsk" for Ribosomal Protein S6 Kinase, as a substrate, we have purified to homogeneity from unfertilized Xenopus eggs a 41-kDa serine/threonine kinase termed rsk kinase. Both microtubule-associated protein-2 and myelin basic protein are good substrates for rsk kinase, whereas alpha-casein, histone H1, protamine, and phosvitin are not. rsk kinase is inhibited by low concentrations of heparin as well as by beta-glycerophosphate and calcium. Activation of rsk kinase during Xenopus oocyte maturation is correlated with phosphorylation on threonine and tyrosine residues. However, in vitro, rsk kinase undergoes autophosphorylation on serine, threonine, and tyrosine residues, identifying it as a "dual specificity" enzyme. Purified rsk kinase can be inactivated in vitro by either a 37-kDa T-cell protein-tyrosine phosphatase or the serine/threonine protein phosphatase 2A. Phosphatase-treated S6KII can be reactivated by rsk kinase, and S6 kinase activity in resting oocyte extracts increases significantly when purified rsk kinase is added. The availability of purified rsk kinase will enhance study of the signal transduction pathway(s) regulating phosphorylation of ribosomal protein S6 in Xenopus oocytes.	UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	BARRETT, CB (corresponding author), UNIV COLORADO,SCH MED,HOWARD HUGHES MED INST,DENVER,CO 80262, USA.				NATIONAL CANCER INSTITUTE [F32CA008743, P30CA046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028353] Funding Source: NIH RePORTER; NCI NIH HHS [F32 CA-08743, 2P30 CA-46934] Funding Source: Medline; NIDDK NIH HHS [DK28353] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1990, J BIOL CHEM, V265, P11487; AHN NG, 1990, J BIOL CHEM, V265, P11495; ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; COOPER JA, 1985, MOL CELL BIOL, V5, P3304, DOI 10.1128/MCB.5.11.3304; COX RA, 1970, BIOCHEM J, V119, P161, DOI 10.1042/bj1190161; DAILEY D, 1990, MOL CELL BIOL, V10, P6244, DOI 10.1128/MCB.10.12.6244; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; ERIKSON E, 1986, J BIOL CHEM, V261, P350; ERIKSON E, 1991, J BIOL CHEM, V266, P5249; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; ERIKSON E, 1977, VIROLOGY, V80, P177, DOI 10.1016/0042-6822(77)90390-7; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GREGORY JS, 1989, J BIOL CHEM, V264, P18397; HACCARD O, 1990, EUR J BIOCHEM, V192, P633, DOI 10.1111/j.1432-1033.1990.tb19270.x; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; IZUMI T, 1991, MOL CELL BIOL, V11, P3860, DOI 10.1128/MCB.11.8.3860; JOHNS EW, 1964, BIOCHEM J, V92, P55, DOI 10.1042/bj0920055; Johnson R A, 1979, Adv Cyclic Nucleotide Res, V10, P135; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; JONES SW, 1989, J BIOL CHEM, V264, P7747; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRETH GE, 1990, J NEUROCHEM, V55, P514, DOI 10.1111/j.1471-4159.1990.tb04165.x; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; NIELSEN PJ, 1982, P NATL ACAD SCI-BIOL, V79, P2937, DOI 10.1073/pnas.79.9.2937; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SANGHERA JS, 1991, J BIOL CHEM, V266, P6700; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; SANGHERA JS, 1990, FEBS LETT, V273, P223, DOI 10.1016/0014-5793(90)81090-B; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; TUNG HYL, 1984, EUR J BIOCHEM, V138, P635, DOI 10.1111/j.1432-1033.1984.tb07962.x; VIK TA, 1990, P NATL ACAD SCI USA, V87, P2685, DOI 10.1073/pnas.87.7.2685; WHITEHOUSE S, 1983, METHOD ENZYMOL, V99, P80	58	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4408	4415						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1311309				2022-12-27	WOS:A1992HF64200025
J	GAULTON, GN; BRASS, LF; KOZBOR, D; PLETCHER, CH; HOXIE, JA				GAULTON, GN; BRASS, LF; KOZBOR, D; PLETCHER, CH; HOXIE, JA			INHIBITION OF T-CELL ANTIGEN RECEPTOR-DEPENDENT PHOSPHORYLATION OF CD4 IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTED-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENVELOPE GLYCOPROTEIN GP120; PROTEIN-TYROSINE KINASE; HOMOSEXUAL MEN; SELECTIVE LOSS; HIV-INFECTION; LYMPHOCYTES-T; PHYSICAL ASSOCIATION; SIGNAL TRANSDUCTION; BINDING PROTEIN; IMMUNE-SYSTEM	Inhibitory effects of human immunodeficiency virus (HIV) on T lymphocyte function have been linked to perturbation of signaling through the T cell antigen receptor-CD3 complex. Comparative biochemical analyses of signaling responses were performed in T cells that were either uninfected or chronically infected with the HIV-1/IIIB strain. Stimulation with antibodies to CD3 triggered both Ca2+ accumulation and phosphoinositide hydrolysis responses that were equivalent in uninfected and infected cells. Treatment with anti-CD3 or with phorbol diester also stimulated serine phosphorylation of CD4 molecules in uninfected T cells. However, phosphorylation of CD4 was not observed after anti-CD3 treatment in HIV-infected T cells despite normal phosphorylation responses to phorbol diester. Identical results were obtained using a T cell line that was infected with an env (gp160/120-) HIV-1 defective variant. These studies indicate that infection with HIV-1 inhibits the activation of protein kinase associated with the T cell receptor-CD3 complex by a mechanism which is independent of viral env protein components.	UNIV PENN,SCH MED,DEPT MED,PHILADELPHIA,PA 19104; THOMAS JEFFERSON UNIV,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107	University of Pennsylvania; Jefferson University	GAULTON, GN (corresponding author), UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,256 MORGAN BLDG,36TH & HAMILTON WALK,PHILADELPHIA,PA 19104, USA.		Kozbor, Danuta/AAF-4200-2019		NHLBI NIH HHS [P01-HL40387] Funding Source: Medline; NIAID NIH HHS [R01-AI25535, R01-AI28208] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025535, R01AI028208] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACRES RB, 1986, J BIOL CHEM, V261, P6210; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BRASS LF, 1991, J BIOL CHEM, V266, P958; BRASS LF, 1986, J BIOL CHEM, V261, P6838; CANTRELL D, 1987, NATURE, V325, P540, DOI 10.1038/325540a0; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; CEFAI D, 1990, J CLIN INVEST, V86, P2117, DOI 10.1172/JCI114950; CHIRMULE N, 1990, BLOOD, V75, P152; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; CRISE B, 1990, J VIROL, V64, P5585, DOI 10.1128/JVI.64.11.5585-5593.1990; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DANIELIAN S, 1989, EUR J IMMUNOL, V19, P2183, DOI 10.1002/eji.1830191202; DIAMOND DC, 1988, J IMMUNOL, V141, P3715; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; FIELDS AP, 1988, NATURE, V333, P278, DOI 10.1038/333278a0; GIORGI JV, 1987, J IMMUNOL, V138, P3725; GOSTING LH, 1987, J CLIN MICROBIOL, V25, P845, DOI 10.1128/JCM.25.5.845-848.1987; GRUTERS RA, 1990, EUR J IMMUNOL, V20, P1039, DOI 10.1002/eji.1830200514; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; HOFFMAN B, 1990, J IMMUNOL, V145, P3699; HORAK ID, 1990, NATURE, V348, P557, DOI 10.1038/348557a0; HOXIE JA, 1988, J VIROL, V62, P2557, DOI 10.1128/JVI.62.8.2557-2568.1988; HOXIE JA, 1988, J IMMUNOL, V140, P786; HOXIE JA, 1986, SCIENCE, V234, P1123, DOI 10.1126/science.3095925; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUSZCZAK RJ, 1991, J BIOL CHEM, V266, P11176; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORNFELD H, 1988, NATURE, V335, P445, DOI 10.1038/335445a0; KOZBOR D, 1990, J IMMUNOL, V144, P3677; KUPFER A, 1987, P NATL ACAD SCI USA, V84, P5888, DOI 10.1073/pnas.84.16.5888; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; LEDBETTER JA, 1988, EUR J IMMUNOL, V18, P525, DOI 10.1002/eji.1830180406; LINETTE GP, 1988, SCIENCE, V241, P573, DOI 10.1126/science.2899908; MANN DL, 1987, J IMMUNOL, V138, P2640; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MCDOUGAL JS, 1986, J IMMUNOL, V137, P2937; MERIDA I, 1990, J BIOL CHEM, V265, P5690; MIEDEMA F, 1990, IMMUNOL TODAY, V11, P293, DOI 10.1016/0167-5699(90)90116-Q; MIEDEMA F, 1988, J CLIN INVEST, V82, P1908, DOI 10.1172/JCI113809; MITTLER RS, 1989, SCIENCE, V245, P1380, DOI 10.1126/science.2571187; MITTLER RS, 1989, P NATL ACAD SCI USA, V86, P8531, DOI 10.1073/pnas.86.21.8531; MURRAY HW, 1988, ARCH INTERN MED, V148, P1613, DOI 10.1001/archinte.148.7.1613; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NYE KE, 1990, AIDS, V4, P41, DOI 10.1097/00002030-199001000-00006; OWENS T, 1987, P NATL ACAD SCI USA, V84, P9209, DOI 10.1073/pnas.84.24.9209; OYAIZU N, 1990, P NATL ACAD SCI USA, V87, P2379, DOI 10.1073/pnas.87.6.2379; ROSENSTEIN Y, 1990, J IMMUNOL, V144, P526; SAIZAWA K, 1987, NATURE, V328, P260, DOI 10.1038/328260a0; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHELLEKENS PTA, 1990, J CLIN IMMUNOL, V10, P121, DOI 10.1007/BF00918194; SHEARER GM, 1985, J CLIN INVEST, V76, P1699, DOI 10.1172/JCI112158; SHEARER GM, 1986, J IMMUNOL, V137, P2514; SHIN J, 1990, EMBO J, V9, P425, DOI 10.1002/j.1460-2075.1990.tb08127.x; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; TERPSTRA FG, 1989, EUR J IMMUNOL, V19, P667, DOI 10.1002/eji.1830190415; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; WASSMER P, 1985, J IMMUNOL, V135, P2237; WEINHOLD KJ, 1989, J IMMUNOL, V142, P3091; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113	63	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4102	4109						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1310988				2022-12-27	WOS:A1992HE60700080
J	KERMODE, JC; DELUCA, AW; ZILBERMAN, A; VALLIERE, J; SHREEVE, SM				KERMODE, JC; DELUCA, AW; ZILBERMAN, A; VALLIERE, J; SHREEVE, SM			EVIDENCE FOR THE FORMATION OF A FUNCTIONAL COMPLEX BETWEEN VASOACTIVE-INTESTINAL-PEPTIDE, ITS RECEPTOR, AND GS IN LUNG MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; G-PROTEINS; MOLECULAR CHARACTERISTICS; BINDING PROTEIN; VIP RECEPTORS; RAT-LIVER; GTP; SOLUBILIZATION; SELECTIVITY; SYSTEM	The molecular weight of the vasoactive intestinal peptide (VIP) receptor in rat lung and its interaction with the stimulatory guanine nucleotide-binding protein (G(s)) were assessed by covalent cross-linking, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and immunological techniques. Studies with two cross-linking agents indicated that the VIP receptor in this tissue is a single polypeptide of M(r) = 54,000. The VIP-occupied receptor could be cross-linked to neighboring proteins after detergent solubilization; higher molecular weight complexes of M(r) = 114,000 and 184,000 were formed. Immunoblotting with antisera against G-protein subunits demonstrated that both complexes contained the alpha-subunit of G(s) as well as the I-125-VIP cross-linked receptor whereas only the M(r) = 184,000 complex contained the beta-subunit. Pretreatment with GTP reduced the prominence of these complexes, verifying the functional nature of this receptor-G(s) association. Studies with a third cross-linking agent, ethylene glycol bis(succinimidyl succinate), provided direct evidence of physically associated, ternary VIP-receptor-G(s) complexes actually in the membrane milieu. That these complexes were functionally associated was shown by their inhibition by anti-G(s)alpha antiserum. Since treatment of membranes with guanosine 5'-O-(3-thiotriphosphate) resulted in the separation of the VIP-cross-linked receptor from G(s) such that no cross-linking could occur, we conclude that the binding of GTP analogs induces a conformational change in G(s) in the membrane milieu.	UNIV VERMONT, COLL MED,VERMONT CTR VASC RES,DEPT PHARMACOL, GIVEN BLDG, BURLINGTON, VT 05405 USA	University of Vermont					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038853] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 38853] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGUI T, 1990, PEPTIDES, V11, P609, DOI 10.1016/0196-9781(90)90065-D; AMATRUDA TT, 1988, J BIOL CHEM, V263, P5008; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOHLEN P, 1973, ARCH BIOCHEM BIOPHYS, V155, P213, DOI 10.1016/S0003-9861(73)80023-2; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CARSTAIRS JR, 1986, J PHARMACOL EXP THER, V239, P249; CHRISTOPHE J, 1986, PEPTIDES, V7, P101, DOI 10.1016/0196-9781(86)90171-3; CODINA J, 1984, J BIOL CHEM, V259, P1408; COUVINEAU A, 1990, EUR J BIOCHEM, V187, P605, DOI 10.1111/j.1432-1033.1990.tb15343.x; COUVINEAU A, 1986, J NEUROCHEM, V47, P1469, DOI 10.1111/j.1471-4159.1986.tb00780.x; DICKINSON KEJ, 1986, PEPTIDES, V7, P791, DOI 10.1016/0196-9781(86)90097-5; FITZGERALD TJ, 1986, J BIOL CHEM, V261, P6871; GILL DM, 1991, METHOD ENZYMOL, V195, P267; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HINSCH KD, 1989, BIOCHIM BIOPHYS ACTA, V1013, P60, DOI 10.1016/0167-4889(89)90128-6; HUCHO F, 1973, FEBS LETT, V38, P11, DOI 10.1016/0014-5793(73)80500-9; KERMODE JC, 1991, BIOCHEM J, V276, P715, DOI 10.1042/bj2760715; KILPATRICK BF, 1983, J BIOL CHEM, V258, P3528; LABURTHE M, 1984, EUR J BIOCHEM, V139, P181, DOI 10.1111/j.1432-1033.1984.tb07992.x; LABURTHE M, 1988, ANN NY ACAD SCI, V527, P296; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIMBIRD LE, 1980, P NATL ACAD SCI-BIOL, V77, P775, DOI 10.1073/pnas.77.2.775; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAUL S, 1989, BIOCHEM PHARMACOL, V38, P699, DOI 10.1016/0006-2952(89)90220-7; PAUL S, 1988, ANN NY ACAD SCI, V527, P282; PROVOW S, 1987, ENDOCRINOLOGY, V120, P2442, DOI 10.1210/endo-120-6-2442; ROBBERECHT P, 1990, ARCH INT PHARMACOD T, V303, P51; ROBBERECHT P, 1981, BIOCHIM BIOPHYS ACTA, V678, P76, DOI 10.1016/0304-4165(81)90049-0; ROBISHAW JD, 1986, P NATL ACAD SCI USA, V83, P1251, DOI 10.1073/pnas.83.5.1251; RORSTAD OP, 1990, MOL PHARMACOL, V37, P971; ROSTENE WH, 1984, PROG NEUROBIOL, V22, P103, DOI 10.1016/0301-0082(84)90022-4; SAID SI, 1970, SCIENCE, V169, P1217, DOI 10.1126/science.169.3951.1217; SAID SI, 1988, ANN NY ACAD SCI, V527, P450; SHREEVE SM, 1988, J PHARMACOL EXP THER, V245, P1060; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; SUNDLER F, 1988, ANN NY ACAD SCI, V527, P143; SVOBODA M, 1988, EUR J BIOCHEM, V174, P59, DOI 10.1111/j.1432-1033.1988.tb14062.x; TAYLOR CW, 1990, BIOCHEM J, V272, P1; TWOBIN H, 1979, P NATL ACAD SCI USA, V76, P4350; VELICELEBI G, 1988, ANN NY ACAD SCI, V527, P266; YI F, 1991, J BIOL CHEM, V266, P3900	44	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3382	3388						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1310685				2022-12-27	WOS:A1992HD15400087
J	CARRE, IA; EDMUNDS, LN				CARRE, IA; EDMUNDS, LN			CAMP-DEPENDENT KINASES IN THE ALGAL FLAGELLATE EUGLENA-GRACILIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMP BINDING-PROTEIN; CYCLIC-AMP	Euglena cells grown in diurnal light-dark cycles exhibit circadian variations of their cAMP content, which we believe to be under the control of an endogenous timer because they persist in constant darkness in the absence of any environmental time cue. We think that these cAMP oscillations may play a role in the regulation of some of the numerous cellular activities that are known to display circadian rhythmicities in this organism. The role of cAMP in algal cells is still controversial, however, since the nature of the cAMP "receptor" is unknown. We show that extracts of the achlorophyllous ZC mutant of Euglena gracilis contain two cAMP-binding proteins, which bind cAMP with a high affinity (K(d) values of 10 nM and 30 nM) and which can be separated by DEAE-cellulose chromatography. Protein kinase activity was assayed using Kemptide as a substrate. Stimulation of kinase activity by cAMP was observed after partial purification by DEAE-cellulose chromatography. Two peaks of activity were resolved, corresponding to distinct enzymes with different cAMP-analog specificities. Thus, cAMP signaling in plant cells may proceed by the phosphorylation of target proteins by cAMP-dependent kinases, in a manner similar to that of animal cells.	SUNY STONY BROOK,DEPT ANAT SCI,DIV BIOL SCI,LIFE SCI BLDG,RM 370,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			CARRE, Isabelle A/D-8802-2011	CARRE, Isabelle A/0000-0002-0548-7378	NCRR NIH HHS [RR05736] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BROWN EG, 1979, PHYTOCHEMISTRY, V18, P9, DOI 10.1016/S0031-9422(00)90904-X; BROWN EG, 1980, PHYTOCHEMISTRY, V19, P2263, DOI 10.1016/S0031-9422(00)91008-2; CALVAYRAC R, 1976, PLANT SCI LETT, V7, P249, DOI 10.1016/0304-4211(76)90151-6; CARRE IA, 1989, J CELL SCI, V94, P267; COBB CE, 1988, METHOD ENZYMOL, V159, P202; CORBIN JD, 1988, ADV SEC MESS PHOSPH, V21, P75; DOSKELAND SO, 1988, METHOD ENZYMOL, V159, P147; Edmunds LN, 1988, CELLULAR MOL BASES B; FRANCKO DA, 1983, ADV CYCL NUCL RES<D>, V15, P97; JANYSTIN B, 1989, PHYTOCHEMISTRY, V28, P329; KELLEY PM, 1991, COLD SPRING HARB SYM, P59; KEMP BE, 1976, P NATL ACAD SCI USA, V73, P1308; NICOLAS P, 1974, FEBS LETT, V49, P254, DOI 10.1016/0014-5793(74)80524-7; POLYA GM, 1981, PLANT PHYSIOL, V68, P577, DOI 10.1104/pp.68.3.577; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443	15	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2135	2137						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1310309				2022-12-27	WOS:A1992HB53200006
J	HOWELL, ML; SANDERSLOEHR, J; LOEHR, TM; ROSEMAN, NA; MATHEWS, CK; SLABAUGH, MB				HOWELL, ML; SANDERSLOEHR, J; LOEHR, TM; ROSEMAN, NA; MATHEWS, CK; SLABAUGH, MB			CLONING OF THE VACCINIA VIRUS RIBONUCLEOTIDE REDUCTASE SMALL SUBUNIT GENE - CHARACTERIZATION OF THE GENE-PRODUCT EXPRESSED IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON CENTER; DIPHOSPHATE REDUCTASE; PROTEIN; CELLS; IDENTIFICATION; OVERPRODUCTION; MOSSBAUER; SEQUENCE; ENZYME; OXYGEN	During its infectious cycle, vaccinia virus expresses a virus-encoded ribonucleotide reductase which is distinct from the host cellular enzyme (Slabaugh, M. B., and Mathews, C. K. (1984) J. Virol. 52, 501-506; Slabaugh, M. B., Johnson, T. L., and Mathews, C. K. (1984) J. Virol. 52, 507-514). We have cloned the gene for the small subunit of vaccinia virus ribonucleotide reductase (designated VVR2) into Escherichia coli and expressed the protein using a T7 RNA polymerase plasmid expression system. After isopropyl beta-D-thiogalactopyranoside induction, accumulation of a 37-kDa peptide was detected by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and this peptide reacted with polyclonal antiserum raised against a TrpE-VVR2 fusion protein. The 37-kDa protein was purified to homogeneity, and gel filtration of the purified protein revealed that the recombinant protein existed as a dimer in solution. Purified recombinant VVR2 protein was shown to complement the activity of purified recombinant ribonucleotide reductase large subunit, with a specific activity that was similar to native VVR2 from a virus-infected cell extract. A CD spectrum of the recombinant viral protein showed that like the mouse protein, the vaccinia virus protein has 50% alpha-helical structure. Like other iron-containing ribonucleotide reductase small subunits, recombinant VVR2 protein contained a stable organic free radical that was detectable by EPR spectroscopy. The EPR spectrum of purified recombinant VVR2 was identical to that of vaccinia virus-infected mammalian cells. Both the hyperfine splitting character and microwave saturation behavior of VVR2 were similar to those of mouse R2 and distinct from E. coli R2. By using amino acid analysis to determine the concentration of VVR2, we determined that almost-equal-to 0.6 radicals were present per R2 dimer. Our results indicate that vaccinia virus small subunit is similar to mammalian ribonucleotide reductases.	OREGON STATE UNIV, DEPT BIOCHEM & BIOPHYS, CORVALLIS, OR 97331 USA; OREGON GRAD INST SCI & TECHNOL, DEPT CHEM & BIOL SCI, BEAVERTON, OR 97006 USA	Oregon State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037508, R55GM037508, R01GM018865] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24294] Funding Source: Medline; NIGMS NIH HHS [GM37508, GM18865] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKIN CL, 1973, J BIOL CHEM, V248, P7464; AVERETT DR, 1983, J BIOL CHEM, V258, P9831; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; COMPTON LA, 1986, ANAL BIOCHEM, V155, P155, DOI 10.1016/0003-2697(86)90241-1; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; FONTECAVE M, 1990, J BIOL CHEM, V265, P10919; GRASLUND A, 1982, J BIOL CHEM, V257, P5711; HARDER J, 1990, FREE RADICAL RES COM, V10, P281, DOI 10.3109/10715769009149896; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANKINEN H, 1982, J VIROL, V41, P893, DOI 10.1128/JVI.41.3.893-900.1982; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; LYNCH JB, 1989, J BIOL CHEM, V264, P8091; MALENCIK DA, 1990, ANAL BIOCHEM, V184, P353, DOI 10.1016/0003-2697(90)90693-4; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; OCHIAI EI, 1990, J BIOL CHEM, V265, P15758; PETERSSON L, 1980, J BIOL CHEM, V255, P6706; ROSEMAN NA, 1990, VIROLOGY, V178, P410, DOI 10.1016/0042-6822(90)90338-R; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAHLIN M, 1990, BIOCHEM BIOPH RES CO, V167, P813, DOI 10.1016/0006-291X(90)92098-K; SAHLIN M, 1987, BIOCHEMISTRY-US, V26, P5541, DOI 10.1021/bi00391a049; SAHLIN M, 1989, BIOCHEMISTRY-US, V28, P2618, DOI 10.1021/bi00432a039; SAHLIN M, 1982, J BIOL CHEM, V257, P366; SALOWE SP, 1986, J BACTERIOL, V165, P363, DOI 10.1128/jb.165.2.363-366.1986; SJOBERG BM, 1983, ADV INORG BIOCHEM, V5, P87; SJOBERG BM, 1987, J BIOL CHEM, V262, P9736; SLABAUGH M, 1988, J VIROL, V62, P519, DOI 10.1128/JVI.62.2.519-527.1988; SLABAUGH MB, 1986, J VIROL, V60, P506, DOI 10.1128/JVI.60.2.506-514.1986; SLABAUGH MB, 1984, J VIROL, V52, P507, DOI 10.1128/JVI.52.2.507-514.1984; SLABAUGH MB, 1984, J VIROL, V52, P501, DOI 10.1128/JVI.52.2.501-506.1984; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TENGELSON LA, 1988, VIROLOGY, V164, P7426; THELANDER L, 1983, BIOCHEM BIOPH RES CO, V110, P859, DOI 10.1016/0006-291X(83)91040-9; THELANDER L, 1973, J BIOL CHEM, V248, P4591; THELANDER M, 1985, J BIOL CHEM, V260, P2737; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAKTMAN P, 1990, CELL, V62, P621, DOI 10.1016/0092-8674(90)90106-O	41	26	26	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1705	1711						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1309792				2022-12-27	WOS:A1992HA48500049
J	CORBETT, AH; ZECHIEDRICH, EL; OSHEROFF, N				CORBETT, AH; ZECHIEDRICH, EL; OSHEROFF, N			A ROLE FOR THE PASSAGE HELIX IN THE DNA CLEAVAGE REACTION OF EUKARYOTIC TOPOISOMERASE-II - A 2-SITE MODEL FOR ENZYME-MEDIATED DNA CLEAVAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DROSOPHILA-MELANOGASTER; SEQUENCE; VISUALIZATION; INTERMEDIATE; GYRASE	Eukaryotic topoisomerase II is capable of binding two separate nucleic acid helices prior to its DNA cleavage and strand passage events (Zechiedrich, E. L., and Osheroff, N. (1990) EMBO J. 9, 4555-4562). Presumably, one of these helices represents the helix that the enzyme cleaves (i.e. cleavage helix), and the other represents the helix that it passes (i.e. passage helix) through the break in the nucleic acid backbone. To determine whether the passage helix is required for reaction steps that precede the enzyme's DNA strand passage event, interactions between Drosophila melanogaster topoisomerase II and a short double-stranded oligonucleotide were assessed. These studies employed a 40-mer that contained a specific recognition/cleavage site for the enzyme. The sigmoidal DNA concentration dependence that was observed for cleavage of the 40-mer indicated that topoisomerase II had to interact with more than a single oligonucleotide in order for cleavage to take place. Despite this requirement, results of enzyme-DNA binding experiments indicated no binding cooperativity for the 40-mer. These findings strongly suggest a two-site model for topoisomerase II action in which the passage and the cleavage helices bind to the enzyme independently, but the passage helix must be present for efficient topoisomerase II-mediated DNA cleavage to occur.	VANDERBILT UNIV, MED CTR, SCH MED, DEPT BIOCHEM, 621 LIGHT HALL, NASHVILLE, TN 37232 USA	Vanderbilt University			Zechiedrich, Elizabeth Lynn/S-4720-2019; Corbett, Anita/AAH-6106-2021	Corbett, Anita/0000-0002-0461-6895; Zechiedrich, Lynn/0000-0003-0533-1637	NCI NIH HHS [5 T32 CA-09582] Funding Source: Medline; NIGMS NIH HHS [GM-33944] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P6237, DOI 10.1021/bi00441a015; GALE KC, 1990, BIOCHEMISTRY-US, V29, P9538, DOI 10.1021/bi00493a007; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; HIGGINS NP, 1982, NUCLEIC ACIDS RES, V10, P6833, DOI 10.1093/nar/10.21.6833; HOWARD MT, 1991, J MOL BIOL, V217, P53, DOI 10.1016/0022-2836(91)90610-I; LEE MP, 1989, J BIOL CHEM, V264, P21779; LEE MP, 1989, J BIOL CHEM, V264, P13510; LUND K, 1990, J BIOL CHEM, V265, P13856; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; MAXWELL A, 1984, J BIOL CHEM, V259, P4472; MULLER MT, 1988, BIOCHEMISTRY-US, V27, P8369, DOI 10.1021/bi00422a012; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P6402, DOI 10.1021/bi00394a015; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; OSHEROFF N, 1983, MECHANISMS DNA REPLI, P55; REGISTER JC, 1987, J BIOL CHEM, V262, P12812; Sambrook J, 1989, MOL CLONING LABORATO; SANDER M, 1985, NUCLEIC ACIDS RES, V13, P1057, DOI 10.1093/nar/13.4.1057; SANDER M, 1983, J BIOL CHEM, V258, P8421; SHELTON ER, 1983, J BIOL CHEM, V258, P9530; SPITZNER JR, 1988, NUCLEIC ACIDS RES, V16, P5533, DOI 10.1093/nar/16.12.5533; SUTCLIFFE JG, 1979, COLD SPRING HARB SYM, V43, P77, DOI 10.1101/SQB.1979.043.01.013; THOMSEN B, 1990, J MOL BIOL, V215, P237, DOI 10.1016/S0022-2836(05)80342-0; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; ZECHIEDRICH EL, 1989, BIOCHEMISTRY-US, V28, P6229, DOI 10.1021/bi00441a014; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x	29	64	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					683	686						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1309770				2022-12-27	WOS:A1992GY96000002
J	GROSS, SS; LEVI, R				GROSS, SS; LEVI, R			TETRAHYDROBIOPTERIN SYNTHESIS - AN ABSOLUTE REQUIREMENT FOR CYTOKINE-INDUCED NITRIC-OXIDE GENERATION BY VASCULAR SMOOTH-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; METHYL-L-ARGININE; INTERFERON-GAMMA; ENDOTHELIAL-CELLS; RELAXING FACTOR; INDUCED HYPOTENSION; MURINE MACROPHAGES; NG-METHYLARGININE; NITROGEN-OXIDES; BLOOD-PRESSURE	Nitric oxide (NO) synthesis is induced in vascular smooth muscle cells by lipopolysaccharide (LPS) where it appears to mediate a variety of vascular dysfunctions. In some cell types tetrahydrobiopterin (BH4) synthesis has also been found to be induced by cytokines. Because BH4 is a cofactor for NO synthase, we investigated whether BH4 synthesis is required for LPS-induced NO production in rat aortic smooth muscle cells (RASMC). The total biopterin content (BH4 and more oxidized states) of untreated RASMC was below our limit of detection. However, treatment with LPS caused a significant rise in biopterin levels and an induction of NO synthesis; both effects of LPS were markedly potentiated by interferon-gamma. 2,4-Diamino-6-hydroxypyrimidine (DAHP), a selective inhibitor of GTP cyclohydrolase I, the rate-limiting enzyme for de novo BH4 synthesis, completely abolished the elevated biopterin levels induced by LPS. DAHP also caused a concentration-dependent inhibition of LPS-induced NO synthesis. Inhibition of NO synthesis by DAHP was reversed by sepiapterin, an agent which circumvents the inhibition of biopterin synthesis by DAHP by serving as a substrate for BH4 synthesis via the pterin salvage pathway. The reversal by sepiapterin was overcome by methotrexate, an inhibitor of the pterin salvage pathway. Sepiapterin, and to a lesser extent BH4, dose-dependently enhanced LPS-induced NO synthesis, indicating that BH4 concentration limits the rate of NO production by LPS-activated RASMC. Sepiapterin also caused LPS-induced NO synthesis to appear with an abbreviated lag period phase, suggesting that BH4 availability also limits the onset of NO synthesis. In contrast to the stimulation of LPS-induced NO synthesis, observed when sepiapterin was given alone, sepiapterin became a potent inhibitor of NO synthesis in the presence of methotrexate. This is attributable to a direct inhibitory action of sepiapterin on GTP cyclohydrolase 1, an activity which is only revealed after blocking the metabolism of sepiapterin to BH4. Further studies with sepiapterin, methotrexate, and N-acetylserotonin (an inhibitor of the BH4 synthetic enzyme, sepiapterin reductase) indicated that the BH4 is synthesized in RASMC predominantly from GTP; however, a lesser amount may derive from pterin salvage. We demonstrate that BH4 synthesis is an absolute requirement for induction of NO synthesis by LPS in vascular smooth muscle. Our findings also suggest that pterin synthesis inhibitors may be useful for the therapy of endotoxin- and cytokine-induced shock.	CORNELL UNIV, MED CTR, COLL MED, DEPT PHARMACOL, NEW YORK, NY 10021 USA	Cornell University	GROSS, SS (corresponding author), ST BARTHOLOMEWS HOSP & MED COLL, WILLIAM HARVEY RES INST, CHARTERHOUSE SQ, LONDON EC1M 6BQ, ENGLAND.				NHLBI NIH HHS [HL34215, HL46403] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034215, P01HL046403] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AISAKA K, 1989, BIOCHEM BIOPH RES CO, V160, P881, DOI 10.1016/0006-291X(89)92517-5; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; BELLAHSENE Z, 1984, BIOCHEM J, V217, P59, DOI 10.1042/bj2170059; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; BUSSOLATI G, 1984, ADV IMMUNOHISTOCHEMI, P325; CURRAN RD, 1990, ANN SURG, V212, P462, DOI 10.1097/00000658-199010000-00009; DINARELLO CA, 1989, CRIT REV IMMUNOL, V9, P1; FEELISCH M, 1987, EUR J PHARMACOL, V139, P19, DOI 10.1016/0014-2999(87)90493-6; FUKUSHIMA T, 1980, ANAL BIOCHEM, V102, P176, DOI 10.1016/0003-2697(80)90336-X; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GAL EM, 1978, NEUROCHEM RES, V3, P69, DOI 10.1007/BF00964361; GROSS SS, 1990, BIOCHEM BIOPH RES CO, V170, P96, DOI 10.1016/0006-291X(90)91245-N; GROSS SS, 1991, BIOCHEM BIOPH RES CO, V178, P823, DOI 10.1016/0006-291X(91)90965-A; GROSS SS, 1991, FASEB J, V5, pA1728; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; JACOBSON KB, 1989, BIOCHEM J, V260, P135, DOI 10.1042/bj2600135; KILBOURN RG, 1990, BIOCHEM BIOPH RES CO, V172, P1132, DOI 10.1016/0006-291X(90)91565-A; KILBOURN RG, 1990, J NATL CANCER I, V82, P772, DOI 10.1093/jnci/82.9.772; KILBOURN RG, 1992, J NATL CANCER I, V84, P1008, DOI 10.1093/jnci/84.13.1008; KILBOURN RG, 1990, P NATL ACAD SCI USA, V87, P3629, DOI 10.1073/pnas.87.9.3629; KILBOURN RG, 1992, PORTL PR P, V1, P236; KWON NS, 1989, J BIOL CHEM, V264, P20496; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MILSTIEN S, 1989, J BIOL CHEM, V264, P8066; MILSTIEN S, 1985, BIOCHEM BIOPH RES CO, V28, P1099; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; NATHAN CF, 1990, J NATL CANCER I, V82, P726, DOI 10.1093/jnci/82.9.726; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; OSBORN MJ, 1958, P SOC EXP BIOL MED, V97, P429; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; REES DD, 1989, P NATL ACAD SCI USA, V86, P3375, DOI 10.1073/pnas.86.9.3375; SCHINI VB, 1991, BIOCHEM BIOPH RES CO, V176, P114, DOI 10.1016/0006-291X(91)90897-G; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SCHMIDT K, 1992, BIOCHEM J, V281, P297, DOI 10.1042/bj2810297; SHEN R, 1988, BIOCHIM BIOPHYS ACTA, V965, P9, DOI 10.1016/0304-4165(88)90144-4; STUEHR DJ, 1992, ADV ENZYMOL RAMB, V65, P287; STUEHR DJ, 1987, J IMMUNOL, V139, P518; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; THIEMERMANN C, 1990, EUR J PHARMACOL, V182, P591, DOI 10.1016/0014-2999(90)90062-B; WACHTER H, 1989, ADV CLIN CHEM, V27, P81, DOI 10.1016/S0065-2423(08)60182-1; WENERFELMAYER G, 1990, J EXP MED, V172, P1599; WERNER ER, 1989, BIOCHEM J, V262, P861, DOI 10.1042/bj2620861; ZIEGLER I, 1990, J BIOL CHEM, V265, P17026	47	459	468	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25722	25729						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1281471				2022-12-27	WOS:A1992KD07300022
J	BEDNARCZYK, JL; SZABO, MC; MCINTYRE, BW				BEDNARCZYK, JL; SZABO, MC; MCINTYRE, BW			POSTTRANSLATIONAL PROCESSING OF THE LEUKOCYTE INTEGRIN-ALPHA-4-BETA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III CONNECTING SEGMENT; CELL-ADHESION; FIBRONECTIN RECEPTOR; GOLGI-APPARATUS; T-CELLS; ENDOCYTIC VESICLES; INTRALYSOSOMAL PH; INTEGRIN VLA-4; WEAK BASES; ALPHA-V	The leukocyte integrin alpha4beta1 (VLA-4, CD49d/CD29) is a receptor for the extracellular matrix protein fibronectin and the endothelial adhesion protein VCAM-1. We have analyzed the biosynthesis and post-translational modifications of the two subunits of this receptor complex. The alpha4 subunit was initially synthesized as a single-chain polypeptide that underwent the formation of complex endoglycosidase H-resistant oligosaccharide side chains and which could be proteolytically cleaved into two noncovalently associated fragments. The level and rate of alpha4 subunit cleavage was dependent on the cell studied. The T cell tumor line HPB-ALL expressed both intact and fragmented alpha4 on the cell surface. The interleukin-2-dependent natural killer line NK 3.3 and long term interleukin-2-dependent activated T lymphocytes cleaved the alpha4 polypeptide earlier and more efficiently than did HPB-ALL cells and did not have detectable levels of intact alpha4 on the cell surface. The proteolysis of alpha4 was blocked by treating cells with either the lysosomotrophic amine NH4Cl or the carboxylic ionophore monensin. The presence of complex N-linked oligosaccharides did not seem to be necessary for alpha4 cleavage or for binding of the alpha4beta1 complex to a synthetic peptide corresponding to the binding site for this receptor on fibronectin.	UNIV TEXAS, MD ANDERSON CANC CTR,DEPT IMMUNOL,BOX 180, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center								AKIYAMA SK, 1987, J BIOL CHEM, V262, P17536; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BEDNARCZYK JL, 1990, J IMMUNOL, V144, P777; BEDNARCZYK JL, 1988, SCAND J IMMUNOL, V27, P83, DOI 10.1111/j.1365-3083.1988.tb02325.x; BEDNARCZYK JL, 1991, J CELL BIOCHEM, V46, P206, DOI 10.1002/jcb.240460304; BEDNARCZYK JL, 1990, J CELL BIOCHEM, V14, P184; BODARY SC, 1990, J BIOL CHEM, V265, P5938; BOSS WF, 1984, EUR J CELL BIOL, V34, P1; BRENNAN SO, 1991, J BIOL CHEM, V266, P21504; BROWN JA, 1985, J CELL BIOL, V100, P1894, DOI 10.1083/jcb.100.6.1894; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHERESH DA, 1987, J BIOL CHEM, V262, P1434; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; CLAYBERGER C, 1987, J IMMUNOL, V138, P1510; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DAVIS LS, 1990, J IMMUNOL, V145, P785; DEAN RT, 1979, BIOL FUNCTIONS PROTE, P49; DEDHAR S, 1990, J CELL BIOL, V110, P2185, DOI 10.1083/jcb.110.6.2185; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; ELDER JH, 1982, P NATL ACAD SCI-BIOL, V79, P4540, DOI 10.1073/pnas.79.15.4540; GALLOWAY CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3334, DOI 10.1073/pnas.80.11.3334; GARCIAPARDO A, 1990, J IMMUNOL, V144, P3361; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HART IR, 1991, CANCER METAST REV, V10, P115, DOI 10.1007/BF00049409; HEINO J, 1989, J BIOL CHEM, V264, P380; HEMLER ME, 1990, IMMUNOL REV, V114, P45, DOI 10.1111/j.1600-065X.1990.tb00561.x; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HIEBSCH RR, 1991, J BIOL CHEM, V266, P20323; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; KORNBLUTH J, 1982, J IMMUNOL, V129, P2831; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDGER PW, 1984, TRENDS BIOCHEM SCI, V9, P313, DOI 10.1016/0968-0004(84)90299-8; MATZUK MM, 1988, J CELL BIOL, V106, P1049, DOI 10.1083/jcb.106.4.1049; MAXFIELD FR, 1982, J CELL BIOL, V95, P676, DOI 10.1083/jcb.95.2.676; MCINTYRE BW, 1989, J BIOL CHEM, V264, P13745; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MOULD AP, 1990, J BIOL CHEM, V265, P4020; NOJIMA Y, 1990, J EXP MED, V172, P1185, DOI 10.1084/jem.172.4.1185; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; POOLE B, 1981, J CELL BIOL, V90, P665, DOI 10.1083/jcb.90.3.665; PULIDO R, 1991, J BIOL CHEM, V266, P10241; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SANCHEZMADRID F, 1986, EUR J IMMUNOL, V16, P1343, DOI 10.1002/eji.1830161106; SHIMIZU Y, 1990, J IMMUNOL, V145, P59; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STEINER DF, 1980, ANN NY ACAD SCI, V300, P1; SYMINGTON BE, 1989, J BIOL CHEM, V264, P13258; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; TEIXIDO J, 1992, J BIOL CHEM, V267, P1786; TULSIANI DRP, 1983, J BIOL CHEM, V258, P7578; UTSUMI K, 1991, P NATL ACAD SCI USA, V88, P5685, DOI 10.1073/pnas.88.13.5685; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; WAYNER EA, 1992, J CELL BIOL, V116, P489, DOI 10.1083/jcb.116.2.489; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WILLIAMS DA, 1991, NATURE, V352, P438, DOI 10.1038/352438a0	67	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25274	25281						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1281155				2022-12-27	WOS:A1992KB60300056
J	LILLYCROP, KA; LATCHMAN, DS				LILLYCROP, KA; LATCHMAN, DS			ALTERNATIVE SPLICING OF THE OCT-2 TRANSCRIPTION FACTOR RNA IS DIFFERENTIALLY REGULATED IN NEURONAL CELLS AND B-CELLS AND RESULTS IN PROTEIN ISOFORMS WITH OPPOSITE EFFECTS ON THE ACTIVITY OF OCTAMER TAATGARAT-CONTAINING PROMOTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENES; HERPES-SIMPLEX VIRUS; IMMUNOGLOBULIN GENES; SENSORY NEURONS; HISTONE H2B; BINDING; EXPRESSION; SEQUENCE; MOTIF; ELEMENTS	The RNA encoding the octamer-binding transcription factor Oct-2 is alternatively spliced in both neuronal cells and in B cells to yield multiple mRNAs encoding different isoforms of the protein. We show that, compared with B cells, neuronal cells overexpress the mRNAs encoding Oct 2.4 and 2.5 which differ from the other forms (Oct 2.1, 2.2, and 2.3) at the C terminus of the protein. When introduced into cells lacking endogenous Oct-2, the various Oct-2 isoforms have different effects on octamer-containing promoters. The Oct 2.1, 2.2, and 2.3 forms stimulate all octamer-containing promoters. Hoewever, the Oct 2.4 and 2.5 forms can repress some promoters and stimulate others, depending on the sequence of the octamer motif and its context within the promoter. In contrast, when introduced into neuronal cells which express a high endogenous level of the inhibitory Oct 2.4 and 2.5 forms, all the Oct-2 isoforms can repress octamer-mediated gene expression. The significance of these findings is discussed with regard to the known inhibitory effect of the octamer motif on viral and cellular gene expression in neuronal cells.	UNIV COLL & MIDDLESEX SCH MED, DIV MOLEC PATHOL, WINDEYER BLDG, CLEVELAND ST, LONDON W1P 6DB, ENGLAND	University of London; University College London								AUGUSTIT.G, 1969, P NATL ACAD SCI USA, V64, P311, DOI 10.1073/pnas.64.1.311; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; DENT CL, 1991, MOL CELL BIOL, V11, P3925, DOI 10.1128/MCB.11.8.3925; FALKNER FG, 1986, NUCLEIC ACIDS RES, V13, P7847; GELMAN IH, 1987, J VIROL, V61, P2286, DOI 10.1128/JVI.61.7.2286-2296.1987; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HATZOPOULOS AK, 1990, DEVELOPMENT, V109, P349; KEMP LM, 1990, NEURON, V4, P215, DOI 10.1016/0896-6273(90)90096-X; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LENARDO MJ, 1989, SCIENCE, V243, P544, DOI 10.1126/science.2536195; LILLYCROP KA, 1991, NEURON, V7, P381, DOI 10.1016/0896-6273(91)90290-G; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUND E, 1985, SCIENCE, V229, P1271, DOI 10.1126/science.2412294; MACPHERSON I, 1962, VIROLOGY, V16, P147, DOI 10.1016/0042-6822(62)90290-8; MASON JO, 1985, CELL, V41, P479, DOI 10.1016/S0092-8674(85)80021-0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MORRIS AE, 1992, NUCLEIC ACIDS RES, V20, P1355, DOI 10.1093/nar/20.6.1355; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PERRY LJ, 1986, J GEN VIROL, V67, P2365, DOI 10.1099/0022-1317-67-11-2365; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SIVE HL, 1986, MOL CELL BIOL, V6, P3329, DOI 10.1128/MCB.6.10.3329; SIVE HL, 1986, P NATL ACAD SCI USA, V83, P6382, DOI 10.1073/pnas.83.17.6382; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; STOW ND, 1986, CANCER CELL, V4, P497; STOYKOVA AS, 1992, NEURON, V8, P541, DOI 10.1016/0896-6273(92)90282-I; SUBURO AM, 1992, NEUROSCIENCE, V46, P881, DOI 10.1016/0306-4522(92)90191-4; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; TANAKA M, 1992, CELL, V68, P755, DOI 10.1016/0092-8674(92)90150-B; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; WHEATLEY SC, 1991, EXP CELL RES, V194, P78, DOI 10.1016/0014-4827(91)90132-E; WHITTON JL, 1984, NUCLEIC ACIDS RES, V12, P2061, DOI 10.1093/nar/12.4.2061; WIRTH T, 1991, NUCLEIC ACIDS RES, V19, P43, DOI 10.1093/nar/19.1.43; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; [No title captured]	46	75	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					24960	24965						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1281152				2022-12-27	WOS:A1992KB60300011
J	TAMURA, M; TAKESHITA, M; CURNUTTE, JT; UHLINGER, DJ; LAMBETH, JD				TAMURA, M; TAKESHITA, M; CURNUTTE, JT; UHLINGER, DJ; LAMBETH, JD			STABILIZATION OF HUMAN NEUTROPHIL NADPH OXIDASE ACTIVATED IN A CELL-FREE SYSTEM BY CYTOSOLIC PROTEINS AND BY 1-ETHYL-3-(3-DIMETHYLAMINOPROPYL) CARBODIIMIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; CHRONIC GRANULOMATOUS-DISEASE; PIG POLYMORPHONUCLEAR LEUKOCYTES; PLASMA-MEMBRANE; ADRENODOXIN REDUCTASE; SUPEROXIDE PRODUCTION; CARBOXYLATE GROUPS; ARACHIDONIC-ACID; CROSS-LINKING; CYTOCHROME-C	The superoxide-generating respiratory burst oxidase (NADPH oxidase) from human neutrophils can be activated in a cell-free system consisting of plasma membrane and cytosol by anionic amphiphiles such as sodium dodecyl sulfate and arachidonate (McPhail, L. C., Shirley, P. S., Clayton, C. C., and Snyderman, R. (1985) J. Clin. Invest. 75, 1735-1739; Curnutte, J. T. (1985) J. Clin. Invest. 75, 1740-1743; Bromberg, Y., and Pick, E. (1984) Cell. Immunol. 88, 213-221). Herein, the activity thus obtained is shown to be very labile at 37-degrees-C. The rate of inactivation varied inversely with cytosol concentration. The stabilizing factor(s) was destroyed by heat and trypsin, indicating that it is protein in nature. Whereas cytosol from normal cells and from a chronic granulomatous disease patient lacking p67phox stabilized the oxidase activity, that from a chronic granulomatous disease patient lacking p47phox did not. Also, dialdehyde NADPH-treated cytosol showed no stabilizing effect, indicating that p47phox and a putative NADPH-binding component both participate in stabilization. The mechanism of inactivation was further explored by examining the stabilizing effect of agents that can act as chemical cross-linkers. Of several tested, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) was the most effective, but others that utilize different chemical mechanisms were also partially effective. EDC extended the half-life at 37-degrees-C from 2 to 120 min, protected against the inactivating effects of Triton X-100 and high salt, and did not affect the K(m) for NADPH. Stabilization required prior activation in the presence of both cytosol and membrane; and EDC treatment of cytosol, membrane, or a mixture of the two prior to the addition of sodium dodecyl sulfate failed to induce stabilization. EDC eliminated the requirement for the continuous presence of cytosol and activator. Dialysis did not cause a loss in activity, whereas control activity was diminished with dialysis and was largely restored with added sodium dodecyl sulfate. In the absence of EDC, the separation of cytosol from the membrane fraction resulted in a significant loss of activity, which was largely restored by the addition of cytosol. However, EDC treatment allowed the isolation of a nearly fully active oxidase in the membrane fraction, the activity of which was not influenced by added cytosol. These results support a model in which the active NADPH oxidase consists of a dissociable complex among membrane and cytosolic components and indicate that the longevity of the activated state requires continuous association of these components.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; EMORY UNIV, SCH MED, DEPT BIOCHEM, ATLANTA, GA 30322 USA	Scripps Research Institute; Emory University	TAMURA, M (corresponding author), MED COLL OITA, DEPT BIOCHEM, OITA 87956, JAPAN.				NCI NIH HHS [CA46508] Funding Source: Medline; NIAID NIH HHS [AI22809] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022809] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMBRUSO DR, 1990, J BIOL CHEM, V265, P924; BABIOR BM, 1982, CAN J PHYSIOL PHARM, V60, P1353, DOI 10.1139/y82-202; BADWEY JA, 1980, ANNU REV BIOCHEM, V49, P695, DOI 10.1146/annurev.bi.49.070180.003403; BELLAVITE P, 1988, FREE RADICAL BIO MED, V4, P225, DOI 10.1016/0891-5849(88)90044-5; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CHIBA T, 1990, BIOCHEM BIOPH RES CO, V173, P376, DOI 10.1016/S0006-291X(05)81068-X; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CURNUTTE JT, 1989, P NATL ACAD SCI USA, V86, P825, DOI 10.1073/pnas.86.3.825; CURNUTTE JT, 1987, J BIOL CHEM, V262, P6450; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; DOUSSIERE J, 1990, BIOCHEMISTRY-US, V29, P2225, DOI 10.1021/bi00461a004; GABIG TG, 1987, J BIOL CHEM, V262, P1685; GABIG TG, 1984, J CLIN INVEST, V73, P701, DOI 10.1172/JCI111262; GARCIA RC, 1988, BIOCHEM J, V252, P901, DOI 10.1042/bj2520901; GEREN LM, 1984, J BIOL CHEM, V259, P2155; GLASS GA, 1986, J BIOL CHEM, V261, P3247; HACKETT CS, 1984, J BIOL CHEM, V259, P3275; HEYWORTH PG, 1989, BIOCHEM J, V260, P243, DOI 10.1042/bj2600243; JESAITIS AJ, 1986, J BIOL CHEM, V261, P3662; KAKINUMA K, 1987, J BIOL CHEM, V262, P12316; KATAYAMA T, 1990, ARCH BIOCHEM BIOPHYS, V278, P431, DOI 10.1016/0003-9861(90)90281-3; LAMBETH JD, 1984, J BIOL CHEM, V259, P25; LAPORTE F, 1990, BIOCHEM BIOPH RES CO, V168, P78, DOI 10.1016/0006-291X(90)91677-K; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LETO TL, 1990, J CELL BIOL, V111, pA49; LIGETI E, 1988, BIOCHEMISTRY-US, V27, P193, DOI 10.1021/bi00401a029; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; LOMAX KJ, 1989, SCIENCE, V246, P987, DOI 10.1126/science.2587992; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAS MT, 1983, J BIOL CHEM, V258, P9332; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; MILLETT F, 1983, BIOCHEMISTRY-US, V22, P546, DOI 10.1021/bi00272a004; NISIMOTO Y, 1988, BIOCHEMISTRY-US, V27, P5869, DOI 10.1021/bi00416a008; NISIMOTO Y, 1988, J BIOL CHEM, V263, P11657; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; QUINN MT, 1989, BIOCHIM BIOPHYS ACTA, V987, P83, DOI 10.1016/0005-2736(89)90458-6; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; ROTROSEN D, 1987, ANNU REV IMMUNOL, V5, P127, DOI 10.1146/annurev.immunol.5.1.127; ROTROSEN D, 1990, J BIOL CHEM, V265, P8745; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SAKANE F, 1987, J BIOCHEM, V102, P247, DOI 10.1093/oxfordjournals.jbchem.a122048; SMITH RM, 1989, J BIOL CHEM, V264, P12243; SMITH RM, 1989, J BIOL CHEM, V264, P1958; TAKASUGI S, 1989, J BIOCHEM-TOKYO, V105, P155, DOI 10.1093/oxfordjournals.jbchem.a122630; TAMBURINI PP, 1987, P NATL ACAD SCI USA, V84, P11, DOI 10.1073/pnas.84.1.11; TAMURA M, 1990, ARCH BIOCHEM BIOPHYS, V280, P313, DOI 10.1016/0003-9861(90)90335-V; TAMURA M, 1989, ARCH BIOCHEM BIOPHYS, V275, P23, DOI 10.1016/0003-9861(89)90345-7; TANAKA T, 1988, J BIOL CHEM, V263, P13670; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195	51	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7529	7538						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1313806				2022-12-27	WOS:A1992HN48500049
J	HEIDARAN, MA; YU, JC; JENSEN, RA; PIERCE, JH; AARONSON, SA				HEIDARAN, MA; YU, JC; JENSEN, RA; PIERCE, JH; AARONSON, SA			A DELETION IN THE EXTRACELLULAR DOMAIN OF THE ALPHA-PLATELET-DERIVED GROWTH-FACTOR (PDGF) RECEPTOR DIFFERENTIALLY IMPAIRS PDGF-AA AND PDGF-BB BINDING AFFINITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EGF-RECEPTOR; SIGNAL TRANSDUCTION; LIGAND-BINDING; CDNA CLONING; CELLS; DIMERIZATION; ESTABLISHES; SPECIFICITY; EXPRESSION; DEFINE	32D cells transfected with the human alpha-platelet-derived. growth factor receptor (alpha-PDGFR) bind PDGF-AA, -AB, and -BB isoforms with high affinity, and the binding of each can be efficiently competed by all three isoforms. In an effort to develop better understanding of spatial relationships of binding sites for PDGF-AA and -BB, we constructed an alpha-PDGFR mutant which deleted amino acids 150-189 within its extracellular domain. This mutant showed a marked decrease in high affinity binding sites for PDGF-AA without comparable alteration in affinity for PDGF-BB. These findings imply that the high affinity binding sites for PDGF-AA and PDGF-BB in the alpha-PDGFR extracellular domain are not structurally coincident.	NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,RM 1E24,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ANDERSEN AS, 1990, BIOCHEMISTRY-US, V29, P7363, DOI 10.1021/bi00484a002; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DROZDOFF V, 1991, J BIOL CHEM, V266, P17165; HEIDARAN MA, 1990, J BIOL CHEM, V265, P18741; HEIDARAN MA, 1991, J BIOL CHEM, V266, P20232; HELDIN CH, 1985, MOL CELL ENDOCRINOL, V39, P169, DOI 10.1016/0303-7207(85)90061-9; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; KELLY JD, 1991, J BIOL CHEM, V266, P8987; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; MUNSON PJ, 1984, COMPUTERS ENDOCRINOL, P117; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	27	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					2884	2887						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1310677				2022-12-27	WOS:A1992HD15400013
J	CLEMENTI, E; SCHEER, H; ZACCHETTI, D; FASOLATO, C; POZZAN, T; MELDOLESI, J				CLEMENTI, E; SCHEER, H; ZACCHETTI, D; FASOLATO, C; POZZAN, T; MELDOLESI, J			RECEPTOR-ACTIVATED CA2+ INFLUX - 2 INDEPENDENTLY REGULATED MECHANISMS OF INFLUX STIMULATION COEXIST IN NEUROSECRETORY PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED CALCIUM ENTRY; FURA-2-LOADED HUMAN-PLATELETS; ADRENAL CHROMAFFIN CELLS; LACRIMAL ACINAR-CELLS; CYTOSOLIC CA-2+ RISE; INOSITOL PHOSPHATES; PLASMA-MEMBRANE; TUMOR PROMOTER; MUSCARINIC RECEPTORS; PHOSPHOINOSITIDE HYDROLYSIS	Receptor-activated Ca2+ influx was investigated in PC12 cells clones loaded with fura-2. Cells were stimulated in a Ca2+-free medium and studied after reintroduction of the cation or addition of Mn2+ into the medium. A first influx component, independent of receptor activation and sustained by depletion of the intracellular inositol 1,4,5-trisphosphate sensitive Ca2+ store (store-dependent Ca2+ influx, SDCI), was identified by experiments with carbachol followed by atropine and with agents that induce store discharge without polyphosphoinositide hydrolysis: thapsigargin, an inhibitor of Ca2+-ATPase activity; ryanodine and caffeine, activators of the ryanodine receptor. A second component of Ca2+ influx, induced by carbachol and rapidly blocked by atropine, relies on receptor-effector coupling via G protein(s) different from that (those) involved in phospholipase C activation. SDCI and receptor-coupled influx are similar in their voltage dependence and insensitivity to forskolin and phorbol esters but they differ with respect to their Mn2+ permeability and their sensitivity to the SC 38249 imidazole blocker. The two components might play different roles. SDCI might act as a safety device to prevent Ca2+ store depletion whereas receptor-dependent influx might control physiological functions such as secretion and growth.	UNIV MILANO,S RAFFAELE SCI INST,DEPT PHARMACOL,VIA OLGETTINA 60,I-20132 MILAN,ITALY; CNR,CTR CYTOPHARMACOL,B CECCARELLI CTR,DEPT PHARMACOL,I-20132 MILAN,ITALY; UNIV PADUA,INST GEN PATHOL,CNR,CTR BIOMEMBRANE,I-35100 PADUA,ITALY; UNIV MONTREAL,DEPT PHARMACOL,MONTREAL H3C 3J7,QUEBEC,CANADA	University of Milan; Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR); University of Padua; Universite de Montreal			Zacchetti, Daniele/AAC-2724-2022; Fasolato, Cristina/AAE-6024-2019	Zacchetti, Daniele/0000-0003-2724-7559; Fasolato, Cristina/0000-0002-9816-7751	Telethon [126] Funding Source: Medline	Telethon(Fondazione Telethon)		BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BLAYNEY LM, 1991, BIOCHEM J, V273, P803, DOI 10.1042/bj2730803; BOTHWELL MA, 1980, CELL, V21, P857, DOI 10.1016/0092-8674(80)90449-3; CIARDO A, 1990, EUR J PHARM-MOLEC PH, V188, P417, DOI 10.1016/0922-4106(90)90204-B; FASOLATO C, 1988, J BIOL CHEM, V263, P17350; Gasic G P, 1991, Curr Opin Neurobiol, V1, P20, DOI 10.1016/0959-4388(91)90006-S; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GROHOVAZ F, 1991, J CELL BIOL, V113, P1341, DOI 10.1083/jcb.113.6.1341; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUILLON G, 1990, ENDOCRINOLOGY, V126, P1699, DOI 10.1210/endo-126-3-1699; HALLAM TJ, 1989, BIOCHEM J, V259, P125, DOI 10.1042/bj2590125; HESS P, 1990, ANNU REV NEUROSCI, V13, P1337; INOUE K, 1988, J BIOL CHEM, V263, P8157; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; KASS GEN, 1990, J BIOL CHEM, V265, P17486; KIM KT, 1989, P NATL ACAD SCI USA, V86, P9881, DOI 10.1073/pnas.86.24.9881; KOMORI S, 1990, J PHYSIOL-LONDON, V427, P395, DOI 10.1113/jphysiol.1990.sp018178; KOVACS T, 1990, FEBS LETT, V266, P171, DOI 10.1016/0014-5793(90)81532-S; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; KWAN CY, 1990, J BIOL CHEM, V265, P678; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LASKEY RE, 1990, J BIOL CHEM, V265, P2613; MAGNI M, 1991, J BIOL CHEM, V266, P6329; MASON MJ, 1991, J BIOL CHEM, V266, P10872; MELDOLESI J, 1987, EXP CELL RES, V171, P271, DOI 10.1016/0014-4827(87)90161-3; MELDOLESI J, 1991, TRENDS PHARMACOL SCI, V12, P289, DOI 10.1016/0165-6147(91)90577-F; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; MUALLEM S, 1990, J BIOL CHEM, V265, P2011; NARASIMHAN V, 1988, J BIOL CHEM, V263, P19626; PANDOL SJ, 1990, J BIOL CHEM, V265, P12846; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; POZZAN T, 1986, BIOCHEM J, V234, P547, DOI 10.1042/bj2340547; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANSOM JT, 1991, J BIOL CHEM, V266, P11738; RINK TJ, 1990, FEBS LETT, V268, P381, DOI 10.1016/0014-5793(90)81290-5; SAGE SO, 1989, BIOCHEM J, V258, P923, DOI 10.1042/bj2580923; SAGE SO, 1990, BIOCHEM J, V265, P675, DOI 10.1042/bj2650675; SHER E, 1988, FEBS LETT, V235, P178, DOI 10.1016/0014-5793(88)81258-4; SHUTTLEWORTH TJ, 1990, BIOCHEM J, V269, P417, DOI 10.1042/bj2690417; SJOLANDER A, 1990, J BIOL CHEM, V265, P20976; STAUDERMAN KA, 1989, J BIOL CHEM, V264, P18349; STAUDERMAN KA, 1990, CELL REGUL, V1, P683, DOI 10.1091/mbc.1.9.683; TAKEMURA H, 1989, BIOCHEM J, V258, P409, DOI 10.1042/bj2580409; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TAKUWA N, 1991, J BIOL CHEM, V266, P1403; TAYLOR CW, 1990, TRENDS PHARMACOL SCI, V11, P269, DOI 10.1016/0165-6147(90)90003-Q; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TSCHARNER V, 1986, NATURE, V324, P369; VICENTINI LM, 1986, BIOCHEM J, V234, P555, DOI 10.1042/bj2340555; VICENTINI LM, 1985, BIOCHEM BIOPH RES CO, V127, P310, DOI 10.1016/S0006-291X(85)80160-1; WRAY D, 1989, ANN NY ACAD SCI, V560, P1; ZACCHETTI D, 1991, J BIOL CHEM, V266, P20152	57	181	182	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2164	2172						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1310310				2022-12-27	WOS:A1992HB53200011
J	MILLER, RJ				MILLER, RJ			VOLTAGE-SENSITIVE CA2+ CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PURIFIED CALCIUM CHANNELS; SKELETAL-MUSCLE; FUNCTIONAL EXPRESSION; XENOPUS OOCYTES; CA-2+ CHANNELS; MESSENGER-RNA; SUBUNIT; BRAIN; CURRENTS; NEURONS				MILLER, RJ (corresponding author), UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,947 E 58TH ST,CHICAGO,IL 60637, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH040165, R01MH040165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002121, R01DA002575] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-02121, DA-02575] Funding Source: Medline; NIMH NIH HHS [MH-40165] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AHLIJANIAN M K, 1991, Society for Neuroscience Abstracts, V17, P774; AHLIJANIAN MK, 1991, J BIOL CHEM, V266, P20192; AHLIJANIAN MK, 1990, NEURON, V4, P819, DOI 10.1016/0896-6273(90)90135-3; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; CATTERALL WA, 1991, SCIENCE, V253, P1499, DOI 10.1126/science.1654596; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; DEJONGH KS, 1989, P NATL ACAD SCI USA, V86, P8585; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; GROVE A, 1991, P NATL ACAD SCI USA, V88, P6418, DOI 10.1073/pnas.88.15.6418; GUNDERSEN CB, 1988, J PHARMACOL EXP THER, V247, P824; GUTIERREZ LM, 1991, J BIOL CHEM, V266, P16387; HIRNING LD, 1988, SCIENCE, V239, P57, DOI 10.1126/science.2447647; HORNE WA, 1991, J BIOL CHEM, V266, P13719; HORNE WA, 1991, BIOPHSY J, V59, P388; HOSEY MM, 1992, IN PRESS MOL ASPECTS; HUI A, 1991, NEURON, V7, P35, DOI 10.1016/0896-6273(91)90072-8; JAY SD, 1991, J BIOL CHEM, V266, P3287; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; KANEKO S, 1987, NEUROSCI LETT, V83, P123, DOI 10.1016/0304-3940(87)90227-8; KASS RS, 1991, J GEN PHYSIOL, V98, P63, DOI 10.1085/jgp.98.1.63; KOCH WJ, 1990, J BIOL CHEM, V265, P17786; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; LANG B, 1990, PROG NEUROENDOCRI IM, V3, P83; LLINAS R, 1989, P NATL ACAD SCI USA, V86, P1689, DOI 10.1073/pnas.86.5.1689; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MILJANICH G, 1991, Society for Neuroscience Abstracts, V17, P1161; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; MILLER RJ, 1990, INTRACELLULAR CALCIU, P97; MINTZ I M, 1991, Society for Neuroscience Abstracts, V17, P341; MINTZ IM, 1991, P NATL ACAD SCI USA, V88, P6628, DOI 10.1073/pnas.88.15.6628; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NAKAYAMA H, 1991, P NATL ACAD SCI USA, V88, P9203, DOI 10.1073/pnas.88.20.9203; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; PUMPLIN DW, 1983, J NEUROCYTOL, V12, P317, DOI 10.1007/BF01148467; REGAN LJ, 1991, NEURON, V6, P269, DOI 10.1016/0896-6273(91)90362-4; REGAN LJ, 1991, J NEUROSCI, V11, P2259; REGULLA S, 1991, EMBO J, V10, P45, DOI 10.1002/j.1460-2075.1991.tb07919.x; RIVNAY B, 1991, Society for Neuroscience Abstracts, V17, P1161; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; RUTH P, 1989, SCIENCE, V245, P115; SAKAMOTO J, 1991, J BIOL CHEM, V266, P18914; SCOTT RH, 1990, MOL PHARMACOL, V38, P711; SEINO S, 1992, IN PRESS P NATL ACAD; SHARP AH, 1989, J BIOL CHEM, V264, P2816; SHER E, 1989, LANCET, V2, P640; SHER E, 1991, NEUROSCIENCE, V42, P301, DOI 10.1016/0306-4522(91)90376-Y; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; STRIESSNIG J, 1990, P NATL ACAD SCI USA, V87, P9108, DOI 10.1073/pnas.87.23.9108; STRIESSNIG J, 1991, IN PRESS P NATL ACAD; TANABE T, 1991, NATURE, V352, P800, DOI 10.1038/352800a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; TARELLI FT, 1991, BRAIN RES, V547, P331, DOI 10.1016/0006-8993(91)90981-Z; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; TSUBOKAWA M, 1991, Society for Neuroscience Abstracts, V17, P1161; UMBACH JA, 1987, P NATL ACAD SCI USA, V84, P5464, DOI 10.1073/pnas.84.15.5464; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; WEI XY, 1991, J BIOL CHEM, V266, P21943; WILLIAMS ME, 1992, IN PRESS NEURON	69	224	232	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1403	1406						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1309781				2022-12-27	WOS:A1992HA48500001
J	NICE, EC; FABRI, L; HAMMACHER, A; HOLDEN, J; SIMPSON, RJ; BURGESS, AW				NICE, EC; FABRI, L; HAMMACHER, A; HOLDEN, J; SIMPSON, RJ; BURGESS, AW			THE PURIFICATION OF A RAP1 GTPASE-ACTIVATING PROTEIN FROM BOVINE BRAIN CYTOSOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE EFFECTOR DOMAIN; RAS-RELATED GENE; BINDING PROTEIN; TYROSINE PHOSPHORYLATION; MOLECULAR-CLONING; EXCHANGE-REACTION; RAS-P21 GTPASE; GROWTH-FACTOR; P21 GTPASE; GAP	Two GTPase-activating proteins (GAPs) have been detected in extracts from bovine brain: GAP-1, which is specific for the activation of ras GTPases, and GAP-3, which is specific for the activation of the rap1 GTPases. We present a strategy for the purification to homogeneity of a cytosolic form of GAP-3 from bovine brain. The 100,000 x g supernatant from homogenized brains was chromatographed sequentially on DEAE Fast Flow, green H-E4BD Sepharose, Bio-Gel A1.5, hydroxyapatite, and phenyl-Sepharose prior to high resolution separation on Mono Q HR 5/5, phenyl-Superose HR 5/5, Mono Q PC 1.6/5, and Superose 12 PC 3.2/30. This procedure resulted in an approximately 18,000-fold purification, yielding 50-mu-g of GAP-3 from 1.6 kg of tissue. Purified cytosolic GAP-3 migrated as a single band of apparent M(r) 55,000 on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. However, on gel filtration cytosolic GAP-3 chromatographed as a dimer with an apparent M(r) 92,000. Purified GAP-3 does not activate ras or rho GTPases and possesses no intrinsic GTPase activity. Amino acid sequence data indicated a proline-rich N terminus. The amino acid sequences of peptides generated by Staphylococcus aureus V8 digestion of reduced and pyridine-ethylated GAP-3 showed no similarity to the predicted primary structure of GAP-1 or any other proteins in the nucleic acid or protein data bases. By comparison with the data of Rubinfeld et al. (Rubinfeld, B., Munemitsu, S., Clark, R., Conroy, L., Watt, K., Crosier, W. J., McCormick, F., and Polakis, P. (1991) Cell 65, 1033-1042), it appears that the membrane-associated (M(r) 85,000-95,000) and cytosolic forms of GAP-3 are derived from equivalent, or closely related, genes.	LUDWIG INST CANC RES,JOINT PROT STRUCT LAB,VICTORIA 3050,AUSTRALIA; ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Walter & Eliza Hall Institute	NICE, EC (corresponding author), LUDWIG INST CANC RES,MELBOURNE TUMOUR BIOL BRANCH,VICTORIA 3050,AUSTRALIA.		Nice, Edouard C/B-1026-2011	Simpson, Richard/0000-0002-9834-0796; fabri, louis/0000-0003-4033-3304				ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BEGG GS, 1989, METHODS PROTEIN SEQU, P108; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HATA Y, 1990, J BIOL CHEM, V265, P7104; HUANG YK, 1990, P NATL ACAD SCI USA, V87, P8008, DOI 10.1073/pnas.87.20.8008; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KLAPPER DG, 1978, ANAL BIOCHEM, V85, P126, DOI 10.1016/0003-2697(78)90282-8; LASKY M, 1978, ELECTROPHORESIS 78, P195; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NICE EC, 1991, J BIOL CHEM, V266, P14425; NICE EC, 1990, NATURE, V348, P462, DOI 10.1038/348462a0; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; REY I, 1989, MOL CELL BIOL, V9, P3904, DOI 10.1128/MCB.9.9.3904; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SIMPSON RJ, 1989, ANAL BIOCHEM, V177, P1; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; UEDA T, 1989, BIOCHEM BIOPH RES CO, V159, P1411, DOI 10.1016/0006-291X(89)92267-5; UEDA T, 1990, J BIOL CHEM, V265, P9373; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; ZULLO JN, 1988, MOL CELL BIOL, V8, P5080, DOI 10.1128/MCB.8.12.5080	60	26	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1546	1553						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1309786				2022-12-27	WOS:A1992HA48500026
J	STRUM, JC; EMILSSON, A; WYKLE, RL; DANIEL, LW				STRUM, JC; EMILSSON, A; WYKLE, RL; DANIEL, LW			CONVERSION OF 1-O-ALKYL-2-ACYL-SN-GLYCERO-3-PHOSPHOCHOLINE TO 1-O-ALK-1'-ENYL-2-ACYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE - A NOVEL PATHWAY FOR THE METABOLISM OF ETHER-LINKED PHOSPHOGLYCERIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING FACTOR; RAT-BRAIN MICROSOMES; PHOSPHOLIPASE-C; LUNG MICROSOMES; BACK-REACTION; CHOLINEPHOSPHOTRANSFERASE; PHOSPHATIDYLCHOLINE; CHOLINE; REVERSIBILITY; ETHANOLAMINE	Madin Darby canine kidney (MACK) cells convert 1-O-[H-3]alkyl-2-acyl-sn-glycero-3-phosphocholine ([H-3]alkylacylGPC) to a product tentatively identified as an ethanolamine-containing phosphoglyceride (PE) (Daniel, L. W., Waite, B. M., and Wykle, R. L. (1986) J. Biol. Chem. 261, 9128-9132). In the present study, analysis of the radiolabeled phosphoglycerides as diradylglycerobenzoate derivatives indicated that [H-3]alkylacylGPC was initially converted to 1-O-[H-3]alkyl-2-acyl-sn-glycero-3-phosphoethanolamine ([H-3]alkylacylGPE) which was subsequently desaturated to 1-O-[H-3]alk-1'-enyl-2-acyl-sn-glycero-3-phosphoethanolamine ([H-3]alkenylacylGPE). The conversion of [H-3]/[P-32]alkyl-lysoGPC to [H-3]alkenylacylGPE indicated that base exchange enzymes were not involved in this pathway. A phosphono analog of alkyl-lysoGPC, resistant to phospholipase D hydrolysis and radiolabeled in the 1-O-alkyl chain was readily incorporated, acylated, and subsequently metabolized to [H-3]alkylacylGPC and [H-3]alkenylacylGPE. Therefore, the involvement of phospholipase D in the conversion pathway was ruled out. The conversion of [H-3]alkylacylGPC or its phosphono analog to [H-3]alkenylacylGPE was significantly enhanced by the addition of 100-mu-M ethanolamine to the culture media, suggesting that [H-3]alkylacylglycerol is an intermediate in the cytidine-dependent pathway of PE synthesis. MDCK cell cytosol and microsomes contained no detectable phospholipase C activity. However, incubation of microsomes with CMP resulted in the degradation of [H-3]alkylacylGPC and accumulation of [H-3]alkylacylglycerol. Furthermore, the addition of CDP-ethanolamine to microsomes following preincubation with CMP, resulted in a decrease in [H-3]alkylacylglycerol with a concomitant increase in [H-3]alkenylacylGPE. Overall, these results suggest that the reverse reaction of choline phosphotransferase may be responsible for the conversion of alkylacylGPC to alkylacylGPE.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT BIOCHEM, WINSTON SALEM, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center					NATIONAL CANCER INSTITUTE [R01CA048995, P30CA012197] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026818] Funding Source: NIH RePORTER; NCI NIH HHS [CA-48995, CA-12197] Funding Source: Medline; NHLBI NIH HHS [HL-26818] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; BAKER RR, 1984, CAN J BIOCHEM CELL B, V62, P379, DOI 10.1139/o84-053; BJORNSTAD P, 1966, J LIPID RES, V7, P38; BLANK ML, 1984, J CHROMATOGR, V298, P473, DOI 10.1016/S0021-9673(01)92744-X; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CABOT MC, 1982, LIFE SCI, V31, P2891, DOI 10.1016/0024-3205(82)90680-4; CHILTON FH, 1984, J BIOL CHEM, V259, P2014; CHRISTIANSEN K, 1975, ANAL BIOCHEM, V66, P93, DOI 10.1016/0003-2697(75)90728-9; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; DANIEL LW, 1986, J BIOL CHEM, V261, P9128; DIAGNE A, 1984, BIOCHIM BIOPHYS ACTA, V793, P221, DOI 10.1016/0005-2760(84)90324-2; FORD DA, 1988, J BIOL CHEM, V263, P2644; GORACCI G, 1977, FEBS LETT, V80, P41, DOI 10.1016/0014-5793(77)80402-X; GORACCI G, 1981, BIOCHIM BIOPHYS ACTA, V664, P373, DOI 10.1016/0005-2760(81)90059-X; Goracci G, 1978, Adv Exp Med Biol, V101, P269; HANAHAN DJ, 1961, J BIOL CHEM, V236, pPC59; HERROCKS LA, 1972, ETHER LIPIDS CHEM BI, P177; HOFFMAN DR, 1986, CANCER RES, V46, P5803; Horrocks L.A., 1982, NEW COMPR BIOCH, V4, P51, DOI [10.1016/s0167-7306(08)60006-x, DOI 10.1016/S0167-7306(08)60006-X]; HORROCKS LA, 1972, FEBS LETT, V22, P190, DOI 10.1016/0014-5793(72)80041-3; HUANG CF, 1990, J BIOL CHEM, V265, P14858; KANOH H, 1973, BIOCHIM BIOPHYS ACTA, V326, P17, DOI 10.1016/0005-2760(73)90023-4; KANOH H, 1973, BIOCHIM BIOPHYS ACTA, V306, P203; KAPOULAS VM, 1969, BIOCHIM BIOPHYS ACTA, V176, P324, DOI 10.1016/0005-2760(69)90190-8; Martonosi, 1985, ENZYMES BIOL MEMBR, V2, P1; MUELLER HW, 1984, J LIPID RES, V25, P383; PAI JK, 1987, CARCINOGENESIS, V8, P173, DOI 10.1093/carcin/8.1.173; PALTAUF F, 1972, FEBS LETT, V20, P79, DOI 10.1016/0014-5793(72)80021-8; PFLEGER RC, 1967, BIOCHIM BIOPHYS ACTA, V144, P633, DOI 10.1016/0005-2760(67)90052-5; RECORD M, 1984, BIOCHIM BIOPHYS ACTA, V778, P449, DOI 10.1016/0005-2736(84)90393-6; REISS PD, 1984, ANAL BIOCHEM, V140, P162, DOI 10.1016/0003-2697(84)90148-9; RENKONEN O, 1968, J LIPID RES, V9, P34; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SLACK CR, 1983, BIOCHIM BIOPHYS ACTA, V754, P10, DOI 10.1016/0005-2760(83)90076-0; SUGIURA T, 1983, LIPIDS, V18, P125, DOI 10.1007/BF02536106; SUNDLER R, 1974, BIOCHIM BIOPHYS ACTA, V337, P248, DOI 10.1016/0005-2760(74)90206-9; SURLES JR, 1985, J MED CHEM, V28, P73, DOI 10.1021/jm00379a015; TERCE F, 1991, BIOCHIM BIOPHYS ACTA, V1084, P69, DOI 10.1016/0005-2760(91)90057-O; TESSNER TG, 1987, J BIOL CHEM, V262, P12660; THOMPSON GA, 1967, BIOCHEMISTRY-US, V6, P2015, DOI 10.1021/bi00859a020; TIETZ A, 1964, J BIOL CHEM, V239, P4081; TSAO FHC, 1986, LIPIDS, V21, P498, DOI 10.1007/BF02535636; VANHEUSDEN GPH, 1982, BIOCHIM BIOPHYS ACTA, V711, P361, DOI 10.1016/0005-2760(82)90046-7; WEISS SB, 1958, J BIOL CHEM, V231, P53; WOLF RA, 1985, J BIOL CHEM, V260, P7295; WYKLE RL, 1991, METHOD ENZYMOL, V197, P583; WYKLE RL, 1972, J BIOL CHEM, V247, P5442; WYKLE RL, 1980, BIOCHIM BIOPHYS ACTA, V619, P58, DOI 10.1016/0005-2760(80)90242-8	49	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1576	1583						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1309787				2022-12-27	WOS:A1992HA48500030
J	STOCKERT, RJ; PAIETTA, E; RACEVSKIS, J; MORELL, AG				STOCKERT, RJ; PAIETTA, E; RACEVSKIS, J; MORELL, AG			POSTTRANSCRIPTIONAL REGULATION OF THE ASIALOGLYCOPROTEIN RECEPTOR BY CGMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL SIGNAL SEQUENCE; HEPATIC BINDING-PROTEIN; MESSENGER-RNA STABILITY; TRANSLATIONAL REGULATION; GUANYLATE-CYCLASE; RAT-LIVER; FERRITIN; BIOTIN; IRON; GLYCOPROTEINS	The human asialoglycoprotein receptor expressed by the HepG2 cell line is composed of the two homologous polypeptides H1 and H2. Transblot analysis of HepG2 cell lysates indicated that the progressive loss in the steady-state level of asialoglycoprotein receptor (ASGR) when cells were maintained in medium supplemented with dialyzed fetal bovine serum was reversed by the addition of cell-permeant 8-bromo-cGMP. Estimates of the steady-state levels of H1- and H2-related mRNA by Northern blot analysis indicated that the reduction of ASGR was not the result of a concomitant reduction in gene transcript number. No difference in the translatability of the mRNAs derived from cells grown in medium supplemented with fetal bovine serum or its dialyzed counterpart was detected. Resolution of the mRNAs by sucrose gradient centrifugation suggests that cGMP-mediated posttranscriptional regulation of ASGR expression was due to a shift of both H1 and H2 mRNAs from the ribonucleoprotein fraction into a translationally active membrane-associated polysomal pool.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,LIVER RES CTR,DEPT BIOCHEM,BRONX,NY 10461; MONTEFIORE MED CTR,ALBERT EINSTEIN COLL MED,DEPT ONCOL,DIV MED ONCOL,BRONX,NY 10467	Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	STOCKERT, RJ (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,LIVER RES CTR,DEPT MED,U-517,1300 MORRIS PK,BRONX,NY 10461, USA.				NCI NIH HHS [CA-43864] Funding Source: Medline; NIDDK NIH HHS [DK-32972, DK-17702] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043864] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032972, P50DK017702] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; ATKINSON BG, 1990, J BIOL CHEM, V265, P14156; Ausubel F, 1990, CURRENT PROTOCOLS MO, V1; BISCHOFF J, 1988, J CELL BIOL, V106, P1067, DOI 10.1083/jcb.106.4.1067; BRAITERMAN LT, 1989, J BIOL CHEM, V264, P1682; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BREITFELD PP, 1985, INT REV CYTOL, V97, P47, DOI 10.1016/S0074-7696(08)62348-7; CAMPBELL CH, 1989, BIOCHEM BIOPH RES CO, V160, P453, DOI 10.1016/0006-291X(89)92454-6; CHAUHAN J, 1971, J BIOL CHEM, V266, P10035; CHITPATIMA ST, 1988, J BIOL CHEM, V263, P7164; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS JC, 1984, HEPATOLOGY, V4, P80, DOI 10.1002/hep.1840040114; COLLINS JC, 1988, J BIOL CHEM, V263, P11280; EVERTS RP, 1984, CANCER RES, V44, P5718; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; HUBER BE, 1986, J BIOL CHEM, V261, P2400; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY S, 1991, P NATL ACAD SCI USA, V88, P3319, DOI 10.1073/pnas.88.8.3319; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCPHAUL M, 1986, P NATL ACAD SCI USA, V83, P8863, DOI 10.1073/pnas.83.23.8863; PETELL JK, 1985, ARCH BIOCHEM BIOPHYS, V241, P550, DOI 10.1016/0003-9861(85)90580-6; ROGERS J, 1987, P NATL ACAD SCI USA, V84, P2277, DOI 10.1073/pnas.84.8.2277; SAINI KS, 1990, MOL CELL BIOCHEM, V96, P15; Sambrook J, 1989, MOL CLONING LABORATO, P324; SCHERRER K, 1990, MOL BIOL REP, V14, P1, DOI 10.1007/BF00422709; SCHWARTZ AL, 1984, CRC CR REV BIOCH MOL, V16, P207, DOI 10.3109/10409238409108716; SHIA MA, 1989, P NATL ACAD SCI USA, V86, P1158, DOI 10.1073/pnas.86.4.1158; SPENCE JT, 1984, J BIOL CHEM, V259, P6393; SPENCE JT, 1983, J BIOL CHEM, V258, P9143; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; SPIESS M, 1985, J BIOL CHEM, V260, P1979; SPIESS M, 1986, CELL, V44, P177, DOI 10.1016/0092-8674(86)90496-4; STOCKERT RJ, 1983, HEPATOLOGY, V3, P750; STOCKERT RJ, 1980, CANCER RES, V40, P3632; STOCKERT RJ, 1990, J BIOL CHEM, V265, P1841; THEIL EC, 1990, J BIOL CHEM, V265, P4771; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VESELY DL, 1982, SCIENCE, V216, P1329, DOI 10.1126/science.6123152; WALDMAN SA, 1984, J BIOL CHEM, V259, P4332; WILMAN T, 1985, BIOCHEM J, V232, P1	43	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					56	59						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1309753				2022-12-27	WOS:A1992GY43900014
J	HORTELANO, S; GENARO, AM; BOSCA, L				HORTELANO, S; GENARO, AM; BOSCA, L			PHORBOL ESTERS INDUCE NITRIC-OXIDE SYNTHASE ACTIVITY IN RAT HEPATOCYTES - ANTAGONISM WITH THE INDUCTION ELICITED BY LIPOPOLYSACCHARIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							L-ARGININE; MACROPHAGE OXIDATION; GUANYLATE-CYCLASE; NITROGEN-OXIDES; KUPFFER CELL; COFACTOR; NITRATE; LIVER; TETRAHYDROBIOPTERIN; PURIFICATION	The incubation of primary cultures of rat hepatocytes with lipopolysaccharide (LPS) or biologically active phorbol esters promotes the release of nitric oxide to the incubation medium. This process is the result of the induction of the Ca2+- and calmodulin-independent form of nitric oxide synthase. Both the release of nitric oxide to the incubation medium and the expression of nitric oxide synthase activity exhibited a lag period of about 45-60 min after cell stimulation. Exposure of hepatocytes to both stimuli produced an antagonistic effect on nitric oxide release, with a half-maximal inhibition obtained with 14 nM phorbol 12,13-dibutyrate at saturating concentration of LPS. Incubation of cells with alpha-phorbol 12,13-didecanoate failed to counteract the effect of LPS or to induce nitric oxide synthase, suggesting that activation of protein kinase C was involved in this process.	UNIV COMPLUTENSE MADRID,FAC FARM,INST BIOQUIM,E-28040 MADRID,SPAIN	Complutense University of Madrid			Hortelano, Sonsoles/A-7954-2010; Bosca, Lisardo/A-2059-2008	Hortelano, Sonsoles/0000-0003-2528-0072; Bosca, Lisardo/0000-0002-0253-5469; Genaro, Ana/0000-0003-0027-3503				BELL RM, 1991, J BIOL CHEM, V266, P4661; BILLIAR TR, 1990, BIOCHEM BIOPH RES CO, V168, P1034, DOI 10.1016/0006-291X(90)91133-D; BILLIAR TR, 1989, J EXP MED, V169, P1467, DOI 10.1084/jem.169.4.1467; BILLIAR TR, 1990, J SURG RES, V48, P349, DOI 10.1016/0022-4804(90)90073-B; BILLIAR TR, 1992, AM J PHYSIOL, V262, pC1077, DOI 10.1152/ajpcell.1992.262.4.C1077; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUGHLER JM, 1979, P NATL ACAD SCI USA, V76, P219, DOI 10.1073/pnas.76.1.219; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; DEVENTE J, 1992, ACTA HISTOCHEM, V92, P13, DOI 10.1016/S0065-1281(11)80138-8; FEELISCH M, 1987, EUR J PHARMACOL, V139, P19, DOI 10.1016/0014-2999(87)90493-6; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; HUE L, 1978, BIOCHEM J, V176, P791, DOI 10.1042/bj1760791; IGNARRO LJ, 1989, FASEB J, V3, P31, DOI 10.1096/fasebj.3.1.2642868; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; ISHII K, 1990, EUR J PHARMACOL, V176, P219; ISHII K, 1991, AM J PHYSIOL, V261, pH598, DOI 10.1152/ajpheart.1991.261.2.H598; KNOWLES RG, 1990, BIOCHEM J, V270, P833, DOI 10.1042/bj2700833; KNOWLES RG, 1990, BIOCHEM BIOPH RES CO, V172, P1042, DOI 10.1016/0006-291X(90)91551-3; KWON NS, 1989, J BIOL CHEM, V264, P20496; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MONCADA S, 1991, PHARMACOL REV, V43, P109; MOY JA, 1991, J BIOL CHEM, V266, P8092; OHSHIMA H, 1992, BIOCHEM BIOPH RES CO, V183, P238, DOI 10.1016/0006-291X(92)91634-3; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PFEILSCHIFTER J, 1992, EUR J BIOCHEM, V203, P251, DOI 10.1111/j.1432-1033.1992.tb19854.x; PFEILSCHIFTER J, 1991, EUR J PHARM-MOLEC PH, V208, P339, DOI 10.1016/0922-4106(91)90081-R; REES DD, 1990, BRIT J PHARMACOL, V101, P746, DOI 10.1111/j.1476-5381.1990.tb14151.x; SALTER M, 1991, FEBS LETT, V291, P145, DOI 10.1016/0014-5793(91)81123-P; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SCHMIDT HHHW, 1992, MOL PHARMACOL, V41, P615; SOUTHAM E, 1991, NEUROSCI LETT, V130, P107, DOI 10.1016/0304-3940(91)90239-P; STADLER J, 1991, AM J PHYSIOL, V260, pC910, DOI 10.1152/ajpcell.1991.260.5.C910; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; YUI Y, 1991, J BIOL CHEM, V266, P12544	40	130	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					24937	24940						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1281151				2022-12-27	WOS:A1992KB60300007
J	CANNY, BJ; JIA, LG; LEONG, DA				CANNY, BJ; JIA, LG; LEONG, DA			CORTICOTROPIN-RELEASING FACTOR, BUT NOT ARGININE VASOPRESSIN, STIMULATES CONCENTRATION-DEPENDENT INCREASES IN ACTH-SECRETION FROM A SINGLE CORTICOTROPE - IMPLICATIONS FOR INTRACELLULAR SIGNALS IN STIMULUS-SECRETION COUPLING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTERIOR-PITUITARY-CELLS; HEMOLYTIC PLAQUE-ASSAY; PROTEIN-KINASE-C; ADRENOCORTICOTROPIN SECRETION; INOSITOL TRISPHOSPHATE; CHROMAFFIN CELLS; CALCIUM RELEASE; HORMONE ACTION; CA-2+; ADENOSINE-3',5'-MONOPHOSPHATE	The two fundamental parameters of corticotropin (ACTH) secretion are the number of secreting corticotropes and the amount of ACTH secreted by each cell. We have measured these parameters in rat corticotropes in response to increasing concentrations of corticotropin-releasing factor (CRF) or arginine vasopressin (AVP). Increasing concentrations of AVP stimulated more corticotropes to secrete, while the amount of ACTH each cell secreted remained relatively fixed (nongraded secretory response). Conversely, increasing concentrations of CRF stimulated more ACTH secretion per cell (graded secretory response), while the number of secretory cells remained relatively constant. When viewed from the perspective of a single corticotrope, it was clear that CRF and AVP induced completely distinct specific responses. We have previously shown, and provide further evidence here, that secretory responses to CRF or AVP occur in the same cell. It is therefore apparent that a single corticotrope is able to generate either a graded, or a nongraded secretory response. We have also considered the potential intracellular changes that must direct graded or nongraded secretion. It is generally accepted that CRF stimulates activation of adenylate cyclase, whereas AVP activates phosphoinositidase in pituitary corticotropes. Our findings, and others surveyed here, suggest that the activation of adenylate cyclase results in graded secretion, while the activation of phosphoinositidase induces the nongraded secretion. Graded or nongraded secretion may therefore be linked to specific second messengers. It is hypothesized that the inositol 1,4,5-trisphosphate-mediated release of an intracellular Ca2+ Store constitutes a mechanism whereby phosphoinositidase-coupled hormones set in motion the nongraded secretory response. These findings suggest novel functions for individual second messengers.	UNIV VIRGINIA, HLTH SCI CTR, DEPT MED, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT NEUROSCI, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT PHYSIOL, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia					NIDDK NIH HHS [DK-35937] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035937, R23DK035937] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUILERA G, 1983, J BIOL CHEM, V258, P8039; ALLAERTS W, 1988, J THEOR BIOL, V131, P441, DOI 10.1016/S0022-5193(88)80040-7; ANTONI FA, 1986, ENDOCR REV, V7, P351, DOI 10.1210/edrv-7-4-351; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BILEZIKJIAN LM, 1987, MOL ENDOCRINOL, V1, P555, DOI 10.1210/mend-1-8-555; BILEZIKJIAN LM, 1983, ENDOCRINOLOGY, V113, P1726, DOI 10.1210/endo-113-5-1726; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BIRNBERG NC, 1983, P NATL ACAD SCI USA, V80, P6892; BOURNE GA, 1987, AM J PHYSIOL, V253, pE290, DOI 10.1152/ajpendo.1987.253.3.E290; CARVALLO P, 1989, MOL ENDOCRINOL, V3, P1935, DOI 10.1210/mend-3-12-1935; CHEEK TR, 1989, J CELL BIOL, V109, P1219, DOI 10.1083/jcb.109.3.1219; CHENG K, 1991, ENDOCRINOLOGY, V129, P3337; CHILDS GV, 1987, ENDOCRINOLOGY, V120, P439, DOI 10.1210/endo-120-2-439; CONN PM, 1981, ENDOCR REV, V2, P174, DOI 10.1210/edrv-2-2-174; CONN PM, 1986, ENDOCR REV, V7, P3, DOI 10.1210/edrv-7-1-3; GOTH MI, 1992, ENDOCRINOLOGY, V130, P939, DOI 10.1210/en.130.2.939; GOTH MI, 1992, ENDOCRINOLOGY, V250, pE650; JIA LG, 1991, ENDOCRINOLOGY, V128, P197, DOI 10.1210/endo-128-1-197; KELLERWOOD ME, 1984, ENDOCR REV, V5, P1, DOI 10.1210/edrv-5-1-1; KIM KT, 1989, P NATL ACAD SCI USA, V86, P9881, DOI 10.1073/pnas.86.24.9881; KWAN CY, 1990, J BIOL CHEM, V265, P678; LABRIE F, 1982, SCIENCE, V216, P1007, DOI 10.1126/science.6281886; LEONG DA, 1991, CELL CALCIUM, V12, P255, DOI 10.1016/0143-4160(91)90025-A; LEONG DA, 1991, J BIOL CHEM, V266, P9016; LEVIN N, 1989, ENDOCRINOLOGY, V125, P2957, DOI 10.1210/endo-125-6-2957; LIU JP, 1990, J BIOL CHEM, V265, P14136; LOESSBERG PA, 1991, J BIOL CHEM, V266, P1363; MADSEN G, 1991, J NEUROENDOCRINOL, V3, P193, DOI 10.1111/j.1365-2826.1991.tb00262.x; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MIYAZAKI S, 1988, J CELL BIOL, V106, P345, DOI 10.1083/jcb.106.2.345; MUALLEM S, 1989, J BIOL CHEM, V264, P205; MUHLEN FV, 1991, P NATL ACAD SCI USA, V88, P926, DOI 10.1073/pnas.88.3.926; MURPHY BEP, 1967, J CLIN ENDOCR METAB, V27, P973, DOI 10.1210/jcem-27-7-973; NEHER E, 1988, J PHYSIOL-LONDON, V395, P193, DOI 10.1113/jphysiol.1988.sp016914; NEILL JD, 1983, ENDOCRINOLOGY, V112, P1135, DOI 10.1210/endo-112-3-1135; NEILL JD, 1987, RECENT PROG HORM RES, V43, P175; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OGDEN DC, 1990, J PHYSIOL-LONDON, V422, P585, DOI 10.1113/jphysiol.1990.sp018002; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; RAPPAY G, 1981, HISTOCHEMISTRY, V73, P131, DOI 10.1007/BF00493139; RAYMOND V, 1985, FEBS LETT, V182, P196, DOI 10.1016/0014-5793(85)81183-2; SHIPSTON MJ, 1991, J ENDOCRINOL, V129, P261, DOI 10.1677/joe.0.1290261; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189; WON JGS, 1990, ENDOCRINOLOGY, V126, P849, DOI 10.1210/endo-126-2-849	45	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8325	8329						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1314823				2022-12-27	WOS:A1992HQ18500057
J	MUNIR, KM; FRENCH, DC; DUBE, DK; LOEB, LA				MUNIR, KM; FRENCH, DC; DUBE, DK; LOEB, LA			PERMISSIBLE AMINO-ACID SUBSTITUTIONS WITHIN THE PUTATIVE NUCLEOSIDE-BINDING SITE OF HERPES-SIMPLEX VIRUS TYPE-1 ESTABLISHED BY RANDOM SEQUENCE MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMIDINE KINASE GENE; ESCHERICHIA-COLI; DNA-BINDING; NUCLEOTIDE-SEQUENCE; BETA-LACTAMASE; PROTEIN; ENZYME; SELECTION; INVITRO; LIGANDS	We determined the essentiality of all amino acid replacements within an 11-codon sequence in the putative nucleoside-binding site of thymidine kinase encoded by herpes simplex virus type 1. This involved partial randomization of 11 codons in the gene to create a degenerate library, followed by genetic complementation using a tk- Escherichia coli strain and selection of unnatural active enzymes. We produced and tested 53,000 variants; of which 190 were found to be biologically active. Sequence analyses of functional variants revealed a high degree of flexibility in accommodating different types of amino acid substitutions in this region. However, no replacement was tolerated at proline-173, whereas tyrosine-172 could be replaced by only phenylalanine. To further define permissible substitutions at specified positions, we constructed a library with randomization at only four test codons. We produced and tested 600,000 variants; of which only 5 were active. Again proline-173 was conserved, and only tyrosine and phenylalanine were found at position 172. The identification of these conserved amino acids should provide important insights into the understanding of the structural basis of catalysis by this enzyme.	UNIV WASHINGTON,DEPT PATHOL,JOSEPH GOTTSTEIN MEM CANC RES LAB,SEATTLE,WA 98195	University of Washington; University of Washington Seattle			Munir, Kerim/D-6910-2015	Munir, Kerim/0000-0002-2404-1806	NATIONAL CANCER INSTITUTE [R35CA039903] Funding Source: NIH RePORTER; NCI NIH HHS [OIG R35-CA-39903] Funding Source: Medline; NIA NIH HHS [AG-00057] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BERTICS PJ, 1988, UCLA S MOL CELLULAR, V74, P157; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; CHEN MS, 1979, J BIOL CHEM, V254, P747; CHENG YC, 1976, J BIOL CHEM, V251, P2605; CRAIK CS, 1985, SCIENCE, V228, P291, DOI 10.1126/science.3838593; Creighton TE, 1983, PROTEINS STRUCTURES; DARBY G, 1986, J GEN VIROL, V67, P753, DOI 10.1099/0022-1317-67-4-753; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; DUBE DK, 1991, BIOCHEMISTRY-US, V30, P11760, DOI 10.1021/bi00115a004; DUBE DK, 1989, BIOCHEMISTRY-US, V28, P5703, DOI 10.1021/bi00440a001; DUBE DK, 1991, GENE AMST, V996, P25; ELION GB, 1977, P NATL ACAD SCI USA, V74, P5716, DOI 10.1073/pnas.74.12.5716; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; GARAPIN AC, 1981, P NATL ACAD SCI-BIOL, V78, P815, DOI 10.1073/pnas.78.2.815; HECHT MH, 1983, P NATL ACAD SCI-BIOL, V80, P2676, DOI 10.1073/pnas.80.9.2676; HERMES JD, 1990, P NATL ACAD SCI USA, V87, P696, DOI 10.1073/pnas.87.2.696; HORWITZ MSZ, 1988, J BIOL CHEM, V263, P14724; HORWITZ MSZ, 1986, P NATL ACAD SCI USA, V83, P7405, DOI 10.1073/pnas.83.19.7405; HOWELL EE, 1986, SCIENCE, V231, P1123, DOI 10.1126/science.3511529; IGARASHI K, 1967, GENETICS, V37, P643; KAISER CA, 1987, SCIENCE, V235, P312, DOI 10.1126/science.3541205; KNOWLES JR, 1987, SCIENCE, V236, P1252; LARDER BA, 1983, J BIOL CHEM, V258, P2027; LIN LN, 1984, BIOCHEMISTRY-US, V23, P5713, DOI 10.1021/bi00319a009; LIU QY, 1988, VIROLOGY, V163, P638, DOI 10.1016/0042-6822(88)90308-X; LUGER K, 1989, SCIENCE, V243, P206, DOI 10.1126/science.2643160; MANDECKI W, 1990, PROTEIN ENG, V3, P221, DOI 10.1093/protein/3.3.221; Maniatis T., 1982, MOL CLONING; MCKEOWN M, 1976, J BACTERIOL, V126, P814, DOI 10.1128/JB.126.2.814-822.1976; MCKNIGHT SL, 1980, NUCLEIC ACIDS RES, V8, P5949, DOI 10.1093/nar/8.24.5949; OLIPHANT AR, 1989, P NATL ACAD SCI USA, V86, P9094, DOI 10.1073/pnas.86.23.9094; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; REIDHAAROLSON JF, 1988, SCIENCE, V241, P53, DOI 10.1126/science.3388019; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SMITH M, 1985, ANNU REV GENET, V19, P423, DOI 10.1146/annurev.genet.19.1.423; SOWEK JA, 1991, BIOCHEMISTRY-US, V30, P3179, DOI 10.1021/bi00227a004; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WAGNER MJ, 1981, P NATL ACAD SCI-BIOL, V78, P1441, DOI 10.1073/pnas.78.3.1441; WALDMAN AS, 1983, J BIOL CHEM, V258, P1571; 1989, BACTERIAL ELECTROTRA, P14	42	49	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6584	6589						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1313013				2022-12-27	WOS:A1992HM05300023
J	SIDDIQUI, RA; EXTON, JH				SIDDIQUI, RA; EXTON, JH			PHOSPHOLIPID BASE-EXCHANGE ACTIVITY IN RAT-LIVER PLASMA-MEMBRANES - EVIDENCE FOR REGULATION BY G-PROTEIN AND P2Y-PURINERGIC RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDES; PHOSPHATIDYLCHOLINE BREAKDOWN; CA2+-STIMULATED INCORPORATION; MICROSOMAL PHOSPHOLIPIDS; PARTIAL-PURIFICATION; BRAIN MICROSOMES; ETHANOLAMINE; ACTIVATION; PHOSPHATIDYLETHANOLAMINE; CHOLINE	Phospholipid base exchange activity using choline as substrate was detected in plasma membranes (PM) and other subcellular fractions of rat liver, with microsomes (MS) showing the highest specific activity. In contrast, phospholipase D activity was only detected in PM. In PM, choline exchanged for phosphatidylcholine (PC), phosphatidylethanolamine (PE), and phosphatidylserine (PS), whereas ethanolamine exchanged for PE and PS, and serine exchanged for PS. Ca2+ (10-mu-M or higher) stimulated choline incorporation into PC in MS and PM, whereas Mg2+ (10-mu-M or higher) stimulated it only in PM. Ethanolamine and serine incorporation into PM phospholipids was also stimulated by Ca2+, and inositol incorporation by Mn2+. Phospholipase D activity was substantial in the presence of EGTA and was slightly stimulated by Ca2+ concentrations less than 500-mu-M. It was undetectable without Mg2+. Low concentrations of oleate (1 mM or less) stimulated phospholipase D activity. These concentrations inhibited choline base exchange activity, whereas higher concentrations (3-8 mM) were stimulatory. Comparison of the subcellular distribution and Ca2+, Mg2+, and oleate effects on choline base exchange and phospholipase D activities supports the view that they are catalyzed by different enzymes. The incorporation of choline, but not ethanolamine or serine, into the phospholipids of PM, but not MS, was stimulated by micromolar concentrations of guanosine 5'-3-O-(thio)triphosphate (GTP-gamma-S) and other slowly hydrolyzable analogues of GTP. GDP, GMP, and other nucleoside triphosphates and their analogues were ineffective. GTP-gamma-S stimulation of base exchange activity was dependent upon Mg2+ and was inhibited by high concentrations of guanosine 5'-O-2(thio)diphosphate. In the presence of low concentrations of GTP-gamma-S, ATP and its slowly hydrolyzable analogues stimulated base exchange activity. Dose-response curves for these nucleotides revealed a potency order consistent with mediation by purinergic receptors of the P2Y type. Base exchange activity stimulated by ATP plus GTP-gamma-S or GTP-gamma-S alone was not altered by treatment with pertussis or cholera toxins. These results suggest that the choline base exchange activity of liver PM is regulated by a pertussis toxin-insensitive G-protein linked to P2Y purinergic receptors.	VANDERBILT UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST LAB,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University			Siddiqui, Rafat A/G-7686-2018		NIGMS NIH HHS [GM40919] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040919] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELLATIF AA, 1972, BIOCHEM PHARMACOL, V21, P436, DOI 10.1016/0006-2952(72)90361-9; BAGINSKI ES, 1974, METHOD ENZYMAT AN, P876; BERGMEYER HU, 1974, METHOD ENZYMAT AN, P574; BERTZ R, 1977, EUR J BIOCHEM, V77, P181; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BJERVE KS, 1971, FEBS LETT, V17, P14, DOI 10.1016/0014-5793(71)80551-3; BJERVE KS, 1973, BIOCHIM BIOPHYS ACTA, V306, P396, DOI 10.1016/0005-2760(73)90178-1; BJERVE KS, 1973, BIOCHIM BIOPHYS ACTA, V296, P549, DOI 10.1016/0005-2760(73)90115-X; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1987, FEBS LETT, V225, P201, DOI 10.1016/0014-5793(87)81157-2; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOYER JL, 1989, J BIOL CHEM, V264, P884; BUCHANAN AG, 1979, J NEUROCHEM, V34, P720; BURNSTOCK G, 1985, GEN PHARMACOL, V16, P433, DOI 10.1016/0306-3623(85)90001-1; CHALIFA V, 1990, J BIOL CHEM, V265, P17512; DENNIS EA, 1970, J LIPID RES, V11, P394; EXTON JH, 1990, J BIOL CHEM, V265, P1; GAITI A, 1975, FEBS LETT, V49, P361, DOI 10.1016/0014-5793(75)80785-X; GAITI A, 1976, LIPIDS, V11, P823, DOI 10.1007/BF02532986; GREEN DE, 1955, J BIOL CHEM, V217, P551; HATTORI H, 1985, J NEUROCHEM, V45, P1578, DOI 10.1111/j.1471-4159.1985.tb07229.x; HINO Y, 1978, J BIOCHEM, V83, P909, DOI 10.1093/oxfordjournals.jbchem.a132018; HOLBROOK PG, 1990, BIOCHIM BIOPHYS ACTA, V1046, P185, DOI 10.1016/0005-2760(90)90187-3; HURST KM, 1990, BIOCHEM J, V272, P749, DOI 10.1042/bj2720749; IRVING HR, 1987, J BIOL CHEM, V262, P3440; KANFER JN, 1991, FEBS LETT, V291, P63, DOI 10.1016/0014-5793(91)81104-G; KANFER JN, 1972, J LIPID RES, V13, P468; KANFER JN, 1980, CAN J BIOCHEM CELL B, V58, P1370, DOI 10.1139/o80-186; KAUFMANN SH, 1981, EXP CELL RES, V132, P105, DOI 10.1016/0014-4827(81)90088-4; KEPPENS S, 1986, BIOCHEM J, V240, P367, DOI 10.1042/bj2400367; KEPPENS S, 1989, FEBS LETT, V248, P137, DOI 10.1016/0014-5793(89)80448-X; KOBAYASHI M, 1987, J NEUROCHEM, V48, P1597, DOI 10.1111/j.1471-4159.1987.tb05707.x; MAEDA T, 1983, BIOCHIM BIOPHYS ACTA, V731, P115, DOI 10.1016/0005-2736(83)90404-2; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; MIURA T, 1976, ARCH BIOCHEM BIOPHYS, V175, P654, DOI 10.1016/0003-9861(76)90556-7; MORI H, 1989, BIOCHIM BIOPHYS ACTA, V1003, P98, DOI 10.1016/0005-2760(89)90105-7; MURRAY JJ, 1990, BIOCHEM J, V270, P63, DOI 10.1042/bj2700063; PAI JK, 1988, BIOCHEM BIOPH RES CO, V150, P355, DOI 10.1016/0006-291X(88)90528-1; PERRIN DD, 1967, TALANTA, V14, P833, DOI 10.1016/0039-9140(67)80105-X; PORCELLATI G, 1971, J NEUROCHEM, V18, P1395, DOI 10.1111/j.1471-4159.1971.tb00004.x; PRPIC V, 1984, J BIOL CHEM, V259, P1382; RIBEIRONETO F, 1987, MOL ENDOCRINOL, V1, P472, DOI 10.1210/mend-1-7-472; SAITO M, 1975, ARCH BIOCHEM BIOPHYS, V169, P304, DOI 10.1016/0003-9861(75)90345-8; SCHACHT J, 1978, J LIPID RES, V19, P1063; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; SHIN SH, 1990, PLANT PHYSIOL, V93, P148, DOI 10.1104/pp.93.1.148; SUZUKI TT, 1985, J BIOL CHEM, V260, P1394; TAKENAWA T, 1980, ARCH BIOCHEM BIOPHYS, V202, P601, DOI 10.1016/0003-9861(80)90467-1; TAKI T, 1978, BIOCHIM BIOPHYS ACTA, V528, P309, DOI 10.1016/0005-2760(78)90020-6; TAKI T, 1973, JPN J EXP MED, V43, P87; TAKI T, 1979, J BIOL CHEM, V254, P9761; TAKI T, 1973, JPN J EXP MED, V43, P219; TAYLOR SJ, 1991, NATURE, V350, P16; VANDOR SL, 1968, CAN J BIOCHEM CELL B, V46, P1309, DOI 10.1139/o68-196; WANG P, 1991, J BIOL CHEM, V266, P14877	56	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5755	5761						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1313419				2022-12-27	WOS:A1992HK31800009
J	HUNDAL, HS; MARETTE, A; MITSUMOTO, Y; RAMLAL, T; BLOSTEIN, R; KLIP, A				HUNDAL, HS; MARETTE, A; MITSUMOTO, Y; RAMLAL, T; BLOSTEIN, R; KLIP, A			INSULIN INDUCES TRANSLOCATION OF THE ALPHA-2-SUBUNIT AND BETA-1-SUBUNIT OF THE NA+/K+-ATPASE FROM INTRACELLULAR COMPARTMENTS TO THE PLASMA-MEMBRANE IN MAMMALIAN SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GLUCOSE TRANSPORTERS; SODIUM; CELLS; (NA++K+)-ATPASE; (NA+,K+)-ATPASE; REDISTRIBUTION; STIMULATION; NA,K-ATPASE; MECHANISM; RECEPTORS	Unlike glucose transport, where translocation of the insulin-responsive glucose transporter (GLUT4) from an intracellular compartment to the plasma membrane is the principal mechanism underlying insulin stimulation, no consensus exists presently for the mechanism by which insulin activates the Na+/K+-ATPase. We have investigated (i) the subunit isoforms expressed and (ii) the effect of insulin on the subcellular distribution of the alpha-beta isoforms of the Na+/K+-ATPase in plasma membranes (PM) and internal membranes (IM) from rat skeletal muscle. Western blot analysis, using isoform-specific antibodies to the various subunits of the Na+/K+-ATPase, revealed that skeletal muscle PM contains the alpha-1 and alpha-2 catalytic subunits and the beta-1 and beta-2 subunits of the Na+ pump. Skeletal muscle IM were enriched in alpha-2, beta-1, and beta-2; alpha-1 was barely detectable in this fraction. After insulin treatment, alpha-2 content in the PM increased, with a parallel decrease in its abundance in the IM pool; insulin did not have any effect on alpha-1 isoform amount or subcellular distribution. The beta-1 subunit, but not beta-2, was also elevated in the PM after insulin treatment, but this increase originated from a sucrose gradient fraction different from that of the alpha-2 subunit. Our findings suggest that insulin induces an isoform-specific translocation of Na+ pump subunits from different intracellular sources to the PM and that the hormone-responsive enzyme in rat skeletal muscle is an alpha-2:beta-1 dimer.	HOSP SICK CHILDREN, DIV CELL BIOL, 555 UNIV AVE, TORONTO M5G 1X8, ONTARIO, CANADA; MONTREAL GEN HOSP, RES INST, MONTREAL H3G 1A4, QUEBEC, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McGill University			Hundal, Hari/A-8990-2008; Marette, Andre/E-9342-2013	Hundal, Hari/0000-0002-7621-4932; 				AHMED A, 1990, AM J PHYSIOL, V259, pE284, DOI 10.1152/ajpendo.1990.259.2.E284; AZUMA KK, 1991, AM J PHYSIOL, V260, pC958, DOI 10.1152/ajpcell.1991.260.5.C958; BRODSKY JL, 1990, AM J PHYSIOL, V258, pC812, DOI 10.1152/ajpcell.1990.258.5.C812; CLAUSEN T, 1987, AM J PHYSIOL, V252, pE492, DOI 10.1152/ajpendo.1987.252.4.E492; CLAUSEN T, 1977, J PHYSIOL-LONDON, V265, P19, DOI 10.1113/jphysiol.1977.sp011703; DAVIS RJ, 1986, J BIOL CHEM, V261, P8708; DOUEN AG, 1989, ENDOCRINOLOGY, V124, P449, DOI 10.1210/endo-124-1-449; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; DOUEN AG, 1991, ENDOCRINOLOGY, V128, P611, DOI 10.1210/endo-128-1-611; ERLIJ D, 1976, J PHYSIOL-LONDON, V259, P13, DOI 10.1113/jphysiol.1976.sp011452; GAVRYCK WA, 1975, J PHYSIOL-LONDON, V252, P43, DOI 10.1113/jphysiol.1975.sp011133; GRINSTEIN S, 1974, NATURE, V251, P57, DOI 10.1038/251057a0; HIRSHMAN MF, 1990, J BIOL CHEM, V265, P987; HORISBERGER JD, 1991, ANNU REV PHYSIOL, V53, P565, DOI 10.1146/annurev.physiol.53.1.565; HUNDAL HS, 1991, CLIN NUTR, V10, P33, DOI 10.1016/0261-5614(91)90112-P; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; KAWAMURA M, 1991, SOC GEN PHY, V46, P45; KLIP A, 1990, DIABETES CARE, V13, P228, DOI 10.2337/diacare.13.3.228; KLIP A, 1986, AM J PHYSIOL, V250, pC720, DOI 10.1152/ajpcell.1986.250.5.C720; KLIP A, 1987, FEBS LETT, V224, P224, DOI 10.1016/0014-5793(87)80452-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LYTTON J, 1985, J BIOL CHEM, V260, P75; MARETTE A, 1992, IN PRESS DIABETES ME; MITSUMOTO Y, 1991, BIOCHEM BIOPH RES CO, V175, P652, DOI 10.1016/0006-291X(91)91615-J; MOORE RD, 1983, BIOCHIM BIOPHYS ACTA, V737, P1, DOI 10.1016/0304-4157(83)90013-8; OMATSUKANBE M, 1990, BIOCHEM J, V272, P727, DOI 10.1042/bj2720727; RENNIE MJ, 1985, CARRIER MEDIATED TRA, P333; RESH MD, 1980, J BIOL CHEM, V255, P938; ROSIC NK, 1985, J BIOL CHEM, V260, P6206; SHOTWELL MA, 1983, BIOCHIM BIOPHYS ACTA, V737, P267, DOI 10.1016/0304-4157(83)90003-5; SHYJAN AW, 1989, BIOCHEMISTRY-US, V28, P4531, DOI 10.1021/bi00437a002; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; WALKER PS, 1990, J BIOL CHEM, V265, P1516; WARDZALA LJ, 1984, J BIOL CHEM, V259, P8378; WEIL E, 1991, AM J PHYSIOL, V261, pC224, DOI 10.1152/ajpcell.1991.261.2.C224	36	231	235	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5040	5043						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1312081				2022-12-27	WOS:A1992HH74700007
J	TAKABATAKE, T; HASEGAWA, M; NAGANO, T; HIROBE, M				TAKABATAKE, T; HASEGAWA, M; NAGANO, T; HIROBE, M			DIFFERENCE IN SUPEROXIDE TOXICITY BETWEEN 4,7-DICYANOBENZOFURAZAN AND PARAQUAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DIOXATHIADIAZA-HETEROPENTALENES; HYDROGEN-PEROXIDE; DISMUTASE MIMICS; PHOSGENE DIMER; OXYGEN; MUTAGENICITY; ENHANCEMENT; EPOXIDATION; INDUCTION	The O2 radical-anion production by aerobically cultured Escherichia coli in the presence of benzofurazan (1), 4,7-dimethylbenzofurazan (2), 4,7-dibromobenzofurazan (3), 4-bromo-6-cyanobenzofurazan (4), and 4,7-dicyanobenzofurazan (5) was examined by using the cytochrome c reduction method in order to elucidate the mechanism of cytotoxicity of benzofurazans. Adding compound 5 to E. coli cell suspension caused cytochrome c reduction, which was completely inhibited by superoxide dismutase. The rate of cytochrome c reduction was in the order of 1 = 2 = 3 < 4 < 5, which correlates well with that of the reduction potentials of these benzofurazans. Adding glucose to the E. coli cell suspension-compound 5-cytochrome c system accelerated the rate of cytochrome c reduction. The formation of 4,7-dicyanobenzofurazan anion radical in the cell suspension-compound 5-glucose system in the absence of O2 was followed by ESR spectroscopy. The ESR signal of the anion radical disappeared when O2 was added. Compound 5 was shown to have an approximately 10-fold greater increasing effect on the flux of O2 radical-anion by E. coli than paraquat (PQ) by the cytochrome c reduction method. The results were confirmed by the electrochemical method with an oxygen electrode. However, compound 5 had a bacteriostatic, but not lethal, effect, while PQ had both effects. The effect of compound 5 and PQ on lethality of E. coli showed a dramatic difference when E. coli was exposed to these two compounds and washed prior to testing the effects of that exposure. This difference probably arose because compound 5 readily leaked from the cells during dilution and plating. Also, the reduced form of compound 5 exits from the cells more readily than the reduced form of PQ and then generates O2 radical-anion in the medium by autoxidation. This suggests the importance of the intracellular production of O2 radical-anion, rather than the extracellular production of O2 radical-anion, for lethal effect.	UNIV TOKYO, FAC PHARMACEUT SCI, HONGO, BUNKYO KU, TOKYO 113, JAPAN; NIHON UNIV, COLL PHARM, FUNABASHI, CHIBA 274, JAPAN	University of Tokyo; Nihon University								BULTER J, 1975, BIOCHIM BIOPHYS ACTA, V488, P215; CAMILLERI P, 1985, BIOCHIM BIOPHYS ACTA, V810, P385, DOI 10.1016/0005-2728(85)90225-7; CAMILLERI P, 1984, BIOCHIM BIOPHYS ACTA, V765, P236, DOI 10.1016/0005-2728(84)90018-5; CAMILLERI P, 1986, J CHEM SOC PERK T 2, P569, DOI 10.1039/p29860000569; CERE V, 1972, TETRAHEDRON, V28, P3271, DOI 10.1016/S0040-4020(01)93668-3; CHESIS PL, 1984, P NATL ACAD SCI-BIOL, V81, P1696, DOI 10.1073/pnas.81.6.1696; FARR SB, 1985, J BACTERIOL, V164, P1309, DOI 10.1128/JB.164.3.1309-1316.1985; GAUGHRAN RJ, 1954, J AM CHEM SOC, V76, P2233, DOI 10.1021/ja01637a063; HALLIWELL B, 1986, FREE RADICAL BIO MED, P206; HASEGAWA M, 1985, SYNTHESIS-STUTTGART, P938; HASEGAWA M, 1991, J HETEROCYCLIC CHEM, V28, P1079, DOI 10.1002/jhet.5570280441; HASSAN HM, 1979, J BIOL CHEM, V254, P846; HASSAN HM, 1978, J BIOL CHEM, V253, P8143; HASSAN HM, 1977, J BIOL CHEM, V252, P7667; HASSAN HM, 1979, ARCH BIOCHEM BIOPHYS, V196, P385, DOI 10.1016/0003-9861(79)90289-3; INOUE H, 1987, J PHARMACOBIO-DYNAM, V10, pS19; INOUE H, 1984, TETRAHEDRON LETT, V25, P317, DOI 10.1016/S0040-4039(00)99872-1; KATORI E, 1981, CHEM PHARM BULL, V29, P3075; KITZLER J, 1986, J BACTERIOL, V167, P346, DOI 10.1128/jb.167.1.346-349.1986; KITZLER JW, 1990, J BACTERIOL, V172, P686, DOI 10.1128/jb.172.2.686-690.1990; KLUG D, 1972, J BIOL CHEM, V247, P4839; KORBASHI P, 1986, J BIOL CHEM, V261, P2472; MARKLUND S, 1976, J BIOL CHEM, V251, P7504; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MINAKAMI H, 1990, FASEB J, V4, P3239, DOI 10.1096/fasebj.4.14.2172063; MINAKAMI H, 1990, J BACTERIOL, V172, P691, DOI 10.1128/jb.172.2.691-695.1990; MINAKAMI H, 1990, FREE RADICAL BIO MED, V8, P387, DOI 10.1016/0891-5849(90)90105-R; MOJE W, 1964, J ORG CHEM, V29, P3722, DOI 10.1021/jo01035a523; NAGANO T, 1983, TETRAHEDRON LETT, V24, P3481, DOI 10.1016/S0040-4039(00)86018-9; NAGANO T, 1984, TETRAHEDRON LETT, V25, P965, DOI 10.1016/S0040-4039(01)80075-7; NAGANO T, 1980, TETRAHEDRON LETT, V21, P5021, DOI 10.1016/S0040-4039(00)71121-X; NAGANO T, 1989, J SYN ORG CHEM JPN, V47, P843, DOI 10.5059/yukigoseikyokaishi.47.843; NAGANO T, 1980, CHEM PHARM BULL, V28, P3719; NAGANO T, 1989, J BIOL CHEM, V264, P9243; NAGANO T, 1991, FREE RADICAL RES COM, V12-3, P221, DOI 10.3109/10715769109145790; NAGANO T, 1990, J AM CHEM SOC, V112, P3529, DOI 10.1021/ja00165a042; PILGRAM K, 1974, J HETEROCYCLIC CHEM, V11, P813, DOI 10.1002/jhet.5570110529; TAKABATAKE T, 1987, J HETEROCYCLIC CHEM, V24, P529, DOI 10.1002/jhet.5570240245; TAKABATAKE T, 1990, CHEM PHARM BULL, V38, P128; TAKAHASHI M, 1989, ARCH BIOCHEM BIOPHYS, V268, P137, DOI 10.1016/0003-9861(89)90574-2; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; YAMAMOTO H, 1988, J BIOL CHEM, V263, P12224; YAMAMOTO H, 1986, J AM CHEM SOC, V108, P539, DOI 10.1021/ja00263a048; YAMANE H, 1987, BIOCHEM BIOPH RES CO, V142, P1104, DOI 10.1016/0006-291X(87)91529-4	44	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4613	4618						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1311315				2022-12-27	WOS:A1992HF64200052
J	KELLY, KL; RUDERMAN, NB; CHEN, KS				KELLY, KL; RUDERMAN, NB; CHEN, KS			PHOSPHATIDYLINOSITOL-3-KINASE IN ISOLATED RAT ADIPOCYTES - ACTIVATION BY INSULIN AND SUBCELLULAR-DISTRIBUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; KINASE-ACTIVITY; FAT-CELLS; GLUCOSE TRANSPORTERS; ADIPOSE-CELLS; TRANSLOCATION; PROTEIN; PHOSPHORYLATION; TRANSFORMATION; MECHANISM	Insulin increases phosphatidylinositol-3-kinase (PI-3-kinase) activity in Chinese hamster ovary cells transfected with human insulin receptor (Ruderman, N. B., Kapeller, R., White, M. F., and Cantley, L. C. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 1411-1415). The subcellular distribution of PI-3-kinase has not been investigated, and it is unclear if insulin has a stimulatory effect on PI-3-kinase in a nonproliferating target tissue, and, if so, whether this effect is subject to counter-regulation. To address these questions, we studied the effect of insulin on PI-3-kinase activity in isolated rat adipocytes. Activity was measured in plasma membranes, intracellular membranes, and cytosol of control and insulin-treated adipocytes, and in anti-Tyr(P) immunoprecipitates prepared from these fractions and from whole cell lysates. Treatment of adipocytes with insulin (200 nM) caused a half-maximal increase in anti-Tyr(P)-immunoprecipitable PI-3-kinase activity in whole cell lysates within 2 min. This effect was concentration-dependent, and it was sensitive to inhibition by norepinephrine. In insulin-stimulated cells, 75% of anti-Tyr(P)-immunoprecipitable PI-3-kinase activity was found in the low density microsomes. This fraction also exhibited the highest specific activity of PI-3-kinase, and insulin caused a further increase in this activity. Anti-Tyr(P)-immunoprecipitable PI-3-kinase activity was also found in the plasma membranes of insulin-treated cells, but this accounted for only a minor portion of the total and anti-Tyr(P)-immunoprecipitable PI-3-kinase activity. The majority of PI-3-kinase activity (90%) in control cells was cytosolic, but this was not increased in response to insulin nor was it anti-Tyr(P)-immunoprecipitable. These data demonstrate that insulin increases the activity of PI-3-kinase in adipocytes and this effect is subject to inhibition by a physiological antagonist of insulin action. The data also indicate that the effect of insulin to increase PI-3-kinase activity is expressed primarily in the low density intracellular membranes and to a lesser extent in the plasma membranes.			KELLY, KL (corresponding author), BOSTON UNIV,MED CTR,DIV DIABET & METAB,BOSTON,MA 02118, USA.			Ruderman, Neil/0000-0002-6589-6587	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042621] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42621] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVRUCH J, 1971, BIOCHIM BIOPHYS ACTA, V233, P334, DOI 10.1016/0005-2736(71)90331-2; BLOK J, 1988, J CELL BIOL, V106, P69, DOI 10.1083/jcb.106.1.69; CANTLEY LC, 1991, CELL, V64, P271; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DELVECCHIO RL, 1989, BIOCHIM BIOPHYS ACTA, V986, P41, DOI 10.1016/0005-2736(89)90270-8; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; Fleischer B, 1974, Methods Enzymol, V31, P180; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; HEDO JA, 1984, J BIOL CHEM, V259, P1083; HESS HH, 1975, ANAL BIOCHEM, V63, P607, DOI 10.1016/0003-2697(75)90388-7; JAMES DE, 1989, P NATL ACAD SCI USA, V86, P8368, DOI 10.1073/pnas.86.21.8368; KAPELLER R, 1991, MOL ENDOCRINOL, V5, P769, DOI 10.1210/mend-5-6-769; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KELLY KL, 1989, J BIOL CHEM, V264, P12754; KLEIN HH, 1991, BIOCHEM J, V274, P787, DOI 10.1042/bj2740787; KLEIN HH, 1986, J BIOL CHEM, V262, P10557; KONO T, 1982, J BIOL CHEM, V257, P942; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; MCKEEL DW, 1970, J CELL BIOL, V44, P417, DOI 10.1083/jcb.44.2.417; Nordlie R.C., 1976, ENZYMES BIOLOGICAL M, V2, P465; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SOORANNA SR, 1978, FEBS LETT, V90, P141, DOI 10.1016/0014-5793(78)80316-0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; VANNIER C, 1985, J BIOL CHEM, V260, P4424; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0	32	137	138	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3423	3428						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1310686				2022-12-27	WOS:A1992HD15400093
J	WILLE, M; JUST, I; WEGNER, A; AKTORIES, K				WILLE, M; JUST, I; WEGNER, A; AKTORIES, K			ADP-RIBOSYLATION OF GELSOLIN-ACTIN COMPLEXES BY CLOSTRIDIAL TOXINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFRINGENS-IOTA TOXIN; BOTULINUM C2 TOXIN; PLASMA-GELSOLIN; SKELETAL-MUSCLE; BINDING-SITES; FILAMENT LENGTH; HUMAN-PLATELETS; CYTOCHALASIN-D; CA-2+ CONTROL; BARBED ENDS	ADP-ribosylation of the 1:1 (G-A) and 1:2 (G-A-A) gelsolin-actin complexes by Clostridium perfringens iota toxin and Clostridium botulinum C2 toxin was studied. Iota toxin ADP-ribosylated actin in the G-A complex from human platelets as effectively as skeletal muscle actin. The K(m) for NAD (4-mu-M) was identical for both substrates. C2 toxin ADP-ribosylated actin in the G-A complex with lower efficacy than nonmuscle actin from platelet cytosol. In the G-A-A complex both actin molecules were ADP-ribosylated by iota toxin. The G-A complex bound ADP-ribosylated actin (A(r)) to form the G-A-A(r) complex in which the weakly bound actin is ADP-ribosylated. Vice versa, ADP-ribosylated 1:1 gelsolin-actin complex (G-A(r)) was able to bind unmodified actin to yield the G-A(r)-A complex. ADP-ribosylation did not change the nucleation activity of either the G-Ar complex or the G-A(r)-A complex. When monomeric actin was added to the G-A-A(r) complex, polymerization of actin was delayed by about 10 min. According to a quantitative kinetic analysis, the delay of polymerization corresponded to the ra te of dissociation of ADP-ribosylated actin from the G-A-A(r) complex. This suggests that the nucleation activity of the G-A-A complex is inhibited by ADP-ribosylation of the weakly bound actin and that the inhibition can be removed by dissociation of ADP-ribosylated actin from the G-A-A(r) complex.	UNIV SAARLAND,INST PHARMACOL & TOXIKOL,BAU 46,W-6650 HOMBURG,GERMANY; UNIV GIESSEN,RUDOLF BUCHHEIM INST PHARMAKOL,W-6300 GIESSEN,GERMANY; RUHR UNIV BOCHUM,INST PHYSIOL CHEM,W-4630 BOCHUM,GERMANY	Saarland University; Justus Liebig University Giessen; Ruhr University Bochum			Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436				AKTORIES K, 1989, TOXICON, V27, P989, DOI 10.1016/0041-0101(89)90149-9; AKTORIES K, 1986, EUR J BIOCHEM, V161, P155, DOI 10.1111/j.1432-1033.1986.tb10136.x; AKTORIES K, 1989, J CELL BIOL, V109, P1385, DOI 10.1083/jcb.109.4.1385; AKTORIES K, 1986, NATURE, V322, P390, DOI 10.1038/322390a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYAN J, 1984, J BIOL CHEM, V259, P7480; BRYAN J, 1988, J CELL BIOL, V106, P1553, DOI 10.1083/jcb.106.5.1553; CHAPONNIER C, 1986, J CELL BIOL, V103, P1473, DOI 10.1083/jcb.103.4.1473; COUE M, 1985, J BIOL CHEM, V260, P5033; DETMERS P, 1981, J BIOL CHEM, V256, P99; GEIPEL U, 1989, EUR J BIOCHEM, V179, P229, DOI 10.1111/j.1432-1033.1989.tb14545.x; GEIPEL U, 1990, BIOCHEM J, V266, P335, DOI 10.1042/bj2660335; HARRIS GLA, 1973, BIOCHIM BIOPHYS ACTA, V291, P701, DOI 10.1016/0005-2736(73)90475-6; HARRIS HE, 1985, FEBS LETT, V190, P81, DOI 10.1016/0014-5793(85)80432-4; HARRIS HE, 1983, BIOCHEMISTRY-US, V22, P2728, DOI 10.1021/bi00280a022; HARRIS HE, 1984, FEBS LETT, V177, P184, DOI 10.1016/0014-5793(84)81280-6; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HOUMEIDA A, 1991, BIOCHEM J, V274, P753, DOI 10.1042/bj2740753; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JANMEY PA, 1985, BIOCHEMISTRY-US, V24, P3714, DOI 10.1021/bi00335a046; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KURTH MC, 1983, J BIOL CHEM, V258, P895; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIND SE, 1982, J CLIN INVEST, V69, P1384, DOI 10.1172/JCI110578; MAUSS S, 1990, EUR J BIOCHEM, V194, P237, DOI 10.1111/j.1432-1033.1990.tb19448.x; OHISHI I, 1980, INFECT IMMUN, V30, P668; POPE B, 1991, FEBS LETT, V280, P70, DOI 10.1016/0014-5793(91)80206-I; PORTE F, 1986, EUR J BIOCHEM, V154, P87, DOI 10.1111/j.1432-1033.1986.tb09362.x; REUNER KH, 1987, EUR J CELL BIOL, V43, P134; SCHERING B, 1988, EUR J BIOCHEM, V171, P225, DOI 10.1111/j.1432-1033.1988.tb13780.x; SELVE N, 1986, J MOL BIOL, V187, P627, DOI 10.1016/0022-2836(86)90341-4; SELVE N, 1986, EUR J BIOCHEM, V160, P379, DOI 10.1111/j.1432-1033.1986.tb09982.x; SELVE N, 1987, EUR J BIOCHEM, V168, P111, DOI 10.1111/j.1432-1033.1987.tb13394.x; SIMPSON LL, 1987, INFECT IMMUN, V55, P118, DOI 10.1128/IAI.55.1.118-122.1987; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STILES BG, 1986, INFECT IMMUN, V54, P683, DOI 10.1128/IAI.54.3.683-688.1986; SUTOH K, 1989, BIOCHEMISTRY-US, V28, P5269, DOI 10.1021/bi00438a052; TELLAM R, 1982, BIOCHEMISTRY-US, V21, P3207, DOI 10.1021/bi00256a027; TELLAM RL, 1986, BIOCHEMISTRY-US, V25, P5799, DOI 10.1021/bi00367a068; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDEKERCKHOVE J, 1987, FEBS LETT, V225, P48, DOI 10.1016/0014-5793(87)81129-8; VANDEKERCKHOVE J, 1988, J BIOL CHEM, V263, P696; WAY M, 1989, J CELL BIOL, V109, P593, DOI 10.1083/jcb.109.2.593; WEGNER A, 1988, J BIOL CHEM, V263, P13739; WEGNER A, 1976, J MOL BIOL, V108, P139, DOI 10.1016/S0022-2836(76)80100-3; WEIGT C, 1989, FEBS LETT, V246, P181, DOI 10.1016/0014-5793(89)80279-0; YIN HL, 1988, J CELL BIOL, V106, P805, DOI 10.1083/jcb.106.3.805; YIN HL, 1980, J BIOL CHEM, V255, P9494; YIN HL, 1981, J BIOL CHEM, V256, P9693	50	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					50	55						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1309748				2022-12-27	WOS:A1992GY43900013
J	HARTMAN, DS; MCCORMACK, M; SCHUBENEL, R; HERTEL, C				HARTMAN, DS; MCCORMACK, M; SCHUBENEL, R; HERTEL, C			MULTIPLE TRKA PROTEINS IN PC12 CELLS BIND NGF WITH A SLOW ASSOCIATION RATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; HIGH-AFFINITY RECEPTORS; NEUROTROPHIC FACTOR; PHEOCHROMOCYTOMA CELLS; MOLECULAR-CLONING; PROTO-ONCOGENE; GENE-TRANSFER; PHOSPHORYLATION; PROTOONCOGENE	Rat pheochromocytoma (PC12) cells express two distinct nerve growth factor receptors (NGFRs), p75NGFR and trkA (p140trk). In addition to these receptors, by using I-125-mNGF affinity labeling and BS3 chemical cross-linking of PC12 cell protein, we have identified two additional trkA protein bands with apparent molecular weights of 220,000 and 300,000. These bands contain trkA, but were not immunoprecipitated by p75NGFR-specific antisera, suggesting that they do not represent trkA/p75NGFR protein complexes. The 220-kDa trkA band apparently represents trkA with alternate post-translational modification. The appearance of the 300-kDa trkA band was dependent on cross-linker concentration and could be diminished in the presence of reducing agents, suggesting that it represents a trkA dimer. All trkA bands were phosphorylated on tyrosine residues when bound to mNGF, suggesting that they participate in NGF-induced signal transduction. NGF binding kinetics to all three trkA bands were indistinguishable, with slow dissociation rates, and a slow association rate that required approximately 1 h to reach equilibrium levels at 4-degrees-C. All three trkA bands bound the related neurotrophin brain-derived neurotrophic factor and neurotrophin-3 with a profile characteristic of trkA.	F HOFFMANN LA ROCHE & CO LTD,DIV PHARMA,CH-4002 BASEL,SWITZERLAND	Roche Holding								BERG MM, 1991, P NATL ACAD SCI USA, V88, P7106, DOI 10.1073/pnas.88.16.7106; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BERND P, 1984, J BIOL CHEM, V259, P5509; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DANIELIAN S, 1989, EUR J IMMUNOL, V19, P2183, DOI 10.1002/eji.1830191202; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GROB PM, 1983, P NATL ACAD SCI-BIOL, V80, P6819, DOI 10.1073/pnas.80.22.6819; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HOSANG M, 1985, J BIOL CHEM, V260, P655; HURLEY TR, 1989, SCIENCE, V245, P407, DOI 10.1126/science.2787934; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LANDRETH GE, 1980, P NATL ACAD SCI-BIOL, V77, P4751, DOI 10.1073/pnas.77.8.4751; LONGO FM, 1989, NERVE GROWTH FACTORS, P3; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; MORI S, 1992, J BIOL CHEM, V267, P6429; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; SCHECHTER AL, 1981, CELL, V24, P867, DOI 10.1016/0092-8674(81)90112-4; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; SUTTER A, 1979, J BIOL CHEM, V254, P5972; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALE RD, 1982, J CELL BIOL, V94, P710, DOI 10.1083/jcb.94.3.710; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; ZIEMIECKI A, 1990, EMBO J, V9, P191, DOI 10.1002/j.1460-2075.1990.tb08095.x	41	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24516	24522						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1280261				2022-12-27	WOS:A1992KA26300057
J	FARMER, K; CATALA, F; WRIGHT, WE				FARMER, K; CATALA, F; WRIGHT, WE			ALTERNATIVE MULTIMERIC STRUCTURES AFFECT MYOGENIN DNA-BINDING ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE FAMILY; MYOD; ENHANCER; IDENTIFICATION; EXPRESSION; PROTEINS; MEMBER; FIBROBLASTS; HOMOLOGY; DISTINCT	The native molecular weight of the basic helix-loop-helix (bHLH) proteins myogenin, MyoD, and E12 was calculated from their mobilities on sucrose gradients and molecular sieve chromatography. The muscle bHLH proteins associate to form a variety of higher order complexes, most of which are larger than dimers. Homodimers bind to DNA sequences such as the MEF-1 site in the creatine kinase enhancer whereas homotetramers and larger forms do not recognize this DNA sequence. The ubiquitous bHLH protein E12 forms monomers or homodimers with little evidence for higher order complexes. Mixtures of myogenin and E12 show some heterodimeric structures, but most of the myogenin remains in large complexes. This result using purified proteins is also obtained in nuclear extracts from differentiated myotubes, in which most of the myogenin is present in large complexes that do not bind to the creatine kinase enhancer. A fusion protein containing only the myogenin HLH region forms large homomeric complexes. A model is presented in which each helix associates with a different subunit to form chains or ring structures to explain these observations. The partition of myogenin in nuclear extracts into dimers that recognize known DNA sequences and higher order complexes that do not raises important new issues concerning the regulation of skeletal muscle bHLH protein activity during myogenesis.	UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,5323 HARRY HINES BLVD,DALLAS,TX 75235; INST PASTEUR,DEPT BIOL MOLEC,F-75724 PARIS,FRANCE	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris					NATIONAL INSTITUTE ON AGING [R01AG001228, R37AG001228] Funding Source: NIH RePORTER; NIA NIH HHS [AG01228] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; BRAUN T, 1991, EUR J BIOCHEM, V198, P187, DOI 10.1111/j.1432-1033.1991.tb16000.x; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; COOPER TG, 1977, TOOLS BIOCH, P169; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OTT MO, 1991, DEVELOPMENT, V111, P1097; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104	29	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5631	5636						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1312093				2022-12-27	WOS:A1992HH74700094
J	STAMELLOS, KD; SHACKELFORD, JE; TANAKA, RD; KRISANS, SK				STAMELLOS, KD; SHACKELFORD, JE; TANAKA, RD; KRISANS, SK			MEVALONATE KINASE IS LOCALIZED IN RAT-LIVER PEROXISOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL CARRIER PROTEIN-2; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE; CHOLESTEROL-SYNTHESIS; ACID; BIOSYNTHESIS; HEPATOCYTES; ENZYMES; PURIFICATION; MICROSOMES; ZELLWEGER	Recent data suggest that rat liver peroxisomes play a critical role in cholesterol synthesis. Specifically, peroxisomes contain a number of enzymes required for cholesterol synthesis as well as sterol carrier protein-2. Furthermore, peroxisomes are involved in the in vitro synthesis of cholesterol from mevalonate and contain significant levels of apolipoprotein E, a major constituent of several classes of plasma lipoproteins. In this study we have investigated the subcellular localization of mevalonate kinase (EC 2.7.1.36; ATP:mevalonate-5-phosphotransferase). Mevalonate kinase is believed to be a cytosolic enzyme and catalyzes the phosphorylation of mevalonate to form mevalonate 5-phosphate. Mevalonate kinase has been purified from rat liver cytosol and a cDNA clone coding for rat mevalonate kinase has also been isolated and characterized. In this study, utilizing monoclonal antibodies made against the purified rat mevalonate kinase, we demonstrate the presence of mevalonate kinase in rat liver peroxisomes and in the cytosol. Each of these compartments contained a different form of the protein. The pI and the M(r) of the peroxisomal protein is 6.2 and 42,000, respectively. The pI and M(r) of the cytosolic protein is 6.9 and 40,000, respectively. The peroxisomal protein was also significantly induced by a number of different hypolipidemic drugs. In addition, we present evidence for the unexpected finding that the purified mevalonate kinase (isolated from the cytosol and assumed to be a cytosolic protein) is actually a peroxisomal protein.	SAN DIEGO STATE UNIV, DEPT BIOL, SAN DIEGO, CA 92182 USA; SQUIBB INST MED RES, DEPT METAB DIS, PRINCETON, NJ 08543 USA	California State University System; San Diego State University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044350] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 44350] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXSON SEH, 1985, J CELL BIOL, V101, P294, DOI 10.1083/jcb.101.1.294; APPELKVIST EL, 1989, EUR J BIOCHEM, V185, P503, DOI 10.1111/j.1432-1033.1989.tb15142.x; APPELKVIST EL, 1990, ARCH BIOCHEM BIOPHYS, V282, P318, DOI 10.1016/0003-9861(90)90123-G; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BEIER K, 1988, EUR J CELL BIOL, V46, P383; Bergmeyer HU, 1974, METHODS ENZYME ANAL, P495; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; GORGAS K, 1989, J LIPID RES, V30, P1859; GOULD SJ, 1990, J CELL BIOL, V110, P27, DOI 10.1083/jcb.110.1.27; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HAYASHI H, 1981, EUR J BIOCHEM, V120, P47, DOI 10.1111/j.1432-1033.1981.tb05668.x; KASE BF, 1985, J CLIN INVEST, V75, P427, DOI 10.1172/JCI111717; KASE BF, 1985, J CLIN INVEST, V76, P2393, DOI 10.1172/JCI112252; KASE F, 1983, J LIPID RES, V24, P1560; KELLER GA, 1986, J CELL BIOL, V103, P875, DOI 10.1083/jcb.103.3.875; KELLER GA, 1989, J CELL BIOL, V108, P1353, DOI 10.1083/jcb.108.4.1353; KELLER GA, 1985, P NATL ACAD SCI USA, V82, P770, DOI 10.1073/pnas.82.3.770; KENNETT RH, 1980, MONOCLONAL ANTIBODIE, P365; KRISANS SK, 1985, J LIPID RES, V26, P1324; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NESS GC, 1982, ARC BIOCH BIOPHYS, V282, P318; NOLAND BJ, 1980, J BIOL CHEM, V255, P4282; NOLTMANN EA, 1966, METHOD ENZYMOL, V9, P557; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PARKER RA, 1989, J BIOL CHEM, V264, P4877; POPJAK G, 1969, METHOD ENZYMOL, V15, P393; PORTER JW, 1985, METHOD ENZYMOL, V110, P71; PRYDZ K, 1986, J LIPID RES, V27, P622; REBUFFAT P, 1988, EXP PATHOL-JENA, V35, P133, DOI 10.1016/S0232-1513(88)80139-7; REDDY JK, 1982, ANN NY ACAD SCI, V386, P81, DOI 10.1111/j.1749-6632.1982.tb21409.x; RUSNAK N, 1987, BIOCHEM BIOPH RES CO, V148, P890, DOI 10.1016/0006-291X(87)90959-4; SCHMIDT E, 1974, METHOD ENZYMAT AN, V2, P650; SMALL GM, 1988, ANAL BIOCHEM, V169, P405, DOI 10.1016/0003-2697(88)90304-1; SUZUKI Y, 1990, CELL STRUCT FUNCT, V15, P301, DOI 10.1247/csf.15.301; TANAKA RD, 1990, J BIOL CHEM, V265, P2391; TANAKA RD, 1990, P NATL ACAD SCI USA, V87, P2872, DOI 10.1073/pnas.87.8.2872; THOMPSON SL, 1987, J BIOL CHEM, V262, P17420; THOMPSON SL, 1990, J BIOL CHEM, V265, P5731	42	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5560	5568						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1312092				2022-12-27	WOS:A1992HH74700084
J	JAMIL, H; UTAL, AK; VANCE, DE				JAMIL, H; UTAL, AK; VANCE, DE			EVIDENCE THAT CYCLIC AMP-INDUCED INHIBITION OF PHOSPHATIDYLCHOLINE BIOSYNTHESIS IS CAUSED BY A DECREASE IN CELLULAR DIACYLGLYCEROL LEVELS IN CULTURED RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; ACETYL-COA CARBOXYLASE; CHOLINE-PHOSPHATE CYTIDYLYLTRANSFERASE; DEPENDENT PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; FATTY-ACID SYNTHESIS; HELA-CELLS; ENDOPLASMIC-RETICULUM; SUBCELLULAR-DISTRIBUTION; II PNEUMOCYTES	The mechanism by which glucagon and cAMP analogues inhibit phosphatidylcholine biosynthesis was investigated in rat hepatocytes. The studies were facilitated by preparation of an antibody to a synthetic peptide (D-F-V-A-H-D-D-I-P-Y-S-S-A) corresponding to residues 164-176 of CTP:phosphocholine cytidylyltransferase. The antibody, which was purified by affinity chromatography, quantitatively immunoprecipitated cytidylyltransferase from rat liver cytosol. Various analogues of cAMP had no effect on the labeling of cytidylyltransferase with P-32(i) in rat hepatocytes. Nor did the cAMP analogues have any effect on the distribution of cytidylyltransferase between cytosol and membranes. These results indicate that the supply of CDP-choline does not limit phosphatidylcholine biosynthesis in hepatocytes treated with cAMP analogues. A decreased supply of diacylglycerol was considered as an alternative mechanism for inhibition of phosphatidylcholine biosynthesis. An approximately 30% decrease in diacylglycerol concentration was observed in hepatocytes treated with the cAMP analogues or glucagon, compared with controls. A similar decrease of phosphatidylcholine biosynthesis was observed. The cAMP-mediated decrease in diacylglycerol levels and inhibition of phosphatidylcholine biosynthesis were reversed by addition of 0.5-1.5 mM oleic acid to the treated hepatocytes. A correlation coefficient of 0.93 was calculated between the levels of diacylglycerol and the rate of phosphatidylcholine biosynthesis. In another approach, the diacylglycerol levels were increased by an inhibitor of diacylglycerol lipase (U-57908) which also reversed the cAMP effects on diacylglycerol levels and phosphatidylcholine biosynthesis. We conclude that the cAMP-mediated inhibition of phosphatidylcholine biosynthesis was not due to an effect on the phosphorylation of cytidylyltransferase. Instead, phosphatidylcholine biosynthesis appears to be inhibited due to a decreased level of diacylglycerol, a substrate for CDP-choline:1,2-diacylglycerol cholinephosphotransferase.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2S2,ALBERTA,CANADA	University of Alberta	JAMIL, H (corresponding author), UNIV ALBERTA,LIPID & LIPOPROT RES GRP,EDMONTON T6G 2S2,ALBERTA,CANADA.							AEBERHARD EE, 1986, BIOCHIM BIOPHYS ACTA, V875, P6, DOI 10.1016/0005-2760(86)90004-4; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BURKHARDT R, 1988, BIOCHEM J, V254, P495, DOI 10.1042/bj2540495; BUTTERWITH SC, 1984, BIOCHEM J, V222, P487, DOI 10.1042/bj2220487; CHANDER A, 1988, BIOCHIM BIOPHYS ACTA, V958, P343, DOI 10.1016/0005-2760(88)90219-6; CHANG JP, 1988, J BIOL CHEM, V263, P18614; CHOY PC, 1979, CAN J BIOCHEM CELL B, V57, P605, DOI 10.1139/o79-076; CORNELL R, 1987, BIOCHIM BIOPHYS ACTA, V919, P26, DOI 10.1016/0005-2760(87)90214-1; DAVIS RA, 1979, J BIOL CHEM, V254, P2010; HARLOW E, 1988, ANTIBODIES LABORATOR; HATCH GM, 1990, BIOCHIM BIOPHYS ACTA, V1042, P374, DOI 10.1016/0005-2760(90)90167-V; HATCH GM, 1991, BIOCHIM BIOPHYS ACTA, V1081, P25, DOI 10.1016/0005-2760(91)90245-D; HAYSTEAD TAJ, 1988, EUR J BIOCHEM, V175, P339, DOI 10.1111/j.1432-1033.1988.tb14202.x; HOLLAND R, 1984, EUR J BIOCHEM, V140, P325, DOI 10.1111/j.1432-1033.1984.tb08105.x; IWASHITA S, 1990, J BIOL CHEM, V265, P10702; JAMIL H, 1990, J BIOL CHEM, V265, P4332; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; KIM KH, 1989, FASEB J, V3, P2250, DOI 10.1096/fasebj.3.11.2570725; KOLESNICK RN, 1990, J BIOL CHEM, V265, P10900; KOLESNICK RN, 1990, BIOCHEM J, V267, P17, DOI 10.1042/bj2670017; LIM P, 1986, BIOCHEM CELL BIOL, V64, P692, DOI 10.1139/o86-095; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PELECH SL, 1983, J BIOL CHEM, V258, P6782; PELECH SL, 1981, J BIOL CHEM, V256, P8283; PELECH SL, 1983, BIOCHEM J, V216, P129, DOI 10.1042/bj2160129; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V779, P217, DOI 10.1016/0304-4157(84)90010-8; PELECH SL, 1984, CAN J BIOCHEM CELL B, V62, P196, DOI 10.1139/o84-028; PREISS J, 1986, J BIOL CHEM, V261, P8597; PRITCHARD PH, 1981, BIOCHEM J, V196, P261, DOI 10.1042/bj1960261; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SANGHERA JS, 1989, J BIOL CHEM, V264, P1215; SLEIGHT R, 1983, J BIOL CHEM, V258, P824; SUNDLER R, 1975, J BIOL CHEM, V250, P3359; SUTHERLAND CA, 1982, J BIOL CHEM, V257, P4006; TERCE F, 1988, J BIOL CHEM, V263, P3142; TIJBURG LBM, 1989, BIOCHEM J, V257, P645, DOI 10.1042/bj2570645; TYAGI SR, 1991, J BIOL CHEM, V266, P3498; UTAL AK, 1991, J BIOL CHEM, V266, P24084; Vance D E, 1981, Methods Enzymol, V71 Pt C, P576; VANCE DE, 1980, J BIOL CHEM, V255, P1064; VANCE DE, 1989, PHOSPHATIDYLCHOLINE, P225; WATKINS JD, 1990, J BIOL CHEM, V265, P2190; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; WEINHOLD PA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P299, DOI 10.1016/0005-2760(89)90017-9; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374; YAO ZM, 1990, J BIOL CHEM, V265, P4326	46	86	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1752	1760						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1309795				2022-12-27	WOS:A1992HA48500056
J	HOGG, PJ; OHLIN, AK; STENFLO, J				HOGG, PJ; OHLIN, AK; STENFLO, J			IDENTIFICATION OF STRUCTURAL DOMAINS IN PROTEIN-C INVOLVED IN ITS INTERACTION WITH THROMBIN-THROMBOMODULIN ON THE SURFACE OF ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GAMMA-CARBOXYGLUTAMIC ACID; PROTEOLYTIC FORMATION; CALCIUM-BINDING; HOMOLOGY DOMAIN; BOVINE PLASMA; GROWTH; ACTIVATION; RECEPTOR; COFACTOR; MICROCARRIERS	The structural domains of protein C involved in its interaction with thrombin-thrombomodulin on the endothelial cell surface have been investigated using isolated intact domains of bovine protein C produced from controlled proteolytic digests of the protein. The fragments investigated include the gamma-carboxyglutamic acid (Gla)-rich module, the two epidermal growth factor (EGF)-like modules, and a fragment consisting of the Gla and the two EGF-like modules. The effects of these fragments on the catalytic efficiency (K(m) and V(max)) of activation of protein C by the endothelial cell surface thrombin-thrombomodulin complex (IIa-TM) have been evaluated in vitro using a stirred microcarrier cell culture of bovine aortic endothelial cells and purified proteins. Neither the Gla nor the two EGF-like modules alone had any discernible effect on protein C activation. The intact Gla-EGF fragment, however, inhibited protein C activation. The results are consistent with a rapid equilibrium competitive inhibition model, in which the Gla-EGF fragment competes with protein C for binding to IIa-TM, and indicate that the Gla-EGF fragment alone accounts for most of the binding energy of intact protein C for IIa-TM. In addition, a requirement for the Gla residues of protein C for binding is implied by the observation that heat-decarboxylated Gla-EGF fragment was not an inhibitor of protein C activation. In addition, chloromethyl ketone-inactivated activated protein C was found to bind to IIa-TM with the same affinity as protein C, suggesting that the changes which occur in protein C upon activation do not affect that part of the protein responsible for binding to IIa-TM, that is the Gla-EGF region. The Gla-EGF region from factor X also weakly inhibited the IIa-TM activation of protein C.	UNIV LUND,MALMO GEN HOSP,DEPT CLIN CHEM,S-21401 MALMO,SWEDEN	Lund University				Hogg, Philip/0000-0001-6486-2863				ASTERMARK J, 1991, J BIOL CHEM, V266, P2430; ASTERMARK J, 1991, J BIOL CHEM, V266, P2438; BAJAJ SP, 1982, J BIOL CHEM, V257, P3726; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BOIADJIEVA S, 1984, LAB INVEST, V50, P239; BOOYSE FM, 1975, THROMB DIATH HAEMOST, V34, P825, DOI 10.1055/s-0038-1654001; BUSCH C, 1982, LAB INVEST, V47, P498; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; DUGGLEBY RG, 1984, COMPUT BIOL MED, V14, P447, DOI 10.1016/0010-4825(84)90045-3; Eadie GS, 1942, J BIOL CHEM, V146, P85; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON NL, 1983, J BIOL CHEM, V258, P5548; FERNLUND P, 1982, J BIOL CHEM, V257, P2170; HOGG PJ, 1991, J BIOL CHEM, V266, P10953; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4893, DOI 10.1021/bi00667a022; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; KUROSAWA S, 1987, J BIOL CHEM, V262, P2206; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; LOTTENBERG R, 1982, THROMB RES, V28, P313, DOI 10.1016/0049-3848(82)90114-1; LUNDBLAD RL, 1975, BIOCHEM BIOPH RES CO, V66, P482, DOI 10.1016/0006-291X(75)90536-7; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; OHLIN AK, 1988, J BIOL CHEM, V263, P7411; OHLIN AK, 1990, BIOCHEMISTRY-US, V29, P644; OWEN W G, 1973, Thrombosis Research, V3, P705, DOI 10.1016/0049-3848(73)90017-0; OWEN WG, 1981, J BIOL CHEM, V256, P5532; OWEN WG, 1974, J BIOL CHEM, V249, P594; PERSSON E, 1989, J BIOL CHEM, V264, P16897; PERSSON E, 1991, J BIOL CHEM, V266, P2444; PERSSON E, 1991, J BIOL CHEM, V266, P2453; PETERSEN TE, 1988, FEBS LETT, V231, P51, DOI 10.1016/0014-5793(88)80700-2; RYAN US, 1980, TISSUE CELL, V12, P619, DOI 10.1016/0040-8166(80)90017-8; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; STEARNS DJ, 1989, J BIOL CHEM, V264, P3352; STENFLO J, 1991, BLOOD, V78, P1637; STENFLO J, 1976, J BIOL CHEM, V251, P355; THALER E, 1975, BRIT J HAEMATOL, V31, P233, DOI 10.1111/j.1365-2141.1975.tb00853.x; ZUSHI M, 1989, J BIOL CHEM, V264, P10351	39	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					703	706						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1309772				2022-12-27	WOS:A1992GY96000007
J	SAHASRABUDHE, SR; SPRUYT, MA; MUENKEL, HA; BLUME, AJ; VITEK, MP; JACOBSEN, JS				SAHASRABUDHE, SR; SPRUYT, MA; MUENKEL, HA; BLUME, AJ; VITEK, MP; JACOBSEN, JS			RELEASE OF AMINO-TERMINAL FRAGMENTS FROM AMYLOID PRECURSOR PROTEIN REPORTER AND MUTATED DERIVATIVES IN CULTURED-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; ALZHEIMERS-DISEASE; BETA-PROTEIN; SOLUBLE DERIVATIVES; CEREBROSPINAL-FLUID; PEPTIDE PRECURSOR; A4 PRECURSOR; CLEAVAGE; IDENTIFICATION; BIOGENESIS	Abnormal proteolytic processing of amyloid precursor protein (APP) is thought to be central to the formation and deposition of beta amyloid peptide in Alzheimer's disease. A putative "secretase' activity normally releases an amino-terminal APP fragment by cleaving APP at residues within the beta amyloid peptide thereby precluding amyloidogenesis. In order to better understand the requirements for APP cleavage by secretase, we have expressed a modified cDNA construct representing the 751-aminoacid isoform of APP (APP-REP) and mutated APP-REP proteins in cultured cells. Here, we show that: (a) APP-REP is predominantly associated with membranes; (b) intracellular turnover and processing of APP-REP is similar to that reported for the intact APP protein; (c) secretion appears unaltered by introduction of the glutamate to glutamine mutation found in the APP gene of patients suffering from hereditary cerebral hemorrhage with amyloidosis of Dutch origin; (d) a mutation in which the 18 juxtamembranous amino acids encompassing the secretase site are deleted also allows release of an amino-terminal fragment into the conditioned medium; and (e) kinetics of cleavage of APP-REP and its mutated derivatives are similar. These results indicate that the secretory cleavage of the extracellular amino-terminal fragments of APP-REP can occur in the presence of different novel juxtamembranous amino acid sequences.	AMER CYANAMID CO,LEDERLE LABS,DIV MED RES,DEPT MOLEC PHARMACOL,200 3615A,PEARL RIVER,NY 10965					Vitek, Michael/0000-0001-8140-8048				BYSTRYN JC, 1982, HYBRIDOMA, V1, P465, DOI 10.1089/hyb.1.1982.1.465; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; DONNELLY RJ, 1988, NEUROBIOL AGING, V9, P333, DOI 10.1016/S0197-4580(88)80078-2; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; EHLERS MRW, 1991, P NATL ACAD SCI USA, V88, P1009, DOI 10.1073/pnas.88.3.1009; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FLOOD JF, 1991, P NATL ACAD SCI USA, V88, P3363, DOI 10.1073/pnas.88.8.3363; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GODFROID E, 1990, BIOCHEM BIOPH RES CO, V171, P1015, DOI 10.1016/0006-291X(90)90785-L; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; ISHIURA S, 1991, J NEUROCHEM, V56, P363, DOI 10.1111/j.1471-4159.1991.tb08160.x; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KOWALL NW, 1991, P NATL ACAD SCI USA, V88, P7247, DOI 10.1073/pnas.88.16.7247; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V179, P1670, DOI 10.1016/0006-291X(91)91767-7; PALMERT MR, 1989, BIOCHEM BIOPH RES CO, V165, P182, DOI 10.1016/0006-291X(89)91052-8; PALMERT MR, 1988, BIOCHEM BIOPH RES CO, V156, P432, DOI 10.1016/S0006-291X(88)80859-3; PALMERT MR, 1989, P NATL ACAD SCI USA, V86, P6338, DOI 10.1073/pnas.86.16.6338; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VANNOSTRAND WE, 1989, NATURE, V341, P546; VANNOSTRAND WE, 1992, P NATL ACAD SCI USA, V89, P2552; WANG R, 1991, J BIOL CHEM, V266, P16960; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; ZUBENKO GS, 1986, BIOL PSYCHIAT, V21, P1365, DOI 10.1016/0006-3223(86)90328-8	33	50	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25602	25608						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1281162				2022-12-27	WOS:A1992KB60300103
J	KAIN, SR; PLATT, EJ; BROWN, KS; BLACK, N; FIRESTONE, GL				KAIN, SR; PLATT, EJ; BROWN, KS; BLACK, N; FIRESTONE, GL			DISRUPTIONS IN INTRACELLULAR MEMBRANE TRAFFICKING AND STRUCTURE PRECLUDE THE GLUCOCORTICOID-DEPENDENT MATURATION OF MOUSE MAMMARY-TUMOR VIRUS PROTEINS IN RAT HEPATOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE-LEUKEMIA-VIRUS; SURFACE-ASSOCIATED GLYCOPROTEINS; BREFELDIN-A; ENDOPLASMIC-RETICULUM; SECRETORY PROTEINS; GOLGI PROTEINS; GAG PROTEINS; WILD-TYPE; ENV GENE; TRANSPORT	We have previously shown that glucocorticoids regulate the trafficking and processing of mouse mammary tumor virus (MMTV) proteins in viral-infected M1.54 rat hepatoma cells. To examine the role of intracellular membrane integrity on MMTV protein maturation, brefeldin A (BFA) was utilized to disrupt membrane flow between the endoplasmic reticulum and Golgi. Immunoprecipitation and immunofluorescence microscopy revealed that in the presence of dexamethasone, BFA inhibited the proteolytic processing, cell surface delivery, and externalization of MMTV glycoproteins. Glycosidase digestion and inhibitors of protein glycosylation confirmed that the observed differences in apparent sizes of MMTV glycoprotein products are due to BFA-induced changes in oligosaccharide processing. BFA treatment inhibited the proteolytic processing of the MMTV phosphoprotein precursor, which normally associates with the cytoplasmic face of intracellular membranes. Similarities in salt extraction efficiency revealed that BFA did not affect the membrane affinity of the uncleaved phosphorylated precursor. In a complementary approach, proteolytic processing of the phosphorylated polyprotein did not occur in glucocorticoid-treated HTC cells transfected with a mutant MMTV provirus encoding a normal phosphorylated precursor, but which express a truncated MMTV glycoprotein missing its transmembrane domain and cytoplasmic tail. These results suggest that the MMTV glycoproteins and phosphoproteins may interact at a late step in the transport pathway in a manner required for their mutual processing in response to glucocorticoids and establishes the importance of functional interactions with intracellular membranes for maturation of the cytoplasmic MMTV phosphoproteins.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BOX 591 LSA, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, CANC RES LAB, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley					NCI NIH HHS [CA-09041, F32 CA09053] Funding Source: Medline; NIDDK NIH HHS [DK-42799] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA009053] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042799, R56DK042799] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; AMACHER SL, 1989, MOL ENDOCRINOL, V3, P1634, DOI 10.1210/mend-3-10-1634; BEATO M, 1991, FASEB J, V5, P2044, DOI 10.1096/fasebj.5.7.2010057; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BISCHOFF J, 1984, BIOCHEM BIOPH RES CO, V125, P324, DOI 10.1016/S0006-291X(84)80371-X; BRAVO DA, 1991, MOL ENDOCRINOL, V5, P336, DOI 10.1210/mend-5-3-336; BRAVO DA, 1989, STEROID THYROID HORM, P239; CARDIFF RD, 1978, VIROLOGY, V85, P157, DOI 10.1016/0042-6822(78)90420-8; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FIRESTONE GL, 1986, J CELL BIOL, V103, P2323, DOI 10.1083/jcb.103.6.2323; FIRESTONE GL, 1987, J CELL BIOCHEM, V35, P271, DOI 10.1002/jcb.240350402; FIRESTONE GL, 1982, NATURE, V300, P221, DOI 10.1038/300221a0; FIRESTONE GL, 1990, METHOD ENZYMOL, V182, P688; FIRESTONE GL, 1988, ENDOCRINE GENES ANAL, P95; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAFFAR OK, 1987, MOL CELL BIOL, V7, P1508, DOI 10.1128/MCB.7.4.1508; HAFFAR OK, 1990, J VIROL, V64, P3100, DOI 10.1128/JVI.64.6.3100-3103.1990; HAFFAR OK, 1988, J CELL BIOL, V106, P1463, DOI 10.1083/jcb.106.5.1463; HANSEN M, 1990, J VIROL, V64, P5306, DOI 10.1128/JVI.64.11.5306-5316.1990; HIZI A, 1989, J VIROL, V63, P2543, DOI 10.1128/JVI.63.6.2543-2549.1989; JOHN NJ, 1988, P NATL ACAD SCI USA, V85, P797, DOI 10.1073/pnas.85.3.797; KARLSEN K, 1986, MOL CELL BIOL, V6, P574, DOI 10.1128/MCB.6.2.574; KATOH I, 1985, VIROLOGY, V145, P280, DOI 10.1016/0042-6822(85)90161-8; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRANGEL MS, 1979, CELL, V18, P976; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MAJORS JE, 1983, J VIROL, V47, P495, DOI 10.1128/JVI.47.3.495-504.1983; MARCUS SL, 1978, VIROLOGY, V86, P398, DOI 10.1016/0042-6822(78)90080-6; MASSEY RJ, 1979, VIROLOGY, V99, P358, DOI 10.1016/0042-6822(79)90015-1; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MURNANE JP, 1982, P NATL ACAD SCI-BIOL, V79, P1960, DOI 10.1073/pnas.79.6.1960; ODA K, 1990, BIOCHEM J, V265, P161, DOI 10.1042/bj2650161; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PEREZ LG, 1987, J VIROL, V61, P2981, DOI 10.1128/JVI.61.10.2981-2988.1987; PERKEL VS, 1988, ENDOCRINOLOGY, V123, P310, DOI 10.1210/endo-123-1-310; PERKEL VS, 1991, ENDOCRINOLOGY, V266, P9173; PLATT EJ, 1986, ANAL BIOCHEM, V156, P126, DOI 10.1016/0003-2697(86)90163-6; PLATT EJ, 1991, J BIOL CHEM, V266, P19384; PLATT EJ, 1991, MOL ENDOCRINOL, V5, P1696, DOI 10.1210/mend-5-11-1696; RACEVSKIS J, 1980, J VIROL, V35, P937, DOI 10.1128/JVI.35.3.937-948.1980; REDMOND SMS, 1983, EMBO J, V2, P125, DOI 10.1002/j.1460-2075.1983.tb01393.x; RINGOLD GM, 1979, P NATL ACAD SCI USA, V76, P665, DOI 10.1073/pnas.76.2.665; SALMONS B, 1985, VIROLOGY, V144, P101, DOI 10.1016/0042-6822(85)90309-5; SKALKA AM, 1989, CELL, V56, P911, DOI 10.1016/0092-8674(89)90621-1; THOMAS TC, 1990, METHOD ENZYMOL, V182, P499; TULSIANI DRP, 1982, J BIOL CHEM, V257, P7936; ULMER JB, 1989, P NATL ACAD SCI USA, V86, P6992, DOI 10.1073/pnas.86.18.6992; ULMER JB, 1991, J BIOL CHEM, V266, P9173; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WHEALY ME, 1991, J VIROL, V65, P1066, DOI 10.1128/JVI.65.3.1066-1081.1991; WHITE BA, 1982, J BIOL CHEM, V257, P8569; WINGUTH SD, 1987, MOL ENDOCRINOL, V1, P823, DOI 10.1210/mend-1-11-823; WITTE ON, 1978, J VIROL, V26, P750, DOI 10.1128/JVI.26.3.750-761.1978; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	60	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8128	8135						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1314817				2022-12-27	WOS:A1992HQ18500027
J	SRINIVASAN, Y; LEWALLEN, M; ANGELIDES, KJ				SRINIVASAN, Y; LEWALLEN, M; ANGELIDES, KJ			MAPPING THE BINDING-SITE ON ANKYRIN FOR THE VOLTAGE-DEPENDENT SODIUM-CHANNEL FROM BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE ANKYRIN; CYTOPLASMIC DOMAIN; ANION-EXCHANGER; RAT-BRAIN; SPECTRIN; MEMBRANE; PROTEINS; ORGANIZATION; PURIFICATION; LOCALIZATION	Erythrocyte ankyrin is a member of a family of proteins that mediate the linkage between membrane proteins and the underlying spectrin-actin-based cytoskeleton. Ankyrin has been shown to interact with a variety of integral membrane proteins such as the anion exchanger, the Na+K+-ATPase, and the voltage-dependent sodium channel (NaCh) in brain. To understand how ankyrin interacts with these proteins and maintains its specificity and high affinity for the voltage-dependent NaCh, we have mapped the binding site on ankyrin for the NaCh by examining the binding of purified ankyrin subfragments, prepared by proteolytic cleavage, to the purified rat brain NaCh incorporated into liposomes. I-125-Labeled ankyrin and the radiolabeled 89- and 43-kDa fragments of ankyrin bind to the NaCh with high affinities and with K(d) values of 34, 22, and 63 nM, respectively, and have stoichiometries of approximately 1 mol/mol NaCh. The 72-kDa spectrin binding domain is inactive and does not bind to the NaCh. Dissection of ankyrin reveals that the 43-kDa domain retains all the binding properties of native ankyrin to the NaCh. Analysis of the primary structure reveals that the NaCh binding site is confined to a domain of ankyrin consisting entirely of the 11 terminal 33-amino acid repeats and is distinct from the ankyrin domains that interact with spectrin and the Na+K+-ATPase.	BAYLOR COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030	Baylor College of Medicine								ANGELIDES KJ, 1988, J CELL BIOL, V106, P1911, DOI 10.1083/jcb.106.6.1911; ARIYASU RG, 1985, J NEUROSCI, V5, P2581; BENNETT V, 1980, J BIOL CHEM, V255, P6424; BENNETT V, 1980, J BIOL CHEM, V255, P2540; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAVIS JQ, 1990, J BIOL CHEM, V265, P17252; DAVIS JQ, 1984, J BIOL CHEM, V259, P3550; DAVIS LH, 1991, J BIOL CHEM, V266, P11163; DAVIS LH, 1990, J BIOL CHEM, V265, P10589; ELMER LW, 1985, BIOCHEMISTRY-US, V24, P8128, DOI 10.1021/bi00348a044; ELMER LW, 1990, BRAIN RES, V532, P222, DOI 10.1016/0006-8993(90)91763-7; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; HALL TG, 1987, J BIOL CHEM, V262, P10537; HARTSHORNE RP, 1984, J BIOL CHEM, V259, P1667; KALOMIRIS EL, 1988, J CELL BIOL, V106, P319, DOI 10.1083/jcb.106.2.319; KORDELI E, 1990, J CELL BIOL, V110, P1341, DOI 10.1083/jcb.110.4.1341; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEVINSON SR, 1979, ANAL BIOCHEM, V99, P72, DOI 10.1016/0003-2697(79)90045-9; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MERRIL CR, 1981, ANAL BIOCHEM, V110, P201, DOI 10.1016/0003-2697(81)90136-6; Morrow JS, 1989, CURR OPIN CELL BIOL, V1, P23, DOI 10.1016/S0955-0674(89)80032-8; MORROW JS, 1989, J CELL BIOL, V108, P455, DOI 10.1083/jcb.108.2.455; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; OTTO E, 1991, J CELL BIOL, V114, P241, DOI 10.1083/jcb.114.2.241; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; WAXMAN SG, 1985, SCIENCE, V228, P1502, DOI 10.1126/science.2409596; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6	32	65	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7483	7489						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1313804				2022-12-27	WOS:A1992HN48500043
J	KATO, H; FUKAMI, K; SHIBASAKI, F; HOMMA, Y; TAKENAWA, T				KATO, H; FUKAMI, K; SHIBASAKI, F; HOMMA, Y; TAKENAWA, T			ENHANCEMENT OF PHOSPHOLIPASE-C-DELTA-1 ACTIVITY IN THE AORTAS OF SPONTANEOUSLY HYPERTENSIVE RATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; SIGNAL TRANSDUCTION; INOSITOL PHOSPHOLIPIDS; SMOOTH-MUSCLE; ERYTHROCYTES; MESSENGER; TURNOVER; SEQUENCE; CALCIUM; CELLS	Spontaneously hypertensive rats (SHR), which develop hypertension approximately 10 weeks after birth, are considered to provide a good animal model for human essential hypertension. We report here that the abnormal activation of phospholipase C-delta-1 (PLC-delta-1) may be one of the main causes of hypertension. Levels of the second messengers inositol 1,4,5-triphophate and diacylglycerol are found to be higher in the aortas of 12-week-old SHR than in age-matched normotensive Wistar-Kyoto rats (WKY), although the levels in the aortas of 7-week-old SHR, which have normal blood pressure, are the same as in WKY. Moreover, PLC activity is also higher in the aortas of 12-week-old SHR. Judging from Western blot analysis and immunoabsorption of PLCs, this activation is found to be due to that of PLC-delta-1. PLC-delta-1 from rat aorta is expressed significantly from 7 to 12 weeks, which correlates with the development of hypertension in SHR. The activity of PLC-delta-1 in the aortas of 12-week-old SHR is more markedly activated at low Ca2+ concentration than that of age-matched WKY. These results suggest that the abnormal enhancement of PLC-delta-1 activity is responsible for accumulation of inositol 1,4,5-trisphosphate and diacylgycerol, leading to continuous hypertonicity of vascular smooth muscle in SHR. The activity of PLC-delta-1 in the aortas of 12-week-old SHR is significantly higher at low Ca2+ concentration than that of normotensive WKY.	TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL, DEPT BIOSIGNAL RES, 35-2 SAKAE CHO, ITABASHI KU, TOKYO 173, JAPAN									BARABAN JM, 1985, P NATL ACAD SCI USA, V82, P604, DOI 10.1073/pnas.82.2.604; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; CANESSA M, 1980, NEW ENGL J MED, V302, P772, DOI 10.1056/NEJM198004033021403; DEMENDONCA M, 1980, P NATL ACAD SCI-BIOL, V77, P4283, DOI 10.1073/pnas.77.7.4283; EMORI Y, 1989, J BIOL CHEM, V264, P21885; FRIEDMAN SM, 1976, EXPERIENTIA, V32, P476, DOI 10.1007/BF01920806; FUKAMI K, 1989, J BIOL CHEM, V264, P14985; GARAY RP, 1980, NATURE, V284, P281, DOI 10.1038/284281a0; GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901; HOMMA Y, 1990, BIOCHEM J, V269, P13, DOI 10.1042/bj2690013; HOMMA Y, 1989, BIOCHEM BIOPH RES CO, V164, P406, DOI 10.1016/0006-291X(89)91734-8; KATO H, 1987, BIOCHEM BIOPH RES CO, V146, P1419, DOI 10.1016/0006-291X(87)90808-4; KISELEV G, 1981, BIOCHEM PHARMACOL, V30, P833, DOI 10.1016/S0006-2952(81)80003-2; KOUTOUZOV S, 1982, AM J PHYSIOL, V243, pH590, DOI 10.1152/ajpheart.1982.243.4.H590; MARCHE P, 1985, J HYPERTENS, V3, P25, DOI 10.1097/00004872-198502000-00005; MATUOKA K, 1988, SCIENCE, V239, P640, DOI 10.1126/science.2829356; NAKANISHI O, 1988, BIOCHEM J, V256, P453, DOI 10.1042/bj2560453; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PALMER FBSC, 1981, J LIPID RES, V22, P1296; POSTNOV YV, 1977, PFLUG ARCH EUR J PHY, V371, P263, DOI 10.1007/BF00586267; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TAKAORI K, 1986, BIOCHEM BIOPH RES CO, V141, P769, DOI 10.1016/S0006-291X(86)80239-X; UEHARA Y, 1988, HYPERTENSION, V11, P28, DOI 10.1161/01.HYP.11.1.28	26	67	69	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6483	6487						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1313006				2022-12-27	WOS:A1992HM05300009
J	OKINO, ST; PENDURTHI, UR; TUKEY, RH				OKINO, ST; PENDURTHI, UR; TUKEY, RH			PHORBOL ESTERS INHIBIT THE DIOXIN RECEPTOR-MEDIATED TRANSCRIPTIONAL ACTIVATION OF THE MOUSE CYP1A-1 AND CYP1A-2 GENES BY 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DNA INTERACTIONS; TUMOR NECROSIS FACTOR; XENOBIOTIC RESPONSIVE ELEMENTS; ARYL-HYDROCARBON HYDROXYLASE; TISSUE-SPECIFIC EXPRESSION; HUMAN METALLOTHIONEIN GENE; RABBIT MESSENGER-RNAS; LIVER DRUG-METABOLISM; HEAT-SHOCK PROTEIN; AH RECEPTOR	Tetradecanoyl phorbol acetate (TPA) has been shown to inhibit 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced mouse P450IA1 benzo[a]pyrene hydroxylase activity (Raunio, H., and Pelkonen, O. (1983) Cancer Res. 43, 782-786). When we co-administered TPA and TCDD to C57BL/6 mice, the accumulation of TCDD-inducible liver P450IA1 and P450IA2 mRNA, as well as kidney P450IA1 mRNA, was greatly inhibited. When nuclear run-on assays were conducted, maximal levels of transcriptional activation were achieved for both liver Cyp1-alpha-1 and Cyp1-alpha-2 with 1-mu-g/kg (almost-equal-to 3.0 nmol/kg) TCDD. TCDD elicited a dose-dependent increase in the rates of gene transcription, which paralleled the induction of P450IA1 and P450IA2 mRNA. Only Cyp1-alpha-1 gene transcription was elevated in kidney. When these experiments were repeated following the co-administration of TPA with TCDD, the levels of TCDD-mediated transcriptional increases in liver Cyp1-alpha-1 and Cyp1-alpha-2 and P450IA1 and P450IA2 mRNAs were dramatically inhibited. The reduction in Cyp1-alpha gene transcription by TPA could be accounted for by reduced DNA binding of the dioxin receptor to the xenobiotic-responsive element (XRE) sequences, as measured by gel-retardation analysis. Analysis of nuclear [H-3]TCDD dioxin receptor by sucrose density gradients demonstrated that the inhibition in Cyp1-alpha gene transcription and DNA binding by TPA resulted from a reduction in nuclear dioxin receptor concentration.	UNIV CALIF SAN DIEGO,CTR CANC 0812,DEPT MED,CANC GENET PROGRAM,9500 GILMAN DR,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR CANC 0812,DEPT PHARMACOL,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NCI NIH HHS [CA37139] Funding Source: Medline; NIGMS NIH HHS [GM36590] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037139] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BERTINI R, 1988, INT J IMMUNOPHARMACO, V10, P525, DOI 10.1016/0192-0561(88)90069-0; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CONNEY AH, 1982, CANCER RES, V42, P4875; CROSSMAN DC, 1990, J BIOL CHEM, V265, P9782; CUTHILL S, 1987, J BIOL CHEM, V262, P3477; DENISON MS, 1986, J BIOL CHEM, V261, P3987; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DINARELLO CA, 1990, LYMPHOKINES IMMUNE R, P145; DING XX, 1990, MOL PHARMACOL, V37, P489; DING XX, 1986, MOL PHARMACOL, V30, P370; DURRIN LK, 1987, MOL CELL BIOL, V7, P3008, DOI 10.1128/MCB.7.8.3008; ELFERINK CJ, 1990, J BIOL CHEM, V265, P20708; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GHEZZI P, 1986, INFECT IMMUN, V54, P837, DOI 10.1128/IAI.54.3.837-840.1986; GHEZZI P, 1986, BIOCHEM BIOPH RES CO, V136, P316, DOI 10.1016/0006-291X(86)90912-5; GILLNER M, 1987, CANCER RES, V47, P4150; GOLDSTEIN JA, 1984, MOL PHARMACOL, V25, P185; GONZALEZ FJ, 1985, NUCLEIC ACIDS RES, V13, P7269, DOI 10.1093/nar/13.20.7269; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; GREENLEE WF, 1979, J BIOL CHEM, V254, P9814; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; HENRY EC, 1989, BIOCHEMISTRY-US, V28, P6430, DOI 10.1021/bi00441a041; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; IMBRA RJ, 1986, NATURE, V323, P555, DOI 10.1038/323555a0; JOHNSON EF, 1977, BIOCHEM BIOPH RES CO, V76, P652, DOI 10.1016/0006-291X(77)91550-9; JONES PBC, 1985, SCIENCE, V227, P1499, DOI 10.1126/science.3856321; JONES PBC, 1986, P NATL ACAD SCI USA, V83, P2802, DOI 10.1073/pnas.83.9.2802; KADLUBAR FF, 1989, MAMMALIAN CYTOCHROME, P81; KARIN M, 1985, MOL CELL BIOL, V5, P2866, DOI 10.1128/MCB.5.10.2866; KIMURA S, 1986, MOL CELL BIOL, V6, P1471, DOI 10.1128/MCB.6.5.1471; LAFYATIS R, 1990, MOL ENDOCRINOL, V4, P973, DOI 10.1210/mend-4-7-973; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIEM HH, 1980, MOL PHARMACOL, V18, P565; MCMANUS ME, 1990, CANCER RES, V50, P3367; MILLER AG, 1983, J BIOL CHEM, V258, P3523; MONTISANO DF, 1985, MOL CELL BIOL, V5, P698, DOI 10.1128/MCB.5.4.698; NEBERT DW, 1988, DRUG METAB DISPOS, V16, P1; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NEGISHI M, 1981, J BIOL CHEM, V256, P3085; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; OKEY AB, 1980, J BIOL CHEM, V255, P1415; OKEY AB, 1979, J BIOL CHEM, V254, P1636; OKINO ST, 1985, P NATL ACAD SCI USA, V82, P5310, DOI 10.1073/pnas.82.16.5310; PASCO DS, 1988, J BIOL CHEM, V263, P8671; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; POLAND A, 1986, J BIOL CHEM, V261, P6352; POLAND A, 1976, J BIOL CHEM, V251, P4936; PROKIPCAK RD, 1988, ARCH BIOCHEM BIOPHYS, V267, P811, DOI 10.1016/0003-9861(88)90091-4; QUATTROCHI LC, 1989, MOL PHARMACOL, V36, P66; QUATTROCHI LC, 1985, DNA-J MOLEC CELL BIO, V4, P395, DOI 10.1089/dna.1985.4.395; RAUNIO H, 1983, CANCER RES, V43, P782; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SHEDLOFSKY SI, 1987, LIFE SCI, V40, P2331, DOI 10.1016/0024-3205(87)90506-6; SHU HP, 1987, REGUL TOXICOL PHARM, V7, P57, DOI 10.1016/0273-2300(87)90048-1; SILVER G, 1988, J BIOL CHEM, V263, P11802; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THORGEIRSSON SS, 1987, ADV CANCER RES, V25, P149; TUKEY RH, 1984, BIOCHEMISTRY-US, V23, P6003, DOI 10.1021/bi00320a016; TUKEY RH, 1981, J BIOL CHEM, V256, P6969; TUKEY RH, 1982, CELL, V31, P275, DOI 10.1016/0092-8674(82)90427-5; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x; YUSPA SH, 1988, ADV CANCER RES, V50, P25, DOI 10.1016/S0065-230X(08)60434-0	70	98	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6991	6998						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1313028				2022-12-27	WOS:A1992HM05300082
J	WU, QY; TSIANG, M; LENTZ, SR; SADLER, JE				WU, QY; TSIANG, M; LENTZ, SR; SADLER, JE			LIGAND SPECIFICITY OF HUMAN THROMBOMODULIN - EQUILIBRIUM BINDING OF HUMAN THROMBIN, MEIZOTHROMBIN, AND FACTOR XA TO RECOMBINANT THROMBOMODULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYZED PROTHROMBIN ACTIVATION; ECHIS-CARINATUS VENOM; PROTEIN-C; INDUCED THROMBOEMBOLISM; NATURAL ANTICOAGULANT; HUMAN PLATELETS; DOMAIN; BLOOD; SITE; INTERMEDIATE	Thrombomodulin is an endothelial glycoprotein that serves as a cofactor for protein C activation. To examine the ligand specificity of human thrombomodulin, we performed equilibrium binding assays with human thrombin, thrombin S205A (wherein the active site serine is replaced by alanine), meizothrombin S205A, and human factor Xa. In competition binding assays with CV-1(18A) cells expressing cell surface recombinant human thrombomodulin, recombinant wild type thrombin and thrombin S205A inhibited I-125-diisopropyl fluorophosphate-thrombin binding with similar affinity (K(d) = 6.4 +/- 0.5 and 5.3 +/- 0.3 nM, respectively). However, no binding inhibition was detected for meizothrombin S205A or human factor Xa (K(d) > 500 nM). In direct binding assays, I-125-labeled plasma thrombin and thrombin S205A bound to thrombomodulin with K(d) values of 4.0 +/- 1.9 and 6.9 +/- 1.2 nM, respectively. I-125-Labeled meizothrombin S205A and human factor Xa did not bind to thrombomodulin (K(d) > 500 nM). We also compared the ability of thrombin and factor Xa to activate human recombinant protein C. The activation of recombinant protein C by thrombin was greatly enhanced in the presence of thrombomodulin, whereas no significant activation by factor Xa was detected with or without thrombomodulin. Similar results were obtained with thrombin and factor Xa when human umbilical vein endothelial cells were used as the source of thrombomodulin. These results suggest that human meizothrombin and factor Xa are unlikely to be important thrombomodulin-dependent protein C activators and that thrombin is the physiological ligand for human endothelial cell thrombomodulin.	WASHINGTON UNIV, SCH MED,HOWARD HUGHES MED INST,660 S EUCLID, BOX 8045, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, JEWISH HOSP ST LOUIS, SCH MED, DEPT MED & BIOCHEM, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, JEWISH HOSP ST LOUIS, SCH MED, DEPT MOLEC BIOPHYS, ST LOUIS, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)			Sadler, Evan/D-8556-2011	Lentz, Steven/0000-0002-8885-4718; Sadler, J. Evan/0000-0001-5705-469X; Wu, Qingyu/0000-0003-0561-9315	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147, T32HL007088] Funding Source: NIH RePORTER; NHLBI NIH HHS [HLBI 14147, T32 HLBI 07088] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOURIN MC, 1988, J BIOL CHEM, V263, P8044; DEGEN SJF, 1983, BIOCHEMISTRY-US, V22, P2087, DOI 10.1021/bi00278a008; DITTMAN WA, 1990, BLOOD, V75, P329; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON NL, 1989, PROG HEMOST THROMB, V9, P29; ESMON NL, 1983, J BIOL CHEM, V258, P5548; ESMON NL, 1988, CIRCULATION, V78, P317; GOMI K, 1990, BLOOD, V75, P1396; HALEY PE, 1989, J BIOL CHEM, V264, P16303; KOYAMA T, 1991, BRIT J HAEMATOL, V78, P515, DOI 10.1111/j.1365-2141.1991.tb04481.x; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KUMADA T, 1988, BLOOD, V71, P728; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENTZ SR, 1991, J CLIN INVEST, V88, P1906, DOI 10.1172/JCI115514; MA SF, 1991, THROMB HAEMOSTASIS, V65, P946; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MARUYAMA I, 1985, J CLIN INVEST, V75, P987, DOI 10.1172/JCI111800; MILETICH JP, 1978, J BIOL CHEM, V253, P6908; MILETICH JP, 1990, J BIOL CHEM, V265, P11397; MORITA T, 1981, METHOD ENZYMOL, V80, P303; NAWA K, 1990, BIOCHEM BIOPH RES CO, V171, P729, DOI 10.1016/0006-291X(90)91207-9; NOE G, 1988, J BIOL CHEM, V263, P11729; NOVOA E, 1980, THROMB RES, V18, P657, DOI 10.1016/0049-3848(80)90220-0; PARKINSON JF, 1990, J BIOL CHEM, V265, P12602; PARKINSON JF, 1990, BIOCHEM BIOPH RES CO, V169, P177, DOI 10.1016/0006-291X(90)91451-W; PEI G, 1991, J BIOL CHEM, V266, P9598; PREISSNER KT, 1990, J BIOL CHEM, V265, P4915; RHEE MJ, 1982, BIOCHEMISTRY-US, V21, P3437, DOI 10.1021/bi00257a029; ROSING J, 1988, THROMB HAEMOSTASIS, V60, P355; ROSING J, 1986, J BIOL CHEM, V261, P4224; SHUMAN MA, 1976, J CLIN INVEST, V58, P1249, DOI 10.1172/JCI108579; STEARNS DJ, 1989, J BIOL CHEM, V264, P3352; THOMPSON EA, 1986, J CLIN INVEST, V78, P13, DOI 10.1172/JCI112541; THOMPSON EA, 1988, THROMB HAEMOSTASIS, V59, P339; TOLLEFSEN DM, 1974, J BIOL CHEM, V249, P2646; TSIANG M, 1990, BIOCHEMISTRY-US, V29, P10602, DOI 10.1021/bi00499a005; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; ZUSHI M, 1989, J BIOL CHEM, V264, P10351	40	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					7083	7088						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1313033				2022-12-27	WOS:A1992HM05300096
J	DOBROWSKY, RT; HANNUN, YA				DOBROWSKY, RT; HANNUN, YA			CERAMIDE STIMULATES A CYTOSOLIC PROTEIN PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CELL-DIFFERENTIATION; BINDING	A sphingomyelin cycle has been identified whereby the action of certain extracellular agents results in reversible sphingomyelin hydrolysis and the concomitant generation of ceramide. Moreover, a cell-permeable ceramide, C2-ceramide (N-acetylsphingosine), is a potent modulator of cell proliferation and differentiation. We report herein that C2-ceramide, C6-ceramide, and natural ceramides activate a cytosolic serine/threonine protein phosphatase in a dose-dependent manner. Initial activation is observed at concentrations of ceramide as low as 0.1-mu-M with peak response occurring at 5-10-mu-M. However, other closely related sphingolipids, sphingosine and sphingomyelin, were largely inactive. Ceramide-stimulated phosphatase was inhibited by okadaic acid, an inhibitor of protein phosphatases, with an IC50 of 0.1-1 nM, depending on the concentration of ceramide. Ceramide-stimulated phosphatase was insensitive to Mg2+ and Mn2+ cations. Using sequential anion exchange chromatography, ceramide-stimulated phosphatase activity could be resolved from ceramide-nonresponsive phosphatases. The activity of partially purified enzyme was stimulated 3.5-fold by ceramide. The identification of a phosphatase as a molecular target for the action of ceramide defines a novel intracellular signaling pathway with potential roles in the regulation of cell proliferation and differentiation.	DUKE UNIV,MED CTR,DEPT MED,DIV HEMATOL ONCOL,BOX 3355,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Duke University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NIA NIH HHS [AG05531] Funding Source: Medline; NIGMS NIH HHS [GM43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, J BIOL CHEM, V264, P21435; COOPER JA, 1989, CELL, V58, P1009, DOI 10.1016/0092-8674(89)90495-9; FOULKES JG, 1981, FEBS LETT, V130, P197, DOI 10.1016/0014-5793(81)81118-0; GAVER RC, 1966, J AM CHEM SOC, V88, P3643, DOI 10.1021/ja00967a032; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; KIM MY, 1991, J BIOL CHEM, V266, P484; Kitano T, 1986, Methods Enzymol, V124, P349; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; UTAL AK, 1991, J BIOL CHEM, V266, P24084	16	375	383	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5048	5051						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1312082				2022-12-27	WOS:A1992HH74700009
J	SCHOPOHL, D; MULLERTAUBENBERGER, A; ORTHEN, B; HESS, H; REUTTER, W				SCHOPOHL, D; MULLERTAUBENBERGER, A; ORTHEN, B; HESS, H; REUTTER, W			PURIFICATION AND PROPERTIES OF A SECRETED AND DEVELOPMENTALLY REGULATED ALPHA-L-FUCOSIDASE FROM DICTYOSTELIUM-DISCOIDEUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; LINKED GLYCANS; PROTEIN; GLYCOPROTEINS; INDUCTION; SEQUENCE; GROWTH; SUGARS; MUTANT; FORM	During its development the eukaryotic microorganism Dictyostelium discoideum secretes an alpha-L-fucosidase (EC 3.2.1.51). In cells of the growth phase almost no alpha-L-fucosidase activity is detectable. The activity increases steadily up to the aggregation stage and accumulates also in the extracellular medium. The developmental regulation is mediated by pulsatile cAMP signals. The alpha-L-fucosidase was purified from extracellular medium. The isolation procedure started with concentration of the enzyme by batchwise anion-exchange chromatography and ammonium sulfate precipitation, followed by Sephacryl S-300 gel filtration and further purification by fast protein liquid chromatography on Mono Q, phenyl-Superose, and finally Superose 12. The purified preparation was found to be essentially free of activities of six other glycosidases also secreted by D. discoideum. On sodium dodecyl sulfate-polyacrylamide gel electrophoresis, the purified enzyme showed one major band with an apparent molecular mass of 62 kilodalton. Gel filtration of the enzyme on a Superose 12 column was consistent with an active monomer. A monoclonal antibody was produced, which recognizes a carbohydrate epitope shared by all lysosomal enzymes in D. discoideum. The pH optimum of the alpha-L-fucosidase is at 3.7. The apparent Michaelis constant for p-nitrophenyl alpha-L-fucoside as substrate is 1.2 mM. The enzyme catalyzes preferentially the hydrolysis of alpha-1 --> 6GlcNAc but also of alpha-1 --> 2Gal and alpha-1 --> 3Glc fucosyl linkages.	FREE UNIV BERLIN,INST MOLEK BIOL & BIOCHEM,W-1000 BERLIN 33,GERMANY	Free University of Berlin	SCHOPOHL, D (corresponding author), MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY.		Müller-Taubenberger, Annette/AAM-3671-2021; Müller-Taubenberger, Annette/AAG-8538-2020	Müller-Taubenberger, Annette/0000-0003-1163-9232				ALHADEFF JA, 1975, J BIOL CHEM, V250, P7106; ALHADEFF JA, 1977, PRACTICAL ENZYMOLOGY, P247; BARKER C, 1988, BIOCHEM J, V254, P861, DOI 10.1042/bj2540861; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRINK M, 1990, J CELL BIOL, V111, P1477, DOI 10.1083/jcb.111.4.1477; Cardelli J.A., 1988, P363; DICIOCCIO RA, 1982, J BIOL CHEM, V257, P714; DIMATTEO G, 1976, BIOCHIM BIOPHYS ACTA, V429, P527, DOI 10.1016/0005-2744(76)90300-4; EVERY D, 1973, BIOCHEM J, V133, P37, DOI 10.1042/bj1330037; FAIX J, 1990, EMBO J, V9, P2709, DOI 10.1002/j.1460-2075.1990.tb07457.x; FISHER KJ, 1989, BIOCHEM J, V264, P695, DOI 10.1042/bj2640695; HOHMANN HP, 1987, J BIOL CHEM, V262, P16618; IVATT RL, 1984, CELL, V38, P561, DOI 10.1016/0092-8674(84)90510-5; KNECHT DA, 1984, J BIOL CHEM, V259, P633; KREISEL W, 1980, P NATL ACAD SCI-BIOL, V77, P1828, DOI 10.1073/pnas.77.4.1828; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM TY, 1981, DEV BIOL, V83, P127, DOI 10.1016/S0012-1606(81)80015-2; LAURYKLEINTOP LD, 1987, BIOCHEM J, V245, P589, DOI 10.1042/bj2450589; MAY T, 1989, MOL CELL BIOL, V9, P4653, DOI 10.1128/MCB.9.11.4653; MULLERTAUBENBERGER A, 1989, FEBS LETT, V246, P185, DOI 10.1016/0014-5793(89)80280-7; OCCHIODORO T, 1989, BIOCHEM BIOPH RES CO, V164, P439, DOI 10.1016/0006-291X(89)91739-7; OPHEIM DJ, 1977, J BIOL CHEM, V252, P739; SCUDDER P, 1990, J BIOL CHEM, V265, P16472; TAKASAKI S, 1974, J BIOCHEM-TOKYO, V76, P783; TAUBER R, 1989, EUR J BIOCHEM, V186, P55, DOI 10.1111/j.1432-1033.1989.tb15177.x; TSUJI Y, 1990, J BIOCHEM-TOKYO, V108, P235, DOI 10.1093/oxfordjournals.jbchem.a123186; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; WILHELMS OH, 1974, EUR J BIOCHEM, V48, P89, DOI 10.1111/j.1432-1033.1974.tb03746.x; WILLEMS PJ, 1991, AM J MED GENET, V38, P111, DOI 10.1002/ajmg.1320380125; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YAMAMOTO K, 1986, AGR BIOL CHEM TOKYO, V50, P1689, DOI 10.1080/00021369.1986.10867654	31	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2400	2405						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1310316				2022-12-27	WOS:A1992HB53200046
J	TORPHY, TJ; STADEL, JM; BURMAN, M; CIESLINSKI, LB; MCLAUGHLIN, MM; WHITE, JR; LIVI, GP				TORPHY, TJ; STADEL, JM; BURMAN, M; CIESLINSKI, LB; MCLAUGHLIN, MM; WHITE, JR; LIVI, GP			COEXPRESSION OF HUMAN CAMP-SPECIFIC PHOSPHODIESTERASE ACTIVITY AND HIGH-AFFINITY ROLIPRAM BINDING IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP PHOSPHODIESTERASE; DROSOPHILA DUNCE+ GENE; NUCLEOTIDE PHOSPHODIESTERASE; INDEPENDENT PHOSPHODIESTERASE; SACCHAROMYCES-CEREVISIAE; INHIBITORS; ISOZYMES; CLONING; BRAIN; CDNA	Studies by various investigators have demonstrated that the low K(m), cAMP-specific phosphodiesterase (PDE IV) is selectively inhibited by a group of compounds typified by rolipram and Ro 20-1724. In addition to inhibiting the catalytic activity of PDE IV, rolipram binds to a high affinity binding site present in brain homogenates. Although it has been assumed that the high affinity rolipram-binding site is PDE IV, no direct evidence has been produced to support this assumption. The present studies were undertaken to determine whether the rolipram-binding site is coexpressed with PDE IV catalytic activity in Saccharomyces cerevisiae genetically engineered to express human recombinant monocytic PDE IV (hPDE IV). Expressing hPDE IV cDNA in yeast resulted in a 20-fold increase in PDE activity that was evident within 1 h of induction and reached a maximum by 3-6 h. The recombinant protein represented hPDE IV as judged by its immunoreactivity, molecular mass (approximately 88 kDa), kinetic characteristics (cAMP K(m) = 3.1-mu-M; cGMP K(m) > 100-mu-M), sensitivity to rolipram (K(i) = 0.06-mu-M), and insensitivity to siguazodan (PDE III inhibitor) and zaprinast (PDE V inhibitor). Saturable, high affinity [H-3] (R)-rolipram-binding sites (K(d) = 1.0 nM) were coexpressed with PDE activity, indicating that both binding activity and catalytic activity are properties of the same protein. A limited number of compounds were tested for their ability to inhibit hPDE IV catalytic activity and compete for [H-3](R)-rolipram binding. Analysis of the data revealed little correlation (r2 = 0.35) in the structure-activity relationships for hPDE IV inhibition versus competition for [H-3](R)-rolipram binding. In fact, certain compounds (e.g. (R)-rolipram, Ro 20-1724) possessed a 10-100-fold selectivity for inhibition of [H-3](R)-rolipram binding over hPDE IV inhibition, whereas others (e.g. dipyridamole, trequinsin) possessed a 10-fold selectivity for PDE inhibition. Thus, although the results of these studies demonstrate that hPDE IV activity and high affinity [H-3](R)-rolipram binding are properties of the same protein, they do not provide clear cut evidence linking the binding site with the PDE inhibitory activity of rolipram and related compounds.	SMITHKLINE BEECHAM PHARMACEUT, DEPT GENE EXPRESS SCI, KING OF PRUSSIA, PA 19406 USA; SMITHKLINE BEECHAM PHARMACEUT, DEPT CELL SCI, KING OF PRUSSIA, PA 19406 USA	GlaxoSmithKline; GlaxoSmithKline	TORPHY, TJ (corresponding author), SMITHKLINE BEECHAM PHARMACEUT, DEPT PHARMACOL, L532, POB 1539, KING OF PRUSSIA, PA 19406 USA.			White, John R/0000-0003-2998-1626				BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN CN, 1986, P NATL ACAD SCI USA, V83, P9313, DOI 10.1073/pnas.83.24.9313; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Cleland W W, 1979, Methods Enzymol, V63, P103; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; COLOTTA F, 1984, J IMMUNOL, V132, P936; DAVIS CW, 1979, J CYCLIC NUCL PROT, V5, P65; DAVIS RL, 1989, P NATL ACAD SCI USA, V86, P3604, DOI 10.1073/pnas.86.10.3604; DENT G, 1991, BRIT J PHARMACOL, V103, P1339, DOI 10.1111/j.1476-5381.1991.tb09790.x; EPSTEIN PM, 1982, ARCH BIOCHEM BIOPHYS, V218, P119, DOI 10.1016/0003-9861(82)90327-7; HICKS JB, 1976, GENETICS, V83, P245; HOROWSKI R, 1985, CURR THER RES CLIN E, V38, P23; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KOE BK, 1990, DRUG DEVELOP RES, V21, P135, DOI 10.1002/ddr.430210206; KRAUSE W, 1990, EUR J CLIN PHARMACOL, V38, P71, DOI 10.1007/BF00314807; LIVI GP, 1990, MOL CELL BIOL, V10, P2678, DOI 10.1128/MCB.10.6.2678; MCHALE MM, 1991, MOL PHARMACOL, V39, P109; MORTIMER RK, 1969, YEASTS, V1, P385; NEMOZ G, 1989, EUR J BIOCHEM, V184, P511, DOI 10.1111/j.1432-1033.1989.tb15044.x; NICHOLSON CD, 1991, TRENDS PHARMACOL SCI, V12, P19, DOI 10.1016/0165-6147(91)90484-A; NIKAWA JI, 1987, MOL CELL BIOL, V7, P3629, DOI 10.1128/MCB.7.10.3629; SACCOMANO NA, 1991, J MED CHEM, V34, P291, DOI 10.1021/jm00105a045; SCHNEIDER HH, 1986, EUR J PHARMACOL, V127, P105, DOI 10.1016/0014-2999(86)90210-4; SCHULTZ JE, 1986, N-S ARCH PHARMACOL, V333, P23, DOI 10.1007/BF00569655; STRADA SJ, 1978, ADV CYCLIC NUCLEOTID, V8, P119; TORPHY TJ, 1991, MOL PHARMACOL, V39, P376; TORPHY TJ, 1990, MOL PHARMACOL, V37, P206; TORPHY TJ, 1991, THORAX, V46, P512, DOI 10.1136/thx.46.7.512; WACHTEL H, 1983, NEUROPHARMACOLOGY, V22, P267, DOI 10.1016/0028-3908(83)90239-3; WEISHAAR RE, 1985, J MED CHEM, V28, P537, DOI 10.1021/jm50001a001; WEISHAAR RE, 1986, J CYCLIC NUCL PROT, V11, P463; WHITE JR, 1990, FASEB J, V4, pA1987; WILSON RB, 1988, MOL CELL BIOL, V8, P505, DOI 10.1128/MCB.8.1.505	35	137	143	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1798	1804						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1309798				2022-12-27	WOS:A1992HA48500062
J	ATTEIA, A; DEVITRY, C; PIERRE, Y; POPOT, JL				ATTEIA, A; DEVITRY, C; PIERRE, Y; POPOT, JL			IDENTIFICATION OF MITOCHONDRIAL PROTEINS IN MEMBRANE PREPARATIONS FROM CHLAMYDOMONAS-REINHARDTII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE-POLYACRYLAMIDE GELS; I REACTION CENTERS; BETA-SUBUNIT; THYLAKOID MEMBRANE; CHLOROPLAST GENOME; ELECTRON-TRANSFER; ATP-SYNTHASE; ELECTROPHORETIC TRANSFER; NUCLEAR TRANSFORMATION; ALGAL PHOTOSYNTHESIS	Preparations enriched in Chlamydomonas reinhardtii thylakoids have proven useful in the study of photosynthesis. Many of their polypeptides however remain unidentified. We report here on three of those, h1 (34 kDa), h2 (11 kDa), and P3 (63 kDa). h1, h2, and P3 are present in all tested mutants of C. reinhardtii lacking either one or several of the photosynthetic chain complexes or depleted in thylakoid membranes. h2 is an ascorbate-reducible, soluble c550-type cytochrome encoded in the nucleus. It cross-reacts immunologically with mitochondrial cytochromes c from various sources and contains a hexapeptide encoded in C. reinhardtii cytochrome c cDNA. P3, a nuclear-encoded peripheral protein, cross-reacts with various ATP synthase beta-subunits. Its N-terminal sequence is encoded in C. reinhardtii mitochondrial beta-subunit cDNA. h1 behaves as an integral hemoprotein; it is absent in a mitochondrial mutant that carries a deletion in apo-cytochrome b gene. We conclude that C. reinhardtii mitochondrial membranes copurify with thylakoid membranes. h, is part of the cytochrome bc1 complex, h2 is cytochrome c, and P3 is the beta-subunit of mitochondrial ATP synthase.	INST BIOL PHYS CHIM,CNRS,URA 1187,13 RUE PIERRE & MARIE CURIE,F-75005 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS)								AMATI BB, 1988, J MOL EVOL, V28, P151, DOI 10.1007/BF02143507; ATTEIA A, 1991, Biophysical Journal, V59, p512A; BELKNAP WR, 1983, PLANT PHYSIOL, V72, P1130, DOI 10.1104/pp.72.4.1130; BENDALL DS, 1986, FEBS LETT, V203, P31, DOI 10.1016/0014-5793(86)81430-2; BENNOUN P, 1981, FEBS LETT, V136, P1, DOI 10.1016/0014-5793(81)81202-1; BENNOUN P, 1983, FEBS LETT, V156, P363, DOI 10.1016/0014-5793(83)80529-8; BENNOUN P, 1982, P NATL ACAD SCI-BIOL, V79, P4352, DOI 10.1073/pnas.79.14.4352; BENNOUN P, 1981, CURR GENET, V3, P251, DOI 10.1007/BF00429829; BOUTRY M, 1985, EMBO J, V4, P2159, DOI 10.1002/j.1460-2075.1985.tb03910.x; BOUTRY M, 1990, 4TH INT WORKSH PLANT; BOYNTON JE, 1973, P NATL ACAD SCI USA, V70, P3463, DOI 10.1073/pnas.70.12.3463; BOYNTON JE, 1988, SCIENCE, V240, P1534, DOI 10.1126/science.2897716; Bulte L, 1990, CURRENT RES PHOTOSYN, V3, P715; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHUA NH, 1977, J CELL BIOL, V74, P441, DOI 10.1083/jcb.74.2.441; CHUA NH, 1975, P NATL ACAD SCI USA, V72, P2175, DOI 10.1073/pnas.72.6.2175; CONDE MF, 1975, MOL GEN GENET, V140, P183, DOI 10.1007/BF00334266; de Vitry C, 1987, PROGR PHOTOSYNTHESIS, VII, P105; DEBUCHY R, 1989, EMBO J, V8, P2803, DOI 10.1002/j.1460-2075.1989.tb08426.x; DELEPELAIRE P, 1981, J BIOL CHEM, V256, P9300; DELEPELAIRE P, 1983, PHOTOBIOCH PHOTOBIOP, V6, P279; DELEPELAIRE P, 1984, EMBO J, V3, P701, DOI 10.1002/j.1460-2075.1984.tb01872.x; DEVITRY C, 1991, J BIOL CHEM, V266, P16614; DEVITRY C, 1989, J CELL BIOL, V109, P991, DOI 10.1083/jcb.109.3.991; DUTTA C, 1990, ANAL BIOCHEM, V184, P96, DOI 10.1016/0003-2697(90)90018-5; ERICKSON JM, 1986, EMBO J, V5, P1745, DOI 10.1002/j.1460-2075.1986.tb04422.x; GIRARD J, 1980, CURR GENET, V2, P215, DOI 10.1007/BF00435689; GIRARDBASCOU J, 1987, CURR GENET, V12, P483, DOI 10.1007/BF00419556; GODDE D, 1980, ARCH MICROBIOL, V127, P245, DOI 10.1007/BF00427200; GODDE D, 1982, ARCH MICROBIOL, V131, P197, DOI 10.1007/BF00405878; GOLDSCHMIDTCLERMONT M, 1990, MOL GEN GENET, V223, P417, DOI 10.1007/BF00264448; GORMAN DS, 1965, P NATL ACAD SCI USA, V54, P1665, DOI 10.1073/pnas.54.6.1665; HANSON MR, 1978, J GEN MICROBIOL, V105, P253, DOI 10.1099/00221287-105-2-253; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HOLTON RW, 1967, BIOCHIM BIOPHYS ACTA, V131, P375, DOI 10.1016/0005-2728(67)90151-X; JOLIOT P, 1988, BIOCHIM BIOPHYS ACTA, V933, P319, DOI 10.1016/0005-2728(88)90039-4; JOLIOT P, 1980, J CHIM PHYS PCB, V77, P209, DOI 10.1051/jcp/1980770209; JOLIOT P, 1984, BIOCHIM BIOPHYS ACTA, V765, P210, DOI 10.1016/0005-2728(84)90015-X; KINDLE KL, 1989, J CELL BIOL, V109, P2589, DOI 10.1083/jcb.109.6.2589; KLEIN U, 1983, PLANT PHYSIOL, V72, P481, DOI 10.1104/pp.72.2.481; LAMAIRE C, 1989, J BIOL CHEM, V264, P10228; LAVERGNE J, 1983, BIOCHIM BIOPHYS ACTA, V725, P25, DOI 10.1016/0005-2728(83)90220-7; LAVERGNE J, 1984, PHOTOBIOCH PHOTOBIOP, V8, P207; LEMAIRE C, 1986, BIOCHIM BIOPHYS ACTA, V851, P229, DOI 10.1016/0005-2728(86)90130-1; MA DP, 1990, PLANT MOL BIOL, V15, P357, DOI 10.1007/BF00036921; MATAGNE RF, 1989, J CELL BIOL, V108, P1221, DOI 10.1083/jcb.108.4.1221; MATSUBAYASHI T, 1987, MOL GEN GENET, V210, P385, DOI 10.1007/BF00327187; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MENDIOLAMORGENTHALER L, 1985, PLANT SCI, V38, P33, DOI 10.1016/0168-9452(85)90076-7; MERCHANT S, 1986, MOL CELL BIOL, V6, P462, DOI 10.1128/MCB.6.2.462; MICHAELIS G, 1990, MOL GEN GENET, V223, P211, DOI 10.1007/BF00265056; MOOS M, 1988, J BIOL CHEM, V263, P6005; NIXON PJ, 1989, J BIOL CHEM, V264, P14129; OHTA S, 1988, J BIOL CHEM, V263, P11257; OHYAMA K, 1988, J MOL BIOL, V203, P281, DOI 10.1016/0022-2836(88)90001-0; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; PELTIER G, 1991, P NATL ACAD SCI USA, V88, P4791, DOI 10.1073/pnas.88.11.4791; PELTIER G, 1987, BIOCHIM BIOPHYS ACTA, V893, P83, DOI 10.1016/0005-2728(87)90151-4; PICCIONI RG, 1981, EUR J BIOCHEM, V117, P93; POPOT JL, 1990, ANNU REV BIOPHYS BIO, V19, P369; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; ROCHAIX JD, 1987, FEMS MICROBIOL LETT, V46, P13, DOI 10.1111/j.1574-6968.1987.tb02449.x; ROCHAIX JD, 1989, EMBO J, V8, P1013, DOI 10.1002/j.1460-2075.1989.tb03468.x; ROITGRUND C, 1990, CURR GENET, V17, P147, DOI 10.1007/BF00312860; RUNSWICK MJ, 1983, J BIOL CHEM, V258, P3081; RYAN R, 1978, P NATL ACAD SCI USA, V75, P3268, DOI 10.1073/pnas.75.7.3268; SARASTE M, 1981, NUCLEIC ACIDS RES, V9, P5287, DOI 10.1093/nar/9.20.5287; SCHOTZ G, 1972, PLANTA, V102, P152; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; STABENAU H, 1974, PLANTA, V118, P35, DOI 10.1007/BF00390501; STEINMULLER K, 1989, MOL GEN GENET, V216, P60, DOI 10.1007/BF00332231; STERN DB, 1991, PLANT CELL, V3, P285; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VASSAROTTI A, 1987, J BIOL CHEM, V262, P411; WOESSNER JP, 1986, GENE, V44, P17; WOESSNER JP, 1984, PLANT MOL BIOL, V3, P177, DOI 10.1007/BF00016065; WOOD PM, 1977, EUR J BIOCHEM, V72, P605, DOI 10.1111/j.1432-1033.1977.tb11283.x; WOOD PM, 1978, EUR J BIOCHEM, V87, P9, DOI 10.1111/j.1432-1033.1978.tb12346.x; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	80	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					226	234						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1309733				2022-12-27	WOS:A1992GY43900040
J	CONKLIN, BR; CHABRE, O; WONG, YH; FEDERMAN, AD; BOURNE, HR				CONKLIN, BR; CHABRE, O; WONG, YH; FEDERMAN, AD; BOURNE, HR			RECOMBINANT-GQ-ALPHA - MUTATIONAL ACTIVATION AND COUPLING TO RECEPTORS AND PHOSPHOLIPASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN PITUITARY-TUMORS; GS-ALPHA; ADENYLYL CYCLASE; PROTEIN; SITE; EXPRESSION; ALTER	G(q) mediates hormonal stimulation of phosphoinositide-specific phospholipase C (PI-PLC). We mutated the alpha-subunit of G(q) (alpha(q)) to replace arginine 183 with cysteine. Mutations that substitute cysteine for the corresponding arginine residues of alpha(s) and alpha(i2) constitutively activate their respective effector pathways, creating the gsp and gip2 oncogenes. Transient expression of alpha(q)-R183C in COS-7 and HEK-293 cells constitutively activates PI-PLC, but wild type (WT) alpha(q) does not. This suggests that the mutated arginines in alpha(s), alpha(i2), and alpha(q) share a common function in regulating the active state of these proteins and that the alpha(q) gene may serve as a target for oncogenic mutations in human tumors. In an attempt to develop an assay for receptor stimulation of recombinant alpha(q), we co-expressed receptors with alpha(q)-WT. We found that the alpha-2-adrenoceptor stimulates PI-PLC activation in HEK-293 cells in a fashion that depends completely on co-expression of alpha(q)-WT. These findings create an experimental model, similar to that provided for alpha(s) by S49 cyc- cells, that should make it possible to analyze receptor and effector coupling by mutant alpha(q) against a null background.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,S1212,BOX 0450,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES CTR,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Conklin, Bruce/E-4738-2019	CHABRE, Olivier/0000-0001-8756-7218; Conklin, Bruce/0000-0003-1463-6061	NHLBI NIH HHS [K11 HL02555] Funding Source: Medline; NIGMS NIH HHS [GM27800, GM28311] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL002555] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027800, R37GM027800, F32GM128311] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOURNE HR, 1988, COLD SPRING HARB SYM, V53, P221, DOI 10.1101/SQB.1988.053.01.028; CLEMENTI E, 1990, ONCOGENE, V5, P1059; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; GUYER CA, 1990, J BIOL CHEM, V265, P17307; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; NAKAMURA F, 1991, J BIOL CHEM, V266, P12676; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; SUAREZ HG, 1991, ONCOGENE, V6, P677; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; VANDOP C, 1984, J BIOL CHEM, V259, P696; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WONG SKF, 1990, J BIOL CHEM, V265, P6219; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0	30	175	176	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					31	34						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1309740				2022-12-27	WOS:A1992GY43900009
J	CHAUDHARI, N				CHAUDHARI, N			A SINGLE NUCLEOTIDE DELETION IN THE SKELETAL MUSCLE-SPECIFIC CALCIUM-CHANNEL TRANSCRIPT OF MUSCULAR DYSGENESIS (MDG) MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DIHYDROPYRIDINE RECEPTOR; MDG/MDG MOUSE; CO-CULTURE; CONTRACTION; MUTATION; MYOTUBES; CELLS; DNA; AMPLIFICATION; INNERVATION	The skeletal muscle-specific dihydropyridine-sensitive calcium channel is a critical component of excitation-contraction coupling in skeletal muscle. A recessive mutation in mice, muscular dysgenesis (mdg), has previously been described as resulting in defective excitation-contraction coupling. Although the channel-forming subunit (alpha1) of the skeletal calcium channel is not detectable immunologically, specific mRNA of normal size is present in dysgenic muscle. cDNA for this calcium channel alpha1 subunit has now been cloned from dysgenic muscle and sequenced in its entirety. A single nucleotide deletion occurs at nucleotide 4010 of the cDNA, resulting in a shift of the translational reading frame. The mutation has been confirmed by direct sequencing of PCR products from homozygous mutant and normal muscle. The mutant polypeptide is predicted to contain the first three repeating domains, five of the normal six transmembrane helices of the last repeating domain, and an altered and truncated C terminus. The mature mRNA encoding the dysgenic alpha1 subunit appears to be labile. It is possible that premature termination of translation renders the mutant mRNA subject to degradation by nucleases. This work resolves a long-standing controversy on the nature of the primary genetic defect in muscular dysgenesis.			CHAUDHARI, N (corresponding author), COLORADO STATE UNIV,DEPT PHYSIOL,FT COLLINS,CO 80523, USA.		Chaudhari, Narendra/S-6219-2019	Chaudhari, Narendra/0000-0003-3018-400X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042652] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42652] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS BA, 1989, J GEN PHYSIOL, V94, P429, DOI 10.1085/jgp.94.3.429; BEAM KG, 1986, NATURE, V320, P168, DOI 10.1038/320168a0; BOURNAUD R, 1989, PFLUG ARCH EUR J PHY, V414, P410, DOI 10.1007/BF00585050; BOWDENES.F, 1972, DEV BIOL, V27, P351, DOI 10.1016/0012-1606(72)90174-1; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CASANOVA JL, 1990, NUCLEIC ACIDS RES, V18, P4028, DOI 10.1093/nar/18.13.4028; CATTERALL WA, 1988, J BIOL CHEM, V263, P3535; CHAUDHARI N, 1989, DEV BIOL, V133, P456, DOI 10.1016/0012-1606(89)90049-3; CHAUDHARI N, 1993, IN PRESS DEV BIOL; CONSTANTIN LL, 1975, PROG BIOPHYS MOL BIO, V29, P197; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HENDERSON C, 1990, TRENDS NEUROSCI, V13, P39, DOI 10.1016/0166-2236(90)90063-G; KLAUS MM, 1983, DEV BIOL, V99, P152, DOI 10.1016/0012-1606(83)90262-2; KNUDSON CM, 1989, J BIOL CHEM, V264, P1345; KOENIG J, 1982, DEV BIOL, V92, P188, DOI 10.1016/0012-1606(82)90162-2; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PAI AC, 1965, DEV BIOL, V11, P82, DOI 10.1016/0012-1606(65)90038-2; PINCONRAYMOND M, 1987, DEV BIOL, V124, P259, DOI 10.1016/0012-1606(87)90477-5; Powell J A, 1979, Ann N Y Acad Sci, V317, P550, DOI 10.1111/j.1749-6632.1979.tb37391.x; POWELL JA, 1984, MUSCLE NERVE, V7, P204, DOI 10.1002/mus.880070304; POWELL JA, 1973, J CELL PHYSIOL, V82, P21, DOI 10.1002/jcp.1040820104; RIEGER F, 1984, DEV BIOL, V106, P296, DOI 10.1016/0012-1606(84)90228-8; RIEGER F, 1981, DEV BIOL, V87, P85, DOI 10.1016/0012-1606(81)90063-4; RIEGER F, 1984, DEV BIOL, V101, P181, DOI 10.1016/0012-1606(84)90128-3; RIEGER F, 1987, NATURE, V330, P563, DOI 10.1038/330563a0; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1990, NATURE, V344, P451, DOI 10.1038/344451a0; TANABE T, 1991, NATURE, V352, P800, DOI 10.1038/352800a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0	37	113	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25636	25639						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1281468				2022-12-27	WOS:A1992KD07300005
J	CAMA, A; QUON, MJ; SIERRA, M; TAYLOR, SI				CAMA, A; QUON, MJ; SIERRA, M; TAYLOR, SI			SUBSTITUTION OF ISOLEUCINE FOR METHIONINE AT POSITION-1153 IN THE BETA-SUBUNIT OF THE HUMAN INSULIN-RECEPTOR - A MUTATION THAT IMPAIRS RECEPTOR TYROSINE KINASE-ACTIVITY, RECEPTOR ENDOCYTOSIS, AND INSULIN ACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; MONOCLONAL-ANTIBODIES; PHOSPHORYLATION SITES; ACANTHOSIS NIGRICANS; RESISTANT PATIENT; GLUCOSE-TRANSPORT; INTACT-CELLS; PROTEIN; ACTIVATION; GENE	The intracellular domain of the insulin receptor possesses activity as a tyrosine-specific protein kinase. The receptor tyrosine kinase is stimulated by insulin binding to the extracellular domain of the receptor. Previously, we have identified a patient with a genetic form of insulin resistance who is heterozygous for a mutation substituting Ile for Met1153 in the tyrosine kinase domain of the receptor near the cluster of the three major autophosphorylation sites (Tyr1158, Tyr1162, and Tyr1163). In this investigation, the Ile1153 mutant receptor was expressed by transfection of mutant cDNA into NIH-3T3 cells. The mutation impairs receptor tyrosine kinase activity and also inhibits the ability of insulin to stimulate 2-deoxyglucose uptake and thymidine incorporation. These data support the hypothesis that the receptor tyrosine activity plays a necessary role in the ability of the receptor to mediate insulin action in vivo. Furthermore, expression of the Ile1153 mutant receptor exerted a dominant negative effect to inhibit the ability of endogenous murine receptors for insulin and insulin-like growth factor I to mediate their actions upon the cell. This observation is consistent with previous suggestions that mutant receptors dimerize with wild type receptors, thereby creating hybrid molecules which lack biological activity. The dominant negative effect of the mutant receptor may explain the dominant mode of inheritance of insulin resistance caused by the Ile1153 mutation. Finally, the mutation inhibits the ability of insulin to stimulate receptor endocytosis. This may explain the normal number of insulin receptors on the surface of the patient's cells in vivo. Despite the presence of markedly elevated levels of insulin in the patient's plasma, the receptors were resistant to down-regulation.	NIDDKD,DIABET BRANCH,BLDG 10,RM 8S-243,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Sierra, Maria/GYU-1134-2022; Quon, Michael/B-1970-2008; CAMA, Alessandro/J-3964-2018	CAMA, Alessandro/0000-0003-3647-1368; QUON, MICHAEL/0000-0002-5289-3707; Quon, Michael/0000-0002-9601-9915				ACCILI D, 1991, J BIOL CHEM, V266, P434; ACCILI D, 1989, EMBO J, V8, P2509, DOI 10.1002/j.1460-2075.1989.tb08388.x; BAR RS, 1978, J CLIN ENDOCR METAB, V47, P620, DOI 10.1210/jcem-47-3-620; BONISCHNETZLER M, 1986, J BIOL CHEM, V261, P5281; CAMA A, 1987, DIABETOLOGIA, V30, P631; CAMA A, 1988, DIABETES, V37, P982, DOI 10.2337/diabetes.37.7.982; CAMA A, 1991, J CLIN ENDOCR METAB, V73, P894, DOI 10.1210/jcem-73-4-894; CHOU CK, 1987, J BIOL CHEM, V262, P1842; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; DEMEYTS P, 1976, J BIOL CHEM, V251, P1877; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; FORSAYETH JR, 1987, P NATL ACAD SCI USA, V84, P3448, DOI 10.1073/pnas.84.10.3448; GOLDSTEIN BJ, 1990, MOL ENDOCRINOL, V4, P235, DOI 10.1210/mend-4-2-235; GRAY A, 1986, EMBO J, V5, P2503; HARI J, 1987, J BIOL CHEM, V262, P15341; HAWLEY DM, 1989, J BIOL CHEM, V264, P2438; HERRERA R, 1986, J BIOL CHEM, V261, P1980; KADOWAKI H, 1990, J BIOL CHEM, V265, P21285; KADOWAKI H, 1991, 73RD ANN M END SOC B, P310; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KASUGA M, 1982, NATURE, V298, P667, DOI 10.1038/298667a0; KUSARI J, 1991, J BIOL CHEM, V266, P5260; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MOLLER DE, 1988, NEW ENGL J MED, V319, P1526, DOI 10.1056/NEJM198812083192306; MOLLER DE, 1990, J BIOL CHEM, V265, P14979; MOLLER DE, 1991, J BIOL CHEM, V266, P10995; MOMOMURA K, 1988, BIOCHEM BIOPH RES CO, V155, P1181, DOI 10.1016/S0006-291X(88)81264-6; MOXHAM CP, 1989, J BIOL CHEM, V264, P13238; ODAWARA M, 1989, SCIENCE, V245, P66, DOI 10.1126/science.2544998; PETRUZZELLI L, 1986, P NATL ACAD SCI USA, V83, P4710, DOI 10.1073/pnas.83.13.4710; RIDGE KD, 1988, P NATL ACAD SCI USA, V85, P9489, DOI 10.1073/pnas.85.24.9489; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SHIER P, 1989, J BIOL CHEM, V264, P14605; SOOS MA, 1989, BIOCHEM J, V263, P553, DOI 10.1042/bj2630553; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUNG CK, 1989, J BIOL CHEM, V264, P18951; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; TAYLOR SI, 1990, DIABETES CARE, V13, P257, DOI 10.2337/diacare.13.3.257; TORDJMAN KM, 1990, BIOCHEM J, V271, P201, DOI 10.1042/bj2710201; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TORNQVIST HE, 1988, J BIOL CHEM, V263, P4593; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; TREADWAY JL, 1991, P NATL ACAD SCI USA, V88, P214, DOI 10.1073/pnas.88.1.214; TREADWAY JL, 1989, J BIOL CHEM, V264, P21450; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WEILAND M, 1990, BIOCHEM J, V270, P331, DOI 10.1042/bj2700331; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1989, BIOCHEMISTRY-US, V28, P785, DOI 10.1021/bi00428a056	55	56	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8383	8389						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1314826				2022-12-27	WOS:A1992HQ18500067
J	MACGREGOR, TM; COPELAND, NG; JENKINS, NA; GIGUERE, V				MACGREGOR, TM; COPELAND, NG; JENKINS, NA; GIGUERE, V			THE MURINE GENE FOR CELLULAR RETINOIC ACID-BINDING PROTEIN TYPE-II - GENOMIC ORGANIZATION, CHROMOSOMAL LOCALIZATION, AND POSTTRANSCRIPTIONAL REGULATION BY RETINOIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; EMBRYONAL CARCINOMA-CELLS; MOLECULAR-CLONING; GROWTH-FACTOR; GM-CSF; RECEPTOR; IDENTIFICATION; EXPRESSION; DIFFERENTIATION; STABILITY	The cellular retinoic acid-binding protein type II (CRABP-II) is a member of the serum and cytoplasmic retinoid-binding protein family. It is expressed during embryonic development and in adult skin and is up-regulated by retinoic acid (RA) in F9 teratocarcinoma cells. We have determined the genomic organization of the murine CRABP-II gene and performed a detailed analysis of its transcriptional unit. The CRABP-II gene, located on mouse chromosome 2, is approximately 4.6 kilobases long and divided into four exons in a structure common to other members of the family of serum and cellular retinoid-binding proteins. Primer extension analysis and S1 nuclease protection assay were used to identify the transcription initiation site which is located 27 base pairs downstream of a typical TATAA box. Sequence analysis of the promoter also revealed a GC-rich region with overlapping putative SP1-binding sites at nucleotides -61 and AP-1 and AP-2-binding sites at nucleotides -518 and -544, respectively. The 3'-untranslated region contains two copies of the pentanucleotide AUUUA shown to be involved in messenger RNA destabilization. Consensus sequence for retinoic acid response elements were not detected in the promoter region of the CRABP-II gene. Results of nuclear run on experiments show that the CRABP-II gene is not transcriptionally activated by RA in F9 teratocarcinoma cells. These results suggest that the up-regulation of CRABP-II mRNA levels by RA is mainly controlled by a post-transcriptional mechanism.	HOSP SICK CHILDREN,RES INST,DIV ENDOCRINOL,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA; NCI,FREDERICK CANC RES & DEV CTR,MAMMALIAN GENET LAB,ABL BASIC RES PROGRAM,FREDERICK,MD 21702	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick				Giguere, Vincent/0000-0001-9567-3694	OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ALTABA ARI, 1991, GENE DEV, V5, P175, DOI 10.1101/gad.5.2.175; AMOS B, 1990, METHOD ENZYMOL, V190, P217; ASTROM A, 1991, J BIOL CHEM, V266, P17662; AVNER P, 1988, TRENDS GENET, V4, P18, DOI 10.1016/0168-9525(88)90123-0; BAILEY JS, 1988, J BIOL CHEM, V263, P9326; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BLOMHOFF R, 1990, SCIENCE, V250, P399, DOI 10.1126/science.2218545; BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BUCHBERG AM, 1988, ONCOGENE RES, V2, P149; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHYTIL F, 1984, RETINOIDS, V2, P89; COLBERGPOLEY AM, 1987, DIFFERENTIATION, V35, P206, DOI 10.1111/j.1432-0436.1987.tb00170.x; DEMMER LA, 1987, J BIOL CHEM, V262, P2458; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; ESPESETH AS, 1989, GENE DEV, V3, P1647, DOI 10.1101/gad.3.11.1647; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GIGUERE V, 1990, P NATL ACAD SCI USA, V87, P6233, DOI 10.1073/pnas.87.16.6233; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GRAVES RA, 1987, CELL, V48, P615, DOI 10.1016/0092-8674(87)90240-6; Green EL, 1981, GENETICS PROBABILITY, P77; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KITAMOTO T, 1988, BIOCHEM BIOPH RES CO, V157, P1302, DOI 10.1016/S0006-291X(88)81016-7; LAROSA GJ, 1988, P NATL ACAD SCI USA, V85, P329, DOI 10.1073/pnas.85.2.329; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARTIN CA, 1990, P NATL ACAD SCI USA, V87, P4804, DOI 10.1073/pnas.87.12.4804; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL RL, 1985, CELL, V40, P29; NIELSEN DA, 1990, MOL ENDOCRINOL, V4, P953, DOI 10.1210/mend-4-7-953; NILSSON MHL, 1988, EUR J BIOCHEM, V173, P45, DOI 10.1111/j.1432-1033.1988.tb13964.x; PACHTER JS, 1987, CELL, V51, P283, DOI 10.1016/0092-8674(87)90155-3; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; ROSSANT J, 1989, TRENDS GENET, V5, P277, DOI 10.1016/0168-9525(89)90102-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHUBEITA HE, 1987, P NATL ACAD SCI USA, V84, P5645, DOI 10.1073/pnas.84.16.5645; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SIMEONE A, 1989, Molecular Reproduction and Development, V1, P107, DOI 10.1002/mrd.1080010205; SIMEONE A, 1991, MECH DEVELOP, V33, P215, DOI 10.1016/0925-4773(91)90029-6; SIRACUSA LD, 1990, GENOMICS, V6, P491, DOI 10.1016/0888-7543(90)90479-E; SIVE HL, 1990, GENE DEV, V4, P932, DOI 10.1101/gad.4.6.932; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SUVA LJ, 1991, MOL CELL BIOL, V11, P2503, DOI 10.1128/MCB.11.5.2503; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TAKASE S, 1986, ARCH BIOCHEM BIOPHYS, V247, P328, DOI 10.1016/0003-9861(86)90591-6; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VAESSEN MJ, 1989, DIFFERENTIATION, V40, P99, DOI 10.1111/j.1432-0436.1989.tb00819.x; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WEI LN, 1990, DNA CELL BIOL, V9, P471, DOI 10.1089/dna.1990.9.471; WEI LN, 1991, DEVELOPMENT, V112, P847; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	76	53	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7777	7783						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1313808				2022-12-27	WOS:A1992HN48500082
J	NORTH, JA; SPECTOR, AA; BUETTNER, GR				NORTH, JA; SPECTOR, AA; BUETTNER, GR			DETECTION OF LIPID RADICALS BY ELECTRON-PARAMAGNETIC RESONANCE SPIN TRAPPING USING INTACT-CELLS ENRICHED WITH POLYUNSATURATED FATTY-ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MURINE LEUKEMIA-CELLS; PEROXIDATION; SENSITIVITY; CHEMISTRY; METALS	Electron paramagnetic resonance (EPR) spin trapping was used to detect lipid-derived free radicals generated by iron-induced oxidative stress in intact cells. Using the spin trap alpha-(4-pyridyl 1-oxide)-N-tert-butylnitrone (POBN), carbon-centered radical adducts were detected. These lipid-derived free radicals were formed during incubation of ferrous iron with U937 cells that were enriched with docosahexaenoic acid (22:6n-3). The EPR spectra exhibited apparent hyperfine splittings characteristic of a POBN/alkyl radical, a(N) = 15.63 +/- 0.06 G and a(H) = 2.66 +/- 0.03 G, generated as a result of beta-scission of alkoxyl radicals. Spin adduct formation depended on the FeSO4 content of the incubation medium and the number of 22:6-enriched cells present; when the cells were enriched with oleic acid (18:1n-9), spin adducts were not detected. This is the first direct demonstration, using EPR, of a lipid-derived radical formed in intact cells in response to oxidant stress.	UNIV IOWA,COLL MED,DEPT BIOCHEM,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT BIOCHEM,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,ELECTRON SPIN RESONANCE FACIL,IOWA CITY,IA 52242	University of Iowa; University of Iowa; University of Iowa			Spector, Arthur/AAG-9860-2020	Buettner, Garry/0000-0002-5594-1903	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039308] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 39308] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BUETTNER GR, 1988, J BIOCHEM BIOPH METH, V16, P27, DOI 10.1016/0165-022X(88)90100-5; BUETTNER GR, 1990, METHOD ENZYMOL, V186, P127; BUETTNER GR, 1990, METHOD ENZYMOL, V186, P125; BUETTNER GR, 1987, FREE RADICAL BIO MED, V3, P295; BURNS CP, 1987, LIPIDS, V22, P178, DOI 10.1007/BF02537299; BURNS CP, 1986, BIOCHIM BIOPHYS ACTA, V888, P10, DOI 10.1016/0167-4889(86)90064-9; BURNS CP, 1977, LIPIDS, V12, P747, DOI 10.1007/BF02570907; CHAMULITRAT W, 1990, ARCH BIOCHEM BIOPHYS, V282, P65, DOI 10.1016/0003-9861(90)90087-F; DAVIES MJ, 1987, CHEM PHYS LIPIDS, V44, P149, DOI 10.1016/0009-3084(87)90048-X; FOLCH J, 1957, J BIOL CHEM, V226, P497; GARDNER HW, 1989, FREE RADICAL BIO MED, V7, P65, DOI 10.1016/0891-5849(89)90102-0; GUFFY MM, 1984, CANCER RES, V44, P1863; Halliwell B., 1989, FREE RADICAL BIO MED, V2nd; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; IWAHASHI H, 1991, ARCH BIOCHEM BIOPHYS, V285, P172, DOI 10.1016/0003-9861(91)90346-K; MILLER DM, 1990, FREE RADICAL BIO MED, V8, P95, DOI 10.1016/0891-5849(90)90148-C; MORRISON WR, 1964, J LIPID RES, V5, P600; PEDERSON TC, 1975, BIOCHIM BIOPHYS ACTA, V385, P232, DOI 10.1016/0304-4165(75)90351-7; Poli G, 1987, Free Radic Res Commun, V3, P251, DOI 10.3109/10715768709069790; PORTER NA, 1984, METHOD ENZYMOL, V105, P273; ROSEN GM, 1981, P NATL ACAD SCI-BIOL, V78, P7346, DOI 10.1073/pnas.78.12.7346; TIEN M, 1981, FED PROC, V40, P179	22	63	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5743	5746						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1313417				2022-12-27	WOS:A1992HK31800006
J	AUSIELLO, DA; STOW, JL; CANTIELLO, HF; DEALMEIDA, JB; BENOS, DJ				AUSIELLO, DA; STOW, JL; CANTIELLO, HF; DEALMEIDA, JB; BENOS, DJ			PURIFIED EPITHELIAL NA+ CHANNEL COMPLEX CONTAINS THE PERTUSSIS TOXIN-SENSITIVE G-ALPHA-I-3 PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; SODIUM-CHANNEL; ALPHA-SUBUNIT; CELL LINE; LOCALIZATION; INHIBITION; ANTIBODIES; TRANSPORT; LLC-PK1; CYCLASE	We have recently demonstrated that the amiloride-sensitive Na+ channel in the apical membrane of the renal epithelial cell line, A6, is modulated by the alpha(i-3) subunit of the G(i-3) protein. We also showed that a 700-kDa protein complex can be purified from the membranes of A6 epithelia which (a) can reconstitute the amiloride-sensitive Na+ influx in liposomes and planar bilayer membranes and (b) consists of six major protein bands observed on reducing sodium dodecyl sulfate-polyacrylamide gels with molecular masses ranging from 35 to 320 kDa. The present study was undertaken to determine if the alpha(i-3) subunit was a member of this Na+ channel complex. G-alpha(i) structure and function were identified by Western blotting with specific G-alpha(i) subunit antibodies and Na+ channel antibodies, through ADP-ribosylation with pertussis toxin, and by immunocytochemical localization of the Na+ channel and G-alpha(i) proteins. We demonstrate that two protein substrates are ADP-ribosylated in the 700-kDa complex in the presence of pertussis toxin and are specifically immunoprecipitated with an anti-Na+ channel polyclonal antibody. One of these substrates, a 41-kDa protein, was identified as the alpha(i-3) subunit of the G(i-3) protein on Western blots with specific antibodies. Na+ channel antibodies do not recognize G-alpha(i-3) on Western blots of Golgi membranes which contain alpha(i-3) but not Na+ channel proteins, nor do they immunoprecipitate alpha(i-3) from solubilized Golgi membranes; however, alpha(i-3) is coprecipitated as part of the Na+ channel complex from A6 cell membranes by polyclonal Na+ channel antibodies. Both alpha(i-3) and the Na+ channel have been localized in A6 cells by confocal imaging and immunofluorescence with specific antibodies and are found to be in distinct but adjacent domains of the apical cell surface. In functional studies, alpha(i-3), but not alpha(i-2), stimulates Na+ channel activity. These data are therefore consistent with the localization of Na+ channel activity and modulatory alpha(i-3) protein at the apical plasma membrane, which together represent a specific signal transduction pathway for ion channel regulation.	HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02114; UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Alabama System; University of Alabama Birmingham	AUSIELLO, DA (corresponding author), MASSACHUSETTS GEN HOSP,RENAL UNIT,149 13TH ST,8TH FL,BOSTON,MA 02129, USA.		Stow, Jennifer/I-4723-2013	Stow, Jennifer/0000-0002-5409-9101	NIDDK NIH HHS [DK37206, DK19406] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019406, R37DK019406, R01DK037206] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANANDSRIVASTAVA MB, 1989, J BIOL CHEM, V264, P9491; BENOS DJ, 1987, J BIOL CHEM, V262, P10613; Birnbaumer L, 1985, Recent Prog Horm Res, V41, P41; BROWN D, 1989, AM J PHYSIOL, V256, pF366, DOI 10.1152/ajprenal.1989.256.2.F366; CANTIELLO HF, 1990, J BIOL CHEM, V265, P21624; CANTIELLO HF, 1986, BIOCHEM BIOPH RES CO, V134, P852, DOI 10.1016/S0006-291X(86)80498-3; CANTIELLO HF, 1989, J BIOL CHEM, V264, P20867; CANTIELLO HF, 1991, AM J PHYSIOL, V261, pC882, DOI 10.1152/ajpcell.1991.261.5.C882; CODINA J, 1987, SCIENCE, V236, P442, DOI 10.1126/science.2436299; EHRENREICH JH, 1973, J CELL BIOL, V59, P45, DOI 10.1083/jcb.59.1.45; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; HAMILTON KL, 1985, AM J PHYSIOL, V249, pC200, DOI 10.1152/ajpcell.1985.249.3.C200; HUBERT JJ, 1986, BIOCHEMISTRY-US, V25, P4156, DOI 10.1021/bi00362a025; HUFF RM, 1986, J BIOL CHEM, V261, P1105; MOHRMANN M, 1987, AM J PHYSIOL, V253, pF372, DOI 10.1152/ajprenal.1987.253.2.F372; PALMER LG, 1988, FASEB J, V2, P3061, DOI 10.1096/fasebj.2.15.2461326; PERKINS FM, 1981, AM J PHYSIOL, V241, pC154, DOI 10.1152/ajpcell.1981.241.3.C154; SARIBANSOHRABY S, 1988, J BIOL CHEM, V263, P13875; SARIBANSOHRABY S, 1986, BIOCHEMISTRY-US, V25, P4639, DOI 10.1021/bi00364a028; SHEN RF, 1986, J BIOL CHEM, V261, P1585; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SMITH P R, 1990, FASEB Journal, V4, pA445; SORSCHER EJ, 1988, AM J PHYSIOL, V255, pC835, DOI 10.1152/ajpcell.1988.255.6.C835; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; TOUSSON A, 1989, J CELL SCI, V93, P349	25	92	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4759	4765						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1311319				2022-12-27	WOS:A1992HF64200072
J	LI, GD; PRALONG, WF; PITTET, D; MAYR, GW; SCHLEGEL, W; WOLLHEIM, CB				LI, GD; PRALONG, WF; PITTET, D; MAYR, GW; SCHLEGEL, W; WOLLHEIM, CB			INOSITOL TETRAKISPHOSPHATE ISOMERS AND ELEVATION OF CYTOSOLIC CA2+ IN VASOPRESSIN-STIMULATED INSULIN-SECRETING RINM5F CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; PROTEIN-KINASE-C; DEPENDENT K+ CHANNELS; FREE CALCIUM; FREE CA-2+; ARGININE-VASOPRESSIN; DIFFERENT MECHANISMS; PLASMA-MEMBRANE; SMOOTH-MUSCLE; ACINAR-CELLS	Signal generation during the stimulation of insulin secretion by arginine vasopressin (AVP) was investigated in RINm5F cells. AVP (0.1-mu-M) caused a biphasic cytosolic Ca2+ ([Ca2+]i) rise, namely a rapid transient marked elevation after stimulation followed by a series of oscillations. In the absence of extracellular Ca2+, the sustained oscillations were abolished, while the initial [Ca2+]i transient was only partly decreased, indicating that the former are due to Ca2+ influx and the latter due mainly to mobilization from internal Ca2+ stores. AVP also evoked a transient depolarization of the average membrane potential. AVP-induced Ca2+ influx during the sustained phase, which was strictly dependent on receptor occupancy, was attenuated by membrane hyperpolarization with diazoxide. However, blockade of Ca2+ channels of the L- or T-type was ineffective. AVP stimulated production of diacylglycerol and inositol phosphates; for the latter both [H-3] inositol labeling and mass determinations were performed. A transient increase in Ins(1,4,5)P3 was followed by a marked enhancement of Ins(1,3,4,5)P4 (8-fold) peaking at 15 s and gradually returning to basal values. Ins(1,3,4,6)P4 and Ins(3,4,5,6)P4 exhibited the most long-lasting augmentation (4- and 1.7-fold, respectively), and therefore correlated best with the period of sustained [Ca2+]i oscillations. InsP5 and InsP6 were not elevated. The effects of AVP, including the stimulation of insulin secretion from perifused cells, were obliterated by a V1 receptor antagonist. In conclusion, AVP induces protracted [Ca2+]i elevation in RINm5F cells which is associated with long-lasting increases in InsP4 isomers. The accumulation of InsP4 isomers reflects receptor occupancy and accelerated metabolism of the inositol phosphates. Activation of second messenger-operated Ca2+ channels is not necessarily implicated because of the attenuating effect of membrane hyperpolarization.	UNIV GENEVA, CTR MED UNIV, DIV BIOCHIM CLIN, CH-1211 GENEVA 4, SWITZERLAND; UNIV GENEVA, DIV MALAD INFECT, CH-1211 GENEVA 4, SWITZERLAND; UNIV GENEVA, RECH MED FDN, CH-1211 GENEVA 4, SWITZERLAND; RUHR UNIV BOCHUM, INST PHYSIOL CHEM, W-4630 BOCHUM, GERMANY	University of Geneva; University of Geneva; University of Geneva; Ruhr University Bochum								AIYAR N, 1986, LIFE SCI, V39, P37, DOI 10.1016/0024-3205(86)90435-2; BALLA T, 1987, J BIOL CHEM, V262, P9952; BANSAL VS, 1990, ANNU REV CELL BIOL, V6, P41, DOI 10.1146/annurev.cellbio.6.1.41; BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BIDEN TJ, 1987, J BIOL CHEM, V262, P9437; BIDEN TJ, 1987, J BIOL CHEM, V262, P3567; BIDEN TJ, 1986, J BIOL CHEM, V261, P1931; CHANGYA L, 1989, FEBS LETT, V251, P43, DOI 10.1016/0014-5793(89)81425-5; DUNNE MJ, 1989, EMBO J, V8, P413, DOI 10.1002/j.1460-2075.1989.tb03392.x; DUNNE MJ, 1987, J MEMBRANE BIOL, V99, P215, DOI 10.1007/BF01995702; DUNNING BE, 1984, PEPTIDES, V5, P871, DOI 10.1016/0196-9781(84)90109-8; DUNNING BE, 1984, AM J PHYSIOL, V246, pE108, DOI 10.1152/ajpendo.1984.246.1.E108; GAO ZY, 1990, J BIOL CHEM, V265, P15724; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GYLFE E, 1988, J BIOL CHEM, V263, P5044; HALLAM TJ, 1989, BIOCHEM J, V259, P125, DOI 10.1042/bj2590125; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; IRVINE RF, 1986, BIOCHEM J, V240, P917, DOI 10.1042/bj2400917; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; IVORRA I, 1991, BIOCHEM J, V273, P317, DOI 10.1042/bj2730317; JACONI MEE, 1988, J BIOL CHEM, V263, P10557; JOSEPH SK, 1989, BIOCHEM J, V258, P261, DOI 10.1042/bj2580261; KANETO A, 1967, ENDOCRINOLOGY, V81, P783, DOI 10.1210/endo-81-4-783; KHALAF LJ, 1988, FEBS LETT, V231, P148, DOI 10.1016/0014-5793(88)80720-8; LI GD, 1988, DIABETOLOGIA, V31, pA514; LI GD, 1990, BIOCHEM J, V272, P637, DOI 10.1042/bj2720637; LI GD, 1991, J BIOL CHEM, V266, P3449; LOESSBERG PA, 1991, J BIOL CHEM, V266, P1363; MALGAROLI A, 1990, J BIOL CHEM, V265, P3005; MANNING M, 1986, J CARDIOVASC PHARM, V8, pS29, DOI 10.1097/00005344-198600087-00007; MARTIN SC, 1989, EMBO J, V8, P3595, DOI 10.1002/j.1460-2075.1989.tb08532.x; MAYR GW, 1990, METHODS INOSITIDE RE, P79; MELDOLESI J, 1987, EXP CELL RES, V171, P271, DOI 10.1016/0014-4827(87)90161-3; MERRITT JE, 1987, J BIOL CHEM, V262, P14912; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; Michell R H, 1979, Biochem Soc Trans, V7, P861; MONACO ME, 1988, BIOCHEM BIOPH RES CO, V151, P717, DOI 10.1016/S0006-291X(88)80339-5; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PETERRIESCH B, 1988, J CLIN INVEST, V81, P1154, DOI 10.1172/JCI113430; PITTET D, 1989, J BIOL CHEM, V264, P18489; PITTET D, 1989, J BIOL CHEM, V264, P7251; PRALONG WF, 1988, FEBS LETT, V242, P79, DOI 10.1016/0014-5793(88)80989-X; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; PRENTKI M, 1988, J BIOL CHEM, V263, P11044; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; REGAZZI R, 1990, J BIOL CHEM, V265, P15003; RICHARDSON SB, 1990, ENDOCRINOLOGY, V126, P1047, DOI 10.1210/endo-126-2-1047; RORSMAN P, 1984, FEBS LETT, V170, P196, DOI 10.1016/0014-5793(84)81398-8; ROSSIER JR, 1989, J BIOL CHEM, V264, P16598; SCHLEGEL W, 1987, NATURE, V329, P719, DOI 10.1038/329719a0; SHEARS SB, 1987, BIOCHEM J, V246, P139, DOI 10.1042/bj2460139; STEPHENS LR, 1988, BIOCHEM J, V249, P283, DOI 10.1042/bj2490283; THORN P, 1991, J MEMBRANE BIOL, V124, P63, DOI 10.1007/BF01871365; TRAUTMANN ME, 1987, BIOCHEM J, V242, P625, DOI 10.1042/bj2420625; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VANRENTERGHEM C, 1988, P NATL ACAD SCI USA, V85, P9365; WOLLHEIM CB, 1984, FEBS LETT, V177, P17, DOI 10.1016/0014-5793(84)80972-2; WOLLHEIM CB, 1986, ANN NY ACAD SCI, V488, P317; WOLLHEIM CB, 1990, FEBS LETT, V268, P376, DOI 10.1016/0014-5793(90)81289-Z; WOLLHEIM CB, 1984, J BIOL CHEM, V259, P2262; WOLLHEIM CB, 1986, J BIOL CHEM, V261, P8314	66	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4349	4356						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1311307				2022-12-27	WOS:A1992HF64200017
J	PATTI, JM; JONSSON, H; GUSS, B; SWITALSKI, LM; WIBERG, K; LINDBERG, M; HOOK, M				PATTI, JM; JONSSON, H; GUSS, B; SWITALSKI, LM; WIBERG, K; LINDBERG, M; HOOK, M			MOLECULAR CHARACTERIZATION AND EXPRESSION OF A GENE ENCODING A STAPHYLOCOCCUS-AUREUS COLLAGEN ADHESIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRONECTIN-BINDING PROTEIN; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; STREPTOCOCCI; IV; ATTACHMENT; RECEPTOR; LAMININ; CLONING; COWAN-1	Some strains of Staphylococcus aureus bind collagen with a high degree of specificity and affinity. This interaction can represent a mechanism of substrate adhesion and may be an important step in the pathogenesis of osteomyelitis and infectious arthritis. We now report on the cloning, sequencing, and expression of a gene named cna, encoding a S. aureus collagen adhesin. The cna gene was isolated from a lambda-GT11 S. aureus genomic library and encodes an 1185 amino acid polypeptide. The deduced amino acid sequence reveals several structural characteristics similar to previously described Gram-positive bacterial cell surface proteins. Antibodies raised against the native collagen adhesin from S. aureus recognize the recombinant collagen adhesin. Collagen binding activity can be detected in a lysate obtained from Escherichia coli cells, which harbor the cloned cna gene on an expression plasmid. Collagen-binding proteins can be detected in the lysate when analyzed by a Western blot type assay in which the membrane-transferred proteins are probed with radioactively labeled collagen. Finally, the bacterial lysate containing the recombinant adhesin can effectively inhibit the binding of soluble collagen to cells of S. aureus.	UNIV ALABAMA,DEPT MICROBIOL,BIRMINGHAM,AL 35294; SWEDISH UNIV AGR SCI,DEPT MICROBIOL,S-75007 UPPSALA,SWEDEN	University of Alabama System; University of Alabama Birmingham; Swedish University of Agricultural Sciences	PATTI, JM (corresponding author), UNIV ALABAMA,DEPT BIOCHEM,BIRMINGHAM,AL 35294, USA.			Guss, Bengt/0000-0002-7044-0701; Jonsson, Hans/0000-0003-0589-4886	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047313] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47313] Funding Source: Medline; PHS HHS [A12062] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ausubel FM., 2006, ENZYMATIC MANIPULATI; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; CARRET G, 1985, ANN INST PASTEUR MIC, V136A, P241, DOI 10.1016/S0769-2609(85)80063-6; CHHATWAL GS, 1987, INFECT IMMUN, V55, P1878, DOI 10.1128/IAI.55.8.1878-1883.1987; DEBOER HA, 1983, P NATL ACAD SCI USA, V80, P22; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EMODY L, 1989, J BACTERIOL, V171, P6674; FITZGERALD TJ, 1984, BRIT J VENER DIS, V60, P357; FLOCK JI, 1987, EMBO J, V6, P2351, DOI 10.1002/j.1460-2075.1987.tb02511.x; FROMAN G, 1987, J BIOL CHEM, V262, P6564; GIBSON X, 1984, STUDIES EPSTEINBARR; GUSS B, 1986, EMBO J, V5, P1567, DOI 10.1002/j.1460-2075.1986.tb04398.x; GUSS B, 1984, EUR J BIOCHEM, V138, P413, DOI 10.1111/j.1432-1033.1984.tb07931.x; HAWIGER J, 1982, BIOCHEMISTRY-US, V21, P1407, DOI 10.1021/bi00535a047; HOLDERBAUM D, 1986, INFECT IMMUN, V54, P359, DOI 10.1128/IAI.54.2.359-364.1986; HOLDERBAUM D, 1987, J CLIN MICROBIOL, V25, P2258, DOI 10.1128/JCM.25.12.2258-2261.1987; HOLLINGSHEAD SK, 1986, J BIOL CHEM, V261, P1677; HUNTER W, 1978, HDB EXPT IMMUNOLOGY; KOSTRZYNSKA M, 1989, FEMS MICROBIOL LETT, V59, P229; KUUSELA P, 1978, NATURE, V276, P718, DOI 10.1038/276718a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU T, 1990, ORAL MICROBIOL IMMUN, V5, P131, DOI 10.1111/j.1399-302X.1990.tb00410.x; LOFDAHL S, 1983, P NATL ACAD SCI-BIOL, V80, P697, DOI 10.1073/pnas.80.3.697; Maniatis T., 1982, MOL CLONING; OLSSON A, 1987, EUR J BIOCHEM, V168, P319, DOI 10.1111/j.1432-1033.1987.tb13423.x; REESE CA, 1981, BIOCHEMISTRY-US, V20, P5443, DOI 10.1021/bi00522a014; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEEWIND O, 1990, J BACTERIOL, V172, P3310, DOI 10.1128/jb.172.6.3310-3317.1990; SIGNAS C, 1989, P NATL ACAD SCI USA, V86, P699, DOI 10.1073/pnas.86.2.699; SPEZIALE P, 1986, J BACTERIOL, V167, P77, DOI 10.1128/jb.167.1.77-81.1986; SWITALSKI LM, 1989, J BIOL CHEM, V264, P21080; SWITALSKI LM, 1989, MOL MECHANISMS MICRO; TARKKANEN AM, 1990, MOL MICROBIOL, V4, P1353, DOI 10.1111/j.1365-2958.1990.tb00714.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERCELLOTTI GM, 1985, AM J PATHOL, V120, P13; WALDVOGEL FA, 1980, NEW ENGL J MED, V303, P360, DOI 10.1056/NEJM198008143030703; WESTERLUND B, 1989, MOL MICROBIOL, V3, P329, DOI 10.1111/j.1365-2958.1989.tb00178.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	39	220	233	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4766	4772						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1311320				2022-12-27	WOS:A1992HF64200073
J	BEJCEK, BE; HOFFMAN, RM; LIPPS, D; LI, DY; MITCHELL, CA; MAJERUS, PW; DEUEL, TF				BEJCEK, BE; HOFFMAN, RM; LIPPS, D; LI, DY; MITCHELL, CA; MAJERUS, PW; DEUEL, TF			THE V-SIS ONCOGENE PRODUCT BUT NOT PLATELET-DERIVED GROWTH-FACTOR (PDGF) A HOMODIMERS ACTIVATE PDGF ALPHA AND BETA-RECEPTORS INTRACELLULARLY AND INITIATE CELLULAR-TRANSFORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN SARCOMA-VIRUS; PHOSPHOLIPASE-C-GAMMA; FACTOR A-CHAIN; TYROSINE PHOSPHORYLATION; AUTOCRINE TRANSFORMATION; SIGNALING COMPLEX; HUMAN-FIBROBLASTS; KINASE-ACTIVITY; GENE-PRODUCT; CDNA CLONES	The v-sis oncogene product p28v-sis and the platelet-derived growth factor (PDGF) B chain share 92% homology with each other and over 50% homology with the PDGF A chain. Exogenously added homodimers of PDGF A and PDGF B and of p28v-sis are potent mitogens but only PDGF B and p28v-sis induce transformation when endogenously expressed with a strong promoter. Because exogenous PDGF AA and PDGF BB both initiate a full mitogenic response, understanding the mechanisms underlying the difference in their transforming potential may clarify how growth factor genes act as oncogenes. In this work, we compared cells expressing high levels of PDGF A and v-sis. We observed that transformation by v-sis correlated directly with the rapid degradation (t1/2 approximately 20 min) of the alpha and beta-PDGF receptors, with a failure of either the alpha or beta-receptor to be fully processed and with the association of high levels of phosphatidylinositol (PI) 3-kinase with immunoprecipitates of the PDGF receptors. In contrast, in cells expressing essentially equal levels of PDGF A, transformation was not detected, alpha and beta-PDGF receptor processing was normal, and association of PI 3-kinase with receptors in immunoprecipitates was not found above control values. The ability of v-sis to autoactivate PDGF receptors within processing compartments and to initiate activation of the PI 3-kinase signaling pathway coupled with the failure of PDGF A to activate its receptor intracellularly and to induce transformation when endogenously expressed at high levels suggests that the internal autoactivation of PDGF receptors may be essential for transformation by v-sis.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DIV HEMATOL ONCOL,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL)	BEJCEK, BE (corresponding author), UNIV MINNESOTA,MED & PATHOL LAB,MINNEAPOLIS,MN 55455, USA.			Mitchell, Christina A/0000-0001-9372-3192	NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147, R01HL031102, R37HL031102] Funding Source: NIH RePORTER; NCI NIH HHS [CA49712] Funding Source: Medline; NHLBI NIH HHS [HL31102, HL14147] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BYWATER M, 1988, MOL CELL BIOL, V8, P2753, DOI 10.1128/MCB.8.7.2753; CHU IM, 1984, CELL, V37, P123; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; GELMANN EP, 1981, P NATL ACAD SCI-BIOL, V78, P3373, DOI 10.1073/pnas.78.6.3373; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANNINK M, 1986, J CELL BIOL, V103, P2311, DOI 10.1083/jcb.103.6.2311; HANNINK M, 1988, J CELL BIOL, V107, P287, DOI 10.1083/jcb.107.1.287; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HUANG JS, 1984, CELL, V39, P79, DOI 10.1016/0092-8674(84)90193-4; HUANG SS, 1988, J BIOL CHEM, V263, P12608; JOHNSSON A, 1984, EMBO J, V3, P951; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KEATING MT, 1987, J BIOL CHEM, V262, P7932; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAROCHELLE WJ, 1990, SCIENCE, V248, P1541, DOI 10.1126/science.2163109; LIPS DL, 1989, J BIOL CHEM, V264, P8759; LOKESHWAR VB, 1990, J BIOL CHEM, V265, P1665; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; RATNER L, 1985, NUCLEIC ACIDS RES, V13, P5007, DOI 10.1093/nar/13.14.5007; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; TARTAKOFF AM, 1983, CELL, V32, P926; TONG BD, 1987, NATURE, V328, P619, DOI 10.1038/328619a0; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	44	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3289	3293						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1310684				2022-12-27	WOS:A1992HD15400074
J	BOUILLON, R; ALLEWAERT, K; VANLEEUWEN, JPTM; TAN, BK; XIANG, DZ; DECLERCQ, P; VANDEWALLE, M; POLS, HAP; BOS, MP; VANBAELEN, H; BIRKENHAGER, JC				BOUILLON, R; ALLEWAERT, K; VANLEEUWEN, JPTM; TAN, BK; XIANG, DZ; DECLERCQ, P; VANDEWALLE, M; POLS, HAP; BOS, MP; VANBAELEN, H; BIRKENHAGER, JC			STRUCTURE-FUNCTION ANALYSIS OF VITAMIN-D ANALOGS WITH C-RING MODIFICATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-BINDING-PROTEIN; CHAIN HYDROXYLATED METABOLITES; ORGANOSELENIUM CHEMISTRY; CALCIUM-METABOLISM; DIFFERENTIATION; 1,25-DIHYDROXYVITAMIN-D3; 25-HYDROXYVITAMIN-D3; PROLIFERATION; KETONES; INVITRO	Analogs of 1-alpha,25-dihydroxyvitamin D3 (1-alpha,25-(OH)2D3) with substitutions on C-11 were synthesized. Small apolar substitutions (11-alpha-methyl, 11-alpha-fluoromethyl) did not markedly decrease the affinity for the vitamin D receptor, but larger (11-alpha-chloromethyl or 11-alpha- or, 11-beta-phenyl) or more polar substitutions (11-alpha-hydroxymethyl, 11-alpha-(2-hydroxyethyl)) decreased the affinity to less than 5% of that of 1-alpha,25-OH)2D3. Their affinity for the vitamin D-binding protein, however, increased up to 4-fold. The biological activity of 11-alpha-methyl-1-alpha,25-(OH)2D3 closely resembled that of the natural hormone on normal and leukemic cell proliferation and bone resorption, whereas its in vivo effect on calcium metabolism of the rachitic chick was about 50% of that of 1-alpha,25-(OH)2D3. The 11-beta-methyl analog had a > 10-fold lower activity. The differentiating effects of the other C-11 analogs on human promyeloid leukemia cells (HL-60) agreed well with their bone-resorbing activity and receptor affinity, but they demonstrated lower calcemic effects in vivo. Large or polar substitutions on C-11 of 1-alpha,25-(OH)2D3 thus impair the binding to the vitamin D receptor but increase the affinity to vitamin D-binding protein. The effects of many C-11-substituted 1-alpha,25-(OH)2D3 analogs on HL-60 cell differentiation exceeded their activity on calcium metabolism.	STATE UNIV GHENT,ORGAN CHEM LAB,B-9000 GHENT,BELGIUM; ERASMUS UNIV ROTTERDAM,SCH MED,DEPT INTERNAL MED 3,3000 DR ROTTERDAM,NETHERLANDS; LAB CELL BIOL & HISTOL,LEIDEN,NETHERLANDS	Ghent University; Erasmus University Rotterdam	BOUILLON, R (corresponding author), CATHOLIC UNIV LEUVEN,ONDERWIJS NAVORSING,EXPTL GENEESKUNDE ENDOCRINOL LAB,B-3000 LOUVAIN,BELGIUM.		van Leeuwen, Johannes/D-5015-2014	van Leeuwen, Johannes/0000-0002-2282-4006				BAGGIOLINI EG, 1986, J ORG CHEM, V51, P3098, DOI 10.1021/jo00366a004; BINDERUP L, 1988, BIOCHEM PHARMACOL, V37, P889, DOI 10.1016/0006-2952(88)90177-3; BOUILLON R, 1980, J STEROID BIOCHEM, V13, P1029, DOI 10.1016/0022-4731(80)90133-8; BOUILLON R, 1989, SAUDI MED J, V140, P260; BOUILLON R, 1986, BINDING PROTEINS STE, P333; BOUILLON R, 1989, J BONE MINER RES  S1, V4, P734; BROWN AJ, 1989, J CLIN INVEST, V84, P728, DOI 10.1172/JCI114229; COX DP, 1984, J ORG CHEM, V49, P3216, DOI 10.1021/jo00191a035; DELUCA HF, 1989, P SOC EXP BIOL MED, V192, P224; HADDAD JG, 1987, BONE MINER RES, V5, P281; IRELAND RE, 1983, J AM CHEM SOC, V105, P1988, DOI 10.1021/ja00345a055; KAWAKAMI M, 1979, BIOCHEM J, V179, P413, DOI 10.1042/bj1790413; KO JS, 1981, AM J ANAT, V4161, P415; KRAGBALLE K, 1988, BRIT J DERMATOL, V119, P223, DOI 10.1111/j.1365-2133.1988.tb03204.x; LIPSHUTZ BH, 1984, TETRAHEDRON, V40, P5005, DOI 10.1016/S0040-4020(01)91251-7; LIPSHUTZ BH, 1987, SYNTHESIS-STUTTGART, P325; MALLON JP, 1980, J STEROID BIOCHEM, V13, P409, DOI 10.1016/0022-4731(80)90347-7; MANOLAGAS SC, 1985, MOL CELL ENDOCRINOL, V43, P113, DOI 10.1016/0303-7207(85)90074-7; MASCARENAS JL, 1986, J ORG CHEM, V51, P1269, DOI 10.1021/jo00358a019; NORMAN AW, 1991, VITAMIN DMOL CELLULA; OKANO T, 1989, BIOCHEM BIOPH RES CO, V163, P1444, DOI 10.1016/0006-291X(89)91140-6; PARTRIDG.JJ, 1974, HELV CHIM ACTA, V57, P764, DOI 10.1002/hlca.19740570330; PAULSON SK, 1990, J BONE MINER RES, V5, P201, DOI 10.1002/jbmr.5650050214; POLS HAP, 1987, BIOCHIM BIOPHYS ACTA, V931, P115, DOI 10.1016/0167-4889(87)90197-2; Posner G. H., 1972, ORG REACTIONS, V19, P1; PUMAR C, 1988, VITAMIN D MOL CELLUL, P54; REICH HJ, 1974, J ORG CHEM, V39, P2133, DOI 10.1021/jo00928a042; REICH HJ, 1973, J AM CHEM SOC, V95, P5813, DOI 10.1021/ja00798a090; REICHEL H, 1989, NEW ENGL J MED, V320, P980, DOI 10.1056/NEJM198904133201506; REVELLE L, 1984, BIOCHEMISTRY-US, V23, P1983, DOI 10.1021/bi00304a016; SARDINA FJ, 1986, J ORG CHEM, V51, P1264, DOI 10.1021/jo00358a018; SUDA T, 1989, P SOC EXP BIOL MED, V191, P214; TEUTSCH G, 1988, J STEROID BIOCHEM, V31, P549, DOI 10.1016/0022-4731(88)90006-4; VANBAELEN H, 1986, BINDING PROTEINS STE, P69; VANHAM G, 1988, J STEROID BIOCHEM, V29, P381, DOI 10.1016/0022-4731(88)90246-4; WILHELM F, 1984, ARCH BIOCHEM BIOPHYS, V233, P322, DOI 10.1016/0003-9861(84)90452-1; YONEDA T, 1989, J BONE MINER RES  S1, V4, P559; ZHOU JY, 1989, BLOOD, V74, P82	38	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3044	3051						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1310680				2022-12-27	WOS:A1992HD15400037
J	CARAFOLI, E				CARAFOLI, E			THE CA2+ PUMP OF THE PLASMA-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CALMODULIN-BINDING DOMAIN; DEPENDENT PROTEIN-KINASE; AMINO-ACID-SEQUENCE; HUMAN-ERYTHROCYTE-MEMBRANE; ION MOTIVE ATPASES; LIGHT CHAIN KINASE; CELL CALCIUM-PUMP; HUMAN RED-CELLS; CA-2+ PUMP; CA-2+-PUMPING ATPASE				CARAFOLI, E (corresponding author), SWISS FED INST TECHNOL,INST BIOCHEM,CH-8092 ZURICH,SWITZERLAND.		Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094				BENAIM G, 1984, J BIOL CHEM, V259, P8471; BRANDT P, 1988, P NATL ACAD SCI USA, V85, P2914, DOI 10.1073/pnas.85.9.2914; BUSCHMEIER B, 1987, J BIOL CHEM, V262, P9454; CARAFOLI E, 1982, BIOCHIM BIOPHYS ACTA, V683, P279, DOI 10.1016/0304-4173(82)90004-0; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CARONI P, 1981, J BIOL CHEM, V256, P9371; CAVIERES JD, 1984, BIOCHIM BIOPHYS ACTA, V771, P241, DOI 10.1016/0005-2736(84)90539-X; CHOQUETTE D, 1984, BIOCHEM BIOPH RES CO, V125, P908, DOI 10.1016/0006-291X(84)91369-X; CLARK A, 1983, CELL CALCIUM, V4, P83, DOI 10.1016/0143-4160(83)90037-4; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; ENYEDI A, 1991, J BIOL CHEM, V266, P8952; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; ENYEDI A, 1987, J BIOL CHEM, V262, P6425; FALCHETTO R, 1991, J BIOL CHEM, V266, P2930; FESCHENKO MS, 1992, IN PRESS J BIOL CHEM, V267; FILOTEO AG, 1987, J BIOL CHEM, V262, P6526; FONG YL, 1990, J BIOL CHEM, V265, P11091; GOPINATH RM, 1977, BIOCHEM BIOPH RES CO, V77, P1203, DOI 10.1016/S0006-291X(77)80107-1; GREEB J, 1989, J BIOL CHEM, V264, P18569; GREEN NM, 1989, BIOCHEM SOC T, V17, P970; HASSELBACH W, 1982, ANN NY ACAD SCI, V402, P459, DOI 10.1111/j.1749-6632.1982.tb25768.x; JAMES P, 1988, J BIOL CHEM, V263, P2905; JAMES P, 1987, BIOCHEM BIOPH RES CO, V149, P7, DOI 10.1016/0006-291X(87)91597-X; JAMES P, 1989, J BIOL CHEM, V264, P8289; JAMES PH, 1989, BIOCHEMISTRY-US, V28, P4253, DOI 10.1021/bi00436a020; JARRETT HW, 1977, BIOCHEM BIOPH RES CO, V77, P1210, DOI 10.1016/S0006-291X(77)80108-3; KENNELLY PJ, 1987, J BIOL CHEM, V262, P11958; KESSLER F, 1990, J BIOL CHEM, V265, P16012; KLEE CB, 1980, PROTEIN PHOSPHORYLAT, P61; KNAUF PA, 1974, J GEN PHYSIOL, V63, P324, DOI 10.1085/jgp.63.3.324; KOSKKOSICKA D, 1988, J BIOL CHEM, V263, P18184; KOSKKOSICKA D, 1990, BIOCHEMISTRY-US, V29, P1875, DOI 10.1021/bi00459a030; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MURACHI T, 1983, TRENDS BIOCHEM SCI, V8, P167, DOI 10.1016/0968-0004(83)90165-2; NEYSES L, 1985, J BIOL CHEM, V260, P283; NIGGLI V, 1982, J BIOL CHEM, V257, P2350; NIGGLI V, 1981, J BIOL CHEM, V256, P395; NIGGLI V, 1979, J BIOL CHEM, V254, P9955; NIGGLI V, 1981, J BIOL CHEM, V256, P8588; OLSON S, 1991, GENOMICS, V9, P629, DOI 10.1016/0888-7543(91)90356-J; OVCHINNIKOV YA, 1988, FEBS LETT, V227, P235, DOI 10.1016/0014-5793(88)80905-0; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PENNISTON JT, 1982, ANN NY ACAD SCI, V402, P296, DOI 10.1111/j.1749-6632.1982.tb25751.x; Penniston JT, 1983, CALCIUM CELL FUNCTIO, P99; REGA AF, 1986, CA2 PLUS PUMP PLASMA; RONNER P, 1977, ARCH BIOCHEM BIOPHYS, V179, P578, DOI 10.1016/0003-9861(77)90146-1; ROSSI JPFC, 1982, J PHYSIOL-LONDON, V327, P1; SARKADI B, 1980, CELL CALCIUM, V1, P287, DOI 10.1016/0143-4160(80)90031-7; Schatzmann H J, 1978, Ann N Y Acad Sci, V307, P125, DOI 10.1111/j.1749-6632.1978.tb41939.x; SCHATZMANN HJ, 1966, EXPERIENTIA, V22, P364, DOI 10.1007/BF01901136; SCHATZMANN HJ, 1973, J PHYSIOL-LONDON, V235, P551, DOI 10.1113/jphysiol.1973.sp010403; SCHATZMANN HJ, 1982, MEMBRANE TRANSPORT C, P41; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SMALLWOOD JI, 1988, J BIOL CHEM, V263, P2195; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; STREHLER EE, 1991, J MEMBRANE BIOL, V120, P1, DOI 10.1007/BF01868586; STREHLER EE, 1989, P NATL ACAD SCI USA, V86, P6908, DOI 10.1073/pnas.86.18.6908; SZASZ I, 1978, BIOCHIM BIOPHYS ACTA, V512, P331, DOI 10.1016/0005-2736(78)90257-2; TAVERNA RD, 1980, BIOCHEM BIOPH RES CO, V94, P652, DOI 10.1016/0006-291X(80)91282-6; VERMA AK, 1988, J BIOL CHEM, V263, P14152; VORHERR T, 1991, J BIOL CHEM, V266, P22; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; WAISMAN DM, 1981, J BIOL CHEM, V256, P415; WANG KKW, 1991, J BIOL CHEM, V266, P9078; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WANG KKW, 1988, ARCH BIOCHEM BIOPHYS, V260, P696, DOI 10.1016/0003-9861(88)90498-5; ZURINI M, 1984, J BIOL CHEM, V259, P618; ZVARITCH E, 1990, BIOCHEMISTRY-US, V29, P8070, DOI 10.1021/bi00487a012	72	374	379	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2115	2118						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1310307				2022-12-27	WOS:A1992HB53200001
J	LOTERSZTAJN, S; PAVOINE, C; DETERRE, P; CAPEAU, J; MALLAT, A; LENGUYEN, D; DUFOUR, M; ROUOT, B; BATAILLE, D; PECKER, F				LOTERSZTAJN, S; PAVOINE, C; DETERRE, P; CAPEAU, J; MALLAT, A; LENGUYEN, D; DUFOUR, M; ROUOT, B; BATAILLE, D; PECKER, F			ROLE OF G-PROTEIN BETA-GAMMA-SUBUNITS IN THE REGULATION OF THE PLASMA-MEMBRANE CA2+ PUMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; CA-2+ PUMP; RAT-LIVER; ADENYLATE-CYCLASE; PHOSPHOLIPASE-C; INHIBITION; GLUCAGON; (CA-2+-MG-2+)-ATPASE; PURIFICATION; STIMULATION	In Zajdela hepatoma cells (ZHC) the plasma membrane Ca2+ pump displayed no sensitivity to glucagon(19-29) (mini-glucagon), whereas in hepatocyte this metabolite of glucagon evoked a biphasic regulation of the Ca2+ pump system via a cholera toxin-sensitive G protein. Analysis of G protein subunits in ZHC membranes indicated the presence of cholera toxin-sensitive G(s)alpha and G-beta-gamma-proteins, whose functionality was manifested by GTP and NaF stimulation of adenylylcyclase activity, and pertussis toxin-catalyzed ADP-ribosylation of G(i)alpha, respectively. However, immunoblotting experiments suggested a lower content in beta-gamma-subunits in ZHC as compared with hepatocyte plasma membranes. Complementation of ZHC or hepatocyte plasma membranes with purified beta-gamma-subunits from transducin (T-beta-gamma) caused inhibition of the basal activity of the Ca2+ pump at 10 and 300 ng/ml, respectively, and revealed (in ZHC) or increased (in hepatocytes) sensitivity of the system to mini-glucagon. After cholera toxin treatment of ZHC, T-beta-gamma no longer reconstituted the response of the Ca2+ pump to mini-glucagon, suggesting that the mechanism of beta-gamma-action is dependent on an association with the alpha-subunit of a cholera toxin-sensitive G protein. It is concluded that G-beta-gamma-subunits control both the basal activity of the plasma membrane Ca2+ pump and its inhibition by mini-glucagon.	CEN,DEPT RECH FONDAMENTALE,BIOL MOLEC & CELLULAIRE LAB,F-38041 GRENOBLE,FRANCE; UNIV PARIS 06,INSERM,U181,F-75571 PARIS 12,FRANCE; CNRS,INSERM PHARMACOL ENDOCRINOL,F-34094 MONTPELLIER,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	LOTERSZTAJN, S (corresponding author), HOP HENRI MONDOR,INSERM,U99,F-94010 CRETEIL,FRANCE.		Pavoine, Catherine/N-4405-2018; Deterre, Philippe/O-8984-2017; Lotersztajn, Sophie/K-9160-2017	Pavoine, Catherine/0000-0002-0598-5545; Deterre, Philippe/0000-0001-9303-0791; lotersztajn, Sophie/0000-0002-0053-7807				BLACHE P, 1990, J BIOL CHEM, V265, P21514; BOCKAERT J, 1985, EMBO J, V4, P1413, DOI 10.1002/j.1460-2075.1985.tb03795.x; BOKOCH GM, 1987, J BIOL CHEM, V262, P589; BOYER JL, 1989, J BIOL CHEM, V264, P13917; CAPEAU J, 1982, ENDOCRINOLOGY, V111, P993, DOI 10.1210/endo-111-3-993; CASEY PJ, 1988, J BIOL CHEM, V263, P2577; DETERRE P, 1984, FEBS LETT, V178, P228, DOI 10.1016/0014-5793(84)80606-7; HOMBURGER V, 1987, MOL PHARMACOL, V31, P313; JESELMA CL, 1987, P NATL ACAD SCI USA, V84, P3623; KATADA T, 1987, J BIOL CHEM, V262, P11897; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; LACOMBE ML, 1976, NATURE, V262, P70, DOI 10.1038/262070a0; LENGUYEN D, 1988, PEPTIDE CHEM 1987, P391; LINDER ME, 1990, J BIOL CHEM, V265, P8243; LOTERSZTAJN S, 1985, J BIOL CHEM, V260, P9692; LOTERSZTAJN S, 1982, J BIOL CHEM, V257, P6638; LOTERSZTAJN S, 1987, J BIOL CHEM, V262, P3114; LOTERSZTAJN S, 1990, J BIOL CHEM, V265, P9876; LOTERSZTAJN S, 1981, J BIOL CHEM, V256, P1209; MALLAT A, 1987, NATURE, V325, P620, DOI 10.1038/325620a0; MORIARTY TM, 1988, P NATL ACAD SCI USA, V85, P8865, DOI 10.1073/pnas.85.23.8865; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; OKABE K, 1990, J BIOL CHEM, V265, P12854; PAVOINE C, 1987, J BIOL CHEM, V262, P5113; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; UNGER RH, 1990, DIABETES MELLITUS, P104	26	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2375	2379						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1310315				2022-12-27	WOS:A1992HB53200042
J	LIBBY, RD; SHEDD, AL; PHIPPS, AK; BEACHY, TM; GERSTBERGER, SM				LIBBY, RD; SHEDD, AL; PHIPPS, AK; BEACHY, TM; GERSTBERGER, SM			DEFINING THE INVOLVEMENT OF HOCL OR CL2 AS ENZYME-GENERATED INTERMEDIATES IN CHLOROPEROXIDASE-CATALYZED REACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPOUND-I; CHLORINATION; OXIDATION; CHLORIDE	Peroxidatic substrates, catechol (CAT) and 2,4,6-trimethylphenol (TMP) were used as probes of the chloride-dependent reactions catalyzed by chloroperoxidase (CPO). TMP is consumed only in the presence of chloride. TMP is a competitive inhibitor versus CAT, but CAT is a noncompetitive inhibitor versus TMP in chloride-dependent CPO-catalyzed peroxidation reactions. The ratio of TMP versus CAT consumed by the chloride-dependent CPO reaction in direct competition studies increases as the chloride concentration is increased from 1.0 to 400 mM. Ratios of non-enzymatic HOCl reactions under conditions otherwise similar to those of the CPO reactions are relatively insensitive to changes in chloride concentration and are experimentally indistinguishable from the values attained by the enzyme system at high chloride concentrations. Comparison of enzymatic ratios with those of the HOCl reactions indicate that the proportion of the enzymatic reaction involving a freely dissociable, enzyme-generated, oxidized halogen species varies from 10% at low chloride concentrations to essentially 100% at high chloride concentrations. All data are consistent with a mechanism in which chloride competes with CAT for binding to both CPO compound I and the CPO chlorinating intermediate (EOCl). Chloride binding to CPO compound I leads to the formation of EOCl and initiates the CPO chloride-dependent pathway. When CAT binds to either compound I or EOCl, it is directly oxidized to product. When chloride binds to EOCl, it either induces release of HOCl or reacts with EOCl to produce Cl2, which is released from the enzyme. TMP and CAT compete for reaction with the free oxidized halogen species. This is the first direct evidence for kinetically significant involvement of a free oxidized halogen species as an intermediate in any CPO-catalyzed reaction.			LIBBY, RD (corresponding author), COLBY COLL,DEPT CHEM,WATERVILLE,ME 04901, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM042078] Funding Source: NIH RePORTER; NIGMS NIH HHS [1 R15 GM42078-01A2] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CLELAND WW, 1982, METHOD ENZYMOL, V87, P390; CORBETT MD, 1978, BIOCHEM J, V175, P353, DOI 10.1042/bj1750353b; COTTON ML, 1973, CAN J CHEM, V51, P582, DOI 10.1139/v73-088; DUNFORD HB, 1987, ARCH BIOCHEM BIOPHYS, V252, P292, DOI 10.1016/0003-9861(87)90034-8; GEIGERT J, 1983, J BIOL CHEM, V258, P2273; GRIFFIN BW, 1985, ARCH BIOCHEM BIOPHYS, V239, P305, DOI 10.1016/0003-9861(85)90840-9; HAGER LP, 1966, J BIOL CHEM, V241, P1769; HAGER LP, 1973, OXIDASES RELATED RED, P311; LAMBEIR AM, 1983, J BIOL CHEM, V258, P3558; LIBBY RD, 1989, J BIOL CHEM, V264, P15284; LIBBY RD, 1982, J BIOL CHEM, V257, P5030; PALCIC MM, 1980, BIOCHEM BIOPH RES CO, V94, P1123, DOI 10.1016/0006-291X(80)90535-5; RAMAKRISHNAN K, 1983, BIOCHEMISTRY-US, V22, P3271, DOI 10.1021/bi00282a036	13	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1769	1775						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1309797				2022-12-27	WOS:A1992HA48500058
J	NEWSHOLME, P; ANGELOS, KL; WALSH, DA				NEWSHOLME, P; ANGELOS, KL; WALSH, DA			HIGH AND INTERMEDIATE AFFINITY CALMODULIN BINDING DOMAINS OF THE ALPHA AND BETA SUBUNITS OF PHOSPHORYLASE-KINASE AND THEIR POTENTIAL ROLE IN PHOSPHORYLATION-DEPENDENT ACTIVATION OF THE HOLOENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; PROTEIN-KINASE; CATALYTIC SUBUNIT; GAMMA-SUBUNIT; PEPTIDES; IDENTIFICATION; INHIBITION; COMPLEXES; CALCIUM; STIMULATION	Phosphorylase kinase is a calcium-regulated multimeric enzyme of composition (alpha-beta-gamma-delta)4, which contains calmodulin as the integral delta-subunit and also is activated further by addition of extrinsic calmodulin. Previous studies by Dasgupta, M., Honeycutt, T., and Blumenthal, D. K. ((1989) J. Biol. Chem. 264, 1715617163) have identified gamma-302-326 and gamma-342-366 as two calmodulin binding regions. Using peptides that were synthesized based on alpha and beta-primary structure and that were predicted to contain the basic amphiphilic alpha-helix motif thought important for calmodulin binding, four additional potential calmodulin binding domains have now been identified: one of high affinity, beta-770-794; two of intermediate affinity, beta-5-28 and beta-920-946; and one with marginally low affinity, alpha-1070-1093. Peptide beta-770-794 was of higher calmodulin affinity than either gamma-302-326 or gamma-342-366; it was of higher affinity than the model synthetic peptide IV defined by O' Neil, K. T., and DeGrado, W. F. ((1990) Trends Biochem. Sci. 15, 59-64); and it is currently the most potent calmodulin-binding peptide so far described. Correlated with their affinity for calmodulin, all six phosphorylase kinase-derived peptides and several other established calmodulin-binding peptides inhibited phosphorylase kinase previously activated by cAMP-dependent phosphorylation, reducing its activity to the level of the nonactivated enzyme. However, these peptides did not inhibit (and some peptides slightly activated) the nonphosphorylated enzyme. Even in the presence of these peptides both activated and nonactivated enzyme remained fully Ca2+-dependent. The beta-770-794 peptide has at least a 5-fold greater calmodulin binding affinity than the holo-phosphorylase kinase. This, and its higher affinity for calmodulin than either of the sites on the gamma-subunit, raises the possibility that in the native enzyme it may be involved in binding the intrinsic delta-subunit. Further, inhibition of activated but not nonactivated enzyme by calmodulin-binding peptides would suggest that the phosphorylation-dependent activation of phosphorylase kinase may be mediated by changes in the binding interactions of the intrinsic calmodulin delta-subunit.			NEWSHOLME, P (corresponding author), UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616, USA.		Newsholme, Philip/D-4939-2016	Newsholme, Philip/0000-0002-0500-6984	NIDDK NIH HHS [DK 13613] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013613] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLUMENTHAL DK, 1988, BIOCHEM BIOPH RES CO, V156, P860, DOI 10.1016/S0006-291X(88)80923-9; BUSCHMEIER B, 1987, J BIOL CHEM, V262, P9454; CAWLEY KC, 1989, BIOCHEM J, V263, P223, DOI 10.1042/bj2630223; CHAN KFJ, 1982, J BIOL CHEM, V257, P5956; CHAN KFJ, 1982, J BIOL CHEM, V257, P5948; CHAN KFJ, 1982, J BIOL CHEM, V257, P5939; COHEN P, 1978, FEBS LETT, V92, P287, DOI 10.1016/0014-5793(78)80772-8; COX JA, 1985, J BIOL CHEM, V260, P2527; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; DEGRADO WF, 1985, J CELL BIOCHEM, V29, P83, DOI 10.1002/jcb.240290204; DEPAOLIROACH AA, 1979, FEBS LETT, V105, P321, DOI 10.1016/0014-5793(79)80639-0; FLETCHER WH, 1986, J BIOL CHEM, V261, P5504; GLASS DB, 1989, J BIOL CHEM, V264, P8802; GLASS DB, 1989, J BIOL CHEM, V264, P14579; GRAND RJA, 1981, EUR J BIOCHEM, V113, P359, DOI 10.1111/j.1432-1033.1981.tb05074.x; HEILMEYER LMG, 1991, BIOCHIM BIOPHYS ACTA, V1094, P168, DOI 10.1016/0167-4889(91)90005-I; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; JAMES P, 1991, J BIOL CHEM, V266, P7087; KEE SM, 1987, J BIOL CHEM, V262, P9448; KEE SM, 1986, J BIOL CHEM, V261, P4732; KILIMANN MW, 1988, P NATL ACAD SCI USA, V85, P9381, DOI 10.1073/pnas.85.24.9381; LAMBOOY PK, 1982, ARCH BIOCHEM BIOPHYS, V213, P551, DOI 10.1016/0003-9861(82)90583-5; NEWTON DL, 1984, J BIOL CHEM, V259, P4419; ONEIL KT, 1987, SCIENCE, V236, P1454, DOI 10.1126/science.3589665; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PAUDEL HK, 1987, J BIOL CHEM, V262, P11912; Pickett-Gies CA., 1986, ENZYMES, V17, P395; PICKETTGIES CA, 1985, J BIOL CHEM, V260, P2046; PICTON C, 1981, CELL CALCIUM, V2, P281, DOI 10.1016/0143-4160(81)90021-X; PICTON C, 1980, EUR J BIOCHEM, V111, P553, DOI 10.1111/j.1432-1033.1980.tb04971.x; RAMACHANDRAN C, 1987, J BIOL CHEM, V262, P3210; SCHIEFER S, 1986, METHOD ENZYMAT AN, V9, P317; Segel I.H., 1975, ENZYME KINETICS; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; SUL HS, 1983, METHOD ENZYMOL, V99, P250; WALSH KX, 1980, J BIOL CHEM, V255, P5036; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693	37	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					810	818						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1309776				2022-12-27	WOS:A1992GY96000023
J	OKAMOTO, S; NIHIRA, T; KATAOKA, H; SUZUKI, A; YAMADA, Y				OKAMOTO, S; NIHIRA, T; KATAOKA, H; SUZUKI, A; YAMADA, Y			PURIFICATION AND MOLECULAR-CLONING OF A BUTYROLACTONE AUTOREGULATOR RECEPTOR FROM STREPTOMYCES-VIRGINIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN GENE-CLUSTER; A-FACTOR; ESCHERICHIA-COLI; BINDING-PROTEIN; BUTANOLIDE-C; ANTHRACYCLINE BIOSYNTHESIS; NUCLEOTIDE-SEQUENCE; NOCARDIA-SP; B-FACTOR; GRISEUS	In streptomyces, low molecular weight compounds termed "autoregulators" have been isolated as primary signal molecules for triggering secondary metabolism and/or cytodifferentiation. Streptomyces virginiae produces a set of autoregulators termed virginiae butanolide A-E which trigger virginiamycin production, and possesses a high-affinity virginiae butanolide receptor (Kim, H. S., Nihira, T., Tada, H., Yanagimoto, M., and Yamada, Y. (1989) J. Antibiot. (Tokyo) 42, 769-778). The virginiae butanolide receptor has now been purified to apparent homogeneity with 14,000-fold purification and an 8.6% activity yield. The purified receptor showed a M(r) of 36,000 on sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and a maximum ligand binding of 33.0 nmol/mg protein, indicating a 1:1 binding stoichiometry (1.18 mol of virginiae butanolide/36 kDa of protein) between virginiae butanolides and the receptor. Due to a blockage at the amino terminus, fragment peptides were generated by lysyl endopeptidase and five partial amino acid sequences were determined. The gene (vbrA) encoding the virginiae butanolide receptor was identified on a 5.0-kbp BamHI fragment by hybridization to synthetic oligonucleotide probes, cloned, and sequenced. Nucleotide-sequence analysis predicted a 319-amino acid open reading frame (vbrA) in which all the partial amino acid sequences of the receptor appeared, and 166 bp downstream from it another open reading frame for a 144-amino acid protein which was designated as a ribosomal protein L11 from its high homology (62-64%) to the amino acid sequences of ribosomal protein L11 of several origins, and thus denoted as rplK. The C-terminal half of VbrA showed 36% overall homology to the amino acid sequence of an essential protein (NusG) of Escherichia coli. Furthermore, the gene assembly of vbrA-rplk of S. virginiae closely resembled that of nusG-rplK of E. coli, suggesting that vbrA may constitute a part of an essential gene cluster encoding components of transcriptional and translational apparatuses.	OSAKA UNIV,FAC ENGN,DEPT BIOTECHNOL,2-1 YAMADA OKA,SUITA,OSAKA 565,JAPAN; UNIV TOKYO,FAC AGR,DEPT AGR CHEM,BUNKYO KU,TOKYO 113,JAPAN	Osaka University; University of Tokyo			岡本, 晋/O-8583-2015	岡本, 晋/0000-0001-5225-2689				ARNDT E, 1990, NUCLEIC ACIDS RES, V18, P1285, DOI 10.1093/nar/18.5.1285; BIBB MJ, 1984, GENE, V30, P157, DOI 10.1016/0378-1119(84)90116-1; CHATER KF, 1989, REGULATION OF PROCARYOTIC DEVELOPMENT, P277; DOWNING WL, 1990, J BACTERIOL, V172, P1621, DOI 10.1128/jb.172.3.1621-1627.1990; GRAFE U, 1983, BIOTECHNOL LETT, V5, P591, DOI 10.1007/BF00130838; GRAFE U, 1982, J ANTIBIOT, V35, P1722, DOI 10.7164/antibiotics.35.1722; HARA O, 1982, J ANTIBIOT, V35, P349, DOI 10.7164/antibiotics.35.349; HOPWOOD DA, 1988, PROC R SOC SER B-BIO, V235, P121, DOI 10.1098/rspb.1988.0067; HOPWOOD DA, 1985, GENETIC MANIPULATION, P70; KAWAGUCHI T, 1988, J ANTIBIOT, V41, P360, DOI 10.7164/antibiotics.41.360; KAWAGUCHI T, 1984, J ANTIBIOT, V37, P1587, DOI 10.7164/antibiotics.37.1587; Khokhlov A. S., 1980, FRONTIERS BIOORGANIC, P201; KIM HS, 1990, J ANTIBIOT, V43, P692, DOI 10.7164/antibiotics.43.692; KIM HS, 1989, J ANTIBIOT, V42, P769, DOI 10.7164/antibiotics.42.769; KLEINER EM, 1976, BIOORG KHIM+, V2, P1142; KONDO K, 1989, J ANTIBIOT, V42, P1873, DOI 10.7164/antibiotics.42.1873; KONDO S, 1987, TETRAHEDRON LETT, V28, P5861, DOI 10.1016/S0040-4039(01)81074-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; Mandel M, 1970, J MOL BIOL, V53, P154; MIYAKE K, 1989, J BACTERIOL, V171, P4298, DOI 10.1128/JB.171.8.4298-4302.1989; MORI K, 1983, TETRAHEDRON, V39, P3107, DOI 10.1016/S0040-4020(01)91552-2; NIHIRA T, 1988, J ANTIBIOT, V41, P1828, DOI 10.7164/antibiotics.41.1828; PERRONYANISCH C, 1985, GENE, V33, P103; POST LE, 1979, P NATL ACAD SCI USA, V76, P1697, DOI 10.1073/pnas.76.4.1697; SAKUDA S, 1991, TETRAHEDRON LETT, V32, P1817, DOI 10.1016/S0040-4039(00)74338-3; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO K, 1989, J FERMENT BIOENG, V68, P170, DOI 10.1016/0922-338X(89)90131-1; SHIMMIN LC, 1989, EMBO J, V8, P1225, DOI 10.1002/j.1460-2075.1989.tb03496.x; SOR F, 1987, MOL GEN GENET, V210, P52, DOI 10.1007/BF00337758; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; YAMADA Y, 1987, J ANTIBIOT, V40, P496, DOI 10.7164/antibiotics.40.496	33	33	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1093	1098						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1309760				2022-12-27	WOS:A1992GY96000067
J	MELEN, K; RONNI, T; BRONI, B; KRUG, RM; VONBONSDORFF, CH; JULKUNEN, I				MELEN, K; RONNI, T; BRONI, B; KRUG, RM; VONBONSDORFF, CH; JULKUNEN, I			INTERFERON-INDUCED MX PROTEINS FORM OLIGOMERS AND CONTAIN A PUTATIVE LEUCINE ZIPPER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATECHOL-O-METHYLTRANSFERASE; HEPTAD REPEAT REGION; INFLUENZA-VIRUS; MOLECULAR-CLONING; BINDING PROTEINS; CELLS; GENE; EXPRESSION; RESISTANCE; TRANSCRIPTION	Interferons induce a number of different protein that mediate the antiproliferative, antiviral, and immunomodulatory functions of interferons. At least three different proteins mediate the antiviral response, and one of them, Mx protein, specifically inhibits the replication of influenza virus and (vesicular stomatitis virus). Mouse and rat Mx1 proteins are nuclear, whereas other presently known Mx proteins are cytoplasmic. The cellular functions of Mx proteins are unknown, but all of them contain a consensus GTP binding site. Very little information is available on the structure and characteristics of the mouse Mx1 protein itself. For biochemical characterization, we expressed mouse Mx1 protein in a baculovirus system and purified it to homogeneity. The purified protein as well as the authentic murine cellular Mx1 protein exists in dimers and trimers in the presence of dissociating solvents, whereas in physiological buffers they form aggregates. Cross-linking experiments done on Mx-expressing cells from various species revealed that mouse, rat, and human Mx proteins exist predominantly in trimers. Amino acid sequence analysis shows that all known Mx proteins have conserved leucine repeats typical for a leucine zipper at their COOH-terminal end. In vitro translation of chimeric catechol O-methyltransferase-Mx1 gene constructs revealed that the leucine zipper domain of Mx1 protein is responsible for the oligomerization. The COOH terminus also functions as a nuclear localization signal. Microinjection of purified oligomers into the cell cytoplasm resulted in a fast accumulation of the protein in the nucleus. Immunoelectron microscopy revealed that nuclear murine Mx1 protein exists in distinct, electron-dense structures separate from nuclear membrane, and chromatin, or nucleolus. These observations reveal that a COOH-terminal leucine zipper domain is an important structural element of all Mx proteins. Its relevance to the biology and functions of Mx proteins is presently not known.	NATL PUBL HLTH INST,MOLEC BIOL PROGRAMME,MANNERHEIMINTIE 166,SF-00300 HELSINKI,FINLAND; RUTGERS STATE UNIV,CTR ADV BIOTECHNOL & MED,DEPT MOLEC BIOL & BIOCHEM,PISCATAWAY,NJ 08854; UNIV HELSINKI,DEPT VIROL,SF-00290 HELSINKI 29,FINLAND; MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021	Finland National Institute for Health & Welfare; Rutgers State University New Brunswick; University of Helsinki; Memorial Sloan Kettering Cancer Center	JULKUNEN, I (corresponding author), NATL PUBL HLTH INST,MOLEC BIOL PROGRAMME,MANNERHEIMINTIE 166,SF-00300 HELSINKI,FINLAND.				FIC NIH HHS [F05-TW03/36] Funding Source: Medline; NCI NIH HHS [CA-80747] Funding Source: Medline; NIAID NIH HHS [AI-11772] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F15TW000336] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI011772, R37AI011772] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AEBI M, 1989, MOL CELL BIOL, V9, P5062, DOI 10.1128/MCB.9.11.5062; ARNHEITER H, 1983, ARCH VIROL, V76, P127, DOI 10.1007/BF01311696; ARNHEITER H, 1990, CELL, V62, P51, DOI 10.1016/0092-8674(90)90239-B; BRONI B, 1990, J VIROL, V64, P6335, DOI 10.1128/JVI.64.12.6335-6340.1990; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; CHONG DK, 1992, EMBO J, V11, P1553; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GARBER EA, 1991, VIROLOGY, V180, P754, DOI 10.1016/0042-6822(91)90088-S; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; HORISBERGER MA, 1991, VIROLOGY, V180, P185, DOI 10.1016/0042-6822(91)90022-4; HORISBERGER MA, 1990, J VIROL, V64, P1171, DOI 10.1128/JVI.64.3.1171-1181.1990; HORISBERGER MA, 1987, J INTERFERON RES, V7, P331, DOI 10.1089/jir.1987.7.331; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JULKUNEN I, 1984, J MED VIROL, V14, P177, DOI 10.1002/jmv.1890140212; KRUG RM, 1985, J VIROL, V56, P201, DOI 10.1128/JVI.56.1.201-206.1985; KRUG RM, 1971, VIROLOGY, V44, P125, DOI 10.1016/0042-6822(71)90159-0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEONE G, 1991, VIROLOGY, V182, P346, DOI 10.1016/0042-6822(91)90678-5; LEONE G, 1991, VIROLOGY, V182, P336, DOI 10.1016/0042-6822(91)90677-4; MARIE I, 1990, J BIOL CHEM, V265, P18601; MARTIN K, 1991, J VIROL, V65, P232, DOI 10.1128/JVI.65.1.232-244.1991; MEIER E, 1988, J VIROL, V62, P2386, DOI 10.1128/JVI.62.7.2386-2393.1988; MEIER E, 1990, J VIROL, V64, P6263, DOI 10.1128/JVI.64.12.6263-6269.1990; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NAKAYAMA M, 1991, J BIOL CHEM, V266, P21404; NOTEBORN M, 1987, J INTERFERON RES, V7, P657, DOI 10.1089/jir.1987.7.657; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; PAVLOVIC J, 1990, J VIROL, V64, P3370, DOI 10.1128/JVI.64.7.3370-3375.1990; PAVLOVIC J, 1992, J VIROL, V66, P2564, DOI 10.1128/JVI.66.4.2564-2569.1992; PLOTCH SJ, 1981, CELL, V23, P847, DOI 10.1016/0092-8674(81)90449-9; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; SALMINEN M, 1990, GENE, V93, P241, DOI 10.1016/0378-1119(90)90231-F; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; Staeheli P, 1990, Adv Virus Res, V38, P147, DOI 10.1016/S0065-3527(08)60862-3; STAEHELI P, 1986, CELL, V44, P147, DOI 10.1016/0092-8674(86)90493-9; STAEHELI P, 1988, MOL CELL BIOL, V8, P4524, DOI 10.1128/MCB.8.10.4524; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TILGMANN C, 1990, FEBS LETT, V264, P95, DOI 10.1016/0014-5793(90)80774-D; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; ULMANEN I, 1991, EUR J BIOCHEM, V202, P1013, DOI 10.1111/j.1432-1033.1991.tb16464.x; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; WEITZ G, 1989, J INTERFERON RES, V9, P679, DOI 10.1089/jir.1989.9.679; ZURCHER T, 1992, EMBO J, V11, P1657, DOI 10.1002/j.1460-2075.1992.tb05212.x	46	104	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25898	25907						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1281477				2022-12-27	WOS:A1992KD07300048
J	CARNEMOLLA, B; LEPRINI, A; ALLEMANNI, G; SAGINATI, M; ZARDI, L				CARNEMOLLA, B; LEPRINI, A; ALLEMANNI, G; SAGINATI, M; ZARDI, L			THE INCLUSION OF THE TYPE-III REPEAT ED-B IN THE FIBRONECTIN MOLECULE GENERATES CONFORMATIONAL MODIFICATIONS THAT UNMASK A CRYPTIC SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMED HUMAN-CELLS; PRE-MESSENGER-RNA; HUMAN-PLASMA FIBRONECTIN; BINDING DOMAIN; SITES; IDENTIFICATION; ANTIBODIES; PRECURSORS; ADHESION; ISOFORM	We have previously reported an anti-fibronectin monoclonal antibody (mAb) (BC-1) which reacts with an ED-B-containing beta-galactosidase-fibronectin fusion protein but not with an identical beta-galactosidase-fibronectin fusion protein in which the ED-B sequence is omitted. In further experiments aimed at localizing more precisely the epitope recognized by this mAb, we demonstrate that 1) the mAb BC-1 is indeed specific for ED-B-containing fibronectin (FN) molecules even though the epitope recognized by this mAb is localized on the type III homology repeat 7 (the one which precedes the ED-B sequence) and 2) in fibronectin molecules lacking the ED-B sequence, this epitope is masked. We further demonstrate that, to mask the epitope recognized by the mAb BC-1, the presence of at least half of the FN type III homology repeat 9 is necessary. We also report the production of the mAb IST-6 which recognizes only FN molecules in which the ED-B sequence is lacking. These data clearly demonstrate that the presence of the ED-B sequence within FN molecules generates conformational modification in the central part of the molecules that unmasks previously cryptic sequences and masks others.			CARNEMOLLA, B (corresponding author), IST NAZL RIC CANC,CELL BIOL LAB,VIALE BENEDETTO XV 10,I-16132 GENOA,ITALY.							ALITALO K, 1982, ADV CANCER RES, V37, P111, DOI 10.1016/S0065-230X(08)60883-0; BARONE MV, 1989, EMBO J, V8, P1079, DOI 10.1002/j.1460-2075.1989.tb03476.x; BORSI L, 1992, EXP CELL RES, V199, P98, DOI 10.1016/0014-4827(92)90466-L; BORSI L, 1987, J CELL BIOL, V104, P595, DOI 10.1083/jcb.104.3.595; BORSI L, 1991, ANAL BIOCHEM, V192, P372, DOI 10.1016/0003-2697(91)90551-4; CARNEMOLLA B, 1989, J CELL BIOL, V108, P1139, DOI 10.1083/jcb.108.3.1139; CASTELLANI P, 1986, J CELL BIOL, V103, P1671, DOI 10.1083/jcb.103.5.1671; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; FFRENCHCONSTANT C, 1989, J CELL BIOL, V109, P903, DOI 10.1083/jcb.109.2.903; FFRENCHCONSTANT C, 1989, DEVELOPMENT, V106, P375; GUTMAN A, 1987, P NATL ACAD SCI USA, V84, P7179, DOI 10.1073/pnas.84.20.7179; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; HYNES R, 1985, ANNU REV CELL BIOL, V1, P67, DOI 10.1146/annurev.cb.01.110185.000435; Hynes RO, 1990, FIBRONECTINS; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; LAITINEN L, 1991, LAB INVEST, V64, P492; NAGAI T, 1991, J CELL BIOL, V114, P1295, DOI 10.1083/jcb.114.6.1295; NARASIMHAN C, 1988, BIOCHEMISTRY-US, V27, P4970, DOI 10.1021/bi00414a003; NARASIMHAN C, 1991, BIOPOLYMERS, V31, P1159, DOI 10.1002/bip.360311004; NORTON PA, 1987, MOL CELL BIOL, V7, P4297, DOI 10.1128/MCB.7.12.4297; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; Owens R J, 1986, Oxf Surv Eukaryot Genes, V3, P141; OYAMA F, 1990, CANCER RES, V50, P1075; OYAMA F, 1989, J BIOL CHEM, V264, P10331; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARZBAUER JE, 1987, EMBO J, V6, P2573, DOI 10.1002/j.1460-2075.1987.tb02547.x; VARTIO T, 1987, J CELL SCI, V88, P419; YAMADA KM, 1983, ANNU REV BIOCHEM, V52, P761, DOI 10.1146/annurev.bi.52.070183.003553; ZARDI L, 1987, EMBO J, V6, P2337, DOI 10.1002/j.1460-2075.1987.tb02509.x; ZARDI L, 1980, INT J CANCER, V25, P325, DOI 10.1002/ijc.2910250304	31	126	144	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24689	24692						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1280266				2022-12-27	WOS:A1992KA26300081
J	BANNO, Y; NAKASHIMA, T; KUMADA, T; EBISAWA, K; NONOMURA, Y; NOZAWA, Y				BANNO, Y; NAKASHIMA, T; KUMADA, T; EBISAWA, K; NONOMURA, Y; NOZAWA, Y			EFFECTS OF GELSOLIN ON HUMAN PLATELET CYTOSOLIC PHOSPHOINOSITIDE-PHOSPHOLIPASE-C ISOZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; KINASE-C; PURIFICATION; ACTIN; POLYPHOSPHOINOSITIDES; EXPRESSION; HYDROLYSIS; MEMBRANE; INVIVO	The effective resolution of human platelet cytosolic phosphoinositide-phospholipase C (PLC) revealed five distinct activity peaks by Q-Sepharose and heparin-Sepharose column chromatographies when assayed using phosphatidylinositol (PI) and phosphatidylinositol 4,5-bisphosphate (PIP2). The results of Western blotting analysis with various antibodies against PLC isozymes showed that peak-Ia (PLC-delta-type), peak-Ib (PLC-gamma(1) type), and peak-IIc (PLC-beta-type) and two unidentified activity peaks (PLC-IIa and PLC-IIb) were present in human platelet cytosol. A protein with guanosine 5'-3-O-(thio)triphosphate-binding activity was coeluted with the PLC-IIa and was purified to homogeneity. It exhibited 86- and 42-kDa polypeptide bands upon sodium dodecyl sulfate-polyacrylamide gel electrophoresis, which were identified as gelsolin and actin by immunostaining, respectively. Large amounts of gelsolin/actin (1:1) complex "gelsolin complex" were detected in the PLC-delta and PLC-gamma(1) fractions. The PLC-gamma(1) and the gelsolin complex were coimmunoprecipitated by the antibody raised against PLC-gamma(1). Furthermore, the partially purified bovine brain PLC-gamma(1) fraction also was found to be associated with the gelsolin complex and the association was released by the addition of 1% sodium cholate. This finding has prompted us to examine effects of the gelsolin complex and the free gelsolin on activities of the above PLC isoforms from platelet cytosol. The gelsolin complex did not affect the PIP2 hydrolyzing activities of all PLC isoforms. In contrast, the purified gelsolin inhibited distinctly PIP2 hydrolyses by PLC-Ia (delta), PLC-Ib (gamma(1)), and PLC-IIa (unidentified), whereas the inhibitory effects for PLC-IIb (unidentified) and PLC-IIc (beta) were moderate. The inhibitory effect of gelsolin on PIP2-hydrolysis by PLC-gamma(1) was diminished by a large amount of PIP2 substrate. These results suggested that the inhibition of PLC by gelsolin is due to sequestration of substrate PIP2 by its competitive binding.	GIFU UNIV, SCH MED, DEPT BIOCHEM, TSUKASAMACHI 40, GIFU 500, JAPAN; GIFU UNIV, SCH MED, DEPT NEUROSURG, GIFU 500, JAPAN; GIFU UNIV, SCH MED, DEPT OTORHINOLARYNGOL, GIFU 500, JAPAN; UNIV TOKYO, FAC MED, DEPT PHARMACOL, TOKYO 113, JAPAN	Gifu University; Gifu University; Gifu University; University of Tokyo								BALDASSARE JJ, 1988, BIOCHEM BIOPH RES CO, V154, P351, DOI 10.1016/0006-291X(88)90692-4; BANNO Y, 1986, BIOCHEM BIOPH RES CO, V140, P728, DOI 10.1016/0006-291X(86)90792-8; BANNO Y, 1986, BIOCHEM BIOPH RES CO, V136, P713, DOI 10.1016/0006-291X(86)90498-5; BANNO Y, 1990, BIOCHEM BIOPH RES CO, V167, P396, DOI 10.1016/0006-291X(90)92035-X; BANNO Y, 1987, BIOCHEM BIOPH RES CO, V146, P861, DOI 10.1016/0006-291X(87)90610-3; BANNO Y, 1991, IN PRESS PLATELET; BENNETT CF, 1987, J BIOL CHEM, V262, P13789; BRYAN J, 1984, J BIOL CHEM, V259, P7480; CARTER HR, 1990, BIOCHIM BIOPHYS ACTA, V1054, P119, DOI 10.1016/0167-4889(90)90213-W; COCKCROFT S, 1987, TRENDS BIOCHEM SCI, V12, P75, DOI 10.1016/0968-0004(87)90035-1; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HOMMA Y, 1989, BIOCHEM BIOPH RES CO, V164, P406, DOI 10.1016/0006-291X(89)91734-8; JANMEY PA, 1988, J BIOL CHEM, V263, P16738; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KUROKAWA H, 1990, BIOCHEM BIOPH RES CO, V168, P451, DOI 10.1016/0006-291X(90)92342-W; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LIND SE, 1987, J CELL BIOL, V105, P833, DOI 10.1083/jcb.105.2.833; MACHESKY LM, 1990, CELL REGUL, V1, P937, DOI 10.1091/mbc.1.12.937; MARTIN TFJ, 1989, J BIOL CHEM, V264, P20917; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; MOBBS CV, 1990, SCIENCE, V249, P566, DOI 10.1126/science.2382136; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; RAAFLAUB J, 1956, Methods Biochem Anal, V3, P301; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1991, METHOD ENZYMOL, V197, P502; RODBELL M, 1985, TRENDS BIOCHEM SCI, V10, P461, DOI 10.1016/0968-0004(85)90032-5; RYU SH, 1990, J BIOL CHEM, V265, P17941; SAKURAI T, 1990, NEUROSCIENCE, V38, P743, DOI 10.1016/0306-4522(90)90067-E; SAKURAI T, 1991, J BIOL CHEM, V266, P4581; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG P, 1988, J BIOCHEM-TOKYO, V103, P137, DOI 10.1093/oxfordjournals.jbchem.a122219; WANG P, 1987, J BIOCHEM-TOKYO, V102, P1275, DOI 10.1093/oxfordjournals.jbchem.a122166; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218	41	88	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6488	6494						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1313007				2022-12-27	WOS:A1992HM05300010
J	DESAUVAGE, FJ; HORUK, R; BENNETT, G; QUAN, C; BURNIER, JP; GOEDDEL, DV				DESAUVAGE, FJ; HORUK, R; BENNETT, G; QUAN, C; BURNIER, JP; GOEDDEL, DV			CHARACTERIZATION OF THE RECOMBINANT HUMAN RECEPTOR FOR ESCHERICHIA-COLI HEAT-STABLE ENTEROTOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GUANYLATE-CYCLASE ACTIVITY; RAT INTESTINAL-CELLS; AMINO-ACID-SEQUENCE; CYCLIC-GMP; ION-TRANSPORT; TOXIN; BINDING; ATRIAL; INVITRO	We report here the molecular characterization of a recombinant cell line (293-STaR) expressing the heat-stable enterotoxin receptor (STaR) from human intestine. We have compared the 293-STaR cell line with the human colonic cell line T84 that endogenously expresses STa binding sites. Scatchard analysis of displacement binding studies revealed a single STa binding site with an affinity (K(i)) of 97 pM in 293-STaR compared with 55 pM in T84 cells. Saturation isotherms of STa binding gave a K(d) of 94 pM for the cloned receptor expressed in 293 cells and 166 pM for the receptor present in T84 cells. Kinetic measurements of STa binding to 293-STaR gave an association rate constant, K1, of 2.4 x 10(8) M-1 min-1 and a dissociation rate constant, K2, of 0.016 min-1. The half-time of dissociation was 43 min, and the K(d) calculated from the ratio of the kinetic constants was 67 pM. The pH profile of STa binding showed that the number of STa binding sites is increased 3-fold at pH 4.0 compared with pH 7.0, with no effect on binding affinity. A polyclonal antibody directed against the extracellular domain of STaR immunoprecipitated two proteins of approximately 140 and 160 kDa from both 293-STaR and T84 cells. Cross-linking of I-125-STa to 293-STaR cells resulted in the labeling of proteins with a molecular mass of approximately 153, 133, 81, 68, 56, and 49 kDa, the two smallest being the more abundant. Similar results have been reported for the STaR present on rat brush border membranes. These data suggest that the STaR-guanylyl cyclase identified by molecular cloning is the only receptor for STa present in T84 cells.	GENENTECH INC, DEPT PROT CHEM, S SAN FRANCISCO, CA 94080 USA; GENENTECH INC, DEPT MED & ANALYT CHEM, S SAN FRANCISCO, CA 94080 USA; GENENTECH INC, DEPT BIOORGANIC CHEM, S SAN FRANCISCO, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	DESAUVAGE, FJ (corresponding author), GENENTECH INC, DEPT MOLEC BIOL, 460 POINT SAN BRUNO BLVD, S SAN FRANCISCO, CA 94080 USA.		de Sauvage, Frederic/ABE-8400-2020	de Sauvage, Frederic/0000-0002-5275-2584				AIMOTO S, 1982, EUR J BIOCHEM, V129, P257, DOI 10.1111/j.1432-1033.1982.tb07047.x; BARANY G, 1980, PEPTIDES, V2, P3; CARPICK BW, 1991, BIOCHEMISTRY-US, V30, P4803, DOI 10.1021/bi00233a023; CHAN SK, 1981, J BIOL CHEM, V256, P7744; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; DESAUVAGE FJ, 1991, J BIOL CHEM, V266, P17912; FIELD M, 1978, P NATL ACAD SCI USA, V75, P2800, DOI 10.1073/pnas.75.6.2800; FRANTZ JC, 1984, INFECT IMMUN, V43, P622, DOI 10.1128/IAI.43.2.622-630.1984; GIANNELLA RA, 1979, INFECT IMMUN, V24, P19, DOI 10.1128/IAI.24.1.19-23.1979; GIANNELLA RA, 1983, AM J PHYSIOL, V245, pG492, DOI 10.1152/ajpgi.1983.245.4.G492; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; GUARINO A, 1987, AM J PHYSIOL, V253, pG775, DOI 10.1152/ajpgi.1987.253.6.G775; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; HUGHES JM, 1978, NATURE, V271, P755, DOI 10.1038/271755a0; IVENS K, 1990, INFECT IMMUN, V58, P1817, DOI 10.1128/IAI.58.6.1817-1820.1990; KUBOTA H, 1989, BIOCHEM BIOPH RES CO, V161, P229, DOI 10.1016/0006-291X(89)91585-4; KUNO T, 1986, J BIOL CHEM, V261, P1470; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; MCPHERSON GA, 1983, COMPUT PROG BIOMED, V17, P107, DOI 10.1016/0010-468X(83)90031-4; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEWSOME PM, 1978, INFECT IMMUN, V22, P290, DOI 10.1128/IAI.22.1.290-291.1978; RAO MC, 1981, INFECT IMMUN, V33, P165, DOI 10.1128/IAI.33.1.165-170.1981; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; TAKAYANAGI R, 1987, BIOCHEM BIOPH RES CO, V144, P244, DOI 10.1016/S0006-291X(87)80502-8; THOMPSON MR, 1985, ANAL BIOCHEM, V148, P26, DOI 10.1016/0003-2697(85)90623-2; THOMPSON MR, 1990, J RECEPTOR RES, V10, P97, DOI 10.3109/10799899009064660; WALDMAN SA, 1986, INFECT IMMUN, V51, P320, DOI 10.1128/IAI.51.1.320-326.1986; YOSHIMURA S, 1985, FEBS LETT, V181, P138, DOI 10.1016/0014-5793(85)81129-7	29	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6479	6482						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1313005				2022-12-27	WOS:A1992HM05300008
J	GEILEN, CC; WIEDER, T; REUTTER, W				GEILEN, CC; WIEDER, T; REUTTER, W			HEXADECYLPHOSPHOCHOLINE INHIBITS TRANSLOCATION OF CTP - CHOLINE-PHOSPHATE CYTIDYLYLTRANSFERASE IN MADIN-DARBY CANINE KIDNEY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; CHINESE-HAMSTER OVARY; PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; MAMMALIAN-CELLS; PHORBOL ESTER; RAT-LIVER; BREAKDOWN; CYTOSOL; 12-O-TETRADECANOYLPHORBOL-13-ACETATE	The mechanism of the inhibition of phosphatidylcholine biosynthesis by the phospholipid analogue, hexadecylphosphocholine, was investigated in Madin-Darby canine kidney cells. In the presence of 50-mu-mol/liter hexadecylphosphocholine, there was a translocation of CTP:choline-phosphate cytidylyltransferase (EC 22.7.7.15) activity from the membranes to the cytosol of the cells. Since we recently demonstrated that hexadecylphosphocholine also inhibits protein kinase C in vitro, [methyl-H-3]choline labeling experiments were repeated with phorbol ester-desensitized cells. In these cells the same inhibitory effect of hexadecylphosphocholine was measured. As a consequence of inhibition, the [methyl-H-3]choline incorporation into the phosphocholine pool was increased time-dependently. In addition, there was no evidence for a difference between the choline uptake of control and hexadecylphosphocholine-treated cells. Likewise, the amount of diacylglycerol, a known activator of the translocation process, was not reduced. Finally, we showed that the inhibitory effect of hexadecylphosphocholine on CTP:choline-phosphate cytidylyltransferase translocation cannot be explained by the detergent properties of this phospholipid analogue. Therefore, we suggest a direct inhibitory effect of hexadecylphosphocholine on the translocation of CTP:choline-phosphate cytidylyltransferase.			GEILEN, CC (corresponding author), FREE UNIV BERLIN,INST MOLEK BIOL & BIOCHEM,ARNIMALLEE 22,W-1000 BERLIN 33,GERMANY.							BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BURN P, 1988, TRENDS BIOCHEM SCI, V13, P79, DOI 10.1016/0968-0004(88)90043-6; CORNELL R, 1987, BIOCHIM BIOPHYS ACTA, V919, P26, DOI 10.1016/0005-2760(87)90214-1; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5881, DOI 10.1021/bi00238a011; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5873, DOI 10.1021/bi00238a010; CULVENOR JG, 1981, J IMMUNOL, V126, P1974; DANIEL LW, 1986, J BIOL CHEM, V261, P9128; DEVES R, 1990, BIOCHIM BIOPHYS ACTA, V1030, P32, DOI 10.1016/0005-2736(90)90235-G; EXTON JH, 1990, J BIOL CHEM, V265, P1; GEILEN CC, 1991, EUR J CANCER, V27, P1650, DOI 10.1016/0277-5379(91)90438-J; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; GRAFTON G, 1991, FEBS LETT, V286, P229, DOI 10.1016/0014-5793(91)80980-H; HAASE R, 1991, FEBS LETT, V288, P129, DOI 10.1016/0014-5793(91)81018-4; HAASE R, 1990, EUR J CELL BIOL S, V51, P33; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HATCH GM, 1991, BIOCHIM BIOPHYS ACTA, V1081, P25, DOI 10.1016/0005-2760(91)90245-D; ISAKOV N, 1990, J BIOL CHEM, V265, P2091; JAMIL H, 1990, J BIOL CHEM, V265, P4332; JONES GA, 1991, ARCH BIOCHEM BIOPHYS, V288, P331, DOI 10.1016/0003-9861(91)90203-U; KOLESNICK RN, 1987, J BIOL CHEM, V262, P14525; LISCOVITCH M, 1987, J BIOL CHEM, V262, P17487; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V795, P447, DOI 10.1016/0005-2760(84)90171-1; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V795, P433, DOI 10.1016/0005-2760(84)90169-3; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V779, P217, DOI 10.1016/0304-4157(84)90010-8; PREISS J, 1986, J BIOL CHEM, V261, P8597; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROSENBERG IL, 1987, BIOCHIM BIOPHYS ACTA, V921, P473, DOI 10.1016/0005-2760(87)90074-9; SANGHERA JS, 1989, J BIOL CHEM, V264, P1215; SKIPSKI VP, 1964, BIOCHEM J, V90, P374, DOI 10.1042/bj0900374; SLEIGHT R, 1983, J BIOL CHEM, V258, P831; SLEIGHT R, 1983, J BIOL CHEM, V258, P836; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOHAL PS, 1990, J BIOL CHEM, V265, P11746; UBERALL F, 1991, CANCER RES, V51, P807; UTAL AK, 1991, J BIOL CHEM, V266, P24084; VANCE DE, 1989, PHOSPHATIDYLCHOLINE, P235; VANCE DE, 1989, PHOSPHATIDYLCHOLINE, P36; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; WEINHOLD PA, 1991, J BIOL CHEM, V266, P6093; WRIGHT PS, 1985, J BIOL CHEM, V260, P7919; YAO ZM, 1990, J BIOL CHEM, V265, P4326; ZHENG B, 1990, CANCER RES, V50, P3025	43	86	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6719	6724						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1313020				2022-12-27	WOS:A1992HM05300041
J	ELFERINK, LA; ANZAI, K; SCHELLER, RH				ELFERINK, LA; ANZAI, K; SCHELLER, RH			RAB15, A NOVEL LOW-MOLECULAR-WEIGHT GTP-BINDING PROTEIN SPECIFICALLY EXPRESSED IN RAT-BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YPT1 PROTEIN; ACTIVATING PROTEIN; PLASMA-MEMBRANE; GOLGI STACK; SECRETION; TRANSPORT; YEAST; DOMAIN; NUCLEOTIDE; PRODUCT	rab3A is a low molecular weight (LMW) GTP-binding protein specifically expressed in brain and localized to synaptic vesicles. rab3A has been proposed to play a role in neurotransmitter release by regulating membrane flow in the nerve terminal. In an attempt to define other LMW GTP-binding proteins that may regulate neurotransmitter release, seven cDNA clones encoding new members of the rab family of LMW GTP-binding proteins were isolated from a rat brain cDNA library. The rab proteins contain the four conserved structural domains essential for GTP binding in addition to domains required for membrane localization and effector protein interactions. One protein, rab16, is closely related to members of the rab3 subfamily, whereas two others are assigned as the rat homologs of canine rab8 and rab10. Four additional clones, rab12, rab13, rab14, and rab15, revealed unique sequences and are new members of the rab family of LMW GTP-binding proteins. The patterns of expression of rab15 and rab3A closely overlap but differ from that observed for all other known LMW GTP-binding proteins. This data suggests that rab15 may act in concert with rab3A in regulating aspects of synaptic vesicle membrane flow within the nerve terminal.	STANFORD UNIV,BECKMAN CTR,DEPT MOLEC & CELLULAR PHYSIOL,HOWARD HUGHES MED INST,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University					NIMH NIH HHS [MH48108] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH048108] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ARIDOR M, 1990, J CELL BIOL, V111, P909, DOI 10.1083/jcb.111.3.909; BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BURNSTEIN ES, 1991, J BIOL CHEM, V266, P2689; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISCHER, 1990, P NATL ACAD SCI USA, V87, P1988; FISCHER V, 1991, NATURE, V349, P79; GODA Y, 1991, J CELL BIOL, V112, P823, DOI 10.1083/jcb.112.5.823; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HAUBRUCK H, 1989, EMBO J, V8, P1427, DOI 10.1002/j.1460-2075.1989.tb03524.x; JOHNSTON PA, 1991, NEURON, V7, P101, DOI 10.1016/0896-6273(91)90078-E; KELLY RB, 1988, NEURON, V1, P431, DOI 10.1016/0896-6273(88)90174-2; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; NGSEE JK, 1991, J BIOL CHEM, V266, P2675; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SANO K, 1989, BIOCHEM BIOPH RES CO, V158, P377, DOI 10.1016/S0006-291X(89)80058-0; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; TRIMBLE WS, 1990, J NEUROSCI, V10, P1380; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; VOLKNANDT W, 1991, MOL BRAIN RES, V11, P283, DOI 10.1016/0169-328X(91)90037-X; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	46	72	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5768	5775						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1313420				2022-12-27	WOS:A1992HK31800011
J	SHABB, JB; CORBIN, JD				SHABB, JB; CORBIN, JD			CYCLIC NUCLEOTIDE-BINDING DOMAINS IN PROTEINS HAVING DIVERSE FUNCTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							GENE ACTIVATOR PROTEIN; AMP RECEPTOR PROTEIN; DICTYOSTELIUM-DISCOIDEUM CELLS; I REGULATORY SUBUNIT; ROD OUTER SEGMENTS; CAMP-BINDING; ESCHERICHIA-COLI; KINASE-I; PREDICTED STRUCTURES; GATED CHANNEL				SHABB, JB (corresponding author), VANDERBILT UNIV, MED CTR, SCH MED, DEPT MOLEC PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041269] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40029] Funding Source: Medline; NIGMS NIH HHS [GM41269] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADHYA S, 1990, J BIOL CHEM, V265, P10797; AIBA H, 1985, EMBO J, V4, P3329, DOI 10.1002/j.1460-2075.1985.tb04084.x; ALTENHOFEN W, 1991, P NATL ACAD SCI USA, V88, P9868, DOI 10.1073/pnas.88.21.9868; ANDERSON WB, 1972, J BIOL CHEM, V247, P2717; BEEBE SJ, 1986, ENZYMES, V17, P43; BELL A, 1990, NUCLEIC ACIDS RES, V18, P7243, DOI 10.1093/nar/18.24.7243; BUBIS J, 1988, J BIOL CHEM, V263, P9668; BUBIS J, 1987, BIOCHEMISTRY-US, V26, P3478, DOI 10.1021/bi00386a035; BUBIS J, 1988, BIOCHEMISTRY-US, V27, P1570, DOI 10.1021/bi00405a026; BUTT E, 1990, FEBS LETT, V263, P47, DOI 10.1016/0014-5793(90)80702-K; CARETTA A, 1985, EUR J BIOCHEM, V153, P49, DOI 10.1111/j.1432-1033.1985.tb09265.x; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; Charbonneau H., 1990, CYCLIC NUCLEOTIDE PH, P267; CORBIN JD, 1986, J BIOL CHEM, V261, P1208; DECROMBRUGGHE B, 1984, SCIENCE, V224, P831, DOI 10.1126/science.6372090; DEVREOTES P, 1989, SCIENCE, V245, P1054, DOI 10.1126/science.2672337; DEWIT RJW, 1984, EUR J BIOCHEM, V142, P255; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; DOOLITTLE RF, 1990, METHOD ENZYMOL, V183, P659; DOSKELAND SO, 1983, BIOCHEMISTRY-US, V22, P1094; DOSTMANN WRG, 1991, BIOCHEMISTRY-US, V30, P8710, DOI 10.1021/bi00099a032; DOSTMANN WRG, 1990, J BIOL CHEM, V265, P10484; ERNEUX C, 1981, EUR J BIOCHEM, V115, P503; FENG DF, 1990, METHOD ENZYMOL, V183, P375; FLOCKHART DA, 1980, J BIOL CHEM, V255, P4435; FRANCIS SH, 1980, J BIOL CHEM, V255, P620; FRANCIS SH, 1990, CYCLIC NUCLEOTIDE PH, P118; GARGES S, 1988, J BACTERIOL, V170, P1417, DOI 10.1128/jb.170.4.1417-1422.1988; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; GRONENBORN AM, 1988, BIOCHEM J, V253, P801, DOI 10.1042/bj2530801; GRONENBORN AM, 1982, BIOCHEMISTRY-US, V21, P4040, DOI 10.1021/bi00260a020; HARMAN JG, 1986, J BIOL CHEM, V261, P6332; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HEYDUK T, 1989, BIOCHEMISTRY-US, V28, P6914, DOI 10.1021/bi00443a021; HUGHES P, 1988, CELL, V55, P343, DOI 10.1016/0092-8674(88)90057-8; JIANG H, 1992, J BIOL CHEM, V267, P1015; JOHNSON DR, 1989, FEBS LETT, V247, P480, DOI 10.1016/0014-5793(89)81395-X; KALDERON D, 1989, J BIOL CHEM, V264, P10738; KALDERON D, 1988, GENE DEV, V2, P1539, DOI 10.1101/gad.2.12a.1539; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KAUPP UB, 1991, TRENDS NEUROSCI, V14, P150; KERLAVAGE AR, 1980, J BIOL CHEM, V255, P8433; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KOCH KW, 1985, J BIOL CHEM, V260, P6788; KUNO T, 1988, BIOCHEM BIOPH RES CO, V153, P1244, DOI 10.1016/S0006-291X(88)81361-5; LANDGRAF W, 1990, BIOCHEMISTRY-US, V29, P9921, DOI 10.1021/bi00494a024; LANDGRAF W, 1991, J BIOL CHEM, V266, P16305; LEE BJ, 1991, BIOCHEMISTRY-US, V30, P9047, DOI 10.1021/bi00101a020; LINCOLN TM, 1977, P NATL ACAD SCI USA, V74, P3239, DOI 10.1073/pnas.74.8.3239; LU XY, 1990, J BIOL CHEM, V265, P3293; LUDWIG J, 1990, FEBS LETT, V270, P24, DOI 10.1016/0014-5793(90)81226-E; LUO Z, 1990, J BIOL CHEM, V265, P3293; LUO ZJ, 1990, J BIOL CHEM, V265, P21804; MARTINS TJ, 1982, J BIOL CHEM, V257, P1973; MCKAY DB, 1981, NATURE, V290, P744, DOI 10.1038/290744a0; MULLER G, 1991, BIOCHEMISTRY-US, V30, P10181; NEITZEL JJ, 1991, BIOCHEMISTRY-US, V30, P733, DOI 10.1021/bi00217a023; OGREID D, 1989, EUR J BIOCHEM, V181, P19; OGREID D, 1988, J BIOL CHEM, V263, P17397; RINGHEIM GE, 1990, J BIOL CHEM, V265, P19472; SAXE CL, 1991, DEV GENET, V12, P6, DOI 10.1002/dvg.1020120104; SCHOLUBBERS HG, 1984, EUR J BIOCHEM, V138, P101, DOI 10.1111/j.1432-1033.1984.tb07887.x; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SHABB JB, 1991, J BIOL CHEM, V266, P24320; SHABB JB, 1989, J BIOL CHEM, V264, P16031; SMITH SB, 1981, P NATL ACAD SCI-BIOL, V78, P1591, DOI 10.1073/pnas.78.3.1591; SORBERA LA, 1991, SCIENCE, V253, P1286, DOI 10.1126/science.1653970; STEINBERG RA, 1987, J BIOL CHEM, V262, P2664; STEINBERG RA, 1991, J BIOL CHEM, V266, P3547; STROOP SD, 1989, J BIOL CHEM, V264, P13718; Swofford D., 1990, PAUP PHYLOGENETIC AN; TANAKA JC, 1989, BIOCHEMISTRY-US, V28, P2776, DOI 10.1021/bi00433a006; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; THOMAS MK, 1990, J BIOL CHEM, V265, P14964; TSANG AS, 1986, J BIOL CHEM, V261, P753; VANHAASTERT PJM, 1983, J BIOL CHEM, V258, P9636; WANG YH, 1991, P NATL ACAD SCI USA, V88, P2446, DOI 10.1073/pnas.88.6.2446; WEBER IT, 1989, BIOCHEMISTRY-US, V28, P6122, DOI 10.1021/bi00440a059; WEBER IT, 1987, BIOCHEMISTRY-US, V26, P343, DOI 10.1021/bi00376a003; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WEBER IT, 1982, P NATL ACAD SCI-BIOL, V79, P7679, DOI 10.1073/pnas.79.24.7679; WOLFE L, 1987, J BIOL CHEM, V262, P16906; WOLFE L, 1990, NATO ASI SERIES H, V44, P133; WOODFORD TA, 1989, J BIOL CHEM, V264, P13321; YAGURA TS, 1981, BIOCHEMISTRY-US, V20, P879, DOI 10.1021/bi00507a035; ZIMMERMAN AL, 1985, P NATL ACAD SCI USA, V82, P8813, DOI 10.1073/pnas.82.24.8813	87	183	184	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5723	5726						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1313416				2022-12-27	WOS:A1992HK31800001
J	LEE, MK; MILNE, RE; GE, AZ; DEAN, DH				LEE, MK; MILNE, RE; GE, AZ; DEAN, DH			LOCATION OF A BOMBYX-MORI RECEPTOR-BINDING REGION ON A BACILLUS-THURINGIENSIS DELTA-ENDOTOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; BUTTERFLY PIERIS-BRASSICAE; CRYSTAL PROTEIN; SPECIFICITY; VESICLES; MIDGUT; AFFINITY; TOXICITY; BERLINER; SITES	Receptor binding studies were performed with I-125-labeled trypsin-activated insecticidal toxins, CryIA(a) and CryIA(c), from Bacillus thuringiensis on brush-border membrane vesicles (BBMV) prepared from Bombyx mori larval midgut. Bioassays were performed by gently force feeding B. mori with diluted toxins. CryIA(a) toxin (LD50; 0.002-mu-g) was 200 times more active against B. mori larvae than CryIA(c) toxin (LD50; 0.421-mu-g) and showed high-affinity saturable binding. The K(d) and the binding site concentration for CryIA(a) toxin were 3.5 nM and 7.95 pmol/mg, respectively. CryIA(c) toxin (K(d), 50.35 nM; B(max), 2.85 pmol/mg) did not demonstrate high-affinity binding to B. mori BBMV. Control experiments with CryIA(a) and CryIA(c) toxins revealed no binding to mouse small intestine BBMV and nonspecific binding to pig kidney BBMV. These data provide evidence that binding to a specific receptor on the membrane of midgut epithelial cells is an important determinant with respect to differences in insecticidal spectrum of insecticidal crystal proteins. To locate a B. mori receptor binding region on the CryIA(a) toxin, homologous and heterologous competition binding studies were performed with a set of mutant proteins which had previously been used to define the B. mori ''specificity domain'' on this toxin (Ge, A. Z., Shivarova, N. I., and Dean, D. H. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 4037-4041). These mutant proteins have had regions of their genes reciprocally exchanged with the cryIA(c) gene. A B. mori receptor binding region on CryIA(a) toxin includes the amino-terminal portion of the hypervariable region, amino acids 332-450, which is identical to the previously described B. mori specificity determining region. These data provide direct evidence that delta-endotoxins contain a tract of amino acids that comprise a binding region and as a results determines the specificity of a toxin.	OHIO STATE UNIV, DEPT BIOCHEM, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, DEPT MICROBIOL, COLUMBUS, OH 43210 USA; FORESTRY PEST MANAGEMENT INST, Sault Ste Marie P6A 5M7, ONTARIO, CANADA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University					NIAID NIH HHS [R01 AI29092] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029092] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADANG MJ, 1985, GENE, V36, P289, DOI 10.1016/0378-1119(85)90184-2; [Anonymous], PATHOGENSIS INVERTEB; BIBER J, 1981, BIOCHIM BIOPHYS ACTA, V647, P169, DOI 10.1016/0005-2736(81)90243-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Dulmage H.T., 1981, MICROBIAL CONTROL PE, P193; ELLAR DJ, 1986, BACTERIAL PROTEIN TO, P41; GE AZ, 1989, P NATL ACAD SCI USA, V86, P4037, DOI 10.1073/pnas.86.11.4037; GE AZ, 1990, GENE, V93, P49, DOI 10.1016/0378-1119(90)90134-D; HAIDER MZ, 1987, BIOCHEM J, V248, P197, DOI 10.1042/bj2480197; HAIDER MZ, 1989, BIOCHIM BIOPHYS ACTA, V978, P216, DOI 10.1016/0005-2736(89)90118-1; HAIDER MZ, 1986, EUR J BIOCHEM, V156, P531, DOI 10.1111/j.1432-1033.1986.tb09612.x; HOFMANN C, 1988, P NATL ACAD SCI USA, V85, P7844, DOI 10.1073/pnas.85.21.7844; HOFMANN C, 1988, EUR J BIOCHEM, V173, P85, DOI 10.1111/j.1432-1033.1988.tb13970.x; HOFTE H, 1986, EUR J BIOCHEM, V161, P273, DOI 10.1111/j.1432-1033.1986.tb10443.x; HOLMES KC, 1965, J MOL BIOL, V14, P572, DOI 10.1016/S0022-2836(65)80205-4; JAQUET F, 1987, APPL ENVIRON MICROB, V53, P500, DOI 10.1128/AEM.53.3.500-504.1987; JARRETT P, 1986, BIOL AGRIC HORTIC, V4, P39, DOI 10.1080/01448765.1986.9754485; KNOWLES BH, 1986, J CELL SCI, V83, P89; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILNE R, 1990, ACS SYM SER, V432, P22; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; REBECCA JG, 1990, BIOTECHNOLOGY, V8, P1011; ROWE GE, 1987, CRIT REV BIOTECHNOL, V6, P87, DOI 10.3109/07388558709086986; RUSSELL R M, 1977, Bulletin of the Entomological Society of America, V23, P209; SCHNEPF HE, 1985, J BIOL CHEM, V260, P6264; SCHNEPF HE, 1990, J BIOL CHEM, V265, P20923; VANFRANKENHUYZEN K, 1987, CAN ENTOMOL, V119, P941, DOI 10.4039/Ent119941-10; VANRIE J, 1989, EUR J BIOCHEM, V186, P239, DOI 10.1111/j.1432-1033.1989.tb15201.x; VANRIE J, 1990, APPL ENVIRON MICROB, V56, P1378, DOI 10.1128/AEM.56.5.1378-1385.1990; WOLFERSBERGER M, 1987, COMP BIOCHEM PHYS A, V86, P301, DOI 10.1016/0300-9629(87)90334-3; WOLFERSBERGER MG, 1990, EXPERIENTIA, V46, P475; WOLFERSBERGER MG, 1986, ZENTRALBL BAKTERIO S, V15, P237; YAMAMOTO T, 1983, J INVERTEBR PATHOL, V41, P122, DOI 10.1016/0022-2011(83)90243-4	33	174	199	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3115	3121						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1310681				2022-12-27	WOS:A1992HD15400047
J	GROSS, M; STARN, TK; RUNDQUIST, C; CROW, P; WHITE, J; OLIN, A; WAGNER, T				GROSS, M; STARN, TK; RUNDQUIST, C; CROW, P; WHITE, J; OLIN, A; WAGNER, T			PURIFICATION AND INITIAL CHARACTERIZATION OF PEPTIDYL-TRANSFER RNA HYDROLASE FROM RABBIT RETICULOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROLLED TRANSLATIONAL REPRESSOR; PROTEIN-SYNTHESIS; METABOLIC ROLE; ESCHERICHIA-COLI; RIBOSOMES; HEMIN; DEACYLATION; INHIBITOR; COMPLEXES; ABSENCE	We have identified an activity in rabbit reticulocyte lysate as peptidyl-tRNA hydrolase, based upon its ability to hydrolyze native reticulocyte peptidyl-tRNA, isolated from polyribosomes, and N-acylaminoacyl-tRNA, and its inability to hydrolyze aminoacyl-tRNA, precisely the same substrate specificity previously reported for peptidyl-tRNA hydrolase from bacteria or yeast. The physiological role of the reticulocyte enzyme may be to hydrolyze and recycle peptidyl-tRNA that has dissociated prematurely from elongating ribosomes, as suggested for the bacterial and yeast enzymes, since reticulocyte peptidyl-tRNA hydrolase is completely incapable of hydrolyzing peptidyl-tRNA that is still bound to polyribosomes. We have purified reticulocyte peptidyl-tRNA hydrolase over 5,000-fold from the postribosomal supernatant with a yield of 14%. The purified product shows a 72-kDa band upon sodium dodecyl sulfate-polyacrylamide gel electrophoresis that has co-purified with enzyme activity and comprises about 90% of the total stained protein, strongly suggesting that the 72-kDa protein is the enzyme. Sucrose density gradient analysis indicates an apparent molecular mass for the native enzyme of 65 kDa, implying that it is a single polypeptide chain. The enzyme is almost completely inactive in the absence of a divalent cation: Mg2+ (1-2 mM) promotes activity best, Mn2+ is partly effective, and Ca2+ and spermidine are ineffective. The hydrolase shows a K(m) of 0.60-mu-M and V(max) of 7.1 nmol/min/mg with reticulocyte peptidyl-tRNA, a K(m) of 60 nM and V(max) of 14 nmol/min/mg with Escherichia coli fMet-tRNA(f)Met, and a K(m) of 100 nM and V(max) of 2.2 nmol/min/mg with yeast N-acetyl-Phe-tRNA(Phe). The enzyme has a pH optimum of 7.0-7.25, it is inactivated by heat (60-degrees-C for 5 min), and its activity is almost completely inhibited by pretreatment with N-ethylmaleimide or incubation with 20 mM phosphate. The fact that the enzyme hydrolyzes E. coli but not yeast or reticulocyte fMet-tRNA(f)Met may be explained, at least in part, by structural similarities between prokaryotic tRNA(f)Met and eukaryotic elongator tRNA that are not shared by eukaryotic tRNA(f)Met.	UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637	University of Chicago	GROSS, M (corresponding author), UNIV CHICAGO,DEPT PATHOL,CHICAGO,IL 60637, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030121] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-30121] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BONNET J, 1972, FEBS LETT, V27, P139, DOI 10.1016/0014-5793(72)80427-7; CAPECCHI MR, 1967, P NATL ACAD SCI USA, V58, P1144, DOI 10.1073/pnas.58.3.1144; CASKEY CT, 1968, SCIENCE, V162, P135, DOI 10.1126/science.162.3849.135; CHAPEVILLE F, 1969, COLD SPRING HARB SYM, V34, P493, DOI 10.1101/SQB.1969.034.01.055; CUZIN F, 1967, P NATL ACAD SCI USA, V58, P2079, DOI 10.1073/pnas.58.5.2079; DEGROOT N, 1969, BIOCHIM BIOPHYS ACTA, V186, P286, DOI 10.1016/0005-2787(69)90006-9; DEGROOT N, 1968, BIOCHEM BIOPH RES CO, V31, P37, DOI 10.1016/0006-291X(68)90027-2; GROSS M, 1987, J BIOL CHEM, V262, P6899; GROSS M, 1992, J BIOL CHEM, V267, P2080; GROSS M, 1986, BIOCHIM BIOPHYS ACTA, V867, P220, DOI 10.1016/0167-4781(86)90037-0; GROSS M, 1983, BIOCHIM BIOPHYS ACTA, V740, P255, DOI 10.1016/0167-4781(83)90134-3; GROSS M, 1979, J BIOL CHEM, V254, P2370; GROSS M, 1976, BIOCHIM BIOPHYS ACTA, V447, P445, DOI 10.1016/0005-2787(76)90082-4; JACKSON RJ, 1983, EUR J BIOCHEM, V131, P289, DOI 10.1111/j.1432-1033.1983.tb07262.x; JOST JP, 1969, J BIOL CHEM, V244, P5866; KOSSEL H, 1968, J MOL BIOL, V35, P539, DOI 10.1016/S0022-2836(68)80013-0; KWAN A, 1984, BIOCHIM BIOPHYS ACTA, V783, P80, DOI 10.1016/0167-4781(84)90081-2; MAXWELL CR, 1971, J MOL BIOL, V58, P317, DOI 10.1016/0022-2836(71)90249-X; MENNINGER JR, 1976, J BIOL CHEM, V251, P3392; MENNINGER JR, 1973, MOL GEN GENET, V121, P307, DOI 10.1007/BF00433230; MENNINGER JR, 1974, BIOCHIM BIOPHYS ACTA, V335, P185, DOI 10.1016/0005-2787(74)90222-6; MUENCH KH, 1966, PROCEDURES NUCLEIC A, P375; PAULIN D, 1968, Febs Letters, V1, P163, DOI 10.1016/0014-5793(68)80048-1; Rappoport S, 1974, Methods Enzymol, V29, P685; ROSA MD, 1977, EUR J BIOCHEM, V78, P141, DOI 10.1111/j.1432-1033.1977.tb11723.x; SCHREIER AA, 1972, BIOCHEMISTRY-US, V11, P1582, DOI 10.1021/bi00759a006; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOURGOUTCHOV A, 1974, EUR J BIOCHEM, V46, P431, DOI 10.1111/j.1432-1033.1974.tb03636.x; VOGEL Z, 1968, P NATL ACAD SCI USA, V61, P701, DOI 10.1073/pnas.61.2.701; WAGNER T, 1989, J BIOL CHEM, V264, P18506; WAGNER T, 1987, FEBS LETT, V212, P317, DOI 10.1016/0014-5793(87)81368-6; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YARUS M, 1972, P NATL ACAD SCI USA, V68, P1915	33	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					2073	2079						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1309807				2022-12-27	WOS:A1992HA48500100
J	SIHRA, TS; BOGONEZ, E; NICHOLLS, DG				SIHRA, TS; BOGONEZ, E; NICHOLLS, DG			LOCALIZED CA2+ ENTRY PREFERENTIALLY EFFECTS PROTEIN DEPHOSPHORYLATION, PHOSPHORYLATION, AND GLUTAMATE RELEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED NERVE-TERMINALS; SYNAPTIC TRANSMITTER RELEASE; RAT CORTICAL SYNAPTOSOMES; CYTOSOLIC FREE CA-2+; SYNAPSIN-I; CALCIUM INFLUX; ACTIVE ZONES; DEPOLARIZATION; TRANSLOCATION; CHANNELS	The release of neurotransmitter glutamate from isolated nerve terminals (synaptosomes) was found to be tightly coupled to the entry of Ca2+ through voltage-dependent Ca2+ channels, but is relatively unresponsive to "bulk" increases in cytosolic Ca2+ concentrations ([Ca2+]c) effected by Ca2+ ionophore. Under the same conditions, this dependence on Ca2+ influx, specifically through Ca2+ channels, was also seen for the dephosphorylation of a 96-kDa protein, (P96), present in the nerve terminals, as well as the phosphorylation of proteins migrating at 75 kDa (P75), corresponding to the synapsins, a group of well characterized synaptic vesicle-associated proteins. P96 dephosphorylation, following Ca2+ influx, was persistent and insensitive to the phosphatase inhibitor okadaic acid, suggesting a phosphatase other than protein phosphatase 1 and 2A as being responsible. Perhaps through the same phosphatase activity the increase in P75 phosphorylation was rapidly reversed with a time course similar to P96 dephosphorylation. When release, P96 dephosphorylation, and P75 phosphorylation were considered as functions of the [Ca2+]c increases achieved by depolarization and Ca2+ ionophore, there was no correlation of any of these with the overall concentration of Ca2+ in the cytosol. Since the fura-2 method used to measure [Ca2+] gives an averaged [Ca2+]c, these results imply that the release and protein dephosphorylation events are functionally coupled to local [Ca2+]c, in the immediate vicinity of Ca2+ channels. The reported clustering of the latter at the active zone area of the synapse and the parallelism between synaptic vesicle exocytosis and the phosphorylation of synaptic vesicle-associated proteins (p75:synapsins Ia/Ib), suggests that P96 may be similarly localized at the active zone area and, therefore, may be of significance in a modulatory role in glutamate release.	UNIV AUTONOMA MADRID, CSIC, DEPT BIOL MOLEC, MADRID 34, SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)	SIHRA, TS (corresponding author), UNIV DUNDEE, DEPT BIOCHEM, DUNDEE DD1 4HN, SCOTLAND.		Sihra, Talvinder S/A-4581-2009; NICHOLLS, DAVID G/K-4300-2012					AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BARRETT EF, 1972, J PHYSIOL-LONDON, V227, P691, DOI 10.1113/jphysiol.1972.sp010054; BLAU L, 1988, BIOCHEMISTRY-US, V27, P5661, DOI 10.1021/bi00415a040; BUMA P, 1989, ACTA MORPHOL NEER SC, V26, P81; DUNKLEY PR, 1986, PROG BRAIN RES, V69, P273; DUNKLEY PR, 1986, BRAIN RES, V372, P115, DOI 10.1016/0006-8993(86)91464-2; GOMEZPUERTAS P, 1991, J NEUROCHEM, V56, P2039, DOI 10.1111/j.1471-4159.1991.tb03464.x; GREENGARD P, 1987, MOL NEUROBIOL, V1, P81, DOI 10.1007/BF02935265; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEUSER JE, 1974, J NEUROCYTOL, V3, P109, DOI 10.1007/BF01111936; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KAUPPINEN RA, 1988, NEUROSCIENCE, V27, P175, DOI 10.1016/0306-4522(88)90228-X; KOMULAINEN H, 1987, NEUROCHEM INT, V10, P55, DOI 10.1016/0197-0186(87)90172-0; KRUEGER BK, 1977, J BIOL CHEM, V252, P2764; MCMAHON HT, 1991, J NEUROCHEM, V56, P86, DOI 10.1111/j.1471-4159.1991.tb02566.x; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; NICHOLLS DG, 1986, NATURE, V321, P772, DOI 10.1038/321772a0; NICHOLLS DG, 1989, J NEUROCHEM, V53, P1325; NICHOLS RA, 1990, NATURE, V343, P647, DOI 10.1038/343647a0; PARSEGIAN VA, 1977, SOC NEUROSCI S, V2, P161; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; PUMPLIN DW, 1981, P NATL ACAD SCI-BIOL, V78, P7210, DOI 10.1073/pnas.78.11.7210; Robinson P J, 1987, Adv Exp Med Biol, V221, P155; ROBINSON PJ, 1985, J NEUROCHEM, V44, P338, DOI 10.1111/j.1471-4159.1985.tb05422.x; ROBINSON PJ, 1991, FEBS LETT, V282, P388, DOI 10.1016/0014-5793(91)80520-D; ROBINSON PJ, 1987, J NEUROCHEM, V48, P187, DOI 10.1111/j.1471-4159.1987.tb13146.x; ROBINSON PJ, 1983, J NEUROCHEM, V41, P909, DOI 10.1111/j.1471-4159.1983.tb09034.x; RUBENSTEIN J L, 1991, Society for Neuroscience Abstracts, V17, P1153; SCHIEBLER W, 1986, J BIOL CHEM, V261, P8383; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V24, P1; SIHRA TS, 1989, P NATL ACAD SCI USA, V86, P8108, DOI 10.1073/pnas.86.20.8108; SIMON SM, 1985, BIOPHYS J, V48, P485, DOI 10.1016/S0006-3495(85)83804-2; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SMITH SJ, 1988, CALCIUM ION CHANNEL, P147; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; TIBBS GR, 1989, J NEUROCHEM, V53, P1693, DOI 10.1111/j.1471-4159.1989.tb09232.x; VERHAGE M, 1991, NEURON, V6, P517, DOI 10.1016/0896-6273(91)90054-4; WALROND JP, 1985, J NEUROSCI, V5, P1118; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; ZUCKER RS, 1983, J NEUROSCI, V3, P1263; ZUCKER RS, 1986, P NATL ACAD SCI USA, V83, P3032, DOI 10.1073/pnas.83.9.3032	42	135	138	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1983	1989						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1309806				2022-12-27	WOS:A1992HA48500089
J	COUNTAWAY, JL; NAIRN, AC; DAVIS, RJ				COUNTAWAY, JL; NAIRN, AC; DAVIS, RJ			MECHANISM OF DESENSITIZATION OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR PROTEIN-TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; LIGAND-INDUCED INTERNALIZATION; TISSUE-SPECIFIC TRANSFORMATION; EGF-RECEPTOR; HUMAN-FIBROBLASTS; A431 CELLS; PHOSPHATIDYLINOSITOL TURNOVER; AUTOPHOSPHORYLATION SITES; SELF-PHOSPHORYLATION; SIGNAL TRANSDUCTION	The intrinsic protein-tyrosine kinase activity of the epidermal growth factor (EGF) receptor is required for signal transduction. Increased protein-tyrosine kinase activity is observed following the binding of EGF to the receptor. However, signaling is rapidly desensitized during EGF treatment. We report that EGF receptors isolated from desensitized cells exhibit a lower protein-tyrosine kinase activity than EGF receptors isolated from control cells. The mechanism of desensitization of kinase activity can be accounted for, in part, by the EGF-stimulated phosphorylation of the receptor at Ser1046/7, a substrate for the multifunctional calmodulin-dependent protein kinase II in vitro. Mutation of Ser1046/7 by replacement with Ala residues blocks desensitization of the EGF receptor protein-tyrosine kinase activity. Furthermore, this mutation causes a marked inhibition of the EGF-stimulated endocytosis and down-regulation of cell surface receptors. Thus, the phosphorylation site Ser1046/7 is required for EGF receptor desensitization in EGF-treated cells. This regulatory phosphorylation site is located at the carboxyl terminus of the EGF receptor within the subdomain that binds src homology 2 regions of signaling molecules.	UNIV MASSACHUSETTS, SCH MED,HOWARD HUGHES MED INST,PROGRAM MOLEC MED, 373 PLANTATION ST, WORCESTER, MA 01605 USA; UNIV MASSACHUSETTS, SCH MED, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01605 USA; ROCKEFELLER UNIV, MOLEC & CELLULAR NEUROSCI LAB, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Rockefeller University				Nairn, Angus/0000-0002-7075-0195	NATIONAL CANCER INSTITUTE [P01CA039240] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037845] Funding Source: NIH RePORTER; NCI NIH HHS [CA39240] Funding Source: Medline; NIGMS NIH HHS [GM37845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; BERTICS PJ, 1988, J BIOL CHEM, V263, P3610; BESTERMAN JM, 1986, J BIOL CHEM, V261, P723; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BOWEN S, 1991, J BIOL CHEM, V266, P1162; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CHINKERS M, 1986, J BIOL CHEM, V261, P8295; COCHET C, 1984, J BIOL CHEM, V259, P2553; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P13642; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; CUNNINGHAM TW, 1989, J BIOL CHEM, V264, P15351; DAVIS RJ, 1985, P NATL ACAD SCI USA, V82, P1974, DOI 10.1073/pnas.82.7.1974; DAVIS RJ, 1985, J BIOL CHEM, V260, P1562; DAVIS RJ, 1986, EMBO J, V5, P653, DOI 10.1002/j.1460-2075.1986.tb04263.x; DAVIS RJ, 1987, J BIOL CHEM, V262, P16041; DAVIS RJ, 1985, J BIOL CHEM, V260, P5315; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DAVIS RJ, 1985, J BIOL CHEM, V260, P2543; DAVIS RJ, 1984, J BIOL CHEM, V259, P8545; DAVIS RJ, 1987, J BIOL CHEM, V262, P6832; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; EARP HS, 1988, J BIOL CHEM, V263, P13868; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FRIEDMAN B, 1989, P NATL ACAD SCI USA, V86, P812, DOI 10.1073/pnas.86.3.812; FRIEDMAN BA, 1984, P NATL ACAD SCI-BIOL, V81, P3034, DOI 10.1073/pnas.81.10.3034; GAMETT DC, 1986, P NATL ACAD SCI USA, V83, P6053, DOI 10.1073/pnas.83.16.6053; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GRAND RJA, 1979, BIOCHEM J, V177, P521, DOI 10.1042/bj1770521; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; HELIN K, 1991, J BIOL CHEM, V266, P8363; HONEGGER A, 1988, EMBO J, V7, P3045, DOI 10.1002/j.1460-2075.1988.tb03169.x; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; HONEGGER AM, 1990, J CELL BIOL, V110, P1541, DOI 10.1083/jcb.110.5.1541; HSU CYJ, 1991, J BIOL CHEM, V266, P603; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; HUNTER T, 1981, CELL, V24, P741, DOI 10.1016/0092-8674(81)90100-8; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KIM JW, 1990, J BIOL CHEM, V265, P3940; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOLAND JG, 1990, BIOCHEM BIOPH RES CO, V166, P90, DOI 10.1016/0006-291X(90)91915-F; KUPPUSWAMY D, 1989, J BIOL CHEM, V264, P3357; LAI WH, 1989, J CELL BIOL, V109, P2751, DOI 10.1083/jcb.109.6.2751; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; LIU XQ, 1991, MOL CELL BIOL, V11, P2511, DOI 10.1128/MCB.11.5.2511; LIVNEH E, 1988, MOL CELL BIOL, V8, P2302, DOI 10.1128/MCB.8.6.2302; LUND KA, 1990, J BIOL CHEM, V265, P20517; MACARA IG, 1986, J BIOL CHEM, V261, P9321; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MAGNI M, 1991, J BIOL CHEM, V266, P6329; MAIHLE N J, 1988, Biochimica et Biophysica Acta, V948, P287; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MASSOGLIA S, 1990, MOL CELL BIOL, V10, P3048, DOI 10.1128/MCB.10.6.3048; MATRISIAN LM, 1982, ANAL BIOCHEM, V125, P339, DOI 10.1016/0003-2697(82)90015-X; MCCUNE BK, 1990, J BIOL CHEM, V265, P9715; MCGUINNESS TL, 1985, J BIOL CHEM, V260, P1696; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MIYAMOTO E, 1990, ADV SEC MESS PHOSPH, V24, P212; MOOLENAAR WH, 1984, J BIOL CHEM, V259, P8066; MOOLENAAR WH, 1986, J BIOL CHEM, V261, P279; MORRIS JDH, 1984, FEBS LETT, V169, P189, DOI 10.1016/0014-5793(84)80316-6; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAIRN AC, 1990, ADV SEC MESS PHOSPH, V24, P202; NISHIBE S, 1990, P NATL ACAD SCI USA, V87, P424, DOI 10.1073/pnas.87.1.424; NORTHWOOD IC, 1989, J BIOL CHEM, V264, P5746; NORTHWOOD IC, 1988, J BIOL CHEM, V263, P7450; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; PELLEY RJ, 1989, P NATL ACAD SCI USA, V86, P7164, DOI 10.1073/pnas.86.18.7164; PELLEY RJ, 1988, J VIROL, V62, P1840, DOI 10.1128/JVI.62.5.1840-1844.1988; PESSIN JE, 1983, J BIOL CHEM, V258, P7386; PIKE LJ, 1987, J BIOL CHEM, V262, P1644; RAINES MA, 1988, J VIROL, V62, P2444, DOI 10.1128/JVI.62.7.2444-2452.1988; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SAWYER ST, 1981, BIOCHEMISTRY-US, V20, P6280, DOI 10.1021/bi00524a057; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SHU HKG, 1990, P NATL ACAD SCI USA, V87, P9103, DOI 10.1073/pnas.87.23.9103; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SORKIN A, 1991, J BIOL CHEM, V266, P8355; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; TRACY SE, 1985, J VIROL, V54, P304, DOI 10.1128/JVI.54.2.304-310.1985; TRACY SE, 1988, THESIS U MASSACHUSET; TSUDA T, 1986, J BIOCHEM-TOKYO, V100, P1631, DOI 10.1093/oxfordjournals.jbchem.a121871; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; USHIRO H, 1980, J BIOL CHEM, V255, P8363; WAHL M, 1988, J BIOL CHEM, V263, P7581; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WAHL MI, 1987, BIOCHEM BIOPH RES CO, V142, P688, DOI 10.1016/0006-291X(87)91469-0; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WHITELEY B, 1986, J CELL BIOL, V103, P1355, DOI 10.1083/jcb.103.4.1355; WILEY HS, 1982, J BIOL CHEM, V257, P4222; WILEY HS, 1989, J BIOL CHEM, V264, P18919; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479; [No title captured]	115	152	154	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1129	1140						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1309762				2022-12-27	WOS:A1992GY96000073
J	NAEGELI, H; BARDWELL, L; HAROSH, I; FRIEDBERG, EC				NAEGELI, H; BARDWELL, L; HAROSH, I; FRIEDBERG, EC			SUBSTRATE-SPECIFICITY OF THE RAD3 ATPASE/DNA HELICASE OF SACCHAROMYCES-CEREVISIAE AND BINDING OF RAD3 PROTEIN TO NUCLEIC-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DEPENDENT ATPASE; SINGLE-STRANDED-DNA; DEOXYRIBONUCLEIC-ACID; GENE-4 PROTEIN; MITOTIC RECOMBINATION; MUTANT ALLELES; YEAST; BACTERIOPHAGE-T7; COMPLEX; RNA	Rad3 protein from the yeast Saccharomyces cerevisiae is a single-stranded DNA-dependent ATPase which catalyzes the unwinding of DNA.DNA duplexes. In the present studies we have demonstrated that the purified enzyme additionally catalyzes the displacement of RNA fragments annealed to complementary DNA. Quantitative comparisons using otherwise identical partially duplex DNA.DNA and DNA.RNA substrates indicate a significant preference for the latter. Competition for ATPase or DNA helicase activity by various homopolymers suggests that Rad3 protein does not discriminate between ribonucleotide and deoxyribonucleotide homopolymers with respect to binding. However, neither single-stranded RNA nor various ribonucleotide homopolymers supported the hydrolysis of nucleoside 5'-triphosphates. Additionally, Rad3 protein was unable to catalyze the displacement of oligo(dA) annealed to poly(U), suggesting that the catalytic domain of the enzyme is exquisitely sensitive to chemical and/or or conformational differences between DNA and RNA. Hence, it appears that Rad3 protein is not an RNA helicase.	UNIV TEXAS,SW MED CTR,DEPT PATHOL,MOLEC PATHOL LAB,5323 HARRY HINES BLVD,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Bardwell, Lee/I-8284-2019	Bardwell, Lee/0000-0002-2393-8363	NATIONAL CANCER INSTITUTE [R37CA012428, R01CA012428] Funding Source: NIH RePORTER; NCI NIH HHS [CA12428, CA09302] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMSON RD, 1988, J BIOL CHEM, V263, P6016; [Anonymous], 1985, DNA REPAIR; BROWN WC, 1989, J BIOL CHEM, V264, P6748; CRUTE JJ, 1991, J BIOL CHEM, V266, P4484; FRESCO JR, 1963, J AM CHEM SOC, V85, P1352, DOI 10.1021/ja00892a031; FRIEDBERG EC, 1988, MICROBIOL REV, V52, P70, DOI 10.1128/MMBR.52.1.70-102.1988; GEIDER K, 1981, ANNU REV BIOCHEM, V50, P233, DOI 10.1146/annurev.bi.50.070181.001313; HAROSH I, 1989, J BIOL CHEM, V264, P20532; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HARTMAN KA, 1965, J AM CHEM SOC, V87, P2033, DOI 10.1021/ja01087a031; HOLCOMB DN, 1965, BIOPOLYMERS, V3, P121, DOI 10.1002/bip.360030203; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LIPSETT MN, 1960, P NATL ACAD SCI USA, V46, P445, DOI 10.1073/pnas.46.4.445; MATSON SW, 1989, P NATL ACAD SCI USA, V86, P4430, DOI 10.1073/pnas.86.12.4430; MATSON SW, 1985, J BIOL CHEM, V260, P2281; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; Michelson A M, 1967, Prog Nucleic Acid Res Mol Biol, V6, P83; MONTELONE BA, 1988, GENETICS, V119, P289; NAEGELI H, 1992, J BIOL CHEM, V267, P392; NAUMOVSKI L, 1985, MOL CELL BIOL, V5, P17, DOI 10.1128/MCB.5.1.17; NAUMOVSKI L, 1983, P NATL ACAD SCI-BIOL, V80, P4818, DOI 10.1073/pnas.80.15.4818; NAUMOVSKI L, 1986, MOL CELL BIOL, V6, P128; OH EY, 1989, J BIOL CHEM, V264, P1336; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; REYNOLDS RJ, 1981, J BACTERIOL, V146, P692, DOI 10.1128/JB.146.2.692-704.1981; SAENGER W, 1984, PRINCIPLES NUCLEIC A; Sambrook J, 1989, MOL CLONING LABORATO; SEKI M, 1986, BIOCHEMISTRY-US, V25, P3239, DOI 10.1021/bi00359a024; SEO YS, 1991, J BIOL CHEM, V266, P13161; SONG JM, 1990, J BACTERIOL, V172, P6620, DOI 10.1128/jb.172.12.6620-6630.1990; STRATLING W, 1973, NATURE, V245, P195, DOI 10.1038/245195a0; Stryer L., 1988, BIOCHEMISTRY-US; SUGINO A, 1986, J BIOL CHEM, V261, P1744; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; SUNG P, 1988, MECHANISMS CONSEQUEN, P191; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; THOMMES P, 1990, FEBS LETT, V268, P325, DOI 10.1016/0014-5793(90)81279-W; TUTEJA N, 1991, NUCLEIC ACIDS RES, V19, P3613, DOI 10.1093/nar/19.13.3613	43	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7839	7844						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1313809				2022-12-27	WOS:A1992HN48500090
J	SATO, S; HUGHES, RC				SATO, S; HUGHES, RC			BINDING-SPECIFICITY OF A BABY HAMSTER-KIDNEY LECTIN FOR H TYPE-I AND TYPE-II CHAINS, POLYLACTOSAMINE GLYCANS, AND APPROPRIATELY GLYCOSYLATED FORMS OF LAMININ AND FIBRONECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; N-ACETYLLACTOSAMINE CHAINS; EXTRACELLULAR-MATRIX; CARBOHYDRATE CHAINS; CELL-BINDING; A-CHAIN; PROTEIN; EXPRESSION; IGE; PURIFICATION	The carbohydrate binding specificity of M(r) = 30,000 lectin (CBP30) from baby hamster kidney (BHK) cells has been studied by inhibition of binding of the radiolabeled lectin to asialofetuin-Sepharose using model oligosaccharides and glycopeptides. CBP30 binds type I or II Gal-beta(1 --> 3(4))GlcNAc chains but not Gal(beta-1 --> 3)GalNAc. The inhibitory potency of straight chain polylactosamine structures or complex-type branched glycans is increased in proportion to the number of Gal(beta-1 --> 3(4)) units present. Fucosylation or sialylation of terminal galactose residues or further substitution by (alpha-1 --> 3)-linked galactose or N-acetylgalactosamine does not affect binding whereas substitution of the penultimate N-acetylglucosamine residue drastically reduces binding. Thus, blood group A, H type I or H type II structures, shows high affinity whereas Le(x), Le(a), and Le(b) structures bind poorly. CBP30 binds to murine Engelbreth-Holm-Swarm (EHS) tumor laminin and human amniotic fluid fibronection but not human plasma fibronectin. Binding involves polylactosamine glycans as well as tri- and tetraantennary complex-type glycans present in EHS laminin and amniotic fluid fibronectin but absent in plasma fibronectin. Proteolytic fragments of EHS laminin (E1X/Nd, P1, E8, and E3) bind CBP30, but only fragment E8 supports attachment and spreading of BHK cells. BHK cell adhesion to EHS laminin or fragment E8 was not disturbed by CBP30-specific antibodies, but at relatively high concentrations (45-mu-g/ml) CBP30 inhibited spreading and partially attachment of cells on laminin.	NATL INST MED RES,MILL HILL,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research								AUMAILLEY M, 1991, EXP CELL RES, V196, P177, DOI 10.1016/0014-4827(91)90248-S; AUMAILLEY M, 1990, EXP CELL RES, V188, P55, DOI 10.1016/0014-4827(90)90277-H; BARONDES SH, 1984, SCIENCE, V223, P1259, DOI 10.1126/science.6367039; BOUZON M, 1990, EXP CELL RES, V190, P47, DOI 10.1016/0014-4827(90)90142-W; CHERAYIL BJ, 1990, P NATL ACAD SCI USA, V87, P7324, DOI 10.1073/pnas.87.18.7324; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; COUCHMAN JR, 1988, J CELL PHYSIOL, V136, P226, DOI 10.1002/jcp.1041360204; DEAN JW, 1990, J BIOL CHEM, V265, P12553; EKBLOM M, 1990, CELL, V60, P337, DOI 10.1016/0092-8674(90)90748-4; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; FENDERSON BA, 1990, BIOESSAYS, V12, P173, DOI 10.1002/bies.950120406; FODDY L, 1990, J CELL SCI, V97, P139; FUJIWARA S, 1988, BIOCHEM J, V252, P453, DOI 10.1042/bj2520453; GIANCOTTI FG, 1986, EXP CELL RES, V163, P47, DOI 10.1016/0014-4827(86)90557-4; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; HIRABAYASHI J, 1984, BIOCHEM BIOPH RES CO, V122, P938, DOI 10.1016/0006-291X(84)91181-1; HUGHES RC, 1986, J CELL PHYSIOL, V128, P402, DOI 10.1002/jcp.1041280309; HUGHES RC, 1981, EUR J CELL BIOL, V26, P198; JIA SH, 1988, J BIOL CHEM, V263, P6009; KLEIN G, 1988, CELL, V55, P331, DOI 10.1016/0092-8674(88)90056-6; KLEIN G, 1990, DEVELOPMENT, V110, P823; KNIBBS RN, 1989, BIOCHEMISTRY-US, V28, P6379, DOI 10.1021/bi00441a034; LAING JG, 1989, J BIOL CHEM, V264, P1907; LEFFLER H, 1986, J BIOL CHEM, V261, P119; LEFFLER H, 1989, BIOCHEMISTRY-US, V28, P9222, DOI 10.1021/bi00449a039; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; MERCURIO AM, 1991, BIOESSAYS, V13, P469, DOI 10.1002/bies.950130907; MERKLE RK, 1988, J BIOL CHEM, V263, P16143; MERKLE RK, 1987, J BIOL CHEM, V262, P8179; ORIOL R, 1987, BIOCHEM SOC T, V15, P596, DOI 10.1042/bst0150596; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; SATO S, 1991, J BIOL CHEM, V266, P11485; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; STOJANOVIC D, 1984, BIOL CELL, V51, P197, DOI 10.1111/j.1768-322X.1984.tb00299.x; STOKER M, 1964, NATURE, V203, P1355, DOI 10.1038/2031355a0; TAKAMOTO M, 1989, J BIOCHEM-TOKYO, V105, P742, DOI 10.1093/oxfordjournals.jbchem.a122738; TAKAMOTO M, 1989, J BIOCHEM-TOKYO, V106, P228, DOI 10.1093/oxfordjournals.jbchem.a122837; TAKASAKI S, 1980, J BIOCHEM-TOKYO, V88, P1587, DOI 10.1093/oxfordjournals.jbchem.a133133; TAKASAKI S, 1991, BIOCHEMISTRY-US, V30, P9102, DOI 10.1021/bi00101a028; TANG YS, 1983, J LABELLED COMPD RAD, V20, P277, DOI 10.1002/jlcr.2580200214; TIMPL R, 1982, METHOD ENZYMOL, V82, P831; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G; WOO HJ, 1990, J BIOL CHEM, V265, P7097; YAMAOKA K, 1991, BIOCHEM BIOPH RES CO, V179, P272, DOI 10.1016/0006-291X(91)91365-J; YAMASHITA K, 1987, J BIOL CHEM, V262, P1602; ZHOU Q, 1990, ARCH BIOCHEM BIOPHYS, V281, P27, DOI 10.1016/0003-9861(90)90408-Q	51	253	259	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6983	6990						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1313027				2022-12-27	WOS:A1992HM05300081
J	BRZESKA, H; MARTIN, B; KULESZALIPKA, D; BAINES, I; KORN, ED				BRZESKA, H; MARTIN, B; KULESZALIPKA, D; BAINES, I; KORN, ED			PREPARATION OF A PHOSPHOLIPID-INSENSITIVE, AUTOPHOSPHORYLATION-ACTIVATED CATALYTIC FRAGMENT OF ACANTHAMOEBA MYOSIN-I HEAVY-CHAIN KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; MICROGRAM QUANTITIES; SYNTHETIC PEPTIDES; COFACTOR PROTEIN; ACTIN ACTIVATION; AMINO-ACID; RAT-BRAIN; C FAMILY; PURIFICATION; CASTELLANII	The actin-activated Mg2+-ATPase activity of Acanthamoeba myosin I depends on phosphorylation of its single heavy chain. The activity of the myosin I heavy chain kinase is increased about 50-fold by autophosphorylation, and the rate of kinase autophosphorylation is enhanced about 20-fold by acidic phospholipids independent of the presence of Ca2+ (Brzeska, H., Lynch, T. J., and Korn, E. D. (1990) J. Biol. Chem. 265, 3591-3594). In this paper, we show that chymotryptic digestion of the kinase produces a 54-kDa fragment which contains three to four of the approximately 11 original phosphorylation sites and whose activity is greatly stimulated by autophosphorylation. However, both the rate of autophosphorylation and the kinase activity of the 54-kDa fragment are independent of phospholipid and comparable to those of intact kinase in the presence of phospholipid. These data imply that the (probably NH2-terminal) region(s) removed by proteolysis is necessary for phospholipid-sensitive inhibition of autophosphorylation of sites residing within the (probably COOH-terminal) 54-kDa fragment. The 54-kDa fragment contains the catalytic site of the kinase as well as three to four sites whose phosphorylation is necessary for full expression of kinase activity. The middle region of the kinase molecule contains proline-rich regions that are similar to the COOH-terminal tail of the kinase substrate, Acanthamoeba myosin I.	NIMH,CLIN NEUROSCI BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	BRZESKA, H (corresponding author), NHLBI,CELL BIOL LAB,BETHESDA,MD 20892, USA.		Korn, Edward D/F-9929-2012	Korn, Edward/0000-0003-3867-6295				ADAMS RJ, 1989, CELL MOTIL CYTOSKEL, V14, P178, DOI 10.1002/cm.970140203; ATKINSON MA, 1991, BIOPHYS J, V59, P230; BAHLER M, 1990, Journal of Cell Biology, V111, p167A; BAINES IC, 1990, J CELL BIOL, V111, P1895, DOI 10.1083/jcb.111.5.1895; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRZESKA H, 1989, J BIOL CHEM, V264, P19340; BRZESKA H, 1990, J BIOL CHEM, V265, P16138; BRZESKA H, 1990, J BIOL CHEM, V265, P3591; BRZESKA H, 1988, J BIOL CHEM, V263, P427; COLLINS JH, 1984, J BIOL CHEM, V259, P4128; COTE GP, 1985, J BIOL CHEM, V260, P4543; ESPREAFICO E, 1990, J CELL BIOL, V111, P167; GADASI H, 1980, NATURE, V286, P452, DOI 10.1038/286452a0; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GOODSON HV, 1990, J CELL BIOL, V111, P168; HAMMER JA, 1983, J BIOL CHEM, V258, P168; HOROWITZ JA, 1990, J BIOL CHEM, V265, P20646; HUANG KP, 1986, J BIOL CHEM, V261, P2134; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; JUNG G, 1987, P NATL ACAD SCI USA, V84, P6720, DOI 10.1073/pnas.84.19.6720; Korn ED, 1990, CURR OPIN CELL BIOL, V2, P57, DOI 10.1016/S0955-0674(05)80031-6; KULESZALIPKA D, 1991, J CELL BIOL, V115, P109, DOI 10.1083/jcb.115.1.109; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGENDRE N, 1988, BIOTECHNIQUES, V6, P154; LI D, 1991, J BIOPHYS, V59, pA229; LILLIE SM, 1990, J CELL BIOL, V111, P168; LYNCH TJ, 1989, J BIOL CHEM, V264, P19333; LYNCH TJ, 1990, METHOD ENZYMOL, V196, P12; MARUTA H, 1979, J BIOL CHEM, V254, P3624; MARUTA H, 1977, J BIOL CHEM, V252, P8329; MATSUDAIRA PT, 1979, J CELL BIOL, V83, P667, DOI 10.1083/jcb.83.3.667; MEDLEY QG, 1990, BIOCHEMISTRY-US, V29, P8992, DOI 10.1021/bi00490a016; MIYATA H, 1989, J CELL BIOL, V109, P1519, DOI 10.1083/jcb.109.4.1519; MONTELL C, 1988, CELL, V52, P757, DOI 10.1016/0092-8674(88)90413-8; MOSHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; POLLARD TD, 1973, J BIOL CHEM, V248, P4691; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; RAVID S, 1989, J BIOL CHEM, V264, P15144; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SHERR E H, 1990, Journal of Cell Biology, V111, p167A; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; SPUDICH JA, 1989, CELL REGUL, V1, P1	46	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4949	4956						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1311323				2022-12-27	WOS:A1992HF64200097
J	LLAHI, S; FAIN, JN				LLAHI, S; FAIN, JN			ALPHA-1-ADRENERGIC RECEPTOR-MEDIATED ACTIVATION OF PHOSPHOLIPASE-D IN RAT CEREBRAL-CORTEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HL-60 GRANULOCYTES; PHOSPHATIDYLCHOLINE HYDROLYSIS; CHEMOTACTIC PEPTIDE; PHOSPHATIDIC-ACID; PHOSPHATIDYLETHANOL FORMATION; REGIONAL DISTRIBUTION; SIGNAL TRANSDUCTION; CALCIUM IONOPHORE; HUMAN-NEUTROPHILS	We have investigated phospholipase D activity in rat brain cortical slices prelabeled with [P-32]orthophosphoric acid. In the presence of ethanol (170 mM), norepinephrine stimulated, in a dose-dependent manner (EC50 = 2.2-mu-M), the accumulation of [P-32]phosphatidylethanol as a result of phospholipase D activity. Norepinephrine-stimulated phospholipase D activity was completely inhibited by prazosin, a specific alpha-1-adrenergic antagonist (K(i) = 2.8 nM). However, no accumulation of phosphatidylethanol was observed in the presence of the muscarinic agonist carbachol. The Ca2+ ionophore ionomycin and the protein kinase C activator phorbol 12-myristate 13-acetate (PMA) also stimulated [P-32]phosphatidylethanol accumulation in cortical slices, in a dose- and time-dependent manner, whereas the inactive phorbol, 4-alpha-phorbol 12, 13-didecanoate, did not stimulate phospholipase D activity. Staurosporine and 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine, two potent inhibitors of protein kinase C, inhibited PMA and ionomycin stimulation of phospholipase D activity, but did not affect the response to norepinephrine. Furthermore, the effects of PMA and norepinephrine were additive. Differences between PMA and norepinephrine stimulation of phospholipase D activity were also found with regard to the extracellular Ca2+ requirement and time course of phosphatidylethanol accumulation. No stimulation of phospholipase D activity by norepinephrine was observed in slices from cerebellum, a brain area with a low density of alpha-1-adrenergic receptors, while the effect of PMA was greater in the cerebellum than in cortical or hippocampal slices. These results strongly suggest that activation of phospholipase D in cortical slices by norepinephrine and PMA involve different mechanisms.	UNIV TENNESSEE CTR HLTH SCI,DEPT BIOCHEM,858 MADISON AVE,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center					NIDDK NIH HHS [DK 37004] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037004] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGWU DE, 1991, J IMMUNOL, V146, P3895; AGWU DE, 1989, J BIOL CHEM, V264, P1405; ANTHES JC, 1989, BIOCHEM BIOPH RES CO, V163, P657, DOI 10.1016/0006-291X(89)92187-6; ANTHES JC, 1991, ARCH BIOCHEM BIOPHYS, V287, P53, DOI 10.1016/0003-9861(91)90387-X; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; CABOT MC, 1989, FEBS LETT, V245, P85, DOI 10.1016/0014-5793(89)80197-8; CAO YZ, 1990, BIOCHEM BIOPH RES CO, V171, P955, DOI 10.1016/0006-291X(90)90777-K; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; DAWSON RMC, 1967, BIOCHEM J, V102, P205, DOI 10.1042/bj1020205; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; EXTON JH, 1990, J BIOL CHEM, V265, P1; FARESE RV, 1987, SCIENCE, V236, P586, DOI 10.1126/science.3107122; GUSTAVSSON L, 1987, BIOCHEM BIOPH RES CO, V142, P958, DOI 10.1016/0006-291X(87)91507-5; HALENDA SP, 1990, BIOCHEM J, V267, P479, DOI 10.1042/bj2670479; HORWITZ J, 1991, J NEUROCHEM, V56, P509, DOI 10.1111/j.1471-4159.1991.tb08179.x; HUANG CF, 1990, J BIOL CHEM, V265, P17468; HUANG CF, 1990, J BIOL CHEM, V265, P14858; HUANG R, 1991, J BIOL CHEM, V266, P1652; HURST KM, 1990, BIOCHEM J, V272, P749, DOI 10.1042/bj2720749; JAKEN S, 1989, INOSITOL LIPIDS CELL, P163; JOHNSON RD, 1985, BRAIN RES, V341, P7, DOI 10.1016/0006-8993(85)91466-0; KANFER JN, 1980, CAN J BIOCHEM CELL B, V58, P1370, DOI 10.1139/o80-186; KISS Z, 1990, PROG LIPID RES, V29, P141, DOI 10.1016/0163-7827(90)90001-2; KISS Z, 1991, BIOCHEM J, V276, P505, DOI 10.1042/bj2760505; KOBAYASHI M, 1988, NEUROCHEM RES, V13, P771, DOI 10.1007/BF00971601; KOBAYASHI M, 1987, J NEUROCHEM, V48, P1597, DOI 10.1111/j.1471-4159.1987.tb05707.x; LAPETINA EG, 1982, TRENDS PHARMACOL SCI, V3, P115, DOI 10.1016/0165-6147(82)91046-X; LASSEGUE B, 1991, BIOCHEM J, V276, P19, DOI 10.1042/bj2760019; LISCOVITCH M, 1989, J BIOL CHEM, V264, P11762; LISCOVITCH M, 1989, J BIOL CHEM, V264, P1450; MARTIN TW, 1989, J BIOL CHEM, V264, P8847; MARTINSON EA, 1990, J BIOL CHEM, V265, P22282; MINNEMAN KP, 1988, PHARMACOL REV, V40, P87; MULLMANN TJ, 1990, BIOCHEM BIOPH RES CO, V170, P1197, DOI 10.1016/0006-291X(90)90520-W; PAI JK, 1991, P NATL ACAD SCI USA, V88, P598, DOI 10.1073/pnas.88.2.598; PAI JK, 1988, BIOCHEM BIOPH RES CO, V150, P355, DOI 10.1016/0006-291X(88)90528-1; PAI JK, 1988, J BIOL CHEM, V263, P12472; PITTNER RA, 1991, BIOCHEM J, V277, P371, DOI 10.1042/bj2770371; PUTNEY JW, 1980, NATURE, V284, P345, DOI 10.1038/284345a0; QIAN Z, 1989, J BIOL CHEM, V264, P21720; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; RUBIN R, 1988, BIOCHEM BIOPH RES CO, V156, P1090, DOI 10.1016/S0006-291X(88)80744-7; SALMON DM, 1980, NATURE, V284, P344, DOI 10.1038/284344a0; SANDMANN J, 1991, J NEUROCHEM, V56, P1312, DOI 10.1111/j.1471-4159.1991.tb11427.x; SHUKLA SD, 1991, LIFE SCI, V48, P851, DOI 10.1016/0024-3205(91)90031-6; SLIVKA SR, 1988, J BIOL CHEM, V263, P12242; TAKI T, 1979, J BIOL CHEM, V254, P9761; TYAGI SR, 1991, J BIOL CHEM, V266, P3498; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10344; VANDERMEULEN J, 1990, BIOCHEM J, V271, P693, DOI 10.1042/bj2710693	55	67	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3679	3685						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1310979				2022-12-27	WOS:A1992HE60700023
J	GABRIELLI, BG; ROY, LM; GAUTIER, J; PHILIPPE, M; MALLER, JL				GABRIELLI, BG; ROY, LM; GAUTIER, J; PHILIPPE, M; MALLER, JL			A CDC2-RELATED KINASE OSCILLATES IN THE CELL-CYCLE INDEPENDENTLY OF CYCLINS G2/M AND CDC2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATURATION-PROMOTING FACTOR; YEAST SCHIZOSACCHAROMYCES-POMBE; P34CDC2 PROTEIN-KINASE; HISTONE H-1 KINASE; DNA-DIVISION CYCLE; SACCHAROMYCES-CEREVISIAE; TYROSINE PHOSPHORYLATION; MEIOTIC MATURATION; ONCOGENE PRODUCT; XENOPUS OOCYTES	The Eg1 gene in Xenopus laevis is related in sequence to the cdc2+ gene. We show here that the Eg1 gene product (cdk2) possesses histone H1 protein kinase activity and binds to PSTAIR antibodies as well as to Sepharose beads linked to the 13-kDa product of the suc 1 gene (p13suc1). Eg1 protein kinase is active only in an M(r) almost-equal-to 200,000 complex with other proteins but is not associated with any of the three known Xenopus mitotic cyclins or with any newly synthesized protein in egg extracts that exhibit cell cycle oscillations in vitro. The protein kinase activity of Eg1 oscillates in the mitotic cell cycle, being high in M-phase and low in interphase. Hyperactivation of cdc2 kinase by the addition of cyclin A has no effect on the activity or oscillatory behavior of Eg1. Inhibition of cdc2 kinase activation by emetine or RNase treatment of oscillating extracts does not inhibit the activation of Eg1 but does block deactivation normally seen during exit from mitosis. These results indicate that Eg1 is regulated by a cell cycle clock independently of cyclin and cdc2 kinase.	UNIV COLORADO, SCH MED,HOWARD HUGHES MED INST,4200 E 9TH AVE, BOX C-236, DENVER, CO 80262 USA; UNIV COLORADO, SCH MED, DEPT PHARMACOL, DENVER, CO 80262 USA; UNIV RENNES 1, CNRS, BIOL & GENET DEV LAB, F-35042 RENNES, FRANCE	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes			Gabrielli, Brian G/B-3655-2011; Gautier, jean/A-2774-2008	Gabrielli, Brian G/0000-0003-3933-1651; 	NCI NIH HHS [F32-CA08914] Funding Source: Medline; NIGMS NIH HHS [GM26743] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA008914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026743] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; CREANOR J, 1986, J CELL SCI, V86, P207; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HARA K, 1980, P NATL ACAD SCI-BIOL, V77, P462, DOI 10.1073/pnas.77.1.462; HAYLES J, 1990, EMBO J, V5, P3573; HINDLEY J, 1987, MOL CELL BIOL, V7, P504, DOI 10.1128/MCB.7.1.504; JOHNS EW, 1964, BIOCHEM J, V92, P55, DOI 10.1042/bj0920055; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEHNER CF, 1990, EMBO J, V9, P3573, DOI 10.1002/j.1460-2075.1990.tb07568.x; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; MATSUSHIME H, 1990, MOL CELL BIOL, V10, P2261, DOI 10.1128/MCB.10.5.2261; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NOVAK B, 1986, J CELL SCI, V86, P191; PARIS J, 1990, DEV BIOL, V140, P221, DOI 10.1016/0012-1606(90)90070-Y; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PICARD A, 1990, SCIENCE, V247, P327, DOI 10.1126/science.2153316; PINES J, 1990, New Biologist, V2, P389; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; ROY LM, 1991, J CELL BIOL, V113, P507, DOI 10.1083/jcb.113.3.507; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SHUTTLEWORTH J, 1990, EMBO J, V9, P3233, DOI 10.1002/j.1460-2075.1990.tb07522.x; SIMON M, 1986, EMBO J, V5, P2697, DOI 10.1002/j.1460-2075.1986.tb04553.x; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; UESONO Y, 1987, NUCLEIC ACIDS RES, V15, P10299, DOI 10.1093/nar/15.24.10299; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	48	63	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1969	1975						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1309805				2022-12-27	WOS:A1992HA48500087
J	JONES, RE; HEIMBROOK, DC; HUBER, HE; WEGRZYN, RJ; ROTBERG, NS; STAUFFER, KJ; LUMMA, PK; GARSKY, VM; OLIFF, A				JONES, RE; HEIMBROOK, DC; HUBER, HE; WEGRZYN, RJ; ROTBERG, NS; STAUFFER, KJ; LUMMA, PK; GARSKY, VM; OLIFF, A			SPECIFIC N-METHYLATIONS OF HPV-16 E7 PEPTIDES ALTER BINDING TO THE RETINOBLASTOMA SUPPRESSOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; INVITRO TRANSFORMING ACTIVITIES; ADENOVIRUS E1A PROTEINS; LARGE T-ANTIGEN; GENE-PRODUCT; HUMAN KERATINOCYTES; MUTATIONAL ANALYSIS; ACTIVATED RAS; PRIMARY-CELLS; IDENTIFICATION	Complex formation between the human papilloma virus type 16 E7 protein (HPV-16 E7) and the retinoblastoma growth suppressor protein (RB) is believed to contribute to the process of cellular transformation that leads to cervical carcinoma. Genetic analysis of the HPV-16 E7 protein has shown that the segment of E7 homologous to the conserved region 2 of adenovirus 5 E1A protein is involved in both RB binding and E7-mediated cell transformation. We have previously shown that a peptide colinear with HPV-16 E7 residues 21-29 was able to block immobilized species of E7 from binding to RB protein. The current study reports the effects of different chemical modifications of this peptide. One type of modification, methylation of the alpha-amino nitrogens contributed by Leu22, Tyr25, and Leu28, resulted in a 45-fold increase in E7/RB binding antagonist activity. This increased antagonist activity is sequence-specific since methylation of the amino groups contributed by Tyr23, Cys24, or Glu26 resulted in a profound loss of binding antagonist activity. Using a newly developed binding assay we determined that the apparent dissociation constant for recombinant HPV-16 E7 protein binding to recombinant human RB protein is 1.3 nm. The peptide Ac[N-MeLeu22,N-MeTyr25, N-MeLeu28]-(21-29)-E7 amide was determined to be a competitive inhibitor of HPV-16 E7 binding to RB with a K(i) value of 32 nM.	MERCK SHARP & DOHME LTD,DEPT CANC RES,BLDG 16-101,W POINT,PA 19486; MERCK SHARP & DOHME LTD,DEPT MED CHEM,W POINT,PA 19486	Merck & Company; Merck & Company								BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; CROOK T, 1988, P NATL ACAD SCI USA, V85, P8820, DOI 10.1073/pnas.85.23.8820; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DYSON N, 1989, CANCER CEL, V7, P235; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; JONES RE, 1990, J BIOL CHEM, V265, P12782; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LINEMEYER DL, 1987, BIO-TECHNOL, V5, P960, DOI 10.1038/nbt0987-960; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; RIVIER J, 1984, J CHROMATOGR, V288, P303, DOI 10.1016/S0021-9673(01)93709-4; SAKAKIBARA S, 1967, B CHEM SOC JPN, V40, P2164, DOI 10.1246/bcsj.40.2164; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Segel IH, 1976, BIOCH CALCULATIONS; SMITH JA, 1980, CRC CR REV BIOCH MOL, V8, P315, DOI 10.3109/10409238009105470; SMOTKIN D, 1987, J VIROL, V61, P1686, DOI 10.1128/JVI.61.5.1686-1689.1987; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; Spatola A.F., 1983, CHEM BIOCHEM AMINO, V7, P267; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; Tam J. P., 1990, PEPTIDES CHEM STRUCT, P75; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245	36	23	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					908	912						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1309779				2022-12-27	WOS:A1992GY96000037
J	BAULDRY, SA; NASRALLAH, VN; BASS, DA				BAULDRY, SA; NASRALLAH, VN; BASS, DA			ACTIVATION OF NADPH OXIDASE IN HUMAN NEUTROPHILS PERMEABILIZED WITH STAPHYLOCOCCUS-AUREUS ALPHA-TOXIN - A LOWER KM WHEN THE ENZYME IS ACTIVATED INSITU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; RESPIRATORY BURST OXIDASE; ARACHIDONIC-ACID RELEASE; PROTEIN KINASE-C; ELECTROPERMEABILIZED NEUTROPHILS; PLASMA-MEMBRANE; CELLS; PHOSPHOLIPASE-A2; STIMULATION	The NADPH oxidase is a multicomponent enzyme system that produces the reduced oxygen species essential for bacterial killing by polymorphonuclear leukocytes (PMN). Study of the oxidase has typically been carried out in cell-free systems in which K(m) values of 20-150-mu-M NADPH have been reported. However, when compared with affinities reported for other navoprotein dehydrogenases and when considering the cellular concentration of NADPH/NADP+ of approximately 35-mu-M, the reported affinity of the oxidase for NADPH appears low. To investigate this apparent discrepancy we have studied the kinetics of NADPH oxidase activation in situ in human PMN permeabilized with Staphylococcus aureus alpha-toxin. Alpha-toxin permeabilization of human PMN did not initiate NADPH oxidase activation at physiologic concentrations of NADPH. If permeabilized cells were stimulated with 1-mu-M formyl-methionyl-leucyl-phenylalanine, 10-mu-M guanosine 5'-O-(3-thiotriphosphate), 0.5 mm Ca2+, 5-mu-g/ml cytochalasin B in the presence of varying concentrations of NADPH, we were able to demonstrate activation of the oxidase complex as shown by superoxide dismutase-inhibitable reduction of cytochrome c. In this system we determined that the K(m) for oxidase activation was 4-7-mu-M NADPH, a 410-fold decrease from reported values. The oxidase was the enzyme being studied as shown by the absence of enzymatic activity in patients with chronic granulomatous disease. In addition, if the enzyme was initially activated in permeabilized cells, the cells homogenized, and the K(m) for the oxidase determined in a cell-free system, the observed K(m) reverted to previously reported values (36-mu-M). These results indicate that NADPH oxidase, studied in situ, has a significantly higher substrate affinity than that observed in isolated membranes and, moreover, indicate that substrate affinity is optimal for catalysis at reported concentrations of cytosolic NADPH.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT PULM & CRIT CARE MED, WINSTON SALEM, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI010732, R01AI014929] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-14929, AI-10732] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHNERTHILGER G, 1985, J BIOL CHEM, V260, P2730; AKARD LP, 1988, BLOOD, V72, P322; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BADER MF, 1986, J BIOL CHEM, V261, P5777; BASHFORD CL, 1986, J BIOL CHEM, V261, P9300; BOLSCHER BGJM, 1990, J BIOL CHEM, V265, P15782; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; CALDWELL SE, 1988, J CLIN INVEST, V81, P1485, DOI 10.1172/JCI113480; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; COHEN HJ, 1984, BLOOD, V63, P114; CRISSMAN HA, 1973, J CELL BIOL, V59, P766, DOI 10.1083/jcb.59.3.766; CURNUTTE JT, 1987, ADV HUM GENET, V16, P229; DOWNEY GP, 1989, BIOCHEM BIOPH RES CO, V160, P18, DOI 10.1016/0006-291X(89)91614-8; FUSSLE R, 1981, J CELL BIOL, V91, P83, DOI 10.1083/jcb.91.1.83; GABIG TG, 1979, J BIOL CHEM, V254, P9070; GOMPERTS BD, 1985, TRENDS BIOCHEM SCI, V10, P414, DOI 10.1016/0968-0004(85)90020-9; GRINSTEIN S, 1988, J BIOL CHEM, V263, P1779; HARSHMAN S, 1988, METHOD ENZYMOL, V165, P3; IYANAGI T, 1984, BIOCHEMISTRY-US, V23, P1418, DOI 10.1021/bi00302a013; KNIGHT DE, 1986, BIOCHEM J, V234, P497, DOI 10.1042/bj2340497; KOJIMA H, 1984, J BIOCH, V102, P1083; KORCHAK HM, 1984, J BIOL CHEM, V259, P7439; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MASSEY V, 1959, BIOCHIM BIOPHYS ACTA, V34, P255, DOI 10.1016/0006-3002(59)90259-8; MCCALL C, 1985, BIOCHEM BIOPH RES CO, V126, P450, DOI 10.1016/0006-291X(85)90626-6; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; NAKAMURA S, 1971, J BIOL CHEM, V246, P6235; NAKASHIMA S, 1987, J BIOCHEM-TOKYO, V101, P1055, DOI 10.1093/oxfordjournals.jbchem.a121948; NAKASHIMA S, 1988, ARCH BIOCHEM BIOPHYS, V261, P375, DOI 10.1016/0003-9861(88)90353-0; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; PARKINSON JF, 1988, J BIOL CHEM, V263, P8859; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PETERSGOLDEN M, 1989, AM REV RESPIR DIS, V140, P1210, DOI 10.1164/ajrccm/140.5.1210; PROSPERI E, 1986, CYTOMETRY, V7, P70, DOI 10.1002/cyto.990070110; ROTMAN B, 1966, P NATL ACAD SCI USA, V55, P134, DOI 10.1073/pnas.55.1.134; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SALMON JM, 1982, PHOTOCHEM PHOTOBIOL, V36, P585, DOI 10.1111/j.1751-1097.1982.tb04420.x; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; SEGAL AW, 1985, NATURE, V316, P547, DOI 10.1038/316547a0; SPARKMAN TB, 1985, BIOCHIM BIOPHYS ACTA, V846, P8, DOI 10.1016/0167-4889(85)90103-X; SUZUKI Y, 1980, J CLIN INVEST, V66, P1409, DOI 10.1172/JCI109994; TAUBER AI, 1979, BIOCHEMISTRY-US, V18, P5576, DOI 10.1021/bi00592a009; VERMILION JL, 1978, J BIOL CHEM, V253, P2694; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; WAKEYAMA H, 1982, BIOCHEM J, V205, P593, DOI 10.1042/bj2050593	47	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					323	330						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1309741				2022-12-27	WOS:A1992GY43900054
J	WENTHOLD, RJ; YOKOTANI, N; DOI, K; WADA, K				WENTHOLD, RJ; YOKOTANI, N; DOI, K; WADA, K			IMMUNOCHEMICAL CHARACTERIZATION OF THE NON-NMDA GLUTAMATE RECEPTOR USING SUBUNIT-SPECIFIC ANTIBODIES - EVIDENCE FOR A HETEROOLIGOMERIC STRUCTURE IN RAT-BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL NERVOUS-SYSTEM; FUNCTIONAL EXPRESSION; MOLECULAR-STRUCTURE; GLYCINE RECEPTOR; ACID; BINDING; PURIFICATION; PROTEINS; CLONING; FAMILY	Antibodies were made to synthetic peptides corresponding to sequences specific to the glutamate receptor (GluR) subunits, GluR1-4. The specificity of the antibodies was established by Western blotting using membranes of simian kidney cells (COS-7) transfected with GluR subunit DNA. Four antibodies were found to be selective for each of the four GluR subunits, and a fifth antibody recognized both GluR2 and 3. All five antibodies immunoadsorbed Triton X-100-solubilized rat brain [H-3]AMPA binding activity and labeled an M(r) = 108,000 band in samples of rat brain. The structure of the Triton X-100-solubilized GluR was studied using subunit-specific antibodies covalently attached to protein A-agarose and analyzing GluR subunits bound to the antibodies by Western blotting. Each of the four subunit-specific antibodies immunoadsorbed its respective GluR subunit as well as the other three forms of GluR, showing that the detergent solubilized GluR exists as hetero-oligomers composed of two or more of the four subunits. Evidence supporting a similar structure for membrane bound GluR was obtained using synaptic membranes chemically cross-linked with dithiobis(succinimidylpropionate). GluR was immunoaffinity-purified using the GluR2 and 3-selective antibody. This antibody, covalently attached to protein A-agarose, adsorbed 55% of [H-3]AMPA binding activity, and after elution with 1 M KSCN, 22-37% of the binding activity was recovered. Analysis of the purified product showed a major immunoreactive band at M(r) = 108,000, and silver staining identified the same major band and no additional polypeptides. The GluR receptor complex, therefore, appears to be made up exclusively of GluR1-4. In the purified GluR preparation, in addition to the M(r) = 108,000 band, three higher molecular weight immunoreactive components were also detected. These bands migrated at M(r) = 325,000, 470,000, and 590,000. Similar sized proteins were seen in the cross-linked synaptic membrane sample, with the M(r) = 590,000 component being substantially enriched after cross-linking. The M(r) = 590,000 band is the largest component detected, and it has a size consistent with its being a pentamer of the M(r) = 108,000 protein.			WENTHOLD, RJ (corresponding author), NIDOCD,NEUROCHEM LAB,BLDG 36,RM 5D08,BETHESDA,MD 20892, USA.							BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; CONTITRONCONI BM, 1982, ANNU REV BIOCHEM, V51, P491, DOI 10.1146/annurev.bi.51.070182.002423; GIULIAN GG, 1983, ANAL BIOCHEM, V129, P277, DOI 10.1016/0003-2697(83)90551-1; GREGOR P, 1989, NATURE, V342, P689, DOI 10.1038/342689a0; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HONORE T, 1982, J NEUROCHEM, V38, P173, DOI 10.1111/j.1471-4159.1982.tb10868.x; HONORE T, 1988, J NEUROCHEM, V51, P457, DOI 10.1111/j.1471-4159.1988.tb01060.x; HUNTER C, 1990, J NEUROCHEM, V54, P118, DOI 10.1111/j.1471-4159.1990.tb13290.x; HUNTER C, 1990, NEUR ABSTR, V16, P543; KARLIN A, 1983, J BIOL CHEM, V258, P6678; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; OLSEN RW, 1987, BRAIN RES, V402, P243, DOI 10.1016/0006-8993(87)90030-8; PFEIFFER F, 1982, J BIOL CHEM, V257, P9389; SAEDI MS, 1991, J CELL BIOL, V112, P1007, DOI 10.1083/jcb.112.5.1007; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SIGEL E, 1983, J BIOL CHEM, V258, P6965; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WADA K, 1989, NATURE, V342, P684, DOI 10.1038/342684a0; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; WEBER K, 1975, PROTEINS, P179; WENTHOLD RJ, 1990, FEBS LETT, V276, P147, DOI 10.1016/0014-5793(90)80529-R	33	461	465	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					501	507						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1309749				2022-12-27	WOS:A1992GY43900080
J	SCHWARTZ, ML; SHNEIDMAN, PS; BRUCE, J; SCHLAEPFER, WW				SCHWARTZ, ML; SHNEIDMAN, PS; BRUCE, J; SCHLAEPFER, WW			ACTINOMYCIN PREVENTS THE DESTABILIZATION OF NEUROFILAMENT MESSENGER-RNA IN PRIMARY SENSORY NEURONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; 3' UNTRANSLATED REGION; GENE-EXPRESSION; RADIAL GROWTH; UP-REGULATION; STEM-LOOP; STABILITY; CELLS; DEGRADATION; PROTEINS	The levels of light, mid-sized, and heavy neurofilament (NF) mRNAs were compared to that of beta-actin mRNA in primary dissociated cultures of adult rat dorsal root ganglia (DRG). Decreases in the levels of all three NF mRNAs occur after 24 h in culture, mimicking the down-regulation of NF mRNAs in axotomized DRG neurons. The loss of NF mRNAs in DRG cultures is prevented by actinomycin and, to a lesser extent, by cycloheximide. Based on decay curves in actinomycin-treated cultures, the half-lives of NF mRNAs are at least 4 days in DRG neurons, but <24 h in PC12 cells. Our data support the view that NF mRNAs are stabilized in DRG neurons and that stabilization prevents destabilization by a transcription-dependent process. We further propose that putative stabilizing factor(s) are able to prevent degradation of NF transcripts in intact neurons, but not in axotomized or cultured neurons.			SCHWARTZ, ML (corresponding author), UNIV PENN,SCH MED,DIV NEUROPATHOL,PHILADELPHIA,PA 19104, USA.				NINDS NIH HHS [T32 NS 07064, R01 NS 15722] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007064, R01NS015722] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEAUDET L, 1992, BIOCHEM CELL BIOL, V70, P279, DOI 10.1139/o92-044; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; BROCK ML, 1983, CELL, V34, P207, DOI 10.1016/0092-8674(83)90151-4; CARDEN MJ, 1987, J NEUROSCI, V7, P3489; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMENS MJ, 1975, J BIOL CHEM, V250, P2213; DELOULME JC, 1991, J NEUROSCI RES, V29, P499, DOI 10.1002/jnr.490290410; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; DICKSON G, 1986, EMBO J, V5, P3449, DOI 10.1002/j.1460-2075.1986.tb04668.x; GOLDSTEIN ME, 1988, MOL BRAIN RES, V3, P287, DOI 10.1016/0169-328X(88)90051-4; GRAVES RA, 1987, CELL, V48, P615, DOI 10.1016/0092-8674(87)90240-6; HOFFMAN PN, 1987, P NATL ACAD SCI USA, V84, P3472, DOI 10.1073/pnas.84.10.3472; HOFFMAN PN, 1985, J NEUROSCI, V5, P2920; HOFFMAN PN, 1991, J CELL BIOL, V415, pA163; IKENAKA K, 1990, J BIOL CHEM, V265, P19782; IWAI Y, 1991, J BIOL CHEM, V266, P17959; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; LEWIS SA, 1985, J CELL BIOL, V100, P843, DOI 10.1083/jcb.100.3.843; LINDENBAUM MH, 1988, J BIOL CHEM, V263, P5662; MARTIN DP, 1990, J NEUROSCI, V10, P184; MONTEIRO MJ, 1990, J CELL BIOL, V111, P1543, DOI 10.1083/jcb.111.4.1543; MORRIS T, 1986, P NATL ACAD SCI USA, V83, P981, DOI 10.1073/pnas.83.4.981; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; MUMA NA, 1991, J NEUROCYTOL, V20, P844, DOI 10.1007/BF01191735; PACHTER JS, 1987, CELL, V51, P283, DOI 10.1016/0092-8674(87)90155-3; PANDEY NB, 1987, MOL CELL BIOL, V7, P4557, DOI 10.1128/MCB.7.12.4557; PONTECORVI A, 1988, EMBO J, V7, P1489, DOI 10.1002/j.1460-2075.1988.tb02967.x; SCHLAEPFER WW, 1990, J NEUROSCI RES, V25, P39, DOI 10.1002/jnr.490250106; SCHWARTZ ML, 1990, J NEUROSCI RES, V27, P193, DOI 10.1002/jnr.490270209; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHNEIDMAN PS, 1992, MOL BRAIN RES, V13, P127, DOI 10.1016/0169-328X(92)90052-D; SHNEIDMAN PS, 1988, MOL BRAIN RES, V4, P217, DOI 10.1016/0169-328X(88)90028-9; VOYVODIC JT, 1989, NATURE, V342, P430, DOI 10.1038/342430a0; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; YEN TJ, 1988, MOL CELL BIOL, V8, P1224, DOI 10.1128/MCB.8.3.1224	36	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24596	24600						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1280263				2022-12-27	WOS:A1992KA26300068
J	TAUB, R; HSU, JC; GARSKY, VM; HILL, BL; ERLANGER, BF; KOHN, LD				TAUB, R; HSU, JC; GARSKY, VM; HILL, BL; ERLANGER, BF; KOHN, LD			PEPTIDE SEQUENCES FROM THE HYPERVARIABLE REGIONS OF 2 MONOCLONAL ANTIIDIOTYPIC ANTIBODIES AGAINST THE THYROTROPIN (TSH) RECEPTOR ARE SIMILAR TO TSH AND INHIBIT TSH-INCREASED CAMP PRODUCTION IN FRTL-5 THYROID-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT PEPTIDES; MOLECULAR-CLONING; PLASMA-MEMBRANES; BINDING; AUTOANTIBODIES; EXPRESSION; DIGESTION; STRATEGY; DOMAIN; SITES	Monoclonal antibodies, D2 and 4G11, selected by the autoantiidiotypic approach following injection of thyrotropin (TSH) into mice, mimic TSH in binding to receptors on thyroid membranes. Based on TSH receptor transfection studies, D2 and 4G11 show unequivocal specificity for the TSH receptor. To see if the complementary determining regions (CDRs) of these antibodies share any primary sequence similarities to regions of TSH critical for receptor binding, we deduced the primary structure of the variable regions of D2 and 4G11 by sequencing the immunoglobulin mRNA. We found that CDR1 of 4G11K and CDR2 of D2-mu show sequence similarity to regions of TSH-alpha and TSH-beta that had been previously implicated in the interaction of the hormone with its receptor. We tested the inhibitory effects of synthetic peptides from D2-mu-CDR2 and 4G11K-CDR1 on the binding of the corresponding antibodies to rat thyroid FRTL-5 cells and found an EC50 of 0.1 and 1-mu-M, respectively. TSH-derived peptides with similarity to D2-mu-CDR2 and 4G11K-CDR1 showed a significant but lesser effect on the binding of 4G11 or D2 to thyroid cells. Additionally, we tested the effects of the CDR peptides and TSH-derived peptides on TSH-stimulated cAMP production in FRTL-5 cells and found that D2-mu-CDR2 and 4G11K-CDR1 inhibited this activity, D2-mu-CDR2 most strongly (EC50 10-mu-M). Thus, linear sequences from the CDRs of these autoantiidiotypic antibodies with similarity to sequences from both subunits of TSH appear to interact with the TSH receptor. These data support previous studies indicating the complexity of the interaction between TSH and its receptor and advance earlier findings that such immunologic approaches are useful in dissecting receptor-ligand interactions.	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104; MERCK SHARP & DOHME LTD,DEPT MED CHEM,W POINT,PA 19486; COLUMBIA UNIV,DEPT MICROBIOL,NEW YORK,NY 10032; NIDDKD,BIOCHEM & METAB LAB,CELL REGULAT SECT,BETHESDA,MD 20892	Howard Hughes Medical Institute; University of Pennsylvania; Merck & Company; Columbia University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	TAUB, R (corresponding author), UNIV PENN,SCH MED,DEPT HUMAN GENET,PHILADELPHIA,PA 19104, USA.				NINDS NIH HHS [NS15581] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015581] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKAMIZU T, 1990, P NATL ACAD SCI USA, V87, P5677, DOI 10.1073/pnas.87.15.5677; Ambesi Impiombato FS., 1986, United States Patent, Patent No. [US 4608341, 4608341]; Ambesi-Impiombato F S, 1979, Int Rev Cytol Suppl, P163; AMIR SM, 1973, J BIOL CHEM, V248, P4092; AVIV H, 1972, P NATL ACAD SCI USA, V69, P264; BEALL GN, 1985, J CLIN INVEST, V75, P1435, DOI 10.1172/JCI111845; BRUCK C, 1986, P NATL ACAD SCI USA, V83, P6578, DOI 10.1073/pnas.83.17.6578; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CATON AJ, 1986, EMBO J, V5, P1577, DOI 10.1002/j.1460-2075.1986.tb04399.x; CHARLESWORTH MC, 1987, J BIOL CHEM, V262, P13409; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEVELAND WL, 1986, METHOD ENZYMOL, V121, P95; CLOTHIA C, 1989, NATURE, V342, P877; ERLANGER BF, 1986, IMMUNOL REV, V94, P23, DOI 10.1111/j.1600-065X.1986.tb01162.x; ERLANGER BF, 1989, IMMUNOL TODAY, V10, P151, DOI 10.1016/0167-5699(89)90170-9; FRAZIER AL, 1990, MOL ENDOCRINOL, V4, P1264, DOI 10.1210/mend-4-8-1264; GAULTON GN, 1986, ANNU REV IMMUNOL, V4, P253, DOI 10.1146/annurev.iy.04.040186.001345; GELIEBTER J, 1987, FOCUS, V9, P5; HILL BL, 1988, ENDOCRINOLOGY, V122, P2840, DOI 10.1210/endo-122-6-2840; ISLAM MN, 1983, EUR J IMMUNOL, V13, P57, DOI 10.1002/eji.1830130113; KABAT EA, 1987, US DEP HLTH HUMAN SE, V37; KOHN LD, 1986, ANN NY ACAD SCI, V475, P157, DOI 10.1111/j.1749-6632.1986.tb20865.x; KOHN LD, 1975, J BIOL CHEM, V250, P6503; KOHN LD, 1986, Patent No. 4609622; KOSUGI S, 1991, J BIOL CHEM, V266, P19413; KOSUGI S, 1991, J BIOL CHEM, V180, P1118; LIBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250, DOI 10.1016/0006-291X(89)92736-8; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; LUSTBADER JW, 1990, 72ND ANN M END SOC A; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MISRAHI M, 1990, BIOCHEM BIOPH RES CO, V166, P394, DOI 10.1016/0006-291X(90)91958-U; MORRIS JC, 1988, J CLIN ENDOCR METAB, V67, P707, DOI 10.1210/jcem-67-4-707; MORRIS JC, 1990, J BIOL CHEM, V265, P1881; MORRIS JC, 1988, ENDOCRINOLOGY, V123, P456, DOI 10.1210/endo-123-1-456; NAGAYAMA Y, 1991, J CLIN INVEST, V88, P336, DOI 10.1172/JCI115297; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; NEAR RI, 1991, J IMMUNOL, V146, P627; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; SAJI M, 1991, BIOCHEM BIOPH RES CO, V176, P94, DOI 10.1016/0006-291X(91)90894-D; SAKAKIBARA S, 1965, B CHEM SOC JPN, V38, P1412, DOI 10.1246/bcsj.38.1412; TAHARA K, 1991, BIOCHEM BIOPH RES CO, V179, P70, DOI 10.1016/0006-291X(91)91335-A; TATE RL, 1975, J BIOL CHEM, V250, P6509; TAUB R, 1989, J BIOL CHEM, V264, P259; VITTI P, 1983, J CLIN ENDOCR METAB, V57, P782, DOI 10.1210/jcem-57-4-782; WILLIAMS WV, 1988, P NATL ACAD SCI USA, V85, P6488, DOI 10.1073/pnas.85.17.6488; WILLIAMS WV, 1989, P NATL ACAD SCI USA, V86, P5537, DOI 10.1073/pnas.86.14.5537; WILLIAMS WV, 1991, IN PRESS J BIOL CHEM; YAVIN E, 1981, P NATL ACAD SCI-BIOL, V78, P3180, DOI 10.1073/pnas.78.5.3180; YOSHIDA T, 1988, J BIOL CHEM, V263, P1634; ZACHARIJA M, 1980, ENDOCRINOLOGY, V107, P2051; ZAKARIJA M, 1987, THYROID AUTOIMMUNITY, P91	53	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5977	5984						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1313425				2022-12-27	WOS:A1992HK31800043
J	YUN, CH; WANG, ZG; CROFTS, AR; GENNIS, RB				YUN, CH; WANG, ZG; CROFTS, AR; GENNIS, RB			EXAMINATION OF THE FUNCTIONAL ROLES OF 5 HIGHLY CONSERVED RESIDUES IN THE CYTOCHROME-B SUBUNIT OF THE BC1 COMPLEX OF RHODOBACTER-SPHAEROIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BEEF-HEART MITOCHONDRIA; ELECTRON-TRANSFER CHAIN; RHODOPSEUDOMONAS-SPHAEROIDES; NUCLEOTIDE-SEQUENCE; READING FRAMES; MEMBRANE; GENES; DNA; OXIDOREDUCTASE; ORGANIZATION	The cytochrome b subunit of the bc1 complexes contains two cytochrome components (b(L) and b(H)) and is the locus of both a quinol-oxidizing site (Q(o) or Q(z)) and a quinone-reducing site (Q(i) or Q(c)). Sequence alignments of this subunit from over 20 eukaryotic and prokaryotic species have revealed a remarkable degree of conservation, including approximately 20 totally conserved residues. In this paper, site-directed mutagenesis has been used to examine the structural or functional roles of 5 of there highly conserved residues, Gly48, Gln58, Ser102, Phe104, and Pro202, all predicted to be within transmembrane alpha-helical segments. The mutants were made in the bc1 complex of Rhodobacter sphaeroides, a photosynthetic bacterium. The ability to use spectroscopic, electrochemical, and flash-induced kinetic methods allows the mutants to be analyzed for influences both on cytochrome spectra and thermodynamic properties and on the kinetics of specific electron transfer reactions. The results show that none of the 5 residues is absolutely essential. Substitution of aspartate or valine for Gly48 results in the loss of photosynthetic growth. The G48V mutant assembles a bc1 complex, but with modified cytochromes b(H) and b(L), and a disfunctional quinone reductase (Q(C-)) site; an alanine is tolerated at this position. Possibly, a small residue is important here for heme packing. Gln58 and Ser102 are the only highly conserved polar residues predicted to be within the transmembrane spans, apart from the histidines which are heme axial ligands. Neither Gln58 nor Ser102 is essential for assembly or function of the bc1 complex, although substitution of other amino acids in these positions does cause subtle, but measurable changes. Phe104 lies midway between the axial ligands to cytochromes b(L) and b(H) and can be modeled to project in the space separating the two hemes. Replacement of this highly conserved aromatic residue by isoleucine has no measurable influence on the rate of electron transfer through the cytochrome b chain containing the two-hemes. Finally, Pro202 is a totally conserved proline which is in the middle of transmembrane helix D, in between the 2 histidines which provide ligands to the hemes. No major inhibition of electron transfer resulted from replacing this proline by a leucine, although subtle changes in spectra of the b cytochromes and their electrochemical properties were noted.	UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,DIV BIOPHYS,URBANA,IL 61801; UNIV ILLINOIS,SCH CHEM SCI,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026305, R01GM035438] Funding Source: NIH RePORTER; NIGMS NIH HHS [5R01 GM35438, 2R01 GM26305] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1985, ENZYMES BIOL MEMBRAN, DOI DOI 10.1007/978-1-4684-4604-3_10; BENNE R, 1983, NUCLEIC ACIDS RES, V11, P6925, DOI 10.1093/nar/11.20.6925; BOWYER JR, 1979, FEBS LETT, V101, P201, DOI 10.1016/0014-5793(79)81326-5; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CRAMER WA, 1987, PHOTOSYNTH RES, V11, P481; CROFTS A, 1987, CYTOCHROME SYSTEMS M, P617; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V726, P149, DOI 10.1016/0304-4173(83)90004-6; CROFTS AR, 1990, HIGHLIGHTS IN UBIQUINONE RESEARCH, P98; CROFTS AR, 1989, PHOTOSYNTH RES, V22, P69, DOI 10.1007/BF00114768; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V723, P202, DOI 10.1016/0005-2728(83)90120-2; CROFTS AR, 1987, SEQANAL SOFTWARE PAC; Degli Esposti M, 1990, HIGHLIGHTS UBIQUINON, P166; DELACRUZ VF, 1984, J BIOL CHEM, V259, P5136; DIRAGO JP, 1988, J BIOL CHEM, V263, P12564; Dutton P L, 1978, Methods Enzymol, V54, P411; ESPOSTI MD, 1989, BIOCHIM BIOPHYS ACTA, V977, P249, DOI 10.1016/S0005-2728(89)80079-9; ESPOSTI MD, 1988, ITAL J BIOCHEM, V38, P1; FURBACHER PN, 1989, BIOCHEMISTRY-US, V28, P8990, DOI 10.1021/bi00449a006; GABELLINI N, 1988, J BIOENERG BIOMEMBR, V20, P59, DOI 10.1007/BF00762138; GLASER EG, 1984, BIOCHIM BIOPHYS ACTA, V766, P322, DOI 10.1016/0005-2728(84)90248-2; HAUSKA G, 1988, J BIOENERG BIOMEMBR, V20, P211, DOI 10.1007/BF00768395; HEINEMEYER W, 1984, CURR GENET, V8, P543, DOI 10.1007/BF00410442; HOWELL N, 1988, J MOL BIOL, V203, P607, DOI 10.1016/0022-2836(88)90195-7; JACKSON JB, 1971, EUR J BIOCHEM, V18, P120, DOI 10.1111/j.1432-1033.1971.tb01222.x; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; KILEY PJ, 1988, MICROBIOL REV, V52, P50, DOI 10.1128/MMBR.52.1.50-69.1988; KRAMER DM, 1990, CURRENT RES PHOTOSYN, V3, P283; LINK TA, 1986, FEBS LETT, V204, P9, DOI 10.1016/0014-5793(86)81378-3; LUEKING DR, 1978, J BIOL CHEM, V253, P451; Maniatis T., 1982, MOL CLONING; MEINHARDT SW, 1983, BIOCHIM BIOPHYS ACTA, V723, P219, DOI 10.1016/0005-2728(83)90121-4; MEINHARDT SW, 1982, FEBS LETT, V149, P217, DOI 10.1016/0014-5793(82)81104-6; MEINHARDT SW, 1984, THESIS U ILLINOIS; PETTY KM, 1976, BIOCHEM BIOPH RES CO, V172, P346; RICH PR, 1988, BIOCHIM BIOPHYS ACTA, V932, P33, DOI 10.1016/0005-2728(88)90137-5; TRON T, 1991, EUR J BIOCHEM, V199, P753, DOI 10.1111/j.1432-1033.1991.tb16180.x; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; VONJAGOW G, 1986, J BIOENERG BIOMEMBR, V18, P157, DOI 10.1007/BF00743462; WIDGER WR, 1984, P NATL ACAD SCI-BIOL, V81, P674, DOI 10.1073/pnas.81.3.674; WOOLFSON DN, 1990, FEBS LETT, V277, P185, DOI 10.1016/0014-5793(90)80839-B; YUN CH, 1991, BIOCHEMISTRY-US, V30, P6747, DOI 10.1021/bi00241a017; YUN CH, 1990, EUR J BIOCHEM, V194, P399, DOI 10.1111/j.1432-1033.1990.tb15633.x; ZIMMERMAN SS, 1977, BIOPOLYMERS, V16, P811, DOI 10.1002/bip.1977.360160408	44	40	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5901	5909						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1313421				2022-12-27	WOS:A1992HK31800031
J	PAYRASTRE, B; NIEVERS, M; BOONSTRA, J; BRETON, M; VERKLEIJ, AJ; HENEGOUWEN, PMPVE				PAYRASTRE, B; NIEVERS, M; BOONSTRA, J; BRETON, M; VERKLEIJ, AJ; HENEGOUWEN, PMPVE			A DIFFERENTIAL LOCATION OF PHOSPHOINOSITIDE KINASES, DIACYLGLYCEROL KINASE, AND PHOSPHOLIPASE-C IN THE NUCLEAR MATRIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER NUCLEI; SWISS 3T3 CELLS; DNA POLYMERASE-ALPHA; INOSITOL TRISPHOSPHATE; LAMIN-B; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; LIPID PHOSPHORYLATION; PROTEIN-COMPOSITION; 2ND MESSENGERS; GROWTH-FACTOR	Several enzymes involved in the phosphoinositide metabolism have been shown to be present in nuclei of rat liver and Friend cells. In this paper we demonstrate that nuclear matrices of mouse NIH 3T3-fibroblasts and rat liver cells, isolated by nuclease treatment and high salt extraction, contain phosphatidylinositol 4-kinase (PdtIns 4-kinase), phosphatidylinositol 4-phosphate 5-kinase (PtdIns(4)P 5-kinase), diacylglycerol kinase, and phospholipase C. By a selective extraction the nucleus can be dissected in the peripheral matrix (lamina-pore complex) and the internal matrix as shown by using marker antibodies. Surprisingly, PtdIns 4-kinase was found exclusively in the peripheral nuclear matrix, whereas PtdIns(4)P 5-kinase was found to be associated to internal matrix structures. Diacylglycerol kinase and phospholipase C activities were also preferentially detected in the internal matrix. These data demonstrate a differential localization of the phosphoinositide kinases in the nucleus and suggest that the phosphoinositide metabolism may play a specific role in the nucleus.	UNIV UTRECHT,DEPT MOLEC CELL BIOL,3584 CH UTRECHT,NETHERLANDS	Utrecht University	PAYRASTRE, B (corresponding author), HOP PURPAN,INSERM,U326,F-31059 TOULOUSE,FRANCE.		van Bergen en Henegouwen, Paul/B-8870-2011	van Bergen en Henegouwen, Paul/0000-0001-6050-9042; , Bernard/0000-0002-8693-0190				AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BELGRADER P, 1991, J CELL SCI, V98, P281; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1984, BIOCHEM J, V222, P195, DOI 10.1042/bj2220195; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CAPCO DG, 1982, CELL, V29, P847, DOI 10.1016/0092-8674(82)90446-9; CAPITANI S, 1989, FEBS LETT, V254, P194, DOI 10.1016/0014-5793(89)81037-3; CAPITANI S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P193, DOI 10.1016/0005-2760(90)90303-F; CARMO-FONSECA M, 1987, European Journal of Cell Biology, V45, P282; COCCO L, 1988, BIOCHEM BIOPH RES CO, V154, P1266, DOI 10.1016/0006-291X(88)90276-8; COCCO L, 1987, BIOCHEM J, V248, P765, DOI 10.1042/bj2480765; DEGRAAF A, 1991, J HISTOCHEM CYTOCHEM, V39, P1035, DOI 10.1177/39.8.1856453; DEJONG L, 1990, INT REP CEL BIOL, V14, P1051; DWORETZKY SI, 1990, P NATL ACAD SCI USA, V87, P4605, DOI 10.1073/pnas.87.12.4605; EVANS WH, 1979, LABORATORY TECHNIQUE, V7, P1; FEY EG, 1986, J CELL BIOL, V102, P1654, DOI 10.1083/jcb.102.5.1654; FIELDS AP, 1988, J BIOL CHEM, V263, P8253; FRANKE WW, 1978, P NATL ACAD SCI USA, V75, P5034, DOI 10.1073/pnas.75.10.5034; GEORGATOS SD, 1987, J CELL BIOL, V105, P117, DOI 10.1083/jcb.105.1.117; GONZALEZ.F, 1968, J LIPID RES, V9, P532; HENEGOUWEN PMPV, 1987, EUR J CELL BIOL, V43, P469; HOKIN LE, 1985, ANNU REV BIOCHEM, V54, P205, DOI 10.1146/annurev.biochem.54.1.205; HORNBECK P, 1988, P NATL ACAD SCI USA, V85, P2279, DOI 10.1073/pnas.85.7.2279; IZAURRALDE E, 1988, J MOL BIOL, V200, P111, DOI 10.1016/0022-2836(88)90337-3; JACKSON DA, 1988, EMBO J, V7, P3667, DOI 10.1002/j.1460-2075.1988.tb03248.x; JACKSON DA, 1981, NATURE, V292, P552, DOI 10.1038/292552a0; KAUFMANN SH, 1984, EXP CELL RES, V155, P477, DOI 10.1016/0014-4827(84)90208-8; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LAZARIDES E, 1982, ANNU REV BIOCHEM, V51, P219, DOI 10.1146/annurev.bi.51.070182.001251; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LLOYD JV, 1984, BRIT J HAEMATOL, V23, P571; MALVIYA AN, 1990, P NATL ACAD SCI USA, V87, P9270, DOI 10.1073/pnas.87.23.9270; MARTELLI AM, 1990, BIOCHEM BIOPH RES CO, V173, P149, DOI 10.1016/S0006-291X(05)81034-4; MARTELLI AM, 1990, EXP CELL RES, V190, P227, DOI 10.1016/0014-4827(90)90190-L; MASMOUDI A, 1989, J BIOL CHEM, V264, P1174; MISRA UK, 1987, BIOCHEM BIOPH RES CO, V145, P760, DOI 10.1016/0006-291X(87)91030-8; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; NICOTERA P, 1990, P NATL ACAD SCI USA, V87, P6858, DOI 10.1073/pnas.87.17.6858; PAYRASTRE B, 1991, BIOCHIM BIOPHYS ACTA, V1056, P19, DOI 10.1016/S0005-2728(05)80068-4; PAYRASTRE B, 1990, BIOCHEM J, V272, P665, DOI 10.1042/bj2720665; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; ROCK CO, 1987, J BIOL CHEM, V262, P5492; SMITH CD, 1983, J BIOL CHEM, V258, P9368; STAUFENBIEL M, 1983, EUR J CELL BIOL, V31, P341; STUURMAN N, 1990, J BIOL CHEM, V265, P5460; SYLVIA V, 1988, CELL, V54, P651, DOI 10.1016/S0092-8674(88)80009-6	48	269	274	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5078	5084						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1312084				2022-12-27	WOS:A1992HH74700014
J	LEE, JK; TAM, JWO; TSAI, MJ; TSAI, SY				LEE, JK; TAM, JWO; TSAI, MJ; TSAI, SY			IDENTIFICATION OF CIS-ACTING AND TRANS-ACTING FACTORS REGULATING THE EXPRESSION OF THE HUMAN INSULIN-RECEPTOR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR; PROMOTER REGION; GLUCOCORTICOID RECEPTOR; PREINITIATION COMPLEX; ENHANCER ELEMENT; DISTAL PROMOTER; BINDING; SEQUENCE; HORMONE	The functional organization of the human insulin receptor (hIR) promoter was analyzed by deletion mutagenesis and protein-DNA interaction studies. A series of deletion mutants was expressed transiently in two human hepatocytes, HepG2 and PLC. The results revealed that the promoter region between -692 and -345 is essential for efficient transcription of the hIR gene. Multiple transacting factors were identified by band shift and footprinting analyses. Sp1 binds to a cluster of GC boxes and two GGGAGG hexamers locating at -637 to -594. Adjacent to GC boxes, there are two regions, from -550 to -530 and from -522 to -503, which bind to two novel factors, IRNF-I and IRNF-II. These two factors are distributed differentially in different cell lines. Linker scanning mutations on GC, GA boxes, or the IRNF-I binding site significantly decreased the transcriptional activity, indicating that IRNF-I and Sp1 are important for hIR promoter activity. In addition, we demonstrated that glucocorticoid-dependent transcriptional induction of hIR mRNA in vivo is conferred by a glucocorticoid response element in the hIR promoter. Taken together, these results imply that transcription of the human insulin receptor gene is regulated by multiple protein-DNA interactions occurring within the defined promoter region.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine					PHS HHS [H D 17379] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARAKI E, 1991, J BIOL CHEM, V266, P3944; ARAKI E, 1987, J BIOL CHEM, V262, P16186; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADSHAW MS, 1988, MOL ENDOCRINOL, V2, P1286, DOI 10.1210/mend-2-12-1286; CZECH MP, 1985, ANNU REV PHYSIOL, V47, P357, DOI 10.1146/annurev.ph.47.030185.002041; Darlington G J, 1987, Methods Enzymol, V151, P19, DOI 10.1016/S0076-6879(87)51006-0; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HANSEN U, 1983, EMBO J, V2, P2293, DOI 10.1002/j.1460-2075.1983.tb01737.x; HEDO JA, 1983, J BIOL CHEM, V258, P20; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HUANG HC, 1990, GENE DEV, V4, P287, DOI 10.1101/gad.4.2.287; JACOBS S, 1981, ENDOCR REV, V2, P251, DOI 10.1210/edrv-2-3-251; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAHN CR, 1980, METABOLISM, V29, P455, DOI 10.1016/0026-0495(80)90171-7; KAHN CR, 1985, ANNU REV MED, V36, P429; KARLSSON FA, 1979, ENDOCRINOLOGY, V104, P1383, DOI 10.1210/endo-104-5-1383; KASUGA M, 1983, P NATL ACAD SCI-BIOL, V80, P2137, DOI 10.1073/pnas.80.8.2137; KASUGA M, 1981, P NATL ACAD SCI-BIOL, V78, P6917, DOI 10.1073/pnas.78.11.6917; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; LAIMINS LA, 1984, J VIROL, V49, P183, DOI 10.1128/JVI.49.1.183-189.1984; MAMULA PW, 1988, DIABETES, V37, P1241, DOI 10.2337/diabetes.37.9.1241; MCDONALD AR, 1988, J CLIN INVEST, V81, P499, DOI 10.1172/JCI113347; MCKEON C, 1990, MOL ENDOCRINOL, V4, P647, DOI 10.1210/mend-4-4-647; MOLLER DE, 1989, MOL ENDOCRINOL, V3, P1263, DOI 10.1210/mend-3-8-1263; MUGGEO M, 1979, ENDOCRINOLOGY, V104, P1393, DOI 10.1210/endo-104-5-1393; NISHIDA Y, 1986, BIOCHEM BIOPH RES CO, V141, P474, DOI 10.1016/S0006-291X(86)80197-8; PASTORCIC M, 1986, MOL CELL BIOL, V6, P2784, DOI 10.1128/MCB.6.8.2784; PETRUZZELLI L, 1986, P NATL ACAD SCI USA, V83, P4710, DOI 10.1073/pnas.83.13.4710; POSNER BI, 1974, ENDOCRINOLOGY, V95, P521, DOI 10.1210/endo-95-2-521; ROUILLER DG, 1988, J BIOL CHEM, V263, P13185; SAKONJU S, 1982, CELL, V31, P395, DOI 10.1016/0092-8674(82)90133-7; SALHANICK AI, 1983, J BIOL CHEM, V258, P4130; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHEIDEREIT C, 1986, DNA-J MOLEC CELL BIO, V5, P383, DOI 10.1089/dna.1986.5.383; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; STATMAUER LA, 1986, J BIOL CHEM, V261, P10000; TAYLOR S I, 1985, Diabetes Metabolism Reviews, V1, P171; TEWARI DS, 1989, J BIOL CHEM, V264, P16238; TSAI SY, 1987, CELL, V50, P701, DOI 10.1016/0092-8674(87)90328-X; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WALKER MD, 1983, NATURE, V306, P557, DOI 10.1038/306557a0; WESTIN G, 1988, EMBO J, V7, P3763, DOI 10.1002/j.1460-2075.1988.tb03260.x; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	52	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4638	4645						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1311316				2022-12-27	WOS:A1992HF64200056
J	WALLACE, CJA; CLARKLEWIS, I				WALLACE, CJA; CLARKLEWIS, I			FUNCTIONAL-ROLE OF HEME LIGATION IN CYTOCHROME-C - EFFECTS OF REPLACEMENT OF METHIONINE-80 WITH NATURAL AND NONNATURAL RESIDUES BY SEMISYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICAL SYNTHESIS; YEAST ISO-1-CYTOCHROME-C; CONFORMATION CHANGE; PROTEIN; ANALOGS; RESOLUTION; SUBSTITUTIONS; CONSEQUENCES; REFINEMENT; FRAGMENTS	The nature of the axial ligation to heme iron has been suggested to be the major determinant of the oxidation-reduction potential of a particular cytochrome, but natural cytochromes that vary significantly in E' m invariably differ from one another in many ways. We proposed to clarify this issue by engineering many different ligation patterns within the same basic molecule, mitochondrial cytochrome c. Since many of the potentially informative substitutions require noncoded amino acids, semisynthesis was the approach we chose, and solid-phase peptide synthesis was used to make a set of nine 39-residue peptides that have been incorporated by autocatalytic fragment religation into the structure of horse cytochrome c. An additional two analogues modified at this position were made by chemical modification of the whole protein. As well as looking at the effect on reduction potential, we examined the effect of varying the ligand sphere on the efficiency of the autocatalytic fragment religation reaction, on the conformation of cytochrome c, on its spectroscopic properties, and in promoting electron transfer between heme c and other redox centers. Substitute residues were chosen to put sulfur, selenium, oxygen, and nitrogen, or even no ligating atom at all in the place of methionine sulfur. We found both subtle and dramatic alterations in spectral properties, which were informative about changes in internal structure and stability brought about by the modifications and which may be useful in identifying novel natural ligation patterns. An unexpected finding was that alanine 80 cytochrome c acquires a hemoglobin-like spectrum, and binds O2 most effectively. Reduction potential changes of > 300 mV with nitrogen, > 400 mV with oxygen, and > 300 mV with thiol sulfur ligation were observed, confirming that variation of the ligand sphere is indeed the most effective way in which the protein coat may modulate the potential of the redox center it encloses. Finally, we obtained more evidence that this axial ligand plays an active role in electron transfer and discovered that histidine could be even more effective in this role.	UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER V6T 1W5,BC,CANADA	University of British Columbia	WALLACE, CJA (corresponding author), DALHOUSIE UNIV,DEPT BIOCHEM,HALIFAX B3H 4H7,NS,CANADA.							BUSHNELL GW, 1990, J MOL BIOL, V214, P585, DOI 10.1016/0022-2836(90)90200-6; CLARKLEWIS I, 1986, SCIENCE, V231, P134, DOI 10.1126/science.3079915; CLARKLEWIS I, 1989, USE HPLC RECEPTOR BI, P43; CORRADIN G, 1971, P NATL ACAD SCI USA, V68, P3036, DOI 10.1073/pnas.68.12.3036; CORRADIN G, 1970, BIOCHIM BIOPHYS ACTA, V221, P489, DOI 10.1016/0005-2795(70)90219-9; CRAIG DB, 1991, BIOCHEM J, V279, P781, DOI 10.1042/bj2790781; CUTLER RL, 1989, BIOCHEMISTRY-US, V28, P3188, DOI 10.1021/bi00434a012; Dickerson R., 1975, ENZYMES, V11, P397; GADSBY PMA, 1987, BIOCHEM J, V246, P43, DOI 10.1042/bj2460043; HARBURY HA, 1978, SEMISYNTHETIC PEPTID, P73; KASSNER RJ, 1973, J AM CHEM SOC, V95, P2674, DOI 10.1021/ja00789a044; KENT SBH, 1988, ANNU REV BIOCHEM, V57, P957, DOI 10.1146/annurev.bi.57.070188.004521; LOUIE GV, 1990, J MOL BIOL, V214, P527, DOI 10.1016/0022-2836(90)90197-T; LOUIE GV, 1988, BIOCHEMISTRY-US, V27, P7870, DOI 10.1021/bi00420a043; MARGOLIASH E., 1966, ADVANCE PROTEIN CHEM, V21, P113, DOI 10.1016/S0065-3233(08)60128-X; MOORE GR, 1977, FEBS LETT, V79, P229, DOI 10.1016/0014-5793(77)80793-X; MOORE GR, 1983, FEBS LETT, V161, P171, DOI 10.1016/0014-5793(83)81001-1; MYER YP, 1987, J PROTEIN CHEM, V6, P321; MYER YP, 1979, J BIOL CHEM, V254, P1202; PANDE J, 1987, J PROTEIN CHEM, V6, P295; PETTIGREW GW, 1990, CYTOCHROMES C 2; PETTIGREW GW, 1978, CYTOCHROMES C 1; PROUDFOOT AEI, 1987, BIOCHEM J, V248, P965, DOI 10.1042/bj2480965; PROUDFOOT AEI, 1989, J BIOL CHEM, V264, P8764; RAPHAEL AL, 1991, J AM CHEM SOC, V113, P1038, DOI 10.1021/ja00003a045; RAPHAEL AL, 1989, PROTEINS, V6, P338, DOI 10.1002/prot.340060316; REES DC, 1980, J MOL BIOL, V141, P323, DOI 10.1016/0022-2836(80)90184-9; SALEMME FR, 1977, ANNU REV BIOCHEM, V46, P299, DOI 10.1146/annurev.bi.46.070177.001503; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; STELLWAGEN E, 1978, NATURE, V275, P73, DOI 10.1038/275073a0; TAKANO T, 1981, J MOL BIOL, V153, P95, DOI 10.1016/0022-2836(81)90529-5; TAKANO T, 1981, J MOL BIOL, V153, P79, DOI 10.1016/0022-2836(81)90528-3; TENKORTENAAR PBW, 1985, P NATL ACAD SCI USA, V82, P8279; WALLACE CJA, 1989, J BIOL CHEM, V264, P15199; WALLACE CJA, 1987, J BIOL CHEM, V262, P16767; WALLACE CJA, 1987, BIOCHEM J, V245, P773, DOI 10.1042/bj2450773; WALLACE CJA, 1987, EUR J BIOCHEM, V170, P293, DOI 10.1111/j.1432-1033.1987.tb13698.x; WALLACE CJA, 1986, PROTEIN ENG, V1, P23, DOI 10.1093/protein/1.1.23; WALLACE CJA, 1991, PEPTIDES 1990, P260; WILGUS H, 1978, J BIOL CHEM, V253, P3265	40	119	121	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3852	3861						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1310985				2022-12-27	WOS:A1992HE60700049
J	BURGOSTRINIDAD, M; ISMAIL, R; ETTINGER, RA; PRAHL, JM; DELUCA, HF				BURGOSTRINIDAD, M; ISMAIL, R; ETTINGER, RA; PRAHL, JM; DELUCA, HF			IMMUNOPURIFIED 25-HYDROXYVITAMIN-D 1-ALPHA-HYDROXYLASE AND 1,25-DIHYDROXYVITAMIN-D 24-HYDROXYLASE ARE CLOSELY RELATED BUT DISTINCT ENZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY MITOCHONDRIA; VITAMIN-D; 24,25-DIHYDROXYVITAMIN-D3 PRODUCTION; MICROGRAM QUANTITIES; POLYACRYLAMIDE GELS; CHICK; PROTEINS; PURIFICATION; METABOLITE; ANTIBODIES	The chick kidney mitochondrial cytochrome P-450 1,25-dihydroxyvitamin D3 24-hydroxylase was partially purified by sequential polyethylene glycol precipitation, aminohexyl-Sepharose 4B, and hydroxylapatite chromatography. The specific activity of the final preparation, when reconstituted with NADPH, adrenodoxin, and adrenodoxin reductase, was 245 pmol/min/mg of protein or 0.56 pmol/min/pmol of P-450. The specific cytochrome P-450 content was 0.45-0.73 nmol/mg of protein. BALB/c mice immunized with this preparation developed serum polyclonal antibodies to the 24-hydroxylase, as demonstrated by immunoprecipitation. Splenic lymphocytes from an immunized mouse were fused with myeloma NSI/1-Ag-4-1 cells, and hybridomas secreting monoclonal antibodies to the 24-hydroxylase were detected by immunoprecipitation. The hybridoma lines were cloned by limiting dilution and further characterized as IgG1, IgG3, and IgM subclasses. In one-dimensional immunoblots of soluble 24-hydroxylase preparations, the monoclonal antibodies revealed a single band with an apparent molecular weight of 59,000. The monoclonal antibodies did not cross-react with cytochrome P-450s from other species but immunoprecipitated and immunoblotted a soluble chick renal mitochondrial 25-hydroxyvitamin D3 1-alpha-hydroxylase preparation, demonstrating the close similarity of these two hydroxylases. These antibodies were coupled to Sepharose CL-4B and used to isolate to homogeneity the two enzymes from chick kidney mitochondria. Amino-terminal sequences and amino acid composition data demonstrate that these enzymes are different but homologous.	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,420 HENRY MALL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NIDDK NIH HHS [DK-1488] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BORT RE, 1988, ENDOCRINOLOGY, V123, P2492; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN AJ, 1985, J BIOL CHEM, V260, P4132; BURGOSTRINIDAD M, 1990, ANAL BIOCHEM, V190, P102, DOI 10.1016/0003-2697(90)90141-U; BURGOSTRINIDAD M, 1986, BIOCHEMISTRY-US, V25, P2692, DOI 10.1021/bi00357a061; CASTILLO L, 1978, MINER ELECTROL METAB, V1, P198; CHANDLER JS, 1984, J BIOL CHEM, V259, P2214; COLSTON K, 1982, J BIOL CHEM, V257, P2504; DeLuca HF, 1984, VITAMIN D BASIC CLIN, P1; EVANS IMA, 1975, CLIN SCI MOL MED, V48, P227, DOI 10.1042/cs0480227; FRASER DR, 1970, NATURE, V228, P764, DOI 10.1038/228764a0; FREEMAN SJ, 1984, ANAL BIOCHEM, V141, P248, DOI 10.1016/0003-2697(84)90453-6; GALFRE G, 1977, NATURE, V266, P550, DOI 10.1038/266550a0; GHAZARIAN JG, 1974, J BIOL CHEM, V249, P3026; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; GOOD AH, 1980, SELECTED METHODS CEL, P278; GRAY RW, 1989, BIOCHEM J, V259, P561, DOI 10.1042/bj2590561; HARLOW E, 1988, ANTIBODIES LABORATOR, P273; HART LE, 1984, J NUTR, V114, P2059, DOI 10.1093/jn/114.11.2059; HENRY HL, 1979, J BIOL CHEM, V254, P2722; HENRY HL, 1984, ANNU REV NUTR, V4, P493, DOI 10.1146/annurev.nu.04.070184.002425; HIWATASHI A, 1982, BIOCHEM BIOPH RES CO, V105, P320, DOI 10.1016/S0006-291X(82)80047-8; HOLICK MF, 1973, J BIOL CHEM, V248, P6691; HOLICK MF, 1972, BIOCHEMISTRY-US, V11, P4251, DOI 10.1021/bi00773a009; HOLLOWAY PW, 1973, ANAL BIOCHEM, V53, P304, DOI 10.1016/0003-2697(73)90436-3; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; INABA M, 1991, ARCH BIOCHEM BIOPHYS, V284, P257, DOI 10.1016/0003-9861(91)90293-R; KOHLER G, 1976, EUR J IMMUNOL, V6, P511, DOI 10.1002/eji.1830060713; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOHN J, 1982, BIOCHEM BIOPH RES CO, V107, P878, DOI 10.1016/0006-291X(82)90604-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANDEL ML, 1990, BIOCHIM BIOPHYS ACTA, V1034, P239, DOI 10.1016/0304-4165(90)90044-W; MANDEL ML, 1990, J CLIN LAB IMMUNOL, V31, P1; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEYER LJ, 1982, CLIN CHIM ACTA, V126, P109, DOI 10.1016/0009-8981(82)90026-2; MOORTHY B, 1991, J BONE MINER RES, V6, P199; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OHYAMA Y, 1991, FEBS LETT, V278, P195, DOI 10.1016/0014-5793(91)80115-J; OHYAMA Y, 1989, FEBS LETT, V255, P405, DOI 10.1016/0014-5793(89)81133-0; OHYAMA Y, 1991, J BIOL CHEM, V266, P8690; OMDAHL J, 1971, BIOCHEMISTRY-US, V10, P2935, DOI 10.1021/bi00791a022; OMURA T, 1964, J BIOL CHEM, V239, P2370; ORMEJOHNSON WH, 1969, J BIOL CHEM, V244, P6143; PEDERSEN JI, 1976, J BIOL CHEM, V251, P3933; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POSTLIND H, 1990, BIOCHEM BIOPH RES CO, V168, P261, DOI 10.1016/0006-291X(90)91702-T; SAAREM K, 1978, COMP BIOCHEM PHYS B, V61, P485, DOI 10.1016/0305-0491(78)90039-1; STEINBUCH M, 1969, ARCH BIOCHEM BIOPHYS, V134, P279, DOI 10.1016/0003-9861(69)90285-9; SUGIYAMA T, 1975, FEBS LETT, V52, P145, DOI 10.1016/0014-5793(75)80658-2; TANAKA Y, 1975, ARCH BIOCHEM BIOPHYS, V171, P521, DOI 10.1016/0003-9861(75)90061-2; TANAKA Y, 1974, SCIENCE, V183, P1198, DOI 10.1126/science.183.4130.1198; THOMAS PE, 1987, FASEB J, V46, P2563	52	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3498	3505						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1310688				2022-12-27	WOS:A1992HD15400103
J	RUTHERFORD, CL; PEERY, RB; SUCIC, JF; YIN, YZ; ROGERS, PV; LUO, S; SELMIN, O				RUTHERFORD, CL; PEERY, RB; SUCIC, JF; YIN, YZ; ROGERS, PV; LUO, S; SELMIN, O			CLONING, STRUCTURAL-ANALYSIS, AND EXPRESSION OF THE GLYCOGEN PHOSPHORYLASE-2 GENE IN DICTYOSTELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 FORMS; GLUCAN PHOSPHORYLASE; SEQUENCE-ANALYSIS; HUMAN-LIVER; CELL-TYPES; DISCOIDEUM; PROTEINS	The glycogen phosphorylase-2 (GP2) activity that appears during the cell differentiation of Dictyostelium was purified to homogeneity. The molecular weight of the nondenatured enzyme was 200,000 as determined by Sephacryl S-300 gel filtration and was 107,000 on sodium dodecyl sulfate-polyacrylamide gel electrophoresis, suggesting that the native enzyme consists of two similar subunits. The intact protein was digested with trypsin and protease V8, and the resulting peptides were purified by microbore high pressure liquid chromatography. The peptides were sequenced, and oligonucleotides were constructed for polymerase chain reaction amplification of the GP2 gene from Dictyostelium genomic DNA template. The resulting polymerase chain reaction products were sequenced directly and were confirmed to encode portions of the GP2 gene. These fragments were used to probe a partial EcoRI genomic library for the remainder of the GP2 gene. The nucleotide sequence of the GP2-selected clones revealed an open reading frame of 2975 base pairs that was interrupted by two introns of 109 and 105 base pairs, respectively. The open reading frame encoded a protein of 992 amino acids with a calculated molecular mass of 112,500 Da and an isoelectric point of 6.4. An unusual sequence within the second exon of GP2, in which the triplet CAA was repeated 11 times, resulted in 11 in-frame glutamine residues of a possible 15 amino acids coded for by this region. The CAA repeat was transcribed, as shown by the sequence of cDNA. Comparison of the amino acid sequence of Dictyostelium GP2 to the phosphorylases from other organisms revealed that the Dictyostelium protein was 50 and 44% identical to yeast and rabbit muscle phosphorylases, respectively. Northern blot analysis showed that GP2 mRNA was absent in amebas and the early stages of development, reached a maximum level of expression at the slug stage, and then decreased in the terminal stages of development. Comparison of the mRNA expression with the appearance of GP2 enzyme protein and enzyme activity revealed that gp2 mRNA and a 113-kDa GP2 enzyme peptide were expressed concurrently at 10 h of development. However, enzyme activity did not appear until 18 h, coincident with a decrease in the level of the 113-kDa peptide and a corresponding increase in the amount of a 106-kDa GP2 peptide. Addition of cAMP to aggregation-competent cells in liquid culture resulted in the induction of GP2 mRNA, GP2 protein, and GP2 enzyme activity.			RUTHERFORD, CL (corresponding author), VIRGINIA POLYTECH INST & STATE UNIV,DEPT BIOL,BLACKSBURG,VA 24061, USA.		Selmin, Ornella/ABC-8971-2020		NIA NIH HHS [AG00677] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDRE E, 1988, J BIOL CHEM, V263, P722; BAUMANN P, 1968, BIOCHEMISTRY-US, V7, P3653, DOI 10.1021/bi00850a044; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRICKEY DA, 1990, MOL CELL BIOCHEM, V97, P17; CHOI YL, 1989, FEBS LETT, V243, P193, DOI 10.1016/0014-5793(89)80128-0; CLELAND SV, 1968, BIOCHIM BIOPHYS ACTA, V156, P44, DOI 10.1016/0304-4165(68)90102-5; CLOUTIER MJ, 1987, J BIOL CHEM, V262, P9486; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERRIS DK, 1968, ARCH BIOCHEM BIOPHYS, V248, P10; FIRTEL RA, 1972, DEV BIOL, V29, P85, DOI 10.1016/0012-1606(72)90046-2; FISHER EH, 1958, J BIOL CHEM, V231, P65; GRANT CE, 1990, NUCLEIC ACIDS RES, V18, P5457, DOI 10.1093/nar/18.18.5457; GUSTAFSON GL, 1972, CRIT REV MICROBIOL, V1, P453; GYLLENSTEN UB, 1989, BIOTECHNIQUES, V7, P700; HIGGINS RC, 1982, J BIOL CHEM, V257, P5068; HWANG PK, 1986, NATURE, V324, P80, DOI 10.1038/324080a0; JONES THD, 1970, J BACTERIOL, V104, P754, DOI 10.1128/JB.104.2.754-761.1970; KIMMEL AR, 1985, MOL CELL BIOL, V5, P2123, DOI 10.1128/MCB.5.8.2123; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NAKANO K, 1986, J BIOL CHEM, V261, P8230; NAKANO K, 1986, FEBS LETT, V204, P283, DOI 10.1016/0014-5793(86)80829-8; NARANAN V, 1988, DIFFERENTIATION, V38, P1, DOI 10.1111/j.1432-0436.1988.tb00584.x; NELLEN W, 1987, METHOD CELL BIOL, V28, P67; NEWGARD CB, 1988, J BIOL CHEM, V263, P3850; NEWGARD CB, 1986, P NATL ACAD SCI USA, V83, P8132, DOI 10.1073/pnas.83.21.8132; OCHMAN H, 1988, GENETICS, V120, P621; PODGORSKI GJ, 1989, MOL CELL BIOL, V9, P3938, DOI 10.1128/MCB.9.9.3938; RUTHERFORD CL, 1976, ARCH BIOCHEM BIOPHYS, V175, P453, DOI 10.1016/0003-9861(76)90533-6; RUTHERFORD CL, 1988, DEV GENET, V9, P469, DOI 10.1002/dvg.1020090424; RUTHERFORD CL, 1986, ARCH BIOCHEM BIOPHYS, V250, P435, DOI 10.1016/0003-9861(86)90746-0; RUTHERFORD CL, 1976, J EMBRYOL EXP MORPH, V35, P335; RUTHERFORD CL, 1976, BIOCHIM BIOPHYS ACTA, V451, P212, DOI 10.1016/0304-4165(76)90272-5; Sambrook J, 1989, MOL CLONING LABORATO; SHAW DR, 1989, MOL GEN GENET, V218, P453, DOI 10.1007/BF00332409; THOMAS DA, 1976, J BIOL CHEM, V251, P1253; WARRICK HM, 1988, NUCLEIC ACIDS RES, V16, P6617, DOI 10.1093/nar/16.14.6617; WHITE GJ, 1961, BIOCHIM BIOPHYS ACTA, V53, P285, DOI 10.1016/0006-3002(61)90441-3; WIDDOWSON DCC, 1989, NUCLEIC ACIDS RES, V17, P8374, DOI 10.1093/nar/17.20.8374	38	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2294	2302						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1310312				2022-12-27	WOS:A1992HB53200030
J	BERMAN, J; GREEN, M; SUGG, E; ANDEREGG, R; MILLINGTON, DS; NORWOOD, DL; MCGEEHAN, J; WISEMAN, J				BERMAN, J; GREEN, M; SUGG, E; ANDEREGG, R; MILLINGTON, DS; NORWOOD, DL; MCGEEHAN, J; WISEMAN, J			RAPID OPTIMIZATION OF ENZYME SUBSTRATES USING DEFINED SUBSTRATE MIXTURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BOMBARDMENT MASS-SPECTROMETRY; FAST ATOM; VERTEBRATE COLLAGENASE; FIBROBLAST COLLAGENASE; PEPTIDE ALDEHYDES; INHIBITORS; PROBE	A strategy is described for the rapid optimization of k(cat)/K(m) for protease substrates. Selected positions of a given peptide substrate sequence are varied through synthesis with mixtures of amino acids. Incubation of the resulting peptide mixture with the enzyme of interest and analysis by high pressure liquid chromatography provides a direct measure of analogs with enhanced k(cat)/K(m). High performance liquid chromatography/continuous flow fast atom bombardment mass spectrometry is used to assign structure to each peak in the chromatogram. As an example of the utility and efficiency of "substrate mapping" we describe optimization of the collagenase substrate Dnp-Pro-Leu-Gly-Leu-Trp-Ala-D-Arg-NH2 (where Dnp is dinitrophenyl) at the P1' and P2' positions. Six different mixtures were prepared for evaluation, representing the synthesis of 128 different synthetic substrates. "Substrate mapping" has led to Dnp-Pro-Leu-Gly-Cys(Me)-His-Ala-D-Arg-NH2, a substrate that possesses a 10-fold better k(cat)/K(m) than Dnp-Pro-Leu-Gly-Leu-Trp-Ala-D-Arg-NH2.	DUKE UNIV,MED CTR,DIV PEDIAT GENET & METAB,DURHAM,NC 27710	Duke University	BERMAN, J (corresponding author), GLAXO RES LABS,RES TRIANGLE PK,NC 27709, USA.							ABELES RH, 1960, J BIOL CHEM, V235, P853; ABELES RH, 1960, J BIOL CHEM, V235; BARTLETT PA, 1983, BIOCHEMISTRY-US, V22, P4618, DOI 10.1021/bi00289a002; CAPRIOLI RM, 1990, ANAL CHEM, V62, pA477, DOI 10.1021/ac00207a001; CAPRIOLI RM, 1986, ANAL CHEM, V58, P2949, DOI 10.1021/ac00127a012; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; FERSHT A, 1985, ENZYME STRUCTURE MEC, P111; FIELDS GB, 1987, J BIOL CHEM, V262, P6221; GEYSEN HM, 1986, MOL IMMUNOL, V23, P709, DOI 10.1016/0161-5890(86)90081-7; Henderson L.E., 1988, UCLA S MOL CELL BIOL, V71, P135; ITO Y, 1985, J CHROMATOGR, V346, P161, DOI 10.1016/S0021-9673(00)90502-8; JOHNSON RS, 1987, ANAL CHEM, V59, P2621, DOI 10.1021/ac00148a019; MASUI Y, 1977, BIOCHEM MED METAB B, V17, P215, DOI 10.1016/0006-2944(77)90026-6; NETZELARNETT S, 1991, J BIOL CHEM, V266, P6747; REIDHAAROLSON JF, 1988, SCIENCE, V241, P53, DOI 10.1126/science.3388019; RUTTER WJ, 1836, Patent No. 10931; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P393; STACK MS, 1989, J BIOL CHEM, V264, P4277; THOMPSON RC, 1979, BIOCHEMISTRY-US, V18, P1552, DOI 10.1021/bi00575a026; THOMPSON RC, 1973, BIOCHEMISTRY-US, V12, P47, DOI 10.1021/bi00725a009; TJOENG FS, 1990, INT J PEPT PROT RES, V35, P141; WESTERIK JO, 1972, J BIOL CHEM, V247, P8195	23	52	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1434	1437						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1309783				2022-12-27	WOS:A1992HA48500009
J	WU, DQ; LEE, CH; RHEE, SG; SIMON, MI				WU, DQ; LEE, CH; RHEE, SG; SIMON, MI			ACTIVATION OF PHOSPHOLIPASE-C BY THE ALPHA-SUBUNITS OF THE GQ AND G11 PROTEINS IN TRANSFECTED COS-7 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEIN; ESCHERICHIA-COLI; PERTUSSIS TOXIN; GS-ALPHA; GTP; PURIFICATION; EXPRESSION; RECEPTOR; IDENTIFICATION; HYDROLYSIS	High efficiency transient transfection was used to introduce cDNA corresponding to various G protein-alpha subunits into Cos-7 cells. The proteins that were subsequently synthesized were detected with specific G protein alpha-subunit antipeptide antiserum and were localized in the membrane fraction of the cell. Cells that were prelabeled with the [H-3]inositol and transfected with G-alpha(q), and G-alpha-11 cDNA showed marked increases in formation of [H-3]inositol phosphates after stimulation with aluminum fluoride. Co-transfection with cDNAs corresponding to phosphoinositide specific phospholipase C beta-1 (PI-PLC, beta-1) and to G-alpha(q) or G-alpha-11 resulted in even higher levels of inositol phosphate formation. The introduction of mutations that convert residue glutamine 209 to leucine in G-alpha(q) and G-alpha-11 resulted in persistent activation of PI-PLC and high steady state levels of inositol phosphates. On the other hand, transfection with a variety of other G-alpha subunit cDNAs, i.e. G-alpha(Z), G-alpha(OA), G-alpha(OB), transducin, and the glutamine 205 to leucine mutants of G-alpha(Z) and of G-alpha(OA) did not increase inositol phosphate formation. To further test the specificity of G protein activation of PI-PLC, a cell-free system was prepared by using washed membranes of transiently transfected cells and purified PI-PLC beta-1. Membranes derived from G-alpha(q) and G-alpha-11, but not G-alpha(OA) transfected cells, showed guanosine 5'-O-thiotriphosphate (GTP-gamma-S)-stimulated PIP2 hydrolysis. The activity seen in the system reconstituted with membranes derived from G-alpha-11-transfected cells was blocked by preincubation with specific G-alpha-11 antipeptide antibodies. All of these results are consistent with the conclusion that G-alpha(q) and G-alpha-11 cDNA encode proteins that in the presence of GTP-gamma-S specifically activate PI-PLC.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA; NHLBI, BIOCHEM LAB, BETHESDA, MD 20892 USA	California Institute of Technology; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034236, R37GM034236] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34236] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BOYER JL, 1989, TRENDS PHARMACOL SCI, V10, P360, DOI 10.1016/0165-6147(89)90008-4; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; COCKCROFT S, 1987, TRENDS BIOCHEM SCI, V12, P75, DOI 10.1016/0968-0004(87)90035-1; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; DEVIVO M, 1990, ADP RIBOSYLATING TOX, P267; EXTON JH, 1988, FASEB J, V2, P2670, DOI 10.1096/fasebj.2.11.2456243; FOECKING MK, 1986, GENE, V45, P101, DOI 10.1016/0378-1119(86)90137-X; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; GRAZIANO MP, 1987, J BIOL CHEM, V262, P11375; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOFMANN SL, 1982, J BIOL CHEM, V257, P4359; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEM J, 1991, NEURON, V6, P201, DOI 10.1016/0896-6273(91)90356-5; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MEISENHELDER J, 1989, CELL, V57, P1108; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; NAKAMURA F, 1991, J BIOL CHEM, V266, P12676; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; PADRELL E, 1991, J BIOL CHEM, V266, P9771; PANG IH, 1990, J BIOL CHEM, V265, P18707; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; RYU SH, 1987, J BIOL CHEM, V262, P12511; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1368; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WANGE RL, 1991, J BIOL CHEM, V266, P11409; WILKIE T, 1991, IN PRESS P NATL ACAD; WOON CW, 1988, J BIOL CHEM, V264, P5687	44	318	319	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1811	1817						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1309799				2022-12-27	WOS:A1992HA48500064
J	ANANT, JS; ONG, OC; XIE, H; CLARKE, S; OBRIEN, PJ; FUNG, BKK				ANANT, JS; ONG, OC; XIE, H; CLARKE, S; OBRIEN, PJ; FUNG, BKK			INVIVO DIFFERENTIAL PRENYLATION OF RETINAL CYCLIC-GMP PHOSPHODIESTERASE CATALYTIC SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PHOTORECEPTOR CGMP PHOSPHODIESTERASE; MEMBRANE-BINDING DOMAIN; C-TERMINAL CYSTEINE; ROD OUTER SEGMENTS; G-PROTEIN; GAMMA-SUBUNIT; METHYL-ESTER; P21RAS; TRANSDUCIN; FARNESYL	A number of phototransducing proteins in vertebrate photoreceptors contain a carboxyl terminal -CXXX motif (where C = cysteine and X = any amino acid), known to be a signal sequence for their post-translational prenylation and carboxyl methylation. To study the roles of these modifications in the visual excitation process, we have utilized an intravitreal injection method to radiolabel the prenylated proteins of rat retinas in vivo. We showed that two of the major prenylated polypeptides in the rod outer segments are the PDE(alpha) and PDE(beta) subunits of cyclic GMP phosphodiesterase (PDE). By chromatographic analyses of the amino acid constituents generated by exhaustive proteolysis of PDE(alpha) and PDE(beta) we further demonstrated that they are differentially prenylated by farnesylation and geranylgeranylation, respectively. While a number of proteins ending with the -CXXX sequence have already been reported to possess either a farnesyl or a geranylgeranyl group, PDE is the first enzyme shown to be modified by both types of prenyl groups. The prenyl modification of PDE most likely plays a major role in membrane attachment and in correctly positioning the PDE molecule for phototransduction.	UNIV CALIF LOS ANGELES,SCH MED,JULES STEIN EYE INST,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; NEI,RETINAL CELL & MOLEC BIOL LAB,BETHESDA,MD 20892	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)					NATIONAL EYE INSTITUTE [R01EY005895] Funding Source: NIH RePORTER; NEI NIH HHS [EY-05895] Funding Source: Medline; NIGMS NIH HHS [GM-26060] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BAEHR W, 1991, FEBS LETT, V278, P107, DOI 10.1016/0014-5793(91)80095-K; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CATTY P, 1991, EUR J BIOCHEM, V199, P263, DOI 10.1111/j.1432-1033.1991.tb16119.x; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FUNG BKK, 1989, BIOCHEMISTRY-US, V28, P3133, DOI 10.1021/bi00434a003; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; JOLY A, 1991, J BIOL CHEM, V266, P13495; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; LIPKIN VM, 1990, J BIOL CHEM, V265, P12955; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MOORES SL, 1991, J BIOL CHEM, V266, P14603; ONG OC, 1989, P NATL ACAD SCI USA, V86, P9238, DOI 10.1073/pnas.86.23.9238; OVCHINNIKOV YA, 1987, FEBS LETT, V223, P169, DOI 10.1016/0014-5793(87)80530-6; PITTLER SJ, 1990, GENOMICS, V6, P272, DOI 10.1016/0888-7543(90)90567-E; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RINE J, 1990, New Biologist, V2, P219; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; STIMMEL JB, 1990, BIOCHEMISTRY-US, V29, P9651, DOI 10.1021/bi00493a021; STJULES RS, 1989, EXP EYE RES, V48, P653, DOI 10.1016/0014-4835(89)90007-9; STRYER L, 1991, J BIOL CHEM, V266, P10711; SWANSON RJ, 1983, J BIOL CHEM, V258, P599; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; XIE H, 1990, Methods (Orlando), V1, P276, DOI 10.1016/S1046-2023(05)80328-7; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286; YAMANE HK, 1989, J BIOL CHEM, V264, P20100; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302	41	155	156	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					687	690						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1309771				2022-12-27	WOS:A1992GY96000003
J	MIYANO, O; KAMESHITA, I; FUJISAWA, H				MIYANO, O; KAMESHITA, I; FUJISAWA, H			PURIFICATION AND CHARACTERIZATION OF A BRAIN-SPECIFIC MULTIFUNCTIONAL CALMODULIN-DEPENDENT PROTEIN-KINASE FROM RAT CEREBELLUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE 3-MONOOXYGENASE; EXPRESSION; SYNAPSIN; MYOSIN	A brain-specific multifunctional calmodulin-dependent protein kinase, calmodulin-dependent protein kinase IV, which exhibited characteristic properties quite different from those of calmodulin-dependent protein kinase II, was purified approximately 230-fold from rat cerebellum. The purified preparation gave two protein bands with-molecular weights of 63,000 (alpha) and 66,000 (beta) on sodium dodecyl sulfate-polyacrylamide gel electrophoresis, both of which showed protein kinase activity as examined by the activity gel method. The molecular weight of the enzyme was estimated as about 67,000 from sedimentation coefficient (3.2 S) and Stokes radius (50 angstrom), indicating a monomeric structure of the enzyme. The enzyme phosphorylated smooth muscle myosin light chain, synapsin I, microtubule-associated protein 2, tau protein, myelin basic protein, histone H1, and tyrosine hydroxylase in a Ca2+/calmodulin dependent manner, suggesting that the enzyme is a multifunctional calmodulin-dependent protein kinase capable of phosphrylating a large number of substrates. A synthetic peptide, Lys-Ser-Asp-Gly-Gly-Val-Lys-Lys-Arg-Lys-Ser-Ser-Ser-Ser, was found to be a specific substrate for this kinase and, using this peptide as substrate, the distribution of the enzyme activity in various rat tissues was examined. The activity was found in cerebral cortex, brain stem, and cerebellum, most abundantly in cerebellum, but other tissues tested, including liver, spleen, kidney, lung, heart, skeletal muscle, and adrenal gland showed very little activity.	ASAHIKAWA MED COLL, DEPT BIOCHEM, ASAHIKAWA, HOKKAIDO 078, JAPAN	Asahikawa Medical College								BENNETT V, 1986, METHOD ENZYMOL, V134, P55; Corbin J D, 1974, Methods Enzymol, V38, P287; EBASHI S, 1976, J BIOCHEM-TOKYO, V79, P229, DOI 10.1093/oxfordjournals.jbchem.a131052; FELLOUS A, 1977, EUR J BIOCHEM, V78, P167, DOI 10.1111/j.1432-1033.1977.tb11726.x; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P11309; FUJISAWA H, 1990, BIOESSAYS, V12, P27, DOI 10.1002/bies.950120106; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KATOH T, 1991, BIOCHIM BIOPHYS ACTA, V1091, P205, DOI 10.1016/0167-4889(91)90063-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT TC, 1964, J CHROMATOGR, V14, P317, DOI 10.1016/S0021-9673(00)86637-6; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; OHMSTEDE CA, 1991, P NATL ACAD SCI USA, V88, P5784, DOI 10.1073/pnas.88.13.5784; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OKUNO S, 1982, EUR J BIOCHEM, V122, P49, DOI 10.1111/j.1432-1033.1982.tb05846.x; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SAHYOUN N, 1991, P NATL ACAD SCI USA, V88, P2643, DOI 10.1073/pnas.88.7.2643; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SIKELA JM, 1987, P NATL ACAD SCI USA, V84, P3038, DOI 10.1073/pnas.84.9.3038; SIKELA JM, 1989, GENOMICS, V4, P21, DOI 10.1016/0888-7543(89)90309-1; TOBIMATSU T, 1988, J BIOL CHEM, V263, P16082; UEDA T, 1977, J BIOL CHEM, V252, P5155; WATTERSON DM, 1976, J BIOL CHEM, V251, P4501; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; YAMAUCHI T, 1980, FEBS LETT, V116, P141, DOI 10.1016/0014-5793(80)80628-4; YAMAUCHI T, 1983, EUR J BIOCHEM, V132, P15, DOI 10.1111/j.1432-1033.1983.tb07319.x; YAMAUCHI T, 1981, BIOCHEM BIOPH RES CO, V100, P807, DOI 10.1016/S0006-291X(81)80246-X	34	159	163	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1198	1203						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1309765				2022-12-27	WOS:A1992GY96000081
J	QIN, N; PITTLER, SJ; BAEHR, W				QIN, N; PITTLER, SJ; BAEHR, W			INVITRO ISOPRENYLATION AND MEMBRANE ASSOCIATION OF MOUSE ROD PHOTORECEPTOR CGMP PHOSPHODIESTERASE ALPHA-SUBUNIT AND BETA-SUBUNIT EXPRESSED IN BACTERIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEIN; OUTER SEGMENTS; GAMMA-SUBUNIT; CYSTEINE; FARNESYL; BINDING; IDENTIFICATION; CONTAIN; RETINA; P21RAS	We investigated the specificity of CAAX box-related isoprenylation of rod photoreceptor cGMP phosphodiesterase (PDE) subunits expressed in bacteria and the consequences of this modification on rod disk membrane association. Full-length cDNA sequences of the alpha and beta-subunits of mouse PDE, inserted into bacterial pET expression vectors, were overexpressed as fusion proteins containing 28 (bMP-alpha) and 26 (bMP-beta) additional amino acid residues at their N termini. Both fusion proteins were overexpressed and stored in inclusion bodies. Purified bMP-alpha and bMP-beta were recognized by bovine PDE-specific polyclonal antibodies, but did not associate with depleted rod disk membranes and were catalytically inactive. Using bovine brain or retina extracts as sources of protein prenyltransferases and tritiated farnesyl- or geranylgeranylpyrophosphate as donors, bMP-alpha (CAAX sequence CCIQ) was exclusively farnesylated, and bMP-beta (CAAX sequence CCIL) was exclusively geranylgeranylated. After isoprenylation, bMP-alpha and bMP-beta each associated with rod photoreceptor outer segment disk membranes under isotonic, but not under hypotonic, conditions. The results indicate that isoprenylated bMP-alpha and bMP-beta each interact independently with membranes and that isoprenylation is the key modification that facilitates membrane association.	BAYLOR COLL MED,DEPT OPHTHALMOL,6501 FANNIN ST,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine			Pittler, Steven/J-7091-2013	Pittler, Steven/0000-0002-8464-9303	NATIONAL EYE INSTITUTE [F32EY006172, R01EY008123] Funding Source: NIH RePORTER; NEI NIH HHS [EY08123, F32 EY06172] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAEHR W, 1979, J BIOL CHEM, V254, P1669; BAEHR W, 1991, FEBS LETT, V278, P107, DOI 10.1016/0014-5793(91)80095-K; BAEHR W, 1982, J BIOL CHEM, V257, P6452; BOOTH DP, 1991, J NEUROCHEM, V56, P1949, DOI 10.1111/j.1471-4159.1991.tb03452.x; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CATTY P, 1991, EUR J BIOCHEM, V199, P263, DOI 10.1111/j.1432-1033.1991.tb16119.x; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FINEGOLD AA, 1991, P NATL ACAD SCI USA, V88, P4448, DOI 10.1073/pnas.88.10.4448; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HURWITZ RL, 1985, J BIOL CHEM, V260, P568; JOLY A, 1991, J BIOL CHEM, V266, P13495; KINSELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934, DOI 10.1073/pnas.88.20.8934; KOHNO T, 1990, METHOD ENZYMOL, V185, P187; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; ONG OC, 1989, P NATL ACAD SCI USA, V86, P9238, DOI 10.1073/pnas.86.23.9238; OPPERT B, 1991, J BIOL CHEM, V266, P16607; OVCHINNIKOV YA, 1987, FEBS LETT, V223, P169, DOI 10.1016/0014-5793(87)80530-6; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PITTLER SJ, 1991, PROG CLIN BIOL RES, V362, P33; PITTLER SJ, 1990, GENOMICS, V6, P272, DOI 10.1016/0888-7543(90)90567-E; PITTLER SJ, 1991, P NATL ACAD SCI USA, V88, P8322, DOI 10.1073/pnas.88.19.8322; PITTLER SJ, 1991, RETINAL DEGENERATION, P455; QIN N, 1991, INVEST OPHTH VIS SCI, V32, P1006; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; STEPHENSON RC, 1990, J BIOL CHEM, V265, P16248; STRYER L, 1988, COLD SPRING HARB SYM, V53, P283, DOI 10.1101/SQB.1988.053.01.035; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SWANSON RJ, 1983, J BIOL CHEM, V258, P599; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TYMINSKI PN, 1984, BIOCHEMISTRY-US, V23, P3986, DOI 10.1021/bi00312a028; VORBURGER K, 1989, EMBO J, V8, P4007, DOI 10.1002/j.1460-2075.1989.tb08583.x; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302	49	61	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8458	8463						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1314827				2022-12-27	WOS:A1992HQ18500077
J	SUNDSETH, R; HANSEN, U				SUNDSETH, R; HANSEN, U			ACTIVATION OF RNA POLYMERASE-II TRANSCRIPTION BY THE SPECIFIC DNA-BINDING PROTEIN LSF - INCREASED RATE OF BINDING OF THE BASAL PROMOTER FACTOR TFIIB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR LATE PROMOTER; FUNCTIONAL PREINITIATION COMPLEX; TATA-BOX FACTOR; ACCURATE TRANSCRIPTION; INVITRO TRANSCRIPTION; ESSENTIAL COMPONENT; INITIATION SITE; FACTOR ATF; GENE; PURIFICATION	While the components of the initiation complex at an RNA polymerase II basal promoter have been well characterized, few mechanistic studies have focused on how upstream DNA-binding, transcriptional activators influence protein assembly at the initiation site. Our analysis of basal transcription on both the simian virus 40 and adenovirus major late promoters demonstrates that two slow steps in initiation of transcription are the assembly of the general transcription factors TFIID and TFIIB onto the template DNA. On the simian virus 40 major late promoter, the rate of initiation complex formation is dramatically increased in the presence of the cellular transcriptional activator LSF. Direct analysis by band mobility shift assays demonstrates that LSF has no effect on the rate of binding, or the stability of TFIID on the promoter, predicting that LSF would not affect the template commitment step. Rather, kinetic analyses demonstrate that LSF reduces the lag in the rate of initiation complex formation attributable to the slow addition of TFIIB and suggest that LSF increases the rate of association of TFIIB with the committed template. In addition, LSF increases the total number of transcription complexes in long term assays, which is also consistent with LSF increasing the rate of association of TFIIB, where TFIIB is not saturating. These results indicate a mechanism for the activation of the initiation of RNA polymerase II transcription by one upstream activating protein, LSF. This mechanism may also be applicable to other activators that function in cases where limiting concentrations of TFIIB in the cell dictate slow binding of TFIIB.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,EUKARYOT TRANSCRIPT LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School				Hansen, Ulla/0000-0001-9803-4185	NATIONAL CANCER INSTITUTE [R01CA038038] Funding Source: NIH RePORTER; NCI NIH HHS [CA38038] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABMAYR SM, 1988, GENE DEV, V2, P542, DOI 10.1101/gad.2.5.542; ABRAVAYA K, 1991, MOL CELL BIOL, V11, P586, DOI 10.1128/MCB.11.1.586; AYER DE, 1990, MOL CELL BIOL, V10, P3635, DOI 10.1128/MCB.10.7.3635; AYER DE, 1988, MOL CELL BIOL, V8, P2021, DOI 10.1128/MCB.8.5.2021; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BRADY J, 1982, CELL, V31, P625, DOI 10.1016/0092-8674(82)90318-X; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CONAWAY JW, 1990, J BIOL CHEM, V265, P7564; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; FIRE A, 1984, J BIOL CHEM, V259, P2509; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; FLORES O, 1988, J BIOL CHEM, V263, P10812; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FROMM M, 1982, Journal of Molecular and Applied Genetics, V1, P457; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HANSEN U, 1983, EMBO J, V2, P2293, DOI 10.1002/j.1460-2075.1983.tb01737.x; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HUANG DH, 1988, J BIOL CHEM, V263, P12596; HUANG HC, 1990, GENE DEV, V4, P287, DOI 10.1101/gad.4.2.287; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KESSLER M, 1984, J VIROL, V52, P277, DOI 10.1128/JVI.52.1.277-280.1984; LASKEY RA, 1977, FEBS LETT, V82, P314, DOI 10.1016/0014-5793(77)80609-1; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEONG K, 1988, MOL CELL BIOL, V8, P1765, DOI 10.1128/MCB.8.4.1765; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; Maniatis T., 1982, MOL CLONING; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PHILIPSEN JNJ, 1988, NUCLEIC ACIDS RES, V16, P9663, DOI 10.1093/nar/16.20.9663; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REINBERG D, 1987, J BIOL CHEM, V262, P3310; REINBERG D, 1987, J BIOL CHEM, V262, P3322; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHMIDT MC, 1989, MOL CELL BIOL, V9, P3299, DOI 10.1128/MCB.9.8.3299; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; SUNDSETH R, 1990, DNA PROTEIN ENG TECH, V2, P57; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; ZHENG XM, 1987, CELL, V50, P361, DOI 10.1016/0092-8674(87)90490-9	65	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7845	7855						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1313810				2022-12-27	WOS:A1992HN48500091
J	BRASS, LF				BRASS, LF			HOMOLOGOUS DESENSITIZATION OF HEL CELL THROMBIN RECEPTORS - DISTINGUISHABLE ROLES FOR PROTEOLYSIS AND PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; HUMAN-PLATELETS; PHORBOL ESTER; PHOSPHOINOSITIDE HYDROLYSIS; ALPHA-2-ADRENERGIC RECEPTOR; ADENYLATE-CYCLASE; PROTEIN; KINASE; TRISPHOSPHATE	Loss of sensitivity to thrombin following an initial response is characteristic of a number of cell types, including platelets. It has recently been proposed that thrombin receptors resemble other G protein-coupled receptors, but that activation involves a novel mechanism in which thrombin cleaves the receptor, exposing a new N terminus that serves as the ligand for the receptor. Based upon this model, we have examined the mechanism of thrombin receptor desensitization by comparing the effects of thrombin with those of a peptide corresponding to the N-terminal sequence of the receptor following proteolysis by thrombin: SFLLRNPNDKYEPF or TRP42/55. Like thrombin, TRP42/55 stimulated pertussis toxin-sensitive inositol 1,4,5-trisphosphate formation, raised cytosolic Ca2+, and inhibited cAMP formation in the megakaryoblastic HEL cell line. Exposure to either thrombin or TRp442/55 desensitized the cells to both, but not to a third agonist, neuropeptide Y. The rate of recovery after desensitization depended upon the order of agonist addition. Resensitization of the cells to thrombin following a brief exposure to thrombin required up to 24 h and could be inhibited with cycloheximide. Resensitization to TRP42/55 after exposure to thrombin, or to thrombin after exposure to TRP42/55, on the other hand, was detectable within 30 min and could be inhibited by serine/threonine phosphatase inhibitors, but not by cycloheximide. Loss of responsiveness to thrombin and TRp42/55 was also observed following addition of the phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA). However, while the protein kinase inhibitor staurosporine completely prevented the desensitization caused by TPA, it had only a limited effect on the desensitization caused by TRP42/55. These results demonstrate that the G protein-mediated effects of thrombin can be reproduced by a receptor-derived peptide and suggest that desensitization occurs by at least two mechanisms. The first, which is seen with thrombin, but not TRp42/55, involves proteolysis and requires protein synthesis for recovery. The second, which occurs with TRp42/55 and TPA, as well as with thrombin, involves phosphorylation, possibly of the receptor itself. Although protein kinase C is activated by thrombin and is presumably responsible for the desensitization caused by TPA, it does not appear to play a major role in receptor desensitization caused by thrombin and TRP42/55. This suggests that other kinases, such as those which inactivate adrenergic receptors and rhodopsin, are involved in the down-regulation of thrombin receptor function.	UNIV PENN,DEPT PATHOL,PHILADELPHIA,PA 19104	University of Pennsylvania	BRASS, LF (corresponding author), UNIV PENN,DEPT MED,HEMATOL ONCOL SECT,SILVERSTEIN 7,3400 SPRUCE ST,PHILADELPHIA,PA 19104, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01-HL40387] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; BRASS LF, 1992, BIOCHEM J, V281, P73, DOI 10.1042/bj2810073; BRASS LF, 1991, J BIOL CHEM, V266, P958; BUSHFIELD M, 1991, BIOCHEM J, V274, P317, DOI 10.1042/bj2740317; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COLLER BS, 1991, BLOOD S1, V78, pS394; GEISSLER JF, 1990, J BIOL CHEM, V265, P22255; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HUANG EM, 1987, BIOCHEM J, V242, P11, DOI 10.1042/bj2420011; JAFFE EA, 1987, J BIOL CHEM, V262, P8557; JAKOBS KH, 1985, EUR J BIOCHEM, V151, P425, DOI 10.1111/j.1432-1033.1985.tb09119.x; JAMIESON GA, 1988, PLATELET MEMBRANE RE, P137; JONES LG, 1989, MOL PHARMACOL, V36, P142; KELLEHER DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4316, DOI 10.1073/pnas.81.14.4316; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; LEEBLUNDBERG LMF, 1985, P NATL ACAD SCI USA, V82, P5651, DOI 10.1073/pnas.82.17.5651; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PARIS S, 1988, J BIOL CHEM, V263, P11250; RAYMOND JR, 1991, J BIOL CHEM, V266, P14747; RITTENHOUSE SE, 1985, J BIOL CHEM, V260, P8657; RYU SH, 1990, J BIOL CHEM, V265, P17941; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SIMMOTEIT R, 1991, FEBS LETT, V285, P99, DOI 10.1016/0014-5793(91)80734-K; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WILLIAMS AG, 1990, BLOOD, V76, P721	30	125	129	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6044	6050						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1313426				2022-12-27	WOS:A1992HK31800051
J	AU, YPT; KENAGY, RD; CLOWES, AW				AU, YPT; KENAGY, RD; CLOWES, AW			HEPARIN SELECTIVELY INHIBITS THE TRANSCRIPTION OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR IN PRIMATE ARTERIAL SMOOTH-MUSCLE CELLS DURING MITOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HUMAN AMNIOTIC MEMBRANE; RAT CAROTID-ARTERY; GENE-EXPRESSION; MESSENGER-RNA; CELLULAR PROLIFERATION; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; CARCINOMA CELLS; PHORBOL ESTERS	How heparin inhibits vascular smooth muscle cell proliferation and migration has not been established. We have investigated the hypothesis that heparin inhibits vascular smooth muscle cell proliferation and migration by interfering with the expression and activity of proteases such as plasminogen activators. In an in vitro mitogenesis model, tissue-type plasminogen activator (tPA) mRNA and protein increase in baboon smooth muscle cells stimulated with fetal bovine serum or phorbol esters. Heparin inhibits smooth muscle cell proliferation and suppresses the induction of tPA mRNA and protein while it has little effect on the mRNA of urokinase-type plasminogen activator, plasminogen activator inhibitor type I, and a number of genes that are also modulated by serum and phorbol esters. The inhibitory effect on tPA mRNA is specific to heparin-like molecules and does not depend on the anticoagulation activity of heparin. The increase in tPA mRNA is due to increased transcription, which is suppressed by heparin. The induction of tPA by serum and phorbol esters is diminished by protein kinase C inhibitors such as H7 or staurosporine and by protein kinase C depletion. Since heparin suppresses the induction of the tPA gene by phorbol esters, these results suggest that heparin may interfere with the protein kinase C pathway.	UNIV WASHINGTON,DEPT SURG,SEATTLE,WA 98195	University of Washington; University of Washington Seattle				Kenagy, Richard/0000-0002-2021-5565	NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030946, P01HL018645] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00166] Funding Source: Medline; NHLBI NIH HHS [HL 18645, HL 30946] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ASAMO T, 1984, J PHARMACOL EXP THER, V231, P141; AU YPT, 1990, J CELL BIOL, V111, pA234; Ausubel FM, CURRENT PROTOCOLS MO; BAND V, 1989, J CELL PHYSIOL, V138, P106, DOI 10.1002/jcp.1041380115; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CASTELLOT JJ, 1982, J BIOL CHEM, V257, P1256; CASTELLOT JJ, 1985, J CELL PHYSIOL, V124, P13, DOI 10.1002/jcp.1041240104; CASTELLOT JJ, 1989, J CELL BIOL, V109, P3147, DOI 10.1083/jcb.109.6.3147; CELANO P, 1989, BIOTECHNIQUES, V7, P942; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOWES AW, 1986, CIRC RES, V58, P839, DOI 10.1161/01.RES.58.6.839; CLOWES AW, 1990, CIRC RES, V67, P61, DOI 10.1161/01.RES.67.1.61; CLOWES AW, 1985, LAB INVEST, V52, P611; COCHRAN DL, 1988, BIOCHIM BIOPHYS ACTA, V967, P289, DOI 10.1016/0304-4165(88)90022-0; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEGEN JL, 1983, J BIOL CHEM, V258, P2153; DEGEN SJF, 1986, J BIOL CHEM, V261, P6972; FEDARKO NS, 1986, J CELL BIOL, V102, P587, DOI 10.1083/jcb.102.2.587; FENG P, 1990, J BIOL CHEM, V265, P2022; FRITZE LMS, 1985, J CELL BIOL, V100, P1041, DOI 10.1083/jcb.100.4.1041; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRIMALDI G, 1986, EMBO J, V5, P855, DOI 10.1002/j.1460-2075.1986.tb04295.x; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HOOVER RL, 1980, CIRC RES, V47, P578, DOI 10.1161/01.RES.47.4.578; HOTCHKISS A, 1988, THROMB HAEMOSTASIS, V60, P255; KAWAMOTO S, 1984, BIOCHEM BIOPH RES CO, V125, P258, DOI 10.1016/S0006-291X(84)80362-9; KIRCHHEIMER JC, 1987, FASEB J, V1, P125, DOI 10.1096/fasebj.1.2.3038646; KIRCHHEIMER JC, 1987, THROMB RES, V48, P291, DOI 10.1016/0049-3848(87)90441-5; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEVIN EG, 1989, J BIOL CHEM, V264, P16030; LIBBY P, 1983, J CELL PHYSL, V115, P1979; MAJACK RA, 1986, P NATL ACAD SCI USA, V83, P9050, DOI 10.1073/pnas.83.23.9050; MAJACK RA, 1984, J CELL PHYSIOL, V118, P253, DOI 10.1002/jcp.1041180306; MAJESKY MW, 1987, CIRC RES, V61, P296, DOI 10.1161/01.RES.61.2.296; MEDCALF RL, 1990, J BIOL CHEM, V265, P14618; MIGNATTI P, 1989, J CELL BIOL, V108, P671, DOI 10.1083/jcb.108.2.671; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; OGRADY RL, 1981, INT J CANCER, V28, P509, DOI 10.1002/ijc.2910280418; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; OSSOWSKI L, 1988, J CELL BIOL, V107, P2437, DOI 10.1083/jcb.107.6.2437; PARANJPE M, 1980, LIFE SCI, V26, P1223, DOI 10.1016/0024-3205(80)90067-3; PEPPER MS, 1987, J CELL BIOL, V105, P2535, DOI 10.1083/jcb.105.6.2535; RABBANI SA, 1990, BIOCHEM BIOPH RES CO, V173, P1058, DOI 10.1016/S0006-291X(05)80893-9; REILLY CF, 1989, J BIOL CHEM, V264, P6990; ROSS R, 1980, HDB PHYSL CARDIOVASC, V2, P61; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SNOW AD, 1990, AM J PATHOL, V137, P313; TAMOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VERDE P, 1984, P NATL ACAD SCI-BIOL, V81, P4727, DOI 10.1073/pnas.81.15.4727; WERB Z, 1977, NEW ENGL J MED, V296, P1017, DOI 10.1056/NEJM197705052961801; WRIGHT TC, 1989, P NATL ACAD SCI USA, V86, P3199, DOI 10.1073/pnas.86.9.3199	64	92	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3438	3444						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1310687				2022-12-27	WOS:A1992HD15400095
J	KALVAKOLANU, DVR; LIU, JS; HANSON, RW; HARTER, ML; SEN, GC				KALVAKOLANU, DVR; LIU, JS; HANSON, RW; HARTER, ML; SEN, GC			ADENOVIRUS-E1A REPRESSES THE CYCLIC AMP-INDUCED TRANSCRIPTION OF THE GENE FOR PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP) IN HEPATOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTER-REGULATORY REGION; E1A PRODUCTS; FUNCTIONAL DOMAINS; PROTEIN-BINDING; RAT-LIVER; EXPRESSION; IDENTIFICATION; TRANSFORMATION; ENHANCER; CAMP	Adenovirus infection of hepatoma cells inhibited transcription of the phosphoenolpyruvate carboxykinase (GTP) (EC 4.1.1.32) (PEPCK) gene and virtually eliminated transcription of a chimeric gene which contained the PEPCK promoter linked to the structural gene for chloramphenicol acetyltransferase (CAT). This effect is due to the viral protein E1A, since adenovirus containing a deletion in the E1A gene did not repress transcription from the PEPCK promoter. Both the 243R and 283R products of the E1A gene were effective. The conserved region 1 (CR-1) domain of E1A was required for this effect. Treatment of hepatoma cells with 8-bromo-cAMP or transfection with plasmids coding for the catalytic subunit of protein kinase A, CAAT/enhancer binding protein-alpha (C/EBP), or Jun, all potent inducers of PEPCK gene transcription, did not relieve the inhibition caused by E1A. This inhibition does not appear to be mediated by major enhancer elements and in the PEPCK gene since transcription from the PEPCK promoter containing block mutations in binding domains for C/EBP and cAMP regulatory element binding protein (CREB) was also inhibited by E1A. Transcription of chimeric genes containing two copies each of the major cAMP response domains (CRE-1 and P-3) linked to a neutral promoter and fused to the CAT structural gene was stimulated by the catalytic subunit of protein kinase A, but this effect was totally inhibited by E1A. The strong repressive effect of E1A on PEPCK gene transcription seems to involve an interruption of an obligatory interaction between factors which bind to the cAMP response element in the PEPCK promoter and the TATA box.	CLEVELAND CLIN FDN, RES INST,DEPT MOLEC BIOL,9500 EUCLID AVE,NC2-105, CLEVELAND, OH 44195 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT BIOCHEM, CLEVELAND, OH 44106 USA	Cleveland Clinic Foundation; Case Western Reserve University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022510] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-22510] Funding Source: Medline; NIDDK NIH HHS [DK-24651, DK-21589] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BOKAR JA, 1988, J BIOL CHEM, V263, P19740; BOSCH F, 1990, J BIOL CHEM, V265, P13677; CHATTERJEE PK, 1988, EMBO J, V7, P835, DOI 10.1002/j.1460-2075.1988.tb02882.x; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHU DTW, 1986, J BIOL CHEM, V261, P6848; DATTA S, 1991, J VIROL, V65, P5297, DOI 10.1128/JVI.65.10.5297-5304.1991; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GIRALT M, 1991, J BIOL CHEM, V266, P21991; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HEN R, 1986, NATURE, V321, P249, DOI 10.1038/321249a0; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; KALVAKOLANU DVR, 1991, J BIOL CHEM, V266, P873; KALVAKOLANU DVR, 1991, P NATL ACAD SCI USA, V88, P7459, DOI 10.1073/pnas.88.17.7459; KO JL, 1986, EMBO J, V7, P835; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LIU JS, 1991, J BIOL CHEM, V266, P19095; LIU JS, 1990, BIOTECHNIQUES, V9, P738; LOOSE DS, 1985, BIOCHEMISTRY-US, V24, P4509, DOI 10.1021/bi00338a004; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; MORAN E, 1986, J VIROL, V57, P765, DOI 10.1128/JVI.57.3.765-775.1986; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; NEVINS JR, 1989, ADV VIRUS RES, V37, P35; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; QUINN PG, 1990, MOL CELL BIOL, V10, P3357, DOI 10.1128/MCB.10.7.3357; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; ROCHETTEEGLY C, 1990, GENE DEV, V4, P137, DOI 10.1101/gad.4.1.137; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SOGAWA K, 1989, EUR J BIOCHEM, V181, P539, DOI 10.1111/j.1432-1033.1989.tb14757.x; STEIN RW, 1987, MOL CELL BIOL, V7, P1164, DOI 10.1128/MCB.7.3.1164; TIMMERS HTM, 1989, J VIROL, V63, P1470, DOI 10.1128/JVI.63.3.1470-1473.1989; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEIGEL RJ, 1990, P NATL ACAD SCI USA, V87, P9878, DOI 10.1073/pnas.87.24.9878; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499	46	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2530	2536						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1310318				2022-12-27	WOS:A1992HB53200065
J	HENDRICH, MP; FOX, BG; ANDERSSON, KK; DEBRUNNER, PG; LIPSCOMB, JD				HENDRICH, MP; FOX, BG; ANDERSSON, KK; DEBRUNNER, PG; LIPSCOMB, JD			LIGATION OF THE DIIRON SITE OF THE HYDROXYLASE COMPONENT OF METHANE MONOOXYGENASE - AN ELECTRON NUCLEAR DOUBLE-RESONANCE STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLOCOCCUS-CAPSULATUS BATH; BINUCLEAR IRON CENTER; REDUCED UTEROFERRIN; PARAMAGNETIC-RES; HEMERYTHRIN; MOSSBAUER; PROTEIN; SPIN; METHEMERYTHRIN; SPECTROSCOPY	Electron nuclear double resonance (ENDOR) spectroscopy is used to probe the coordination of the mixed valence (Fe(II).Fe(III)) diiron cluster of the methane monooxygenase hydroxylase component (MMOH-) isolated from Methylosinus trichosporium OB3b. ENDOR resonances are observed along the principal axis directions g1 = 1.94 and g3 = 1.76 from at least nine different protons and two different nitrogens. The nitrogens are strongly coupled and appear to be directly coordinated to the cluster irons. The ratio of their superhyperfine coupling constants is roughly 4:7, which equals the ratio of the spin expectation values of the Fe(II) and Fe(III) in the ground state and suggests that at least one nitrogen is coordinated to each iron of the mixed valence cluster. Moreover, the superhyperfine and quadrupole coupling constants assigned to the Fe(III) site (A(N) = 13.6 MHz, P(N) = 0.7 MHz) are comparable with those observed for semimethemerythrin sulfide (A(N) = 12.1 MHz, P(N) = 0.7 MHz), for which the nitrogen ligands are histidines. At least three of the coupled protons exchange slowly when MMOH- is incubated in D2O, and H-2 ENDOR resonances are subsequently observed. These observations are also consistent with histidine ligation of the iron cluster. On addition of the inhibitor dimethyl sulfoxide (Me2SO) to MMOH- the EPR spectrum sharpens and shifts dramatically. Only one set of N-14 ENDOR resonances is observed with frequencies equal to those assigned to the Fe(III)-histidine resonances of uncomplexed MMOH- suggesting that the nitrogen coordination to the Fe(II) site is altered or possibly lost in the presence of Me2SO. H-2 ENDOR resonances are observed in the presence of d6-Me2SO indicating that the inhibitor Me2SO binds near or possibly to the diiron cluster. In contrast, no H-2 ENDOR resonances are observed from d4-methanol upon addition to MMOH-. Thus, the changes observed in the EPR spectrum of MMOH- upon addition of methanol may result from binding to a site away from the diiron cluster or from bulk solvent effects on the protein structure.	UNIV MINNESOTA,SCH MED,DEPT BIOCHEM,MINNEAPOLIS,MN 55455; UNIV ILLINOIS,DEPT PHYS,URBANA,IL 61801	University of Minnesota System; University of Minnesota Twin Cities; University of Illinois System; University of Illinois Urbana-Champaign			Andersson, K Kristoffer/F-9624-2010	Lipscomb, John/0000-0002-8158-5594	NIGMS NIH HHS [R01 GM040466, GM12996, GM16406, GM40466] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM012996, R01GM040466] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abragam A., 1970, ELECT PARAMAGNETIC R; ANDERSSON KK, 1991, NEW J CHEM, V15, P411; ANTANAITIS BC, 1985, J BIOL CHEM, V260, P4572; Anthony C., 1982, BIOCH METHYLOTROPHS; ARMSTRONG WH, 1984, J AM CHEM SOC, V106, P4632, DOI 10.1021/ja00328a064; BECK JL, 1988, J AM CHEM SOC, V110, P3317, DOI 10.1021/ja00218a061; BRITT RD, 1991, BIOCHEMISTRY-US, V30, P1892, DOI 10.1021/bi00221a023; CARDY DLN, 1991, MOL MICROBIOL, V5, P335, DOI 10.1111/j.1365-2958.1991.tb02114.x; CARLSON J, 1984, P NATL ACAD SCI-BIOL, V81, P4294, DOI 10.1073/pnas.81.14.4294; DALTON H, 1980, ADV APPL MICROBIOL, V26, P71; DALTON H, 1980, MICROBIAL GROWTH C1, P1; DAY EP, 1988, J BIOL CHEM, V263, P15561; DOI K, 1988, J BIOL CHEM, V263, P5757; ERICSON A, 1988, J AM CHEM SOC, V110, P2330, DOI 10.1021/ja00215a070; FOX BG, 1990, GAS, OIL, AND COAL BIOTECHNOLOGY 1, P197; FOX BG, 1988, J BIOL CHEM, V263, P10553; FOX BG, 1991, J BIOL CHEM, V266, P540; FOX BG, 1990, METHOD ENZYMOL, V188, P191; FOX BG, 1989, J BIOL CHEM, V264, P1003; GUIGLIARELLI B, 1986, J CHEM PHYS, V85, P1869; GURBIEL RJ, 1989, BIOCHEMISTRY-US, V28, P4861, DOI 10.1021/bi00437a051; HENDRICH MP, 1990, J AM CHEM SOC, V112, P5861, DOI 10.1021/ja00171a029; HIGGINS IJ, 1980, NATURE, V286, P561, DOI 10.1038/286561a0; HOFFMAN BM, 1984, J MAGN RESON, V59, P110, DOI 10.1016/0022-2364(84)90287-7; KURTZ DM, 1983, J BIOL CHEM, V258, P2115; LUKAT GS, 1985, BIOCHEMISTRY-US, V24, P3464, DOI 10.1021/bi00335a012; MCCORMICK JM, 1990, J AM CHEM SOC, V112, P2005, DOI 10.1021/ja00161a060; MULKS CF, 1979, J AM CHEM SOC, V101, P1645, DOI 10.1021/ja00501a001; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; QUE L, 1990, PROGR INORGANIC CHEM, V38, P201; SAGE JT, 1989, J AM CHEM SOC, V111, P7239, DOI 10.1021/ja00200a052; SANDERSLOEHR J, 1989, IRON CARRIERS IRON P, P373; SCARROW RC, 1990, J AM CHEM SOC, V112, P657, DOI 10.1021/ja00158a025; SCHOLES CP, 1982, J AM CHEM SOC, V104, P2724, DOI 10.1021/ja00374a007; SHIEMKE AK, 1984, J AM CHEM SOC, V106, P4951, DOI 10.1021/ja00329a054; STENKAMP RE, 1984, J AM CHEM SOC, V106, P618, DOI 10.1021/ja00315a027; VINCENT JB, 1990, CHEM REV, V90, P1447, DOI 10.1021/cr00106a004; WOODLAND MP, 1984, J BIOL CHEM, V259, P53	38	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					261	269						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1309736				2022-12-27	WOS:A1992GY43900045
J	DOU, DX; OWOLABI, JB; DEY, S; ROSEN, BP				DOU, DX; OWOLABI, JB; DEY, S; ROSEN, BP			CONSTRUCTION OF A CHIMERIC ARSA-ARSB PROTEIN FOR OVEREXPRESSION OF THE OXYANION-TRANSLOCATING ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARSENICAL RESISTANCE OPERON; ESCHERICHIA-COLI K-12; MESSENGER-RNA; ANION PUMP; MOLECULAR CHARACTERIZATION; TETRACYCLINE RESISTANCE; NUCLEOTIDE-SEQUENCE; BETA-GALACTOSIDASE; FUMARATE REDUCTASE; GENE CLONING	Resistance to toxic oxyanions of arsenic and antimony in Escherichia coli is conferred by the conjugative R-factor R773, which encodes an ATP-driven anion extrusion pump. The ars operon is composed of three structural genes, arsA, arsB, and arsC. Although transcribed as a single unit, the three genes are differentially expressed as a result of translational differences, such that the ArsA and ArsC proteins are produced in high amounts relative to the amount of ArsB protein made. Consequently, biochemical characterization of the ArsB protein, which is an integraL membrane protein containing the anion-conducting pathway, has been limited, precluding studies of the mechanism of this oxyanion pump. To overexpress the arsB gene, a series of changes were made. First, the second codon, an infrequently used leucine codon, was changed to a more frequently utilized codon. Second, a GC-rich stem-loop (DELTAG = -17 kcal/mol) between the third and twelfth codons was destabilized by changing several of the bases of the base-paired region. Third, the re-engineered arsB gene was fused 3' in frame to the first 1458 base pairs of the arsA gene to encode a 914-residue chimeric protein (486 residues of the ArsA protein plus 428 residues of the mutated ArsB protein) containing the entire re-engineered ArsB sequence except for the initiating methionine. The ArsA-ArsB chimera has been overexpressed at approximately 15-20% of the total membrane proteins. Cells producing the chimeric ArsA-ArsB protein with an arsA gene in trans excluded (AsO2-)-As-73 from cells, demonstrating that the chimera can function as a component of the oxyanion-translocating ATPase.	WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM, 540 E CANFIELD AVE, DETROIT, MI 48201 USA	Wayne State University	ROSEN, BP (corresponding author), WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM, 540 E CANFIELD AVE, DETROIT, MI 48201 USA.			Rosen, Barry P./0000-0002-5230-4271	NIAID NIH HHS [AI19793] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019793] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARRAIANO CM, 1988, J BACTERIOL, V170, P4625, DOI 10.1128/jb.170.10.4625-4633.1988; BROOMESMITH JK, 1986, GENE, V49, P341, DOI 10.1016/0378-1119(86)90370-7; BROSIUS J, 1984, GENE, V27, P151, DOI 10.1016/0378-1119(84)90136-7; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHEN CM, 1986, J BIOL CHEM, V261, P5030; CHEN CM, 1985, J BACTERIOL, V161, P758, DOI 10.1128/JB.161.2.758-763.1985; CHOPRA I, 1981, J GEN MICROBIOL, V126, P45; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; ERNI B, 1986, J BIOL CHEM, V261, P6398; FERREIRA GC, 1992, J BIOL CHEM, V267, P5460; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FRANCISCO MJDS, 1989, MOL MICROBIOL, V3, P15, DOI 10.1111/j.1365-2958.1989.tb00098.x; HEDGES RW, 1973, J BACTERIOL, V115, P459, DOI 10.1128/JB.115.1.459-460.1973; HICKMAN RK, 1990, MOL MICROBIOL, V4, P1241, DOI 10.1111/j.1365-2958.1990.tb00703.x; HSU CM, 1989, J BIOL CHEM, V264, P17349; HUI A, 1984, EMBO J, V3, P623, DOI 10.1002/j.1460-2075.1984.tb01858.x; IKEMURA T, 1981, J MOL BIOL, V151, P389, DOI 10.1016/0022-2836(81)90003-6; ITO K, 1991, MOL MICROBIOL, V5, P2243, DOI 10.1111/j.1365-2958.1991.tb02154.x; KAUR P, 1992, PLASMID, V27, P29, DOI 10.1016/0147-619X(92)90004-T; KLEID DG, 1981, SCIENCE, V214, P1125, DOI 10.1126/science.6272395; KUNG HF, 1972, P NATL ACAD SCI USA, V69, P925, DOI 10.1073/pnas.69.4.925; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMIRE BD, 1983, J BACTERIOL, V155, P391, DOI 10.1128/JB.155.1.391-397.1983; Marston F. A. O., 1987, DNA CLONING, P59; MOBLEY HLT, 1983, MOL GEN GENET, V191, P421, DOI 10.1007/BF00425757; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; OWOLABI JB, 1990, J BACTERIOL, V172, P2367, DOI 10.1128/jb.172.5.2367-2371.1990; ROEPE PD, 1989, P NATL ACAD SCI USA, V86, P6087, DOI 10.1073/pnas.86.16.6087; ROSEN BP, 1984, BIOCHEM BIOPH RES CO, V124, P760, DOI 10.1016/0006-291X(84)91023-4; ROSEN BP, 1988, J BIOL CHEM, V263, P3067; RULE GS, 1985, J BACTERIOL, V161, P1059, DOI 10.1128/JB.161.3.1059-1068.1985; Sambrook J, 1989, MOL CLONING LABORATO; SANFRANCISCO MJD, 1990, NUCLEIC ACIDS RES, V18, P619; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; SILVER S, 1981, J BACTERIOL, V146, P983, DOI 10.1128/JB.146.3.983-996.1981; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; TISA LS, 1990, J BIOL CHEM, V265, P190; TRISLER P, 1984, J BACTERIOL, V160, P184, DOI 10.1128/JB.160.1.184-191.1984; WEINER JH, 1984, J BACTERIOL, V158, P590, DOI 10.1128/JB.158.2.590-596.1984; WILSON ML, 1988, J BACTERIOL, V170, P588, DOI 10.1128/jb.170.2.588-597.1988; WU JH, 1992, J BIOL CHEM, V267, P12570; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOUNG IG, 1978, GENE, V4, P25, DOI 10.1016/0378-1119(78)90012-4	48	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25768	25775						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1281474				2022-12-27	WOS:A1992KD07300031
J	HADCOCK, JR; PORT, JD; GELMAN, MS; MALBON, CC				HADCOCK, JR; PORT, JD; GELMAN, MS; MALBON, CC			CROSS-TALK BETWEEN TYROSINE KINASE AND G-PROTEIN-LINKED RECEPTORS - PHOSPHORYLATION OF BETA(2)-ADRENERGIC RECEPTORS IN RESPONSE TO INSULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; MESSENGER-RNA; BETA-2-ADRENERGIC RECEPTOR; ELECTROPHORETIC TRANSFER; NITROCELLULOSE SHEETS; POLYACRYLAMIDE GELS; ADENYLATE-CYCLASE; MEDIATED PATHWAYS; DOWN-REGULATION; FAT-CELLS	Protein kinases play a pivotal role in the propagation and modulation of transmembrane signaling pathways. Two major classes of receptors, G-protein-linked and tyrosine kinase receptors not only propagate signals but also are substrates for phosphorylation in response to stimulation by agonist ligands. Insulin (operating via tyrosine kinase receptors) and catecholamines (operating by G-protein-linked receptors) are counterregulatory with respect to lipid and carbohydrate metabolism. How, on a cellular level, these two distinct classes of receptors may cross-regulate each other remains controversial. In the present work we identify a novel cross-talk between members of two distinct classes of receptors, tyrosine kinase (insulin) and G-protein-linked (beta-adrenergic) receptors. Treatment of DDT1 MF-2 hamster vas deferens smooth muscle cells with insulin promoted a marked attenuation (desensitization) of beta-adrenergic receptor-mediated activation of adenylylcyclase. Measured by immune precipitation of beta2-adrenergic receptors from cells metabolically labeled with [P-32]orthophosphate, the basal state of receptor phosphorylation was increased 2-fold by insulin. Phosphoamino acid analysis revealed that for insulin-stimulated cells, the beta2-adrenergic receptors showed increased phosphorylation on tyrosyl and decreased phosphorylation on threonyl residues. Phosphorylation of the beta-adrenergic receptor was rapid and peaked at 30 min following stimulation of cells by insulin. Beta-adrenergic receptor phosphorylation and attenuation of catecholamine-sensitive adenylylcyclase provide a biochemical basis for the counterregulatory effects of insulin upon catecholamine action.	SUNY STONY BROOK,HLTH SCI CTR,SCH MED,DEPT PHARMACOL,DIABET & METAB DIS RES PROGRAM,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	MALBON, CC (corresponding author), SUNY STONY BROOK,HLTH SCI CTR,SCH MED,DEPT PHARMACOL,DIABET & METAB DIS RES PROGRAM,STONY BROOK,NY 11794, USA.		malbon, craig/ABF-3604-2020	Port, Jonathan D./0000-0001-7048-3544	NIDDK NIH HHS [DK30111, DK25410, T32 DK07521] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007521, R01DK025410, R01DK030111] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENOVIC JL, 1985, J BIOL CHEM, V260, P7094; BLACKSHEAR PJ, 1991, J BIOL CHEM, V266, P10946; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; CLARK RB, 1988, P NATL ACAD SCI USA, V85, P1442, DOI 10.1073/pnas.85.5.1442; ENGFELDT P, 1988, J BIOL CHEM, V263, P15553; ERICKSON PF, 1982, J IMMUNOL METHODS, V51, P241, DOI 10.1016/0022-1759(82)90263-0; GEORGE ST, 1988, BIOCHEM BIOPH RES CO, V150, P665, DOI 10.1016/0006-291X(88)90443-3; HADCOCK JR, 1991, J BIOL CHEM, V266, P11915; HADCOCK JR, 1990, J BIOL CHEM, V265, P14784; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P5021, DOI 10.1073/pnas.85.14.5021; HADCOCK JR, 1989, J BIOL CHEM, V264, P13956; HADCOCK JR, 1989, J BIOL CHEM, V264, P19298; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HEYWORTH CM, 1983, BIOCHEM J, V214, P547, DOI 10.1042/bj2140547; HOUSLAY MD, 1986, BIOCHEM SOC T, V14, P183, DOI 10.1042/bst0140183; LEWIS RE, 1990, J BIOL CHEM, V265, P947; LIU CY, 1990, J ANIM SCI, V68, P1603; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCHMONT RJ, 1980, NATURE, V286, P904, DOI 10.1038/286904a0; MARTINY L, 1991, FEBS LETT, V286, P105, DOI 10.1016/0014-5793(91)80951-X; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OLANSKY L, 1984, METABOLISM, V33, P76, DOI 10.1016/0026-0495(84)90165-3; PORT JD, 1992, J BIOL CHEM, V267, P8468; RAPIEJKO PJ, 1989, J BIOL CHEM, V264, P16183; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; STADTMAUER L, 1986, J BIOL CHEM, V261, P3402; STROSBERG AD, 1992, MOL NEUROBIOL, V4, P211; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VILA MD, 1990, BIOCHEMISTRY-US, V29, P8735, DOI 10.1021/bi00489a033; Wang H Y, 1990, Receptor, V1, P13; WANG HY, 1989, J BIOL CHEM, V264, P14424; WATKINS DC, 1989, J BIOL CHEM, V264, P4186	34	97	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					26017	26022						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1281480				2022-12-27	WOS:A1992KD07300065
J	OSTEDGAARD, LS; WELSH, MJ				OSTEDGAARD, LS; WELSH, MJ			PARTIAL-PURIFICATION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; BINDING-PROTEIN; ANION PUMP; R-DOMAIN; GENE; IDENTIFICATION; TRANSPORT; EXPRESSION; CELLS; PHOSPHORYLATION	We have investigated several purification strategies for the cystic fibrosis transmembrane regulator (CFTR) based on its structural similarity to other proteins of the traffic ATPase/ABC transporter family. Recombinant CFTR expressed in heterologous cells was readily solubilized by digitonin and initially separated from the majority of other cellular proteins by sucrose density gradient centrifugation. CFTR, with two predicted nucleotide binding domains, bound avidly to several triazine dye columns, although elution with MgATP, MgCl2, or high ionic strength buffers was inefficient. CFTR did not bind to either ATP or ADP coupled to agarose. Because CFTR is a glycoprotein we investigated its binding to lectin columns. CFTR bound readily to wheat germ agglutinin, but poorly to Lens culinaris agglutinin. CFTR was enriched 9-10 times when eluted from wheat germ agglutinin with N-acetylglucosamine. This enrichment was tripled if lectin chromatography followed sucrose gradient centrifugation. Our results suggest the combination of sucrose density gradient centrifugation and lectin chromatography would be a satisfactory approach to initial purification of CFTR expressed in heterologous cells.	UNIV IOWA,COLL MED,DEPT INTERNAL MED,HOWARD HUGHES MED INST,500 EMRB,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Howard Hughes Medical Institute; University of Iowa; University of Iowa	WELSH, MJ (corresponding author), UNIV IOWA,COLL MED,DEPT INTERNAL MED,HOWARD HUGHES MED INST,500 EMRB,IOWA CITY,IA 52242, USA.			Ostedgaard, Lynda/0000-0001-7717-3442; Welsh, Michael/0000-0002-1646-6206				AMES GF, 1990, FEMS MICROBIOL REV, V6, P429; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; BLACK ME, 1990, J BIOL CHEM, V265, P17584; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; GOLDFINE ID, 1987, ENDOCR REV, V8, P235, DOI 10.1210/edrv-8-3-235; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HAMILTON SL, 1989, BIOCHEMISTRY-US, V28, P7820, DOI 10.1021/bi00445a044; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; HIGGINS CF, 1990, PHILOS T R SOC B, V326, P353, DOI 10.1098/rstb.1990.0017; HOBSON AC, 1984, P NATL ACAD SCI-BIOL, V81, P7333, DOI 10.1073/pnas.81.23.7333; HSU CM, 1989, J BIOL CHEM, V264, P17349; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCENERY MW, 1984, J BIOL CHEM, V259, P4642; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1979, J BIOL CHEM, V254, P2701; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROSEN BP, 1988, J BIOL CHEM, V263, P3067; ROY SN, 1985, CANCER RES, V45, P3856; SARKADI B, 1992, J BIOL CHEM, V267, P2087; SCOPES RK, 1986, J CHROMATOGR, V376, P131, DOI 10.1016/S0378-4347(00)80830-0; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; THOMPSON ST, 1975, P NATL ACAD SCI USA, V72, P669, DOI 10.1073/pnas.72.2.669	34	20	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					26142	26149						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1281484				2022-12-27	WOS:A1992KD07300083
J	VISKUPIC, E; CAO, YJ; ZHANG, WM; CHENG, C; DEPAOLIROACH, AA; ROACH, PJ				VISKUPIC, E; CAO, YJ; ZHANG, WM; CHENG, C; DEPAOLIROACH, AA; ROACH, PJ			RABBIT SKELETAL-MUSCLE GLYCOGENIN - MOLECULAR-CLONING AND PRODUCTION OF FULLY FUNCTIONAL PROTEIN IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHASE; INITIATION; BIOGENESIS; PHOSPHORYLATION; SEQUENCE; GLUCOSE; WEIGHT; PRIMER	Glycogenin is a self-glucosylating protein involved in the initiation reactions of glycogen synthesis. Initiation occurs in two stages, requiring first the covalent attachment of a glucose residue to Tyr-194 of glycogenin and then elongation to form an oligosaccharide chain. The latter reaction is known to be catalyzed by glycogenin itself. The glycogenin sequence determined from the protein by Campbell and Cohen (Campbell, D. G., and Cohen, P. (1989) Eur. J. Biochem. 185, 119-125) was used to design oligonucleotide probes to screen a rabbit muscle lambdagt11 library. A cDNA was isolated that predicted an amino acid sequence identical to that of Campbell and Cohen, except that Cys residues replaced Ser-88 and Leu-97. Northern analysis indicated a strongly hybridizing message of 1.8 kilobases, present in most tissues including skeletal muscle, but much weaker in kidney and scarcely detectable in liver. A much weaker 3-kilobase message was also detected in muscle. Polymerase chain reaction was used to isolate DNA fragments encoding a portion of glycogenin from rat and cow. The sequence of this segment was >90% identical at the amino acid level across the three species, indicating that glycogenin is a highly conserved protein. Using the pET-8c vector, the glycogenin protein was expressed in Escherichia coli. Incubation of the recombinant glycogenin with UDP-[C-14]glucose and Mn2+ resulted in labeling of the glycogenin protein, indicating that the recombinant glycogenin was enzymatically active and capable of self-glucosylation. Furthermore, after incubation with UDP-glucose, the recombinant glycogenin could serve as a substrate for glycogen synthase, leading to the production of high M(r) polysaccharide. Therefore, production of functional glycogenin did not require the intervention of any other mammalian protein.	INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, 635 BARNHILL DR, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	ROACH, PJ (corresponding author), INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, 635 BARNHILL DR, INDIANAPOLIS, IN 46202 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027221, R37DK027221, P60DK020542, K04DK001690] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK27221, DK20542, DK01690] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARENGO R, 1975, FEBS LETT, V53, P274, DOI 10.1016/0014-5793(75)80035-4; CAMPBELL DG, 1989, EUR J BIOCHEM, V185, P119, DOI 10.1111/j.1432-1033.1989.tb15090.x; COHEN P, 1988, PROC R SOC SER B-BIO, V234, P115, DOI 10.1098/rspb.1988.0040; Kennedy L., 1985, MEMBRANES MUSCLE, P65; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KRISMAN CR, 1972, BIOCHEM BIOPH RES CO, V46, P1206, DOI 10.1016/S0006-291X(72)80103-7; LARNER J, 1976, MOL CELL BIOCHEM, V12, P131, DOI 10.1007/BF01741711; LOMAKO J, 1991, FEBS LETT, V279, P223, DOI 10.1016/0014-5793(91)80154-U; LOMAKO J, 1990, BIOCHEM INT, V21, P251; LOMAKO J, 1988, FASEB J, V2, P3097, DOI 10.1096/fasebj.2.15.2973423; LOMAKO J, 1990, FEBS LETT, V268, P8, DOI 10.1016/0014-5793(90)80959-M; LOMAKO J, 1992, CARBOHYD RES, V227, P331, DOI 10.1016/0008-6215(92)85082-B; NEWGARD CB, 1986, P NATL ACAD SCI USA, V83, P8132, DOI 10.1073/pnas.83.21.8132; PITCHER J, 1988, EUR J BIOCHEM, V176, P391, DOI 10.1111/j.1432-1033.1988.tb14294.x; PITCHER J, 1987, EUR J BIOCHEM, V169, P497, DOI 10.1111/j.1432-1033.1987.tb13637.x; PREISS J, 1989, ADV MICROB PHYSIOL, V30, P183; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; RODRIGUEZ IR, 1988, ARCH BIOCHEM BIOPHYS, V260, P628, DOI 10.1016/0003-9861(88)90491-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMYTHE C, 1989, EUR J BIOCHEM, V183, P205, DOI 10.1111/j.1432-1033.1989.tb14914.x; SMYTHE C, 1991, EUR J BIOCHEM, V200, P625, DOI 10.1111/j.1432-1033.1991.tb16225.x; SMYTHE C, 1988, EMBO J, V7, P2681, DOI 10.1002/j.1460-2075.1988.tb03121.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAN AWH, 1979, BIOCHIM BIOPHYS ACTA, V582, P543, DOI 10.1016/0304-4165(79)90146-6; WHELAN WJ, 1986, BIOESSAYS, V5, P136, DOI 10.1002/bies.950050312; ZHANG WM, 1989, FASEB J, V3, P2532, DOI 10.1096/fasebj.3.13.2509275	26	54	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25759	25763						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1281472				2022-12-27	WOS:A1992KD07300029
J	IMOKAWA, G; YADA, Y; MIYAGISHI, M				IMOKAWA, G; YADA, Y; MIYAGISHI, M			ENDOTHELINS SECRETED FROM HUMAN KERATINOCYTES ARE INTRINSIC MITOGENS FOR HUMAN MELANOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE INTESTINAL CONTRACTOR; MALIGNANT-MELANOMA CELLS; FIBROBLAST GROWTH-FACTOR; SMOOTH-MUSCLE CELLS; ALLERGIC CONTACT-DERMATITIS; GLYCOSYLATION INHIBITORS; VASOCONSTRICTOR PEPTIDE; SIGNAL TRANSDUCTION; NUCLEOTIDE-SEQUENCE; I-125 ENDOTHELIN-1	We recently demonstrated that human melanocyte proliferation and differentiation could be stimulated by endothelin (ET) derivatives via a receptor-mediated signal transduction pathway (Yada, Y., Higuchi, K., and Imokawa, G. (1991) J. Biol. Chem. 266, 18352-18357). We show here that the growth factors for human melanocytes are produced and secreted by the surrounding cells, namely human keratinocytes for ET-1 and Big-ET-1. Northern blots have revealed the presence of ET-1 gene transcripts in proliferating human keratinocytes. The ET-1 production by human keratinocytes increased after irradiation with ultraviolet B (UVB) in a dose-dependent manner, accompanied by the significant secretion of interleukin 1alpha (IL-1alpha). Among the cytokines related to UVB-induced cellular reactions and keratinocyte growth, only IL-1alpha and -1beta stimulated the secretion of ET-1 and Big-ET-1 but not of ET-3 and Big-ET-3 in a time-dependent manner. Northern blots for IL-1alpha-stimulated or UVB-exposed human keratinocytes revealed that production of ET-1 gene transcripts markedly increased (by about 300 or 1,200%) with constant levels of beta-actin gene transcripts. In a parallel study, the medium conditioned by UVB-exposed human keratinocytes elicited a significant anti-ET-1 antibody-suppressible increase in DNA synthesis by cultured human melanocytes in a UV dose-dependent manner, which was associated with a marked and rapid (80 s) increase in the intracellular calcium level upon incubation with human melanocytes. These studies suggest that ETs produced and secreted by keratinocytes play an essential role in the maintenance of melanocyte proliferation and UV hyperpigmentation in the epidermis.			IMOKAWA, G (corresponding author), KAO CORP,TOCHIGI RES LAB,ICKIKAIMACHI 2606,TOCHIGI 32134,JAPAN.		Miyagishi, Makoto/L-8174-2016	Miyagishi, Makoto/0000-0001-7654-3616				ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVENPORT AP, 1989, J CARDIOVASC PHARM, V13, pS166, DOI 10.1097/00005344-198900135-00045; FABREGAT I, 1990, BIOCHEM BIOPH RES CO, V167, P161, DOI 10.1016/0006-291X(90)91745-E; FU T, 1990, BIOCHEM J, V272, P71, DOI 10.1042/bj2720071; GAHRING L, 1984, P NATL ACAD SCI-BIOL, V81, P1198, DOI 10.1073/pnas.81.4.1198; GORDON PR, 1989, J INVEST DERMATOL, V92, P565, DOI 10.1111/1523-1747.ep12709595; HALABAN R, 1988, J CELL BIOL, V107, P1611, DOI 10.1083/jcb.107.4.1611; HALABAN R, 1991, CANCER METAST REV, V10, P129, DOI 10.1007/BF00049410; Halaban R, 1988, PIGM CELL RES, V1, P18; HEARING VJ, 1976, BIOCHEM J, V157, P549, DOI 10.1042/bj1570549; IMOKAWA G, 1981, BRIT J DERMATOL, V104, P169, DOI 10.1111/j.1365-2133.1981.tb00041.x; IMOKAWA G, 1986, ARCH DERMATOL RES, V278, P352, DOI 10.1007/BF00418162; IMOKAWA G, 1984, J INVEST DERMATOL, V83, P196, DOI 10.1111/1523-1747.ep12263562; IMOKAWA G, 1990, J INVEST DERMATOL, V95, P39, DOI 10.1111/1523-1747.ep12873289; IMOKAWA G, 1982, CANCER RES, V42, P1994; IMOKAWA G, 1987, J INVEST DERMATOL, V89, P540, DOI 10.1111/1523-1747.ep12461181; IMOKAWA G, 1992, IN PRESS J INVEST DE; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; ISSEROFF RR, 1983, J INVEST DERMATOL, V80, P217, DOI 10.1111/1523-1747.ep12534464; ITOH Y, 1988, FEBS LETT, V231, P440, DOI 10.1016/0014-5793(88)80867-6; JIMBOW K, 1982, J INVEST DERMATOL, V78, P108, DOI 10.1111/1523-1747.ep12505758; KOSEKI C, 1989, J CARDIOVASC PHARM, V13, pS153, DOI 10.1097/00005344-198900135-00040; LERNER AB, 1950, PHYSIOL REV, V30, P91, DOI 10.1152/physrev.1950.30.1.91; NAKAKI T, 1989, BIOCHEM BIOPH RES CO, V158, P880, DOI 10.1016/0006-291X(89)92804-0; NEUSER D, 1989, J CARDIOVASC PHARM, V13, pS67, DOI 10.1097/00005344-198900135-00016; OHNISHISUZAKI A, 1990, BIOCHEM BIOPH RES CO, V166, P608, DOI 10.1016/0006-291X(90)90852-E; PAWELEK JM, 1982, AM SCI, V70, P136; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SAIDA K, 1989, J BIOL CHEM, V264, P14613; SIMONSON MS, 1989, J CLIN INVEST, V83, P708, DOI 10.1172/JCI113935; SUPATTAPONE S, 1989, BIOCHEM BIOPH RES CO, V165, P1115, DOI 10.1016/0006-291X(89)92718-6; WILLIAMS DA, 1985, NATURE, V318, P558, DOI 10.1038/318558a0; YAAR M, 1991, J INVEST DERMATOL, V7, P611; YADA Y, 1989, BIOCHEM BIOPH RES CO, V163, P1517, DOI 10.1016/0006-291X(89)91152-2; YADA Y, 1991, J BIOL CHEM, V266, P18352; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	38	318	332	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24675	24680						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1280264				2022-12-27	WOS:A1992KA26300079
J	VARELAECHAVARRIA, A; GARVEY, N; PRESTON, BD; DOUGHERTY, JP				VARELAECHAVARRIA, A; GARVEY, N; PRESTON, BD; DOUGHERTY, JP			COMPARISON OF MOLONEY MURINE LEUKEMIA-VIRUS MUTATION-RATE WITH THE FIDELITY OF ITS REVERSE-TRANSCRIPTASE INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; DEPENDENT DNA POLYMERASE; ESCHERICHIA-COLI; RETROVIRAL DNA; PHOSPHOTRANSFERASE GENE; NUCLEAR EXTRACTS; SARCOMA-VIRUS; CELL-LINES; REPLICATION; SEQUENCE	The role of Moloney murine leukemia virus (MoMLV) reverse transcriptase (RT) in the generation of base substitution mutations during retroviral replication was analyzed. To that effect, the in vitro fidelity of the MoMLV RT was compared to the rate of base substitution mutations occurring during the replication of an MoMLV-based retroviral vector. Using the vector in an amber reversion assay, the base substitution mutation rate at a single locus was found to be 2 x 10(-6)/base pair in one cycle of vector virus replication. Analysis of the fidelity of the purified RT using the same template sequence revealed that, of the two mispairs (A.C and T.G) that would lead to reversion of the amber codon during replication, A.C occurs at a rate of 4.0 x 10(-6), and T.G occurs at a rate of 0.7 x 10(-4). While the rate of formation of A.C is very similar to the vector mutation rate, the rate of formation of T.G is more than 30 times higher. This discrepancy in rates suggests that there are other elements in the infected cells that contribute to the fidelity of viral replication.	RUTGERS STATE UNIV, COLL PHARM, CANC LAB, PISCATAWAY, NJ 08854 USA	Rutgers State University New Brunswick	VARELAECHAVARRIA, A (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT MOLEC GENET & MICROBIOL, PISCATAWAY, NJ 08854 USA.				NATIONAL CANCER INSTITUTE [R29CA050777, R29CA048174] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES005022] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA48174, 5 R29 CA50777-03] Funding Source: Medline; NIEHS NIH HHS [P30 ES05022] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSON RP, 1986, ACCURACY MOL PROCESS, P159; ARECCO A, 1988, MUTAT RES, V200, P165, DOI 10.1016/0027-5107(88)90079-6; BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BOWERMAN B, 1989, GENE DEV, V3, P469, DOI 10.1101/gad.3.4.469; Coffin J. M., 1990, Applied Virology Research, V2, P11; DICKSON C, 1984, RNA TUMOR VIRUSES, V1, P513; DOUGHERTY JP, 1987, P NATL ACAD SCI USA, V84, P1197, DOI 10.1073/pnas.84.5.1197; DOUGHERTY JP, 1988, J VIROL, V62, P2817, DOI 10.1128/JVI.62.8.2817-2822.1988; FERSHT A, 1985, ENZYME STRUCTURE MEC, P98; FUETTERER J, 1987, TRENDS BIOCHEM SCI, V12, P92, DOI 10.1016/0968-0004(87)90044-2; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; GARVEY N, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P307; GERARD GF, 1986, DNA-J MOLEC CELL BIO, V5, P271, DOI 10.1089/dna.1986.5.271; GOJOBORI T, 1985, P NATL ACAD SCI USA, V82, P4198, DOI 10.1073/pnas.82.12.4198; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; JI JP, 1992, BIOCHEMISTRY-US, V31, P954, DOI 10.1021/bi00119a002; JORGENSEN RA, 1979, MOL GEN GENET, V177, P65, DOI 10.1007/BF00267254; KATZ RA, 1990, ANNU REV GENET, V24, P409, DOI 10.1146/annurev.ge.24.120190.002205; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; KORNBERG A, 1992, DNA REPLICATION, P47; KUNKEL TA, 1988, BIOCHIM BIOPHYS ACTA, V951, P1, DOI 10.1016/0167-4781(88)90020-6; KUNKEL TA, 1986, J BIOL CHEM, V261, P3610; LEIDER JM, 1988, J VIROL, V62, P3084, DOI 10.1128/JVI.62.9.3084-3091.1988; MANNS A, 1991, NUCLEIC ACIDS RES, V19, P533, DOI 10.1093/nar/19.3.533; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MUN BJ, 1991, MOL CELL BIOL, V11, P20, DOI 10.1128/MCB.11.1.20; NORTH TW, 1980, J BIOL CHEM, V255, P6640; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6019, DOI 10.1073/pnas.87.16.6019; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; RICCHETTI M, 1990, EMBO J, V9, P1583, DOI 10.1002/j.1460-2075.1990.tb08278.x; ROBERTS JD, 1989, MOL CELL BIOL, V9, P469, DOI 10.1128/MCB.9.2.469; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; ROTH MJ, 1985, J BIOL CHEM, V260, P9326; ROTH MJ, 1989, CELL, V58, P47, DOI 10.1016/0092-8674(89)90401-7; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; STECK FT, 1966, VIROLOGY, V29, P628, DOI 10.1016/0042-6822(66)90287-X; TAKEUCHI Y, 1988, J VIROL, V62, P3900, DOI 10.1128/JVI.62.10.3900-3902.1988; TANAKA K, 1984, ANAL BIOCHEM, V139, P35, DOI 10.1016/0003-2697(84)90386-5; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; VARMUS H, 1984, RNA TUMOR VIRUSES, V1, P369; WABL M, 1985, P NATL ACAD SCI USA, V82, P479, DOI 10.1073/pnas.82.2.479; WEBER J, 1989, NUCLEIC ACIDS RES, V17, P1379, DOI 10.1093/nar/17.4.1379; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	55	61	63	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24681	24688						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1280265				2022-12-27	WOS:A1992KA26300080
J	SHARP, AH; SNYDER, SH; NIGAM, SK				SHARP, AH; SNYDER, SH; NIGAM, SK			INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS - LOCALIZATION IN EPITHELIAL TISSUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; SUBCELLULAR-DISTRIBUTION; TRISPHOSPHATE RECEPTOR; BINDING-PROTEINS; PLASMA-MEMBRANE; PURKINJE-CELLS; RAT-LIVER; CALCIUM; EXPRESSION; PANCREAS	Using a Polyclonal antiserum raised against the inositol 1,4,5-trisphosphate receptor (IP3R) purified from rat cerebellum, we examined the subcellular distribution of IP3R in canine pancreatic homogenates. IP3R was present primarily in a smooth microsomal fraction (low density), a (high density) rough microsomal (RM) fraction previously shown to consist of highly purified rough endoplasmic reticulum (RER) vesicles, and, to a much lesser extent, in an intermediate density microsomal fraction which did not contain markers for RER or plasma membrane. When the RM fraction was subjected to isopycnic centrifugation on sucrose gradients, IP3R equilibrated at high sucrose densities. When ribosomes were extracted from the RM fraction by treatment with puromycin/high salt, IP3R equilibrated at considerably lighter sucrose densities. This shift in density indicated that IP3R which was present in the RM fraction is associated with the RER. Because of a Significant amount of IP3R fractionating into the smooth microsomal fraction (which contains plasma membrane, among other "smooth" membranes) and a considerable amount of IP3R present in the nuclear pellet which is also enriched in plasma membrane, we examined the possibility that IP3R may be present in plasma membrane. Further subfractionation of a crude plasma membrane pellet from rat liver revealed that IP3R coenriched with a plasma membrane marker and strongly suggested an association of IP3R with plasma membrane. The issue of why the same receptor is found in multiple biochemically and morphologically distinct membrane fractions is discussed in terms of the possibility of RER subcompartmentalization and IP3R subtypes. The fractionation pattern of IP3R in pancreas is significantly different from that previously reported for calcium (Ca2+)-binding proteins and an intracellular Ca-ATPase (Nigam, S. K. and Towers, T. (1990) J. Cell Biol. 111, 197-200), raising questions as to links between these latter proteins and IP3 sensitive Ca2+ pools. Nevertheless, although the fractionation patterns are different, all of these proteins are clearly associated with the RER.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,725 N WOLFE ST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,HARVARD CTR KIDNEY DIS,BOSTON,MA 02115	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital					NIDA NIH HHS [DA-00074] Funding Source: Medline; NIMH NIH HHS [MH-18501, MH-09953] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH018501, R01MH018501, F32MH009953] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADELMAN MR, 1973, J CELL BIOL, V56, P206, DOI 10.1083/jcb.56.1.206; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BLOBEL G, 1967, J MOL BIOL, V26, P279, DOI 10.1016/0022-2836(67)90297-5; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOLENDER RP, 1974, J CELL BIOL, V61, P269, DOI 10.1083/jcb.61.2.269; CAMPBELL KP, 1980, BIOCHIM BIOPHYS ACTA, V602, P97, DOI 10.1016/0005-2736(80)90293-X; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GUILLEMETTE G, 1988, J BIOL CHEM, V263, P4541; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LYTTON J, 1992, IN PRESS CURR OPIN C, V4; MAEDA N, 1989, DEV BIOL, V133, P67, DOI 10.1016/0012-1606(89)90297-2; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; NIGAM SK, 1990, J CELL BIOL, V111, P197, DOI 10.1083/jcb.111.1.197; NIGAM SK, 1990, P NATL ACAD SCI USA, V87, P1296, DOI 10.1073/pnas.87.4.1296; NIGAM SK, 1989, J BIOL CHEM, V264, P16927; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; ROSSIER MF, 1991, BIOCHEM J, V274, P643, DOI 10.1042/bj2740643; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; SCHULZ I, 1989, CELL CALCIUM, V10, P325, DOI 10.1016/0143-4160(89)90058-4; SONG CS, 1969, J CELL BIOL, V41, P124, DOI 10.1083/jcb.41.1.124; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERMA A, 1990, BIOCHEM BIOPH RES CO, V172, P811, DOI 10.1016/0006-291X(90)90747-B; VOLPE P, 1988, P NATL ACAD SCI USA, V85, P1091, DOI 10.1073/pnas.85.4.1091; WIBO M, 1981, J CELL BIOL, V89, P456, DOI 10.1083/jcb.89.3.456; WORLEY PF, 1987, J BIOL CHEM, V262, P12132	35	66	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7444	7449						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1313801				2022-12-27	WOS:A1992HN48500037
J	ASANO, S; KAMIYA, S; TAKEGUCHI, N				ASANO, S; KAMIYA, S; TAKEGUCHI, N			THE ENERGY TRANSDUCTION MECHANISM IS DIFFERENT AMONG P-TYPE ION-TRANSPORTING ATPASES - ACETYL PHOSPHATE CAUSES UNCOUPLING BETWEEN HYDROLYSIS AND ION-TRANSPORT IN H+,K+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SARCOPLASMIC-RETICULUM; FLUORESCEIN ISOTHIOCYANATE; GASTRIC-MUCOSA; CONFORMATIONAL TRANSITIONS; ADENOSINE TRIPHOSPHATASES; COMPLEMENTARY-DNA; ATP HYDROLYSIS; + K+)-ATPASE; VESICLES	H+,K+-ATPase, Na+,K+-ATPase, and Ca2+-ATPase belong to the P-type ATPase group. Their molecular mechanisms of energy transduction have been thought to be similar until now. Ca2+-ATPase and Na+,K+-ATPase are phosphorylated from both ATP and acetyl phosphate (ACP) and dephosphorylated, resulting in active ion transport. However, we found that H+,K+-ATPase did not transport proton nor K+ when ACP was used as a substrate, resulting in uncoupling between energy and ion transport. ACP bound competitively to the ATP-binding site of H+,K+-ATPase. The hydrolysis of ACP by H+,K+-ATPase was stimulated by cytosolic K+, the half-maximal stimulating K+ concentration (K0.5) being 2.5 mM, whereas the hydrolysis of ATP was stimulated by luminal K+, the K0.5 being 0.2 mM. Furthermore, during the phosphorylation from ACP in the absence of K+, the fluorescence intensity of H+,K+-ATPase labeled with fluorescein isothiocyanate increased, but those of Na+,K+-ATPase and Ca2+-ATPase decreased. These results indicate that phosphorylated intermediates of H+,K+-ATPase formed from ACP are not rich in energy and that there is a striking difference(s) in the mechanism of energy transduction between H+,K+-ATPase and other cation-transporting ATPases.			ASANO, S (corresponding author), TOYAMA MED & PHARMACEUT UNIV, FAC PHARMACEUT SCI, SUGITANI, TOYAMA 93001, JAPAN.			Asano, Shinji/0000-0003-1443-8970				ASANO S, 1990, J BIOL CHEM, V265, P22167; ASANO S, 1989, J BIOCHEM-TOKYO, V106, P1074, DOI 10.1093/oxfordjournals.jbchem.a122967; BEAUGE L, 1984, BIOCHIM BIOPHYS ACTA, V772, P411, DOI 10.1016/0005-2736(84)90159-7; BERBERIAN G, 1991, BIOCHIM BIOPHYS ACTA, V1063, P217, DOI 10.1016/0005-2736(91)90374-H; BODLEY AL, 1987, J BIOL CHEM, V262, P13997; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CAMPOS M, 1988, BIOCHIM BIOPHYS ACTA, V940, P43, DOI 10.1016/0005-2736(88)90006-5; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; DEMEIS L, 1969, BIOCHIM BIOPHYS ACTA, V172, P340; DEMEIS L, 1969, J BIOL CHEM, V244, P3733; DUDDING WF, 1971, BIOCHIM BIOPHYS ACTA, V241, P650, DOI 10.1016/0005-2736(71)90062-9; FALLER LD, 1991, BIOCHEMISTRY-US, V30, P3503, DOI 10.1021/bi00228a022; FARLEY RA, 1985, J BIOL CHEM, V260, P3899; FERREIRA ST, 1988, J BIOL CHEM, V263, P9973; FRIEDMAN Z, 1970, FEBS LETT, V11, P69, DOI 10.1016/0014-5793(70)80494-X; GANSER AL, 1973, BIOCHIM BIOPHYS ACTA, V307, P169, DOI 10.1016/0005-2736(73)90035-7; INESI G, 1971, SCIENCE, V171, P901, DOI 10.1126/science.171.3974.901; JACKSON RJ, 1983, BIOCHIM BIOPHYS ACTA, V731, P9, DOI 10.1016/0005-2736(83)90391-7; KASAI M, 1976, J BIOCHEM-TOKYO, V79, P1053, DOI 10.1093/oxfordjournals.jbchem.a131147; KAWAKAMI K, 1985, NATURE, V316, P733, DOI 10.1038/316733a0; KIRLEY TL, 1985, BIOCHEM BIOPH RES CO, V130, P732, DOI 10.1016/0006-291X(85)90477-2; LEE J, 1974, BIOCHEM BIOPH RES CO, V60, P825, DOI 10.1016/0006-291X(74)90315-5; Lehninger A.L, 1975, BIOCHEMISTRY-US, P387; LIPMANN F, 1945, J BIOL CHEM, V159, P21; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MAEDA M, 1988, BIOCHEM BIOPH RES CO, V157, P203, DOI 10.1016/S0006-291X(88)80033-0; MEIS LD, 1971, J BIOL CHEM, V246, P4759; NAKAMURA Y, 1978, J BIOCHEM-TOKYO, V83, P571, DOI 10.1093/oxfordjournals.jbchem.a131945; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PICK U, 1981, FEBS LETT, V123, P131, DOI 10.1016/0014-5793(81)80036-1; PICK U, 1981, FEBS LETT, V123, P127, DOI 10.1016/0014-5793(81)80035-X; RABON EC, 1990, J BIOL CHEM, V265, P19594; REPHAELI A, 1986, J BIOL CHEM, V261, P6248; ROSSI B, 1979, J BIOL CHEM, V254, P2302; SACHS G, 1976, J BIOL CHEM, V251, P7690; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; STADTMAN ER, 1957, METHOD ENZYMOL, V3, P228, DOI 10.1016/S0076-6879(57)03379-0; STEKHOVEN FS, 1981, PHYSIOL REV, V61, P1; TADA M, 1978, PHYSIOL REV, V58, P1; TAKAKUWA Y, 1984, J BIOCHEM-TOKYO, V95, P543, DOI 10.1093/oxfordjournals.jbchem.a134637; TAKEGUCHI N, 1983, J BIOL CHEM, V258, P3094; TAKEGUCHI N, 1986, J BIOL CHEM, V261, P2560; TANIGUCHI K, 1988, J BIOL CHEM, V263, P12943; WALDERHAUG MO, 1985, J BIOL CHEM, V260, P3852; WALLMARK B, 1980, J BIOL CHEM, V255, P5313; WALLMARK B, 1979, J BIOL CHEM, V254, P1899; YODA A, 1970, BIOCHEM BIOPH RES CO, V40, P880, DOI 10.1016/0006-291X(70)90985-X	49	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6590	6595						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1313014				2022-12-27	WOS:A1992HM05300024
J	BOEHMER, PE; EMMERSON, PT				BOEHMER, PE; EMMERSON, PT			THE RECB SUBUNIT OF THE ESCHERICHIA-COLI RECBCD ENZYME COUPLES ATP HYDROLYSIS TO DNA UNWINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; HELICASE-II; PROTEINS; GENE; RECONSTITUTION; PHAGE	The RecB subunit of the Escherichia coli RecBCD enzyme has previously been reported to possess DNA-dependent ATPase activity (Hickson, I. D., Robson, C. N., Atkinson, K. E., Hutton, L., and Emmerson, P. T. (1985) J. Biol. Chem. 260, 1224-1229). Here we demonstrate that a specific interaction between RecB protein and ATP can also be shown by photoaffinity labeling with the ATP analogue 8-azido-ATP. Furthermore, the capacity of the RecB protein to support ATP hydrolysis varies with the structure and length of the DNA cofactor. Single-stranded linear and circular DNA are markedly better in promoting ATP hydrolysis than duplex DNA. The purified RecB protein can function as a DNA helicase, displacing oligonucleotides annealed to viral M13 DNA in an ATP-dependent and orientation-specific manner.	UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT BIOCHEM & GENET,NEWCASTLE TYNE NE2 4HH,ENGLAND	Newcastle University - UK				Boehmer, Paul/0000-0003-4479-0529				BOEHMER PE, 1991, GENE, V102, P1, DOI 10.1016/0378-1119(91)90529-K; BRAEDT G, 1989, P NATL ACAD SCI USA, V86, P871, DOI 10.1073/pnas.86.3.871; CRUTE JJ, 1988, NUCLEIC ACIDS RES, V16, P6585, DOI 10.1093/nar/16.14.6585; FINCH PW, 1986, NUCLEIC ACIDS RES, V14, P8583, DOI 10.1093/nar/14.21.8583; FINCH PW, 1986, NUCLEIC ACIDS RES, V14, P8573, DOI 10.1093/nar/14.21.8573; HICKSON ID, 1985, J BIOL CHEM, V260, P1224; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; JULIN DA, 1987, J BIOL CHEM, V262, P9044; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEATHERBARROW RJ, 1987, ENZFITTER SOFTWARE B; LIEBERMAN RP, 1974, P NATL ACAD SCI USA, V71, P4816, DOI 10.1073/pnas.71.12.4816; Maniatis T., 1982, MOL CLONING; MATSON SW, 1987, J BIOL CHEM, V262, P2066; MATSON SW, 1986, J BIOL CHEM, V261, P169; MILLER H, 1987, METHOD ENZYMOL, V152, P145; ROMAN LJ, 1989, J BIOL CHEM, V264, P18340; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2873, DOI 10.1021/bi00433a019; ROMAN LJ, 1991, P NATL ACAD SCI USA, V88, P3367, DOI 10.1073/pnas.88.8.3367; SMITH GR, 1988, MICROBIOL REV, V52, P1; TAYLOR AF, 1988, GENETIC RECOMBINATIO, P231; TIPTON KF, 1979, COMP BIOCH, V2, P327; TWIGG AJ, 1980, NATURE, V283, P216, DOI 10.1038/283216a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	24	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4981	4987						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1311326				2022-12-27	WOS:A1992HF64200102
J	BODE, AM; FOSTER, JD; NORDLIE, RC				BODE, AM; FOSTER, JD; NORDLIE, RC			GLYCONEOGENESIS FROM L-PROLINE INVOLVES METABOLITE INHIBITION OF THE GLUCOSE-6-PHOSPHATASE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GLYCOGEN-SYNTHESIS; 3-MERCAPTOPICOLINIC ACID; INORGANIC PYROPHOSPHATE; GLUCOSE-UPTAKE; AMINO-ACIDS; LIVER; RAT; STIMULATION; HEPATOCYTES; PHOSPHATE	L-Proline's glycogenic action is unlike that of other amino acids in that it produces effects beyond those explainable by a simple increase in osmolarity (Baquet, A., Hue, L., Meijer, A. J., van Woerkom, G. M., and Plomp, P. J. A. M. (1990) J. Biol. Chem. 265, 955-959). We postulate that this effect may relate to inhibition of hepatic glucose-6-P hydrolysis by a proline-derived metabolite. We tested this hypothesis with isolated livers from rats fasted 48 h which were perfused with L-proline or L-glutamine. Net glucose and net glycogen production and levels of glucose-6-P and certain other hepatic metabolites were measured. The data obtained support our hypothesis by demonstrating fundamental differences in the metabolic fates of proline and glutamine in the liver. Both pass through a-ketoglutarate in the initial stage of gluconeogenesis, but proline supports hepatic glycogen formation while glutamine does not. The concomitant increase in hepatic glucose-6-P and proline-associated glyconeogenesis suggests that inhibition of glucose-6-P hydrolysis by a proline-derived metabolite may divert glucose-6-P produced from proline from glucose production and to glycogen synthesis. This conclusion is supported by the effects of perfusions with and without proline (3-mercaptopicolinate present) on (a) glyconeogenesis and glucose formation from dihydroxyacetone, (b) net glucose uptake and glycogen formation with 30 mM glucose as substrate, and (c) glucose production from endogenous glycogen in perfused livers from fed rats.	UNIV N DAKOTA,SCH MED,DEPT BIOCHEM & MOLEC BIOL,IRELAND RES LAB,GRAND FORKS,ND 58202	University of North Dakota Grand Forks					NIDDK NIH HHS [DK07141] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK007141] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVARES FL, 1977, J BIOL CHEM, V252, P8404; ARION WJ, 1980, J BIOL CHEM, V255, P396; BAQUET A, 1990, J BIOL CHEM, V265, P955; BICKERSTAFF G F, 1980, Biochemical Society Transactions, V8, P389; CHEN KS, 1985, J BIOL CHEM, V260, P4683; COHEN PP, 1964, MANOMETRIC TECHNIQUE, P149; COOK GA, 1978, ANAL BIOCHEM, V91, P557, DOI 10.1016/0003-2697(78)90543-2; DITULLIO NW, 1974, BIOCHEM J, V138, P387, DOI 10.1042/bj1380387; DIXON WJ, 1957, INTRO STATISTICAL AN, P19; FOSTER JD, 1992, IN PRESS BIOCH BIOPH; HEMS DA, 1972, BIOCHEM J, V129, P529, DOI 10.1042/bj1290529; Hohorst H.-J., 1965, METHOD ENZYMAT AN, P134, DOI DOI 10.1016/B978-0-12-395630-9.50025-6; JOMAINBAUM M, 1976, J BIOL CHEM, V251, P37; KATZ J, 1976, P NATL ACAD SCI USA, V73, P3433, DOI 10.1073/pnas.73.10.3433; KATZ J, 1984, J CLIN INVEST, V74, P1901, DOI 10.1172/JCI111610; Keppler D, 1974, METHOD ENZYMAT AN, V4, P1127; MERSMANN HJ, 1967, P NATL ACAD SCI USA, V58, P1688, DOI 10.1073/pnas.58.4.1688; MURRAY RK, 1990, HARPERS BIOCH, P284; Nordlie R C, 1974, Curr Top Cell Regul, V8, P33; NORDLIE RC, 1980, J BIOL CHEM, V255, P1834; NORDLIE RC, 1966, METHOD ENZYMOL, V9, P619; PLOMP PJAM, 1990, EUR J BIOCHEM, V191, P237, DOI 10.1111/j.1432-1033.1990.tb19115.x; ROGNSTAD R, 1985, BIOCHEM BIOPH RES CO, V130, P229, DOI 10.1016/0006-291X(85)90406-1; SMITH EL, 1983, PRINCIPLES BIOCH GEN, P646; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUKALSKI KA, 1986, J BIOL CHEM, V261, P6860; GOD PERID REAGENT KI	27	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					2860	2863						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1310675				2022-12-27	WOS:A1992HD15400007
J	KANG, S; WOHLRAB, F; WELLS, RD				KANG, S; WOHLRAB, F; WELLS, RD			METAL-IONS CAUSE THE ISOMERIZATION OF CERTAIN INTRAMOLECULAR TRIPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOPURINE-HOMOPYRIMIDINE SEQUENCES; UNUSUAL DNA STRUCTURES; B-DNA; SUPERHELICAL DENSITIES; SUPERCOILED PLASMIDS; H-DNA; CRUCIFORM; CONFORMATIONS; OLIGOPURINE; SPECIFICITY	The influence of cations on the capacity of five oligopurine.oligopyrimidine mirror repeat sequences to adopt intramolecular triplexes (the usual H-y3 isomer and/or the rare H-y5 isomer) in recombinant plasmids was investigated. Unexpectedly, the presence of certain metal ions (magnesium, zinc, manganese, and calcium) stabilized the (GAA)4TTCGC(GAA)4 insert in the rare H-y5 when cloned into either of two different sequence backgrounds. Alternatively, either shortening or lengthening the sequence at the central interruption, which becomes the loop of the triplex, led to the formation of the canonical H-y3 under all conditions tested. Similarly, other oligopurine.oligopyrimidine mirror repeat sequences (i.e. (GAA)8 or (GGA)8) formed only the H-y3 under all experimental conditions. All triplexes were stabilized by negative supercoiling at pH 5.0; chemical probe and primer extension analyses served as critical structural tools. Hence, the nature of the central interruption sequence (the loop) of the mirror repeat is important for the stabilization of the H-y5. This region may be important for metal ion binding in the initial stages of triplex formation and thus may play a critical role in determining which isomer is formed. The possible biological role of a DNA sequence adopting three different conformations is discussed.	UNIV ALABAMA,SCH MED,DEPT BIOCHEM,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,DEPT BIOCHEM,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030822] Funding Source: NIH RePORTER; NCI NIH HHS [CA13148] Funding Source: Medline; NIGMS NIH HHS [GM30822] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNUES J, 1989, EMBO J, V8, P2087, DOI 10.1002/j.1460-2075.1989.tb03617.x; BERNUES J, 1990, NUCLEIC ACIDS RES, V18, P4067, DOI 10.1093/nar/18.14.4067; CASTELL SE, 1986, NUCLEIC ACIDS RES, V14, P7213, DOI 10.1093/nar/14.18.7213; COLLIER DA, 1990, J BIOL CHEM, V265, P10653; DUCKETT DR, 1990, EMBO J, V9, P583, DOI 10.1002/j.1460-2075.1990.tb08146.x; FURLONG JC, 1989, BIOCHEMISTRY-US, V28, P2009, DOI 10.1021/bi00431a008; GREAVES DR, 1985, J MOL BIOL, V185, P461, DOI 10.1016/0022-2836(85)90064-6; HANVEY JC, 1988, J BIOL CHEM, V263, P7386; HANVEY JC, 1989, J BIOL CHEM, V264, P5950; HOLBROOK SR, 1977, NUCLEIC ACIDS RES, V4, P2811, DOI 10.1093/nar/4.8.2811; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; KANG DS, 1985, J BIOL CHEM, V260, P7783; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; LYAMICHEV VI, 1986, J BIOMOL STRUCT DYN, V3, P667, DOI 10.1080/07391102.1986.10508454; LYAMICHEV VI, 1985, J BIOMOL STRUCT DYN, V3, P327, DOI 10.1080/07391102.1985.10508420; MANIATIS T, 1982, MOL CLONING LABORATO, P90; MCCLELLAN JA, 1987, J MOL BIOL, V197, P707, DOI 10.1016/0022-2836(87)90477-3; MCLEAN MJ, 1987, NUCLEIC ACIDS RES, V15, P6917, DOI 10.1093/nar/15.17.6917; MCLEAN MJ, 1986, P NATL ACAD SCI USA, V83, P5884, DOI 10.1073/pnas.83.16.5884; PARNIEWSKI P, 1989, NUCLEIC ACIDS RES, V17, P617, DOI 10.1093/nar/17.2.617; PULLEYBLANK DE, 1985, CELL, V42, P271, DOI 10.1016/S0092-8674(85)80122-7; RAJAGOPALAN M, 1990, J BIOL CHEM, V265, P17294; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SHIMIZU M, 1989, J BIOL CHEM, V264, P5944; SHIMIZU M, 1990, BIOCHEMISTRY-US, V29, P4704, DOI 10.1021/bi00471a027; SINGLETON CK, 1983, J BIOL CHEM, V258, P7661; SINGLETON CK, 1982, ANAL BIOCHEM, V122, P253, DOI 10.1016/0003-2697(82)90277-9; SULLIVAN KM, 1987, J MOL BIOL, V193, P397, DOI 10.1016/0022-2836(87)90227-0; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; VOJTISKOVA M, 1987, J BIOMOL STRUCT DYN, V5, P283, DOI 10.1080/07391102.1987.10506394; WELLS RD, 1988, J BIOL CHEM, V263, P1095; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; Wells RD, 1987, UNUSUAL DNA STRUCTUR; WOHLRAB F, 1989, J BIOL CHEM, V264, P8207; ZACHARIAS W, 1988, P NATL ACAD SCI USA, V85, P7069, DOI 10.1073/pnas.85.19.7069	36	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1259	1264						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1309767				2022-12-27	WOS:A1992GY96000090
J	KATI, WM; JOHNSON, KA; JERVA, LF; ANDERSON, KS				KATI, WM; JOHNSON, KA; JERVA, LF; ANDERSON, KS			MECHANISM AND FIDELITY OF HIV REVERSE-TRANSCRIPTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE-I KLENOW; STEADY-STATE KINETICS; DNA-POLYMERASE; ESCHERICHIA-COLI; RNASE-H; INHIBITION; EXPRESSION; TEMPLATE; 3'-AZIDO-3'-DEOXYTHYMIDINE	We have examined the RNA-dependent and DNA-dependent polymerase and ribonuclease H catalytic activities of human immunodeficiency virus reverse transcriptase using rapid transient kinetic methods with defined synthetic 25/45-mer DNA/RNA and DNA/DNA primer/templates. The K(d) value for interaction of the enzyme with duplex DNA was 4.7 nM, and the value for RNA/DNA heteroduplex was of similar magnitude. A pre-steady state burst of nucleoside triphosphate incorporation was observed for both DNA and RNA templates. Analysis of the dATP concentration dependence of the burst rate provided K(d) values for dATP of 4 and 14 muM and maximum rates of single nucleotide incorporation, k(pol) of 33 and 74 s-1, for DNA and RNA templates, respectively. Subsequent turnovers were limited by the rate of dissociation of the primer/template from the enzyme at rates of 0.18 and 0.06 s-1 for duplex DNA and RNA/DNA heteroduplex, respectively. Analysis of rates of DNA polymerization and RNA cleavage using the RNA template revealed that the two activities are independent of one another. The polymerization rate (4-70 s-1) was dependent on dATP concentration, whereas the RNA cleavage occurred at a constant rate of 10 s-1 over the 100-fold dATP concentration range (2-200 muM). Examination of the RNA cleavage products resulting from a single turnover indicates that the polymerase and ribonuclease domains of the enzyme are separated by a distance corresponding to 19 bases of RNA/DNA heteroduplex, consistent with the recently published crystal structure (Kohlstaedt, L. A., Wang, J., Friedman, J., Rice, P. A., and Steitz, T. A. (1992) Science 256, 1783-1790). Analysis of the kinetics of processive synthesis suggested that the initial binding of dNTP leads to a faster rate of dissociation of DNA from the enzyme. Further investigation supported a two-step dNTP binding mechanism with the formation of an initial E.DNA.dNTP complex followed by a more stable E'.DNA-dNTP complex. The K(d) values for incorporation of incorrect nucleoside triphosphates opposite a DNA template thymidine were 1010 muM for dGTP, 1240 muM for dCTP, and 840 muM for dTTP. The corresponding maximum k(pol) rates were 4.8 s-1 for dGTP, 0.52 s-1 for dCTP, and 0.41 s-1 for dTTP. These values provide fidelity estimates of 1740 for discrimination against dGTP, 19,700 for dCTP, and 16,900 for dTTP misincorporations at this site.	PENN STATE UNIV, DEPT MOLEC & CELL BIOL, 106 ALTHOUSE LAB, University Pk, PA 16802 USA; YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT 06510 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Yale University	JOHNSON, KA (corresponding author), PENN STATE UNIV, DEPT MOLEC & CELL BIOL, 106 ALTHOUSE LAB, University Pk, PA 16802 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014469, R01GM044613] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44613, GM14469] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KS, 1988, BIOCHEMISTRY-US, V27, P7395, DOI 10.1021/bi00419a034; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; CHEN MS, 1987, BIOCHEM PHARMACOL, V36, P4361, DOI 10.1016/0006-2952(87)90685-X; CLARK PK, 1990, AIDS RES HUM RETROV, V6, P753, DOI 10.1089/aid.1990.6.753; DAHLBERG ME, 1991, BIOCHEMISTRY-US, V30, P4835, DOI 10.1021/bi00234a002; DOWNEY KM, 1988, CANCER CELLS EUKARYO, V6, P403; FURFINE ES, 1991, J BIOL CHEM, V266, P406; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; HANSEN J, 1988, EMBO J, V7, P239, DOI 10.1002/j.1460-2075.1988.tb02805.x; HIZI A, 1988, P NATL ACAD SCI USA, V85, P1218, DOI 10.1073/pnas.85.4.1218; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JI JP, 1992, BIOCHEMISTRY-US, V31, P954, DOI 10.1021/bi00119a002; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KOPP EB, 1991, NUCLEIC ACIDS RES, V19, P3035, DOI 10.1093/nar/19.11.3035; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; LOWE DM, 1991, FEBS LETT, V282, P231, DOI 10.1016/0014-5793(91)80484-K; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; Maniatis T., 1982, MOL CLONING; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; MITSUYA H, 1987, P NATL ACAD SCI USA, V84, P2033, DOI 10.1073/pnas.84.7.2033; MIZRAHI V, 1989, ARCH BIOCHEM BIOPHYS, V273, P347, DOI 10.1016/0003-9861(89)90493-1; MULLER B, 1989, J BIOL CHEM, V264, P13975; MULLER B, 1991, BIOCHEMISTRY-US, V30, P3709, DOI 10.1021/bi00229a017; NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006; ODONNELL ME, 1987, J BIOL CHEM, V262, P4260; PARKER WB, 1991, J BIOL CHEM, V266, P1754; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; REARDON JE, 1990, J BIOL CHEM, V265, P20302; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; REARDON JE, 1991, J BIOL CHEM, V266, P14128; REPASKE R, 1989, J VIROL, V63, P1460, DOI 10.1128/JVI.63.3.1460-1464.1989; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; TABOR S, 1987, J BIOL CHEM, V262, P16212; TANESE N, 1988, P NATL ACAD SCI USA, V85, P1777, DOI 10.1073/pnas.85.6.1777; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WEBER J, 1989, NUCLEIC ACIDS RES, V17, P1379, DOI 10.1093/nar/17.4.1379; WEBSTER KR, 1990, J BIOL CHEM, V265, P19007; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; YU H, 1992, J BIOL CHEM, V267, P10888; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	47	499	509	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25988	25997						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1281479				2022-12-27	WOS:A1992KD07300061
J	JOHNSON, P; OSTERGAARD, HL; WASDEN, C; TROWBRIDGE, IS				JOHNSON, P; OSTERGAARD, HL; WASDEN, C; TROWBRIDGE, IS			MUTATIONAL ANALYSIS OF CD45 - A LEUKOCYTE-SPECIFIC PROTEIN TYROSINE PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING; COMMON ANTIGEN; HUMAN-PLACENTA; RECEPTOR; KINASE; FAMILY; ADENOSINE; EVOLUTION; SEQUENCE	The cytoplasmic domain of murine CD45 has been expressed using an in vitro transcription/translation system. The recombinant protein was isolated by immunoprecipitation with a specific rabbit antiserum and was shown to have protein tyrosine phosphatase (PTPase) activity. Oligonucleotide-directed mutagenesis was then used to investigate the structural requirements for PTPase activity. Although the cysteine crucial for PTPase activity resides in domain I, this domain was not active alone. Both PTPase domains of CD45 and the membrane proximal region of 77 amino acids were required for enzymatic activity. Deletion of 78 residues at the carboxyl terminus of the cytoplasmic region did not influence activity, but an additional deletion of 13 amino acids from PTPase domain II totally abolished activity. Excision of the 21-residue acidic insert in the second PTPase domain resulted in a decrease of activity of approximately 4-fold. Nine conserved residues around the critical cysteine in the first domain were found to be important for activity. Of the 3 conserved tyrosine residues in domain I, only Tyr729 was specifically required for activity.	SALK INST,DEPT CANC BIOL,SAN DIEGO,CA 92186	Salk Institute				Johnson, Pauline/0000-0001-7367-4653	NCI NIH HHS [CA-17733] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA017733, R01CA017733] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BHATNAGAR D, 1984, BIOCHEMISTRY-US, V23, P4350, DOI 10.1021/bi00314a016; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; OSTERGAARD HL, 1991, SCIENCE, V253, P1423, DOI 10.1126/science.1654595; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; STREULI M, 1988, J EXP MED, V168, P1553; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; THOMAS ML, 1987, P NATL ACAD SCI USA, V84, P5360, DOI 10.1073/pnas.84.15.5360; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TROWBRIDGE IS, 1991, BIOCHIM BIOPHYS ACTA, V1095, P46, DOI 10.1016/0167-4889(91)90043-W; WEAVER CT, 1991, MOL CELL BIOL, V11, P4415, DOI 10.1128/MCB.11.9.4415; ZOLLER MJ, 1981, J BIOL CHEM, V256, P837	27	78	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8035	8041						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1314815				2022-12-27	WOS:A1992HQ18500015
J	MIGNERY, GA; JOHNSTON, PA; SUDHOF, TC				MIGNERY, GA; JOHNSTON, PA; SUDHOF, TC			MECHANISM OF CA2+ INHIBITION OF INOSITOL 1,4,5-TRISPHOSPHATE (INSP3) BINDING TO THE CEREBELLAR INSP3 RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECONSTITUTED LIPID VESICLES; PROTEIN KINASE-C; TRISPHOSPHATE RECEPTOR; SMOOTH-MUSCLE; ENDOPLASMIC-RETICULUM; CALCIUM RELEASE; BRAIN; CA-2+; PHOSPHORYLATION; HETEROGENEITY	Ca2+ efficiently inhibits binding of inositol 1,4,5-trisphosphate (InsP3) to the InsP3 receptor in cerebellar membranes but not to the purified receptor. We have now investigated the mechanism of action by which Ca2+ inhibits InsP3 binding. Our results suggest that Ca2+ does not cause the stable association of a Ca2+-binding protein with the receptor. Instead, Ca2+ leads to the production of a soluble, heat-stable, low molecular weight substance from cerebellar membranes that competes with InsP3 for binding. This inhibitory substance probably represents endogenously generated InsP3 as judged by the fact that it co-purifies with InsP3 on anion-exchange chromatography, competes with [H-3]InsP3 binding in a pattern similar to unlabeled InsP3, and is in itself capable of releasing Ca-45(2+) from permeabilized cells. A potent Ca2+-activated phospholipase C activity producing InsP3 was found in cerebellar microsomes that exhibited a Ca2+ dependence identical to the Ca2+-dependent inhibition of InsP3 binding. Together these results suggest that the Ca2+-dependent inhibition of InsP3 binding to the cerebellar receptor is due to activation of a Ca2+-sensitive phospholipase C enriched in cerebellum. Nevertheless, Ca2+ probably also modulates the InsP3 receptor function by a direct interaction with the receptor that does not affect InsP3 binding but regulates InsP3-dependent channel gating.	UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Johnston, Paul/0000-0001-5815-3091	NHLBI NIH HHS [R01 HL39644] Funding Source: Medline; NIMH NIH HHS [R01 MH47510] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039644] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH047510] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; CHALLISS RAJ, 1990, BIOCHEM J, V265, P421, DOI 10.1042/bj2650421; DANOFF SK, 1988, BIOCHEM J, V254, P701, DOI 10.1042/bj2540701; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; JOSEPH SK, 1989, BIOCHEM J, V258, P261, DOI 10.1042/bj2580261; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARKS AR, 1990, J BIOL CHEM, V265, P20719; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MUALLEM S, 1987, BIOCHEM BIOPH RES CO, V149, P213, DOI 10.1016/0006-291X(87)91626-3; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PIETRI F, 1990, J BIOL CHEM, V265, P17478; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; SHAH J, 1987, BRAIN RES, V419, P1, DOI 10.1016/0006-8993(87)90562-2; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; WALAAS SI, 1986, J NEUROSCI, V6, P954; WILSON DB, 1984, J BIOL CHEM, V259, P1718; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; YAMAMOTO H, 1989, J NEUROCHEM, V53, P917, DOI 10.1111/j.1471-4159.1989.tb11792.x; ZHAO H, 1990, J BIOL CHEM, V265, P21419	37	115	119	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7450	7455						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1313802				2022-12-27	WOS:A1992HN48500038
J	CLERC, A; BENNETT, N				CLERC, A; BENNETT, N			ACTIVATED CGMP PHOSPHODIESTERASE OF RETINAL RODS - A COMPLEX WITH TRANSDUCIN ALPHA SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; AMINO-ACID SEQUENCE; GTP-BINDING PROTEIN; OUTER SEGMENTS; GAMMA-SUBUNIT; INHIBITORY SUBUNIT; CDNA SEQUENCE; BETA-SUBUNIT; MECHANISM; PHOTORECEPTORS	Purified G-protein (transducin) activated with the nonhydrolyzable analog guanosine 5'-O-(thiotriphosphate) (GTP(gamma)S) and cGMP phosphodiesterase (PDE) from retinal rods are added to protein-stripped disc membranes. Specific binding of the mainly soluble alpha subunit of G-protein with GTP(gamma)S bound (G-alpha-GTP(gamma)S, activator of the PDE) to the disc membrane in the presence of PDE is measured from gel scans or experiments with labeled G-protein alpha subunit (G-alpha). Its variation as a function of G concentration matches the theoretical variation of G-alpha involved in the activation of PDE calculated with previously estimated dissociation constants (Bennett, N., and Clerc, A. (1989) Biochemistry 28, 7418-7424), and the G-alpha bound/PDE ratio at saturation is close to 2. No increase of G-alpha binding to the membrane is observed when purified inhibitory subunit of PDE (PDE(gamma)) is added together with or instead of total PDE, and excess PDE(gamma) remains soluble. These results suggest that activated PDE is a complex with the activator G-alpha-GTP rather than PDE from which the inhibitory subunits have been removed. A method for purifying PDE(gamma) with a high yield of recovery and activity is described.	CEN, BIOPHYS MOLEC & CELLULAIRE LAB, CNRS, UA 520, F-38041 GRENOBLE, FRANCE	Centre National de la Recherche Scientifique (CNRS)								BAEHR W, 1979, J BIOL CHEM, V254, P1669; BENNETT N, 1989, BIOCHEMISTRY-US, V28, P7418, DOI 10.1021/bi00444a040; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN JR, 1975, FED PROC, V34, P591; COMPTON SJ, 1985, ANAL BIOCHEM, V151, P369, DOI 10.1016/0003-2697(85)90190-3; DETERRE P, 1986, Proteins Structure Function and Genetics, V1, P188, DOI 10.1002/prot.340010210; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; Fazekas de St Groth S., 1963, BIOCHIM BIOPHYS ACTA, V71, P377; FUNG BKK, 1989, BIOCHEMISTRY-US, V28, P3133, DOI 10.1021/bi00434a003; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; GRISWOLDPRENNER I, 1989, BIOCHEMISTRY-US, V28, P6145, DOI 10.1021/bi00441a003; HINGORANI VN, 1988, J BIOL CHEM, V263, P6916; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; KROLL S, 1989, J BIOL CHEM, V264, P4490; Kuhn H, 1984, PROGR RETINAL RES, V3, P123; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBMAN PA, 1982, METHOD ENZYMOL, V81, P532; LIPKIN VM, 1990, J BIOL CHEM, V265, P12955; MEDYNSKI DC, 1985, P NATL ACAD SCI USA, V82, P4311, DOI 10.1073/pnas.82.13.4311; MORRISON DF, 1989, J BIOL CHEM, V264, P11671; NAVON SE, 1987, J BIOL CHEM, V262, P15746; OVCHINNIKOV YA, 1987, FEBS LETT, V223, P169, DOI 10.1016/0014-5793(87)80530-6; OVCHINNIKOV YA, 1985, FEBS LETT, V179, P107, DOI 10.1016/0014-5793(85)80201-5; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; PHILLIPS WJ, 1989, J BIOL CHEM, V264, P16679; PUGH EN, 1990, VISION RES, V30, P1923, DOI 10.1016/0042-6989(90)90013-B; SITARAMAYYA A, 1986, BIOCHEMISTRY-US, V25, P651, DOI 10.1021/bi00351a021; SUGIMOTO K, 1985, FEBS LETT, V191, P235, DOI 10.1016/0014-5793(85)80015-6; TANABE T, 1985, NATURE, V315, P242, DOI 10.1038/315242a0; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; WHALEN MM, 1989, BIOCHEM J, V259, P13, DOI 10.1042/bj2590013; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P4316, DOI 10.1073/pnas.82.13.4316	36	62	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6620	6627						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1313017				2022-12-27	WOS:A1992HM05300028
J	ROMAN, LJ; EGGLESTON, AK; KOWALCZYKOWSKI, SC				ROMAN, LJ; EGGLESTON, AK; KOWALCZYKOWSKI, SC			PROCESSIVITY OF THE DNA HELICASE ACTIVITY OF ESCHERICHIA-COLI RECBCD ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOLOGOUS RECOMBINATION; POLYMERASE-I; PHAGE-LAMBDA; CHI SITES; HYDROLYSIS; BINDING; PROTEIN; K-12; ATP	A fluorescence assay was used to measure the processivity of Escherichia coli recBCD enzyme helicase activity. Under standard conditions, recBCD enzyme unwinds an average of 30 +/- 3.2 kilobase pairs (kb)/DNA end before dissociating. The average processivity (P(obs)) of DNA unwinding under these conditions is 0.99997, indicating that the probability of unwinding another base pair is 30,000-fold greater than the probability of dissociating from the double-stranded DNA. The average number of base pairs unwound per binding event (N) is sensitive to both mono- and divalent salt concentration and ranges from 36 kb at 80 mM NaCl to 15 kb at 280 mm NaCl. The processivity of unwinding increases in a hyperbolic manner with increasing ATP concentration, yielding a K(N) value for ATP of 41 +/- 9-mu-M and a limiting value of 32 +/- 1.8 kb/end for the number of base pairs unwound. The importance of the processivity of recBCD enzyme helicase activity to the recBCD enzyme-dependent stimulation of recombination at Chi sites observed in vivo is discussed.	NORTHWESTERN UNIV,SCH MED,DEPT MOLEC BIOL,CHICAGO,IL 60611	Northwestern University					NIAID NIH HHS [AI-18987] Funding Source: Medline; NIGMS NIH HHS [GM-41347] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041347] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAMBARA RA, 1978, J BIOL CHEM, V253, P413; CHENG KC, 1989, GENETICS, V123, P5; DIXON DA, 1991, CELL, V66, P361, DOI 10.1016/0092-8674(91)90625-9; DYKSTRA CC, 1984, COLD SPRING HARB SYM, V49, P463, DOI 10.1101/SQB.1984.049.01.052; EICHLER DC, 1977, J BIOL CHEM, V252, P499; EMMERSON PT, 1967, J BACTERIOL, V93, P1729, DOI 10.1128/JB.93.5.1729-1731.1967; ENNIS DG, 1987, GENETICS, V115, P11; HOWARDFLANDERS P, 1966, GENETICS, V53, P1137; JULIN DA, 1987, J BIOL CHEM, V262, P9044; KOWALCZYKOWSKI SC, 1990, UCLA S MOL CELLULAR, P357; LEBOWITZ J, 1985, THESIS J HOPKINS U B; MACKAY V, 1976, J BIOL CHEM, V251, P3716; Maniatis T., 1982, MOL CLONING; McClure W R, 1980, Methods Enzymol, V64, P277; MCCLURE WR, 1975, J BIOL CHEM, V250, P4073; MCMILIN KD, 1974, GENETICS, V77, P409; MESSING J, 1983, METHOD ENZYMOL, V101, P20; ROMAN LJ, 1989, J BIOL CHEM, V264, P18340; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2873, DOI 10.1021/bi00433a019; ROMAN LJ, 1991, P NATL ACAD SCI USA, V88, P3367, DOI 10.1073/pnas.88.8.3367; ROSAMOND J, 1979, J BIOL CHEM, V254, P8646; RUYECHAN WT, 1975, BIOCHEMISTRY-US, V14, P5529, DOI 10.1021/bi00696a023; SMITH GR, 1984, COLD SPRING HARB SYM, V49, P485, DOI 10.1101/SQB.1984.049.01.055; SMITH GR, 1988, MICROBIOL REV, V52, P1; STAHL MM, 1983, P NATL ACAD SCI-BIOL, V80, P2310, DOI 10.1073/pnas.80.8.2310; TAYLOR AF, 1985, CELL, V41, P153, DOI 10.1016/0092-8674(85)90070-4; TAYLOR AF, 1985, J MOL BIOL, V185, P431, DOI 10.1016/0022-2836(85)90414-0; TAYLOR AF, 1988, GENETIC RECOMBINATIO, P231; Telander-Muskavitch K.M, 1981, ENZYMES, P233; TELANDERMUSKAVI.KM, 1982, J BIOL CHEM, V257, P2641; Thaler D.S., 1988, MECH CONSEQUENCES DN, P413; WANG TC, 1989, MOL GEN GENET, V216, P314; ZIVIN R, 1980, VIROLOGY, V104, P205, DOI 10.1016/0042-6822(80)90378-5	34	100	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4207	4214						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1310990				2022-12-27	WOS:A1992HE60700094
J	BAXTER, G; OTO, E; DANIELISSAKANI, S; STRULOVICI, B				BAXTER, G; OTO, E; DANIELISSAKANI, S; STRULOVICI, B			CONSTITUTIVE PRESENCE OF A CATALYTIC FRAGMENT OF PROTEIN KINASE-C-EPSILON IN A SMALL-CELL LUNG-CARCINOMA CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER RECEPTOR; GASTRIN-RELEASING PEPTIDE; EPIDERMAL GROWTH-FACTOR; SWISS 3T3 FIBROBLASTS; CANCER-CELLS; BOMBESIN RECEPTOR; SIGNAL TRANSDUCTION; PKC-EPSILON; FAMILY; EXPRESSION	Protein kinase C (PKC) has been implicated in a variety of cellular responses such as proliferation, differentiation, and secretion. We assessed the role of PKC in the mitogenic effects of gastrin-releasing peptide (in a small cell lung cancer (SCLC) cell line. Using antisera that specifically recognize the PKC isoforms alpha, beta, gamma, delta, and epsilon, we determined that PKC-epsilon is the major isoform in the SCLC cell line NCI-N417, followed by PKC-alpha and delta. In addition to the 90-kDa PKC-epsilon, our anti-PKC-epsilon antiserum specifically detected a 40-kDa immunoreactive protein. Treatment of the cells with either 20 nM phorbol myristate acetate or 50 nM GRP enhanced significantly the level of the 40-kDa protein in a time-dependent (1-8 h), cycloheximide-sensitive fashion. Subcellular fractionation revealed that 90% of PKC-epsilon was in particulate form, while the 40-kDa immunoreactive protein was cytosolic. To test the hypothesis that the 40-kDa soluble protein represented a catalytically independent PKC-epsilon fragment, cytosolic extracts were assayed for kinase activity. 45-50% of the activity was apparent in the absence of the PKC activators phosphatidylserine and diacylglycerol. This effector-independent kinase activity was further purified by affinity chromatography using a synthetic peptide corresponding to the pseudosubstrate region of PKC-epsilon (ERMRPRKRQGAVRRRV) coupled to Sepharose. The partially purified protein, recognized by the anti-PKC-epsilon antiserum, exhibited histone kinase activity with kinetics similar to those of the tryptically generated catalytic fragment of brain PKC-epsilon. This activity was inhibited by staurosporine (IC50 = 1 x 10(-8) M) and by the pseudosubstrate inhibitor peptide (IC50 = 7.7 x 10(-8) M). The SCLC kinase and the brain PKC-epsilon catalytic fragment were similar as indicated by the relative sizes of the PKC-epsilon immunoreactive peptides generated with protease V8 from Staphylococcus aureus (M(r) is similar to 37,000, 34,000, 28,000, 26,000, and 25,000). Taken together, we conclude that a variant SCLC cell line expresses a constitutively active catalytic fragment of PKC-epsilon. Regulation by 12-O-tetradecanoyl-13-acetate or GRP via de novo protein synthesis suggests a novel mechanism of control of PKC diversity with implications for small cell lung cancer and possibly other malignancies.	SYNTEX INC, INST CANC & DEV BIOL,DEPT BIOCHEM, 3401 HILLVIEW AVE,53-1, PALO ALTO, CA 94304 USA	Syntex Corporation								AKITA Y, 1990, J BIOL CHEM, V265, P354; ANDERSON WB, 1985, ADV CYCLIC NUCL PROT, V19, P287; BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BONIKOS DS, 1977, AM J MED, V63, P765, DOI 10.1016/0002-9343(77)90163-2; BORNER C, 1989, J BIOL CHEM, V264, P13902; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUNN PA, 1990, P NATL ACAD SCI USA, V87, P2162, DOI 10.1073/pnas.87.6.2162; CARNEY DN, 1985, NEURAL ENDOCRINE PEP, P431; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COUSSENS L, 1987, DNA-J MOLEC CELL BIO, V6, P389, DOI 10.1089/dna.1987.6.389; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; ELDAR H, 1990, J BIOL CHEM, V265, P13290; FISCHER JB, 1988, J BIOL CHEM, V263, P2808; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HEIDENREICH KA, 1990, J BIOL CHEM, V265, P15076; HIRAI M, 1989, JPN J CANCER RES, V80, P204, DOI 10.1111/j.1349-7006.1989.tb02292.x; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KILEY S, 1990, J BIOL CHEM, V265, P15704; KILEY S, 1987, P NATL ACAD SCI USA, V84, P4418; KRIS RM, 1987, J BIOL CHEM, V262, P11215; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee E Y, 1980, Adv Cyclic Nucleotide Res, V13, P95; LEIBERSPERGER H, 1990, J BIOL CHEM, V265, P16108; LINNENBACH AJ, 1988, P NATL ACAD SCI USA, V85, P74, DOI 10.1073/pnas.85.1.74; MARUNO K, 1989, CANCER RES, V49, P629; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; MELLONI E, 1987, P NATL ACAD SCI USA, V84, P5282, DOI 10.1073/pnas.84.15.5282; NIEDEL J E, 1986, P47; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1988, J BIOL CHEM, V263, P6927; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; PELOSIN JM, 1987, BIOCHEM BIOPH RES CO, V147, P382, DOI 10.1016/S0006-291X(87)80133-X; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PFEFFER LM, 1990, P NATL ACAD SCI USA, V87, P6537, DOI 10.1073/pnas.87.17.6537; ROSEJOHN S, 1988, GENE, V74, P465, DOI 10.1016/0378-1119(88)90179-5; SAUSVILLE EA, 1988, ANN NY ACAD SCI, V547, P310, DOI 10.1111/j.1749-6632.1988.tb23899.x; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SCHAAP D, 1990, EUR J BIOCHEM, V191, P431, DOI 10.1111/j.1432-1033.1990.tb19139.x; STRULOVICI B, 1991, J BIOL CHEM, V266, P168; STRULOVICI B, 1989, BIOCHEMISTRY-US, V28, P3569, DOI 10.1021/bi00434a063; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TREPEL JB, 1988, BIOCHEM BIOPH RES CO, V156, P1383, DOI 10.1016/S0006-291X(88)80785-X; WEBER S, 1985, J CLIN INVEST, V75, P306, DOI 10.1172/JCI111690; WOLFSON M, 1986, INT J CANCER, V37, P589, DOI 10.1002/ijc.2910370418; WOLL PJ, 1989, BIOCHEM BIOPH RES CO, V164, P66, DOI 10.1016/0006-291X(89)91683-5; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211; ZACHARY I, 1987, BIOCHEM BIOPH RES CO, V146, P456, DOI 10.1016/0006-291X(87)90551-1	56	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1910	1917						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1309802				2022-12-27	WOS:A1992HA48500079
J	DONALDSON, L; CAPONE, JP				DONALDSON, L; CAPONE, JP			PURIFICATION AND CHARACTERIZATION OF THE CARBOXYL-TERMINAL TRANSACTIVATION DOMAIN OF VMW65 FROM HERPES-SIMPLEX VIRUS TYPE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; SECONDARY-STRUCTURE; REGULATORY PROTEIN; AMINO-ACIDS; YEAST; SEQUENCE; GCN4	A glutathione S-transferase fusion to the COOH-terminal acidic transactivation domain of Vmw65 from herpes simplex virus type 1 was overexpressed in Escherichia coli and isolated by affinity chromatography on glutathione-Sepharose. Following cleavage of the fusion protein with thrombin, the transactivation domain was purified to homogeneity by ion exchange chromatography yielding approximately 0.6 mg of protein/liter of bacterial culture. Equilibrium sedimentation analysis showed the purified polypeptide to be monomeric; however, it displayed aberrant electrophoretic and chromatographic properties. Contrary to secondary structure predictions, circular dichroism spectroscopy demonstrated that this transactivation domain was devoid of significant alpha-helical structure at physiological conditions. The polypeptide, however, became notably more structured under hydrophobic conditions or at low pH, suggesting that it was sensitive to its environment. Near-UV circular dichroism suggested that phenylalanyl and tyrosyl residues were under influence from tertiary structure.			DONALDSON, L (corresponding author), MCMASTER UNIV,DEPT BIOCHEM,HAMILTON L8N 3Z5,ONTARIO,CANADA.							CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CHAMPBELL KP, 1983, J BIOL CHEM, V258, P11267; CHANG JY, 1985, EUR J BIOCHEM, V151, P217, DOI 10.1111/j.1432-1033.1985.tb09091.x; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COUSENS DJ, 1989, EMBO J, V8, P2337, DOI 10.1002/j.1460-2075.1989.tb08361.x; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DALRYMPLE MA, 1985, NUCLEIC ACIDS RES, V13, P7865, DOI 10.1093/nar/13.21.7865; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GOTO Y, 1990, P NATL ACAD SCI USA, V87, P573, DOI 10.1073/pnas.87.2.573; GREEN MR, 1973, ANAL BIOCHEM, V56, P43, DOI 10.1016/0003-2697(73)90167-X; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; LEHRMAN SR, 1990, BIOCHEMISTRY-US, V29, P5590, DOI 10.1021/bi00475a025; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LORET EP, 1991, BIOCHEMISTRY-US, V30, P6013, DOI 10.1021/bi00238a027; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TREIZENBERG SJ, 1988, GENES DEV, V2, P730; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WERSTUCK G, 1989, J VIROL, V63, P5509, DOI 10.1128/JVI.63.12.5509-5513.1989; XIAO P, 1990, MOL CELL BIOL, V10, P4974, DOI 10.1128/MCB.10.9.4974; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3; ZHU QL, 1990, PROTEINS, V8, P156, DOI 10.1002/prot.340080205	36	82	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1411	1414						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1309782				2022-12-27	WOS:A1992HA48500003
J	YOUNES, A; KAHN, DW; BESTERMAN, JM; BITTMAN, R; BYUN, HS; KOLESNICK, RN				YOUNES, A; KAHN, DW; BESTERMAN, JM; BITTMAN, R; BYUN, HS; KOLESNICK, RN			CERAMIDE IS A COMPETITIVE INHIBITOR OF DIACYLGLYCEROL KINASE INVITRO AND IN INTACT HUMAN LEUKEMIA (HL-60) CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; PITUITARY-CELLS; DIFFERENTIATION; PHOSPHATIDYLCHOLINE; 1,2-DIACYLGLYCEROL	Prior studies demonstrated that ceramide was phosphorylated by a novel Ca2+-dependent kinase distinct from diacylglycerol.(DG) kinase in human myelogenous leukemia (HL-60) cells (Kolesnick, R. N., and Hemer, M. R. (1990) J. Biol. Chem. 265, 10900-10904). The present studies were initiated to determine whether mammalian DG kinase purified to homogeneity possessed phosphotransferase activity toward ceramide. A high molecular weight rat brain DG kinase demonstrated Mg2+-(but not Ca2+-) dependent DG kinase activity and did not phosphorylate ceramide in the presence of either cation. In contrast, ceramide served as a competitive inhibitor with an inhibition constant (K(i)) 2-6-fold greater than the K(m) for DG. Inhibition was noncompetitive with respect to ATP and Mg2+. A cell-permeable ceramide, N-octanoyl sphingosine (C8-cer), was used to study effects of ceramide on DG kinase in intact HL-60 cells. C8-cer induced dose- and time-dependent increases in cellular DG levels. As little as 1-mu-M C8-cer increased DG from a basal level of 103 to 177 pmol.10(6) cells-1, and a maximal 2.9-fold elevation to 292 pmol.10(6) cells-1 occurred with 10-mu-M C8-cer. DG elevation was detected after 1 min, maximal by 7.5 min, and sustained for 30 min. The DG elevation was accompanied by a reduction in P-32 incorporation in phosphatidic acid in cells short term-labeled with [P-32]orthophosphoric acid, consistent with inhibition of DG kinase. In contrast, a similar elevation in the DG level induced by exogenous phospholipase C increased P-32 incorporation into phosphatidic acid. C8-cer was not metabolized to sphingomyelin, indicating that DG was not generated through the phosphatidylcholine:ceramide cholinephosphotransferase reaction. DG elevation after C8-cer or phospholipase C treatment was sufficient to redistribute protein kinase C from cytosol to membrane. These findings provide evidence that ceramide may serve as a competitive inhibitor of DG kinase.	CORNELL UNIV,MED CTR,COLL MED,PROGRAM MOLEC PHARMACOL & THERAPEUT,SIGNAL TRANSDUCT LAB,NEW YORK,NY 10021; GALAXO RES INST,DEPT CELL BIOL,RES TRIANGLE PK,NC 27709; CUNY QUEENS COLL,DEPT CHEM & BIOCHEM,FLUSHING,NY 11367	Cornell University; City University of New York (CUNY) System; Queens College NY (CUNY)					NATIONAL CANCER INSTITUTE [T32CA009207] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016660, R37HL016660] Funding Source: NIH RePORTER; NCI NIH HHS [CA-42385, CA-09207-14] Funding Source: Medline; NHLBI NIH HHS [HL 16660] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAJJALIEH SM, 1989, J BIOL CHEM, V264, P14354; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P6785, DOI 10.1073/pnas.83.18.6785; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; HJELMELAND LM, 1984, METHOD ENZYMOL, V104, P305; KAHN DW, 1991, P NATL ACAD SCI USA, V88, P6137, DOI 10.1073/pnas.88.14.6137; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK RN, 1990, J BIOL CHEM, V265, P10900; KOLESNICK RN, 1990, J BIOL CHEM, V265, P18803; KOLESNICK RN, 1990, BIOCHEM J, V267, P17, DOI 10.1042/bj2670017; MATHIAS S, 1991, IN PRESS P NATL ACAD; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PREISS J, 1986, J BIOL CHEM, V261, P8597; REBECCHI MJ, 1983, J BIOL CHEM, V258, P227; SAKANE F, 1989, FEBS LETT, V255, P409, DOI 10.1016/0014-5793(89)81134-2; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; SCHNEIDER EG, 1973, J BIOL CHEM, V248, P3739; STONE RM, 1988, BLOOD, V72, P739	24	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					842	847						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1309777				2022-12-27	WOS:A1992GY96000027
J	CASCIOLAROSEN, LA; HUBBARD, AL				CASCIOLAROSEN, LA; HUBBARD, AL			LUMENAL LABELING OF RAT HEPATOCYTE EARLY ENDOSOMES - PRESENCE OF MULTIPLE MEMBRANE-RECEPTORS AND THE NA+,K+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; LIVER ASIALOGLYCOPROTEIN RECEPTOR; PLASMA-MEMBRANE; MEDIATED ENDOCYTOSIS; MONOCLONAL-ANTIBODIES; TRANSFERRIN RECEPTOR; RECOGNITION SYSTEM; MAMMALIAN LIVER; CDNA SEQUENCE; PROTON PUMP	We used lactoperoxidase-mediated iodination to investigate the lumenal polypeptide composition of rat hepatocyte endosomes. A chemical conjugate of asialoorosomucoid and lactoperoxidase that binds specifically to hepatocyte asialoglycoprotein receptors was perfused through isolated rat livers at 16-degrees-C in the presence of mannan, resulting in the accumulation of ligand in early endosomes. Endosome containing low density vesicle fractions were subsequently isolated from sucrose gradients of microsomes, and the lactoperoxidase moiety was used to catalyze the iodination of lumenal-facing proteins. After gel electrophoresis, I-125-labeled early endosomes reproducibly showed a distinct I-125-polypeptide profile containing prominently labeled bands migrating at 43, 52, 58, 90, 110, 135, 230, and > 300 kDa. The asialoglycoprotein receptor (43-, 52-, and 58-kDa subunits) was by far the predominantly labeled protein even when iodinations were performed under conditions of receptor-ligand dissociation, and we conclude that it is the most abundant hepatocyte early endosomal protein. Furthermore, the iodination profile of the three asialoglycoprotein receptor subunits differed strikingly from their chemical amounts. Using immunoprecipitation, we directly identified the Na+,K+-ATPase; to our knowledge, this is the first biochemical evidence for the Na+,K+-ATPase in rat hepatocyte early endosomes. We also directly identified receptors for mannose 6-phosphate, epidermal growth factor, transferrin, and polymeric IgA in I-125-labeled early endosomes.	JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,725 N WOLFE ST,BALTIMORE,MD 21205	Johns Hopkins University					NIGMS NIH HHS [GM29133] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM129133, R01GM029133] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI I, 1990, J BIOL CHEM, V265, P967; BAENZIGER JU, 1986, J BIOL CHEM, V261, P7445; BARTLES JR, 1985, J CELL BIOL, V100, P1126, DOI 10.1083/jcb.100.4.1126; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BRAITERMAN LT, 1989, J BIOL CHEM, V264, P1682; BROWN MS, 1983, CELL, V32, P663, DOI 10.1016/0092-8674(83)90052-1; BROWN WR, 1989, IMMUNOL INVEST, V18, P269, DOI 10.3109/08820138909112242; CAIN CC, 1989, P NATL ACAD SCI USA, V86, P544, DOI 10.1073/pnas.86.2.544; CHANDLER LP, 1985, J BIOL CHEM, V260, P3360; COURTOY PJ, 1984, J CELL BIOL, V98, P870, DOI 10.1083/jcb.98.3.870; CROZE E, 1989, J CELL BIOL, V108, P1597, DOI 10.1083/jcb.108.5.1597; DIPAOLA M, 1984, J BIOL CHEM, V259, P9163; DONNER DB, 1983, J BIOL CHEM, V258, P2736; DUNN WA, 1983, METHOD ENZYMOL, V98, P225; DUNN WA, 1980, J BIOL CHEM, V255, P5971; FUCHS R, 1989, J BIOL CHEM, V264, P2212; FUCHS R, 1989, P NATL ACAD SCI USA, V86, P539, DOI 10.1073/pnas.86.2.539; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; HALBERG DF, 1987, J BIOL CHEM, V262, P9828; HARIKUMAR P, 1983, J BIOL CHEM, V258, P403; HERRERA VLM, 1987, J CELL BIOL, V105, P1855, DOI 10.1083/jcb.105.4.1855; HERZ J, 1990, J BIOL CHEM, V265, P21355; HOLLAND EC, 1984, P NATL ACAD SCI-BIOL, V81, P7338, DOI 10.1073/pnas.81.23.7338; HOPPE CA, 1985, J CELL BIOL, V101, P2113, DOI 10.1083/jcb.101.6.2113; Hubbard AL, 1989, CURR OPIN CELL BIOL, V1, P675, DOI 10.1016/0955-0674(89)90033-1; HUBBARD AL, 1979, J CELL BIOL, V83, P47, DOI 10.1083/jcb.83.1.47; HUBBARD AL, 1985, J CELL BIOL, V100, P1115, DOI 10.1083/jcb.100.4.1115; HUBBARD AL, 1983, J CELL BIOL, V96, P230, DOI 10.1083/jcb.96.1.230; HUBBARD AL, 1976, BIOCH ANAL MEMBRANES, P427; JEFFERIES WA, 1985, IMMUNOLOGY, V54, P333; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RT, 1987, BIOCHEMISTRY-US, V26, P6320, DOI 10.1021/bi00394a005; LOBEL P, 1988, J BIOL CHEM, V263, P2563; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARXER A, 1989, J CELL BIOL, V109, P1057, DOI 10.1083/jcb.109.3.1057; MATHEWS LS, 1989, J BIOL CHEM, V264, P9905; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; MESSNER DJ, 1989, J CELL BIOL, V108, P2149, DOI 10.1083/jcb.108.6.2149; MOSTOV KE, 1984, NATURE, V308, P37, DOI 10.1038/308037a0; MUELLER SC, 1986, J CELL BIOL, V102, P932, DOI 10.1083/jcb.102.3.932; PARK JE, 1991, J CELL BIOL, V112, P245, DOI 10.1083/jcb.112.2.245; PRICER WE, 1976, J BIOL CHEM, V251, P7539; RENFREW CA, 1992, IN PRESS METHODS MOL; ROMAN LM, 1983, J CELL BIOL, V96, P1548, DOI 10.1083/jcb.96.6.1548; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; SCHWARTZ AL, 1981, P NATL ACAD SCI-BIOL, V78, P3348, DOI 10.1073/pnas.78.6.3348; SHULL GE, 1986, NATURE, V321, P429, DOI 10.1038/321429a0; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TAMKUN MM, 1986, J BIOL CHEM, V261, P1009; TOLLESHAUG H, 1980, EUR J CELL BIOL, V23, P104; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WALL DA, 1985, J CELL BIOL, V101, P2104, DOI 10.1083/jcb.101.6.2104; WALL DA, 1981, J CELL BIOL, V90, P687, DOI 10.1083/jcb.90.3.687; WALL DA, 1980, CELL, V21, P79, DOI 10.1016/0092-8674(80)90116-6; WATTS C, 1984, EMBO J, V3, P1965, DOI 10.1002/j.1460-2075.1984.tb02077.x; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8	58	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8213	8221						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1314820				2022-12-27	WOS:A1992HQ18500040
J	ANN, DK; HASEGAWA, J; KO, JL; CHEN, ST; LEE, NM; LOH, HH				ANN, DK; HASEGAWA, J; KO, JL; CHEN, ST; LEE, NM; LOH, HH			SPECIFIC REDUCTION OF DELTA-OPIOID RECEPTOR-BINDING IN TRANSFECTED NG108-15 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; COMPLEMENTARY RNA; GENE-EXPRESSION; DNA; PROTEIN; SEQUENCES; ACID; TRANSFORMATION; PROLIFERATION; INHIBITION	We have recently identified and sequenced the cDNA for an opioid-binding protein with homologies to cell adhesion molecules (OBCAM) (Schofield, P. R., McFarlard, K. C., Hayflick, J. S., Wilcox, J. N., Cho, T. M., Roy, S., Lee, N. M., Loh, H. H., and Seeburg, P. H. (1989) EMBO J. 8, 489-495). Several lines of evidence using antibodies suggest that OBCAM may play a functional role in NG 108-15 neuroblastoma x glioma cells, a useful model system that contains a homogeneous population of delta-opioid receptors. A logical extension of this research is to further test this hypothesis. As part of this study, NG108-15 cells were stably transfected with either sense or antisense sequences of a portion of pROM, the rat cDNA for OBCAM. [H-3] Diprenorphine binding was greatly reduced in antisense-transfected cells relative to non-transfected cells. Binding to alpha-2-adrenergic, muscarinic, and insulin receptors was unaffected. These results further support the notion that OBCAM or its analogue is part (or a subunit) of an opioid receptor. Furthermore, our observation of an apparently specific reduction in opioid binding in these transfected cells suggests that they may provide a novel genetic approach for studying regulation of the opioid receptor in this defined cell line.			ANN, DK (corresponding author), UNIV MINNESOTA,SCH MED,DEPT PHARMACOL,MINNEAPOLIS,MN 55455, USA.				NIDA NIH HHS [K05-DA70554] Funding Source: Medline; PHS HHS [01583, 02643] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [K05DA070554] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ANN DK, 1987, J BIOL CHEM, V262, P899; BRAKENHOFF RH, 1991, NUCLEIC ACIDS RES, V19, P1949, DOI 10.1093/nar/19.8.1949; BURD JF, 1974, J BIOL CHEM, V249, P7094; CHANG KJ, 1979, J BIOL CHEM, V254, P2610; CHANG KJ, 1982, NATURE, V296, P446, DOI 10.1038/296446a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; ENGLUND PT, 1971, J BIOL CHEM, V246, P3269; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; INOUYE M, 1988, GENE, V72, P25, DOI 10.1016/0378-1119(88)90124-2; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; KOSKI G, 1981, P NATL ACAD SCI-BIOL, V78, P4185, DOI 10.1073/pnas.78.7.4185; LAW PY, 1983, MOL PHARMACOL, V24, P413; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MIZUNO T, 1984, P NATL ACAD SCI-BIOL, V81, P1966, DOI 10.1073/pnas.81.7.1966; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; ROY S, 1988, BIOCHEM BIOPH RES CO, V150, P237, DOI 10.1016/0006-291X(88)90511-6; Sambrook J, 1989, MOL CLONING LABORATO; SCHOFIELD PR, 1989, EMBO J, V8, P489, DOI 10.1002/j.1460-2075.1989.tb03402.x; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P590, DOI 10.1073/pnas.72.2.590; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TEMPLETON D, 1984, MOL CELL BIOL, V4, P817, DOI 10.1128/MCB.4.5.817; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VANDERKROL AR, 1988, BIOTECHNIQUES, V6, P958	31	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7921	7926						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1313812				2022-12-27	WOS:A1992HN48500100
J	WATSON, AJ; HANKINSON, O				WATSON, AJ; HANKINSON, O			DIOXIN-DEPENDENT AND AH RECEPTOR-DEPENDENT PROTEIN-BINDING TO XENOBIOTIC RESPONSIVE ELEMENTS AND G-RICH DNA STUDIED BY INVIVO FOOTPRINTING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME P-450C GENE; FACTORS INTERACT; CYP1A1 GENE; ENHANCER; PROMOTER; EXPRESSION; UPSTREAM; TRANSCRIPTION; REQUIREMENT; INDUCTION	DNA-protein interactions before and after transcriptional activation of the carcinogen- and dioxin-inducible enhancer of the murine CYP1A1 gene were detected in vivo by treatment with dimethyl sulfate followed by ligation-mediated, polymerase chain reaction-aided genomic sequencing. Following 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) treatment of mouse Hepa-1 hepatoma cells, evidence of protein binding was detected at the sequence 5' CACGCNA/T 3' within two previously defined xenobiotic response elements (XREs). The observed XRE footprint was similar to that previously identified by in vitro methylation protection footprints and attributed to the binding protein for 2,3,7,8-tetrachlorodibenzo-p-dioxin the Ah receptor. No XRE footprinting was observed in Hepa-1 mutant cells possessing a defective Ah receptor. Unexpectedly, evidence of protein binding was also detected at a G-rich DNA sequence immediately adjacent to one of the XREs. Footprinting of the G-rich sequence element, like that of XRE1 and XRE2, was dependent on the presence of a functional Ah receptor. The Ah receptor is therefore able to bind to its own DNA target sites in vivo and is also required for the binding of a second factor to the G-rich element.	UNIV CALIF LOS ANGELES,BIOMED & ENVIRONM SCI LAB,900 VET AVE,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH PUBL HLTH,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT PATHOL & LAB MED,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL CANCER INSTITUTE [R01CA028868] Funding Source: NIH RePORTER; NCI NIH HHS [CA 28868] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAVAYA K, 1991, MOL CELL BIOL, V11, P586, DOI 10.1128/MCB.11.1.586; ANDERSEN RD, 1987, MOL CELL BIOL, V7, P3574, DOI 10.1128/MCB.7.10.3574; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; DENISON MS, 1989, J BIOL CHEM, V264, P16478; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; ELFERINK CJ, 1990, J BIOL CHEM, V265, P20708; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FISHER JM, 1990, J BIOL CHEM, V265, P9676; FUJISAWASEHARA A, 1986, NUCLEIC ACIDS RES, V14, P1465; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GILBERT W, 1976, CONTROL RIBOSOME SYN, P139; GODING CR, 1987, NUCLEIC ACIDS RES, V15, P7761, DOI 10.1093/nar/15.19.7761; GONZALEZ FJ, 1985, NUCLEIC ACIDS RES, V13, P7269, DOI 10.1093/nar/13.20.7269; HANKINSON O, 1985, J BIOL CHEM, V260, P1790; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; HAPGOOD J, 1991, MOL CELL BIOL, V11, P4314, DOI 10.1128/MCB.11.9.4314; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; JOHNSRUD L, 1978, P NATL ACAD SCI USA, V75, P5314, DOI 10.1073/pnas.75.11.5314; JONES KW, 1990, MOL CELL BIOL, V10, P5098, DOI 10.1128/MCB.10.10.5098; JONES PBC, 1986, J BIOL CHEM, V261, P6647; JONES PBC, 1985, SCIENCE, V227, P1499, DOI 10.1126/science.3856321; KARA CJ, 1991, SCIENCE, V252, P709, DOI 10.1126/science.1902592; LEGRAVEREND C, 1982, J BIOL CHEM, V257, P6402; Maxam A M, 1980, Methods Enzymol, V65, P499; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NEUHOLD LA, 1989, MOL CELL BIOL, V9, P2378, DOI 10.1128/MCB.9.6.2378; NEUHOLD LA, 1986, DNA-J MOLEC CELL BIO, V5, P403, DOI 10.1089/dna.1986.5.403; PELKONEN O, 1982, PHARMACOL REV, V34, P189; POLAND A, 1975, MOL PHARMACOL, V11, P389; SAATCIOGLU F, 1990, J BIOL CHEM, V265, P9251; SAATCIOGLU F, 1990, MOL CELL BIOL, V10, P6408, DOI 10.1128/MCB.10.12.6408; SHEN ES, 1989, J BIOL CHEM, V264, P17754; WEIH F, 1990, GENE DEV, V4, P1437, DOI 10.1101/gad.4.8.1437; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251	37	62	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6874	6878						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1313025				2022-12-27	WOS:A1992HM05300065
J	RAJ, PA; JOHNSSON, M; LEVINE, MJ; NANCOLLAS, GH				RAJ, PA; JOHNSSON, M; LEVINE, MJ; NANCOLLAS, GH			SALIVARY STATHERIN - DEPENDENCE ON SEQUENCE, CHARGE, HYDROGEN-BONDING POTENCY, AND HELICAL CONFORMATION FOR ADSORPTION TO HYDROXYAPATITE AND INHIBITION OF MINERALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PAROTID SALIVA; CALCIUM-PHOSPHATE PRECIPITATION; PROLINE-RICH PROTEINS; NUCLEAR MAGNETIC-RESONANCE; CIRCULAR-DICHROISM; CONTAINING PEPTIDES; ACIDIC PEPTIDE; CHAIN-LENGTH; ALAMETHICIN; PHOSPHOSERINE	The structural domains of salivary statherin that are partly responsible for the protection and recalcification of tooth enamel were examined with respect to charge, sequence, hydrophobicity, hydrogen bonding potential, and conformation. Several fragments of statherin, 1-15 (SN15), 5-15 (SN11), 15-29 (SM15), 29-43 (SC15), 19-43 (SC25), and analogs of the N-terminal 15-residue sequence, where phosphoserines at positions 2 and 3 have been replaced by Ser (SN(S)15) and Asp (SN(A)15), respectively, were synthesized. The abilities of these fragments to adsorb at hydroxyapatite (HAP) surfaces and to inhibit its mineralization in supersaturated solutions were determined and compared with those of the whole statherin molecule, reported previously. The conformational preferences of the fragments both in aqueous and nonaqueous solutions were examined by circular dichroism. The highly charged N-terminal SN15 fragment has the greatest adsorption to HAP as compared with statherin and all other fragments. Its mineralization inhibitory activity is significantly greater than those of other fragments and comparable with that of the whole molecule. The dephosphorylated N-terminal fragment SN(S)15 shows a decreased tendency to adhere to and inhibit the formation of HAP, as compared with SN15. However, the substitution of Asp residues in place of phosphoserines (SN(A)15), restores the binding affinity and crystal growth inhibition properties, suggesting that the negative charge density at the N-terminal rather than any specific interaction of the phosphate group is important for HAP surface interactions. The C-terminal SC15 and SC25 fragments elicit a much higher affinity for HAP surface than that of the middle sequence (SM15), indicating that hydrogen bonding potential of the C-terminal sequence also contributes to the interaction of statherin with HAP. CD studies provide evidence that the N-terminal SN15 fragment has a strong tendency to adopt an ordered helical conformation, whereas the shorter N-terminal sequence, middle, and C-terminal fragments are structurally flexible and prefer to adopt scattered turn structures or unordered random conformations in organic and aqueous solutions. Collectively, the data indicate that the negative charge density, sequence (1-15), and helical conformation at the N-terminal region of statherin are important for its surface interaction with HAP.	SUNY BUFFALO, DEPT CHEM, BUFFALO, NY 14214 USA; SUNY BUFFALO, DEPT BIOMAT, BUFFALO, NY 14214 USA; SUNY BUFFALO, DENT RES INST, BUFFALO, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	RAJ, PA (corresponding author), SUNY BUFFALO, DEPT ORAL BIOL, BUFFALO, NY 14214 USA.		RAJ, PROFESSORDES/AAA-1007-2020	RAJ, PROFESSORDES/0000-0002-4050-4778	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE003223] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE007585, R37DE003223, P50DE008240] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE08240, DE03223, DE07585] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AOBA T, 1984, CALCIFIED TISSUE INT, V36, P651, DOI 10.1007/BF02405385; BENNICK A, 1979, BIOCHEM J, V183, P115, DOI 10.1042/bj1830115; BENNICK A, 1981, J BIOL CHEM, V256, P4741; BRUCH MD, 1991, PROTEINS, V10, P130, DOI 10.1002/prot.340100206; DOUGLAS WH, 1991, BIOCHEM BIOPH RES CO, V180, P91, DOI 10.1016/S0006-291X(05)81259-8; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; ELGAVISH GA, 1984, INT J PEPT PROT RES, V23, P230; GIBBONS RJ, 1988, INFECT IMMUN, V56, P439, DOI 10.1128/IAI.56.2.439-445.1988; GIERASCH LM, 1981, BIOCHEMISTRY-US, V20, P4730, DOI 10.1021/bi00519a032; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GRON P, 1973, ARCH ORAL BIOL, V18, P1385, DOI 10.1016/0003-9969(73)90112-X; HAUSCHKA PV, 1989, ANAT REC, V224, P180, DOI 10.1002/ar.1092240208; HAY DI, 1973, ARCH ORAL BIOL, V18, P1531, DOI 10.1016/0003-9969(73)90128-3; HAY DI, 1974, ARCH ORAL BIOL, V19, P627, DOI 10.1016/0003-9969(74)90130-7; HAY DI, 1984, J DENT RES, V63, P857, DOI 10.1177/00220345840630060901; HAY DI, 1982, CALCIFIED TISSUE INT, V34, P531, DOI 10.1007/BF02411299; HAY DI, 1979, INORG PERSPECT BIOL, V2, P271; HAY DI, 1977, CALCIUM BINDING PROT, P401; Hay DI, 1989, HUMAN SALIVA CLIN CH, P131; HAY DI, 1983, HDB EXPT ASPECTS ORA, P319; JENSEN JL, 1991, ARCH ORAL BIOL, V36, P529, DOI 10.1016/0003-9969(91)90147-M; JOHNSSON M, 1991, ARCH ORAL BIOL, V36, P631, DOI 10.1016/0003-9969(91)90014-L; JUNG G, 1975, EUR J BIOCHEM, V54, P395, DOI 10.1111/j.1432-1033.1975.tb04150.x; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; KRESAK M, 1977, J COLLOID INTERF SCI, V59, P283, DOI 10.1016/0021-9797(77)90010-8; LOOMIS RE, 1985, INT J PEPT PROT RES, V26, P621; Lowenstam HA, 1989, BIOMINERALIZATION; MAYR W, 1979, BIOPOLYMERS, V18, P425, DOI 10.1002/bip.1979.360180217; OEKONOMOPULOS R, 1980, BIOPOLYMERS, V19, P203, DOI 10.1002/bip.1980.360190114; OPPENHEIM FG, 1971, BIOCHEMISTRY-US, V10, P4233, DOI 10.1021/bi00799a013; PERICH JW, 1988, TETRAHEDRON LETT, V29, P2369, DOI 10.1016/S0040-4039(00)86062-1; POSNER AS, 1958, ACTA CRYSTALLOGR, V11, P308, DOI 10.1107/S0365110X58000815; RAJ PA, 1990, J BIOL CHEM, V265, P3898; RAJ PA, 1985, BIOPOLYMERS, V24, P1131, DOI 10.1002/bip.360240703; RAMASUBBU N, 1991, BIOCHEM J, V280, P341, DOI 10.1042/bj2800341; RONISH EW, 1974, BIOPOLYMERS, V13, P1635, DOI 10.1002/bip.1974.360130810; SCHLESINGER DH, 1977, J BIOL CHEM, V252, P1689; SCHLESINGER DH, 1987, INT J PEPT PROT RES, V30, P257; SCHLESINGER DH, 1977, PEPTIDES, P56; Simkiss K, 1989, BIOMINERALIZATION CE; SMITH JA, 1980, CRC CR REV BIOCH MOL, V8, P315, DOI 10.3109/10409238009105470; STEWART JM, 1984, SOLID PHASE PEPTIDE, P90; SUDHA TS, 1983, INT J PEPT PROT RES, V22, P464; TOMSON MB, 1978, SCIENCE, V200, P1059, DOI 10.1126/science.200.4345.1059; TOMSON MB, 1977, ATOMIC ABSORPTION NE, V16, P117; VEIS A, 1991, ACS SYM SER, V444, P1; VIJAYAKUMAR EKS, 1984, BIOPOLYMERS, V23, P877, DOI 10.1002/bip.360230505; VOGEL HJ, 1982, BIOCHEMISTRY-US, V21, P5825, DOI 10.1021/bi00266a016; WEINER S, 1991, TRENDS BIOCHEM SCI, V16, P252, DOI 10.1016/0968-0004(91)90098-G; Woody RW, 1974, PEPTIDES POLYPEPTIDE, P338; 1968, BIOCHEMISTRY-US, V7, P2703	51	212	219	0	52	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5968	5976						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1313424				2022-12-27	WOS:A1992HK31800042
J	BERKOWITZ, P; HUH, NW; BROSTROM, KE; PANEK, MG; WEBER, DJ; TULINSKY, A; PEDERSEN, LG; HISKEY, RG				BERKOWITZ, P; HUH, NW; BROSTROM, KE; PANEK, MG; WEBER, DJ; TULINSKY, A; PEDERSEN, LG; HISKEY, RG			A METAL ION-BINDING SITE IN THE KRINGLE REGION OF BOVINE PROTHROMBIN FRAGMENT-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-BINDING; PEPTIDE	Ca-45(II) binding studies (equilibrium dialysis) on the kringle domain of bovine prothrombin fragment 1 were conducted using a mixture of peptides (residues 43-156 and 46-156) resulting from limited alpha-chymotryptic hydrolysis of fragment 1. Analysis of the Scatchard plot of these data indicates a single, low affinity Ca(II)-binding site to be present. Similar results were obtained from studies on the decarboxylated fragment 1 derivative, 10-gamma-MGlu-fragment 1. Acetylation of bovine fragment 1 in the absence of Ca(II) or Mg(II) ions results in the loss of the metal ion-promoted quenching of the intrinsic Trp fluorescence of the protein and the Ca(II)-mediated binding to phosphatidylserine/phosphatidylcholine (PS/PC) vesicles. The acetylation of the NH2-alpha-group of Ala-1 has been shown (Welsch, D. J., and Nelsestuen, G. L. (1988) Biochemistry 27, 4946-4952) to abolish the PS/PC binding property of fragment 1. The present study demonstrates that acetylation of a second site possibly Ser-79 or Thr-81 using the conditions described in the preceding paper results in loss of both the fluorescence transition and the Ca(II)-mediated PS/PC binding of the resulting protein derivative. Removal of the O-acetyl group at the Ser-79/Thr-81 site is accomplished by aminolysis with 0.2 M hydroxylamine, pH 10, 50-degrees-C; the fluorescence transition is partially restored. PS/PC binding is partially restored if the NH2-group of Ala-1 is trinitrophenylated but is not restored if the NH2-alpha-group of Ala-1 is acetylated. We conclude that the Ser-79/Thr-81 site may represent a portion of the metal ion-binding site within the kringle domain of fragment 1. Occupancy of this site by a Ca(II) ion appears to be important in the binding of the protein to PS/PC vesicles.	UNIV N CAROLINA,DEPT CHEM,CHAPEL HILL,NC 27599; MICHIGAN STATE UNIV,DEPT CHEM,E LANSING,MI 48824	University of North Carolina; University of North Carolina Chapel Hill; Michigan State University			Pedersen, Lee G/E-3405-2013; Weber, David J/B-5349-2011	Pedersen, Lee G/0000-0003-1262-9861; Weber, David J/0000-0002-8824-1110	NHLBI NIH HHS [HL-06350, HL-27995, HL-20161] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL027995, R37HL020161, R01HL020161] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		DUBRAY G, 1982, ANAL BIOCHEM, V119, P325, DOI 10.1016/0003-2697(82)90593-0; HELDEBRANT CM, 1973, J BIOL CHEM, V248, P3642; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANN KG, 1977, METHOD ENZYMOL, V451, P123; MANTLE M, 1978, Biochemical Society Transactions, V6, P607; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4164, DOI 10.1021/bi00638a005; PLETCHER CH, 1980, J BIOL CHEM, V255, P7433; POLLOCK JS, 1988, J BIOL CHEM, V263, P14216; SESHADRI TP, 1991, J MOL BIOL, V220, P481, DOI 10.1016/0022-2836(91)90025-2; SORIANOGARCIA M, 1989, BIOCHEMISTRY-US, V28, P6805, DOI 10.1021/bi00443a004; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; WEBER DJ, 1992, J BIOL CHEM, V267, P4564; WELSCH DJ, 1988, BIOCHEMISTRY-US, V27, P4939, DOI 10.1021/bi00413a052; WELSCH DJ, 1988, BIOCHEMISTRY-US, V27, P4933, DOI 10.1021/bi00413a051; WELSCH DJ, 1988, BIOCHEMISTRY-US, V27, P7513, DOI 10.1021/bi00419a050; WELSCH DJ, 1988, CURRENT ADV VITAMIN, P371; ZAPATA GA, 1988, J BIOL CHEM, V263, P8150	17	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4570	4576						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1311313				2022-12-27	WOS:A1992HF64200046
J	WITCHER, DR; STRIFLER, BA; JONES, LR				WITCHER, DR; STRIFLER, BA; JONES, LR			CARDIAC-SPECIFIC PHOSPHORYLATION SITE FOR MULTIFUNCTIONAL CA2+ CALMODULIN-DEPENDENT PROTEIN-KINASE IS CONSERVED IN THE BRAIN RYANODINE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM VESICLES; SENSITIVE CALCIUM CHANNELS; MOLECULAR-WEIGHT PROTEINS; CA-2+ RELEASE CHANNEL; MEMBRANES; SOLUBILIZATION; PURIFICATION; SLICES	An antiserum raised against the region of the cardiac ryanodine receptor (residues 2805-2819) containing the phosphorylation site for multifunctional Ca2+/calmodulin-dependent protein kinase (CaM kinase) was used to identify the brain ryanodine receptor. This antiserum, which is cardiac isoform-specific, immunoprecipitated greater than 90% of the [H-3]ryanodine receptor binding sites solubilized from guinea pig brain membranes. The immunoprecipitated brain receptor exhibited the characteristic cardiac-type mobility on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The brain ryanodine receptor, like the cardiac ryanodine receptor, was a substrate for CaM kinase. Affinity-purified, site-specific antibodies completely blocked phosphorylation of both brain and cardiac receptors by CaM kinase, and two-dimensional peptide mapping identified the same major P-32-labeled peptide in receptors from both tissues. I-125-Labeled receptors also gave the same peptide maps. These results confirm that mammalian brain expresses the cardiac isoform of the ryanodine receptor. Furthermore, the unique CaM kinase phosphorylation site, which has been shown to regulate Ca2+ channel activity, is conserved.	INDIANA UNIV, SCH MED, DEPT PHARMACOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT MED, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	WITCHER, DR (corresponding author), INDIANA UNIV, SCH MED, KRANNERT INST CARDIOL, INDIANAPOLIS, IN 46202 USA.				NHLBI NIH HHS [HL06308, HL28556] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028556] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHLEY RH, 1989, J MEMBRANE BIOL, V111, P179, DOI 10.1007/BF01871781; ELDER JH, 1977, J BIOL CHEM, V252, P6510; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; IMAGAWA T, 1989, J BIOCHEM-TOKYO, V106, P342, DOI 10.1093/oxfordjournals.jbchem.a122855; JONES LR, 1985, J BIOL CHEM, V260, P7721; JONES LR, 1975, J BIOL CHEM, V250, P973; JUDD RC, 1990, METHOD ENZYMOL, V182, P613; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCPHERSON PS, 1990, J BIOL CHEM, V265, P18454; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; OTSU K, 1990, J BIOL CHEM, V265, P13472; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; PESSAH IN, 1985, BIOCHEM BIOPH RES CO, V128, P449, DOI 10.1016/0006-291X(85)91699-7; RARDON DP, 1990, CIRC RES, V67, P84, DOI 10.1161/01.RES.67.1.84; RARDON DP, 1989, CIRC RES, V64, P779, DOI 10.1161/01.RES.64.4.779; SCHULMAN H, 1988, ADV SEC MESS PHOSPH, V22, P39; SEILER S, 1984, J BIOL CHEM, V259, P8550; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; THAYER SA, 1988, MOL PHARMACOL, V34, P664; WALTON PD, 1991, J CELL BIOL, V113, P1145, DOI 10.1083/jcb.113.5.1145; WITCHER DR, 1991, J BIOL CHEM, V266, P11144	25	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4963	4967						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1311325				2022-12-27	WOS:A1992HF64200099
J	VERMA, RS; GULLAPALLI, S; ANTONY, AC				VERMA, RS; GULLAPALLI, S; ANTONY, AC			EVIDENCE THAT THE HYDROPHOBICITY OF ISOLATED, INSITU, AND DENOVO-SYNTHESIZED NATIVE HUMAN PLACENTAL FOLATE RECEPTORS IS A FUNCTION OF GLYCOSYL-PHOSPHATIDYLINOSITOL ANCHORING TO MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN KB-CELLS; AMINO-ACID-SEQUENCE; BINDING-PROTEIN; METHOTREXATE TRANSPORT; HYDROPHILIC FORMS; PHOSPHOLIPASE-C; MA104 CELLS; IDENTIFICATION; CDNA; 5-METHYLTETRAHYDROFOLATE	Although normal human chorionic villi-associated hydrophobic placental folate receptors (PFR) are converted to hydrophilic forms by an endogenous, EDTA-sensitive, Mg2+-dependent protease under serum-free conditions (Verma, R. S., and Antony, A. C. (1991) J. Biol. Chem. 266, 12522-12535), it is not known whether hydrophobic PFR are also susceptible to conversion by endogenous phospholipases. We isolated and characterized hydrophobic PFR, and tested the hypothesis that purified, in situ, and de novo-synthesized native PFR were covalently linked to glycosyl-phosphatidylinositol (GPI) anchors. I-125-hydrophobic PFR, but not I-125-hydrophilic PFR, (i) separated into the Triton X-114 micellar phase at 30-degrees-C, (ii) efficiently incorporated into phosphatidylcholine-cholesterol liposomes, and (iii) were covalently labeled by the hydrophobic probe 3-(trifluoromethyl)-3-(meta[I-125]iodophenyl)diazirine, [I-125]TID. (iv) [I-125]TID-labeled- and [phenyl-H-3]Triton X-100-bound hydrophobic PFR, as well as native PFR in situ, were released as hydrophilic forms by recombinant (r) GPI-specific phospholipase(PL) C (GPI-PLC), and GPI-PLD (but not by PLC), in the absence and presence of a concentration of EDTA known to inhibit endogenous Mg2+-dependent protease. (v) Nitrous acid deamination of [I-125]TID-labeled hydrophobic PFR as well as (r)GPI-PLC cleavage of [phenyl-H-3]Triton-X-100- and [I-125] TID-labeled hydrophobic PFR, released hydrophobic radiolabeled moieties which comigrated on thin layer chromatography distinct from free radiolabel. Finally, (vi) biosynthetic studies on chorionic villi cultured in vitro revealed incorporation of radiolabeled precursors into the GPI anchor of hydrophobic PFR. We conclude that native hydrophobic PFR are linked to GPI anchors and are therefore potential substrates for three distinct endogenous enzymes (GPI-PLC, GPI-PLD, and specific Mg2+-dependent metalloprotease) in maternal serum and placenta in vivo.	INDIANA UNIV,SCH MED,DEPT MED,DIV HEMATOL ONCOL,INDIANAPOLIS,IN 46223	Indiana University System; Indiana University-Purdue University Indianapolis				Verma, Rama/0000-0001-7287-7803	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020889] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008307] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA-08307] Funding Source: Medline; NICHD NIH HHS [HD-20889] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Antony A. C., 1991, HEMATOLOGY BASIC PRI, P392; ANTONY AC, 1989, BIOCHIM BIOPHYS ACTA, V979, P62, DOI 10.1016/0005-2736(89)90523-3; ANTONY AC, 1987, J CLIN INVEST, V80, P711, DOI 10.1172/JCI113126; ANTONY AC, 1985, J BIOL CHEM, V260, P4911; ANTONY AC, 1991, J CLIN INVEST, V87, P313, DOI 10.1172/JCI114989; ANTONY AC, 1982, J BIOL CHEM, V257, P81; ANTONY AC, 1987, J CLIN INVEST, V80, P1618, DOI 10.1172/JCI113249; ANTONY AC, 1989, J BIOL CHEM, V264, P1911; ANTONY AC, 1987, ANAL BIOCHEM, V162, P224, DOI 10.1016/0003-2697(87)90031-5; ANTONY AC, 1981, J BIOL CHEM, V256, P9684; BABIOR B, 1989, HEMATOLOGY, P453; BLOW D, 1991, NATURE, V351, P444, DOI 10.1038/351444a0; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRUNNER J, 1980, J BIOL CHEM, V255, P3313; BRUNNER J, 1981, BIOCHEMISTRY-US, V20, P7174, DOI 10.1021/bi00528a019; COLE BR, 1978, ELECTROPHORESIS 78, P79; DEUTSCH JC, 1989, ARCH BIOCHEM BIOPHYS, V274, P327, DOI 10.1016/0003-9861(89)90446-3; DOERING TL, 1990, J BIOL CHEM, V265, P611; ELWOOD PC, 1986, J BIOL CHEM, V261, P5416; ELWOOD PC, 1989, J BIOL CHEM, V264, P14893; ELWOOD PC, 1991, J BIOL CHEM, V266, P2346; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; HENDERSON GB, 1990, ANNU REV NUTR, V10, P319, DOI [10.1146/annurev.nutr.10.1.319, 10.1146/annurev.nu.10.070190.001535]; HENDERSON GB, 1988, J MEMBRANE BIOL, V101, P247, DOI 10.1007/BF01872839; HENNER DJ, 1988, NUCLEIC ACIDS RES, V16, P10383, DOI 10.1093/nar/16.21.10383; HIBBS ML, 1989, SCIENCE, V246, P1608, DOI 10.1126/science.2531918; JANSEN G, 1989, CANCER RES, V49, P1959; JANSEN G, 1989, CANCER RES, V49, P2455; JANSEN G, 1990, J BIOL CHEM, V265, P18272; KAMEN BA, 1989, J CLIN INVEST, V84, P1379, DOI 10.1172/JCI114310; KAMEN BA, 1986, P NATL ACAD SCI USA, V83, P5983, DOI 10.1073/pnas.83.16.5983; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KAMEN BA, 1975, P NATL ACAD SCI USA, V77, P4261; KANE MA, 1986, J BIOL CHEM, V261, P44; KANE MA, 1986, J BIOL CHEM, V261, P5625; KANE MA, 1988, J CLIN INVEST, V81, P1398, DOI 10.1172/JCI113469; KREBS J, 1984, BIOCHEMISTRY-US, V23, P400, DOI 10.1021/bi00298a002; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; LANIER LL, 1989, SCIENCE, V246, P1611, DOI 10.1126/science.2531919; LAVAPPA KS, 1976, NATURE, V259, P212; LOW MG, 1989, FASEB J, V3, P1600, DOI 10.1096/fasebj.3.5.2522071; LOW MG, 1988, J IMMUNOL METHODS, V113, P101, DOI 10.1016/0022-1759(88)90386-9; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; LOW MG, 1987, BIOCHEM J, V244, P1; LOW MG, 1988, P NATL ACAD SCI USA, V85, P980, DOI 10.1073/pnas.85.4.980; LUHRS CA, 1989, J BIOL CHEM, V264, P21446; LUHRS CA, 1986, ARCH BIOCHEM BIOPHYS, V250, P94, DOI 10.1016/0003-9861(86)90705-8; LUHRS CA, 1987, P NATL ACAD SCI USA, V84, P6546, DOI 10.1073/pnas.84.18.6546; LUHRS CA, 1990, BLOOD, V76, P152; MALIK AS, 1986, BIOCHEM J, V240, P519, DOI 10.1042/bj2400519; MCHUGH M, 1979, J BIOL CHEM, V254, P1312; PAGE ST, 1990, BLOOD, V76; RATNAM M, 1989, BIOCHEMISTRY-US, V28, P8249, DOI 10.1021/bi00446a042; ROBERTS WL, 1987, P NATL ACAD SCI USA, V84, P7817, DOI 10.1073/pnas.84.22.7817; ROBERTS WL, 1986, BIOCHEMISTRY-US, V25, P3091, DOI 10.1021/bi00359a004; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SADASIVAN E, 1989, J BIOL CHEM, V264, P5806; SADASIVAN E, 1990, J BIOL CHEM, V265, P1821; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SVENDSEN IB, 1982, CARLSBERG RES COMMUN, V47, P371, DOI 10.1007/BF02907775; TARANTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665; TAYLOR MA, 1979, FATTY ACIDS, P195; VERMA RS, 1991, J BIOL CHEM, V266, P12522	64	64	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4119	4127						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1310989				2022-12-27	WOS:A1992HE60700082
J	CHEN, CH; CHENG, YC				CHEN, CH; CHENG, YC			THE ROLE OF CYTOPLASMIC DEOXYCYTIDINE KINASE IN THE MITOCHONDRIAL EFFECTS OF THE ANTI-HUMAN-IMMUNODEFICIENCY-VIRUS COMPOUND, 2',3'-DIDEOXYCYTIDINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DEOXYRIBONUCLEIC-ACID; DNA REPLICATION; HELA-CELLS; 3'-AZIDO-3'-DEOXYTHYMIDINE; INFECTIVITY; INHIBITION; THYMIDINE; INVITRO; ANALOGS	2',3'-Dideoxycytidine (ddC) is a potent inhibitor of human immunodeficiency virus replication in vitro and shows beneficial effects in AIDS therapy. The compound inhibits mitochondrial DNA (mtDNA) synthesis at a clinically relevant concentration, which could be responsible for the side effects of ddC observed in the clinic. Thymidine (dThd), one of the substrates of mitochondrial deoxypyrimidine kinase (dPyd kinase), was not able to reverse the mitochondrial toxicity of ddC in CEM cells. Furthermore, the cytoplasmic deoxycytidine kinase (dCyd kinase)-deficient CEM cells were highly resistant to the mitochondrial toxicity of ddC. These data suggest a critical role for cytoplasmic dCyd kinase in the mitochondrial toxicity of ddC. The metabolites of ddC, but not ddC itself, were able to inhibit mtDNA synthesis in isolated mitochondria. The potency of the inhibitory effect was in the order of ddCTP > ddCDP > ddCMP > ddC. The lack of inhibition by ddC of mtDNA synthesis could be due to the inefficient ddC phosphorylation in mitochondria. Although the mitochondrial dPyd kinase was reported to phosphorylate ddC, the phosphorylation of ddC in isolated mitochondria was not detectable. The data suggest that ddC is phosphorylated to ddCTP in the cytoplasm and then transported into mitochondria to exert its inhibitory effect on mtDNA synthesis.	YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510	Yale University								BESTWICK RK, 1982, J BIOL CHEM, V257, P9300; BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991; BRESSER J, 1983, DNA-J MOLEC CELL BIO, V2, P243, DOI 10.1089/dna.1983.2.243; CHEN CH, 1989, J BIOL CHEM, V264, P11934; COONEY DA, 1986, BIOCHEM PHARMACOL, V35, P2065, DOI 10.1016/0006-2952(86)90571-X; DUBINSKY RM, 1989, MUSCLE NERVE, V12, P856, DOI 10.1002/mus.880121012; LEE LS, 1976, BIOCHEMISTRY-US, V15, P3686, DOI 10.1021/bi00662a007; MITRA RS, 1970, J BIOL CHEM, V245, P1255; MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911; ROBIN ED, 1988, J CELL PHYSIOL, V136, P507, DOI 10.1002/jcp.1041360316; RUTH JL, 1981, MOL PHARMACOL, V20, P415; SIMPSON MV, 1989, BIOCHEM PHARMACOL, V38, P1033, DOI 10.1016/0006-2952(89)90245-1; STARNES MC, 1987, J BIOL CHEM, V262, P988; VAZQUEZPADUA MA, 1990, CANCER COMMUN, V2, P55, DOI 10.3727/095535490820874740; YARCHOAN R, 1988, LANCET, V1, P76; ZIMMERMANN W, 1980, J BIOL CHEM, V255, P1847	16	77	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					2856	2859						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1310674				2022-12-27	WOS:A1992HD15400006
J	BACKER, JM; SCHROEDER, GG; KAHN, CR; MYERS, MG; WILDEN, PA; CAHILL, DA; WHITE, MF				BACKER, JM; SCHROEDER, GG; KAHN, CR; MYERS, MG; WILDEN, PA; CAHILL, DA; WHITE, MF			INSULIN STIMULATION OF PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY MAPS TO INSULIN-RECEPTOR REGIONS REQUIRED FOR ENDOGENOUS SUBSTRATE PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; TYROSINE KINASE-ACTIVITY; COOH-TERMINAL TRUNCATION; GROWTH-FACTOR RECEPTORS; PDGF RECEPTOR; MIDDLE-T; INTACT-CELLS; BETA-SUBUNIT; BINDING SITE; PROTEIN	We have studied the phosphatidylinositol 3-kinase (PtdIns 3-kinase) in insulin-stimulated Chinese hamster ovary (CHO) cells expressing normal (CHO/IR) and mutant human insulin receptors. Insulin stimulation of CHO/IR cells results in an increase in PtdIns 3-kinase activity associated with anti-phosphotyrosine (alpha-PY) immunoprecipitates, which has been previously shown to correlate with the in vivo production of PtdIns(3,4)P2, and PtdIns(3,4,5)P3 (Ruderman, N., Kapeller, R., White, M. F., and Cantley, L. C. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 1411-1415). Stimulation was maximal within 1 min and showed a dose response identical to that of insulin receptor autophosphorylation. The PtdIns 3-kinase also associated with the insulin receptor in an insulin-stimulated manner, as approximately 50% of the total alpha-PY-precipitable activity could be specifically immunoprecipitated with anti-insulin receptor antibody. Mutant insulin receptors displayed variable ability to stimulate the PtdIns 3-kinase, but in all cases the presence of PtdIns 3-kinase in alpha-PY immunoprecipitates correlated closely with the tyrosyl phosphorylation of the endogenous substrate pp185. In CHO cells expressing a kinase-deficient mutant (IR(A1018)), there was no observable insulin stimulation of PtdIns 3-kinase activity in alpha-PY immunoprecipitates and no tyrosyl phosphorylation of pp185. Substitution of Tyr1146 in the insulin receptor regulatory region with phenylalanine partially impaired receptor autophosphorylation, pp185 phosphorylation, and insulin-stimulated increases in alpha-PY-precipitable PtdIns 3-kinase activity. In contrast, a deletion mutant lacking 12 amino acids from the juxtamembrane region (IR(DELTA-960)) displayed normal in vivo autophosphorylation but failed to stimulate the PtdIns 3-kinase or phosphorylate pp185. Finally, a mutant receptor from which the C-terminal 43 amino acids had been deleted (IR(DELTA-CT)) exhibited normal insulin-stimulated autophosphorylation, pp185 phosphorylation, and stimulation of the PtdIns 3-kinase activity in alpha-PY immunoprecipitates. These data suggest that the PtdIns 3-kinase is itself a substrate of the insulin receptor kinase or associates preferentially with a substrate. A comparison of the biological activities of the mutant receptors with their activation of the PtdIns 3-kinase furthermore suggests that the PtdIns 3-kinase may be linked to insulin's ability to regulate DNA synthesis and cell growth.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	BACKER, JM (corresponding author), BRIGHAM & WOMENS HOSP, JOSLIN DIABET CTR, DEPT MED, DIV RES, 1 JOSLIN PL, BOSTON, MA 02115 USA.		Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NIDDK NIH HHS [DK33201, DK38712, DK36836] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033201, R29DK038712, R55DK038712, P30DK036836, R01DK038712] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1990, J BIOL CHEM, V265, P16450; BACKER JM, 1981, BIOCHEMISTRY-US, V30, P6366; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CHOUDHURY GG, 1991, J BIOL CHEM, V266, P8068; COHEN B, 1990, MOL CELL BIOL, V10, P2909, DOI 10.1128/MCB.10.6.2909; COHEN B, 1990, P NATL ACAD SCI USA, V87, P4458, DOI 10.1073/pnas.87.12.4458; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FUKUI Y, 1991, MOL CELL BIOL, V11, P1972, DOI 10.1128/MCB.11.4.1972; HEIDARAN MA, 1991, MOL CELL BIOL, V11, P134, DOI 10.1128/MCB.11.1.134; Kahn C R, 1981, Recent Prog Horm Res, V37, P477; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KAPELLER R, 1991, MOL ENDOCRINOL, V5, P769, DOI 10.1210/mend-5-6-769; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPS DL, 1989, J BIOL CHEM, V264, P8759; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MARON R, 1984, DIABETOLOGIA, V27, P118, DOI 10.1007/BF00275665; MCCLAIN DA, 1988, J BIOL CHEM, V263, P8904; MYERS MG, 1991, J BIOL CHEM, V266, P10616; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PIGNATARO OP, 1990, J BIOL CHEM, V265, P1718; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SHYMKO RM, 1989, BIOCHEM BIOPH RES CO, V164, P191, DOI 10.1016/0006-291X(89)91701-4; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SOEDA E, 1980, NATURE, V283, P445, DOI 10.1038/283445a0; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITE MF, 1991, METHOD ENZYMOL, V201, P65; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	60	144	145	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1367	1374						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1309768				2022-12-27	WOS:A1992GY96000107
J	COOPER, CE; SALERNO, JC				COOPER, CE; SALERNO, JC			CHARACTERIZATION OF A NOVEL G' = 2.95 EPR SIGNAL FROM THE BINUCLEAR CENTER OF MITOCHONDRIAL CYTOCHROME-C-OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RES; ABSORPTION FINE-STRUCTURE; ESCHERICHIA-COLI; ACTIVE-SITE; COPPER; CYANIDE; COMPLEX; MODELS; FORM; IRON	The oxidized binuclear heme a3/Cu(B) center of slow forms of bovine cytochrome oxidase exhibits a characteristic EPR signal at g' = 12. Following the (rapid) dithionite reduction of heme a and Cu(A), an additional EPR signal becomes apparent at g' = 2.95. As electrons enter the binuclear center this signal decays at the same slow rate as the g' = 12 signal. In the fully oxidized slow enzyme the small g' = 2.95 signal is usually masked by the g = 3 heme a signal, but it is readily detectable at low temperatures and high microwave powers. It is present in both the intrinsic and formate-ligated slow enzymes, but not in any form of fast preparation. The g' = 2.95 signal has similar temperature dependence and microwave power saturation characteristics to the g' = 12 signal. We conclude that the signal arises from the same population of binuclear centers responsible for the g' = 12 signal. The appearance of a signal at g' = 2.95 in X-band EPR is consistent with, but does not prove, the model of Hagen where the g' = 12 signal arises from a ferryl heme a3, with Cu(B) cuprous and EPR-silent (Hagen, W. R. (1982) Biochim. Biophys. Acta 708, 82-98).	RENSSELAER POLYTECH INST,DEPT BIOL,TROY,NY 12181	Rensselaer Polytechnic Institute	COOPER, CE (corresponding author), KINGS COLL LONDON,DIV BIOMOLEC SCI,CAMPDEN HILL RD,LONDON W8 7AH,ENGLAND.		salerno, john c/A-2595-2014	Cooper, Chris/0000-0003-0381-3990				AASA R, 1976, BIOCHIM BIOPHYS ACTA, V422, P260, DOI 10.1016/0005-2744(76)90137-6; ANTONINI E, 1977, P NATL ACAD SCI USA, V74, P3128, DOI 10.1073/pnas.74.8.3128; BAKER GM, 1987, J BIOL CHEM, V262, P595; BEINERT H, 1977, BIOCHIM BIOPHYS ACTA, V462, P121, DOI 10.1016/0005-2728(77)90194-3; BOELENS R, 1979, BIOCHIM BIOPHYS ACTA, V547, P296, DOI 10.1016/0005-2728(79)90012-4; BRANDT U, 1989, EUR J BIOCHEM, V182, P705, DOI 10.1111/j.1432-1033.1989.tb14882.x; BREWER GA, 1984, INORG CHEM, V23, P2532, DOI 10.1021/ic00184a031; BRODIE JD, 1970, BIOCHIM BIOPHYS ACTA, V198, P423, DOI 10.1016/0005-2744(70)90121-X; BRUDVIG GW, 1981, BIOCHEMISTRY-US, V20, P3912, DOI 10.1021/bi00516a039; BRUNORI M, 1981, FEBS LETT, V126, P195, DOI 10.1016/0014-5793(81)80240-2; BRUNORI M, 1979, J BIOL CHEM, V254, P769; CHANPLUNG V, 1985, J CHEM SOC CHEM COMM, P1761; CHEPURI V, 1990, BIOCHIM BIOPHYS ACTA, V1018, P124, DOI 10.1016/0005-2728(90)90231-R; CLINE J, 1983, J BIOL CHEM, V258, P5124; COOPER CE, 1991, BIOCHEM SOC T, V19, pS259, DOI 10.1042/bst019259s; DUNHAM WR, 1983, BIOCHIM BIOPHYS ACTA, V748, P73, DOI 10.1016/0167-4838(83)90029-8; ELLIOTT CM, 1987, INORG CHEM, V26, P3655, DOI 10.1021/ic00269a008; ELLIOTT CM, 1982, J AM CHEM SOC, V104, P2671, DOI 10.1021/ja00373a072; GREENAWAY FT, 1977, BIOCHIM BIOPHYS ACTA, V490, P62, DOI 10.1016/0005-2795(77)90106-4; GUNTER MJ, 1984, J AM CHEM SOC, V106, P4227, DOI 10.1021/ja00327a027; HAGEN WR, 1982, BIOCHIM BIOPHYS ACTA, V708, P82, DOI 10.1016/0167-4838(82)90206-0; HILL BC, 1984, BIOCHEM J, V224, P591, DOI 10.1042/bj2240591; HOLM L, 1987, EMBO J, V6, P2819, DOI 10.1002/j.1460-2075.1987.tb02578.x; IOANNIDIS N, 1991, THESIS U LONDON; JENSEN P, 1981, FEBS LETT, V125, P161, DOI 10.1016/0014-5793(81)80709-0; JONES MG, 1984, BIOCHEM J, V220, P57, DOI 10.1042/bj2200057; KAERLSSON B, 1981, BIOCHIM BIOPHYS ACTA, V635, P73; Keilin D, 1940, PROC R SOC SER B-BIO, V129, P277, DOI 10.1098/rspb.1940.0040; KEYHANI J, 1980, BIOCHEM BIOPH RES CO, V92, P327, DOI 10.1016/0006-291X(80)91556-9; KUBOYAMA M, 1972, J BIOL CHEM, V247, P6375; KUMAR C, 1984, J BIOL CHEM, V259, P1668; LI PM, 1987, BIOCHEMISTRY-US, V26, P2091, DOI 10.1021/bi00382a005; MALMSTROM BG, 1989, FEBS LETT, V250, P9, DOI 10.1016/0014-5793(89)80675-1; MOODY AJ, 1991, BIOCHIM BIOPHYS ACTA, V1059, P189, DOI 10.1016/S0005-2728(05)80204-X; NAQUI A, 1984, BIOCHEMISTRY-US, V23, P6222, DOI 10.1021/bi00320a051; PALMER G, 1988, CHEM SCRIPTA, V28A, P41; PALMER G, 1976, P NATL ACAD SCI USA, V73, P2206, DOI 10.1073/pnas.73.7.2206; PAPADOPOULOS PG, 1991, BIOCHEMISTRY-US, V30, P840, DOI 10.1021/bi00217a038; PETTY RH, 1980, J AM CHEM SOC, V102, P611, DOI 10.1021/ja00522a028; POWERS L, 1981, BIOPHYS J, V34, P465, DOI 10.1016/S0006-3495(81)84863-1; REINHAMMAR B, 1980, J BIOL CHEM, V255, P5000; RUPP H, 1978, BIOCHIM BIOPHYS ACTA, V537, P255, DOI 10.1016/0005-2795(78)90509-3; SALERNO JC, 1990, J BIOL CHEM, V265, P4364; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SCHOONOVER JR, 1991, BIOCHEMISTRY-US, V30, P7541, DOI 10.1021/bi00244a025; SCOTT RA, 1989, ANNU REV BIOPHYS BIO, V18, P137, DOI 10.1146/annurev.bb.18.060189.001033; SERR BR, 1990, INORG CHEM, V29, P2663, DOI 10.1021/ic00339a025; STEVENS TH, 1981, J BIOL CHEM, V256, P1069; VANBUUREN KJ, 1972, BIOCHIM BIOPHYS ACTA, V256, P258, DOI 10.1016/0005-2728(72)90057-6; WILSON DF, 1976, ARCH BIOCHEM BIOPHYS, V175, P160, DOI 10.1016/0003-9861(76)90495-1; WITT SN, 1986, J BIOL CHEM, V261, P8104; WRIGGLESWORTH JM, 1988, BIOCHIM BIOPHYS ACTA, V936, P452, DOI 10.1016/0005-2728(88)90023-0; WRIGGLESWORTH JM, 1991, BIOCHEM SOC T, V19, pS258, DOI 10.1042/bst019258s; YOUNG LJ, 1988, BIOCHEMISTRY-US, V27, P5115, DOI 10.1021/bi00414a025	54	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					280	285						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1309737				2022-12-27	WOS:A1992GY43900047
J	KASPAR, RL; KAKEGAWA, T; CRANSTON, H; MORRIS, DR; WHITE, MW				KASPAR, RL; KAKEGAWA, T; CRANSTON, H; MORRIS, DR; WHITE, MW			A REGULATORY CIS ELEMENT AND A SPECIFIC BINDING-FACTOR INVOLVED IN THE MITOGENIC CONTROL OF MURINE RIBOSOMAL-PROTEIN L32 TRANSLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DECARBOXYLASE MESSENGER-RNA; 5' UNTRANSLATED REGION; ACTIVATED LYMPHOCYTES; GENE-EXPRESSION; IDENTIFICATION; INITIATION; VIRUS; CELLS; SITE; PURIFICATION	The mRNA encoding ribosomal protein L32 redistributes from untranslated subribosomal particles into polysomes after mitogenic activation of quiescent T-lymphocytes and fibroblasts. To identify the regions of the L32 mRNA which are important in regulating its cytoplasmic location we constructed a plasmid containing the murine L32 cDNA under the control of the Rous sarcoma virus (RSV) long terminal repeat promoter and introduced this construct into murine 3T3 fibroblasts. The mRNA transcribed from the RSV-L32 construct redistributed from subribosomal particles into polysomes in response to mitogenic activation in a manner similar to endogenous L32 mRNA. A conserved polypyrimidine region present at the 5' terminus of all ribosomal protein mRNAs is required for translational regulation of L32 mRNA since deletion of this sequence resulted in a mRNA that was not sequestered in subribosomal particles in quiescent cells. A radioactive RNA probe containing the first 34 nucleotides of the L32 5'-untranslated region, including the polypyrimidine region, specifically interacted with a protein of about 56 kDa. This protein did not bind detectably to RNA probes lacking the polypyrimidine sequence. Binding activity was similar in protein extracts made from resting and activated cells, suggesting that binding of the 56-kDa protein as measured in this assay is not regulated. This protein is a member of what may be an emerging family of polyribopyrimidine-binding proteins with diverse biochemical functions.	MONTANA STATE UNIV,DEPT VET MOLEC BIOL,BOZEMAN,MT 59717; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	Montana State University System; Montana State University Bozeman; University of Washington; University of Washington Seattle			Morris, David/G-4503-2011; White, Michael/A-4978-2012		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007183] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA039053] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042791] Funding Source: NIH RePORTER; NCI NIH HHS [CA39053] Funding Source: Medline; NICHD NIH HHS [HD07183] Funding Source: Medline; NIGMS NIH HHS [GM42791] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; BOWMAN LH, 1987, MOL CELL BIOL, V7, P4464, DOI 10.1128/MCB.7.12.4464; DEGEN JL, 1983, J BIOL CHEM, V258, P2153; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; ERLICH HA, 1989, PCR TECHNOLOGY PRINC, P35; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GEYER PK, 1982, MOL CELL BIOL, V2, P685, DOI 10.1128/MCB.2.6.685; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HARIHARAN N, 1990, P NATL ACAD SCI USA, V87, P1526, DOI 10.1073/pnas.87.4.1526; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; JACOBSLORENA M, 1989, TRANSLATIONAL REGULA, P63; JANG SK, 1990, GENE DEV, V4, P1560, DOI 10.1101/gad.4.9.1560; KASPAR RL, 1990, J BIOL CHEM, V265, P3619; KUHN R, 1990, J VIROL, V64, P4625; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEVY S, 1991, P NATL ACAD SCI USA, V88, P3319, DOI 10.1073/pnas.88.8.3319; MAGER WH, 1988, BIOCHIM BIOPHYS ACTA, V949, P1, DOI 10.1016/0167-4781(88)90048-6; MANIATIS T, 1982, MOL CLONING LABORATO, P247; MARIOTTINI P, 1990, MOL CELL BIOL, V10, P816, DOI 10.1128/MCB.10.2.816; MARIOTTINI P, 1988, GENE, V67, P69, DOI 10.1016/0378-1119(88)90009-1; MEEROVITCH K, 1989, GENE DEV, V3, P1026, DOI 10.1101/gad.3.7.1026; MEYUHAS O, 1980, GENE, V10, P113, DOI 10.1016/0378-1119(80)90129-8; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NOMURA M, 1984, ANNU REV BIOCHEM, V53, P75, DOI 10.1146/annurev.bi.53.070184.000451; Sambrook J, 1989, MOL CLONING LABORATO; SANDHU GS, 1989, BIOTECHNIQUES, V7, P689; SEYFRIED CE, 1983, METHOD ENZYMOL, V94, P373; TUSHINSKI RJ, 1982, J CELL PHYSIOL, V112, P128, DOI 10.1002/jcp.1041120119; WAGNER M, 1985, MOL CELL BIOL, V5, P3560, DOI 10.1128/MCB.5.12.3560; WHITE MW, 1990, BIOCHEM J, V268, P657, DOI 10.1042/bj2680657; WHITE MW, 1987, EUR J BIOCHEM, V170, P87, DOI 10.1111/j.1432-1033.1987.tb13670.x; WOOL IG, 1990, STRUCTURE FUNCTION E, P203; YAMAMOTO T, 1980, CELL, V22, P787, DOI 10.1016/0092-8674(80)90555-3; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243	38	88	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					508	514						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1309750				2022-12-27	WOS:A1992GY43900081
J	CHAPPELL, DA; FRY, GL; WAKNITZ, MA; IVERIUS, PH; WILLIAMS, SE; STRICKLAND, DK				CHAPPELL, DA; FRY, GL; WAKNITZ, MA; IVERIUS, PH; WILLIAMS, SE; STRICKLAND, DK			THE LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN ALPHA-2-MACROGLOBULIN RECEPTOR BINDS AND MEDIATES CATABOLISM OF BOVINE-MILK LIPOPROTEIN-LIPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED FIBROBLASTS; HIGH-AFFINITY; PLASMA; METABOLISM; IDENTIFICATION; MECHANISM; LIVER; INTERNALIZATION; CHYLOMICRONS; REMNANTS	Lipoprotein lipase (LPL), the major lipolytic enzyme involved in the conversion of triglyceride-rich lipoproteins to remnants, was found to compete with binding of activated alpha2-macroglobulin (alpha2M*) to the low density lipoprotein receptor-related protein (LRP)/alpha2-macroglobulin receptor. Bovine milk LPL displaced both I-125-labeled alpha2M* and 39-kDa alpha2M receptor-associated protein (RAP) from the surface of cultured mutant fibroblasts lacking LDL receptors with apparent K(I) values at 4-degrees-C of 6.8 and 30 nM, respectively. Furthermore, LPL inhibited the cellular degradation of I-125-alpha2M* at 37-degrees-C. Because both alpha2M+ and RAP interact with LRP, these data suggest that LPL binds specifically to this receptor. This was further supported by observing that an immunoaffinity-isolated polyclonal antibody against LRP blocked cellular degradation of I-125-LPL in a dose-dependent manner. In addition, I-125-LPL bound to highly purified LRP in a solid-phase assay with a K(D) of 18 nM, and this binding could be partially displaced with alpha2M* (K(I) = 7 nM) and RAP (K(I) = 3 nM). Taken together, these data establish that LPL binds with high affinity to LRP and undergoes LRP-mediated cellular uptake. The implication of these findings for lipoprotein catabolism in vivo may be important if LRP binding is preserved when LPL is attached to lipoproteins. If so, LPL might facilitate LRP-mediated clearance of lipoproteins.	UNIV UTAH,VET AFFAIRS MED CTR,DEPT INTERNAL MED,SALT LAKE CITY,UT 84148; AMER RED CROSS,BIOCHEM LAB,ROCKVILLE,MD 20855	US Department of Veterans Affairs; Veterans Health Administration (VHA); Utah System of Higher Education; University of Utah; American Red Cross	CHAPPELL, DA (corresponding author), UNIV IOWA,COLL MED,DEPT INTERNAL MED,E318,IOWA CITY,IA 52242, USA.				NHLBI NIH HHS [HL02024, HL39595] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL039595, K08HL002024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BERGMAN EN, 1971, J CLIN INVEST, V50, P1831, DOI 10.1172/JCI106674; CHAPPELL DA, 1992, J BIOL CHEM, V254, P270; CHENG CF, 1981, J BIOL CHEM, V256, P2893; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DICKSON RB, 1981, J BIOL CHEM, V256, P3454; FELTS JM, 1975, BIOCHEM BIOPH RES CO, V66, P1467, DOI 10.1016/0006-291X(75)90524-0; FUCHS HE, 1982, BIOCHIM BIOPHYS ACTA, V716, P151, DOI 10.1016/0304-4165(82)90263-X; GARFINKEL AS, 1983, J LIPID RES, V24, P775; GOLDBERG IJ, 1986, J CLIN INVEST, V78, P1523, DOI 10.1172/JCI112744; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HOBBS HH, 1987, NEW ENGL J MED, V317, P734, DOI 10.1056/NEJM198709173171204; HOUGHTEN RA, 1986, BIOTECHNIQUES, V4, P522; IVERIUS PH, 1976, J BIOL CHEM, V251, P7791; JACKSON RL, 1986, METHOD ENZYMOL, V128, P288; KAPLAN J, 1979, J BIOL CHEM, V254, P7323; KERN PA, 1990, J LIPID RES, V31, P17; KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P3623, DOI 10.1073/pnas.79.11.3623; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; NILSSONEHLE P, 1980, ANNU REV BIOCHEM, V49, P667, DOI 10.1146/annurev.bi.49.070180.003315; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; PETERSON J, 1985, BIOCHIM BIOPHYS ACTA, V837, P262, DOI 10.1016/0005-2760(85)90049-9; SAXENA U, 1991, J BIOL CHEM, V266, P17516; SAXENA U, 1990, J BIOL CHEM, V265, P12880; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; STALENHOEF AFH, 1984, P NATL ACAD SCI-BIOL, V81, P1839, DOI 10.1073/pnas.81.6.1839; STEINER JP, 1985, BIOCHEMISTRY-US, V24, P2993, DOI 10.1021/bi00333a028; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VANLEUVEN F, 1979, J BIOL CHEM, V254, P5155; VILARO S, 1988, BIOCHIM BIOPHYS ACTA, V959, P106, DOI 10.1016/0005-2760(88)90021-5; VILARO S, 1986, BIOCHEM J, V236, P273, DOI 10.1042/bj2360273; WALLINDER L, 1984, BIOCHIM BIOPHYS ACTA, V795, P513, DOI 10.1016/0005-2760(84)90181-4; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLINGHAM MC, 1979, J CELL BIOL, V82, P614, DOI 10.1083/jcb.82.3.614; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907	43	155	158	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25764	25767						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1281473				2022-12-27	WOS:A1992KD07300030
J	VANDRAANEN, NA; TUCKER, SC; BOYD, FL; TROTTER, BW; REARDON, JE				VANDRAANEN, NA; TUCKER, SC; BOYD, FL; TROTTER, BW; REARDON, JE			BETA-L-THYMIDINE 5'-TRIPHOSPHATE ANALOGS AS DNA-POLYMERASE SUBSTRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE; STEREOCHEMICAL COURSE; ABSOLUTE-CONFIGURATION; ESCHERICHIA-COLI; I KLENOW; MECHANISM; POLYMERIZATION; PROCESSIVITY; INHIBITION	Beta-L-3'-deoxythymidine 5'-triphosphate (L-ddTTP) and beta-L-3'-deoxy-2',3'-didehydrothymidine 5'-triphosphate (L-d4TTP) were substrates for human immunodeficiency virus reverse transcriptase, Escherichia coli DNA polymerase I (Klenow), and Sequenase (modified T7 DNA polymerase). The beta-D- and beta-L-enantiomers of 5-methyluridine 5'-triphosphate (rTTP) were inhibitors but not substrates of reverse transcriptase. The steady-state K(m) values for L-ddTTP and L-d4TTP, with all three enzymes, were 12-70-fold larger than the K(m) values for the corresponding D-enantiomers. The K(m) value of reverse transcriptase for L-ddTTP was 50-fold larger than that for D-ddTTP because the K(d) for L-ddTTP was 5-fold larger than that for D-ddTTP, and the first-order rate constant for incorporation of L-ddTMP into the template-primer was 10% that of the D-enantiomer. The D- and L-enantiomers had k(cat) values with reverse transcriptase and Sequenase that were similar to k(cat) for the natural substrate, thymidine 5'-triphosphate (dTTP). Thus, the rate determining step appeared to be dissociation of the enzyme-chain-terminated template-primer complex. In contrast, k(cat) values for the L-enantiomers with Klenow were only 0.1% that of dTTP, and the k(cat) values for the D-enantiomers were 15% the k(cat) for dTTP. The reduced k(cat) values were due to a change in rate determining step from dissociation of the Klenow-chain-terminated template-primer complex to an earlier step in the reaction mechanism, presumably catalysis. Thus, these DNA polymerases did not stereospecifically recognize D-nucleoside 5'-triphosphate analogs as substrates.	WELLCOME RES LABS, DIV EXPTL THERAPY, RES TRIANGLE PK, NC 27709 USA	Wellcome Research Laboratories								Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; ATKINSON MR, 1969, BIOCHEMISTRY-US, V8, P4897, DOI 10.1021/bi00840a037; BARTLETT PA, 1982, J BIOL CHEM, V257, P8879; BRODY RS, 1982, BIOCHEMISTRY-US, V21, P2570, DOI 10.1021/bi00539a042; BURGERS PMJ, 1978, P NATL ACAD SCI USA, V75, P4798, DOI 10.1073/pnas.75.10.4798; CATALANO CE, 1989, BIOCHEMISTRY-US, V28, P4374, DOI 10.1021/bi00436a038; CHANEY AL, 1962, CLIN CHEM, V8, P130; CHU CK, 1990, J ORG CHEM, V55, P1418, DOI 10.1021/jo00292a006; Cleland W W, 1979, Methods Enzymol, V63, P103; COATES JAV, 1992, ANTIMICROB AGENTS CH, V36, P202, DOI 10.1128/AAC.36.1.202; HANESSIAN S, 1985, TETRAHEDRON LETT, V26, P5627, DOI 10.1016/S0040-4039(01)80904-7; HOPKINS S, 1989, BIOCHEM BIOPH RES CO, V163, P106, DOI 10.1016/0006-291X(89)92105-0; HUBER HE, 1989, J BIOL CHEM, V264, P4669; KOVACS T, 1988, TETRAHEDRON LETT, V29, P4525, DOI 10.1016/S0040-4039(00)80537-7; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; MANSURI MM, 1991, BIOORG MED CHEM LETT, V1, P65, DOI 10.1016/S0960-894X(01)81093-3; NAKAYAMA C, 1979, J CARB-NUCLEOS-NUCL, V6, P295; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; RAVID U, 1978, TETRAHEDRON, V34, P1449, DOI 10.1016/0040-4020(78)80164-1; REARDON JE, 1990, J BIOL CHEM, V265, P20302; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; ROMANIUK PJ, 1982, J BIOL CHEM, V257, P7684; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; VINCE R, 1990, BIOCHEM BIOPH RES CO, V168, P912, DOI 10.1016/0006-291X(90)91115-9; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; WRIGHT GE, 1990, PHARMACOL THERAPEUT, V47, P447, DOI 10.1016/0163-7258(90)90066-B	27	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25019	25024						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1281153				2022-12-27	WOS:A1992KB60300019
J	NAGANO, Y; HAMANO, T; NAKASHIMA, N; ISHIKAWA, M; MIYAZAKI, K; HAYASHI, M				NAGANO, Y; HAMANO, T; NAKASHIMA, N; ISHIKAWA, M; MIYAZAKI, K; HAYASHI, M			YOLK VITRONECTIN - PURIFICATION AND DIFFERENCES FROM ITS BLOOD HOMOLOG IN MOLECULAR-SIZE, HEPARIN BINDING, COLLAGEN BINDING, AND BOUND CARBOHYDRATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM SPREADING FACTOR; PLASMINOGEN-ACTIVATOR INHIBITOR-1; S-PROTEIN VITRONECTIN; HUMAN-PLASMA; CELL-ADHESION; SUBSTRATE ADHESION; ANTITHROMBIN-III; IDENTIFICATION; COMPLEX; THROMBIN	This is the first report on a unique vitronectin molecule, yolk vitronectin, which is similar to its blood homologue in cell spreading activity but different in molecular size, bound carbohydrate, and heparin and collagen binding activity. Yolk vitronectin was purified 2,500-fold from chick egg yolk by a combination of hydroxylapatite, DEAE-cellulose, and anti-vitronectin-Sepharose column chromatographies. In SDS-polyacrylamide gel electrophoresis under reducing conditions, yolk vitronectin was separated into 54- and 45-kDa bands, which are 16 and 25 kDa smaller, respectively, than the 70-kDa major band of chick blood vitronectin. The 54-kDa band shares the same NH2-terminal sequence as chick blood vitronectin. In contrast, the NH2-terminal sequence of the 45-kDa band is somewhat homologous with the internal sequences of mammalian vitronectins beginning at the 50th amino acid from the NH2 terminus. The bound carbohydrate of the 54- and 45-kDa species of yolk vitronectin is similar to, but distinct from, that of blood vitronectin. Unlike blood vitronectin, yolk vitronectin cannot bind to either heparin or collagen.	OCHANOMIZU UNIV, DEPT BIOL, BUNKYO KU, TOKYO 112, JAPAN	Ochanomizu University								ALI IU, 1978, CELL, V14, P439, DOI 10.1016/0092-8674(78)90129-0; BARNES DW, 1983, J BIOL CHEM, V258, P2548; BARNES DW, 1985, J BIOL CHEM, V260, P9117; BARNES DW, 1985, J CELL PHYSIOL, V125, P207, DOI 10.1002/jcp.1041250206; BASARA ML, 1985, CANCER RES, V45, P2487; BELITZ HD, 1987, FOOD CHEM, P408; COOPER S, 1988, DEVELOPMENT, V104, P565; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; EKBLOM P, 1986, ANNU REV CELL BIOL, V2, P27, DOI 10.1146/annurev.cb.02.110186.000331; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; GEBB C, 1986, J BIOL CHEM, V261, P6698; HARLOW E, 1988, ANTIBODIES; HAYASHI M, 1985, J BIOCHEM-TOKYO, V98, P1135, DOI 10.1093/oxfordjournals.jbchem.a135363; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; HAYMAN EG, 1982, J CELL BIOL, V95, P20, DOI 10.1083/jcb.95.1.20; HILDEBRAND A, 1988, J BIOL CHEM, V263, P2436; ILL CR, 1985, J BIOL CHEM, V260, P5610; ISHIKAWA M, 1992, BIOCHIM BIOPHYS ACTA, V1121, P173, DOI 10.1016/0167-4838(92)90351-D; IZUMI M, 1988, CELL STRUCT FUNCT, V13, P217, DOI 10.1247/csf.13.217; JENNE D, 1985, THROMB RES, V38, P401, DOI 10.1016/0049-3848(85)90138-0; JENNE D, 1989, EUR J BIOCHEM, V185, P391, DOI 10.1111/j.1432-1033.1989.tb15127.x; JENNE D, 1985, EMBO J, V4, P3153, DOI 10.1002/j.1460-2075.1985.tb04058.x; KITAGAKIOGAWA H, 1990, BIOCHIM BIOPHYS ACTA, V1033, P49, DOI 10.1016/0304-4165(90)90193-Z; KITAGAKIOGAWA H, 1986, EUR J BIOCHEM, V161, P779, DOI 10.1111/j.1432-1033.1986.tb10507.x; KOMAZAKI S, 1987, DEV GROWTH DIFFER, V29, P517; KORCGRODZICKI B, 1988, BIOCHEM BIOPH RES CO, V157, P1131; KUBOTA K, 1988, CELL STRUCT FUNCT, V13, P123, DOI 10.1247/csf.13.123; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCGUIRE EA, 1988, J BIOL CHEM, V263, P1942; MIYAZAKI K, 1992, EXP CELL RES, V199, P106, DOI 10.1016/0014-4827(92)90467-M; MOOS M, 1988, J BIOL CHEM, V263, P6005; MOSESSON MW, 1970, J BIOL CHEM, V245, P5728; NAITO M, 1991, EXP CELL RES, V194, P154, DOI 10.1016/0014-4827(91)90145-K; NAKASHIMA N, 1992, BIOCHIM BIOPHYS ACTA, V1120, P1, DOI 10.1016/0167-4838(92)90417-C; NOLL H, 1985, P NATL ACAD SCI USA, V82, P8062, DOI 10.1073/pnas.82.23.8062; PODACK ER, 1978, J IMMUNOL, V120, P1841; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; PREISSNER KT, 1989, BLOOD, V74, P1989; PREISSNER KT, 1987, BIOCHEM J, V243, P105, DOI 10.1042/bj2430105; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; ROVASIO RA, 1983, J CELL BIOL, V96, P462, DOI 10.1083/jcb.96.2.462; SANDERS L C, 1991, Plant Cell, V3, P629; SANE DC, 1988, BIOCHEM BIOPH RES CO, V157, P115, DOI 10.1016/S0006-291X(88)80020-2; SATO R, 1990, J BIOL CHEM, V265, P21232; SATTA G, 1980, IN VITRO CELL DEV B, V16, P738, DOI 10.1007/BF02619307; SEIFFERT D, 1991, P NATL ACAD SCI USA, V88, P9402, DOI 10.1073/pnas.88.21.9402; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; THIERY JP, 1985, ANNU REV CELL BIOL, V1, P91, DOI 10.1146/annurev.cellbio.1.1.91; THIERY JP, 1989, FIBRONECTIN, P181; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGNER VT, 1992, P NATL ACAD SCI USA, V89, P3644, DOI 10.1073/pnas.89.8.3644; Wallace R A, 1985, Dev Biol (N Y 1985), V1, P127; WIMAN B, 1988, YAMAMO, V242, P125; YAMADA KM, 1976, P NATL ACAD SCI USA, V73, P1217, DOI 10.1073/pnas.73.4.1217; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	62	19	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24863	24870						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1280270				2022-12-27	WOS:A1992KA26300105
J	OKAMOTO, T; NISHIMOTO, I				OKAMOTO, T; NISHIMOTO, I			DETECTION OF G-PROTEIN-ACTIVATOR REGIONS IN M4 SUBTYPE MUSCARINIC, CHOLINERGIC, AND ALPHA-2-ADRENERGIC RECEPTORS BASED UPON CHARACTERISTICS IN PRIMARY STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; BETA-ADRENERGIC-RECEPTOR; GTP-BINDING PROTEINS; GROWTH FACTOR-II; NUCLEOTIDE REGULATORY PROTEINS; PHOSPHOLIPID-VESICLES; LIGAND-BINDING; RHODOPSIN; TRANSDUCIN; IDENTIFICATION	The 14-residue region Arg2410-Lys2423 of the human insulin-like growth factor II receptor possesses the ability to stimulate G(i), the activity being dependent on two structural characteristics: (i) at least two basic residues at the N-terminal side and (ii) the C-terminal motif, B-B-X-B or B-B-X-X-B (where B is a basic residue and X is a non-basic residue). The regions satisfying (i) and (ii) with 10 less-than-or-equal-to a residue length less-than-or-equal-to 26 were located in all of the third inner loops and some of the other intracellular domains of the G(i)-coupled M4 subtype muscarinic cholinergic receptor (M4AChR) and the alpha-2-adrenergic receptor (alpha-2AR). Both the second inner loop 130-147 and the C-terminal portion of the third inner loop 382-400 (MIII) of human M4AChR had the ability to stimulate G proteins with the order G(i) almost-equal-to G(o) > G(s), but only MIII could activate G(i)/G(o) at nanomolar concentrations. In contrast, the N-terminal portion of the third inner loop 218-228 of human alpha-2AR-C10 activated G(i), G(o), and G(s) at micromolar concentrations with equal potency, whereas the further C-terminal portion of the third inner loop 301-313 of this receptor lacked the ability to activate any G protein. Among these active regions, only MIII indicated Mg2+-dependent G(i)-stimulating function. Therefore, the search for the regions satisfying (i) and (ii) was useful to localize the G protein-activating activity of G(i)-coupled receptors in limited regions, which were not always in the C-terminal portions of the third intracellular loops and activated G proteins in various modes of actions.	UNIV TOKYO,SCH MED,DEPT INTERNAL MED 4,LIFE SCI LAB,3-28-6 MEJIRODAI,BUNKYO KU,TOKYO 112,JAPAN	University of Tokyo								BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; CERIONE RA, 1986, J BIOL CHEM, V261, P3901; CERIONE RA, 1985, J BIOL CHEM, V260, P1493; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; HAGA K, 1989, MOL PHARMACOL, V35, P286; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; KATADA T, 1987, FEBS LETT, V213, P353, DOI 10.1016/0014-5793(87)81521-1; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; KUHN H, 1981, BIOCHEMISTRY-US, V20, P2410; MURAYAMA Y, 1990, J BIOL CHEM, V265, P17456; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; OKAMOTO T, 1991, BIOCHEM BIOPH RES CO, V179, P10, DOI 10.1016/0006-291X(91)91326-8; OKAMOTO T, 1990, BIOCHEM BIOPH RES CO, V168, P1201, DOI 10.1016/0006-291X(90)91156-M; OKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P8020, DOI 10.1073/pnas.88.18.8020; OVCHINNIKOV YA, 1982, FEBS LETT, V148, P179, DOI 10.1016/0014-5793(82)80805-3; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; RUBENSTEIN RC, 1987, J BIOL CHEM, V262, P16655; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; STRADER CD, 1987, J BIOL CHEM, V262, P16439; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; WANG SKF, 1990, J BIOL CHEM, V265, P6219; WEISS ER, 1988, J BIOL CHEM, V263, P6150	28	200	204	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8342	8346						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1314825				2022-12-27	WOS:A1992HQ18500060
J	MCMANUS, JD; BRUNE, DC; HAN, J; SANDERSLOEHR, J; MEYER, TE; CUSANOVICH, MA; TOLLIN, G; BLANKENSHIP, RE				MCMANUS, JD; BRUNE, DC; HAN, J; SANDERSLOEHR, J; MEYER, TE; CUSANOVICH, MA; TOLLIN, G; BLANKENSHIP, RE			ISOLATION, CHARACTERIZATION, AND AMINO-ACID-SEQUENCES OF AURACYANINS, BLUE COPPER PROTEINS FROM THE GREEN PHOTOSYNTHETIC BACTERIUM CHLOROFLEXUS-AURANTIACUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; ELECTRON-TRANSPORT; CRYSTAL-STRUCTURE; ALCALIGENES-DENITRIFICANS; PRIMARY PHOTOCHEMISTRY; POPLAR PLASTOCYANIN; REACTION CENTERS; FREE FLAVIN; AZURIN; CHLAMYDOMONAS	Three small blue copper proteins designated auracyanin A, auracyanin B-1, and auracyanin B-2 have been isolated from the thermophilic green gliding photosynthetic bacterium Chloroflexus aurantiacus. All three auracyanins are peripheral membrane proteins. Auracyanin A was described previously (Trost, J. T., McManus, J. D., Freeman, J. C., Ramakrishna, B. L., and Blankenship, R. E. (1988) Biochemistry 27, 7858-7863) and is not glycosylated. The two B forms are glycoproteins and have almost identical properties to each other, but are distinct from the A form. The sodium dodecyl sulfate-polyacrylamide gel electrophoresis apparent monomer molecular masses are 14 (A), 18 (B-2), and 22 (B-1) kDa. The amino acid sequences of the B forms are presented. All three proteins have similar absorbance, circular dichroism, and resonance Raman spectra, but the electron spin resonance signals are quite different. Laser flash photolysis kinetic analysis of the reactions of the three forms of auracyanin with lumiflavin and flavin mononucleotide semiquinones indicates that the site of electron transfer is negatively charged and has an accessibility similar to that found in other blue copper proteins. Copper analysis indicates that all three proteins contain 1 mol of copper per mol of protein. All three auracyanins exhibit a midpoint redox potential of +240 mV. Light-induced absorbance changes and electron spin resonance signals suggest that auracyanin A may play a role in photosynthetic electron transfer. Kinetic data indicate that all three proteins can donate electrons to cytochrome c-554, the electron donor to the photosynthetic reaction center.	ARIZONA STATE UNIV,DEPT CHEM & BIOCHEM,CTR STUDY EARLY EVENTS PHOTOSYNTHESIS,TEMPE,AZ 85287; OREGON GRAD INST SCI & TECHNOL,DEPT CHEM & BIOL SCI,BEAVERTON,OR 97006; UNIV ARIZONA,DEPT BIOCHEM,TUCSON,AZ 85721	Arizona State University; Arizona State University-Tempe; University of Arizona					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015057] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021277, R01GM018865] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK15057] Funding Source: Medline; NIGMS NIH HHS [GM21277, GM18865] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adman E.T., 1985, METALLOPROTEINS ME 1, P1; ADMAN ET, 1978, J MOL BIOL, V123, P35, DOI 10.1016/0022-2836(78)90375-3; ADMAN ET, 1991, IN PRESS ADV PROTEIN, V42; AMBLER RP, 1989, BIOCHEM J, V261, P495, DOI 10.1042/bj2610495; AMBLER RP, 1985, BIOCHEM J, V232, P451, DOI 10.1042/bj2320451; AMESZ J, 1987, PHOTOSYNTHETICA, V21, P225; BEANLAND TJ, 1990, J THEOR BIOL, V145, P535, DOI 10.1016/S0022-5193(05)80487-4; BEZKOROVAINY A, 1965, ARCH BIOCHEM BIOPHYS, V110, P558, DOI 10.1016/0003-9861(65)90450-9; BLANKENSHIP RE, 1985, PHOTOSYNTH RES, V6, P317, DOI 10.1007/BF00054106; BLANKENSHIP RE, 1992, IN PRESS PHOTOSYNTHE; BLANKENSHIP RE, 1985, GREEN PHOTOSYNTHETIC, P57; BOAS JF, 1984, COPPER PROTEINS COPP, V1, P5; BRAUER AW, 1984, ANAL BIOCHEM, V137, P134, DOI 10.1016/0003-2697(84)90359-2; BRUCE BD, 1982, P NATL ACAD SCI-BIOL, V79, P6532, DOI 10.1073/pnas.79.21.6532; BRUNE DC, 1987, BIOCHEMISTRY-US, V26, P8652, DOI 10.1021/bi00400a024; CHAN SI, 1990, BIOCHEMISTRY-US, V29, P1, DOI 10.1021/bi00453a001; COLLYER CA, 1990, J MOL BIOL, V211, P617, DOI 10.1016/0022-2836(90)90269-R; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; DAUL C, 1981, COMPUT PHYS COMMUN, V21, P385, DOI 10.1016/0010-4655(81)90015-1; DEISENHOFER J, 1989, SCIENCE, V245, P1463, DOI 10.1126/science.245.4925.1463; DIMITROV MI, 1987, FEBS LETT, V226, P17, DOI 10.1016/0014-5793(87)80542-2; DRACHEVA S, 1991, BIOCHEMISTRY-US, V30, P11451, DOI 10.1021/bi00112a012; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; DUTTON PL, 1986, PHOTOSYNTHESIS, V3, P197; FAIRCHILD CD, 1991, J BACTERIOL, V173, P2985, DOI 10.1128/JB.173.9.2985-2992.1991; FLETCHER AP, 1963, BIOCHIM BIOPHYS ACTA, V74, P311, DOI 10.1016/0006-3002(63)91373-8; FREEMAN JC, 1990, PHOTOSYNTH RES, V23, P29, DOI 10.1007/BF00030060; GENDER JE, 1984, METHOD ENZYMOL, V104, P447; GEWIRTH AA, 1988, J AM CHEM SOC, V110, P3811, DOI 10.1021/ja00220a015; GUSS JM, 1988, SCIENCE, V241, P806, DOI 10.1126/science.3406739; GUSS JM, 1983, J MOL BIOL, V169, P521; HAEHNEL W, 1986, PHOTOSYNTHESIS, V3, P547; HAN J, 1991, BIOCHEMISTRY-US, V30, P10904, DOI 10.1021/bi00109a014; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; JIN HY, 1989, J AM CHEM SOC, V111, P4262, DOI 10.1021/ja00194a017; KIRMAIER C, 1987, PHOTOSYNTH RES, V13, P225, DOI 10.1007/BF00029401; KRONECK PMH, 1990, FEBS LETT, V268, P274, DOI 10.1016/0014-5793(90)81026-K; LECHNER J, 1989, ANNU REV BIOCHEM, V58, P173, DOI 10.1146/annurev.bi.58.070189.001133; MALKIN R, 1973, BIOCHIM BIOPHYS ACTA, V292, P169, DOI 10.1016/0005-2728(73)90261-2; Matsudaira P, 1989, PRACTICAL GUIDE PROT; MCMANUS JD, 1990, THESIS ARIZONA STATE; MERCHANT S, 1986, MOL CELL BIOL, V6, P462, DOI 10.1128/MCB.6.2.462; MERCHANT S, 1986, J BIOL CHEM, V261, P5850; MEYER TE, 1989, ARCH BIOCHEM BIOPHYS, V272, P254, DOI 10.1016/0003-9861(89)90217-8; MEYER TE, 1987, ARCH BIOCHEM BIOPHYS, V258, P307, DOI 10.1016/0003-9861(87)90349-3; MINO Y, 1987, BIOCHEMISTRY-US, V26, P8059, DOI 10.1021/bi00399a006; NORRIS GE, 1986, J AM CHEM SOC, V108, P2784, DOI 10.1021/ja00270a064; NORRIS GE, 1983, J MOL BIOL, V165, P501, DOI 10.1016/S0022-2836(83)80216-2; PETRATOS K, 1987, FEBS LETT, V218, P209, DOI 10.1016/0014-5793(87)81048-7; PIERSON BK, 1974, ARCH MICROBIOL, V100, P5, DOI 10.1007/BF00446302; RONK M, 1991, BIOCHEMISTRY-US, V30, P9435, DOI 10.1021/bi00103a007; ROUSSEAU F, 1990, FEBS LETT, V260, P241, DOI 10.1016/0014-5793(90)80113-W; RYDEN L, 1984, COPPER PROTEINS COPP, V1, P157; RYDEN L, 1988, OXIDASES RELATED RED, P349; SANDMANN G, 1983, ARCH MICROBIOL, V134, P23, DOI 10.1007/BF00429401; SANDMANN G, 1980, PLANT SCI LETT, V17, P417, DOI 10.1016/0304-4211(80)90128-5; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHICHI H, 1963, ARCH BIOCHEM BIOPHYS, V100, P185, DOI 10.1016/0003-9861(63)90060-2; SOLOMON EI, 1980, J AM CHEM SOC, V102, P168, DOI 10.1021/ja00521a029; SYKES AG, 1985, CHEM SOC REV, V14, P283, DOI 10.1039/cs9851400283; TOLLIN G, 1986, BIOCHEMISTRY-US, V25, P3363, DOI 10.1021/bi00359a041; TROST JT, 1988, BIOCHEMISTRY-US, V27, P7858, DOI 10.1021/bi00420a041; VANDEKAMP M, 1990, EUR J BIOCHEM, V194, P109; VANVLIET P, 1991, EUR J BIOCHEM, V199, P317; VISSER JWM, 1974, BIOCHIM BIOPHYS ACTA, V333, P279, DOI 10.1016/0005-2728(74)90011-5; WEILAND F, 1988, BIOCHIMIE PARIS, V70, P1493; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; WOOD PM, 1978, EUR J BIOCHEM, V87, P9, DOI 10.1111/j.1432-1033.1978.tb12346.x; WOODRUFF WH, 1988, BIOL APPLICATIONS RA, V3, P413; WYNN RM, 1987, BIOCHIM BIOPHYS ACTA, V891, P216, DOI 10.1016/0005-2728(87)90217-9; YANO T, 1991, FEBS LETT, V288, P159, DOI 10.1016/0014-5793(91)81025-4; ZANNONI D, 1985, FEBS LETT, V193, P93, DOI 10.1016/0014-5793(85)80086-7; [No title captured]	73	44	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6531	6540						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1313011				2022-12-27	WOS:A1992HM05300016
J	SHEN, ES; WHITLOCK, JP				SHEN, ES; WHITLOCK, JP			PROTEIN-DNA INTERACTIONS AT A DIOXIN-RESPONSIVE ENHANCER - MUTATIONAL ANALYSIS OF THE DNA-BINDING SITE FOR THE LIGANDED AH RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-P1-450 GENE-EXPRESSION; MOUSE HEPATOMA-CELLS; AROMATIC-HYDROCARBONS; TRANSCRIPTION; INDUCTION; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN; REQUIREMENT; MECHANISM; ELEMENTS; PROMOTER	The liganded Ah receptor activates transcription by binding to a specific DNA-recognition motif within a dioxin-responsive enhancer upstream of the CYP1A1 gene. Analyses of mutant enhancers by gel retardation reveal that each base pair within the domain 5'GCAC(CGTG)3' is essential to the receptor-enhancer interaction. The three base pairs immediately flanking each end of the essential domain contribute less strongly to receptor binding. Analyses of enhancer function by transfection reveal that a mutation in the essential domain, which abolishes receptor-DNA binding, obliterates enhancer function. Mutations outside the essential domain, which diminish, but do not abolish, receptor-DNA binding, also obliterate enhancer function. Additionally, one mutation adjacent to the essential binding motif does not affect receptor-DNA binding, but destroys enhancer activity. These findings imply that transcriptional enhancement by the dioxin-responsive system cannot be predicted solely by the strength of the receptor-enhancer interaction.			SHEN, ES (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT PHARMACOL,STANFORD,CA 94305, USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003719] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 03719] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; Bailar J C 3rd, 1991, N Engl J Med, V324, P260, DOI 10.1056/NEJM199101243240409; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONNEY AH, 1982, CANCER RES, V42, P4875; DENISON MS, 1989, J BIOL CHEM, V264, P16478; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; ELFERINK CJ, 1990, J BIOL CHEM, V265, P5718; FINGERHUT MA, 1991, NEW ENGL J MED, V324, P260; FISHER JM, 1990, J BIOL CHEM, V265, P9676; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; ISRAEL DI, 1984, J BIOL CHEM, V259, P5400; JONES PBC, 1985, SCIENCE, V227, P1499, DOI 10.1126/science.3856321; JONES PBC, 1986, P NATL ACAD SCI USA, V83, P2802, DOI 10.1073/pnas.83.9.2802; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; Kimbrough R. D., 1989, HALOGENATED BIPHENYL; Lu P, 1985, Adv Biophys, V20, P153, DOI 10.1016/0065-227X(85)90035-8; MANIATIS T, 1982, MOL CLONING LABORATO, P123; MILLER AG, 1983, J BIOL CHEM, V258, P3523; NEUHOLD LA, 1989, MOL CELL BIOL, V9, P2378, DOI 10.1128/MCB.9.6.2378; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; SAATCIOGLU F, 1990, J BIOL CHEM, V265, P9251; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHEN ES, 1989, J BIOL CHEM, V264, P17754; WEN LP, 1990, P NATL ACAD SCI USA, V87, P8545, DOI 10.1073/pnas.87.21.8545; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251	31	117	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6815	6819						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1313023				2022-12-27	WOS:A1992HM05300055
J	MARSTERS, SA; FRUTKIN, AD; SIMPSON, NJ; FENDLY, BM; ASHKENAZI, A				MARSTERS, SA; FRUTKIN, AD; SIMPSON, NJ; FENDLY, BM; ASHKENAZI, A			IDENTIFICATION OF CYSTEINE-RICH DOMAINS OF THE TYPE-1 TUMOR-NECROSIS-FACTOR RECEPTOR INVOLVED IN LIGAND-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GROWTH-FACTOR RECEPTOR; MOLECULAR-CLONING; FACTOR-ALPHA; EXPRESSION; INHIBITOR; SEQUENCE; CDNA; DNA	The extracellular portion of the type 1 (p55) and type 2 (p75) tumor necrosis factor (TNF) receptors contains a repetitive amino acid sequence pattern of four cysteine-rich domains (CRDs). This pattern is found also in several other cell surface proteins, including the p75 nerve growth factor receptor and the CD40, 4-1BB, OX40, Fas, and CD27 antigens. To investigate whether CRDs play a role in TNF binding, we have constructed soluble variants of the extracellular portion of human type 1 TNF receptor (sTNFR1), in which CRD1 (N-terminal) or CRD4 (C-terminal) was deleted by mutagenesis. These variants or a wild type sTNFR1 were linked in their C terminus to the hinge and Fc portion of IgG1 heavy chain to create STNFR1-IgG chimeras (immunoadhesins). Deletion of either CRD1 or -4 did not cause any major perturbations in the structure of the sTNFR1 variants, as evidenced by their efficient expression and secretion from transfected cells, and by their binding to conformation-dependent monoclonal antibodies that recognize diverse epitopes on sTNFR1. The wild type sTNFR1 immunoadhesin exhibited high affinity binding to TNF-alpha (K(d) = 65 pM) and TNF-beta (K(d) = 640 pM). Deletion of CRD4 resulted in about a 10-fold reduction in affinity for TNF-alpha (K(d) = 660 pM) and for TNF-beta (K(d) = 5.7 nM). In contrast, deletion of CRD1 resulted in a complete loss of binding to TNF-alpha and to TNF-beta. These results indicate that CRD4 is important but not necessary for TNF binding, while CRD1 is required. In addition, the results suggest some overlap between the TNFR1 binding sites for TNF-alpha and TNF-beta, despite low amino acid sequence homology between these cytokines.	GENENTECH INC,DEPT IMMUNOBIOL,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT MED & ANALYT CHEM,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech			Ashkenazi, Avi/ABG-2712-2020	Ashkenazi, Avi/0000-0002-6890-4589				ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; CAMERINI D, 1991, J IMMUNOL, V147, P3165; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; ECK MJ, 1989, J BIOL CHEM, V264, P17595; GOEDDEL DV, 1986, COLD SPRING HARB SYM, V51, P597, DOI 10.1101/SQB.1986.051.01.072; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Grunfeld C, 1990, Adv Intern Med, V35, P45; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; KWON BS, 1989, P NATL ACAD SCI USA, V86, P1963, DOI 10.1073/pnas.86.6.1963; LESSLAUER W, 1991, EUR J IMMUNOL, V21, P2883, DOI 10.1002/eji.1830211134; LOETSCHER H, 1991, J BIOL CHEM, V266, P18324; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; NOVICK D, 1989, J EXP MED, V170, P1409, DOI 10.1084/jem.170.4.1409; PEETRE C, 1988, EUR J HAEMATOL, V41, P414; PENNICA D, 1992, BIOCHEMISTRY-US, V31, P1134, DOI 10.1021/bi00119a023; PEPPEL K, 1991, J EXP MED, V174, P1483, DOI 10.1084/jem.174.6.1483; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SECKINGER P, 1989, J BIOL CHEM, V264, P11966; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; UPTON C, 1987, VIROLOGY, V160, P20, DOI 10.1016/0042-6822(87)90039-0; UPTON C, 1991, VIROLOGY, V184, P370, DOI 10.1016/0042-6822(91)90853-4; VANOSTADE X, 1991, EMBO J, V10, P827, DOI 10.1002/j.1460-2075.1991.tb08015.x; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P159, DOI 10.1073/pnas.88.1.159; YAN H, 1991, J BIOL CHEM, V266, P12099	36	60	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5747	5750						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1313418				2022-12-27	WOS:A1992HK31800007
J	HIDAKA, M; KOBAYASHI, T; ISHIMI, Y; SEKI, M; ENOMOTO, T; ABDELMONEM, M; HORIUCHI, T				HIDAKA, M; KOBAYASHI, T; ISHIMI, Y; SEKI, M; ENOMOTO, T; ABDELMONEM, M; HORIUCHI, T			TERMINATION COMPLEX IN ESCHERICHIA-COLI INHIBITS SV40 DNA-REPLICATION INVITRO BY IMPEDING THE ACTION OF T-ANTIGEN HELICASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE TUMOR-ANTIGEN; EXHIBIT POLAR INHIBITION; BINDING-PROTEIN; TERMINUS REGION; PHYSICAL MAP; SEQUENCE; CHROMOSOME; IDENTIFICATION; GENE; SITE	DNA replication terminus (ter)-binding protein (TBP) in Escherichia coli binds specifically to the terminus (ter) site, and the resulting complex severely blocks DNA replication in an unique orientation by inhibiting the action of helicases. To generalize the intrinsic nature of the orientated ter-TBP complex against various helicases, we tested the potential of the complex to inhibit the action of three helicases, DNA helicase I, simian virus 40 (SV40) large tumor (T) antigen, and helicase B, derived from F plasmid, SV40, and mouse FM3A cell, respectively. The complex impeded the unwinding activities of all tested helicases in a specific orientation, with the same polarity observed in case of blockage of a replication fork, and, as a result, there was a block of SV40 DNA replication in both crude and purified enzyme systems in vitro. As the specificity in polarity of inhibition extends to heterologous systems, there may be common structure/mechanism features in helicases.	MAX PLANCK INST MED RES,ZELLPHYSIOL ABT,W-6900 HEIDELBERG 1,GERMANY; MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN; UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,BUNKYO KU,TOKYO 113,JAPAN	Max Planck Society; University of Tokyo	HIDAKA, M (corresponding author), NATL INST BASIC BIOL,GENE EXPRESS & REGULAT LAB,38 NISHIGONAKA,OKAZAKI,AICHI 444,JAPAN.							ABDELMONEM M, 1976, EUR J BIOCHEM, V65, P441, DOI 10.1111/j.1432-1033.1976.tb10359.x; ABDELMONEM M, 1983, P NATL ACAD SCI-BIOL, V80, P4659, DOI 10.1073/pnas.80.15.4659; BASTIA D, 1981, P NATL ACAD SCI-BIOL, V78, P2095, DOI 10.1073/pnas.78.4.2095; BEDROSIAN CL, 1991, P NATL ACAD SCI USA, V88, P2618, DOI 10.1073/pnas.88.7.2618; BOUCHE JP, 1982, J MOL BIOL, V154, P1, DOI 10.1016/0022-2836(82)90413-2; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; CARRIGAN CM, 1987, NUCLEIC ACIDS RES, V15, P8501, DOI 10.1093/nar/15.20.8501; DEMASSY B, 1987, P NATL ACAD SCI USA, V84, P1759; GERMINO J, 1981, CELL, V23, P681, DOI 10.1016/0092-8674(81)90431-1; GOETZ GS, 1988, J BIOL CHEM, V263, P383; HERNANDEZ P, 1988, EMBO J, V7, P303, DOI 10.1002/j.1460-2075.1988.tb02813.x; HIDAKA M, 1989, J BIOL CHEM, V264, P21031; HIDAKA M, 1988, CELL, V55, P467, DOI 10.1016/0092-8674(88)90033-5; HILL TM, 1987, P NATL ACAD SCI USA, V84, P1754, DOI 10.1073/pnas.84.7.1754; HILL TM, 1989, P NATL ACAD SCI USA, V86, P1593, DOI 10.1073/pnas.86.5.1593; HILL TM, 1988, CELL, V55, P459, DOI 10.1016/0092-8674(88)90032-3; HORIUCHI T, 1988, CELL, V54, P515, DOI 10.1016/0092-8674(88)90073-6; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; ISHIMI Y, 1991, J BIOL CHEM, V266, P16141; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; KOBAYASHI T, 1989, EMBO J, V8, P2435, DOI 10.1002/j.1460-2075.1989.tb08374.x; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KUEMPEL PL, 1989, CELL, V59, P581, DOI 10.1016/0092-8674(89)90001-9; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; LEWIS PJ, 1989, J BACTERIOL, V171, P3564, DOI 10.1128/jb.171.6.3564-3567.1989; REYGERS U, 1991, EMBO J, V10, P2689, DOI 10.1002/j.1460-2075.1991.tb07812.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKI M, 1990, BIOCHEMISTRY-US, V29, P1003, DOI 10.1021/bi00456a024; SEKI M, 1988, BIOCHEMISTRY-US, V27, P1766, DOI 10.1021/bi00405a057; SISTA PR, 1991, GENE DEV, V5, P74, DOI 10.1101/gad.5.1.74; SISTA PR, 1989, P NATL ACAD SCI USA, V86, P3026, DOI 10.1073/pnas.86.9.3026; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; WIEKOWSKI M, 1988, J BIOL CHEM, V263, P436; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710	36	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5361	5365						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1312088				2022-12-27	WOS:A1992HH74700056
J	HUTCHISON, KA; BROTT, BK; DELEON, JH; PERDEW, GH; JOVE, R; PRATT, WB				HUTCHISON, KA; BROTT, BK; DELEON, JH; PERDEW, GH; JOVE, R; PRATT, WB			RECONSTITUTION OF THE MULTIPROTEIN COMPLEX OF PP60(SRC), HSP90, AND P50 IN A CELL-FREE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; DNA-BINDING STATE; HEAT-SHOCK PROTEINS; GLUCOCORTICOID RECEPTOR; TRANSFORMING PROTEIN; PROGESTERONE-RECEPTOR; HORMONE; PARAMETERS; ACTIVATION; PP60SRC	A rabbit reticulocyte lysate system that has been used to reconstitute functional complexes between steroid receptors and the 90-kDa heat shock protein (hsp90) has been used here to form complexes between the pp60src tyrosine kinase and hsp90. Reticulocyte lysate forms complexes between hsp90 and a temperature-sensitive mutant of Rous sarcoma virus pp60v-src, which is normally present in cytosol virtually entirely in the multiprotein complex form. In addition, hsp90 in the lysate complexes with wild-type pp60v-src, of which only a small portion is normally recovered in cytosol in the native multiprotein complex, and with the cellular homolog, pp60c-src, which has never been recovered in cytosol in the form of a native multiprotein complex with hsp90. Moreover, the reticulocyte lysate-reconstituted complex also contains the 50-kDa phosphoprotein component of the native pp60v-src multiprotein complex. The native and reconstituted pp60src-hsp90 complexes have similar thermal stability and, like steroid receptor heterocomplexes, they are stabilized by molybdate. As previously shown with reticulocyte lysate-reconstituted steroid receptor heteroprotein complexes, the reconstituted pp60src multiprotein complex contains hsp70, which is a major candidate for providing the protein unfoldase activity required for hsp90 association.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT MICROBIOL & IMMUNOL,ANN ARBOR,MI 48109; PURDUE UNIV,DEPT FOODS & NUTR,W LAFAYETTE,IN 47907	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Purdue University System; Purdue University; Purdue University West Lafayette Campus					NCI NIH HHS [CA28010, CA47809] Funding Source: Medline; NIEHS NIH HHS [ES04869] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA047809, R01CA028010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004869, R29ES004869] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BISHOP JM, 1984, RNA TUMOR VIRUSES, P999; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; BRUGGE J, 1983, MOL CELL BIOL, V3, P9, DOI 10.1128/MCB.3.1.9; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; COURTNEIDGE SA, 1982, P NATL ACAD SCI-BIOL, V79, P7117, DOI 10.1073/pnas.79.23.7117; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DALMAN FC, 1990, J BIOL CHEM, V265, P3615; DALMAN FC, 1991, BIOCHEMISTRY-US, V30, P5605, DOI 10.1021/bi00236a038; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; ERHART JC, 1988, ONCOGENE, V3, P595; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; JOVE R, 1986, J VIROL, V60, P849, DOI 10.1128/JVI.60.3.849-857.1986; JOVE R, 1986, J VIROL, V60, P840, DOI 10.1128/JVI.60.3.840-848.1986; KAWAI S, 1980, J VIROL, V34, P772, DOI 10.1128/JVI.34.3.772-776.1980; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; MESHINCHI S, 1988, J BIOL CHEM, V263, P16809; MESHINCHI S, 1990, J BIOL CHEM, V265, P4863; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PRATT WB, 1987, J CELL BIOCHEM, V35, P51, DOI 10.1002/jcb.240350105; PRATT WB, 1990, MOL CELL ENDOCRINOL, V74, pC69, DOI 10.1016/0303-7207(90)90198-H; PRATT WB, 1991, IN PRESS J STEROID B; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1987, J BIOL CHEM, V262, P6986; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SEFTON BM, 1982, J VIROL, V44, P467, DOI 10.1128/JVI.44.2.467-474.1982; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1990, J BIOL CHEM, V265, P3996; TAMURA T, 1983, CELL, V34, P587, DOI 10.1016/0092-8674(83)90391-4; WHEELER RH, 1981, J BIOL CHEM, V256, P434; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436	40	90	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					2902	2908						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1310678				2022-12-27	WOS:A1992HD15400016
J	SMITH, MK; COLBRAN, RJ; BRICKEY, DA; SODERLING, TR				SMITH, MK; COLBRAN, RJ; BRICKEY, DA; SODERLING, TR			FUNCTIONAL DETERMINANTS IN THE AUTOINHIBITORY DOMAIN OF CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE-II - ROLE OF HIS282 AND MULTIPLE BASIC RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING; ALPHA-SUBUNIT; CA-2+-INDEPENDENT ACTIVITY; REGULATORY DOMAIN; AUTOPHOSPHORYLATION; MECHANISM; THREONINE-286; MUTAGENESIS; SITE	Important determinants in the autoinhibitory domain of calcium/calmodulin-dependent protein kinase II (CaMK-II), corresponding to residues 281-302 of the kinase alpha-subunit sequence, were identified. Replacement of Thr286 with Ala (CaMK-(281-302 Ala286)) had no effect on either the potency (IC50 = 2-mu-M) or inhibitory mechanism (competitive with ATP) using the catalytic fragment of CaMK-II. Single replacement of charged residues in CaMK-(281-302, Ala286) identified His282, Arg283, Lys291, Arg297, and Lys298 as important determinants (> 10-fold increase in IC50) for potent inhibition of CaMK-II. Glu285, Asp288, Lys291, Arg296, and Lys300 were not as essential (< 4-fold change in IC50) for potent CaMK-II inhibition. Replacement of either Arg283, Lys291, or Arg297, and Lys298 with Ala did not alter the ATP-competitive mechanism of inhibition although the K(i) values increased 16-530-fold. However, replacement of His282 with Ala decreased the IC50 by 20-fold and altered the mechanism of inhibition to noncompetitive with respect to ATP. The non-protonated form of His282 Was functionally active since decreasing the pH from 7.5 to 5.5 increased the IC50 of CaMK-(281-302, Ala286) almost 20-fold. Histidine protonation also appeared to disrupt the autoinhibitory domain of intact forms of CaMK-II since preincubation of non-proteolyzed rat brain CaMK-II with calcium/calmodulin (in the absence of ATP) at pH 5.5 generated up to 16% calcium-independent activity when assayed at pH 5.5. Similarly, the level of calcium-independent activity of a baculovirus-expressed Asp286 mutant CaMK-II ((D286)mCaMK-alpha) increased to almost 80% calcium independence when assayed at pH 5.5 compared to only 20% when assayed at pH 7.5. The levels of calcium-independent activity of both the (D286)mCaMK-alpha (at pH 5.5 and 7.5) and the rat brain CaMK-II (at pH 5.5) were sensitive to the concentrations of both ATP and peptide substrate (syntide-2) in the assays. These data suggest that the basic residues Arg283, Lya291, Arg297, and Lys298 are important for potent inhibition of CaMK-II and that the non-protonated form of His282 may play a unique role in the ATP-directed mechanism of inhibition by the CaMK-II autoinhibitory domain.			SMITH, MK (corresponding author), VANDERBILT UNIV, MED CTR, SCH MED, DEPT MOLEC PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA.		Colbran, Roger/AAU-7708-2021	Colbran, Roger/0000-0001-7401-8244	NIDDK NIH HHS [DK07563] Funding Source: Medline; NIGMS NIH HHS [GM41292] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRICKEY DA, 1990, BIOCHEM BIOPH RES CO, V173, P578, DOI 10.1016/S0006-291X(05)80074-9; CHAKRABARTTY A, 1991, NATURE, V351, P586, DOI 10.1038/351586a0; COHEN P, 1988, MOL ASPECTS CELLULAR, V5, P145; COHEN P, 1988, MOL ASPECTS CELLULAR, V5; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; COLBRAN RJ, 1988, J BIOL CHEM, V263, P18145; COLBRAN RJ, 1989, J BIOL CHEM, V264, P4800; FONG YL, 1989, J BIOL CHEM, V264, P16759; FONG YL, 1990, J BIOL CHEM, V265, P11091; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HANLEY RM, 1988, BIOCHEM BIOPH RES CO, V152, P122, DOI 10.1016/S0006-291X(88)80688-0; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; KELLY PT, 1988, P NATL ACAD SCI USA, V85, P4991, DOI 10.1073/pnas.85.14.4991; KEMP BE, 1989, CELL SIGNAL, V1, P303, DOI 10.1016/0898-6568(89)90049-1; KING MM, 1988, J BIOL CHEM, V263, P4754; KING MM, 1988, J NEUROCHEM, V43, P1599; KWIATKOWSKI AP, 1990, BIOCHEMISTRY-US, V29, P153, DOI 10.1021/bi00453a019; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; PAYNE ME, 1983, J BIOL CHEM, V258, P2376; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; PONGOR S, 1987, METHOD ENZYMOL, V154, P450; Rasmussen H, 1990, Curr Top Cell Regul, V31, P1; RICH DP, 1989, THESIS VANDERBILT U; RICOUART A, 1991, J MED CHEM, V34, P73, DOI 10.1021/jm00105a012; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SCHULMAN H, 1988, ADV SEC MESS PHOSPH, V22, P39; SCHWORER CM, 1988, J BIOL CHEM, V263, P13486; SHIELDS SM, 1984, J NEUROCHEM, V43, P1599, DOI 10.1111/j.1471-4159.1984.tb06084.x; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002; WAXHAM MN, 1990, P NATL ACAD SCI USA, V87, P1273, DOI 10.1073/pnas.87.4.1273	35	98	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1761	1768						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1309796				2022-12-27	WOS:A1992HA48500057
J	VARIN, L; IBRAHIM, RK				VARIN, L; IBRAHIM, RK			NOVEL FLAVONOL 3-SULFOTRANSFERASE - PURIFICATION, KINETIC-PROPERTIES, AND PARTIAL AMINO-ACID-SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; HYDROXYSTEROID SULFOTRANSFERASE; FLAVERIA-CHLORAEFOLIA; MOLECULAR-BIOLOGY; ARYL SULFATASE; CDNA; PHYTOALEXINS; CLONING; ELICITATION; PLANTS	A flavonol sulfotransferase (EC 2.8.2.-), which catalyzes the transfer of the sulfate group from 3'-phosphoadenosine 5'-phosphosulfate to the 3-hydroxyl group of flavonol aglycones, has been purified to apparent homogeneity from Flaveria chloraefolia. The specific activity of flavonol 3-sulfotransferase was enriched 2000-fold, as compared with the homogenate, with a recovery of 9%. The molecular mass of the native and denatured enzyme was found to be 34.5 kDa, suggesting that the active from of the enzyme is a monomer. The enzyme exhibited expressed specificity for position 3 of flavonol aglycones, showed two activity optima at pH 6.0 and 8.5, did not require divalent cations, and was not inhibited by either EDTA or sulfhydryl group reagents. The results of substrate interaction kinetics and product inhibition are consistent with an Ordered Bi Bi mechanism where 3'-phosphoadenosine 5'-phosphosulfate is the first substrate to bind to the enzyme and 3'-phosphoadenosine 5'-phosphate is the final product to be released. The amino acid sequence of two peptides representing 17 and 33 amino acids showed no significant sequence similarity with the amino acid sequences reported for animal sulfotransferases. Antibodies raised against F. chloraefolia 3-sulfotransferase were found to cross-react with the 3'- and 4'-sulfotransferase activities of the same plant, suggesting that the three enzymes are structurally related.	CONCORDIA UNIV,DEPT BIOL,PLANT BIOCHEM LAB,MONTREAL H3G 1M8,QUEBEC,CANADA	Concordia University - Canada								ANDREWS PC, 1987, ANAL BIOCHEM, V161, P524, DOI 10.1016/0003-2697(87)90484-2; [Anonymous], 1979, EUR J BIOCHEM, V97, P319; BARNES S, 1989, J LIPID RES, V30, P529; BARRON D, 1988, Z NATURFORSCH C, V43, P625; BARRON D, 1987, TETRAHEDRON, V43, P5197, DOI 10.1016/S0040-4020(01)87695-X; BARRON D, 1988, Z NATURFORSCH C, V43, P631; BARRON D, 1986, PHYTOCHEMISTRY, V25, P1719, DOI 10.1016/S0031-9422(00)81243-1; BARRON D, 1988, PHYTOCHEMISTRY, V27, P2375, DOI 10.1016/0031-9422(88)87003-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLELAND WW, 1967, ENZYMES, V2, P1; DARVILL AG, 1984, ANNU REV PLANT PHYS, V35, P243, DOI 10.1146/annurev.pp.35.060184.001331; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DIXON RA, 1983, ADV ENZYMOL RAMB, V55, P1; DIXON RA, 1986, BIOL REV, V61, P239, DOI 10.1111/j.1469-185X.1986.tb00719.x; FALANY CN, 1990, ARCH BIOCHEM BIOPHYS, V278, P312, DOI 10.1016/0003-9861(90)90265-Z; HAHLBROCK K, 1989, ANNU REV PLANT PHYS, V40, P347, DOI 10.1146/annurev.pp.40.060189.002023; HARBORNE JB, 1975, PHYTOCHEMISTRY, V14, P1147, DOI 10.1016/S0031-9422(00)98585-6; HOBKIRK R, 1985, CAN J BIOCHEM CELL B, V63, P1127, DOI 10.1139/o85-141; HOLLMANN J, 1986, BIOL CHEM H-S, V367, P5, DOI 10.1515/bchm3.1986.367.1.5; JACOBS M, 1988, SCIENCE, V241, P346, DOI 10.1126/science.241.4863.346; JAKOBY WB, 1980, ENZYMATIC BASIS DETO, P199; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONG SR, 1989, CELL, V56, P203, DOI 10.1016/0092-8674(89)90893-3; LYON ES, 1980, ARCH BIOCHEM BIOPHYS, V202, P474, DOI 10.1016/0003-9861(80)90452-X; NASH AR, 1988, AUST J BIOL SCI, V41, P507; OGURA K, 1989, BIOCHEM BIOPH RES CO, V165, P168, DOI 10.1016/0006-291X(89)91050-4; OGURA K, 1990, BIOCHEM BIOPH RES CO, V166, P1494, DOI 10.1016/0006-291X(90)91036-R; OZAWA S, 1990, NUCLEIC ACIDS RES, V18, P4001, DOI 10.1093/nar/18.13.4001; Roy A.B., 1981, SULFATION DRUGS RELA, P83; Segel I.H., 1975, ENZYME KINETICS; SMITH DA, 1986, PHYTOCHEMISTRY, V25, P979, DOI 10.1016/S0031-9422(00)81542-3; VARIN L, 1991, PLANT PHYSIOL, V95, P1254, DOI 10.1104/pp.95.4.1254; VARIN L, 1989, PLANT PHYSIOL, V90, P977, DOI 10.1104/pp.90.3.977; VARIN L, 1987, ANAL BIOCHEM, V161, P176, DOI 10.1016/0003-2697(87)90669-5	34	44	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1858	1863						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1309801				2022-12-27	WOS:A1992HA48500072
J	LINK, E; KERR, LD; SCHRECK, R; ZABEL, U; VERMA, I; BAEUERLE, PA				LINK, E; KERR, LD; SCHRECK, R; ZABEL, U; VERMA, I; BAEUERLE, PA			PURIFIED I-KAPPA-B-BETA IS INACTIVATED UPON DEPHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ENHANCER-BINDING-PROTEIN; SODIUM DODECYL-SULFATE; TUMOR-NECROSIS-FACTOR; DNA-BINDING; TRANSCRIPTION FACTOR; REL ONCOGENE; KINASE-C; LYMPHOID-CELLS; 65-KD SUBUNIT	In uninduced cells, the NF-kappa-B transcription factor resides in the cytoplasm in complex with an inhibitory protein, I-kappa-B. I-kappa-B is a specific inhibitor of DNA binding and apparently prevents nuclear uptake of NF-kappa-B. Stimulation of cells, for instance with the cytokine tumor necrosis factor, releases I-kappa-B and allows nuclear translocation and DNA binding of NF-kappa-B to regulatory DNA sequences in many genes. We recently reported on the purification of a major form of I-kappa-B, referred to as I-kappa-B-alpha, with a molecular size of 37 kDa. Here, we purified and characterized I-kappa-B-beta, a chromatographically distinct second form of I-kappa-B. I-kappa-B-beta has a size of 43 kDa and, as I-kappa-B-alpha, an acidic isoelectric point between 4.8 and 5.0. Both forms of I-kappa-B were inactivated by a treatment with protein kinases A and C in vitro. In contrast to I-kappa-B-alpha, I-kappa-B-beta lost its inhibiting activity upon a treatment with phosphatase. Phosphatase treatment also released active NF-kappa-B from its inactive complex with I-kappa-B-beta suggesting that the activation of NF-kappa-B in intact cells might not only rely on phosphate transfer onto I-kappa-B but also on phosphate removal from one form of I-kappa-B.	GENE CTR,MOLEC BIOL LAB,KLOPFERSPITZ 18A,O-8033 MARTINSRIED,GERMANY; SALK INST BIOL STUDIES,MOLEC BIOL & VIROL LAB,SAN DIEGO,CA 92138	Salk Institute					NCI NIH HHS [CA44360A, T2CA09370C] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044360, T32CA009370] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baeuerle P. A., 1991, MOL ASPECTS CELLULAR, P409; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BOMSZTYK K, 1990, J BIOL CHEM, V265, P9413; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWNELL E, 1988, ONCOGENE, V3, P93; BROWNELL E, 1989, ONCOGENE, V4, P935; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; IP YT, 1991, CELL, V64, P439; JENTSCH S, 1990, TRENDS BIOCHEM SCI, V15, P195, DOI 10.1016/0968-0004(90)90161-4; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ROEDERER M, 1990, P NATL ACAD SCI USA, V87, P4884, DOI 10.1073/pnas.87.12.4884; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHROTER H, 1989, NUCLEIC ACIDS RES, V17, P6415, DOI 10.1093/nar/17.15.6415; SCHUTZE S, 1990, J IMMUNOL, V144, P2604; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; THEVENIN C, 1990, New Biologist, V2, P793; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; URBAN MB, 1991, NEW BIOL, V3, P279; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; ZABEL U, 1991, J BIOL CHEM, V266, P252; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	39	99	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					239	246						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1309735				2022-12-27	WOS:A1992GY43900042
J	LYNCH, SR; SHERMAN, D; COPELAND, RA				LYNCH, SR; SHERMAN, D; COPELAND, RA			CYTOCHROME-C BINDING AFFECTS THE CONFORMATION OF CYTOCHROME-A IN CYTOCHROME-C-OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECTROSCOPIC ANALYSIS; COMPLEX-FORMATION; CYANIDE; PH	Second derivative absorption spectroscopy has been used to assess the effects of complex formation between cytochrome c and cytochrome c oxidase on the conformation of the cytochrome a cofactor. When ferrocytochrome c is complexed to the cyanide-inhibited reduced or mixed valence enzyme, the conformation of ferrocytochrome a is affected. The second derivative spectrum of these enzyme forms displays two electronic transitions at 443 and 451 nm before complex formation, but only the 443-nm transition after cytochrome c is bound. This effect is not induced by poly-L-lysine, a homopolypeptide which is known to bind to the cytochrome c binding domain of cytochrome c oxidase. The effect is limited to cyanide-inhibited forms of the enzyme; no effect was observed for the fully reduced unliganded or fully reduced carbon monoxide-inhibited enzyme. The spectral signatures of these changes and the fact that they are exclusively associated with the cyanide-inhibited enzyme are both reminiscent of the effects of low pH on the conformation of cytochrome a (Ishibe, N., Lynch, S., and Copeland, R. A. (1991) J. Biol. Chem. 266, 23916-23920). These results are discussed in terms of possible mechanisms of communication between the cytochrome c binding site, cytochrome a, and the oxygen binding site within the cytochrome c oxidase molecule.	UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637	University of Chicago								ALLEYNE TA, 1987, BIOCHEM J, V247, P475, DOI 10.1042/bj2470475; ANDREEV IM, 1983, BIOORG KHIM+, V9, P216; BISSON R, 1977, FEBS LETT, V81, P147, DOI 10.1016/0014-5793(77)80948-4; BLAIR DF, 1982, BIOCHEMISTRY-US, V21, P6928, DOI 10.1021/bi00269a048; Brautigan D L, 1978, Methods Enzymol, V53, P128; BRIGGS MM, 1978, BIOCHEM BIOPH RES CO, V80, P553, DOI 10.1016/0006-291X(78)91604-2; CHING YC, 1985, BIOCHEMISTRY-US, V24, P4938, DOI 10.1021/bi00339a032; COOPER TG, 1977, TOOLS BIOCH, P51; COPELAND RA, 1991, P NATL ACAD SCI USA, V88, P7281, DOI 10.1073/pnas.88.16.7281; FERGUSONMILLER S, 1978, J BIOL CHEM, V253, P149; Fersht A. R., 1985, ENZYME STRUCTURE MEC, P155; HARTZELL CR, 1974, BIOCHIM BIOPHYS ACTA, V368, P318, DOI 10.1016/0005-2728(74)90178-9; HILDEBRANDT P, 1990, BIOCHEMISTRY-US, V29, P1661, DOI 10.1021/bi00458a044; HILL BC, 1991, J BIOL CHEM, V266, P2219; ISHIBE N, 1991, J BIOL CHEM, V266, P23916; MICHEL B, 1984, J BIOL CHEM, V259, P85; Nicholls D.G., 1982, BIOENERGETICS INTRO; SHERMAN D, 1991, P NATL ACAD SCI USA, V88, P4265, DOI 10.1073/pnas.88.10.4265; THORNSTROM PE, 1988, BIOCHIM BIOPHYS ACTA, V935, P103, DOI 10.1016/0005-2728(88)90206-X; WEBER C, 1987, P NATL ACAD SCI USA, V84, P6687, DOI 10.1073/pnas.84.19.6687	20	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					298	302						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1309738				2022-12-27	WOS:A1992GY43900050
J	NAEGELI, H; BARDWELL, L; FRIEDBERG, EC				NAEGELI, H; BARDWELL, L; FRIEDBERG, EC			THE DNA HELICASE AND ADENOSINE-TRIPHOSPHATASE ACTIVITIES OF YEAST RAD3 PROTEIN ARE INHIBITED BY DNA DAMAGE - A POTENTIAL MECHANISM FOR DAMAGE-SPECIFIC RECOGNITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; GENE-4 PROTEIN; DEOXYRIBONUCLEIC-ACID; (A)BC EXCINUCLEASE; EXCISION REPAIR; BACTERIOPHAGE-T7; BINDING; COMPLEX; ATPASE	Purified Rad3 protein from the yeast Saccharomyces cerevisiae is a single-stranded DNA-dependent ATPase and also acts as a DNA helicase on partially duplex DNA. In this study we show that the DNA helicase activity is inhibited when a partially duplex circular DNA substrate is exposed to ultraviolet (UV) radiation. Inhibition of DNA helicase activity is sensitive to the particular strand of the duplex region which carries the damage. Inhibition is retained if the single-stranded circle is irradiated prior to annealing to an unirradiated oligonucleotide, but not if a UV-irradiated oligonucleotide is annealed to unirradiated circular single-stranded DNA. UV irradiation of single-stranded DNA or deoxyribonucleotide homopolymers also inhibits the ability of these polynucleotides to support the hydrolysis of ATP by Rad3 protein. UV radiation damage apparently blocks translocation of Rad3 protein and results in the formation of stable Rad3 protein-UV-irradiated DNA complexes. As a consequence, Rad3 protein remains sequestered on DNA, presumably at sites of base damage. The sensitivity of Rad3 protein to the presence of DNA damage on the strand along which it translocates provides a potential mechanism for damage recognition during nucleotide excision repair and may explain the absolute requirement for Rad3 protein for damage-specific incision of DNA in yeast.	UNIV TEXAS,SW MED CTR,DEPT PATHOL,MOLEC PATHOL LAB,DALLAS,TX 75235; STANFORD UNIV,PROGRAM CANC BIOL,STANFORD,CA 94305	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Stanford University			Bardwell, Lee/I-8284-2019	Bardwell, Lee/0000-0002-2393-8363	NCI NIH HHS [CA12428, CA09302] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA012428, R01CA012428] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1985, DNA REPAIR; BEDNARCZUK TA, 1991, BIOTECHNIQUES, V10, P478; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN WC, 1989, J BIOL CHEM, V264, P6748; FRIEDBERG EC, 1988, MICROBIOL REV, V52, P70, DOI 10.1128/MMBR.52.1.70-102.1988; GRAFSTROM RH, 1982, J BIOL CHEM, V257, P13465; HAROSH I, 1989, J BIOL CHEM, V264, P20532; KOO HS, 1991, P NATL ACAD SCI USA, V88, P1212, DOI 10.1073/pnas.88.4.1212; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN JJ, 1989, BIOCHEMISTRY-US, V28, P7979, DOI 10.1021/bi00446a002; MATSON SW, 1989, P NATL ACAD SCI USA, V86, P4430, DOI 10.1073/pnas.86.12.4430; MATSON SW, 1985, J BIOL CHEM, V260, P2281; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1983, J BIOL CHEM, V258, P4009; NAUMOVSKI L, 1985, MOL CELL BIOL, V5, P17, DOI 10.1128/MCB.5.1.17; NAUMOVSKI L, 1987, THESIS STANFORD U; OGDEN RC, 1987, METHOD ENZYMOL, V152, P61; OH EY, 1989, J BIOL CHEM, V264, P1336; OH EY, 1987, P NATL ACAD SCI USA, V84, P3638, DOI 10.1073/pnas.84.11.3638; RUNYON GT, 1989, J BIOL CHEM, V264, P17502; Sambrook J, 1989, MOL CLONING LABORATO; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SEELEY TW, 1989, P NATL ACAD SCI USA, V86, P6577, DOI 10.1073/pnas.86.17.6577; SELBY CP, 1990, MUTAT RES, V236, P203, DOI 10.1016/0921-8777(90)90005-P; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U	28	80	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					392	398						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1309743				2022-12-27	WOS:A1992GY43900064
J	ZHUANG, ZP; MARKS, B; MCCAULEY, RB				ZHUANG, ZP; MARKS, B; MCCAULEY, RB			THE INSERTION OF MONOAMINE OXIDASE-A INTO THE OUTER-MEMBRANE OF RAT-LIVER MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR PROTEIN; INVITRO INSERTION; INNER MEMBRANE; B ACTIVITIES; IMPORT; UBIQUITIN; BINDING; TRANSLOCATION; REQUIRES; MATRIX	Human monoamine oxidase A that had been synthesized in a reticulocyte lysate translation system was capable of binding to and inserting into either rat liver mitochondria or isolated mitochondrial outer membranes. The inserted form was as resistant to proteinase K as endogenous mitochondrial monoamine oxidase A. The insertion, but not the binding, of monoamine oxidase A was prevented by depleting the reaction mixture of either ATP (with apyrase) or ubiquitin (with purified antibodies against this polypeptide). Addition of ATP or ubiquitin, respectively, to these depleted mixtures restored the insertion of the enzyme. In the absence of mitochondria, in vitro synthesized monoamine oxidase A did not catalyze its own alkylation by the mechanism-based inhibitor, [H-3]clorgyline. However, both monoamine oxidase A that had been membrane-inserted in vitro and monoamine oxidase A that had been bound to the mitochondria under conditions of ATP depletion catalyzed adduct formation. Furthermore, reaction of either clorgyline or another mechanism-based inhibitor, pargyline, with the membrane-bound enzyme during ATP depletion inhibited the insertion of monoamine oxidase A when ATP was restored. These observations indicate that monoamine oxidase A acquired a catalytically active conformation on interaction with the mitochondrial outer membranes prior to its ATP and ubiquitin-dependent insertion into the membrane.			ZHUANG, ZP (corresponding author), WAYNE STATE UNIV,DEPT PHARMACOL,DETROIT,MI 48201, USA.							BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; CANTILLO J, 1984, THESIS WAYNE STATE U; CHEN WJ, 1987, CELL, V49, P651, DOI 10.1016/0092-8674(87)90541-1; CHUANG HYK, 1974, J BIOL CHEM, V249, P2381; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; FINELY D, 1987, CELL, V48, P1035; FINELY D, 1989, NATURE, V338, P394; GASSER SM, 1983, J BIOL CHEM, V258, P3427; GODING JW, 1978, J IMMUNOL METHODS, V20, P241, DOI 10.1016/0022-1759(78)90259-4; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HWANG ST, 1989, P NATL ACAD SCI USA, V86, P8432, DOI 10.1073/pnas.86.21.8432; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTINEZ P, 1977, BIOCHIM BIOPHYS ACTA, V497, P437, DOI 10.1016/0304-4165(77)90201-X; MCCAULEY R, 1976, BIOCHEM PHARMACOL, V25, P2214, DOI 10.1016/0006-2952(76)90136-2; MCCAULEY R, 1973, MOL CELL BIOCHEM, V1, P73, DOI 10.1007/BF01659940; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MEYER EM, 1986, J BIOL CHEM, V261, P4365; NAVARROWELCH C, 1982, J BIOL CHEM, V257, P13645; ONO H, 1987, EUR J BIOCHEM, V168, P509, DOI 10.1111/j.1432-1033.1987.tb13447.x; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PFALLER R, 1987, EMBO J, V6, P2635, DOI 10.1002/j.1460-2075.1987.tb02554.x; PFANNER N, 1988, J BIOL CHEM, V263, P4049; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; SCHENBORN E, 1985, NUCLEIC ACIDS RES, V12, P7035; SHORE GC, 1981, J BIOL CHEM, V256, P8761; SMITH D, 1985, BIOCHIM BIOPHYS ACTA, V831, P1, DOI 10.1016/0167-4838(85)90141-4; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; SULLIVAN JP, 1986, BIOCHEM PHARMACOL, V35, P3255, DOI 10.1016/0006-2952(86)90421-1; VERNER K, 1987, EMBO J, V6, P2449, DOI 10.1002/j.1460-2075.1987.tb02524.x; WEISS S, 1979, 4TH INT CAT S, P198; ZELLER E, 1976, MONOAMINE OXIDASE ST, P101; ZHAUNG ZP, 1989, J BIOL CHEM, V264, P14594; ZHUANG Z, 1988, FEBS LETT, V238, P185, DOI 10.1016/0014-5793(88)80253-9	35	47	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					591	596						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1309756				2022-12-27	WOS:A1992GY43900092
